3

Pharmacists Pharmacopeia

Official May 1, 2009 August 1, 2009

USP Pharmacists Pharmacopeia

P
Notice and Warning

S
Concerning U.S. Patent or Trademark Rights

U
The inclusion in the USP Pharmacists Pharmacopeia of a monograph on any drug in respect to which pat-
ent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to

9
exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are
vested in the patent or trademark owner, and no other person may exercise the same without express per-

0
mission, authority, or license secured from such patent or trademark owner.

2 0
Concerning Use of the USP Pharmacists Pharmacopeia Text
Use of the USP Pharmacists Pharmacopeia is subject to the terms and conditions of the USP Pharmacists
Pharmacopeia License Agreement. Attention is called to the fact that USP Pharmacists Pharmacopeia text

is fully copyrighted. Authors and others wishing to use portions of the text should request permission to
do so from the Legal Department of the United States Pharmacopeial Convention.

Copyright 2009 The United States Pharmacopeial Convention

ISSN: 1930-2908
ISSN online: 1930-2916
12601 Twinbrook Parkway, Rockville, MD 20852
All rights reserved.

S3/ii
USP Pharmacists Pharmacopeia

Contents
USP Pharmacists Pharmacopeia

Section 1 Section 8
Mission and Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/1 Dietary Supplement Monographs
and General Chapters . . . . . . . . . . . . . . . . . . . . . . . . . S3/72
Section 2
Section 13

P
General Notices and Requirements . . . . . . . . . . . . . . S3/9
Reference Tables of USPNF . . . . . . . . . . . . . . . . . . . S3/76

S
Section 3
Drug Substance and Compounded Preparation Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/130

U
Monographs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/22

Section 7

9
Pharmacy-Related General Chapters . . . . . . . . . . . . S3/41

2 0 0

S3/iii
USP Pharmacists Pharmacopeia

Introduction

Background
The history of the United States Pharmacopeia dates back to 1817 when Lyman Spalding, a physician, recognized the need
for standardization to eliminate regional differences among names and formulations of medicines. He and ten fellow physi-
cians held the first United States Pharmacopeial Convention (USPC) in the U.S. Capitol building in January 1820. That meeting
resulted in the formation of a committee that compiled the first Pharmacopeia of the United States of America (USP). The
equivalent of that committee still exists today as the USP Council of Experts, and the USPC still works to ensure good phar-

P
maceutical care for all.

S
In 1975, USPC combined the USP and another compendium, the National Formulary (NF), in a single volume, the USPNF.
In general, the USP contains standards for active drug substances and dietary ingredients, while the NF contains standards

U
for excipients.
Standards in the USPNF apply to compounded preparations as well as to manufactured products. They are enforceable

9
under the Federal Food, Drug, and Cosmetic Act, and may be enforceable to practitioners under state and local laws, as well.

The USP Pharmacists Pharmacopeia

2 0 0
The USP Pharmacists Pharmacopeia contains two types of text: official text and authorized text.
Official text is text that is reproduced from the USPNF. Each page of the book that contains official text is designated
with a footer explaining its official status and the USPNF revision from which it is reprinted. This text is derived from the

standards-setting activities of the Council of Experts and is presented here in an easy-to-use abridged form. Official text that
is reprinted in this volume maintains the same legal status as it does when published in the USPNF.
Authorized text has been developed and approved by the Council of Experts, but has not been published as official text
in the USPNF. Authorized text in this publication includes monographs published in the Food Chemicals Codex (FCC), Sixth
edition; veterinary information monographs discussing the use of medications and specific preparations for animals; pro-
posed monographs for compounded preparations that are still available for comment and that may be included in the USP
NF in the future; authored text previously published in the Pharmacopeial Forum and other USPC publications; copyrighted
text reprinted with permission; and text that is in the public domain, including laws and regulations. This text is provided for
reference purposes only, to aid in the practices of pharmacy and medicine.
The USPNF and the FCC are modified through continuing revision, and the corresponding text in this volume will be
updated accordingly. Because of varying publication schedules, changes to the USPNF and FCC may not immediately appear
as changes to the USP Pharmacists Pharmacopeia. The text as it appears in the USPNF and FCC is determinative and should
be referred to when specific questions arise.

Second Edition
This Second Edition of the USP Pharmacists Pharmacopeia is significantly revised from the 2005 publication. Section 3 has
been enhanced to include new compounding monographs that are relevant to todays contemporary practicing pharmacist.
The addition of content related to veterinary practice in Section 6, including the information on compounds for veterinary
use, should increase the utility of this volume for veterinary pharmacists. The addition of quality standards for food-grade
substances from the FCC in Section 4 also should be useful to compounding professionals seeking ingredients of appropri-
ate quality when a USPNF standard does not exist. The compounding support information in Section 9 has been expanded,

S3/iv
USP Pharmacists Pharmacopeia

and the laws and regulations in Section 11 have been updated to reflect the most recent changes by Congress and by the
Drug Enforcement Administration.

Acknowledgements
The staff at USP would like to express their sincere gratitude to the members of all expert committees, especially the Com-
pounding Pharmacy Expert Committee and the Sterile Compounding Expert Committee for their diligent and untiring efforts
in the preparation of this book.

Compounding Pharmacy Expert Committee

Loyd V. Allen, Jr., Ph.D., Chair
Judith E. Thompson, R.Ph., M.S., Vice Chair
Lisa D. Ashworth, B.S., R.Ph.
Robin H. Bogner, Ph.D.
Gigi S. Davidson, R.Ph.

P
Mary Ann F. Kirkpatrick, Ph.D.
Mark G. Klang, R.Ph., M.S.

S
Lawson G. Kloesel, R.Ph.
Linda McElhiney, Pharm.D.

U
Lawrence A. Trissel, B.S., R.Ph.

9
Sterile Compounding Expert Committee

0
David W. Newton, Ph.D., Chair

0
Lawrence A. Trissel, B.S., R.Ph., Vice Chair

2
Samuel C. Augustine, Pharm.D.
Mary B. Baker, Pharm.D.
James F. Cooper, Pharm.D.

Donald J. Filibeck, Pharm.D.
Larry W. Griffin, B.S.
Kenneth L. Hughes, B.S.
Eric S. Kastango, M.B.A.
Keith H. St. John, M.S.
Laura A. Thoma, Pharm.D.
James Wagner

S3/
USP Pharmacists Pharmacopeia

Admissions

New Articles Appearing in This Supplement

Section 3
rAlbumin Human Granisetron Hydrochloride
Corn Syrup Lisinopril and Hydrochlorothiazide Tablets
Erythorbic Acid Mirtazapine Orally Disintegrating Tablets

P
Alfuzosin Hydrochloride Pantoprazole Sodium

S
Bicalutamide Tablets Pantoprazole Sodium Delayed-Release Tablets
Cabergoline Piperazine Adipate
Cefdinir Piperazine Dihydrochloride

U
Cefdinir Capsules Piperazine Phosphate
Cefdinir for Oral Suspension Potassium Bromide Oral Solution, Veterinary

9
Fenofibrate Capsules Propofol Injectable Emulsion

0
Flavoxate Hydrochloride Sodium Bromide Injection, Veterinary

0
Flavoxate Hydrochloride Tablets Sodium Bromide Oral Solution, Veterinary
Formoterol Fumarate Tamsulosin Hydrochloride

2
Foscarnet Sodium

No Longer Appearing in Section 6

Potassium Bromide Oral Solution, Veterinary Sodium Bromide Oral Solution, Veterinary
Sodium Bromide Injection, Veterinary

Section 8
Arginine Capsules Soy Isoflavones Capsules
Arginine Tablets Soy Isoflavones Tablets
Curcuminoids Turmeric
Curcuminoids Capsules Powdered Turmeric
Curcuminoids Tablets Powdered Turmeric Extract
Powdered Soy Isoflavones Extract

Changes in Official Titles

The following title changes are official May 1, 2009

New Title Former Title

61 Microbiological Examination of Nonsterile Products: 61 Microbial Limit Tests
Microbial Enumeration Tests
62 Microbiological Examination of Nonsterile Products:
Tests for Specified Microorganisms
1111 Microbiological Examination of Nonsterile Products: 1111 Microbiological Attributes of Nonsterile
Acceptance Criteria for Pharmaceutical Preparations and Pharmaceutical Products
Substances for Pharmaceutical Use

S3/vi
USP Pharmacists Pharmacopeia

Annotated List

General Notices, Monographs, General Chapters, Reagents, and Tables Affected by

Changes Appearing in This Supplement
NoteIn the material below, if a section is new or if a subsection is added to or deleted from an existing section, it is labeled
as such in parentheses after the section or subsection name. Items on this list that appear without the designation new,
added, or deleted, are items in which changes have been made to existing official text.

P
General Notices and Requirements Betadex

S
Chemical information
General Chapters Packaging and storage

U
USP Reference standards
General Tests and Assays
pH (added)

9
Other Tests and Assays Bicalutamide Tablets (new)
381 Elastomeric Closures for Injections

0
Bupivacaine Hydrochloride
Introduction Chemical information

0
Test Procedures Cabergoline (new)

2
Physical Tests and Determinations Carbomer 934
621 Chromatography Title change
Glossary of Symbols Definition

Packaging and storage
General Information Viscosity
1121 Nomenclature Carbomer 934P
General Nomenclature Forms Title change
Definition
Packaging and storage
Reference Tables Viscosity
Description and Relative Solubility of USP and NF Articles Carbomer 940
Title change
Definition
Excipients
Packaging and storage
Monographs Viscosity
Carbomer 941
Section 3 Title change
rAlbumin Human (new) Definition
Alendronate Sodium Tablets Packaging and storage
Labeling Viscosity
Alfadex Carbomer Copolymer
USP Reference standards Definition
Alfuzosin Hydrochloride (new) Labeling
Aminophylline Viscosity
Chemical information

S3/vii
USP Pharmacists Pharmacopeia

Carbomer Homopolymer Lecithin

Definition Chemical information
Labeling Packaging and storage
Viscosity Labeling (added)
Carbomer Interpolymer USP Reference standards (added)
Definition Lisinopril and Hydrochlorothiazide Tablets (new)
Labeling Pantoprazole Sodium (new)
Viscosity Pantoprazole Sodium Delayed-Release Tablets (new)
Cefdinir (new) Piperazine Adipate (new)
Cefdinir Capsules (new) Piperazine Dihydrochloride (new)
Cefdinir for Oral Suspension (new) Piperazine Phosphate (new)
Corn Syrup (new) Polyvinyl Alcohol
Didanosine Definition
USP Reference standards Packaging and storage
Dimethyl Sulfoxide Labeling (added)
Definition USP Reference standards (added)

P
Dronabinol Viscosity
Packaging and storage Potassium Bromide Oral Solution, Veterinary (new)

S
Dyclonine Hydrochloride Prednisolone Sodium Phosphate
Chemical information Definition

U
Erythorbic Acid (new) Propofol Injectable Emulsion (new)
Fenofibrate Capsules (new) Propylene Glycol Monolaurate

9
Flavoxate Hydrochloride (new) USP Reference standards

0
Flavoxate Hydrochloride Tablets (new) Sodium Bromide Injection, Veterinary (new)

0
Formoterol Fumarate (new) Sodium Bromide Oral Solution, Veterinary (new)
Foscarnet Sodium (new) Tamsulosin Hydrochloride (new)

2
Liquid Glucose
Chemical information
Section 8

Packaging and storage
Labeling (added)
USP Reference standards (added)
Glyceryl Monooleate
Chemical information
USP Reference standards
Granisetron Hydrochloride (new)
Iopamidol
Chemical structure
USP Reference standards
Isopropyl Alcohol
USP Reference standards
Ivermectin Tablets, 2730
Dissolution (added)
Arginine Capsules (new)
Arginine Tablets (new)
Curcuminoids (new)
Curcuminoids Capsules (new)
Curcuminoids Tablets (new)
Powdered Soy Isoflavones Extract (new)
Soy Isoflavones Capsules (new)
Soy Isoflavones Tablets (new)
Turmeric (new)
Powdered Turmeric (new)
Powdered Turmeric Extract (new)

S3/viii
USP Pharmacists Pharmacopeia

Section 1
Mission and Preface

S P
T U
he Mission and Preface to the USP-NF provides general information about

9
the compendia and about USPs standards-setting processes. In addition,

0 0
this section includes information about USP and its role in setting standards for
compounded preparations.

2

USP Pharmacists Pharmacopeia

Section Contents

Mission and Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/3

S P
9 U
2 0 0

Official text. Reprinted from USP 32NF 27. Section 1, Mission and Preface S3/
USP Pharmacists Pharmacopeia
Mission and Preface USP 32NF 27
This section provides background information on the United States
Pharmacopeial Convention (USP), as well as general information about
the 32nd revision of the United States Pharmacopeia (USP 32) and
the 27th edition of the National Formulary (NF 27). Additional official
information about the specific uses of these texts is provided in the
General Notices and Requirements section, which has been signifi-
cantly revised (see www.usp.org/USPNF/GeneralNotices for a summary
of revisions).
Mission Statement
USPNF is published in continuing pursuit of the mission of USP: To
improve the health of people around the world through public stan-
dards and related programs that help ensure the quality and safety of
medicines and foods.
History
On January 1, 1820, 11 physicians met in the Senate Chamber of the
U.S. Capitol building to establish a pharmacopeia for the United States.
These practitioners sought to create a compendium of the best thera-
peutic products, give them useful names, and provide recipes for their
preparation. Nearly a year later, on December 15, 1820, the first edition
of The Pharmacopoeia of the United States was published. Over time,
the nature of the United States Pharmacopeia (USP) changed from
0
being a compendium of recipes to a compendium of documentary
0
standards that increasingly are allied with reference materials, which
together establish the identity of an article through tests for strength,
2
quality, and purity. The publishing schedule of the USP also changed
over time. From 1820 to 1942, the USP was published at 10-year in-
tervals; from 1942 to 2000, at 5-year intervals; and beginning in 2002,
annually.
In 1888, the American Pharmaceutical Association published the
first national formulary under the title The National Formulary of Un-
oficinal [sic] Preparations (NF). Both the USP and the NF were recog-
nized in the Federal Food and Drugs Act of 1906 and again in the Fed-
eral Food, Drug, and Cosmetic Act 1938. In 1975, USP acquired the
National Formulary (NF), which now contains excipients standards with
references to allied reference materials. Today, USP continues to devel-
op USP and NF through the work of the Council of Experts into com-
pendia that provide standards for articles based on advances in analyti-
cal and metrological science. As these and allied sciences evolve, so do
USP and NF.
USP 32NF 27
USP 32NF 27 text is official May 1, 2009, unless otherwise noted. USP
NF contains official substance and preparation (product) monographs.
The terms official substance and official preparation are defined in
the General Notices of this Pharmacopeia. With few exceptions, all ar-
ticles for which monographs are provided in USP 32NF 27 are legally
marketed in the United States or are contained in legally marketed
articles.
A USPNF monograph for an official substance or preparation
includes the articles definition; packaging, storage, and other re-
quirements; and a specification. The specification consists of a se-
ries of universal (description, identification, impurities, assay) and
specific tests, one or more analytical procedures for each test, and
Official text. Reprinted from USP 32NF 27. Section 1, Mission and Preface S3/
Mission and Preface
acceptance criteria. Ingredients are defined as either drug substances
or excipients. An excipient is any component, other than the active
substance(s), intentionally added to the formulation of a dosage form.
Excipients are not necessarily inert. Drug substances and excipients
may be synthetic, semisynthetic, drawn from nature (natural source),
or manufactured using recombinant technology. Larger molecules and
mixtures requiring a potency test are usually referred to as biologicals
or biotechnological articles.
USP 32NF 27 contains approximately 4,303 monographs and more
than 220 General Tests and Assays (General Chapters numbered 1,000
and below) and USP General Information Chapters (numbered above
1,000). General Chapters provide frequently cited procedures, some-
times with acceptance criteria, in order to compile into one location
repetitive information that appears in many monographs. New and re-
vised monographs and General Chapters and obsolete matter deleted
from this edition are indicated in the Admissions section.
USP 32NF 27 OrganizationUSP 32NF 27 is printed as a three-vol-
P
ume set. Volume 1 includes front matter (Mission and Preface, People,
S
Governance pages and websites, Admissions/Annotations, and Com-
mentary). It also includes USP General Notices, General Chapters, Di-
etary Supplement chapters, Reagents, Reference Tables, Dietary Sup-
U
plement monographs, NF Admissions, Excipients, and NF monographs.
Volume 2 includes USP monographs AL, and Volume 3 includes USP
monographs MZ. Volumes 2 and 3 also include the USP General No-
9
tices and the Guide to General Chapters, and all three volumes include
the full index. General Chapters specific to dietary supplements are
included in numerical order with the rest of the General Chapters in
USP. Excipient monographs usually are presented in NF but also may
appear in USP with suitable cross-referencing when they are also drug
substances. The Excipients section (Volume 1) presents a tabulation of
excipients by functional category.
USP 32NF 27 Spanish EditionIn 2006, USP began providing an offi-
cial Spanish edition of USPNF. Maintenance of this edition follows the
same revision approaches as the English edition.
RevisionsUSPNF is continuously revised. Revisions are presented
annually, in twice-yearly Supplements, in Interim Revision Announce-
ments (IRAs), and in Revision Bulletins (on the USP website).
SupplementsThe First Supplement to USP 32NF 27 will be published
in February 2009 and will become official in August 2009. The Second
Supplement will be published in June 2009 and will become official in
December 2009. Users of USP print products must retain Supplements
and subscriptions to Pharmacopeial Forum (PF) in order to have up-to-
date information. The USPNF online version is updated with each
Supplement or annual revision. Each time a new edition or Supple-
ment is released during the subscription period, a new CD-ROM will
be issued. The Index in each Supplement is cumulative and includes
citations to the annual revision and, for the Second Supplement, cita-
tions to the First Supplement. The contents of the two Supplements
are integrated into the annual edition of the following year, along with
new official revisions that have been adopted since the Second Sup-
plement to the previous compendia.
Interim Revision Announcements (IRAs)IRAs contain revisions that
become official in the interval between publication of the annual revi-
sion and Supplements, and thus provide an expedited mechanism for
making revisions official. They appear in USPs bimonthly journal, Phar-
macopeial Forum (PF), with the official date noted in the publication.
They are subsequently incorporated into the next published Supple-
ment or annual revision, although their official dates may precede the
official date of that publication.
USP Pharmacists Pharmacopeia
Revision BulletinsIf the circumstances require immediate publica-
tion of official text, a proposal or postponement may be published
through a Revision Bulletin. Revision Bulletins are posted on the USP
website and published in the next USPNF or Supplement, as applica-
ble. Revision Bulletin official dates are specified in the individual Revi-
sion Bulletin.
Pharmacopeial Forum (PF)Each PF contains several sections. The
Policies and Announcements section provides information about pub-
lication and comment deadlines, USP news, and summaries of issues
discussed by the Council of Experts and its Expert Committees. Pro-
posals for revision are presented as In-Process Revisions and represent
draft revisions that are expected to advance to official status pending
final review and approval by the relevant Expert Committee.
PF also includes Pending and Canceled Proposals and a Harmoni-
zation section. The Stimuli to the Revision Process section presents re-
ports or statements of authoritative bodies, scientific articles relevant
to compendial issues, general commentaries by interested parties, and
summaries of comments received in response to policy initiatives. PF
concludes with sections containing Nomenclature, Index, and Chro-
matographic Reagents used in USPNF and PF. Each issue of PF also
provides a cumulative index for the given calendar year.
Symbols Indicating Change to Official TextSymbols identify the be-
ginning and end of each revision. The following table summarizes
the types of symbols and the associated subscripts used in USP
publications:
Revision Type Symbol Subscript
Interim Revision
0
Announcement new text 16
1
new text for most substances and are amenable to search and retrieval. The two
0
Revision Bulletin 1 (RB 1-Jan-2009)
Text deletion or
1S (USP31) or
2
1
USP31
Adopted in Supplement
new text1S (USP31) 1 or 2S (USP annual
edition)
Adopted in USPNF
new textUSP31 USP annual edition
Interim revisions are shown with new text (if any) enclosed in circles,
new text . New text revised in Revision Bulletins is enclosed in cir-
1 able in print form. In addition, USPNF and its two annual Supple-
cles, new text1. Text enclosed in squares, new text1S (USP31), has al-
ready been adopted in a Supplement. Text that has been adopted in
the USPNF is enclosed in triangles, new textUSP32. Where the sym-
bols appear together with no enclosed text, such as 1 or 1S (USP31), it
means that text has been deleted and no new text has been proposed
to replace it.
In all revisions, the closing symbol is accompanied by a subscript
number or date that indicates the Interim Revision Announcement
(IRA), Revision Bulletin, or Supplement in which the revision first ap-
peared. An example of a revision that was officially adopted in the
Second Interim Revision Announcement would be 2 ; an example of a
revision that was officially adopted in the Revision Bulletin on June 18,
2008, would be 1. An example of revision that was officially adopted in
the Second Supplement to USP 31 would be 2S (USP31). Last, an example
of a revision that was officially adopted in USP 32NF 27 would be
USP32. The following table shows symbols and official dates for Interim
Revision Announcements and Supplements to USP 32NF 27:
Official text. Reprinted from USP 32NF 27. Section 1, Mission and Preface S3/
Mission and Preface
USP 32NF 27
Revision Document
Interim Revision
Supplement Announcement Official Date Symbols
35(1) Feb. 1, 2009 and
1
35(2) Apr. 1, 2009 and
2
35(3) June 1, 2009 and
3
1 Aug. 1, 2009
and1S (USP32)
35(4) Aug. 1, 2009 and
4
35(5) Oct. 1, 2009 and
5
2 Dec. 1, 2009
and2S (USP32)
and
35(6) Dec. 1, 2009 6
Chemical Names and CAS Registry NumbersChemical subtitles giv-
en in the monographs are index names used by the Chemical Abstracts
Service (CAS) of the American Chemical Society. They are provided
only in monographs in which the titles specify substances that are de-
finable chemical entities. The first subtitle is the inverted form of the
systematic chemical name developed by CAS. This is presented in ac-
P
cordance with the rules established over the years by the International
Union of Pure and Applied Chemistry (IUPAC) and the International
S
Union of Biochemistry, and this form is employed in the current issues
of Chemical Abstracts (CA). The second subtitle, given in uninverted
form, is of a systematic type formerly used in CA. It is identical with, or
U
closely resembles, the chemical name sanctioned and employed by
IUPAC and by the World Health Organization (WHO). IUPAC names
9
make generous use of nonsystematic and semisystematic (often re-
ferred to as trivial) names and qualifying terms, all of which impede
electronic manipulation. In contrast, CAS names are fully systematic
subtitles referred to above are frequently identical, and a CAS synonym
is occasionally supplied as a third subtitle. Monographs with chemical
subtitles generally also carry CAS registry numbers. These italicized,
bracketed numbers function independently of nomenclature as invari-
ant numerical designators of unique, unambiguous chemical sub-
stances in the CAS registry and thus are convenient and widely used.
Print and Electronic PresentationsAll USPNF publications are avail-
ments are available in compact disc (CD) and online versions. The CD
version makes USPNF accessible to users on their computer hard
drives. The online format allows individual registered users to access
the online format through the Internet. Both electronic formats pro-
vide access to official USPNF content, along with extensive search
options. The electronic formats are cumulatively updated to integrate
the content of Supplements. Searchable electronic versions of PF and
of the USP Dictionary also are available.
USP Governance, Standards-Setting,
and Advisory Bodies
USPs governing, standards-setting, and advisory bodies include the
USP Convention, the Board of Trustees, the Council of Experts and its
Expert Committees, Advisory Panels, and staff. Additional volunteer
bodies include Stakeholder Forums, Project Teams, and Advisory
Groups, which act in an advisory capacity to provide input to USPs
governing, standards-setting, and management bodies.
USP ConventionUSPs direction and priorities are determined by
more than 400 Convention members divided into nine categories (see
the People section). Eligible organizations within each membership
category are invited to appoint a representative. Convention composi-
tion is determined to ensure suitable representation of those sections
of the health care system that are influenced by, and in turn influence,
USPs activities. Convention members elect USPs President, Treasurer,
USP Pharmacists Pharmacopeia Mission and Preface

and other members of the Board of Trustees as well as the Council of Stakeholder Forums and Project TeamsUSP has formed several do-
Experts. They also vote on resolutions to guide USPs scientific policy mestic and international Stakeholder Forums and Project Teams in the
and public health initiatives and update, as needed, USPs Constitution 20052010 cycle to exchange information and receive comment on
and By-Laws. The next meeting of the USP Convention is scheduled for USPs standards-setting activities. Depending on the topic, a stake-
April 2010 in Washington, DC. holder forum may form project teams to work on selected topics. USP
Board of TrusteesUSPs Board of Trustees is entrusted with manage- has also formed country and regional Stakeholder Forums. The follow-
ment of the business affairs, finances, and property of USP. During its ing are lists of Stakeholder Forums for the 20052010 cycle.
five-year term, the Board defines USPs strategic direction through its Domestic Stakeholder Forums (United States and Canada)
key policy and operational decisions. A listing of the members of the Prescription/Nonprescription
20052010 Board of Trustees appears in the People section. Biologics and Biotechnology
Council of ExpertsThe Council of Experts is the standards-setting Compounding
body of USP. It is composed of 57 Expert Committee Chairs elected to
Dietary Supplements
five-year terms by USPs Convention members. A Nominating Commit-
tee, consisting of the Chair of the Council of Experts, the Convention Food Ingredients
President, and the Vice Chair of the Nominating Committee for the Patient Safety
Council of Experts, nominates individuals who are subsequently elect- International Stakeholder Forums
ed by the members of the Council of Experts to serve as Expert Com- Europe
mittee members. Collectively, the Expert Committee Chairs and mem-
India
bers comprise more than 500 volunteers drawn from 50 countries. The
Latin America

P
41 Standards Expert Committees are responsible for the content of
USPNF, the Food Chemicals Codex, and associated publications (see USP also conducts Annual Scientific Meetings in the United States,

S
Figure 1) and organized in Collaborative Groups for topics of common India, China, Latin America, and the Middle East/North Africa.
interest. The Information Expert Committees focus on development of StaffUSP maintains a staff of over 500 scientists, professionals, and
Model Guidelines for the Medicare Modernization Act and other in- administrative personnel at its Rockville, Maryland, headquarters. Ad-

U
formation activities. The Executive Committee of the Council of Experts ditional staff members are located at the account management office
(see the People section) provides overall direction, is an appeals body, in Basel, Switzerland, and laboratory complexes in Hyderabad, India;

9
and performs other functions that support the Councils operations. Shanghai, China; and So Paolo, Brazil.
Advisory Panels to the Council of ExpertsThe Chair of the Council of

0
Experts may appoint Advisory Panels to assist the Council of Experts in
Rules and Procedures

0
reaching scientific decisions and implementing new USP directives re-
lating to USPNF. A listing of Advisory Panels is provided in the People
Governing DocumentsUSPNF standards are recognized widely

2
section. This list changes frequently as the work of Advisory Panels
because they are authoritative and science-based and are established
concludes and new ones start their deliberations. There are more than
by a transparent and credible process. See the Articles of Incorpora-
350 Advisory Panel members who contribute to the standards-setting
tion section in this book; the Constitution and Bylaws and the Rules
activities of the Council of Experts.

and Procedures of the 20052010 Council of Experts are available on

Figure 1. Organization of the 20052010 USP Council of Experts

Official text. Reprinted from USP 32NF 27. Section 1, Mission and Preface S3/
USP Pharmacists Pharmacopeia
USPs website (www.usp.org). Collectively, these documents serve USP
volunteers and staff as the governing principles for USPs standards-
setting activities.
Conflicts of InterestUSPs Conflict of Interest provisions require all
members of the Council of Experts, its Expert Committees, Advisory
Panels, Board of Trustees, and key staff to disclose significant financial
interests in companies or other entities that are subject to USPNF
standards or that may be affected by USPNF information. Members of
the Board of Trustees, Council of Experts, and related bodies are not
allowed to vote on any matter in which they have a conflict of interest
or the appearance of a conflict of interest.
Confidentiality and Document DisclosureMembers of the Council
of Experts, Expert Committees, and Advisory Panels sign confidentiality
agreements, in keeping with the confidentiality provisions of the Rules
and Procedures of the Council of Experts. The USP Document Disclo-
sure Policy, available on USPs website, contributes to the transparency
of the standards-setting process by making information available to the
public, yet provides protection to manufacturers and others who sub-
mit confidential information to USP.
Authority for PublicationUSPNF is published in accordance with
Chapter VI, Section 8, of the USP Bylaws, which states, The Board of
Trustees shall authorize the revision and release of text to the United
States Pharmacopeia and the National Formulary. Upon approval of the
content by the Council of Experts, in accordance with the rules and
procedures adopted under Section 9, the Board of Trustees shall then
act upon releasing the text and upon designating the date when it is to
become official, said date to be reasonably distant from the date of its
release. The Executive Vice PresidentCEO shall, annually or more fre-
0
quently, upon specific request of the Board of Trustees, certify that the
0
information contained in the United States Pharmacopeia, National
Formulary, or other authorized publications has been prepared in ac-
2
cordance with the rules and procedures under Section 9.
USPNF Revision Process
Public ParticipationAlthough USPs Council of Experts is the ultimate
decision-making body for USPNF standards, these standards are de-
veloped by an exceptional process of public involvement and substan-
tial interaction between USP and its stakeholders, both domestically
and internationally. Participation in the revision process results from
the support of many individuals and groups and also from scientific,
technical, and trade organizations.
Requests for revision of monographs, either new monographs or
those needing updating, contain information submitted voluntarily by
manufacturers and other interested parties. At times USP staff may de-
velop information to support a monograph Request for Revision. USP
has prepared a document titled Guideline for Submitting Requests
for Revision to USPNF (available at www.usp.org, click on USPNF).
Via PF, USP solicits and encourages public comment on these mono-
graphs, General Chapters, and other draft documents. USP scientific
liaisons to Expert Committees review these responses and create draft
proposals that are provided to the Council of Experts. These drafts
become official when Expert Committees ballot to make them official
in USPNF. Thus, the USP standards-setting process gives those who
manufacture, regulate, and use therapeutic products the opportunity
to comment on the development and revision of USPNF standards.
Because of the voting process and its special link to the U.S. govern-
ment in law, USP is not considered a voluntary, consensus standards-
setting body. Figure 2 shows the public review and comment process
and its relationship to standards development.
Working with the Food and Drug Administration (FDA)As specified
in U.S. law, USP works with the Secretary of the Department of Health
and Human Services in many ways. Principal agencies in the Depart-
Official text. Reprinted from USP 32NF 27. Section 1, Mission and Preface S3/
Mission and Preface
ment for this work are the Food and Drug Administration and the
Centers for Medicare and Medicaid Services. The FDA Liaison Program
allows FDA representatives to participate in Expert Committee meet-
ings, enabling continuing interactions between FDA scientific staff and
Expert Committee activities. Staff in the FDA Centers who are respon-
sible for review of compendial activities provide specific links and op-
portunities for exchange of comments. Mr. Larry A. Ouderkirk in the
Center for Drug Evaluation and Research provides a primary compen-
dial link between FDA and USP.
Legal Recognition
Recognition of USPNFUSPNF is recognized by law and custom in
many countries throughout the world. In the United States, the federal
Food, Drug, and Cosmetic Act (FD&C Act) defines the term official
compendium as the official USP, the official NF, the official Homeo-
pathic Pharmacopeia of the United States, or any supplement to them.
FDA may enforce compliance with official standards in USPNF under
the adulteration and misbranding provisions of the FD&C Act. These
P
provisions extend broad authority to FDA to prevent entry to or re-
move designated products from the United States market on the basis
S
of standards in the USPNF.
The identity of an official article, as expressed by its name, is es-
U
tablished if it conforms in all respects to the requirements of its mono-
graph and other relevant portions of the compendia. The FD&C Act
stipulates that an article may differ in strength, quality, or purity and
9
still have the same name if the difference is stated on the articles label.
FDA requires that names for articles that are not official must be clearly
distinguishing and differentiating from any name recognized in an
official compendium. Official preparations (a drug product, a dietary
supplement including nutritional supplements, or a finished device)
may contain additional suitable ingredients. (See General Notices.)
DrugsUSPs goal is to have substance and preparation (product)
monographs in USPNF for all FDA-approved drugs, including biolog-
ics, and their ingredients. USP also develops monographs for thera-
peutic products not approved by FDA, e.g., pre-1938 drugs, dietary
supplements, and compounded preparations. Although submission of
information needed to develop a monograph by the Council of Experts
is voluntary, compliance with a USPNF monograph, if available, is
mandatory.
BiologicsIn the United States, although some biologics are regulated
under the provisions of the Public Health Service Act (PHSA), provi-
sions of the FD&C Act also apply to these products. For this reason,
products approved under the PHSA should comply with the adultera-
tion and misbranding provisions of the FD&C Act at Section 501(b) and
502(g) and, thus, should conform to applicable official monographs in
USPNF.
Medical DevicesSection 201(h) of the FD&C Act defines a device as
an instrument, apparatus, similar article, or component thereof recog-
nized in USPNF. Section 502(e) of the FD&C Act defines the estab-
lished name of a device in the absence of an FDA designation of the
official name as the official title in an official compendium. Despite
these statutory provisions, there is no comparable recognition of USPs
standards-setting authority and ability to define a medical device as
exists for other FDA-regulated therapeutic products. Under authority
granted by the Food and Drug Administration Modernization Act of
1997, the Center for Devices and Radiological Health recognizes na-
tional and international standards, including some USP tests and as-
says, for medical devices.
Dietary SupplementsThe Dietary Supplement Health and Education
Act of 1994 amendments to the FD&C Act name USP and NF as the of-
ficial compendia for dietary supplements. The amendments also pro-
vide that a dietary supplement may be deemed misbranded if it is cov-
USP Pharmacists Pharmacopeia
2 0 0
Figure 2. Public Review Process
ered by a monograph in an official compendium, is represented as
conforming to this monograph, but fails to conform. The dietary sup-
plement must be represented as conforming to a USPNF dietary sup-
plement monograph in order for the compendial standards to apply.
This contrasts with pharmaceutical products, wherein conformance to
the monograph is mandatory whether or not the product claims to
conform.
Compounded PreparationsPreparation monographs provide infor-
mation or standards applicable in compounding. Compounding means
the preparation, mixing, assembling, packaging, or labeling of a drug
or device or other article, as the result of a practitioners order or in
anticipation of such an order based on routine, regularly observed
prescribing patterns. Standards in USPNF for compounded prepara-
tions may be enforced at both the state and federal levels, e.g., if a
practitioner writes a prescription for a compounded preparation that is
named in a USPNF monograph, the preparation, when tested, must
conform to the stipulations of the monograph so named.
Official text. Reprinted from USP 32NF 27. Section 1, Mission and Preface S3/
Mission and Preface
S P
9 U
NomenclatureIn the United States, FDA has authority to establish
names for drug products and ingredients and to determine proper
names for biologics. In most cases, however, FDA works with the Unit-
ed States Adopted Names (USAN) Council to determine names for
drug and biological substances and with USP to determine drug prod-
uct names. Oversight of proprietary names and proper names is the
responsibility of FDA, working with applicants.
The USAN Councils program began in 1961 by providing ingredi-
ent names for drugs prior to their marketing. USP participates in this
activity, together with the American Medical Association, the American
Pharmacists Association, and FDA. The Councils output is incorporat-
ed, along with other names for drugs (including generic, proprietary,
and chemical names and code designations), in the USP Dictionary of
USAN and International Drug Names. Since 1988 this publication has
been recognized by federal regulation as the source of established
names for drug substances in the United States.
USP Pharmacists Pharmacopeia
Drug product names can be established by FDA, but more often
are developed cooperatively by FDA and the USP Council of Experts
Nomenclature Expert Committee. The names developed by this Expert
Committee are used as the titles of the relevant monographs, and as
such are recognized as the established names for drug products
under section 502(e)(3) of the FD&C Act. The USP Drug Nomenclature
Committee was formed in 1986 to supplement the Executive Commit-
tees of the Drug Standards Division and the Information Division and
to prevent any inconsistency regarding nomenclature. Following the
2000 meeting of the USP Convention, the responsibilities for devising
and, when necessary, revising labeling requirements were delegated to
this Expert Committee, which is now named the Nomenclature Expert
Committee. The Expert Committees work does not overlap that of
the USAN Council. Rather, it is complementary and is concerned with
standardization of compendial names, particularly dosage form names,
and names for combination drug products.
Harmonization Activities
Pharmacopeial Discussion GroupUSP harmonizes pharmacopeial
excipient monographs and General Chapters through the Pharmaco-
peial Discussion Group (PDG), which includes representatives from
the European, Japanese, and United States pharmacopeias, and WHO
(as an observer). According to the PDG definition, a pharmacopeial
general chapter or other pharmacopeial document is harmonized
when a pharmaceutical substance or product tested by the documents
harmonized procedure yields the same results, and the same accept/
reject decision is reached. General Information Chapter 1196, Phar-
0
macopeial Harmonization, provides (1) the PDG Policy Statement, (2)
the PDG Working Procedures and a definition of each stage of harmo-
0
nization, (3) a discussion, (4) a status report, and (5) a glossary.
2
Other USPNF Related Publications
Chromatographic ReagentsThis comprehensive reference provides
detailed information needed to conduct chromatographic procedures
found in USPNF. Chromatographic Reagents lists the brand names of
the column reagents cited in every proposal for new or revised gas- or
liquid-chromatographic analytical procedures that have been pub-
lished in PF since 1980. Chromatographic Reagents also helps to track
which column reagents were used to validate analytical procedures
that have become official. The branded column reagents list is updated
bimonthly in PF.
Official text. Reprinted from USP 32NF 27. Section 1, Mission and Preface S3/
Mission and Preface
USP Pharmacists PharmacopeiaUSPNF is directed primarily to phar-
maceutical and dietary supplement manufacturers, although it con-
tains many monographs and allied text useful for compounding
practitioners. To better accommodate the needs of these practitioners
and more generally the needs of the pharmacy community, USP has
made available the USP Pharmacists Pharmacopeia. This text provides
pharmacy-relevant abridged official text from the USPNF as well as
authorized information. The former refers to standards for official
articles; the latter is more general information designed to be useful
to practitioners. Both types of text are developed under the Rules and
Procedures of the Council of Experts. The USP Pharmacists Pharmaco-
peia is available both in print and in a web-based version.
USP DictionaryThe USP Dictionary of USAN and International Drug
Names provides in a single volume the most up-to-date United States
Adopted Names of drugs; official USPNF names; nonproprietary,
brand, and chemical names; graphic formulas; molecular formulas and
weights; CAS registry numbers and code designations; drug manufac-
turers; and pharmacologic and therapeutic categories. The Dictionary
helps to ensure the accuracy of the following: product labeling; re-
ports, articles, and correspondence; FDA regulatory filings; and phar-
P
maceutical package inserts. It is published annually (latest edition April
S
2008) and is recognized by FDA as the official source for established
drug names (See Nomenclature section.)
USP CatalogWhen referenced in a compendial procedure, use of
U
official USPNF Reference Standards promotes uniform quality of
drugs and supports first-, second-, and third-party testing of all manu-
9
factured and compounded articles. The publication listing the collec-
tion of official USPNF Reference Standards can be accessed on the
USP website at www.usp.org and is available in print form by contact-
ing USP Sales and Marketing staff at 301-816-8237. The listing identifies
new items, replacement lots, lots of a single item that are simultane-
ously official, lots deleted from official status, and a preview of items
eventually to be adopted. Purchase order information is included, and
the names of distributors who can facilitate international availability of
these items are suggested. This program benefits from the widespread
voluntary contribution of suitable materials and test data from pharma-
ceutical manufacturers. USP advances this unofficial material to official
status via careful characterization studies and collaborative testing, fol-
lowed by review and, if appropriate, approval by the Reference Stan-
dards Committee of the Council of Experts.
USP Pharmacists Pharmacopeia

Section 2
General Notices and Requirements

S P
T U
he General Notices and Requirements of USP provide guidelines for the

9
interpretation and application of the monographs and general chapters

2 0
in the USP. To assist the pharmacy practitioner, the USP Pharmacists

0
Pharmacopeia provides an unofficial summation of key parts of the General
Notices and Requirements in the following section. This summation is

explanatory only and is not considered to be official text. Following this
summation, the official General Notices and Requirements are provided
verbatim from the USP.
USP Pharmacists Pharmacopeia

Section Contents

USP General Notices and Requirements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/11

S P
9 U
2 0 0

Official text. Reprinted from USP 32NF 27. Section 2, General Notices S3/10
USP Pharmacists Pharmacopeia
General Notices and Requirements
The General Notices and Requirements section (the General Notices)
presents the basic assumptions, definitions, and default conditions for
the interpretation and application of the United States Pharmacopeia
(USP) and the National Formulary (NF).
Requirements stated in these General Notices apply to all articles
recognized in the USP and NF (the compendia) and to all general
chapters unless specifically stated otherwise. Where the requirements
of an individual monograph differ from the General Notices or a gen-
eral chapter, the monograph requirements apply and supersede the
requirements of the General Notices or the general chapter, whether
or not the monograph explicitly states the difference.
1. Title and Revision
The full title of this publication (consisting of three volumes and in-
cluding its Supplements), is The Pharmacopeia of the United States of
America, Thirty-Second Revision and the National Formulary, Twenty-
Seventh Edition. These titles may be abbreviated to United States Phar
macopeia, Thirty-Second Revision (or to USP 32), to NF 27, and to USP
32NF 27. The United States Pharmacopeia, Thirty-Second Revision,
and the National Formulary, Twenty-Seventh Edition, supersede all
earlier revisions. Where the terms USP, NF, or USPNF are used the USP and NF may vary by country, users should understand appli-
without further qualification during the period in which these com-
pendia are official, they refer only to USP 32, NF 27, and any Sup
0
plement(s) thereto. The same titles, with no further distinction, apply
equally to print or electronic presentation of these contents. Although
0
USP and NF are published under one cover and share these General
Notices, they are separate compendia.
2
This revision is official beginning May 1, 2009, unless otherwise
indicated in specific text.
Supplements to USP and NF are published periodically.
Interim Revision Announcements are revisions to USP and NF that
are published in Pharmacopeial Forum. Interim Revision Announce
ments contain official revisions and their effective dates, announce-
ments of the availability of new USP Reference Standards, and an-
nouncements of tests or procedures that are held in abeyance pending
availability of required USP Reference Standards.
Revision Bulletins are revisions to official text or postponements
that require expedited publication. They are published on the USP
website and generally are official immediately unless otherwise speci-
fied in the Revision Bulletin.
Errata are corrections to items erroneously published that have not
received the approval of the Council of Experts and that do not reflect
the official requirements. Errata are effective upon publication.
2. Official Status and Legal Recognition
2.10. Official Text
Official text is text contained in USP and NF, including monographs,
general chapters, and these General Notices. Revisions to official text
are provided in Supplements, Interim Revision Announcements, and
Revision Bulletins. General chapters numbered from 1000 to 1999 are
considered interpretive and are intended to provide information on,
give definition to, or describe a particular subject. They contain no
mandatory requirements applicable to any official article unless spe-
cifically referenced in these General Notices, a monograph, or a gen-
eral chapter numbered below 1000. General chapters numbered above
2000 apply only to articles that are intended for use as dietary ingredi-
ents and dietary supplements.
Official text. Reprinted from USP 32NF 27. Section 2, General Notices S3/11
General Notices
2.20. Official Articles
An official article is an article that is recognized in USP or NF. An article
is deemed to be recognized and included in a compendium when a
monograph for the article is published in the compendium and an of-
ficial date is generally or specifically assigned to the monograph.
The title specified in a monograph is the official title for such arti-
cle. Other names considered to be synonyms of the official titles may
not be used as substitutes for official titles.
Official articles include both official substances and official prod
ucts. An official substance is a drug substance, excipient, dietary ingre-
dient, other ingredient, or component of a finished device for which
the monograph title includes no indication of the nature of the fin-
ished form.
An official product is a drug product, dietary supplement, com-
pounded preparation, or finished device for which a monograph is
provided.
P
2.30. Legal Recognition
S
The USP and NF are recognized in the laws and regulations of many
countries throughout the world. Regulatory authorities may enforce
U
the standards presented in the USP and NF, but because recognition of
cable laws and regulations. More information about the legal status of
9
the USP and NF is provided in the Mission and Preface.
3. Conformance to Standards
3.10. Applicability of Standards
Standards for an article recognized in a USP compendium are ex-
pressed in the articles monograph, applicable general chapters, and
these General Notices. Unless specifically exempted elsewhere in a
compendium, the identity, strength, quality, and purity of an article are
determined by the official tests, procedures, and acceptance criteria,
whether incorporated in the monograph itself, in the General Notices,
or in the applicable general chapters.
The standards in the relevant monograph, general chapter(s), and
General Notices apply at any time in the life of the article from produc-
tion to expiration. The manufacturers specifications, and good manu-
facturing practices generally, are developed and followed to ensure
that the article will comply with compendial standards until its expira-
tion date, when stored as directed. Thus, any official article tested as
directed in the relevant monograph shall comply.
At times, compendial standards take on the character of statistical
procedures, with multiple units involved and perhaps a sequential
procedural design to allow the user to determine that the tested article
meets or does not meet the standard. The similarity to statistical proce-
dures may seem to suggest an intent to make inference to some larger
group of units, but in all cases, statements about whether the compen-
dial standard is met apply only to the units tested. Repeats, replicates,
statistical rejection of outliers, or extrapolations of results to larger
populations, as well as the necessity and appropriate frequency of
batch testing, are neither specified nor proscribed by the compendia.
First-party (manufacturer), second-party (buyer), or third-party (regula-
tor) compliance testing may or may not require examination of addi-
tional specimens, in accordance with predetermined guidelines or
sampling strategies.
Official products other than dietary supplements are prepared
from ingredients that meet USP or NF standards, where standards for
such ingredients exist.
USP Pharmacists Pharmacopeia
Official substances are prepared according to recognized princi-
ples of good manufacturing practice and from ingredients complying
with specifications designed to ensure that the resultant substances
meet the requirements of the compendial monographs.
3.10.10. Applicability of Standards to Drug Products, Drug
Substances, and Excipients
The applicable USP or NF standard applies to any article marketed in
the United States that (1) is recognized in the compendium and (2) is
intended or labeled for use as a drug or as an ingredient in a drug. The
applicable standard applies to such articles whether or not the added
designation USP or NF is used. The standards apply equally to arti-
cles bearing the official titles or names derived by transposition of the
definitive words of official titles or transposition in the order of the
names of two or more active ingredients in official titles.
3.10.20. Applicability of Standards to Medical Devices, Dietary
Supplements, and Their Components and Ingredients
An article recognized in USP or NF shall comply with the compendial
standards if the article is a medical device, component intended for a
medical device, dietary supplement, dietary ingredient, or other ingre-
dient that is intended for incorporation into a dietary supplement, and
is labeled as conforming to the USP or NF.
Generally, dietary supplements are prepared from ingredients that
meet USP, NF, or Food Chemicals Codex standards. Where such stan-
dards do not exist, substances may be used in dietary supplements if
they have been shown to be of acceptable food grade quality using
other suitable procedures.
0
3.20. Indicating Conformance
A drug product, drug substance, or excipient may use the designation
0
USP or NF in conjunction with its official title or elsewhere on the
2
label only when (1) a monograph is provided in the specified compen-
dium and (2) the article complies with the identity prescribed in the
specified compendium.
When a drug product, drug substance, or excipient differs from
the relevant USP or NF standard of strength, quality, or purity, as deter-
mined by the application of the tests, procedures, and acceptance cri-
teria set forth in the relevant compendium, its difference shall be
plainly stated on its label.
When a drug product, drug substance, or excipient fails to comply
with the identity prescribed in USP or NF or contains an added sub-
stance that interferes with the prescribed tests and procedures, the
article shall be designated by a name that is clearly distinguishing and
differentiating from any name recognized in USP or NF.
A medical device, dietary supplement, or ingredient or compo-
nent of a medical device or dietary supplement may use the designa-
tion USP or NF in conjunction with its official title or elsewhere on
the label only when (1) a monograph is provided in the specified com-
pendium and (2) the article complies with the monograph standards
and other applicable standards in the compendium.
The designation USP or NF on the label may not and does not
constitute an endorsement by USP and does not represent assurance
by USP that the article is known to comply with the relevant standards.
USP may seek legal redress if an article purports to be or is represent-
ed as an official article in one of USPs compendia and such claim is
determined by USP not to be made in good faith.
The designation USPNF may be used on the label of an article
provided that the label also bears a statement such as Meets NF stan-
dards as published by USP, indicating the particular compendium to
which the article purports to apply.
When the letters USP, NF, or USPNF are used on the label of chapters may contain the following:
an article to indicate compliance with compendial standards, the let-
ters shall appear in conjunction with the official title of the article. The
Official text. Reprinted from USP 32NF 27. Section 2, General Notices S3/12
General Notices
letters are not to be enclosed in any symbol such as a circle, square,
etc., and shall appear in capital letters.
If a dietary supplement does not comply with all applicable com-
pendial requirements but contains one or more dietary ingredients or
other ingredients that are recognized in USP or NF, the individual
ingredient(s) may be designated as complying with USP or NF stan-
dards or being of USP or NF quality provided that the designation is
limited to the individual ingredient(s) and does not suggest that the
dietary supplement complies with USP standards.
4. Monographs and General Chapters
4.10. Monographs
Monographs set forth the articles name, definition, specification, and
other requirements related to packaging, storage, and labeling. The
specification consists of tests, procedures, and acceptance criteria that
help ensure the identity, strength, quality, and purity of the article. For
general requirements relating to specific monograph sections, see sec-
tion 5, Monograph Components.
P
Because monographs may not provide standards for all relevant
characteristics, some official substances may conform to the USP or NF
S
standard but differ with regard to nonstandardized properties that are
relevant to their use in specific preparations. To assure interchange-
U
ability in such instances, users may wish to ascertain functional equiva-
lence or determine such characteristics before use.
9
4.10.10. Applicability of Test Procedures
A single monograph may include several different tests, procedures,
and/or acceptance criteria that reflect attributes of different manufac-
turers articles. Such alternatives may be presented for different poly-
morphic forms, impurities, hydrates, and dissolution cases. Mono-
graphs indicate the tests, procedures, and/or acceptance criteria to be
used and the required labeling.
4.10.20. Acceptance Criteria
The acceptance criteria allow for analytical error, for unavoidable varia-
tions in manufacturing and compounding, and for deterioration to an
extent considered acceptable under practical conditions. The exis-
tence of compendial acceptance criteria does not constitute a basis for
a claim that an official substance that more nearly approaches 100 per-
cent purity exceeds compendial quality. Similarly, the fact that an ar-
ticle has been prepared to tighter criteria than those specified in the
monograph does not constitute a basis for a claim that the article ex-
ceeds the compendial requirements.
An official product shall be formulated with the intent to provide
100 percent of the quantity of each ingredient declared on the label.
Where the minimum amount of a substance present in a dietary sup-
plement is required by law to be higher than the lower acceptance cri-
terion allowed for in the monograph, the upper acceptance criterion
contained in the monograph may be increased by a corresponding
amount.
The acceptance criteria specified in individual monographs and in
the general chapters for compounded preparations are based on such
attributes of quality as might be expected to characterize an article
compounded from suitable bulk drug substances and ingredients, us-
ing the procedures provided or recognized principles of good com-
pounding practice, as described in these compendia.
4.20. General Chapters
Each general chapter is assigned a number that appears in angle brack-
ets adjacent to the chapter name (e.g., Chromatography 621). General
Descriptions of tests and procedures for application through indi-
vidual monographs,
USP Pharmacists Pharmacopeia
Descriptions and specifications of conditions and practices for
pharmaceutical compounding,
General information for the interpretation of the compendial
requirements,
Descriptions of general pharmaceutical storage, dispensing, and
packaging practices, or
General guidance to manufacturers of official substances or offi-
cial products.
When a general chapter is referenced in a monograph, acceptance
criteria may be presented after a colon.
Some chapters may serve as introductory overviews of a test or of
analytical techniques. They may reference other general chapters that
contain techniques, details of the procedures, and, at times, accep-
tance criteria.
5. Monograph Components
5.10. Molecular Formula
The use of the molecular formula for the active ingredient(s) named in
defining the required strength of a compendial article is intended to
designate the chemical entity or entities, as given in the complete
chemical name of the article, having absolute (100 percent) purity.
5.20. Added Substances, Excipients, and Ingredients
Substances are regarded as unsuitable for inclusion in an official article
and therefore prohibited unless: (1) they do not exceed the minimum
quantity required for providing their intended effect; (2) their presence
0
does not impair the bioavailability, therapeutic efficacy, or safety of
the official article; and (3) they do not interfere with the assays and
0
tests prescribed for determining compliance with the compendial
2
standards.
The air in a container of an official article may, where appropriate,
be evacuated or be replaced by carbon dioxide, helium, argon, or ni-
trogen, or by a mixture of these gases. The use of such gas need not be
declared in the labeling.
5.20.10. Added Substances, Excipients, and Ingredients in Official
Substances
Official substances may contain only the specific added substances
that are permitted by the individual monograph. Where such addition
is permitted, the label shall indicate the name(s) and amount(s) of any
added substance(s).
5.20.20. Added Substances, Excipients, and Ingredients in Official
Products
Suitable substances and excipients such as antimicrobial agents, phar-
maceutical bases, carriers, coatings, flavors, preservatives, stabilizers,
and vehicles may be added to an official product to enhance its stabil-
ity, usefulness, or elegance, or to facilitate its preparation, unless oth-
erwise specified in the individual monograph.
Added substances and excipients employed solely to impart color
may be incorporated into official products other than those intended
for parenteral or ophthalmic use, in accordance with the regulations
pertaining to the use of colors issued by the U.S. Food and Drug Ad-
ministration (FDA), provided such added substances or excipients are
otherwise appropriate in all respects. (See also Added Substances un-
der Injections 1.)
The proportions of the substances constituting the base in oint-
ment and suppository products and preparations may be varied to
maintain a suitable consistency under different climatic conditions,
provided that the concentrations of active ingredients are not varied
and provided that the bioavailability, therapeutic efficacy, and safety of
the preparation are not impaired.
Official text. Reprinted from USP 32NF 27. Section 2, General Notices S3/13
General Notices
5.20.20.1. In Compounded Preparations
Compounded preparations for which a complete composition is given
shall contain only the ingredients named in the formulas unless spe-
cifically exempted herein or in the individual monograph. Deviation
from the specified processes or methods of compounding, although
not from the ingredients or proportions thereof, may occur provided
that the finished preparation conforms to the relevant standards and
to preparations produced by following the specified process.
Where a monograph for a compounded preparation calls for an
ingredient in an amount expressed on the dried basis, the ingredient
need not be dried before use if due allowance is made for the water or
other volatile substances present in the quantity taken.
Specially denatured alcohol formulas are available for use in ac-
cordance with federal statutes and regulations of the Internal Revenue
Service. A suitable formula of specially denatured alcohol may be sub-
stituted for Alcohol in the manufacture of official preparations intend-
ed for internal or topical use, provided that the denaturant is volatile
and does not remain in the finished product. A preparation that is in-
tended for topical application to the skin may contain specially dena-
P
tured alcohol, provided that the denaturant is either a usual ingredient
in the preparation or a permissible added substance; in either case the
S
denaturant shall be identified on the label of the topical preparation.
Where a process is given in the individual monograph, any preparation
compounded using denatured alcohol shall be identical to that pre-
U
pared by the monograph process.
5.20.20.2. In Dietary Supplements
9
Additional ingredients may be added to dietary supplement products
provided that the additional ingredients: (1) comply with applicable
regulatory requirements; and (2) do not interfere with the assays and
tests prescribed for determining compliance with compendial
standards.
5.30. Description and Solubility
Only where a quantitative solubility test is given in a monograph and is
designated as such is it a test for purity.
A monograph may include information regarding the articles de-
scription. Information about an articles description and solubility
also is provided in the reference table Description and Relative Solubil
ity of USP and NF Articles. The reference table merely denotes the
properties of articles that comply with monograph standards. The ref-
erence table is intended primarily for those who use, prepare, and dis-
pense drugs and/or related articles. Although the information provided
in monographs and the information in the reference table may indi-
rectly assist in the preliminary evaluation of an article, it is not intended
to serve as a standard or test for purity.
The approximate solubility of a compendial substance is indicated
by one of the following descriptive terms:
Parts of Solvent Required for
Descriptive Term 1 Part of Solute
Very soluble Less than 1
Freely soluble From 1 to 10
Soluble From 10 to 30
Sparingly soluble From 30 to 100
Slightly soluble From 100 to 1,000
Very slightly soluble From 1,000 to 10,000
Practically insoluble, or Insoluble Greater than or equal to 10,000
5.40. Identification Test
The compendial test titled Identification is provided as an aid in verify-
ing the identity of articles as they are purported to be, e.g., those taken
from labeled containers. Tests presented in the Identification section
shall be used to assist in establishing the identity of the substance but
are not necessarily sufficient to establish proof of identity. Other tests
USP Pharmacists Pharmacopeia
and specifications in the monograph often are necessary to establish
or confirm the identity of an article. Failure of an article to meet the
requirements of a prescribed Identification test may indicate that the
article is mislabeled.
5.50. Assay
Assay tests for compounded preparations are not intended for evaluat-
ing a compounded preparation before dispensing, but instead are in-
tended to serve as the official test in the event of a question or dispute
regarding the preparations conformance to official standards.
5.50.10. Units of Potency (Biological)
For substances that cannot be completely characterized by chemical
and physical means, it may be necessary to express quantities of activ-
ity in biological units of potency, each defined by an authoritative,
designated reference standard.
Units of biological potency defined by the World Health Organiza-
tion (WHO) for International Biological Standards and International
Biological Reference Preparations are termed International Units (IU).
Monographs refer to the units defined by USP Reference Standards as
USP Units. For biological products, units of potency are defined by
the corresponding U.S. Standard established by FDA, whether or not
International Units or USP Units have been defined (see Biologics
1041).
5.60. Impurities and Foreign Substances
Tests for the presence of impurities and foreign substances are pro-
vided to limit such substances to amounts that are unobjectionable
under conditions in which the article is customarily employed (see
0
also Impurities in Official Articles 1086).
Nonmonograph tests and acceptance criteria suitable for detect-
0
ing and controlling impurities that may result from a change in the
2
processing methods or that may be introduced from external sources
should be employed in addition to the tests provided in the indivi-
dual monograph, where the presence of the impurity is inconsistent
with applicable good manufacturing practices or good pharmaceutical
practice.
5.60.10. Other Impurities in USP and NF Articles
If a USP or NF monograph includes an assay or organic impurity test
based on chromatography, other than a test for residual solvents, and
that monograph procedure does not detect an impurity present in the
substance, the amount and identity of the impurity, where both are
known, shall be stated in the labeling (certificate of analysis) of the of-
ficial substance, under the heading Other Impurity(ies).
The presence of any unlabeled other impurity in an official sub-
stance is a variance from the standard if the content is 0.1% or greater.
The sum of all Other Impurities combined with the monograph-de-
tected impurities may not exceed 2.0% (see Ordinary Impurities 466),
unless otherwise stated in the monograph.
The following categories of drug substances are excluded from
Other Impurities requirements:
fermentation products and semi-synthetics derived therefrom,
radiopharmaceuticals,
biologics,
biotechnology-derived products,
peptides,
herbals, and
crude products of animal or plant origin.
Any substance known to be toxic shall not be listed under Other
Impurities.
Official text. Reprinted from USP 32NF 27. Section 2, General Notices S3/14
General Notices
5.60.20. Residual Solvents in USP and NF Articles
All USP and NF articles are subject to relevant control of residual sol-
vents, even when no test is specified in the individual monograph. If
solvents are used during production, they must be of suitable quality.
In addition, the toxicity and residual level of each solvent shall be taken
into consideration, and the solvents limited according to the principles
defined and the requirements specified in Residual Solvents 467, us-
ing the general methods presented therein or other suitable methods.
5.70. Performance Tests
Where content uniformity determinations have been made using the
same analytical methodology specified in the Assay, with appropriate
allowances made for differences in sample preparation, the average of
all of the individual content uniformity determinations may be used as
the Assay value.
5.80. USP Reference Standards
USP Reference Standards are authentic specimens that have been ap-
proved by the USP Reference Standards Expert Committee as suitable
for use as comparison standards in USP or NF tests and assays. (See
P
USP Reference Standards 11.) Current official lots of USP Reference
Standards are published in the USP Reference Standards Catalog.
S
Where a procedure calls for the use of a compendial article rather than
for a USP Reference Standard as a material standard of reference, a
substance meeting all of the compendial monograph requirements for
U
that article shall be used. No new USP or NF standard or procedure
requiring the use of a new USP Reference Standard shall be official
9
until the specified USP Reference Standard is available.
Unless a reference standard label bears a specific potency or con-
tent, assume the reference standard is 100.0% pure in the official ap-
plication. Unless otherwise directed in the procedure in the individual
monograph or in a general chapter, USP Reference Standards are to be
used in accordance with the instructions on the label of the Reference
Standard.
6. Testing Practices and Procedures
6.10. Safe Laboratory Practices
In performing compendial procedures, safe laboratory practices shall
be followed, including precautionary measures, protective equipment,
and work practices consistent with the chemicals and procedures
used. Before undertaking any procedure described in the compendia,
the analyst should be aware of the hazards associated with the chemi-
cals and the techniques and means of protecting against them. These
compendia are not designed to describe such hazards or protective
measures.
6.20. Automated Procedures
Automated and manual procedures employing the same basic chemis-
try are considered equivalent.
6.30. Alternative and Harmonized Methods and Procedures
Alternative methods and/or procedures may be used if they provide
advantages in terms of accuracy, sensitivity, precision, selectivity, or
adaptability to automation or computerized data reduction, or in other
special circumstances. Such alternative procedures and methods shall
be validated as described in the general chapter Validation of Compen
dial Procedures 1225 and must be shown to give equivalent or better
results. Only those results obtained by the methods and procedures
given in the compendium are conclusive.
Alternative procedures should be submitted to USP for evaluation
as a potential replacement or addition to the standard (see section
4.10, Monographs).
USP Pharmacists Pharmacopeia
Certain general chapters contain a statement that the text in ques-
tion is harmonized with the corresponding text of the European Phar
macopoeia and/or the Japanese Pharmacopoeia and that these texts
are interchangeable. Therefore, if a substance or preparation is found
to comply with a requirement using an interchangeable method or
procedure from one of these pharmacopeias, it should comply with
the requirements of the USP. When a difference appears, or in the
event of dispute, only the result obtained by the method and/or proce-
dure given in the USP is conclusive.
6.40. Dried, Anhydrous, Ignited, or Solvent-Free Basis
All calculations in the compendia assume an as-is basis unless other-
wise specified.
Test procedures may be performed on the undried or unignited
substance and the results calculated on the dried, anhydrous, or ignit-
ed basis, provided a test for Loss on drying, or Water, or Loss on igni
tion, respectively, is given in the monograph. Where the presence of
moisture or other volatile material may interfere with the procedure,
previous drying of the substance is specified in the individual mono-
graph and is obligatory.
The term solvent-free signifies that the calculation shall be cor-
rected for the presence of known solvents as determined using the
methods described in Residual Solvents 467 unless a test for limit of
organic solvents is provided in the monograph.
The term previously dried without qualification signifies that the
substance shall be dried as directed under Loss on Drying 731 or Wa
ter Determination 921 (gravimetric determination).
Where drying in vacuum over a desiccant is directed, a vacuum
0
desiccator, a vacuum drying pistol, or other suitable vacuum drying
apparatus shall be used.
0
6.40.10. Ignite to Constant Weight
2
Ignite to constant weight means that ignition shall be continued at
800 25, unless otherwise indicated, until two consecutive weighings,
the second of which is taken after an additional period appropriate to
the nature and quantity of the residue, do not differ by more than 0.50
mg per g of substance taken.
6.40.20. Dried to Constant Weight
Dried to constant weight means that drying shall be continued until
two consecutive weighings, the second of which is taken after an ad-
ditional drying period appropriate to the nature and quantity of the
residue, do not differ by more than 0.50 mg per g of substance taken.
6.50. Preparation of Solutions
6.50.10. Filtration
Where a procedure gives direction to filter without further qualifica-
tion, the liquid shall be passed through suitable filter paper or equiva-
lent device until the filtrate is clear. Due to the possibility of filter ef-
fects, the initial volumes of a filtrate may be discarded.
6.50.20. Solutions
Unless otherwise specified, all solutions shall be prepared with Puri-
fied Water. Solutions for quantitative measures shall be prepared using
accurately weighed or accurately measured analytes (see section 8.20,
About).
An expression such as (1 in 10) means that 1 part by volume of
a liquid shall be diluted with, or 1 part by weight of a solid shall be
dissolved in, a sufficient quantity of the diluent or solvent to make
the volume of the finished solution 10 parts by volume. An expres-
sion such as (20:5:2) means that the respective numbers of parts, by
volume, of the designated liquids shall be mixed, unless otherwise
indicated.
Official text. Reprinted from USP 32NF 27. Section 2, General Notices S3/15
General Notices
6.50.20.1. Adjustments to Solutions
When a specified concentration is called for in a procedure, a solution
of other normality or molarity may be used, provided that allowance is
made for the difference in concentration and that the change does not
increase the error of measurement.
Unless otherwise indicated, analyte concentrations shall be pre-
pared to within ten percent (10%) of the indicated value. In the special
case in which a procedure is adapted to the working range of an in-
strument, solution concentrations may differ from the indicated value
by more than ten percent (10%), with appropriate changes in associat-
ed calculations. Any changes shall fall within the validated range of the
instrument.
When adjustment of pH is indicated with either an acid or base
and the concentration is not indicated, appropriate concentrations of
that acid or base may be used.
6.50.20.2. Test Solutions
Information on Test Solutions (TS) is provided in the Test Solutions
portion of the Reagents, Indicators, and Solutions section of the USP
NF. Use of an alternative Test Solution or a change in the Test Solution
P
used may require validation.
S
6.50.20.3. Indicator Solutions
Where a procedure specifies the use of an indicator TS, approximately
U
0.2 mL, or 3 drops, of the solution shall be added unless otherwise
directed.
9
6.60. Units Necessary to Complete a Test
Unless otherwise specified, a sufficient number of units to ensure a
suitable analytical result shall be taken.
6.60.10. Tablets
Where the procedure of a Tablet monograph directs to weigh and
finely powder not fewer than a given number of Tablets, a counted
number of Tablets shall be weighed and reduced to a powder. The por-
tion of the powdered Tablets taken shall be representative of the
whole Tablets and shall, in turn, be weighed accurately.
6.60.20. Capsules
Where the procedure of a Capsule monograph gives direction to re-
move, as completely as possible, the contents of not fewer than a given
number of the Capsules, a counted number of Capsules shall be care-
fully opened and the contents quantitatively removed, combined,
mixed, and weighed accurately. The portion of mixed Capsules con-
tents taken shall be representative of the contents of the Capsules and
shall, in turn, be weighed accurately.
6.70. Reagents
The proper conduct of the compendial procedures and the reliability
of the results depend, in part, upon the quality of the reagents used in
the performance of the procedures. Unless otherwise specified, re-
agents conforming to the specifications set forth in the current edition
of Reagent Chemicals published by the American Chemical Society
(ACS) shall be used. Where such ACS reagent specifications are not
available or where the required purity differs, compendial specifica-
tions for reagents of acceptable quality are provided (see the Reagents,
Indicators, and Solutions section of the USPNF). Reagents not covered
by any of these specifications should be of a grade suitable to the
proper performance of the method of assay or test involved.
Listing of these reagents, including the indicators and solutions
employed as reagents, in no way implies that they have therapeutic
utility; furthermore, any reference to USP or NF in their labeling shall
include also the term reagent or reagent grade. USP may supply re-
agents if they otherwise may not be generally commercially available.
USP Pharmacists Pharmacopeia
6.80. Equipment
Unless otherwise specified, a specification for a definite size or type of
container or apparatus in a procedure is given solely as a recommen-
dation. Other dimensions or types may be used if they are suitable for
the intended use.
6.80.10. Apparatus for Measurement
Where volumetric flasks or other exact measuring, weighing, or sort-
ing devices are specified, this or other equipment of at least equivalent
accuracy shall be employed.
6.80.10.1. Pipet
Where a pipet is specified, a suitable buret may be substituted. Where
a to contain pipet is specified, a suitable volumetric flask may be
substituted.
6.80.10.2. Light Protection
Where low-actinic or light-resistant containers are specified, either
containers specially treated to protect contents from light or clear con-
tainers that have been rendered opaque by application of a suitable
coating or wrapping may be used.
6.80.20. Instrumental Apparatus
An instrument may be substituted for the specified instrument if the
substitute uses the same fundamental principles of operation and is of
equivalent or greater sensitivity and accuracy. These characteristics
shall be qualified as appropriate. Where a particular brand or source of
a material, instrument, or piece of equipment, or the name and ad-
dress of a manufacturer or distributor, is mentioned (ordinarily in a
footnote), this identification is furnished solely for informational pur-
0
poses as a matter of convenience, without implication of approval, en-
0
dorsement, or certification.
2
6.80.20.1. Chromatographic Tubes and Columns
The term diameter refers to internal diameter (ID).
6.80.20.2. Tubing
The term diameter refers to outside diameter (OD).
6.80.20.3. Steam Bath
Where use of a steam bath is directed, use actively flowing steam or an
other regulated heat source controlled at an equivalent temperature.
6.80.20.4. Water Bath
A water bath requires vigorously boiling water unless otherwise
specified.
7. Test Results
7.10. Interpretation of Requirements
Analytical results observed in the laboratory (or calculated from exper
imental measurements) are compared with stated acceptance criteria to
determine whether the article conforms to compendial requirements.
The reportable value, which often is a summary value for several
individual determinations, is compared with the acceptance criteria.
The reportable value is the end result of a completed measurement
procedure, as documented.
Where acceptance criteria are expressed numerically herein
through specification of an upper and/or lower limit, permitted values
include the specified values themselves, but no values outside the
limit(s). Acceptance criteria are considered significant to the last digit
shown.
7.10.10. Equivalence Statements in Titrimetric Procedures
The directions for titrimetric procedures conclude with a statement of
the weight of the analyte that is equivalent to each mL of the standard-
Official text. Reprinted from USP 32NF 27. Section 2, General Notices S3/16
General Notices
ized titrant. In such an equivalence statement, the number of signifi-
cant figures in the concentration of the titrant should be understood
to correspond to the number of significant figures in the weight of the
analyte. Corrections to calculations based on the blank determination
are to be made for all titrimetric assays where appropriate (see Titrim
etry 541).
7.20. Rounding Rules
The observed or calculated values shall be rounded off to the number
of decimal places that is in agreement with the limit expression. Num-
bers should not be rounded until the final calculations for the report-
able value have been completed. Intermediate calculations (e.g., slope
for linearity) may be rounded for reporting purposes, but the original
(not rounded) value should be used for any additional required calcu-
lations. Acceptance criteria are fixed numbers and are not rounded.
When rounding is required, consider only one digit in the decimal
place to the right of the last place in the limit expression. If this digit is
smaller than 5, it is eliminated and the preceding digit is unchanged. If
this digit is equal to or greater than 5, it is eliminated and the preced-
ing digit is increased by 1.
P
Illustration of Rounding Numerical Values for Comparison
S
with Requirements
U
Unrounded
Compendial Requirement Value Rounded Result Conforms
Assay limit 98.0% 97.96% 98.0% Yes
9
97.92% 97.9% No
97.95% 98.0% Yes
Assay limit 101.5% 101.55% 101.6% No
101.46% 101.5% Yes
101.45% 101.5% Yes
Limit test 0.02% 0.025% 0.03% No
0.015% 0.02% Yes
0.027% 0.03% No
Limit test 3 ppm 3.5 ppm 4 ppm No
3.4 ppm 3 ppm Yes
2.5 ppm 3 ppm Yes
8. Terms and Definitions
8.10. Abbreviations
RS refers to a USP Reference Standard.
CS refers to a Colorimetric Solution.
TS refers to a Test Solution.
VS refers to a Volumetric Solution that is standardized in accor-
dance with directions given in the individual monograph or in the
Reagents, Indicators, and Solutions section of USPNF.
8.20. About
About indicates a quantity within 10%.
If the measurement is stated to be accurately measured or ac-
curately weighed, follow the statements in the general chapters Volu
metric Apparatus 31 and Weights and Balances 41, respectively.
8.30. Alcohol Content
Percentages of alcohol, such as those under the heading Alcohol con
tent, refer to percentage by volume of C2H5OH at 15.56. Where a for-
mula, test, or assay calls for alcohol, ethyl alcohol, or ethanol, the USP
monograph article Alcohol shall be used. Where reference is made to
C2H5OH, absolute (100 percent) ethanol is intended. Where a proce-
dure calls for dehydrated alcohol, alcohol absolute, or anhydrous alco-
hol, the USP monograph article Dehydrated Alcohol shall be used.
USP Pharmacists Pharmacopeia
8.40. Atomic Weights
Atomic weights used in computing molecular weights and the factors
in the assays and elsewhere are those established by the IUPAC Com-
mission on Atomic Weights and Isotopic Abundances.
8.50. Blank Determinations
Where it is directed that any necessary correction be made by a
blank determination, the determination shall be conducted using the
same quantities of the same reagents treated in the same manner as
the solution or mixture containing the portion of the substance under
assay or test, but with the substance itself omitted.
8.60. Concomitantly
Concomitantly denotes that the determinations or measurements
are to be performed in immediate succession.
8.70. Desiccator
The instruction in a desiccator indicates use of a tightly closed con-
tainer of suitable size and design that maintains an atmosphere of low
moisture content by means of a suitable desiccant such as anhydrous
calcium chloride, magnesium perchlorate, phosphorus pentoxide, or
silica gel. See also section 8.220, Vacuum Desiccator.
8.80. Logarithms
Logarithms are to the base 10.
8.90. Microbial Strain
A microbial strain cited and identified by its ATCC catalog number shall
be used directly or, if subcultured, shall be used not more than five
passages removed from the original strain.
0
8.100. Negligible
0
Negligible indicates a quantity not exceeding 0.50 mg.
2
8.110. NLT/NMT
NLT means not less than. NMT means not more than.
8.120. Odor
Odorless, practically odorless, a faint characteristic odor, and of the appropriate water monograph in USP or NF.
variations thereof indicate evaluation of a suitable quantity of freshly
opened material after exposure to the air for 15 minutes. An odor des-
ignation is descriptive only and should not be regarded as a standard
of purity for a particular lot of an article.
8.130. Percent
Percent used without qualification means:
For mixtures of solids and semisolids, percent weight in weight;
For solutions or suspensions of solids in liquids, percent weight in
volume;
For solutions of liquids in liquids, percent volume in volume;
For solutions of gases in liquids, percent weight in volume.
For example, a 1 percent solution is prepared by dissolving 1 g of a
solid or semisolid, or 1 mL of a liquid, in sufficient solvent to make 100
mL of the solution.
8.140. Percentage Concentrations
Percentage concentrations are expressed as follows:
Percent Weight in Weight (w/w) is defined as the number of g of a
solute in 100 g of solution.
Percent Weight in Volume (w/v) is defined as number of g of a sol-
ute in 100 mL of solution.
Percent Volume in Volume (v/v) is defined as the number of mL of
a solute in 100 mL of solution.
Official text. Reprinted from USP 32NF 27. Section 2, General Notices S3/17
General Notices
8.150. Pressure
Pressure is determined by use of a suitable manometer or barometer
calibrated in terms of the pressure exerted by a column of mercury of
the stated height.
8.160. Reaction Time
Reaction time is 5 minutes unless otherwise specified.
8.170. Specific Gravity
Specific gravity is the weight of a substance in air at 25 divided by the
weight of an equal volume of water at the same temperature.
8.180. Temperatures
Temperatures are expressed in centigrade (Celsius) degrees, and all
measurements are made at 25 unless otherwise indicated. Where
moderate heat is specified, any temperature not higher than 45(113F)
is indicated.
8.190. Time
Unless otherwise specified, rounding rules, as described in section
7.20, Rounding Rules, apply to any time specified.
P
8.200. Transfer
S
Transfer indicates a quantitative manipulation.
8.210. Vacuum
U
Vacuum denotes exposure to a pressure of less than 20 mm of mer-
cury (2.67 kPas), unless otherwise indicated.
9
8.220. Vacuum Desiccator
Vacuum desiccator indicates a desiccator that maintains a low-mois-
ture atmosphere at a reduced pressure of not more than 20 mm of
mercury (2.67 kPas) or at the pressure designated in the individual
monograph.
8.230. Water
8.230.10. Water as an Ingredient in an Official Product
As an ingredient in an official product, water meets the requirements
8.230.20. Water in the Manufacture of Official Substances
When used in the manufacture of official substances, water may meet
the requirements for drinking water as set forth in the regulations of
the U.S. Environmental Protection Agency (potable water).
8.230.30. Water in a Compendial Procedure
When water is called for in a compendial procedure, the USP article
Purified Water shall be used unless otherwise specified. Definitions for
High-Purity Water and Carbon DioxideFree Water are provided in Con
tainersGlass 660. Definitions of other types of water are provided in
Water for Pharmaceutical Purposes 1231.
8.240. Weights and Measures
In general, weights and measures are expressed in the International
System of Units (SI) as established and revised by the Confrence g
nrale des poids et mesures. For compendial purposes, the term
weight is considered to be synonymous with mass.
Molality is designated by the symbol m preceded by a number
that represents the number of moles of the designated solute con-
tained in 1 kilogram of the designated solvent.
Molarity is designated by the symbol M preceded by a number
that represents the number of moles of the designated solute con-
tained in an amount of the designated solvent that is sufficient to pre-
pare 1 liter of solution.
Normality is designated by the symbol N preceded by a number
that represents the number of equivalents of the designated solute
contained in an amount of the designated solvent that is sufficient to
prepare 1 liter of solution.
USP Pharmacists Pharmacopeia
Symbols commonly employed for SI metric units and other units
are as follows:
Bq = becquerel dL = deciliter
kBq = kilobecquerel L = liter
MBq = megabecquerel mL = milliliterc
GBq = gigabecquerel L = microliter
Ci = curie Eq = gram-equivalent weight
mCi = millicurie mEq = milliequivalent
Ci = microcurie mol = gram-molecular weight (mole)
nCi = nanocurie Da = dalton (relative molecular mass)
Gy = gray mmol = millimole
mGy = milligray Osmol = osmole
m = meter mOsmol = milliosmole
dm = decimeter Hz = hertz
cm = centimeter kHz = kilohertz
mm = millimeter MHz = megahertz
m = micrometer (0.001mm) V = volts
nm = nanometera MeV = million electron volts
kg = kilogram keV = kilo-electron volt
g = gram mV = millivolt
mg = milligram psi = pounds per square inch
g; mcg = microgramb Pa = pascal
ng = nanogram kPa = kilopascal
pg = pictogram g = gravity (in centrifugation)
fg = femtogram Articles intended for sale without prescription are also required to
a
reviously the symbol m (for millimicron) was used.
P
b
One milliliter (mL) is used herein as the equivalent of one cubic centimeter (cc).
c
The symbol g is used in the USP and NF to represent micrograms, but micrograms
may be represented as mcg for labeling and prescribing purposes. The term
gamma, symbolized by , frequently is used to represent micrograms in biochemi-
cal literature.
0
0
9. Prescribing and Dispensing
2
9.10 Use of Metric Units
Prescriptions for compendial articles shall be written to state the quan-
tity and/or strength desired in metric units unless otherwise indicated
in the individual monograph (see also Units of Potency, section 5.50.10
above). If an amount is prescribed by any other system of measure-
ment, only an amount that is the metric equivalent of the prescribed
amount shall be dispensed. Apothecary unit designations on labels
and labeling shall not be used.
9.20 Changes in Volume
In the dispensing of prescription medications, slight changes in vol-
ume owing to variations in room temperatures may be disregarded.
10. Preservation, Packaging, Storage,
and Labeling
10.10. Storage Under Nonspecific Conditions
If no specific directions or limitations are provided in the Packaging
and Storage section of an individual USP monograph or in the labeling
of an article recognized in USP, the conditions of storage shall include
storage at controlled room temperature, protection from moisture,
and, where necessary, protection from light. Such articles shall be pro-
tected from moisture, freezing, and excessive heat, and, where neces-
sary, from light during shipping and distribution. Drug substances are
exempt from the requirements in this paragraph.
Regardless of quantity, where no specific storage directions or
limitations are provided in an individual NF monograph or stated in
the labeling of an article recognized in NF, the conditions of storage
and distribution shall include protection from moisture, freezing, ex-
cessive heat, and, where necessary, from light.
Official text. Reprinted from USP 32NF 27. Section 2, General Notices S3/18
General Notices
10.20. Containers
The container is that which holds the article and is or may be in direct
contact with the article. The immediate container is that which is in di-
rect contact with the article at all times. The closure is a part of the
container.
Before being filled, the container should be clean. Special precau-
tions and cleaning procedures may be necessary to ensure that each
container is clean and that extraneous matter is not introduced into or
onto the article.
The container does not interact physically or chemically with the
article placed in it so as to alter the strength, quality, or purity of the
article beyond the official requirements.
The compendial requirements for the use of specified containers
apply also to articles as packaged by the pharmacist or other dispenser,
unless otherwise indicated in the individual monograph.
10.20.10. Tamper-Evident Packaging
The container or individual carton of a sterile article intended for oph-
thalmic or otic use, except where extemporaneously compounded for
P
immediate dispensing on prescription, shall be so sealed that the con-
tents cannot be used without obvious destruction of the seal.
S
comply with the tamper-evident packaging and labeling requirements
of the FDA where applicable.
U
Preferably, the immediate container and/or the outer container or
protective packaging used by a manufacturer or distributor for all dos-
9
age forms that are not specifically exempt is designed so as to show
evidence of any tampering with the contents.
10.20.20. Light-Resistant Container
A light-resistant container (see Light Transmission Test under Contain
ersPerformance Testing 671) protects the contents from the effects
of light by virtue of the specific properties of the material of which it is
composed, including any coating applied to it. Alternatively, a clear and
colorless or a translucent container may be made light-resistant by
means of an opaque covering, in which case the label of the container
bears a statement that the opaque covering is needed until the con-
tents are to be used or administered. Where it is directed to protect
from light in an individual monograph, preservation in a light-resis-
tant container is intended.
Where an article is required to be packaged in a light-resistant
container, and if the container is made light-resistant by means of an
opaque covering, a single-use, unit-dose container or mnemonic pack
for dispensing may not be removed from the outer opaque covering
before dispensing.
10.20.30. Well-Closed Container
A well-closed container protects the contents from extraneous solids
and from loss of the article under the ordinary or customary condi-
tions of handling, shipment, storage, and distribution.
10.20.40. Tight Container
A tight container protects the contents from contamination by extrane-
ous liquids, solids, or vapors; from loss of the article; and from efflo-
rescence, deliquescence, or evaporation under the ordinary or cus-
tomary conditions of handling, shipment, storage, and distribution;
and is capable of tight reclosure. Where a tight container is specified,
it may be replaced by a hermetic container for a single dose of an
article.
A gas cylinder is a metallic container designed to hold a gas under
pressure. As a safety measure, for carbon dioxide, cyclopropane, heli-
um, nitrous oxide, and oxygen, the Pin-Index Safety System of matched
fittings is recommended for cylinders of Size E or smaller.
USP Pharmacists Pharmacopeia
[noteWhere packaging and storage in a tight container or a well-
closed container is specified in the individual monograph, the con-
tainer used for an article when dispensed on prescription meets the
requirements under ContainersPerformance Testing 671.]
10.20.50. Hermetic Container
A hermetic container is impervious to air or any other gas under the
ordinary or customary conditions of handling, shipment, storage, and
distribution.
10.20.60. Single-Unit Container
A single-unit container is one that is designed to hold a quantity of
drug product intended for administration as a single dose or a single
finished device intended for use promptly after the container is
opened. Preferably, the immediate container and/or the outer contain-
er or protective packaging shall be so designed as to show evidence of
any tampering with the contents. Each single-unit container shall be
labeled to indicate the identity, quantity and/or strength, name of the
manufacturer, lot number, and expiration date of the article.
10.20.70. Single-Dose Container
A single-dose container is a single-unit container for articles intended
for parenteral administration only. A single-dose container is labeled as
such. Examples of single-dose containers include prefilled syringes,
cartridges, fusion-sealed containers, and closure-sealed containers
when so labeled. (See also Containers for Injections under Injections
1.)
10.20.80. Unit-Dose Container
A unit-dose container is a single-unit container for articles intended
0
for administration by other than the parenteral route as a single dose,
0
direct from the container.
10.20.90. Unit-of-Use Container
2
A unit-of-use container is one that contains a specific quantity of a
drug product and that is intended to be dispensed as such without
further modification except for the addition of appropriate labeling. A
unit-of-use container is labeled as such.
10.20.100. Multiple-Unit Container
A multiple-unit container is a container that permits withdrawal of suc-
cessive portions of the contents without changing the strength, quality,
or purity of the remaining portion.
10.20.110. Multiple-Dose Container
A multiple-dose container is a multiple-unit container for articles in-
tended for parenteral administration only. (See also Containers for In
jections under Injections 1).
10.20.120. Requirements under the Poison Prevention Packaging Act
(PPPA)
This act (see the website, www.cpsc.gov/businfo/pppa.html) requires
special packaging of most human oral prescription drugs, oral con-
trolled drugs, certain non-oral prescription drugs, certain dietary sup-
plements, and many over-the-counter (OTC) drug preparations in or-
der to protect the public from personal injury or illness from misuse of
these preparations (16 CFR 1700.14).
The immediate packaging of substances regulated under the PPPA
shall comply with the special packaging standards (16 CFR 1700.15
and 16 CFR 1700.20). The PPPA regulations for special packaging apply
to all packaging types including reclosable, nonclosable, and unit-dose
types.
Special packaging is not required for drugs dispensed within a
hospital setting for inpatient administration. Manufacturers and pack-
agers of bulk-packaged prescription drugs do not have to use special
packaging if the drug will be repackaged by the pharmacist. PPPA-regu-
lated prescription drugs may be dispensed in nonchild-resistant
Official text. Reprinted from USP 32NF 27. Section 2, General Notices S3/19
General Notices
packaging upon the request of the purchaser or when directed in a le-
gitimate prescription (15 U.S.C. 1473).
Manufacturers or packagers of PPPA-regulated OTC preparations
are allowed to package one size in nonchild-resistant packaging as
long as popular-size, special packages are also supplied. The non
child-resistant package requires special labeling (16 CFR 1700.5).
Various types of child-resistant packages are covered in ASTM In-
ternational Standard D-3475, Standard Classification of Child-Resistant
Packaging. Examples are included as an aid in the understanding and
comprehension of each type of classification.
10.30. Storage Temperature and Humidity
Specific directions are stated in some monographs with respect to the
temperatures and humidity at which official articles shall be stored and
distributed (including the shipment of articles to the consumer) when
stability data indicate that storage and distribution at a lower or a
higher temperature and a higher humidity produce undesirable re-
sults. Such directions apply except where the label on an article states
a different storage temperature on the basis of stability studies of that
particular formulation. Where no specific storage directions or limita-
P
tions are provided in the individual monograph, but the label of an ar-
ticle states a storage temperature that is based on stability studies of
S
that particular formulation, such labeled storage directions apply. (See
also Pharmaceutical Stability 1150.) The conditions are defined by the
U
following terms.
10.30.10. Freezer
9
Freezer indicates a place in which the temperature is maintained
thermostatically between 25 and 10 (13 and 14F).
10.30.20. Cold
Any temperature not exceeding 8 (46F) is cold. A refrigerator is a
cold place in which the temperature is maintained thermostatically
between 2 and 8 (36 and 46F).
10.30.30. Cool
Any temperature between 8 and 15 (46 and 59F) is cool. An article
for which storage in a cool place is directed may, alternatively, be
stored and distributed in a refrigerator, unless otherwise specified by
the individual monograph.
10.30.40. Controlled Cold Temperature
Controlled cold temperature is defined as temperature maintained
thermostatically between 2 and 8 (36 and 46F), that allows for excur-
sions in temperature between 0 and 15 (32 and 59F) that may be
experienced during storage, shipping, and distribution such that
the allowable calculated mean kinetic temperature is not more than 8
(46F). Transient spikes up to 25 (77F) may be permitted if the manu-
facturer so instructs and provided that such spikes do not exceed 24
hours unless supported by stability data or the manufacturer instructs
otherwise.
10.30.50. Room Temperature
Room temperature indicates the temperature prevailing in a working
area.
10.30.60. Controlled Room Temperature
Controlled room temperature indicates a temperature maintained
thermostatically that encompasses the usual and customary working
environment of 20 to 25 (68 to 77F); that results in a mean kinetic
temperature calculated to be not more than 25; and that allows for
excursions between 15 and 30 (59 and 86F) that are experienced in
pharmacies, hospitals, and warehouses. Provided the mean kinetic
temperature remains in the allowed range, transient spikes up to 40
are permitted as long as they do not exceed 24 hours. Spikes above 40
may be permitted if the manufacturer so instructs. Articles may be la-
beled for storage at controlled room temperature or at up to 25, or
USP Pharmacists Pharmacopeia
other wording based on the same mean kinetic temperature. The
mean kinetic temperature is a calculated value that may be used as an
isothermal storage temperature that simulates the nonisothermal ef-
fects of storage temperature variations. (See also Pharmaceutical Sta
bility 1150.)
An article for which storage at controlled room temperature is di-
rected may, alternatively, be stored and distributed in a cool place, un-
less otherwise specified in the individual monograph or on the label.
10.30.70. Warm
Any temperature between 30 and 40 (86 and 104F) is warm.
10.30.80. Excessive Heat
Excessive heat means any temperature above 40 (104F). istration of drugs, the quantity of active ingredient when expressed in
10.30.90. Protection From Freezing
Where, in addition to the risk of breakage of the container, freezing
subjects an article to loss of strength or potency, or to destructive al-
teration of its characteristics, the container label bears an appropriate
instruction to protect the article from freezing.
10.30.100. Dry Place
The term dry place denotes a place that does not exceed 40% aver-
age relative humidity at Controlled Room Temperature or the equiva-
lent water vapor pressure at other temperatures. The determination
may be made by direct measurement at the place or may be based on
reported climatic conditions. Determination is based on not less than
12 equally spaced measurements that encompass either a season, a
year, or, where recorded data demonstrate, the storage period of the
article. There may be values of up to 45% relative humidity provided
0
that the average value is 40% relative humidity.
0
Storage in a container validated to protect the article from mois-
ture vapor, including storage in bulk, is considered storage in a dry
2
place.
10.40. Labeling
The term labeling designates all labels and other written, printed, or
graphic matter upon an immediate container of an article or upon, or
in, any package or wrapper in which it is enclosed, except any outer
shipping container. The term label designates that part of the label-
ing upon the immediate container.
A shipping container containing a single article, unless such con-
tainer is also essentially the immediate container or the outside of the
consumer package, is labeled with a minimum of product identifica-
tion (except for controlled articles), lot number, expiration date, and
conditions for storage and distribution.
Articles in these compendia are subject to compliance with such
labeling requirements as may be promulgated by governmental bodies
in addition to the compendial requirements set forth for the articles.
10.40.10. Amount of Ingredient Per Dosage Unit
The strength of a drug product is expressed on the container label in
terms of micrograms or milligrams or grams or percentage of the ther-
apeutically active moiety or drug substance, whichever form is used in
the title, unless otherwise indicated in an individual monograph. Both
the active moiety and drug substance names and their equivalent
amounts are then provided in the labeling.
Official articles in capsule, tablet, or other unit dosage form shall
be labeled to express the quantity of each active ingredient or recog-
nized nutrient contained in each such unit; except that, in the case of
unit-dose oral solutions or suspensions, whether supplied as liquid
preparations or as liquid preparations that are constituted from solids
upon addition of a designated volume of a specific diluent, the label
shall express the quantity of each active ingredient or recognized nu-
Official text. Reprinted from USP 32NF 27. Section 2, General Notices S3/20
General Notices
trient delivered under the conditions prescribed in Deliverable Volume
698. Official drug products not in unit dosage form shall be labeled to
express the quantity of each active ingredient in each milliliter or in
each gram, or to express the percentage of each such ingredient (see
8.140., Percentage Concentrations), except that oral liquids or solids
intended to be constituted to yield oral liquids may, alternatively, be
labeled in terms of each 5-mL portion of the liquid or resulting liquid.
Unless otherwise indicated in a monograph or chapter, such declara-
tions of strength or quantity shall be stated only in metric units. See
also 5.50.10., Units of Potency (Biological).
10.40.20. Use of Leading and Terminal Zeros
To help minimize the possibility of errors in the dispensing and admin-
whole numbers shall be shown without a decimal point that is fol-
lowed by a terminal zero (e.g., express as 4 mg [not 4.0 mg]). The quan-
tity of active ingredient when expressed as a decimal number smaller
than 1 shall be shown with a zero preceding the decimal point (e.g.,
express as 0.2 mg [not .2 mg]).
10.40.30. Labeling of Salts of Drugs
P
It is an established principle that official articles shall have only one
S
official title. For purposes of saving space on labels, and because
chemical symbols for the most common inorganic salts of drugs are
well known to practitioners as synonymous with the written forms, the
U
following alternatives are permitted in labeling official articles that are
salts: HCl for hydrochloride; HBr for hydrobromide; Na for sodium;
9
and K for potassium. The symbols Na and K are intended for use in ab-
breviating names of the salts of organic acids, but these symbols are
not used where the word Sodium or Potassium appears at the begin-
ning of an official title (e.g., Phenobarbital Na is acceptable, but Na Sa-
licylate is not to be written).
10.40.40. Labeling Vitamin-Containing Products
The vitamin content of an official drug product shall be stated on the
label in metric units per dosage unit. The amounts of vitamins A, D,
and E may be stated also in USP Units. Quantities of vitamin A declared
in metric units refer to the equivalent amounts of retinol (vitamin A al-
cohol). The label of a nutritional supplement shall bear an identifying
lot number, control number, or batch number.
10.40.50. Labeling Botanical-Containing Products
The label of an herb or other botanical intended for use as a dietary
supplement bears the statement, If you are pregnant or nursing a
baby, seek the advice of a health professional before using this
product.
10.40.60. Labeling Parenteral and Topical Preparations
The label of a preparation intended for parenteral or topical use states
the names of all added substances (see 5.20., Added Substances, Ex
cipients, and Ingredients and see Labeling under Injections 1), and, in
the case of parenteral preparations, also their amounts or proportions,
except that for substances added for adjustment of pH or to achieve
isotonicity, the label may indicate only their presence and the reason
for their addition.
10.40.70. Labeling Electrolytes
The concentration and dosage of electrolytes for replacement therapy
(e.g., sodium chloride or potassium chloride) shall be stated on the la-
bel in milliequivalents (mEq). The label of the product shall indicate
also the quantity of ingredient(s) in terms of weight or percentage
concentration.
10.40.80. Labeling Alcohol
The content of alcohol in a liquid preparation shall be stated on the
label as a percentage (v/v) of C2H5OH.
USP Pharmacists Pharmacopeia
10.40.90. Special Capsules and Tablets
The label of any form of Capsule or Tablet intended for administration
other than by swallowing intact bears a prominent indication of the
manner in which it shall be used.
10.40.100. Expiration Date and Beyond-Use Date
The label of an official drug product or nutritional or dietary supple-
ment product shall bear an expiration date. All articles shall display the
expiration date so that it can be read by an ordinary individual under
customary conditions of purchase and use. The expiration date shall
be prominently displayed in high contrast to the background or sharp-
ly embossed, and easily understood (e.g., EXP 6/08, Exp. June 08, or aging the dosage forms shall afford better protection than polyvinyl
Expires 6/08). [noteFor additional information and guidance, refer
to the Consumer Healthcare Products Associations Voluntary Codes
and Guidelines of the Self-Medication Industry.]
The monographs for some preparations state how the expiration
date that shall appear on the label shall be determined. In the absence
of a specific requirement in the individual monograph for a drug prod-
uct or nutritional supplement, the label shall bear an expiration date
assigned for the particular formulation and package of the article, with
the following exception: the label need not show an expiration date in
the case of a drug product or nutritional supplement packaged in a
container that is intended for sale without prescription and the label-
ing of which states no dosage limitations, and which is stable for not
less than 3 years when stored under the prescribed conditions.
Where an official article is required to bear an expiration date,
such article shall be dispensed solely in, or from, a container labeled
with an expiration date, and the date on which the article is dispensed
0
shall be within the labeled expiry period. The expiration date identifies
the time during which the article may be expected to meet the require-
0
ments of the compendial monograph, provided it is kept under the
2
prescribed storage conditions. The expiration date limits the time dur-
ing which the article may be dispensed or used. Where an expiration
date is stated only in terms of the month and the year, it is a represen-
tation that the intended expiration date is the last day of the stated
month. The beyond-use date is the date after which an article shall not
be used. The dispenser shall place on the label of the prescription
container a suitable beyond-use date to limit the patients use of the
article based on any information supplied by the manufacturer and the
General Notices. The beyond-use date placed on the label shall not be
later than the expiration date on the manufacturers container.
For articles requiring constitution before use, a suitable beyond-
use date for the constituted product shall be identified in the labeling.
For all other dosage forms, in determining an appropriate period
of time during which a prescription drug may be retained by a patient
after its dispensing, the dispenser shall take into account, in addition
to any other relevant factors, the nature of the drug; the container in
which it was packaged by the manufacturer and the expiration date
thereon; the characteristics of the patients container, if the article is
repackaged for dispensing; the expected storage conditions to which
the article may be exposed; any unusual storage conditions to which
the article may be exposed; and the expected length of time of the
course of therapy. The dispenser shall, on taking into account the fore-
going, place on the label of a multiple-unit container a suitable be-
yond-use date to limit the patients use of the article. Unless otherwise
specified in the individual monograph, or in the absence of stability
Official text. Reprinted from USP 32NF 27. Section 2, General Notices S3/21
General Notices
data to the contrary, such beyond-use date shall be not later than (a)
the expiration date on the manufacturers container, or (b) 1 year from
the date the drug is dispensed, whichever is earlier. For nonsterile solid
and liquid dosage forms that are packaged in single-unit and unit-dose
containers, the beyond-use date shall be 1 year from the date the drug
is packaged into the single-unit or unit-dose container or the expira-
tion date on the manufacturers container, whichever is earlier, unless
stability data or the manufacturers labeling indicates otherwise.
The dispenser shall maintain the facility where the dosage forms
are packaged and stored, at a temperature such that the mean kinetic
temperature is not greater than 25. The plastic material used in pack-
chloride, which does not provide adequate protection against mois-
ture permeation. Records shall be kept of the temperature of the facil-
ity where the dosage forms are stored, and of the plastic materials
used in packaging.
10.40.100.1. Compounded Preparations
The label on the container or package of an official compounded
preparation shall bear a beyond-use date. The beyond-use date is the
P
date after which a compounded preparation is not to be used. Because
compounded preparations are intended for administration immedi-
S
ately or following short-term storage, their beyond-use dates may be
assigned based on criteria different from those applied to assigning
U
expiration dates to manufactured drug products.
The monograph for an official compounded preparation typically
includes a beyond-use requirement that states the time period follow-
9
ing the date of compounding during which the preparation, properly
stored, may be used. In the absence of stability information that is ap-
plicable to a specific drug and preparation, recommendations for
maximum beyond-use dates have been devised for nonsterile com-
pounded drug preparations that are packaged in tight, light-resistant
containers and stored at controlled room temperature unless other-
wise indicated (see Stability Criteria and Beyond-Use Dating under
Stability of Compounded Preparations in the general test chapter Phar
maceutical CompoundingNonsterile Preparations 795).
10.50. Guidelines for Packaging and Storage Statements in USPNF
Monographs
In order to provide users of the USP and NF with proper guidance on
how to package and store official articles, every monograph in the USP
and NF shall have a packaging and storage specification.
For the packaging portion of the statement, the choice of contain-
ers is given in this section 10, Preservation, Packaging, Storage, and La
beling, and includes Light-Resistant Container, Well-Closed Container,
Tight Container, Hermetic Container, Single-Unit Container, Single-
Dose Container, Unit-Dose Container, and Unit-of-Use Container. For
most preparations, the choice is determined by the container in which
it shall be dispensed (e.g., tight, well-closed, hermetic, unit-of-use,
etc.). For drug substances, the choice would appear to be tight, well-
closed, or, where needed, a light-resistant container. For excipients,
given their typical nature as large-volume commodity items, with con-
tainers ranging from drums to tank cars, a well-closed container is an
appropriate default. Therefore, in the absence of data indicating a
need for a more protective class of container, the phrase Preserve in
well-closed containers should be used as a default for excipients.
USP Pharmacists Pharmacopeia

Section 3
Drug Substance and Compounded
Preparation Monographs

S P
T
9 U
he USP Pharmacists Pharmacopeia contains two types of official USPNF

0
monographs: compounded preparation monographs and monographs for

0
drug substances and ingredients.

2
Monographs for 127 compounded preparations are provided to help pharma-
cists ensure that a patient consistently receives a preparation that meets USP

standards. For the most part, these monographs have been tested to meet USP
standards of strength, quality, and purity until the stated beyond-use date (BUD).
In some instances, data from articles published in peer-reviewed scientific jour-
nals have been used for this purpose. (For additional information on BUD, see
general chapter Pharmaceutical CompoundingNonsterile Preparations 795.)
As outlined in the Federal Food, Drug, and Cosmetic Act (see section 11) any
compounded drug must meet compendial (USPNF) standards, if it uses the
compendial name. Pharmacists must be aware that if they prepare medications
that are named in the official USPNF (and provided here in the USP
Pharmacists Pharmacopeia), those products must meet the USPNF standards
for strength, quality and purity.
This section also includes abridged versions of the official USP and NF mono-
graphs for drug substances and ingredients that may be used in compounding.
While it is not expected that all compounding pharmacists will be able to
perform the procedures found herein, the standards in these monographs are
useful for evaluating Certificates of Analysis. A list of functional categories for
excipients also is provided at the end of this section.
USP Pharmacists Pharmacopeia
Section Contents
rAlbumin Human . . . . . . . . . . . . . . S3/24
Alendronate Sodium Tablets . . . . S3/24
Alfadex . . . . . . . . . . . . . . . . . . . . . . . . S3/24
Alfuzosin Hydrochloride . . . . . . . . S3/24
Aminophylline . . . . . . . . . . . . . . . . . S3/25
Betadex . . . . . . . . . . . . . . . . . . . . . . . S3/25
Bicalutamide Tablets . . . . . . . . . . . . S3/25
Bupivacaine Hydrochloride . . . . . S3/25
Cabergoline . . . . . . . . . . . . . . . . . . . S3/25
Carbomer 934 . . . . . . . . . . . . . . . . . . S3/26
Carbomer 934P . . . . . . . . . . . . . . . . . S3/26
Carbomer 940 . . . . . . . . . . . . . . . . . . S3/26
0
Carbomer 941 . . . . . . . . . . . . . . . . . . S3/27
0
Carbomer Copolymer . . . . . . . . . . S3/27
2
Carbomer Homopolymer . . . . . . . S3/27
Carbomer Interpolymer . . . . . . . . S3/28
Cefdinir . . . . . . . . . . . . . . . . . . . . . . . . S3/28
Cefdinir Capsules . . . . . . . . . . . . . . S3/28
Cefdinir for Oral Suspension . . . . S3/29
Corn Syrup . . . . . . . . . . . . . . . . . . . . S3/29
Didanosine . . . . . . . . . . . . . . . . . . . . S3/29
Dimethyl Sulfoxide . . . . . . . . . . . . . S3/29
Dronabinol . . . . . . . . . . . . . . . . . . . . S3/29
Dyclonine Hydrochloride . . . . . . . S3/29
Erythorbic Acid . . . . . . . . . . . . . . . . S3/30
Fenofibrate Capsules . . . . . . . . . . . S3/30
Flavoxate Hydrochloride . . . . . . . . S3/30
Flavoxate Hydrochloride
Tablets . . . . . . . . . . . . . . . . . . . . . . S3/30
Formoterol Fumarate . . . . . . . . . . . S3/30
Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/23
Foscarnet Sodium . . . . . . . . . . . . . . S3/30
Liquid Glucose . . . . . . . . . . . . . . . . . S3/31
Glyceryl Monooleate . . . . . . . . . . . S3/31
Granisetron Hydrochloride . . . . . S3/31
Iopamidol . . . . . . . . . . . . . . . . . . . . . S3/31
Isopropyl Alcohol . . . . . . . . . . . . . . S3/31
Lecithin . . . . . . . . . . . . . . . . . . . . . . . S3/31
P
Lisinopril and Hydrochlorothiazide
Tablets . . . . . . . . . . . . . . . . . . . . . . S3/32
S
Mirtazapine Orally Disintegrating
U
Tablets . . . . . . . . . . . . . . . . . . . . . . S3/32
9
Pantoprazole Sodium . . . . . . . . . . . S3/32
Pantoprazole Sodium Delayed-
Release Tablets . . . . . . . . . . . . . . S3/32
Piperazine Adipate . . . . . . . . . . . . . . S3/32
Piperazine Dihydrochloride . . . . . S3/32
Piperazine Phosphate . . . . . . . . . . . S3/33
Polyvinyl Alcohol . . . . . . . . . . . . . . . S3/33
Potassium Bromide Oral Solution,
Veterinary . . . . . . . . . . . . . . . . . . . S3/33
Prednisolone Sodium
Phosphate . . . . . . . . . . . . . . . . . . S3/33
Propofol Injectable Emulsion . . . . S3/33
Propylene Glycol Monolaurate . . S3/34
Sodium Bromide Injection,
Veterinary . . . . . . . . . . . . . . . . . . . S3/34
Sodium Bromide Oral Solution,
Veterinary . . . . . . . . . . . . . . . . . . . S3/34
Tamsulosin Hydrochloride . . . . . . S3/34
USP and NF Excipients,
Listed by Category . . . . . . . . . . . S3/35
USP Pharmacists Pharmacopeia rAlbumin

rAlbumin Human Alfadex

source: NF source: NF

(C6H10O5)6 972.84
C2936H4624N786O889S41 66,438 Da Alpha cyclodextrin [10016-20-3].

Recombinant Albumin Human (rHA) is produced by recombi- Alfadex is composed of six alpha-(1-4) linked d-glucopyranosyl
nant DNA expression in Saccharomyces cerevisiae. Structural units. It contains not less than 98.0 percent and not more than
equivalence (primary, secondary, and tertiary) between rHA and 101.0 percent of (C6H10O5)6, calculated on the anhydrous basis.
human serum albumin (HSA) has been demonstrated. It con-

P
sists of 3 domains composed of 585 amino acids containing a Packaging and storagePreserve in tight containers. No storage require-
ments specified.
single tryptophan (Trp214), one free thiol (Cys34), and 17 disulfide

bridges. It is presented as a sterile and nonpyrogenic aqueous
liquid consisting of a 10 percent (w/v) or 20 percent (w/v) solu-
S
USP Reference standards 11USP Alpha Cyclodextrin RS. USP Beta Cy-
clodextrin RS. USP Gamma Cyclodextrin RS. USP Dextrose RS.
pH 791The pH of the mixture of 30 mL of its aqueous solution (1 in 100)

U
tion in Water for Injection. No human- or animal-derived raw
and 1 mL of Potassium chloride solution is 5.0 to 8.0.
material is involved in its manufacture. Not less than 99 percent
of its total protein is albumin. It contains not less than 95 per- Potassium chloride solutionTransfer 22.4 g of potassium chloride

9
into a 100-mL volumetric flask, and dilute with water to volume.
cent and not more than 105 percent of the labeled amount. It

0
contains no added antimicrobial agents, but it may contain ap-
propriate stabilizing agents. Alfuzosin Hydrochloride

0
The presence of process-related impurities, host cell DNA, and source: USP
host cell proteins is process specific; suitable limits should be

2
determined by appropriately validated methods. However, the
limit for host cell proteins should be not more than 0.15 ppm
(0.15 mg per g).

Packaging and storagePreserve in tight glass containers, and store be-
tween 2 and 8. Do not freeze. C19H27N5O4HCl 425.91
LabelingLabel it to indicate that the material is of recombinant DNA 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)-
origin. methylamino]propyl]tetrahydro-, monohydrochloride ().
USP Reference standards 11USP rAlbumin Human RS. USP Endotoxin ()-N-[3-[(4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]-
RS. tetrahydro-2-furamide monohydrochloride [81403- 68-1].
Bacterial endotoxins 85It contains not more than 0.5 USP Endotoxin Unit
RS per mL. Alfuzosin Hydrochloride contains not less than 99.0 percent
Sterility 71: meets the requirements. and not more than 101.0 percent of C19H27N5O4HCl, calculated
pH 791: between 6.4 and 7.4 when diluted with 0.9% (w/v) sodium chlo- on the anhydrous basis.
ride to obtain a solution containing 1% (w/v) protein.
Packaging and storagePreserve in tight, well-closed containers, protected
from light and humidity. Store at room temperature.
Alendronate Sodium Tablets USP Reference standards 11USP Alfuzosin Hydrochloride RS. USP Alfu-
zosin System Suitability Mixture RS.
source: USP
pH 791: between 4.0 and 5.5
Alendronate Sodium Tablets contain an amount of Alendro- Test solution: 20 mg per mL, in carbon dioxide-free water.
nate Sodium equivalent to not less than 90.0 percent and not
more than 110.0 percent of the labeled amount of alendronic
acid (C4H13NO7P2).
Packaging and storagePreserve in tight containers. Store between 15
and 30.
LabelingThe labeling indicates weekly dosing where appropriate. When
more than one Dissolution test is given, the labeling states the test used
only if Test 1 is not used.
USP Reference standards 11USP Alendronate Sodium RS.
Uniformity of dosage units 905: meet the requirements.

Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/24
USP Pharmacists Pharmacopeia
Aminophylline
source: USP
C16H24N10O4 (anhydrous) 420.43
1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, compd. with 1,2-
ethanediamine (2:1).
Theophylline compound with ethylenediamine (2:1) [317-34-0].
Dihydrate 456.46 [5897-66-5].
Aminophylline is anhydrous or contains not more than two
molecules of water of hydration. It contains not less than 84.0
percent and not more than 87.4 percent of anhydrous theophyl-
line (C7H8N4O2), calculated on the anhydrous basis.
Packaging and storagePreserve in tight containers.
LabelingLabel it to indicate whether it is anhydrous or hydrous and also
to state the content of anhydrous theophylline.
USP Reference standards 11USP Theophylline RS.
Betadex
source: NF
0
2 0
(C6H10O5)7 1134.98
Beta Cyclodextrin [7585-39-9].
Betadex is a nonreducing cyclic compound composed of
seven alpha-(1-4) linked d-glucopyranosyl units. It contains not
less than 98.0 percent and not more than 102.0 percent of
(C6H10O5)7, calculated on the anhydrous basis.
Packaging and storagePreserve in tight containers. No storage require-
ments specified.
USP Reference standards 11USP Alpha Cyclodextrin RS. USP Beta Cy-
clodextrin RS. USP Gamma Cyclodextrin RS. USP Dextrose RS.
pH 791Add 0.1 mL of a saturated solution of potassium chloride to 10
mL of Betadex aqueous solution (1 in 100). The pH of the solution is be-
tween 5.0 and 8.0.
Bicalutamide Tablets
source: USP
Bicalutamide Tablets contain not less than 90.0 percent and
not more than 110.0 percent of the labeled amount of bicaluta-
mide (C18H14F4N2O4S).
Packaging and storagePreserve in tight containers. Store at controlled
room temperature.
Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/25
Aminophylline
USP Reference standards 11USP Bicalutamide RS. USP Bicalutamide
Related Compound B RS.
Uniformity of dosage units 905: meet the requirements.
procedure for content uniformity
1% Sodium lauryl sulfate solutionDissolve 15 g of sodium
lauryl sulfate in 1.5 L of water.
Standard solutionDissolve an accurately weighed quantity of
USP Bicalutamide RS in a minimum amount of tetrahydrofuran, and
dilute quantitatively with 1% Sodium lauryl sulfate solution to obtain a
solution having a known concentration of about 0.05 mg per ml.
Test solutionTransfer 1 Tablet to a 100-mL volumetric flask, add about
10 mL of water, and sonicate for approximately 30 minutes. Add about
80 mL of tetrahydrofuran, and sonicate for 30 minutes to complete dissolu-
tion of the bicalutamide. Allow to cool to room temperature, and dilute
with tetrahydrofuran to volume. Pass this solution through a 0.45-mm suit-
able filter unit, transfer 10.0 mL of filtrate to a 100-mL volumetric flask, and
dilute with 1% Sodium lauryl sulfate solution to volume.
ProcedureConcomitantly determine the UV absorbances of the
Standard solution and the Test solution with a suitable spectrophotometer
at 270 nm, using 1% Sodium lauryl sulfate solution as the blank. Calculate
the quantity, in mg, of bicalutamide (C18H14F4N2O4S) in the Tablet taken by
P
the formula:
S
1000C(AU/AS)
in which C is the concentration, in mg per mL, of USP Bicalutamide RS in
the Standard solution; and AU and AS are the absorbances obtained from
U
the Test solution and the Standard solution, respectively.
9
Bupivacaine Hydrochloride
source: USP
C18H28N2OHClH2O 342.90
2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-,
monohydrochloride, monohydrate, ()-.
()-1-Butyl-2',6'-pipecoloxylidide monohydrochloride,
monohydrate [73360-54-0].
Anhydrous 324.90 [18010-40-7].
Bupivacaine Hydrochloride contains not less than 98.5 percent
and not more than 101.5 percent of C18H28N2OHCl, calculated
on the anhydrous basis.
Packaging and storagePreserve in well-closed containers.
USP Reference standards 11USP Bupivacaine Hydrochloride RS.
pH 791: between 4.5 and 6.0, in a solution (1 in 100).
Cabergoline
source: USP
C26H37N5O2 451.60
Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-[(ethyl-
amino)carbonyl]-6-(2-propenyl)-.
1-[(6-Allylergolin-8-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-
ethylurea [81409-90-7].
USP Pharmacists Pharmacopeia
Cabergoline contains not less than 98.0 percent and not more
than 102.0 percent of C26H37N5O2, calculated on the anhydrous
basis.
Packaging and storageStore in tight containers, protected from light.
USP Reference standards 11USP Cabergoline RS.
Carbomer 934
(Any article currently titled Carbomer 934 that is manufactured with-
out the use of benzene will be officially titled Carbomer Homopoly-
mer after January 1, 2011, and will meet the requirements of the new
Carbomer Homopolymer monograph after January 1, 2007.)
source: NF
Carbomer 934 is a high molecular weight polymer of acrylic
acid cross-linked with allyl ethers of sucrose. Carbomer 934,
previously dried in vacuum at 80 for 1 hour, contains not less
than 56.0 percent and not more than 68.0 percent of carboxylic
acid (COOH) groups. The viscosity of a neutralized 0.5 percent
aqueous dispersion of Carbomer 934 is between 30,500 and
39,400 mPas.
[noteEffective January 1, 2011, the heading of this monograph
will no longer constitute the official title for Carbomer 934
manufactured without the use of benzene. When benzene is
not used in the manufacturing process, the name of the article
will be Carbomer Homopolymer and will meet the require-
ments of the Carbomer Homopolymer monograph.]
0
Packaging and storagePreserve in tight containers. No storage require-
0
ments specified.
LabelingLabel it to indicate that it is not intended for internal use. A car-
2
bomer homopolymer manufactured using benzene and complying with
the unique requirements of this monograph will be officially titled Car-
bomer 934 and will not be referred to as Carbomer Homopolymer.
ViscosityProceed as directed in the test for Viscosity under Carbomer
934P. It is between 30,500 and 39,400 mPas.
Carbomer 934P
(Any article currently titled Carbomer 934P that is manufactured with-
out the use of benzene will be officially titled Carbomer Homopoly-
mer after January 1, 2011, and will meet the requirements of the new
Carbomer Homopolymer monograph after January 1, 2007.)
source: NF
Carbomer 934P is a high molecular weight polymer of acrylic
acid cross-linked with allyl ethers of sucrose or pentaerythritol.
Carbomer 934P, previously dried in vacuum at 80 for 1 hour,
contains not less than 56.0 percent and not more than 68.0 per-
cent of carboxylic acid (COOH) groups. The viscosity of a
neutralized 0.5 percent aqueous dispersion of Carbomer 934P
is between 29,400 and 39,400 mPas.
[noteEffective January 1, 2011, the heading of this monograph
will no longer constitute the official title for Carbomer 934P
manufactured without the use of benzene. When benzene is
not used in the manufacturing process, the name of the article
will be Carbomer Homopolymer and will meet the require-
ments of the Carbomer Homopolymer monograph.]
Packaging and storagePreserve in tight containers. No storage require-
ments specified.
LabelingA carbomer homopolymer manufactured using benzene and
complying with the unique requirements of this monograph will be
officially titled Carbomer 934P and will not be referred to as Carbomer
Homopolymer.
Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/26
Carbomer
Viscosity 911Carefully add 2.50 g, previously dried in a vacuum at 80 for
1 hour, to 500 mL of water in a 1000-mL beaker, while stirring continuously
at 1000 10 rpm, with the stirrer shaft set at an angle of 60 and to one side
of the beaker, with the propeller positioned near the bottom of the beaker.
Allow 45 to 90 seconds for addition of the test preparation at a uniform rate,
being sure that loose aggregates of powder are broken up, and continue
stirring at 1000 10 rpm for 15 minutes. Remove the stirrer, and place the
beaker containing the dispersion in a 25 0.1 water bath for 30 minutes.
Insert the stirrer to a depth necessary to ensure that air is not drawn into
the dispersion, and, while stirring at 300 10 rpm, titrate (see Titrimetry
541) with a calomel-glass electrode system to a pH of between 7.3 and 7.8
by adding sodium hydroxide solution (18 in 100) below the surface, deter-
mining the endpoint potentiometrically. Stir for 2 to 3 minutes until neutral-
ization is complete. Then determine the final pH. [noteIf the pH is below
7.3, raise it with additional sodium hydroxide. If it is above 7.8, discard the
mucilage, and prepare another using a smaller amount of sodium hydrox-
ide for titration.] Return the neutralized mucilage to the 25 water bath for
1 hour. Measure the pH again and make certain that the mucilage pH is
between 7.3 and 7.8. Perform the viscosity determination without delay to
avoid slight viscosity changes that occur 75 minutes after neutralization.
Equip a suitable rotational viscometer with a spindle having a cylinder 1.5
cm in diameter and 0.2 cm high attached to a shaft 0.3 cm in diameter, the
P
distance from the top of the cylinder to the lower tip of the shaft being 3.0
cm. The spindle rotates at 20 rpm at an immersion depth of 4.9 cm. Follow
S
the instrument manufacturers directions to measure the apparent viscos-
ity: the viscosity is between 29,400 and 39,400 mPas.
U
Carbomer 940
9
(Any article currently titled Carbomer 940 that is manufactured with-
out the use of benzene will be officially titled Carbomer Homopoly-
mer after January 1, 2011, and will meet the requirements of the new
Carbomer Homopolymer monograph after January 1, 2007.)
source: NF
Carbomer 940 is a high molecular weight polymer of acrylic
acid cross-linked with allyl ethers of pentaerythritol. Carbomer
940, previously dried in vacuum at 80 for 1 hour, contains not
less than 56.0 percent and not more than 68.0 percent of carbox-
ylic acid (COOH) groups. The viscosity of a neutralized 0.5
percent aqueous dispersion of Carbomer 940 is between 40,000
and 60,000 mPas.
[noteEffective January 1, 2011, the heading of this monograph
will no longer constitute the official title for Carbomer 940
manufactured without the use of benzene. When benzene is
not used in the manufacturing process, the name of the article
will be Carbomer Homopolymer and will meet the require-
ments of the Carbomer Homopolymer monograph.]
Packaging and storagePreserve in tight containers. No storage require-
ments specified.
LabelingLabel it to indicate that it is not intended for internal use. A car-
bomer homopolymer manufactured using benzene and complying with
the unique requirements of this monograph will be officially titled Car-
bomer 940 and will not be referred to as Carbomer Homopolymer.
ViscosityProceed as directed in the test for Viscosity under Carbomer
934P, except to use a spindle having a shaft about 0.3 cm in diameter, the
distance from the top of the shaft to the lower tip of the shaft being 5.0 cm,
and the immersion depth being 5.5 cm.1 The viscosity is between 40,000 and
60,000 mPas.
Available as an RV7 spindle from Brookfield, or the equivalent.
1
USP Pharmacists Pharmacopeia Carbomer

Carbomer 941
(Any article currently titled Carbomer 941 that is manufactured with-
out the use of benzene will be officially titled Carbomer Homopoly-
mer after January 1, 2011, and will meet the requirements of the new
Carbomer Homopolymer monograph after January 1, 2007.)
source: NF
Carbomer 941 is a high molecular weight polymer of acrylic
acid cross-linked with allyl ethers of pentaerythritol. Carbomer
941, previously dried in vacuum at 80 for 1 hour, contains not
less than 56.0 percent and not more than 68.0 percent of carbox-
ylic acid (COOH) groups. The viscosity of a neutralized 0.5
percent aqueous dispersion of Carbomer 941 is between 4000
and 11,000 mPas.
[noteEffective January 1, 2011, the heading of this monograph
will no longer constitute the official title for Carbomer 941
manufactured without the use of benzene. When benzene is
not used in the manufacturing process, the name of the article
will be Carbomer Homopolymer and will meet the require-
If benzene is not used in the manufacturing process, label it to indicate
whether it is Type A, B, or C; and label it to state the measured viscosity,
giving the viscosity measurement parameters, concentration of the solu-
tion and the type of equipment used, the solvent or solvents used in the
polymerization process, and the nominal and residual solvent levels for
each solvent.
Viscosity 911Carefully add 5.00 g of Carbomer Copolymer, previously
dried in vacuum at 80 for 1 hour, to 500 mL of water in a 1000-mL beaker,
while stirring continuously at 1000 50 rpm, with the stirrer shaft set to one
side of the beaker at an angle of 60 and the propeller positioned near the
bottom of the beaker. The stirrer used is a three-blade, 2-inch diameter
marine impeller. Add the Carbomer Copolymer at a uniform rate over a
period of 45 to 90 seconds, being sure that loose aggregates of powder are
broken up, and continue stirring at 1000 50 rpm for 15 minutes. Remove
the stirrer, and place the beaker containing the dispersion in a 25 0.1
water bath for 30 minutes. Insert a paddle stirrer to a depth necessary to
ensure that air is not drawn into the dispersion, and while stirring at 300
25 rpm, titrate potentiometrically (see Titrimetry 541) with a calomelglass
electrode system to a pH between 7.3 and 7.8 by adding sodium hydroxide
solution (18 in 100) below the surface. Stir 2 to 3 minutes until neutraliza-
tion is complete. Then determine the final pH. [noteIf the pH is below
7.3, raise the pH with additional sodium hydroxide. If it is above 7.8, discard

P
ments of the Carbomer Homopolymer monograph.]
the mucilage, and prepare another batch, using a smaller amount of sodi-
um hydroxide for titration.] Return the beaker containing the neutralized

Packaging and storagePreserve in tight containers. No storage require-
ments specified.
LabelingLabel it to indicate that it is not intended for internal use. A car-
S
mucilage to the 25 0.1 water bath for 1 hour. Measure the pH again, mak-
ing certain that the mucilage pH is between 7.3 and 7.8. Using a rotational

U
viscometer equipped with a suitable spindle at a spindle immersion depth
bomer homopolymer manufactured using benzene and complying with
as defined in Table 1 (where A is the cylinder diameter, in cm; B is the cyl-
the unique requirements of this monograph will be officially titled Car-
inder height, in cm; C is the shaft diameter, in cm; D is the distance, in cm,
bomer 941 and will not be referred to as Carbomer Homopolymer.

9
from the top of the cylinder to the lower tip of the shaft; and E is the spin-
ViscosityProceed as directed in the test for Viscosity under Carbomer dle immersion depth, in cm), perform the viscosity determination with-

0
934P, except to use a spindle having a disk about 2.1 cm in diameter and 0.2 out delay to avoid the slight viscosity changes that occur 75 minutes after
cm high, attached to a shaft 0.3 cm in diameter, the distance from the top neutralization.

0
of the disk to the lower tip of the shaft being 2.7 cm, and the immersion
With the spindle rotating at 20 rpm, observe and record the scale read-
depth being 4.9 cm1. The viscosity is between 4000 and 11,000 mPas.
ing. Calculate the viscosity, in millipascal seconds, by multiplying the scale

2
reading by the constant for the spindle used at 20 rpm. The viscosity value
so obtained is within the limits specified in Table 2.
Carbomer Copolymer

source: NF
Carbomer Copolymer is a high molecular weight copolymer
of acrylic acid and a long chain alkyl methacrylate cross-linked
with allyl ethers of polyalcohols.
[noteThe heading of this monograph does not constitute the
official title for a Carbomer Copolymer manufactured with
the use of benzene. When benzene is used in the manufactur-
ing process, the name will be Carbomer 1342, provided it com-
plies with the existing requirements in the Carbomer 1342
monograph.]
Packaging and storagePreserve in tight containers, at a temperature not
exceeding 45.
LabelingIf benzene has been used in the manufacturing process, the
name of the article will be Carbomer 1342, provided it complies with and is
labeled in accordance with the requirements set forth in that monograph.
1
Available as an RV5 spindle from Brookfield, or the equivalent.
Table 2
Carbomer Copolymer 1% Viscosity Specification (mPas)
A 450013,500
B 10,00029,000
C 25,00045,000
Carbomer Homopolymer
(Title for this new monographto become official January 1, 2011)
(Prior to January 1, 2011, the current practice of labeling the article of
commerce with the name Carbomer 934, Carbomer 934P, Carbomer
940, or Carbomer 941, whichever is appropriate, may be continued.)
source: NF
Carbomer Homopolymer is a high molecular weight polymer
of acrylic acid cross-linked with allyl ethers of polyalcohols.
Carbomer Homopolymer, previously dried, contains not less
than 56.0 percent and not more than 68.0 percent of carboxylic
acid (COOH) groups.

Table 1
Viscosity Ranges (mPas) Spindle No. A B C D E Multiplier
100400 1 5.6 2.2 0.3 2.7 6.1 5
4001600 2 4.7 0.2 0.3 2.7 4.9 20
10004000 3 3.5 0.2 0.3 2.7 4.9 50
20008000 4 2.7 0.2 0.3 2.7 4.9 100
400016,000 5 2.1 0.2 0.3 2.7 4.9 200
10,00040,000 6 1.5 0.2 0.3 3.0 4.9 500
40,000160,000 7 0.3 5.5 2,000

Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/27
USP Pharmacists Pharmacopeia
[noteThis monograph applies to, but is not limited to, Car-
bomer 934, Carbomer 934P, Carbomer 940, and Carbomer 941
manufactured without benzene. The heading of this mono-
graph does not constitute the official title for a Carbomer Ho-
mopolymer manufactured with the use of benzene. When
benzene is used in the manufacturing process, the name of the
article will be Carbomer 934, Carbomer 934P, Carbomer 940, or
Carbomer 941, whichever is appropriate.]
Packaging and storagePreserve in tight containers, at a temperature not
exceeding 45.
LabelingLabel it to indicate whether it is Type A, B, or C; and also to state
the measured viscosity, giving the viscosity measurement parameters, the
concentration of the solution, and the type of equipment used; the solvent
or solvents used in the polymerization process; and the nominal and re-
sidual solvent levels for each solvent.
Viscosity 911Carefully add 2.50 g of the resin, which has been previ-
ously dried, to 500 mL of water in a 800-mL beaker, while stirring continu-
ously at 1000 50 rpm. The stirrer shaft is set at an angle of 60 and posi-
tioned at one side of the beaker, and the propeller is positioned near the
bottom of the beaker. The stirrer used should be a three-blade, 2-inch
marine impeller. Add Carbomer Homopolymer at a uniform rate over a
period of 45 to 60 seconds, being sure that loose aggregates of powder are
broken up, and continue stirring at 1000 50 rpm for 15 minutes. [note
Proper dispersion of the Carbomer Homopolymer resin is imperative for
accurate viscosity readings.] Remove the stirrer, and allow the beaker con-
taining the dispersion to stand at controlled room temperature for 30
minutes. Insert a paddle stirrer to a depth necessary to ensure that the air
is not drawn into the dispersion, and while stirring at 300 25 rpm, titrate
potentiometrically (see Titrimetry 541) with sodium hydroxide solution (18
0
in 100) to a pH of between 7.3 and 7.8. After adding the sodium hydroxide
solution, stir with a paddle mixer at 300 25 rpm for 2 to 3 minutes. [note
0
After neutralization, care must be taken to avoid excessively high shearing,
as aggressive mixing will break the polymer chains and reduce the viscos-
2
ity reading.] Take the final pH reading with a pH meter to make sure it is
between 7.3 and 7.8. [noteIf the pH is below 7.3, raise the pH with addi-
tional sodium hydroxide. If the pH is above 7.8, discard the mucilage, and
prepare another using a smaller amount of sodium hydroxide for titration.]
Place the neutralized mucilage into a water bath maintained at 25 0.1 for
1 hour. Measure the pH again, and make certain the mucilage pH is be-
tween 7.3 and 7.8. Perform the viscosity determination without delay to
avoid slight viscosity changes occurring after 75 minutes of neutralization.
Equip a suitable rotational viscometer1 with a suitable spindle, as defined
in the chart below. For spindle dimensions, consult the table under
Carbomer Copolymer.
Expected Viscosity (mPas) Spindle Number Multiplier
100400 1 5
4001600 2 20
10004000 3 50
20008000 4 100
400016,000 5 200
10,00040,000 6 500
40,000160,000 7 2000
The spindle rotates at 20 rpm. Follow the instrument manufacturers direc-
tions to measure the apparent viscosity. The viscosity values, determined
by the conditions specified herein, are within the limits specified in the
accompanying table.
Carbomer Homopolymer Viscosity Specified (mPas)
A 4,00011,000
B 25,00045,000
C 40,00060,000
1
Available as a Brookfield RV viscometer, or the equivalent.
Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/28
Carbomer
Carbomer Interpolymer
source: NF
Carbomer Interpolymer is a carbomer homopolymer or copoly
mer that contains a block copolymer of polyethylene glycol and
a long chain alkyl acid ester.
Packaging and storagePreserve in tight containers, at a temperature not
exceeding 45.
LabelingLabel it to indicate whether it is Type A, B, or C. Also label it to
state the measured viscosity, giving the viscosity measurement parameters,
the concentration of the solution, and the type of equipment used; the
solvent or solvents used in the polymerization process; and the nominal
and measured residual solvent levels for each solvent.
Viscosity 911
Carbomer Interpolymer AProceed as directed for Viscosity under
Carbomer Copolymer, except to perform the test on a 0.5% aqueous disper-
sion prepared by using 2.50 g instead of 5.00 g of copolymer.
Carbomer Interpolymer BProceed as directed for Viscosity under
Carbomer Copolymer, except to adjust the pH of the dispersion to a range
P
of 5.8 to 6.3 instead of 7.3 to 7.8.
Carbomer Interpolymer CProceed as directed for Viscosity under
S
Carbomer Copolymer, except to perform the test on a 0.5% aqueous disper-
sion prepared by using 2.50 g instead of 5.00 g of copolymer and to adjust
the pH of the dispersion to a range of 5.8 to 6.3 instead of 7.3 to 7.8. The
U
viscosity values, determined by the conditions specified herein, are within
the limits specified in the accompanying table.
9
Carbomer Interpolymer Viscosity Specifications (mPas)
A 45,00065,000
B 47,00077,000
C 8,50016,500
Cefdinir
source: USP
C14H13N5O5S2 395.41
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-
thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-,
[6R-[6,7(Z)]]-.
(-)-(6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-vinyl-5-
thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 72-(Z)-
oxime [91832-40-5].
Cefdinir contains not less than 960 mg per mg and not more
than 1020 mg per mg of C14H13N5O5S2, calculated on the anhy-
drous basis.
Packaging and storagePreserve in tight, light-resistant containers.
USP Reference standards 11USP Cefdinir RS. USP Cefdinir Related Com-
pound A RS.
Cefdinir Capsules
source: USP
Cefdinir Capsules contain not less than 90.0 percent and not
more than 110.0 percent of the labeled amount ofC14H13N5O5S2.
Packaging and storagePreserve in tight, light-resistant containers, and
store at controlled room temperature.
USP Pharmacists Pharmacopeia Cefdinir

USP Reference standards 11USP Cefdinir RS. USP Cefdinir Related Com- Dimethyl Sulfoxide
pound A RS. USP Cefdinir Related Compound B RS.
source: USP
Uniformity of dosage units 905: meet the requirements.

Cefdinir for Oral Suspension

source: USP
Cefdinir for Oral Suspension contains not less than 90.0 per-
cent and not more than 110.0 percent of the labeled amount of
C14H13N5O5S2. It may contain one or more suitable buffers, fla-
vors, preservatives, stabilizing agents, sweeteners, and suspend-
ing agents.
Packaging and storagePreserve in tight, light-resistant containers, and
store at controlled room temperature.
LabelingThe label specifies the directions for the constitution of the
powder and states the equivalent amount of C14H13N5O5S2 in a given volume
of Oral Suspension after constitution.
USP Reference standards 11USP Cefdinir RS. USP Cefdinir Related Com-
pound A RS. USP Cefdinir Related Compound B RS.
C2H6OS 78.13
Methane, sulfinylbis-.
Methyl sulfoxide [67-68-5].
Dimethyl Sulfoxide contains not less than 99.9 percent of
C2H6OS, calculated on the anhydrous basis.
Packaging and storagePreserve in tight, light-resistant containers.
USP Reference standards 11USP Dimethyl Sulfoxide RS.
Specific gravity 841: between 1.095 and 1.101.
Refractive index 831: between 1.4755 and 1.4775.
Dronabinol

P
source: USP
Uniformity of dosage units 905For Oral Suspension packaged in single-

S
unit containers: meets the requirements.
pH 791: between 3.5 and 4.5.

U
Corn Syrup

9
source: NF C21H30O2 314.46
[8029-43-4]. 6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-

0
pentyl-, (6aR-trans)-.
Corn Syrup is an aqueous solution of saccharides obtained by

0
(6aR,10aR)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-
partial hydrolysis of edible corn starch by food grade acids and/ dibenzo[b,d]-pyran-1-ol [1972-08-3].
or enzymes. It contains not less than 20.0 percent reducing

2
sugar content (dextrose equivalent) expressed as d-glucose, Dronabinol is D9-tetrahydrocannabinol. It contains not less
calculated on the dried basis. than 95.0 percent of C21H30O2.

Packaging and storagePreserve in tightly closed containers. No storage Packaging and storagePreserve in tight, light-resistant glass containers in
requirements are specified. inert atmosphere. Store as per labeling instructions.
LabelingLabel it to indicate its nominal dextrose equivalent. Label it also USP Reference standards 11USP Exo-tetrahydrocannabinol RS. USP 9-
to indicate the presence of sulfur dioxide if the residual concentration is Tetrahydrocannabinol RS.
greater than 10 g per g.
USP Reference standards 11USP Dextrose RS.
Dyclonine Hydrochloride
source: USP
Didanosine
source: USP

C10H12N4O3 236.23
Inosine, 2',3'-dideoxy-.
2',3'-Dideoxyinosine [69655-05-6].
Didanosine contains not less than 98.0 percent and not more
than 102.0 percent of C10H12N4O3, calculated on the anhydrous
basis.
Packaging and storagePreserve in well-closed containers, and store at
controlled room temperature.
USP Reference standards 11USP Didanosine RS. USP Didanosine Re-
lated Compound A RS. USP Didanosine Related Compound B RS. USP Di-
danosine System Suitability Mixture RS.
C18H27NO2HCl 325.87
1-Propanone, 1-(4-butoxyphenyl)-3-(1-piperidinyl)-hydrochloride.
4'-Butoxy-3-piperidinopropiophenone hydrochloride [536-43-6].
Dyclonine Hydrochloride contains not less than 98.0 percent
and not more than 102.0 percent of C18H27NO2HCl, calculated
on the dried basis.
Packaging and storagePreserve in tight, light-resistant containers.
USP Reference standards 11USP Dyclonine Hydrochloride RS.
Melting range 741: between 173 and 178.
pH 791: between 4.0 and 7.0, in a solution (1 in 100).

Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/29
USP Pharmacists Pharmacopeia Erythorbic

Erythorbic Acid Packaging and storagePreserve in well-closed containers, protected from

light, and store at room temperature.
source: NF
USP Reference standards 11USP Flavoxate Hydrochloride RS. USP Fla-
voxate Related Compound A RS.

Flavoxate Hydrochloride Tablets

C6H8O6 176.13
o-Araboascorbic acid.
d-Erythro-hex-2-enoic acid delta-lactone.
Isoascorbic acid, d-isoascorbic acid. [89-65-6].
Erythorbic Acid contains not less than 99.0 percent and not
more than the equivalent of 100.5 percent of C6H8O6, calculated
on the dried basis.
Packaging and storagePreserve in tight, light-resistant containers.
USP Reference standards 11USP Erythorbic Acid RS.
source: USP
Flavoxate Hydrochloride Tablets contain not less than 90.0
percent and not more than 110.0 percent of C24H25NO4HCl,
based on the label claim.
Packaging and storagePreserve in well-closed containers, protected from
light.
USP Reference standards 11USP Flavoxate Hydrochloride RS. USP Fla-
voxate Related Compound A RS.
Uniformity of dosage units 905: meet the requirements.

Fenofibrate Capsules Formoterol Fumarate

P
source: USP source: USP

S
Fenofibrate Capsules contain not less than 90.0 percent and
not more than 110.0 percent of the labeled amount of fenofi-

U
brate (C20H21ClO4).
Packaging and storagePreserve in well-closed containers, and store at

9
controlled room temperature.
LabelingWhen more than one Dissolution test is given, the labeling

0
states the test used only if Test 1 is not used.
(C19H24N2O4)2C4H4O4 2H2O 840.91

0
USP Reference standards 11USP Fenofibrate RS. USP Fenofibrate Re-
lated Compound B RS. ()-2'-Hydroxy-5'-[(R*)-1-hydroxy-2-[[(R*)-p-methoxy--methyl-

2
Uniformity of dosage units 905: meet the requirements.
procedure for content uniformity
Buffer solution pH 2.9, Mobile phase, Standard preparation, and Chro-
phenethyl]amino]ethyl]formanilide fumarate (2:1) (salt),
dihydrate [43229-80-7].
Formoterol Fumarate contains not less than 98.5 percent and

matographic systemProceed as directed In the Assay.
Test solutionPlace 1 Capsule in a suitable volumetric flask, add Buf-
fer solution pH 2.9 to 10% to 20% of the final volume, and stir for 20 min-
utes to disintegrate the Capsule. Fill the flask to about 80% with methanol,
sonicate for 10 minutes, stir for 15 minutes, and dilute with methanol to
volume to obtain a solution having a known concentration of about 0.4 to
0.7 mg of fenofibrate per mL, based on the label claim. Quantitatively dilute
an aliquot with Mobile phase, to obtain a solution having a known concen-
tration of about 0.06 to 0.07 mg per mL, and pass it through a 0.45-um PVDF
filter, discarding the first 5 mL.
ProcedureProceed as directed in the Assay, except to inject the Test
solution instead of the Assay preparation.
not more than 101.5 percent of (C19H24N2O4)2C4H4O4, calculated
on the anhydrous basis.
Packaging and storagePreserve in well-closed, light-resistant containers.
LabelingThe labeling states with which Content of related compound I
the test article complies if a test other than Content of related compound I,
Test 1 is used.
USP Reference standards 11USP Formoterol Fumarate RS. USP For-
moterol Fumarate System Suitability Mixture RS. USP Formoterol Fumarate
Resolution Mixture RS.
pH 791: between 5.5 and 6.5, in a solution in water containing 1 mg per
mL.

Flavoxate Hydrochloride Foscarnet Sodium

source: USP source: USP

C24H25NO4HCl 427.92
4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-
piperidinyl)ethyl ester, hydrochloride.
2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-
carboxylate hydrochloride [3717-88-2].
Flavoxate Hydrochloride contains not less than 98.0 percent
and not more than 102.0 percent of C24H25NO4HCl, calculated
on the dried basis.
CNa3O5P6H2O 300.04
Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt,
hexahydrate.
Phosphonoformic acid, trisodium salt, hexahydrate [34156-56-4].
Foscarnet Sodium contains not less than 98.5 percent and not
more than 101.0 percent of CNa3O5P, calculated on the dried
basis.
Packaging and storagePreserve in tight, light-resistant containers. Store
at room temperature.

Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/30
USP Pharmacists Pharmacopeia
USP Reference standards 11USP Foscarnet Sodium RS. USP Foscarnet
Related Compound B RS. USP Foscarnet Related Compound D RS.
pH 791: between 9.0 and 11.0, in a carbon dioxide-free aqueous solution
containing 20 mg of Foscarnet Sodium per mL.
Liquid Glucose
source: NF
[8027-56-3].
Liquid Glucose is a product obtained by the incomplete hy-
drolysis of starch. It consists chiefly of dextrose, dextrins, malt-
ose, and water.
Packaging and storagePreserve in tightly closed containers. No storage
requirements specified.
LabelingLabel it to indicate the natural source of starch. Label it to indi-
cate its nominal dextrose equivalent.
USP Reference standards 11USP Dextrose RS.
Glyceryl Monooleate
source: NF
Oleic acid, 2,3-dihydroxypropyl ester, ().
(RS)-1-Glyceryl oleate 356.54 [25496-72-4].
Glyceryl Monooleate is a mixture of monoglycerides, mainly
glyceryl monooleate, together with variable quantities of diglyc-
erides and triglycerides. It is obtained by partial glycerolysis of
0
vegetable oil that consists mainly of triglycerides of oleic acid,
or by esterification of glycerol with oleic acid of vegetable or
0
animal origin. It is defined by the nominal content of monoglyc-
2
erides, and the assay requirements differ as set forth in the ac-
companying table. A suitable antioxidant may be added.
Nominal Content of
Monoglycerides (%)
40 60 90
Monoglycerides 32.052.0 55.065.0 90.0101.0
Diglycerides 30.050.0 15.035.0 <10.0
Triglycerides 5.020.0 2.010.0 <2.0
Packaging and storagePreserve in tight containers. No storage require-
ments specified.
LabelingThe labeling indicates the nominal content of monoglycerides
and the name and the concentration of any added antioxidant.
USP Reference standards 11USP Glyceryl Monooleate 40% RS. USP Gly-
ceryl Monooleate 90% RS.
Granisetron Hydrochloride
source: USP
C18H24N4OHCl 348.87
1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-
azabicyclo[3.3.1]non-3-yl)-, monohydrochloride, endo-.
1-Methyl-N-(9-methyl-endo-9-azabicyclo[3.3.1]non-3-yl)-1H-indazole-3-
carboxamide monohydrochloride [107007-99-8].
Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/31
Glucose
Granisetron Hydrochloride contains not less than 97.0 percent
and not more than 102.0 percent of C18H24N4OHCl, calculated
on the dried basis.
Packaging and storagePreserve in well-closed containers, protected from
light. Store at room temperature.
USP Reference standards 11USP Granisetron Hydrochloride RS. USP
Granisetron Related Compound A RS. USP Granisetron Related Compound
B RS. USP Granisetron Related Compound E RS.
pH 791: between 4.0 and 6.5, in a solution in carbon dioxide-free water,
containing 10 mg per mL.
Iopamidol
source: USP
P
S
C17H22I3N3O8 777.09
1,3-Benzenedicarboxamide, N,N-bis[2-hydroxy-1-(hydroxymethyl)-
U
ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-, (S)-.
(S)-N,N-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-5-
9
lactamidoisophthalamide [60166-93-0].
Iopamidol contains not less than 98.0 percent and not more
than 101.0 percent of iopamidol, calculated on the dried basis.
Packaging and storagePreserve in well-closed, light-resistant containers.
Store at 25, excursions permitted between 15 and 30.
USP Reference standards 11USP Iopamidol RS. USP Iopamidol Related
Compound A RS. USP Iopamidol Related Compound C RS.
Isopropyl Alcohol
source: USP
C3H8O 60.10
2-Propanol.
Isopropyl alcohol [67-63-0].
Isopropyl Alcohol contains not less than 99.0 percent of
C3H8O.
Packaging and storagePreserve in tight containers, remote from heat.
USP Reference standards 11USP 2-Propanol RS.
Specific gravity 841: between 0.783 and 0.787.
Refractive index 831: between 1.376 and 1.378 at 20.
Lecithin
source: NF
[8002-43-5].
Lecithin is a complex mixture of acetone-insoluble phospha-
tides, which consist chiefly of phosphatidyl choline, phosphati-
dyl ethanolamine, phosphatidyl serine, and phosphatidyl inosi-
tol, combined with various amounts of other substances such
as triglycerides, fatty acids, and carbohydrates, as separated
from the crude vegetable oil source. It contains not less than
50.0 percent of acetone-insoluble matter.
USP Pharmacists Pharmacopeia
Packaging and storagePreserve in well-closed, light-resistant containers.
Store at the temperature indicated on the label. Protect from excess heat
and moisture.
LabelingLabel it to indicate the storage conditions.
USP Reference standards 11USP Choline Chloride RS.
Lisinopril and Hydrochlorothiazide Tablets
source: USP
Lisinopril and Hydrochlorothiazide Tablets contain not less
than 90.0 percent and not more than 110.0 percent of the la-
beled amount of lisinopril (C21H31N3O5) and hydrochlorothiazide
(C7H8ClN3O4 S2).
Packaging and storagePreserve in well-closed containers, and store at
controlled room temperature.
USP Reference standards 11USP Lisinopril RS. USP Hydrochlorothiazide
RS. USP Benzothiadiazine Related Compound A RS. USP Lisinopril Related
Compound A RS.
Uniformity of dosage units 905: meet the requirements.
Mirtazapine Orally Disintegrating Tablets
source: USP
Mirtazapine Orally Disintegrating Tablets contain not less than
90.0 percent and not more than 110.0 percent of the labeled
amount of Mirtazapine (C17H19N3), calculated on the anhydrous
basis.
0
0
Packaging and storageStore at controlled room temperature. Protect
from light and moisture.
2
USP Reference standards 11USP Mirtazapine RS.
Uniformity of dosage units 905: meet the requirements.
Pantoprazole Sodium
source: USP
C16H14F2N3NaO4S1.5H2O 432.37
1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-
pyridyl)methyl]sulfinyl]-, sodium salt, hydrate (2:3).
5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-
benzimidazole, sodium salt, sesquihydrate [164579-32-2].
Pantoprazole Sodium contains not less than 98.0 percent and
not more than 102.0 percent of C16H14F2N3NaO4S, calculated on
the anhydrous basis.
Packaging and storagePreserve in well-closed, light-resistant containers.
Store at room temperature.
LabelingIf a test for Related compounds other than Test 1 is used, then
the labeling states the test with which the article complies.
USP Reference standards 11USP Pantoprazole Sodium RS. USP Pantop
razole Related Compound A RS. USP Pantoprazole Related Compound
B RS. USP Pantoprazole Related Compound C RS. USP Pantoprazole Related
Compound D and F Mixture RS. USP Pantoprazole Related Compound
E RS.
Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/32
Lisinopril
Pantoprazole Sodium Delayed-Release Tablets
source: USP
Pantoprazole Sodium Delayed-Release Tablets contain an
amount of Pantoprazole Sodium equivalent to not less than 90.0
percent and not more than 110.0 percent of the labeled amount
of pantoprazole (C16H15F2N3O4S).
Packaging and storagePreserve in well-closed containers. Store at con-
trolled room temperature.
LabelingLabel Tablets to indicate that they must not be split, chewed, or
crushed before administration. When more than one Dissolution test is
given, the labeling states the test used only if Test 1 is not used.
USP Reference standards 11USP Pantoprazole Sodium RS. USP Pantop-
razole Related Compound A RS. USP Pantoprazole Related Compound B
RS.
Uniformity of dosage units 905: meet the requirements.
Piperazine Adipate
P
source: USP
S
U
C4H10N2C6H10O4 232.3
Piperazine, compound with 1,4-butanediacarboxylic acid (1:1).
9
Piperazine, compound with hexanedioic acid (1:1) [142-88-1].
Piperazine Adipate contains not less than 98.0 percent and not
more than 101.0 percent of C4H10N2C6H10O4, calculated on the
anhydrous basis.
Packaging and storagePreserve in well-closed containers, and store at
room temperature.
LabelingLabel it to indicate that it is for veterinary use only.
USP Reference standards 11USP Piperazine Adipate RS.
Piperazine Dihydrochloride
source: USP
C4H10N22HClxH2O (anhydrous) 159.02
Piperazine dihydrochloride hydrate [142-64-3].
Piperazine Dihydrochloride contains not less than 98.5 per-
cent and not more than 100.5 percent of C4H10N22HCl, calcu-
lated on the anhydrous basis.
Packaging and storagePreserve in well-closed containers, and store at
room temperature.
LabelingLabel it to indicate that it is for veterinary use only.
USP Reference standards 11USP Piperazine Dihydrochloride RS.
pH 791: between 3.0 and 3.4, in a solution (1 in 20).
USP Pharmacists Pharmacopeia
Piperazine Phosphate
source: USP
C4H10N2H3PO4H2O 202.15 mg and not more than 185 mg of bromide (Br ) per mL (see
Piperazine phosphate (1:1), monohydrate.
Piperazine phosphate (1:1), monohydrate [18534-18-4].
Anhydrous 184.13 [14538-56-8].
Piperazine Phosphate contains not less than 98.5 percent and
not more than 100.5 percent of C4H10N2H3PO4, calculated on
the anhydrous basis.
Packaging and storagePreserve in tight containers, and store at room
temperature.
LabelingLabel it to indicate that it is for veterinary use only.
USP Reference standards 11USP Piperazine Phosphate RS.
pH 791: between 6.0 and 6.5, in a solution (1 in 100).
Polyvinyl Alcohol
source: USP
(C2H4O)n
Ethenol, homopolymer.
0
Vinyl alcohol polymer [9002-89-5].
0
Polyvinyl Alcohol is a water-soluble synthetic resin, repre-
sented by the formula:
2
(C2H4O)n
in which the average value of n lies between 500 and 5000. It is
prepared by 85 percent to 89 percent hydrolysis of polyvinyl
acetate. The apparent viscosity, in mPas, at 20, of a 4% (w/w)
aqueous solution is not less than 85.0 percent and not more
than 115.0 percent of that stated on the label.
Packaging and storagePreserve in well-closed containers, and store at
room temperature in a dry place.
LabelingLabel it to indicate the viscosity, giving the viscosity measure-
ment parameters, the concentration of the solution, and the type of equip-
ment used.
USP Reference standards 11USP Acetone RS. USP Methyl Acetate RS.
USP Methyl Alcohol RS. USP Polyvinyl Alcohol RS.
Viscosity 911After determining the Loss on drying, weigh a quantity of
undried Polyvinyl Alcohol, equivalent to 6.00 g on the dried basis. Over a
period of seconds, transfer the test specimen with continuous slow stirring
to about 140 mL of water contained in a suitable tared flask. When the
specimen is well-wetted, increase the rate of stirring, avoiding mixing in
excess air. Heat the mixture to 90, and maintain the temperature at 90 for
about 5 minutes. Discontinue heating, and continue stirring for 1 hour. Add
water to make the mixture weigh 150 g. Resume stirring to obtain a homog-
enous solution. Filter the solution through a tared 100-mesh screen into a
250-mL conical flask, cool the filtrate to about 15, and mix. Determine its
viscosity at 20 0.1, using an appropriate viscometer: the apparent viscos-
ity is between 85.0% and 115.0% of the value stated on the label.
pH 791: between 5.0 and 8.0, in a solution (1 in 25).
Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/33
Piperazine
Potassium Bromide Oral Solution, Veterinary
source: USP
Potassium Bromide Oral Solution, Veterinary contains an
amount of Potassium Bromide equivalent to not less than 151
Pharmaceutical CompoundingNonsterile Preparations 795):
Potassium Bromide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 g
Purified Water . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60 mL
Corn Syrup, FCC, a sufficient quantity to make . . . . 100 mL
Dissolve an accurately weighed quantity of Potassium Bromide
in water. Add Corn Syrup to volume with mixing.
Packaging and storagePackage in a tight container, and store in a
r efrigerator.
LabelingLabel it to indicate that it is to be discarded after 180 days, to
state that it is to be kept out of the reach of children, to indicate the nomi-
nal content of potassium bromide in the Oral Solution, Veterinary and to
state that it is for veterinary use only.
P
USP Reference standards 11USP Sodium Bromide RS.
S
Prednisolone Sodium Phosphate
U
source: USP
C21H27Na2O8P 484.39
Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-(phosphono oxy)-,
9
disodium salt, (11)-.
11,17,21-Trihydroxypregna-1,4-diene-3,20-dione 21-(disodium
phosphate) [125-02-0].
Prednisolone Sodium Phosphate contains not less than 96.0
percent and not more than 102.0 percent of C21H27Na2O8P, cal-
culated on the anhydrous basis.
Packaging and storagePreserve in tight containers.
USP Reference standards 11USP Prednisolone RS. USP Prednisolone
Sodium Phosphate RS.
pH 791: between 7.5 and 10.5, in a solution (1 in 100).
Propofol Injectable Emulsion
source: USP
Propofol Injectable Emulsion contains Propofol in a 10 percent
(w/v) oil-in-water sterile emulsion. The aqueous component
contains glycerol, a suitable antimicrobial agent, and Water for
Injection. It contains not less than 90.0 percent and not more
than 110.0 percent of the labeled amount of propofol (C12H18O).
It contains a suitable emulsifying agent.
Packaging and storagePreserve under an inert atmosphere of nitrogen.
Store at controlled room temperature. Do not freeze.
LabelingLabel it to include the following: Shake well before use. Do not
use if there is evidence of excessive creaming or aggregation, if large drop-
lets are visible, or if there are other forms of phase separation indicating
that the stability of the product has been compromised. Slight creaming,
which should disappear after shaking, may be visible upon prolonged
standing.
USP Reference standards 11USP Endotoxin RS. USP Propofol RS. USP
Propofol Related Compound A RS. USP Propofol Related Compound B RS.
Bacterial endotoxins 85It contains not more than 0.33 USP Endotoxin
Units per mg of propofol.
Sterility 71: meets the requirements.
pH 791: between 7.0 and 8.5.
USP Pharmacists Pharmacopeia Propylene

Propylene Glycol Monolaurate
source: NF
Dodecanoic acid, monoester with 1,2-propanediol.
Lauric acid, monoester with propane-1,2-diol.
Propylene Glycol Monolaurate is a mixture of the propylene
glycol mono- and di-esters of lauric acid. The requirements for
monoester and diester content differ for the two types of Pro-
pylene Glycol Monolaurate, as set forth in the accompanying
table.
Content of Content of
monoesters (%) diesters (%)
Min. Max. Min. Max.
Type I 45.0 70.0 30.0 55.0
Type II 90.0 10.0
Packaging and storagePreserve in well-closed containers, and protect
from moisture. No storage requirements specified.
LabelingLabel it to indicate the type (Type I or Type II).
Bacterial endotoxins 85It contains not more than 0.03 USP Endotoxin
Unit per mg of sodium bromide.
Sterility 71: meets the requirements.
Sodium Bromide Oral Solution, Veterinary
source: USP
Sodium Bromide Oral Solution, Veterinary contains an amount
of Sodium Bromide equivalent to not less than 151 mg and not
more than 185 mg of bromide (Br) per mL (see Pharmaceutical
CompoundingNonsterile Preparations 795):
Sodium Bromide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21.6 g
Purified Water . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60 mL
Corn Syrup, FCC, a sufficient quantity to make . . . . 100 mL
Dissolve an accurately weighed quantity of Sodium Bromide in
water. Add Corn Syrup to volume with mixing.
Packaging and storagePackage in a tight container, and store in a
r efrigerator.

P
USP Reference standards 11USP Propylene Glycol RS. USP Propylene
LabelingLabel it to indicate that it is to be discarded after 180 days, to
Glycol Monolaurate Type I RS. USP Propylene Glycol Monolaurate Type II
state that it is to be kept out of the reach of children, to indicate the nomi-

S
RS.
nal content of sodium bromide in the Oral Solution, Veterinary and to state
that it is for veterinary use only.
Sodium Bromide Injection, Veterinary USP Reference standards 11USP Sodium Bromide.

U
source: USP
Tamsulosin Hydrochloride

9
Sodium Bromide Injection, Veterinary contains an amount of
Sodium Bromide equivalent to not less than 21.0 mg and not source: USP

0
more than 25.6 mg of bromide (Br) per mL (see Pharmaceutical

0
CompoundingSterile Preparations 797):
Sodium Bromide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.0 g

2
Sterile Water for Injection, USP,
a sufficient quantity to make . . . . . . . . . . . . . . . . . . . 100 mL
C20H28N2O5SHCl 444.97
Dissolve an accurately weighed quantity of Sodium Bromide in

Sterile Water for Injection to volume with mixing. Sterilize by a
suitable means such as sterile filtration or autoclaving.
Packaging and storagePreserve in single-dose containers, preferably of
Type I glass, and store in a refrigerator.
LabelingLabel it to indicate that it is to be discarded after 180 days, to
state that it is to be kept out of the reach of children, and to indicate the
nominal content of sodium bromide in the Injection. Label it to indicate
that it is for infusion only at a rate not to exceed 150 mg of sodium bromide
per kg body weight per hour. Label it to indicate that it is for veterinary use
only.
USP Reference standards 11USP Endotoxin RS. USP Sodium Bromide
RS.
Benzenesulfonamide, 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-
2-methoxy-, monohydrochloride, (R)-.
(-)-(R)-5-[2-[[2-(o-Ethoxyphenoxy)ethyl]amino]propyl]-2-methoxyben-
zenesulfonamide monohydrochloride. [106463-17-6].
Tamsulosin Hydrochloride contains not less than 98.5 percent
and not more than 101.0 percent of C20H28N2O5SHCl, calculated
on the dried basis.
Packaging and storagePreserve in tight containers. Store at controlled
room temperature.
USP Reference standards 11USP Tamsulosin Hydrochloride RS. USP
Racemic Tamsulosin Hydrochloride RS.

Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/34
USP Pharmacists Pharmacopeia Excipients

USP and NF Excipients, Listed by Category

In the following reference table, the grouping of excipients by functional category is intended to summarize the most typically identified purpose
that these excipients serve in drug product formulations. The list of substances included in each category is not comprehensive. The statement of
category is intended neither to limit in any way the choice or use of the substance nor to indicate that it has no other utility.

Acidifying Agent Cresol

Acetic Acid Dehydroacetic Acid
Acetic Acid, Glacial Erythorbic Acid
Citric Acid, Anhydrous Ethylparaben
Citric Acid Monohydrate Methylparaben
Fumaric Acid Methylparaben Sodium
Hydrochloric Acid Phenol
Hydrochloric Acid, Diluted Phenoxyethanol
Malic Acid Phenylethyl Alcohol
Nitric Acid Phenylmercuric Acetate
Phosphoric Acid Phenylmercuric Nitrate
Phosphoric Acid, Diluted Potassium Benzoate
Propionic Acid Potassium Sorbate
Sulfuric Acid Propylparaben
Propylparaben Sodium

P
Tartaric Acid
Sodium Benzoate
Aerosol Propellant Sodium Dehydroacetate

S
Butane Sodium Propionate
Dichlorodifluoromethane Sorbic Acid

U
Dichlorotetrafluoroethane Thimerosal
Isobutane Thymol
Propane

9
Trichloromonofluoromethane Antioxidant
Ascorbic Acid

0
Air Displacement Ascorbyl Palmitate
Carbon Dioxide Butylated Hydroxyanisole

0
Nitrogen Butylated Hydroxytoluene
Stannous Chloride

2
Alcohol Denaturant Erythorbic Acid
Denatonium Benzoate Hypophosphorous Acid
Methyl Isobutyl Ketone Monothioglycerol

Sucrose Octaacetate Potassium Metabisulfite
Propyl Gallate
Alkalizing Agent Sodium Bisulfite
Ammonia Solution, Strong Sodium Formaldehyde Sulfoxylate
Ammonium Carbonate Sodium Metabisulfite
Diethanolamine Sodium Sulfite
Potassium Hydroxide Sodium Thiosulfate
Sodium Bicarbonate Sulfur Dioxide
Sodium Borate Tocopherol
Sodium Carbonate Tocopherols Excipient
Sodium Hydroxide
Trolamine Buffering Agent
Acetic Acid
Anticaking Agent (See Glidant) Adipic Acid
Ammonium Carbonate
Antifoaming Agent Ammonium Phosphate
Dimethicone Boric Acid
Myristic Acid Citric Acid, Anhydrous
Palmitic Acid Citric Acid Monohydrate
Simethicone Lactic Acid
Phosphoric Acid
Antimicrobial Preservative Potassium Citrate
Benzalkonium Chloride Potassium Metaphosphate
Benzalkonium Chloride Solution Potassium Phosphate, Dibasic
Benzethonium Chloride Potassium Phosphate, Monobasic
Benzoic Acid Sodium Acetate
Benzyl Alcohol Sodium Citrate
Butylparaben Sodium Lactate Solution
Cetrimonium Bromide Sodium Phosphate, Dibasic
Cetylpyridinium Chloride Sodium Phosphate, Monobasic
Chlorobutanol Succinic Acid
Chlorocresol

Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/35
USP Pharmacists Pharmacopeia Excipients

Bulking Agent for Freeze-Drying Emollient

Creatinine Alkyl (C12-15) Benzoate
Mannitol Hydrogenated Soybean Oil
Polydextrose Hydrogenated Polydecene
Pullulan Oleyl Oleate

Capsule Lubricant (See Tablet and/or Capsule Lubricant) Emulsifying and/or Solubilizing Agent
Acacia
Chelating Agent Carbomer Copolymer
Edetate Calcium Disodium Carbomer Interpolymer
Edetate Disodium Cholesterol
Edetic Acid Stannous Chloride
Coconut Oil
Coating Agent Diethanolamine (Adjunct)
Amino Methacrylate Copolymer Diethylene Glycol Stearates
Ammonio Methacrylate Copolymer Ethylene Glycol Stearates
Ammonio Methacrylate Copolymer Dispersion Gamma Cyclodextrin
Carboxymethylcellulose, Sodium Glyceryl Distearate
Cellaburate Glyceryl Monolinoleate
Cellacefate (formerly Cellulose Acetate Phthalate) Glyceryl Monooleate
Cellulose Acetate Glyceryl Monostearate
Cellulose Acetate Phthalate (see Cellacefate) Lanolin Alcohols

P
Coconut Oil Lecithin
Copovidone Mono- and Di-glycerides

S
Corn Syrup Solids Monoethanolamine (Adjunct)
Ethyl Acrylate and Methyl Methacrylate Copolymer Dispersion Oleic Acid (Adjunct)
Ethylcellulose Oleyl Alcohol (Stabilizer)

U
Ethylcellulose Aqueous Dispersion Oleyl Oleate
Gelatin Palm Kernel Oil
Glaze, Pharmaceutical

9
Poloxamer
Hydroxypropyl Cellulose Polyoxyethylene 50 Stearate

0
Hydroxypropyl Methylcellulose (see Hypromellose) Polyoxyl 10 Oleyl Ether
Hydroxypropyl Methylcellulose Phthalate (see Hypromellose Polyoxyl 20 Cetostearyl Ether

0
Phthalate) Polyoxyl 35 Castor Oil
Hypromellose (formerly Hydroxypropyl Methylcellulose) Polyoxyl 40 Hydrogenated Castor Oil

2
Hypromellose Acetate Succinate Polyoxyl 40 Stearate
Hypromellose Phthalate (formerly Hydroxypropyl Methylcellulose Polyoxyl Lauryl Ether
Phthalate) Polyoxyl Stearyl Ether
Maltodextrin Polysorbate 20

Methacrylic Acid Copolymer Polysorbate 40
Methacrylic Acid Copolymer Dispersion Polysorbate 60
Methylcellulose Polysorbate 80
Palm Kernel Oil Propylene Glycol Dicaprylate/Dicaprate
Polyethylene Glycol Propylene Glycol Monocaprylate
Polyvinyl Acetate Phthalate Propylene Glycol Monostearate
Pullulan Superglycerinated Fully Hydrogenated Rapeseed Oil
Fully Hydrogenated Rapeseed Oil Sodium Cetostearyl Sulfate
Superglycerinated Fully Hydrogenated Rapeseed Oil Sodium Lauryl Sulfate
Shellac Sodium Stearate
Starch, Pregelatinized Modified Sorbitan Monolaurate
Sucrose Sorbitan Monooleate
Titanium Dioxide Sorbitan Monopalmitate
Wax, Carnauba Sorbitan Monostearate
Wax, Microcrystalline Sorbitan Sesquioleate
Zein Sorbitan Trioleate
Stearic Acid
Color Trolamine
Caramel Wax, Emulsifying
Ferric Oxide, red, yellow, or blends
Filtering Aid
Complexing Agent Cellulose, Powdered
Edetate Calcium Disodium Siliceous Earth, Purified
Edetate Disodium
Edetic Acid Flavors and Perfumes
Oxyquinoline Sulfate Almond Oil
Anethole
Desiccant Benzaldehyde
Calcium Chloride Ethyl Acetate
Calcium Sulfate Ethyl Vanillin
Silicon Dioxide

Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/36
USP Pharmacists Pharmacopeia Excipients

Lactitol Polymer Membrane

Maltol Amino Methacrylate Copolymer
Menthol Ammonio Methacrylate Copolymer
Methyl Salicylate Ammonio Methacrylate Copolymer Dispersion
Monosodium Glutamate Cellaburate
Peppermint Cellulose Acetate
Peppermint Oil Ethyl Acrylate and Methyl Methacrylate Copolymer Dispersion
Peppermint Spirit Pullulan
Rose Oil
Rose Water, Stronger Sequestering Agent
Thymol Beta Cyclodextrin (see Betadex)
Vanillin Betadex (formerly Beta Cyclodextrin)
Hydroxypropyl Betadex
Glidant and/or Anticaking Agent Gamma Cyclodextrin
Calcium Silicate Pullulan
Magnesium Silicate Sodium Tartrate
Hydrophobic Colloidal Silica
Silicon Dioxide, Colloidal Solvent
Talc Acetone
Alcohol
Humectant Alcohol, Diluted
Corn Syrup Solids Amylene Hydrate

P
Erythritol Benzyl Benzoate
Glycerin Butyl Alcohol

S
Hexylene Glycol Canola Oil
Inositol Caprylocaproyl Polyoxylglycerides
Maltitol Corn Oil

U
Polydextrose Cottonseed Oil
Propylene Glycol Diethylene Glycol Monoethyl Ether
Sorbitol

9
Ethyl Acetate
Sorbitol Sorbitan Solution Glycerin

0
Tagatose Hexylene Glycol
Hydrogenated Polydecene

0
Ointment Base Isopropyl Alcohol
Caprylocaproyl Polyoxylglycerides Lauroyl Polyoxylglycerides

2
Diethylene Glycol Monoethyl Ether Linoleoyl Polyoxylglycerides
Hydrogenated Polydecene Methyl Alcohol
Lanolin Methylene Chloride
Lauroyl Polyoxylglycerides Methyl Isobutyl Ketone

Linoleoyl Polyoxylglycerides Mineral Oil
Ointment, Hydrophilic Oleoyl Polyoxylglycerides
Ointment, White Peanut Oil
Ointment, Yellow Polyethylene Glycol
Oleoyl Polyoxylglycerides Polyethylene Glycol Monomethyl Ether
Polyethylene Glycol Monomethyl Ether Propylene Glycol
Petrolatum Sesame Oil
Petrolatum, Hydrophilic Stearoyl Polyoxylglycerides
Petrolatum, White Water for Injection
Rose Water Ointment Water for Injection, Sterile
Squalane Water for Irrigation, Sterile
Stearoyl Polyoxylglycerides Water, Purified
Vegetable Oil, Hydrogenated, Type II
Sorbent
Plasticizer Cellulose, Powdered
Acetyltributyl Citrate Charcoal, Activated
Acetyltriethyl Citrate Siliceous Earth, Purified
Castor Oil
Diacetylated Monoglycerides Sorbent, Carbon Dioxide
Dibutyl Sebacate Barium Hydroxide Lime
Diethyl Phthalate Soda Lime
Glycerin
Polyethylene Glycol Stiffening Agent
Polyethylene Glycol Monomethyl Ether Castor Oil, Hydrogenated
Propylene Glycol Cetostearyl Alcohol
Pullulan Cetyl Alcohol
Sorbitol Sorbitan Solution Cetyl Esters Wax
Triacetin Cetyl Palmitate
Tributyl Citrate Hard Fat
Triethyl Citrate Paraffin

Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/37
USP Pharmacists Pharmacopeia Excipients

Synthetic Paraffin Aspartame Acesulfame

Fully Hydrogenated Rapeseed Oil Corn Syrup
Superglycerinated Fully Hydrogenated Rapeseed Oil Corn Syrup Solids
Stearyl Alcohol High Fructose Corn Syrup
Wax, Emulsifying Dextrates
Wax, White Dextrose
Wax, Yellow Dextrose Excipient
Erythritol
Suppository Base Fructose
Cocoa Butter Galactose
Hard Fat Maltitol
Polyethylene Glycol Maltose
Mannitol
Suspending and/or Viscosity-Increasing Agent Saccharin
Acacia Saccharin Calcium
Agar Saccharin Sodium
Alamic Acid Sorbitol
Alginic Acid Sorbitol Solution
Aluminum Monostearate Sucralose
Attapulgite, Activated Sucrose
Attapulgite, Colloidal Activated Sugar, Compressible
Bentonite Sugar, Confectioners

P
Bentonite, Purified Syrup
Bentonite Magma Tagatose

S
Carbomer 910
Carbomer 934 Tablet Binder
Carbomer 934P Acacia

U
Carbomer 940 Alginic Acid
Carbomer 941 Amino Methacrylate Copolymer
Carbomer 1342 Ammonio Methacrylate Copolymer

9
Carbomer Copolymer Ammonio Methacrylate Copolymer Dispersion

0
Carbomer Homopolymer Carbomer Copolymer
Carbomer Interpolymer Carbomer Homopolymer

0
Carboxymethylcellulose Calcium Carbomer Interpolymer
Carboxymethylcellulose Sodium Carboxymethylcellulose Sodium

2
Carboxymethylcellulose Sodium 12 Cellulose, Microcrystalline
Carrageenan Copovidone
Cellulose, Microcrystalline, and Carboxymethylcellulose Sodium Corn Syrup
Corn Syrup Corn Syrup Solids

Corn Syrup Solids Dextrin
Dextrin Ethyl Acrylate and Methyl Methacrylate Copolymer Dispersion
Gelatin Ethylcellulose
Gellan Gum Gelatin
Guar Gum Glucose, Liquid
Hydroxyethyl Cellulose Guar Gum
Hydroxypropyl Cellulose Low-Substituted Hydroxypropyl Cellulose
Hydroxypropyl Methylcellulose (see Hypromellose) Hydroxypropyl Methylcellulose (see Hypromellose)
Hypromellose (formerly Hydroxypropyl Methylcellulose) Hypromellose (formerly Hydroxypropyl Methylcellulose)
Magnesium Aluminum Silicate Hypromellose Acetate Succinate
Maltodextrin Maltodextrin
Methylcellulose Maltose
Pectin Methylcellulose
Polyethylene Oxide Polyethylene Oxide
Polyvinyl Alcohol Povidone
Povidone Pullulan
Propylene Glycol Alginate Starch, Corn
Pullulan Starch, Potato
Hydrophobic Colloidal Silica Starch, Pregelatinized
Silicon Dioxide Starch, Pregelatinized Modified
Silicon Dioxide, Colloidal Starch, Tapioca
Sodium Alginate Starch, Wheat
Starch, Corn Syrup
Starch, Potato
Starch, Tapioca Tablet and/or Capsule Diluent
Starch, Wheat Calcium Carbonate
Tragacanth Calcium Phosphate, Dibasic
Xanthan Gum Calcium Phosphate, Tribasic
Calcium Sulfate
Sweetening Agent Cellulose, Microcrystalline
Acesulfame Potassium Cellulose, Powdered
Aspartame Corn Syrup

Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/38
USP Pharmacists Pharmacopeia Excipients

Corn Syrup Solids Stearic Acid, Purified

Dextrates Talc
Dextrin Vegetable Oil, Hydrogenated, Type I
Dextrose Excipient Zinc Stearate
Fructose
Kaolin Tonicity Agent
Lactitol Corn Syrup
Lactose, Anhydrous Corn Syrup Solids
Lactose, Monohydrate Dextrose
Maltitol Glycerin
Maltodextrin Mannitol
Maltose Potassium Chloride
Mannitol Sodium Chloride
Propylene Glycol Monocaprylate
Pullulan Vehicle
Sorbitol flavored and/or sweetened
Starch Aromatic Elixir
Starch, Corn Benzaldehyde Elixir, Compound
Starch, Potato Corn Syrup Solids
Starch, Pregelatinized Dextrose
Starch, Pregelatinized Modified Peppermint Water
Starch, Tapioca Sorbitol Solution

P
Starch, Wheat Syrup
Sucrose oleaginous

S
Sugar, Compressible Alkyl (C12-15) Benzoate
Sugar, Confectioners Almond Oil
Canola Oil

U
Tablet Disintegrant Corn Oil
Alginic Acid Cottonseed Oil
Cellulose, Microcrystalline

9
Ethyl Oleate
Croscarmellose Sodium Hydrogenated Polydecene

0
Crospovidone Isopropyl Myristate
Low-Substituted Hydroxypropyl Cellulose Isopropyl Palmitate

0
Maltose Mineral Oil
Polacrilin Potassium Mineral Oil, Light

2
Pullulan Octyldodecanol
Sodium Starch Glycolate Olive Oil
Starch Peanut Oil
Starch, Corn Safflower Oil

Starch, Potato Sesame Oil
Starch, Pregelatinized Soybean Oil
Starch, Pregelatinized Modified Squalane
Starch, Tapioca solid carrier
Starch, Wheat Corn Syrup Solids
Propylene Glycol Dicaprylate/Dicaprate
Tablet and/or Capsule Lubricant Propylene Glycol Monocaprylate
Calcium Stearate Sugar Spheres
Glyceryl Behenate sterile
Magnesium Stearate rAlbumin Human
Mineral Oil, Light Sodium Chloride Injection, Bacteriostatic
Polyethylene Glycol Water for Injection, Bacteriostatic
Polyoxyl 10 Oleyl Ether
Polyoxyl 20 Cetostearyl Ether Viscosity-Increasing (See Suspending Agent)
Polyoxyl 35 Castor Oil
Polyoxyl 40 Hydrogenated Castor Oil Water Repelling Agent
Polyoxyl 40 Stearate Cyclomethicone
Polysorbate 20 Dimethicone
Polysorbate 40 Simethicone
Polysorbate 60
Polysorbate 80 Wetting and/or Solubilizing Agent
Sodium Lauryl Sulfate Benzalkonium Chloride
Sodium Stearyl Fumarate Benzethonium Chloride
Sorbitan Monolaurate Cetylpyridinium Chloride
Sorbitan Monooleate Docusate Sodium
Sorbitan Monopalmitate Nonoxynol 9
Sorbitan Monostearate Octoxynol 9
Sorbitan Sesquioleate Poloxamer
Sorbitan Trioleate Polyoxyl 10 Oleyl Ether
Starch Polyoxyl 20 Cetostearyl Ether
Stearic Acid Polyoxyl 35 Castor Oil

Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/39
USP Pharmacists Pharmacopeia Excipients

Polyoxyl 40 Hydrogenated Castor Oil Sorbitan Monolaurate

Polyoxyl 40 Stearate Sorbitan Monooleate
Polysorbate 20 Sorbitan Monopalmitate
Polysorbate 40 Sorbitan Monostearate
Polysorbate 60 Sorbitan Sesquioleate
Polysorbate 80 Sorbitan Trioleate
Pullulan Tyloxapol
Sodium Lauryl Sulfate

S P
9 U
2 0 0

Official text. Reprinted from USP 32NF 27. Section 3, Drug Substance and Compounded Preparation Monographs S3/40
USP Pharmacists Pharmacopeia

Section 7
Pharmacy-Related General Chapters

S P
T U
hese pharmacy-related general chapters may be needed regularly in the

9
daily pharmacy practice. The mandatory chapters, numbered below 1000,

0 0
may have test requirements specified. The informational chapters, numbered

2
above 1000, are used as a guide to the practitioner.

USP Pharmacists Pharmacopeia

Section Contents

61 Microbiological Examination of Nonsterile Products: Microbial

Enumeration Tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/43

62 Microbiological Examination of Nonsterile Products:

Tests for Specified Microorganisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/47

381 Elastomeric Closures for Injections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/51

621 Chromatography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/55

1111 Microbiological Examination of Nonsterile Products:

Acceptance Criteria for Pharmaceutical Preparations and Substances

S P
U
for Pharmaceutical Use . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/67

9
1121 Nomenclature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/68

2 0 0

Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/42
USP Pharmacists Pharmacopeia 61 Microbiological Examination

61 Microbiological Examination Enumeration Methods

of Nonsterile Products: Microbial
Enumeration Tests
Introduction
The tests described hereafter will allow quantitative enumeration of
mesophilic bacteria and fungi that may grow under aerobic conditions.
The tests are designed primarily to determine whether a substance
or preparation complies with an established specification for microbio-
logical quality. When used for such purposes, follow the instructions
given below, including the number of samples to be taken, and inter-
pret the results as stated below.
The methods are not applicable to products containing viable mi-
croorganisms as active ingredients.
Alternative microbiological procedures, including automated
methods, may be used, provided that their equivalence to the Pharma-
copeial method has been demonstrated.
Use the Membrane Filtration method or one of the Plate-Count Meth-
ods, as directed. The Most-Probable-Number (MPN) Method is gener-
ally the least accurate method for microbial counts; however, for cer-
tain product groups with very low bioburden, it may be the most
appropriate method.
The choice of a method is based on factors such as the nature of
the product and the required limit of microorganisms. The method
chosen must allow testing of a sufficient sample size to judge compli-
ance with the specification. The suitability of the chosen method must
be established.
Growth Promotion Test and Suitability of
the Counting Method
General Considerations
The ability of the test to detect microorganisms in the presence of

P
product to be tested must be established.
Suitability must be confirmed if a change in testing performance

S
General Procedures or a change in the product that may affect the outcome of the test, is
introduced.
Carry out the determination under conditions designed to avoid ex-

U
trinsic microbial contamination of the product to be examined. The
precautions taken to avoid contamination must be such that they do
Preparation of Test Strains

9
not affect any microorganisms that are to be revealed in the test.
If the product to be examined has antimicrobial activity, this is, in- Use standardized stable suspensions of test strains or prepare as stated

0
sofar as possible, removed or neutralized. If inactivators are used for below. Seed-lot culture maintenance techniques (seed-lot systems) are
used so that the viable microorganisms used for inoculation are not

0
this purpose, their efficacy and their absence of toxicity for microor-
ganisms must be demonstrated. more than 5 passages removed from the original master seed-lot. Grow

2
If surface-active substances are used for sample preparation, their each of the bacterial and fungal test strains separately as described in
absence of toxicity for microorganisms and their compatibility with any Table 1.
inactivators used must be demonstrated.

Growth Promotion

Microorganism
Staphylococcus aureus
such as ATCC 6538,

Table 1. Preparation and Use of Test Microorganisms

Preparation of
Test Strain
SoybeanCasein
Digest Agar or
Total Aerobic
Microbial Count
SoybeanCasein
Digest Agar and Soy-
Total Yeasts and
Molds Count
Suitability of Counting Method in the

Total Aerobic
Presence of Product

Microbial Count
SoybeanCasein
Digest Agar/MPN Soy-
Total Yeasts and
Molds Count

NCIMB 9518, CIP 4.83, SoybeanCasein beanCasein Digest beanCasein Digest

or NBRC 13276 Digest Broth 3035 Broth 100 cfu Broth 100 cfu
1824 hours 3035 3 days 3035 3 days
Pseudomonas aeruginosa SoybeanCasein SoybeanCasein SoybeanCasein
such as ATCC 9027, Digest Agar or Digest Agar and Soy- Digest Agar/MPN Soy-
NCIMB 8626, CIP 82.118, SoybeanCasein beanCasein Digest beanCasein Digest
or NBRC 13275 Digest Broth 3035 Broth 100 cfu Broth 100 cfu
1824 hours 3035 3 days 3035 3 days
Bacillus subtilis such as SoybeanCasein SoybeanCasein SoybeanCasein
ATCC 6633, NCIMB 8054, Digest Agar or Digest Agar and Soy- Digest Agar/MPN Soy-
CIP 52.62, or NBRC 3134 SoybeanCasein beanCasein Digest beanCasein Digest
Digest Broth 3035 Broth 100 cfu Broth 100 cfu
1824 hours 3035 3 days 3035 3 days
Candida albicans such as Sabouraud Dextrose SoybeanCasein Sabouraud Dextrose SoybeanCasein Sabouraud Dextrose
ATCC 10231, NCPF 3179, Agar or Sabouraud Digest Agar 100 cfu Agar 100 cfu 2025 Digest Agar 100 cfu Agar 100 cfu 2025
IP 48.72, or NBRC 1594 Dextrose Broth 3035 5 days 5 days 3035 5 days MPN: 5 days
2025 23 days not applicable
Aspergillus niger such as Sabouraud Dextrose SoybeanCasein Sabouraud Dextrose SoybeanCasein Sabouraud Dextrose
ATCC 16404, IMI 149007, Agar or Potato Digest Agar 100 cfu Agar 100 cfu 2025 Digest Agar 100 cfu Agar 100 cfu 2025
IP 1431.83, or NBRC 9455 Dextrose Agar 2025 3035 5 days 5 days 3035 5 days MPN: 5 days
57 days, or until good not applicable
sporulation is achieved

Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/43
USP Pharmacists Pharmacopeia
Use Buffered Sodium ChloridePeptone Solution pH 7.0 or Phos-
phate Buffer Solution pH 7.2 to make test suspensions; to suspend A.
niger spores, 0.05% of polysorbate 80 may be added to the buffer. Use
the suspensions within 2 hours, or within 24 hours if stored between 2
and 8. As an alternative to preparing and then diluting a fresh suspen-
sion of vegetative cells of A. niger or B. subtilis, a stable spore sus
pension is prepared and then an appropriate volume of the spore
suspension is used for test inoculation. The stable spore suspension
may be maintained at 2 to 8 for a validated period of time.
Negative Control
To verify testing conditions, a negative control is performed using the
chosen diluent in place of the test preparation. There must be no
growth of microorganisms.
Growth Promotion of the Media
Test each batch of ready-prepared medium and each batch of medium
prepared either from dehydrated medium or from the ingredients
described.
Inoculate portions/plates of SoybeanCasein Digest Broth and
SoybeanCasein Digest Agar with a small number (not more than 100
cfu) of the microorganisms indicated in Table 1, using a separate por-
tion/plate of medium for each. Inoculate plates of Sabouraud Dextrose
Agar with a small number (not more than 100 cfu) of the microorgan-
isms indicated in Table 1, using a separate plate of medium for each.
0
Incubate according to the conditions described in Table 1.
For solid media, growth obtained must not differ by a factor great-
0
er than 2 from the calculated value for a standardized inoculum. For a
2
freshly prepared inoculum, growth of the microorganisms comparable
to that previously obtained with a previously tested and approved
batch of medium occurs. Liquid media are suitable if clearly visible
growth of the microorganisms comparable to that previously obtained
with a previously tested and approved batch of medium occurs.
Suitability of the Counting Method
in the Presence of Product
Preparation of the Sample
The method for sample preparation depends on the physical charac-
teristics of the product to be tested. If none of the procedures de-
scribed below can be demonstrated to be satisfactory, a suitable alter-
native procedure must be developed.
Water-Soluble ProductsDissolve or dilute (usually a 1 in 10 dilution is
prepared) the product to be examined in Buffered Sodium Chloride
Peptone Solution pH 7.0, Phosphate Buffer Solution pH 7.2, or Soy-
beanCasein Digest Broth. If necessary, adjust to a pH of 6 to 8. Further
dilutions, where necessary, are prepared with the same diluent.
Nonfatty Products Insoluble in WaterSuspend the product to be ex-
amined (usually a 1 in 10 dilution is prepared) in Buffered Sodium
ChloridePeptone Solution pH 7.0, Phosphate Buffer Solution pH 7.2,
or SoybeanCasein Digest Broth. A surface-active agent such as 1 g per
L of polysorbate 80 may be added to assist the suspension of poorly
wettable substances. If necessary, adjust to a pH of 6 to 8. Further dilu-
tions, where necessary, are prepared with the same diluent.
Fatty ProductsDissolve in isopropyl myristate sterilized by filtration,
or mix the product to be examined with the minimum necessary quan-
tity of sterile polysorbate 80 or another noninhibitory sterile surface-
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/44
61 Microbiological Examination
active reagent heated, if necessary, to not more than 40 or, in excep-
tional cases, to not more than 45. Mix carefully and if necessary
maintain the temperature in a water bath. Add a sufficient quantity of
the prewarmed chosen diluent to make a 1 in 10 dilution of the original
product. Mix carefully, while maintaining the temperature for the
shortest time necessary for the formation of an emulsion. Further serial
10-fold dilutions may be prepared using the chosen diluent containing
a suitable concentration of sterile polysorbate 80 or another noninhibi-
tory sterile surface-active reagent.
Fluids or Solids in Aerosol FormAseptically transfer the product into
a membrane filter apparatus or a sterile container for further sampling.
Use either the total contents or a defined number of metered doses
from each of the containers tested.
Transdermal PatchesRemove the protective cover sheets (release
liners) of the transdermal patches and place them, adhesive side up-
wards, on sterile glass or plastic trays. Cover the adhesive surface with
a suitable sterile porous material (e.g., sterile gauze) to prevent the
patches from sticking together, and transfer the patches to a suitable
volume of the chosen diluent containing inactivators such as polysor-
P
bate 80 and/or lecithin. Shake the preparation vigorously for at least 30
minutes.
S
Inoculation and Dilution
U
Add to the sample prepared as directed above and to a control (with
no test material included) a sufficient volume of the microbial suspen-
sion to obtain an inoculum of not more than than 100 cfu. The volume
9
of the suspension of the inoculum should not exceed 1% of the vol-
ume of diluted product.
To demonstrate acceptable microbial recovery from the product,
the lowest possible dilution factor of the prepared sample must be
used for the test. Where this is not possible due to antimicrobial activ-
ity or poor solubility, further appropriate protocols must be developed.
If inhibition of growth by the sample cannot otherwise be avoided, the
aliquot of the microbial suspension may be added after neutralization,
dilution, or filtration.
Neutralization/Removal of Antimicrobial Activity
The number of microorganisms recovered from the prepared sample
diluted as described in Inoculation and Dilution and incubated follow-
ing the procedure described in Recovery of Microorganisms in the
Presence of Product, is compared to the number of microorganisms
recovered from the control preparation.
If growth is inhibited (reduction by a factor greater than 2), then
modify the procedure for the particular enumeration test to ensure
the validity of the results. Modification of the procedure may include,
for example,
(1) An increase in the volume of the diluent or culture medium;
(2) Incorporation of a specific or general neutralizing agents into the
diluent;
(3) Membrane filtration; or
(4) A combination of the above measures.
Neutralizing AgentsNeutralizing agents may be used to neutralize
the activity of antimicrobial agents (see Table 2). They may be added to
the chosen diluent or the medium preferably before sterilization. If
used, their efficacy and their absence of toxicity for microorganisms
must be demonstrated by carrying out a blank with neutralizer and
without product.
USP Pharmacists Pharmacopeia
Table 2. Common Neutralizing Agents/Methods
for Interfering Substances
Potential Neutralizing Agents/
Interfering Substance Method
Glutaraldehyde, mercurials Sodium hydrogen sulfite
(Sodium bisulfite)
Phenolics, alcohol, aldehydes, Dilution
sorbate Pour-Plate Method.
Aldehydes Glycine
Quaternary ammonium compounds Lecithin
(QACs), parahydroxybenzoates
(parabens), bis-biguanides od or the Plate-Count Method. Unreliable results are obtained particu-
QACs, iodine, parabens Polysorbate
Mercurials Thioglycollate
Mercurials, halogens, aldehydes Thiosulfate
EDTA (edetate) Mg or Ca ions
If no suitable neutralizing method can be found, it can be as-
sumed that the failure to isolate the inoculated organism is attributable
to the microbicidal activity of the product. This information serves to
indicate that the article is not likely to be contaminated with the given
species of the microorganism. However, it is possible that the product
inhibits only some of the microorganisms specified herein, but does
not inhibit others not included among the test strains or those for
which the latter are not representative. Then, perform the test with the
highest dilution factor compatible with microbial growth and the spe-
cific acceptance criterion.
Recovery of Microorganisms in the Presence of Product
0
For each of the microorganisms listed, separate tests are performed.
0
Only microorganisms of the added test strain are counted.
Membrane FiltrationUse membrane filters having a nominal pore
2
size not greater than 0.45 m. The type of filter material is chosen in
such a way that the bacteria-retaining efficiency is not affected by the
components of the sample to be investigated. For each of the microor-
ganisms listed, one membrane filter is used.
Transfer a suitable quantity of the sample prepared as described
under Preparation of the Sample, Inoculation and Dilution, and Neu-
tralization/Removal of Antimicrobial Activity (preferably representing
1 g of the product, or less if large numbers of cfu are expected) to the
membrane filter, filter immediately, and rinse the membrane filter with
an appropriate volume of diluent.
For the determination of total aerobic microbial count (TAMC),
transfer the membrane filter to the surface of the SoybeanCasein Di-
gest Agar. For the determination of total combined yeasts and molds
count (TYMC), transfer the membrane to the surface of the Sabouraud
Dextrose Agar. Incubate the plates as indicated in Table 1. Perform the
counting.
Plate-Count MethodsPerform plate-count methods at least in dupli-
cate for each medium, and use the mean count of the result.
Pour-Plate MethodFor Petri dishes 9 cm in diameter, add to the
dish 1 mL of the sample prepared as described under Preparation of
the Sample, Inoculation and Dilution, and Neutralization/Removal of
Antimicrobial Activity and 15 to 20 mL of SoybeanCasein Digest Agar
or Sabouraud Dextrose Agar, both media maintained at not more than
45. If larger Petri dishes are used, the amount of agar medium is in-
creased accordingly. For each of the microorganisms listed in Table 1,
at least two Petri dishes are used.
Incubate the plates as indicated in Table 1. Take the arithmetic
mean of the counts per medium, and calculate the number of cfu in
the original inoculum.
Surface-Spread MethodFor Petri dishes 9 cm in diameter, add 15
to 20 mL of SoybeanCasein Digest Agar or Sabouraud Dextrose Agar at
about 45 to each Petri dish, and allow to solidify. If larger Petri dishes
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/45
61 Microbiological Examination
are used, the volume of the agar is increased accordingly. Dry the
plates, for example, in a laminar-airflow cabinet or in an incubator. For
each of the microorganisms listed in Table 1, at least two Petri dishes
are used. Spread a measured volume of not less than 0.1 mL of the
sample, prepared as directed under Preparation of the Sample, Inocu-
lation and Dilution, and Neutralization/Removal of Antimicrobial Activ-
ity over the surface of the medium. Incubate and count as directed for
Most-Probable-Number (MPN) MethodThe precision and accuracy
of the MPN Method is less than that of the Membrane Filtration meth-
larly for the enumeration of molds. For these reasons, the MPN Method
is reserved for the enumeration of TAMC in situations where no other
method is available. If the use of the method is justified, proceed as
follows.
Prepare a series of at least three serial 10-fold dilutions of the
product as described for Preparation of the Sample, Inoculation and
Dilution, and Neutralization/Removal of Antimicrobial Activity. From
each level of dilution, three aliquots of 1 g or 1 mL are used to inocu-
P
late three tubes with 9 to 10 mL of SoybeanCasein Digest Broth. If
necessary a surface-active agent such as polysorbate 80, or an inactiva-
S
tor of antimicrobial agents may be added to the medium. Thus, if three
levels of dilution are prepared, nine tubes are inoculated.
Incubate all tubes at 30 to 35 for not more than 3 days. If reading
U
of the results is difficult or uncertain owing to the nature of the prod-
uct to be examined, subculture in the same broth or in Soybean
9
Casein Digest Agar for 1 to 2 days at the same temperature, and use
these results. From Table 3, determine the most probable number of
microorganisms per g or mL of the product to be examined.
Table 3. Most-Probable-Number Values
of Microorganisms
Observed Combinations MPN per g or 95%
of Numbers of Tubes Showing per mL of Confidence
Growth in Each Set Product Limits
Number of g or mL
of Product per Tube
0.1 0.01 0.001
0 0 0 <3 09.4
0 0 1 3 0.19.5
0 1 0 3 0.110
0 1 1 6.1 1.217
0 2 0 6.2 1.217
0 3 0 9.4 3.535
1 0 0 3.6 0.217
1 0 1 7.2 1.217
1 0 2 11 435
1 1 0 7.4 1.320
1 1 1 11 435
1 2 0 11 435
1 2 1 15 538
1 3 0 16 538
2 0 0 9.2 1.535
2 0 1 14 435
2 0 2 20 538
2 1 0 15 438
2 1 1 20 538
2 1 2 27 994
2 2 0 21 540
2 2 1 28 994
2 2 2 35 994
2 3 0 29 994
2 3 1 36 994
3 0 0 23 594
3 0 1 38 9104
3 0 2 64 16181
(continued)
USP Pharmacists Pharmacopeia
Table 3. Most-Probable-Number Values
of Microorganisms (continued)
Observed Combinations MPN per g or 95%
of Numbers of Tubes Showing per mL of Confidence
Growth in Each Set Product Limits
Number of g or mL
of Product per Tube the Counting Method, transfer the appropriate amount to each of two
0.1 0.01 0.001
3 1 0 43 9181
3 1 1 75 17199
3 1 2 120 30360
3 1 3 160 30380
3 2 0 93 18360
3 2 1 150 30380
3 2 2 210 30400
3 2 3 290 90990
3 3 0 240 40990
3 3 1 460 901980
3 3 2 1100 2004000
3 3 3 >1100
Results and Interpretation
When verifying the suitability of the Membrane Filtration method or
the Plate-Count Method, a mean count of any of the test organisms not
differing by a factor greater than 2 from the value of the control de-
fined in Inoculation and Dilution in the absence of product must be
obtained. When verifying the suitability of the MPN Method, the calcu-
lated value from the inoculum must be within 95% confidence limits of
0
the results obtained with the control.
0
If the above criteria cannot be met for one of more of the organ-
isms tested with any of the described methods, the method and
2
test conditions that come closest to the criteria are used to test the
product.
Testing of Products
Amount Used for the Test
Unless otherwise directed, use 10 g or 10 mL of the product to be ex-
amined taken with the precautions referred to above. For fluids or sol-
ids in aerosol form, sample 10 containers. For transdermal patches,
sample 10 patches.
The amount to be tested may be reduced for active substances
that will be formulated in the following conditions: the amount per
dosage unit (e.g., tablet, capsule, injection) is less than or equal to
1 mg, or the amount per g or mL (for preparations not presented in
dose units) is less than 1 mg. In these cases, the amount of sample to
be tested is not less than the amount present in 10 dosage units or 10 g
or 10 mL of the product.
For materials used as active substances where the sample quantity
is limited or batch size is extremely small (i.e., less than 1000 mL or 1000
g), the amount tested shall be 1% of the batch unless a lesser amount
is prescribed or justified and authorized.
For products where the total number of entities in a batch is less
than 200 (e.g., samples used in clinical trials), the sample size may be
reduced to two units, or one unit if the size is less than 100.
Select the sample(s) at random from the bulk material or from the
available containers of the preparation. To obtain the required quantity,
mix the contents of a sufficient number of containers to provide the
sample.
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/46
61 Microbiological Examination
Examination of the Product
Membrane Filtration
Use a filtration apparatus designed to allow the transfer of the filter to
the medium. Prepare the sample using a method that has been shown
to be suitable as described in Growth Promotion Test and Suitability of
membrane filters, and filter immediately. Wash each filter following the
procedure shown to be suitable.
For the determination of TAMC, transfer one of the membrane fil-
ters to the surface of SoybeanCasein Digest Agar. For the determina-
tion of TYMC, transfer the other membrane to the surface of Sab-
ouraud Dextrose Agar. Incubate the plate of SoybeanCasein Digest
Agar at 30 to 35 for 3 to 5 days and the plate of Sabouraud Dextrose
Agar at 20 to 25 for 5 to 7 days. Calculate the number of cfu per g or
per mL of product.
When examining transdermal patches, separately filter 10% of the
volume of the preparation described for Preparation of the Sample
through each of two sterile filter membranes. Transfer one membrane
P
to SoybeanCasein Digest Agar for TAMC and the other membrane to
Sabouraud Dextrose Agar for TYMC.
S
Plate-Count Methods
U
Pour-Plate MethodPrepare the sample using a method that has been
shown to be suitable as described in Growth Promotion Test and Suit-
ability of the Counting Method. Prepare for each medium at least two
9
Petri dishes for each level of dilution. Incubate the plates of Soybean
Casein Digest Agar at 30 to 35 for 3 to 5 days and the plates of Sab-
ouraud Dextrose Agar at 20 to 25 for 5 to 7 days. Select the plates cor-
responding to a given dilution and showing the highest number of
colonies less than 250 for TAMC and 50 for TYMC. Take the arithmetic
mean per culture medium of the counts, and calculate the number of
cfu per g or per mL of product.
Surface-Spread MethodPrepare the sample using a method that has
been shown to be suitable as described in Growth Promotion Test and
Suitability of the Counting Method. Prepare at least two Petri dishes for
each medium and each level of dilution. For incubation and calculation
of the number of cfu, proceed as directed for the Pour-Plate Method.
Most-Probable-Number Method
Prepare and dilute the sample using a method that has been shown to
be suitable as decribed in Growth Promotion Test and Suitability of the
Counting Method. Incubate all tubes for 3 to 5 days at 30 to 35. Sub-
culture if necessary, using the procedure shown to be suitable. Record
for each level of dilution the number of tubes showing microbial
growth. Determine the most probable number of microorganisms per
g or mL of the product to be examined from Table 3.
Interpretation of the Results
The total aerobic microbial count (TAMC) is considered to be equal to
the number of cfu found using SoybeanCasein Digest Agar; if colo-
nies of fungi are detected on this medium, they are counted as part of
TAMC. The total combined yeasts and molds count (TYMC) is consid-
ered to be equal to the number of cfu found using Sabouraud Dex-
trose Agar; if colonies of bacteria are detected on this medium, they
are counted as part of TYMC. When the TYMC is expected to exceed
the acceptance criterion due to the bacterial growth, Sabouraud Dex-
trose Agar containing antibiotics may be used. If the count is carried
out by the MPN Method, the calculated value is TAMC.
When an acceptance criterion for microbiological quality is pre-
scribed, it is interpreted as follows:
USP Pharmacists Pharmacopeia
101 cfu: maximum acceptable count = 20;
102 cfu: maximum acceptable count = 200;
103 cfu: maximum acceptable count = 2000; and so forth.
The recommended solutions and media are described in Tests for
Specified Microorganisms 62
(Official May 1, 2009)
62 Microbiological Examination
of Nonsterile Products: Tests for
Specified Microorganisms
Introduction
The tests described hereafter will allow determination of the absence
of, or limited occurrence of, specified microorganisms that may be de-
tected under the conditions described.
The tests are designed primarily to determine whether a substance
or preparation complies with an established specification for microbio-
logical quality. When used for such purposes, follow the instructions
given below, including the number of samples to be taken, and inter-
pret the results as stated below.
Alternative microbiological procedures, including automated
methods, may be used, provided that their equivalence to the Pharma-
copeial method has been demonstrated.
0
0
General Procedures
2
The preparation of samples is carried out as described in Microbiologi-
cal Examination of Nonsterile Products: Microbial Enumeration Tests
61.
If the product to be examined has antimicrobial activity, this is in-
sofar as possible removed or neutralized as described in Microbiologi-
cal Examination of Nonsterile Products: Microbial Enumeration Tests
61.
If surface-active substances are used for sample preparation, their
absence of toxicity for microorganisms and their compatibility with any
inactivators used must be demonstrated as described in Microbiologi-
cal Examination of Nonsterile Products: Microbial Enumeration Tests
61.
Growth-Promoting and Inhibitory
Properties of the Media and Suitability
of the Test
The ability of the test to detect microorganisms in the presence of the
product to be tested must be established. Suitability must be con-
firmed if a change in testing performance or a change in the product
that may affect the outcome of the test is introduced.
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/47
62 Microbiological Examination
Preparation of Test Strains
Use standardized stable suspensions of test strains as stated below.
Seed-lot culture maintenance techniques (seed-lot systems) are used
so that the viable microorganisms used for inoculation are not more
than five passages removed from the original master seed-lot.
Aerobic Microorganisms
Grow each of the bacterial test strains separately in containers contain-
ing SoybeanCasein Digest Broth or on SoybeanCasein Digest Agar at
30 to 35 for 18 to 24 hours. Grow the test strain for Candida albicans
separately on Sabouraud Dextrose Agar or in Sabouraud Dextrose
Broth at 20 to 25 for 2 to 3 days.
Staphylococcus aureus such as ATCC 6538, NCIMB 9518,
CIP 4.83, or NBRC 13276
Pseudomonas aeruginosa such as ATCC 9027, NCIMB 8626,
CIP 82.118, or NBRC 13275
Escherichia coli such as ATCC 8739, NCIMB 8545,
CIP 53.126, or NBRC 3972
P
Salmonella enterica ssp. enterica such as ATCC 14028
serotype typhimurium or,
S
as an alternative,
Salmonella enterica ssp. enterica such as NBRC 100797, NCTC 6017,
serotype abony or CIP 80.39
U
Candida albicans such as ATCC 10231, NCPF 3179, IP
48.72, or NBRC 1594
9
Use Buffered Sodium ChloridePeptone Solution pH 7.0 or Phos-
phate Buffer Solution pH 7.2 to make test suspensions. Use the sus-
pensions within 2 hours or within 24 hours if stored at 2 to 8.
Clostridia
Use Clostridium sporogenes such as ATCC 11437 (NBRC 14293, NCIMB
12343, CIP 100651) or ATCC 19404 (NCTC 532 or CIP 79.3). Grow the
clostridial test strain under anaerobic conditions in Reinforced Medium
for Clostridia at 30 to 35 for 24 to 48 hours. As an alternative to pre-
paring and then diluting down a fresh suspension of vegetative cells of
Cl. sporogenes, a stable spore suspension is used for test inoculation.
The stable spore suspension may be maintained at 2 to 8 for a vali-
dated period.
Negative Control
To verify testing conditions, a negative control is performed using the
chosen diluent in place of the test preparation. There must be no
growth of microorganisms.
Growth Promotion and Inhibitory Properties
of the Media
Test each batch of ready-prepared medium and each batch of medium
prepared either from dehydrated medium or from ingredients. Verify
suitable properties of relevant media as described in Table 1.
USP Pharmacists Pharmacopeia 62 Microbiological Examination

Table 1. Growth Promoting, Inhibitory, and Indicative Properties of Media

Test/Medium Property Test Strains
Test for bile-tolerant Gram-negative bacteria
Enterobacteria Enrichment Broth Mossel Growth promoting E. coli
P. aeruginosa
Inhibitory S. aureus
Violet Red Bile Glucose Agar Growth promoting + Indicative E. coli
P. aeruginosa
Test for Escherichia coli
MacConkey Broth Growth promoting E. coli
Inhibitory S. aureus
MacConkey Agar Growth promoting + Indicative E. coli
Test for Salmonella
Rappaport Vassiliadis Salmonella Enrichment Broth Growth promoting Salmonella enterica ssp. enterica serotype
typhimurium or
Salmonella enterica ssp. enterica serotype abony
Inhibitory S. aureus
Xylose Lysine Deoxycholate Agar Growth promoting + Indicative Salmonella enterica ssp. enterica serotype
typhimurium or
Salmonella enterica ssp. enterica serotype abony
Indicative E. coli

P
Test for Pseudomonas aeruginosa
Cetrimide Agar Growth promoting P. aeruginosa

S
Inhibitory E. coli
Test for Staphylococcus aureus
Mannitol Salt Agar Growth promoting + Indicative S. aureus

U
Inhibitory E. coli
Test for Clostridia

9
Reinforced Medium for Clostridia Growth promoting Cl. sporogenes
Columbia Agar Growth promoting Cl. sporogenes

0
Test for Candida albicans
Sabouraud Dextrose Broth Growth promoting C. albicans

0
Sabouraud Dextrose Agar Growth promoting + Indicative C. albicans

2 Suitability of the Test Method

Test for Growth-Promoting Properties, Liquid MediaInoculate a por-
tion of the appropriate medium with a small number (not more than

100 cfu) of the appropriate microorganism. Incubate at the specified
temperature for not more than the shortest period of time specified in
the test. Clearly visible growth of the microorganism comparable to
that previously obtained with a previously tested and approved batch
of medium occurs.
Test for Growth-Promoting Properties, Solid MediaPerform Surface-
Spread Method (see Plate-Count Methods under Microbiological Ex-
amination of Nonsterile Products: Microbial Enumeration Tests 61),
inoculating each plate with a small number (not more than 100 cfu) of
the appropriate microorganism. Incubate at the specified temperature
for not more than the shortest period of time specified in the test.
Growth of the microorganism comparable to that previously obtained
with a previously tested and approved batch of medium occurs.
Test for Inhibitory Properties, Liquid or Solid MediaInoculate the
appropriate medium with at least 100 cfu of the appropriate microor-
ganism. Incubate at the specified temperature for not less than the
longest period of time specified in the test. No growth of the test mi-
croorganism occurs.
Test for Indicative PropertiesPerform Surface-Spread Method (see
Plate-Count Methods under Microbiological Examination of Nonsterile
Products: Microbial Enumeration Tests 61), inoculating each plate with
a small number (not more than 100 cfu) of the appropriate microorgan-
ism. Incubate at the specified temperature for a period of time within
the range specified in the test. Colonies are comparable in appearance
and indication reactions to those previously obtained with a previously
tested and approved batch of medium.
For each new product to be tested perform sample preparation as de-
scribed in the relevant paragraph under Testing of Products. At the
time of mixing, add each test strain in the prescribed growth medium.
Inoculate the test strains individually. Use a number of microorganisms
equivalent to not more than 100 cfu in the inoculated test preparation.
Perform the test as described in the relevant paragraph under
Testing of Products using the shortest incubation period prescribed.
The specified microorganisms must be detected with the indica-
tion reactions as described under Testing of Products.
Any antimicrobial activity of the product necessitates a modifica-
tion of the test procedure (see Neutralization/Removal of Antimicrobial
Activity under Microbiological Examination of Nonsterile Products: Mi-
crobial Enumeration Tests 61).
For a given product, if the antimicrobial activity with respect to a
microorganism for which testing is prescribed cannot be neutralized,
then it is to be assumed that the inhibited microorganism will not be
present in the product.
Testing of Products
Bile-Tolerant Gram-Negative Bacteria
Sample Preparation and Pre-IncubationPrepare a sample using a 1 in
10 dilution of not less than 1 g of the product to be examined as de-
scribed in Microbiological Examination of Nonsterile Products: Micro-
bial Enumeration Tests 61, but using SoybeanCasein Digest Broth as
the chosen diluent, mix, and incubate at 20 to 25 for a time sufficient
to resuscitate the bacteria but not sufficient to encourage multiplica-
tion of the organisms (usually 2 hours but not more than 5 hours).

Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/48
USP Pharmacists Pharmacopeia
Test for AbsenceUnless otherwise prescribed, use the volume cor-
responding to 1 g of the product, as prepared in Sample Preparation
and Pre-Incubation, to inoculate Enterobacteria Enrichment Broth Mos-
sel. Incubate at 30 to 35 for 24 to 48 hours. Subculture on plates of
Violet Red Bile Glucose Agar. Incubate at 30 to 35 for 18 to 24 hours.
The product complies with the test if there is no growth of
colonies.
Quantitative Test
Selection and SubcultureInoculate suitable quantities of Entero-
bacteria Enrichment Broth Mossel with the preparation as directed un-
der Sample Preparation and Pre-Incubation and/or dilutions of it con-
taining respectively 0.1 g, 0.01 g, and 0.001 g (or 0.1 mL, 0.01 mL, and
0.001 mL) of the product to be examined. Incubate at 30 to 35 for 24
to 48 hours. Subculture each of the cultures on a plate of Violet Red
Bile Glucose Agar. Incubate at 30 to 35 for 18 to 24 hours.
InterpretationGrowth of colonies constitutes a positive result.
Note the smallest quantity of the product that gives a positive result
and the largest quantity that gives a negative result. Determine from
Table 2 the probable number of bacteria.
Table 2. Interpretation of Results
Results for Each Quantity
of Product
0.1 g or 0.01 g or 0.001 g or Probable Number of Bacteria
0.1 mL 0.01 mL 0.001 mL per g or mL of Product
+ + + more than 103
+ + less than 103 and more than 102
0
+ less than 102 and more than 10
less than 10
0
2
Escherichia coli
Sample Preparation and Pre-IncubationPrepare a sample using a 1 in
10 dilution of not less than 1 g of the product to be examined as de-
scribed in Microbiological Examination of Nonsterile Products: Micro-
bial Enumeration Tests 61, and use 10 mL or the quantity correspond-
ing to 1 g or 1 mL, to inoculate a suitable amount (determined as
described under Suitability of the Test Method) of SoybeanCasein
Digest Broth, mix, and incubate at 30 to 35 for 18 to 24 hours.
Selection and SubcultureShake the container, transfer 1 mL of Soy-
beanCasein Digest Broth to 100 mL of MacConkey Broth, and incubate
at 42 to 44 for 24 to 48 hours. Subculture on a plate of MacConkey
Agar at 30 to 35 for 18 to 72 hours.
InterpretationGrowth of colonies indicates the possible presence of
E. coli. This is confirmed by identification tests.
The product complies with the test if no colonies are present or if
the identification tests are negative.
Salmonella
Sample Preparation and Pre-IncubationPrepare the product to be
examined as described in Microbiological Examination of Nonsterile
Products: Microbial Enumeration Tests 61, and use the quantity corre-
sponding to not less than 10 g or 10 mL to inoculate a suitable amount
(determined as described under Suitability of the Test Method) of Soy-
beanCasein Digest Broth, mix, and incubate at 30 to 35 for 18 to 24
hours.
Selection and SubcultureTransfer 0.1 mL of SoybeanCasein Digest
Broth to 10 mL of Rappaport Vassiliadis Salmonella Enrichment Broth,
and incubate at 30 to 35 for 18 to 24 hours. Subculture on plates of
Xylose Lysine Deoxycholate Agar. Incubate at 30 to 35 for 18 to 48
hours.
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/49
62 Microbiological Examination
InterpretationThe possible presence of Salmonella is indicated by
the growth of well-developed, red colonies, with or without black cen-
ters. This is confirmed by identification tests.
The product complies with the test if colonies of the types de-
scribed are not present or if the confirmatory identification tests are
negative.
Pseudomonas aeruginosa
Sample Preparation and Pre-IncubationPrepare a sample using a 1 in
10 dilution of not less than 1 g of the product to be examined as de-
scribed in Microbiological Examination of Nonsterile Products: Micro-
bial Enumeration Tests 61, and use 10 mL or the quantity correspond-
ing to 1 g or 1 mL to inoculate a suitable amount (determined as
described under Suitability of the Test Method) of SoybeanCasein
Digest Broth, and mix. When testing transdermal patches, filter the
volume of sample corresponding to one patch of the preparation (see
Transdermal Patches under Preparation of the Sample in Microbiologi-
cal Examination of Nonsterile Products: Microbial Enumeration Tests
P
61) through a sterile filter membrane, and place in 100 mL of Soy-
beanCasein Digest Broth. Incubate at 30 to 35 for 18 to 24 hours.
S
Selection and SubcultureSubculture on a plate of Cetrimide Agar,
and incubate at 30 to 35 for 18 to 72 hours.
U
InterpretationGrowth of colonies indicates the possible presence of
P. aeruginosa. This is confirmed by identification tests.
9
The product complies with the test if colonies are not present or if
the confirmatory identification tests are negative.
Staphylococcus aureus
Sample Preparation and Pre-IncubationPrepare a sample using a 1 in
10 dilution of not less than 1 g of the product to be examined as de-
scribed in Microbiological Examination of Nonsterile Products: Micro-
bial Enumeration Tests 61, and use 10 mL or the quantity correspond-
ing to 1 g or 1 mL to inoculate a suitable amount (determined as
described under Suitability of the Test Method) of SoybeanCasein
Digest Broth, and homogenize. When testing transdermal patches, fil-
ter the volume of sample corresponding to one patch of the prepara-
tion (see Transdermal Patches under Preparation of the Sample in Mi-
crobiological Examination of Nonsterile Products: Microbial
Enumeration Tests 61) through a sterile filter membrane, and place in
100 mL of SoybeanCasein Digest Broth. Incubate at 30 to 35 for 18 to
24 hours.
Selection and SubcultureSubculture on a plate of Mannitol Salt Agar,
and incubate at 30 to 35 for 18 to 72 hours.
InterpretationThe possible presence of S. aureus is indicated by the
growth of yellow or white colonies surrounded by a yellow zone. This
is confirmed by identification tests.
The product complies with the test if colonies of the types de-
scribed are not present or if the confirmatory identification tests are
negative.
Clostridia
Sample Preparation and Heat TreatmentPrepare the product to be
examined as described in Microbiological Examination of Nonsterile
Products: Microbial Enumeration Tests 61. Take two equal portions
corresponding to not less than 1 g or 1 mL of the product to be exam-
ined. Heat one portion at 80 for 10 minutes, and cool rapidly. Do not
heat the other portion.
Selection and SubcultureTransfer 10 mL of each of the mixed por-
tions to two containers (38 mm 200 mm) or other containers contain-
USP Pharmacists Pharmacopeia
ing 100 mL of Reinforced Medium for Clostridia. Incubate under an-
aerobic conditions at 30 to 35 for 48 hours. After incubation, make
subcultures from each tube on Columbia Agar, and incubate under
anaerobic conditions at 30 to 35 for 48 hours.
InterpretationThe occurrence of anaerobic growth of rods (with or
without endospores) giving a negative catalase reaction indicates the
presence of Clostridia.
If no anaerobic growth of microorganisms is detected on Colum-
bia Agar or the catalase test is positive, the product complies with the
test.
Candida albicans
Sample Preparation and Pre-IncubationPrepare the product to be
examined as described in Microbiological Examination of Nonsterile
Products: Microbial Enumeration Tests 61, and use 10 mL or the quan-
tity corresponding to not less than 1 g or 1 mL, to inoculate 100 mL of
Sabouraud Dextrose Broth, and mix. Incubate at 30 to 35 for 3 to 5
days.
Selection and SubcultureSubculture on a plate of Sabouraud Dex-
trose Agar, and incubate at 30 to 35 for 24 to 48 hours.
InterpretationGrowth of white colonies may indicate the presence
of C. albicans. This is confirmed by identification tests.
The product complies with the test if such colonies are not pres-
ent or if the confirmatory identification tests are negative.
0
Recommended Solutions
0
and Culture Media
2
[noteThis section is given for information.]
The following solutions and culture media have been found satis-
factory for the purposes for which they are prescribed in the test for
microbial contamination in the Pharmacopeia. Other media may be
used if they have similar growth-promoting and inhibitory properties.
Stock Buffer SolutionTransfer 34 g of potassium dihydrogen phos-
phate to a 1000-mL volumetric flask, dissolve in 500 mL of Purified Wa-
ter, adjust with sodium hydroxide to a pH of 7.2 0.2, add Purified Wa-
ter to volume, and mix. Dispense in containers, and sterilize. Store at a
temperature of 2 to 8.
Phosphate Buffer Solution pH 7.2Prepare a mixture of Purified Water
and Stock Buffer Solution (800:1 v/v), and sterilize.
Buffered Sodium ChloridePeptone Solution pH 7.0
Potassium Dihydrogen Phosphate 3.6 g
Disodium Hydrogen Phosphate Dihydrate 7.2 g (equivalent to
0.067 M phosphate)
Sodium Chloride 4.3 g
Peptone (meat or casein) 1.0 g
Purified Water 1000 mL
Sterilize in an autoclave using a validated cycle.
SoybeanCasein Digest Broth
Pancreatic Digest of Casein 17.0 g
Papaic Digest of Soybean 3.0 g
Sodium Chloride 5.0 g
Dibasic Hydrogen Phosphate 2.5 g
Glucose Monohydrate 2.5 g
Purified Water 1000 mL
Adjust the pH so that after sterilization it is 7.3 0.2 at 25. Sterilize in
an autoclave using a validated cycle.
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/50
62 Microbiological Examination
SoybeanCasein Digest Agar
Pancreatic Digest of Casein 15.0 g
Papaic Digest of Soybean 5.0 g
Sodium Chloride 5.0 g
Agar 15.0 g
Purified Water 1000 mL
Adjust the pH so that after sterilization it is 7.3 0.2 at 25. Sterilize in
an autoclave using a validated cycle.
Sabouraud Dextrose Agar
Dextrose 40.0 g
Mixture of Peptic Digest of Animal Tissue and Pancreatic
Digest of Casein (1:1) 10.0 g
Agar 15.0 g
Purified Water 1000 mL
Adjust the pH so that after sterilization it is 5.6 0.2 at 25. Sterilize in
an autoclave using a validated cycle.
Potato Dextrose Agar
P
Infusion from potatoes 200 g
S
Dextrose 20.0 g
Agar 15.0 g
Purified Water 1000 mL
U
Adjust the pH so that after sterilization it is 5.6 0.2 at 25. Sterilize in
an autoclave using a validated cycle.
9
Sabouraud Dextrose Broth
Dextrose 20.0 g
Mixture of Peptic Digest of Animal Tissue
and Pancreatic Digest of Casein (1:1)
10.0 g
Purified Water 1000 mL
Adjust the pH so that after sterilization it is 5.6 0.2 at 25. Sterilize in
an autoclave using a validated cycle.
Enterobacteria Enrichment Broth Mossel
Pancreatic Digest of Gelatin 10.0 g
Glucose Monohydrate 5.0 g
Dehydrated Ox Bile 20.0 g
Potassium Dihydrogen Phosphate 2.0 g
Disodium Hydrogen Phosphate Dihydrate 8.0 g
Brilliant Green 15 mg
Purified Water 1000 mL
Adjust the pH so that after heating it is 7.2 0.2 at 25. Heat at 100 for
30 minutes, and cool immediately.
Violet Red Bile Glucose Agar
Yeast Extract 3.0 g
Pancreatic Digest of Gelatin 7.0 g
Bile Salts 1.5 g
Sodium Chloride 5.0 g
Glucose Monohydrate 10.0 g
Agar 15.0 g
Neutral Red 30 mg
Crystal Violet 2 mg
Purified Water 1000 mL
Adjust the pH so that after heating it is 7.4 0.2 at 25. Heat to boiling;
do not heat in an autoclave.
USP Pharmacists Pharmacopeia
MacConkey Broth
Pancreatic Digest of Gelatin 20.0 g
Lactose Monohydrate 10.0 g
Dehydrated Ox Bile 5.0 g
Bromocresol Purple 10 mg
Purified Water 1000 mL
Adjust the pH so that after sterilization it is 7.3 0.2 at 25. Sterilize in
an autoclave using a validated cycle.
MacConkey Agar
Pancreatic Digest of Gelatin 17.0 g
Peptones (meat and casein) 3.0 g
Lactose Monohydrate 10.0 g
Sodium Chloride 5.0 g
Bile Salts 1.5 g
Agar 13.5 g
Neutral Red 30.0 mg
Crystal Violet 1 mg
Purified Water 1000 mL
Adjust the pH so that after sterilization it is 7.1 0.2 at 25. Boil for 1
minute with constant shaking, then sterilize in an autoclave using a
validated cycle.
Rappaport Vassiliadis Salmonella Enrichment Broth
Soya Peptone 4.5 g
Magnesium Chloride Hexahydrate 29.0 g
Sodium Chloride 8.0 g
Dipotassium Phosphate 0.4 g
0
Potassium Dihydrogen Phosphate 0.6 g
Malachite Green 0.036 g
0
Purified Water 1000 mL
2
Dissolve, warming slightly. Sterilize in an autoclave using a validated
cycle, at a temperature not exceeding 115. The pH is to be 5.2 0.2 at
25 after heating and autoclaving.
Xylose Lysine Deoxycholate Agar
Xylose 3.5 g
l-Lysine 5.0 g
Lactose Monohydrate 7.5 g
Sucrose 7.5 g
Sodium Chloride 5.0 g
Yeast Extract 3.0 g
Phenol Red 80 mg
Agar 13.5 g
Sodium Deoxycholate 2.5 g
Sodium Thiosulfate 6.8 g
Ferric Ammonium Citrate 0.8 g
Purified Water 1000 mL
Adjust the pH so that after heating it is 7.4 0.2 at 25. Heat to boiling,
cool to 50, and pour into Petri dishes. Do not heat in an autoclave.
Cetrimide Agar
Pancreatic Digest of Gelatin 20.0 g
Magnesium Chloride 1.4 g
Dipotassium Sulfate 10.0 g
Cetrimide 0.3 g
Agar 13.6 g
Purified Water 1000 mL
Glycerol 10.0 mL
Heat to boiling for 1 minute with shaking. Adjust the pH so that after
sterilization it is 7.2 0.2 at 25. Sterilize in an autoclave using a validat-
ed cycle.
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/51
381 Elastomeric Closures for Injections
Mannitol Salt Agar
Pancreatic Digest of Casein 5.0 g
Peptic Digest of Animal Tissue 5.0 g
Beef Extract 1.0 g
d-Mannitol 10.0 g
Sodium Chloride 75.0 g
Agar 15.0 g
Phenol Red 0.025 g
Purified Water 1000 mL
Heat to boiling for 1 minute with shaking. Adjust the pH so that after
sterilization it is 7.4 0.2 at 25. Sterilize in an autoclave using a validat-
ed cycle.
Reinforced Medium for Clostridia
Beef Extract 10.0 g
Peptone 10.0 g
Yeast Extract 3.0 g
Soluble Starch 1.0 g
Glucose Monohydrate 5.0 g
Cysteine Hydrochloride 0.5 g
P
Sodium Chloride 5.0 g
Sodium Acetate 3.0 g
S
Agar 0.5 g
Purified Water 1000 mL
U
Hydrate the agar, and dissolve by heating to boiling with continuous
stirring. If necessary, adjust the pH so that after sterilization it is about
6.8 0.2 at 25. Sterilize in an autoclave using a validated cycle.
9
Columbia Agar
Pancreatic Digest of Casein 10.0 g
Meat Peptic Digest 5.0 g
Heart Pancreatic Digest 3.0 g
Yeast Extract 5.0 g
Maize Starch 1.0 g
Sodium Chloride 5.0 g
Agar, according to gelling power 10.015.0 g
Purified Water 1000 mL
Hydrate the agar, and dissolve by heating to boiling with continuous
stirring. If necessary, adjust the pH so that after sterilization it is 7.3
0.2 at 25. Sterilize in an autoclave using a validated cycle. Allow to cool
to 45 to 50; add, where necessary, gentamicin sulfate corresponding
to 20 mg of gentamicin base, and pour into Petri dishes.
(Official May 1, 2009)
381 Elastomeric Closures
for Injections
Introduction
Elastomeric closures for containers used in the types of preparations
defined in the general test chapter Injections 1 are made of materials
obtained by vulcanization (cross-linking) polymerization, polyaddition,
or polycondensation of macromolecular organic substances (elasto-
mers). Closure formulations contain natural or synthetic elastomers
and inorganic and organic additives to aid or control vulcanization,
impart physical and chemical properties or color, or stabilize the clo-
sure formulation.
This chapter applies to closures used for long-term storage of
preparations defined in the general test chapter Injections 1. Such
closures are typically used as part of a vial, bottle, or pre-fill syringe
package system.
USP Pharmacists Pharmacopeia
This chapter applies to closures formulated with natural or syn-
thetic elastomeric substances. This chapter does not apply to closures
made from silicone elastomer; however, it does apply to closures
treated with silicone (e.g., Dimethicone, NF). When performing the
tests in this chapter, it is not required that closures be treated with sili-
cone, although there is no restriction prohibiting the use of siliconized
closures.
This chapter also applies to closures coated with other lubricious
materials (e.g., materials chemically or mechanically bonded to the
closure) that are not intended to, and in fact do not provide, a barrier
to the base elastomer. When performing the tests, closures with lubri-
cious non-barrier coatings are to be tested in their coated state.
The following comments relate solely to closures laminated or
coated with materials intended to provide, or in fact function as, a bar-
rier to the base elastomer (e.g., PTFE or lacquer coatings). It is not per-
missible to use a barrier material in an attempt to change a closure that
does not meet compendial requirements to one that does conform.
Therefore, all Physicochemical Tests apply to the base formula of such
closures, as well as to the coated or laminated closure. To obtain Physi-
cochemical Tests results, the tests are to be performed on uncoated or
non-laminated closures of the same elastomeric compound, as well as
to the laminated or coated closure. The Functionality Tests apply to
and are to be performed using the laminated or coated elastomeric
closure. Biological Tests apply to the lamination or coating material, as
well as to the base formula. Biological Tests may be performed on the
laminated or coated closure, or they may be performed on the lami-
nate/coating material and the uncoated or non-laminated closures of
the same elastomeric compound. In the latter case, the results are to
0
be reported separately. The base formula used for physicochemical or
biological tests intended to support the compendial compliance of a
0
barrier-coated closure should be similar to the corresponding coated
2
closure in configuration and size.
For all Elastomeric Closures for Injection 381 tests performed on
any closure type, it is important to document the closure being tested,
including a full description of the elastomer, and any lubrication, coat-
ing, laminations, or treatments applied.
This chapter states test limits for Type I and Type II elastomeric
closures. Type I closures are those used for aqueous preparations.
Type II closures are typically intended for nonaqueous preparations
and are those which, having properties optimized for special uses, may
not meet all requirements listed for Type I closures because of physical
configuration, material of construction, or both. If a closure fails to
meet one or more of the Type I test requirements, but still meets the
Type II requirements for the test(s), the closure is assigned a final clas-
sification of Type II.
This chapter is intended as an initial screen to identify elastomeric
closures that might be appropriate for use with injectable preparations
on the basis of their biological compatibility, their aqueous extract
physicochemical properties, and their functionality. All elastomeric
closures suitable for use with injectable preparations comply with ei-
ther Type I or Type II test limits. However, this specification is not in-
tended to serve as the sole evaluation criteria for the selection of such
closures.
The following closure evaluation requirements are beyond the
scope of this chapter:
The establishment of closure identification tests and specifications
The verification of closureproduct physicochemical compatibility
The identification and safety determination of closure leachables
found in the packaged product
The verification of packaged product closure functionality under
actual storage and use conditions
The manufacturer of the injectable product (the end user) must
obtain from the closure supplier an assurance that the composition of
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/52
381 Elastomeric Closures for Injections
the closure does not vary and that it is the same as that of the closure
used during compatibility testing. When the supplier informs the end
user of changes in the composition, compatibility testing must be re-
peated, totally or partly, depending on the nature of the changes. Clo-
sures must be properly stored, cleaned for removal of environmental
contaminants and endotoxins, and sterilized prior to use in packaging
injectable products.
Characteristics
Elastomeric closures are translucent or opaque and have no character-
istic color, the latter depending on the additives used. They are homo-
geneous and practically free from flash and adventitious materials
(e.g., fibers, foreign particles, and waste rubber.)
Identification
Closures are made of a wide variety of elastomeric materials and op-
tional polymeric coatings. For this reason, it is beyond the scope of this
P
chapter to specify identification tests that encompass all possible clo-
sure presentations. However, it is the responsibility of the closure sup-
S
plier and the injectable product manufacturer (the end user) to verify
the closure elastomeric formulation and any coating or laminate mate-
U
rials used according to suitable identification tests. Examples of some
of the analytical test methodologies that may be used include specific
gravity, percentage of ash analysis, sulfur content determination, FTIR-
9
ATR test, thin-layer chromatography of an extract, UV absorption spec-
trophotometry of an extract, or IR absorption spectrophotometry of a
pyrolysate.
Test Procedures
Elastomeric closures shall conform to biological, physicochemical, and
functionality requirements both as they are shipped by the closure
supplier to the injectable product manufacturer (the end user), and in
their final ready-to-use state by the end user.
For those elastomeric closures processed by the supplier prior to
distribution to the end user, the supplier shall demonstrate compen-
dial conformance of closures exposed to such processing and/or steril-
ization steps. Similarly, if elastomeric closures received by the end user
are subsequently processed or sterilized, the end user is responsible
for demonstrating the continued conformance of closures to compen-
dial requirements subsequent to such processing and/or sterilization
conditions (i.e., in their ready-to-use state). This is especially important
if closures shall be exposed to processes or conditions that may sig-
nificantly impact the biological, physicochemical, or functionality char-
acteristics of the closure (e.g., gamma irradiation).
For closures that are normally lubricated with silicone prior to use,
it is permissible to perform physicochemical testing on non-lubricated
closures, in order to avoid potential method interference and/or diffi-
culties in interpreting test results. For closures supplied with other lu-
bricious non-barrier coatings, all tests are to be performed using the
coated closure.
For closures coated or laminated with coatings intended to pro-
vide a barrier function (e.g., PTFE or lacquer coatings), physicochemical
compendial tests apply to the uncoated base elastomer, as well as to
the coated closure. In this case, suppliers are responsible for demon-
strating physicochemical compendial compliance of the coated clo-
sure, as well as of the uncoated closure, processed or treated in a
manner simulating conditions typically followed by the supplier for
such coated closures prior to shipment to the end user. The uncoated
closure subject to physicochemical tests should be similar to the cor-
responding coated closure in size and configuration. End users of
USP Pharmacists Pharmacopeia 381 Elastomeric Closures for Injections

Table 1
Closure Types Test Requirements
(As Supplied or Used) Physicochemical Tests Functionality Tests Biological Tests
Closure with or without Tests are to be performed. Tests are to be performed. Tests are to be performed.
Silicone Coating Silicone use is optional. Silicone use is optional. Silicone use is optional.
Responsibility: supplier and end user Responsibility: supplier and end user Responsibility: supplier and end user
Closures with Lubricious Tests are to be performed on Tests are to be performed on Tests are to be performed on
Coating (Non-Barrier coated closures. coated closures. coated closures.
Material; Not Silicone) Responsibility: supplier and end user Responsibility: supplier and end user Responsibility: supplier and end user
Closures with Barrier Tests are to be performed on Tests are to be performed on Tests are to be performed on
Coating coated closures. coated closures. coated closures.
Responsibility: supplier and end user Responsibility: supplier and end user OR:
AND: Tests are to be performed on
Tests are to be performed on uncoated uncoated closures (base formula)
closures (base formula). and the laminate/coating material
Responsibility: supplier (report results separately).
Responsibility: supplier and end user

P
coated closures are also responsible for demonstrating the continued so that a temperature of 121 2C is reached within 20 to 30 minutes,
physicochemical compendial conformance of the coated closure, pro- and maintain this temperature for 30 minutes. Cool to room tempera-

S
cessed or treated in a manner simulating conditions typically employed ture over a period of about 30 minutes. Add Purified Water or Water
by the end user prior to use. for Injection to bring it up to the original mass. Shake, and immediately

U
In all cases, it is appropriate to document all conditions of closure decant and collect the solution. [noteThis solution must be shaken
processing, pretreatment, sterilization or lubrication when reporting before being used in each of the tests.]
test results.

9
Table 1 summarizes the testing requirements of closures, and the
Preparation of Blank

0
responsibilities of the supplier and the end user.

0
Prepare a blank solution similarly, using 200 mL of Purified Water or
Water for Injection omitting the closures.
Biological Tests

2
Two stages of testing are indicated. The first stage is the performance
of an in vitro test procedure as described in general test chapter Bio- Appearance of Solution (Turbidity/

logical Reactivity Tests, In Vitro 87. Materials that do not meet the re-
quirements of the in vitro test are subjected to the second stage of
testing, which is the performance of the in vivo tests, Systemic Injec-
tion Test and Intracutaneous Test, according to the procedures set
forth in the general test chapter Biological Reactivity Tests, In Vivo 88.
Materials that meet the requirements of the in vitro test are not re-
quired to undergo in vivo testing.
Type I and Type II closures must both conform to the require-
ments of either the in vitro or the in vivo biological reactivity tests.
[noteAlso see the general information chapter The Biocompatibility
of Material Used in Drug Containers, Medical Devices, and Implants
1031.]
Physicochemical Tests
Preparation of Solution S
Place whole, uncut closures corresponding to a surface area of 100 10
cm2 into a suitable glass container. Cover the closures with 200 mL of
Purified Water or Water for Injection. If it is not possible to achieve the
prescribed closure surface area (100 10 cm2) using uncut closures,
select the number of closures that will most closely approximate 100
cm2, and adjust the volume of water used to the equivalent of 2 mL per
each 1 cm2 of actual closure surface area used. Boil for 5 minutes, and
rinse five times with cold Purified Water or Water for Injection
Place the washed closures into a Type I glass wide-necked flask
(see ContainersGlass 660), add the same quantity of Purified Water
or Water for Injection initially added to the closures, and weigh. Cover
the mouth of the flask with a Type I glass beaker. Heat in an autoclave
Opalescence and Color)
Determination of Turbidity (Opalescence)
noteThe determination of turbidity may be performed by visual
comparison (Procedure A), or instrumentally using a suitable ratio tur-
bidimeter (Procedure B). For a discussion of turbidimetry, see Spectro-
photometry and Light-Scattering 851. Instrumental assessment of
clarity provides a more discriminatory test that does not depend on
the visual acuity of the analyst.
Hydrazine Sulfate SolutionDissolve 1.0 g of hydrazine sulfate, in
water and dilute with water to 100.0 mL. Allow to stand for 4 to 6
hours.
Hexamethylenetetramine SolutionDissolve 2.5 g of hexmethy-
lenetetramine in 25.0 mL of water in a 100 mL glass stoppered flask.
Opalescence Stock SuspensionAdd 25.0 mL of Hydrazine Sulfate
Solution to the Hexamethylenetetramine Solution in the flask. Mix,
and allow to stand for 24 hours. This suspension is stable for 2 months,
provided it is stored in a glass container free from surface defects. The
suspension must not adhere to the glass and must be well mixed be-
fore use.
Opalescence Standard SuspensionPrepare a suspension by di-
luting 15.0 mL of the Opalescence Stock Suspension with water to
1000.0 mL. Opalescence Standard Suspension is stable for about 24
hours after preparation.
Reference SuspensionsPrepare according to Table 2. Mix and
shake before use. [noteStabilized formazin suspensions that can be
used to prepare stable, diluted turbidity standards are available com-
mercially and may be used after comparison with the standards pre-
pared as described.]

Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/53
USP Pharmacists Pharmacopeia 381 Elastomeric Closures for Injections

Table 2
Reference Suspension A Reference Suspension B Reference Suspension C Reference Suspension D
Standard of Opalescence 5.0 mL 10.0 mL 30.0 mL 50.0 mL
Water 95.0 mL 90.0 mL 70.0 mL 50.0 mL
Nephelometric turbidity units 3 NTU 6 NTU 18 NTU 30 NTU

Table 3
Comparison Method
Opalescence Requirements Procedure A (Visual) Procedure B (Instrumental)
Type I closures no more opalescent that Suspension B no more than 6 NTU
Type II closures no more opalescent than Suspension C no more than 18 NTU

Procedure A: Visual ComparisonUse identical test tubes made of
colorless, transparent, neutral glass with a flat base and an internal di-
ameter of 15 to 25 mm. Fill one tube to a depth of 40 mm with Solution
S, one tube to the same depth with water, and four others to the same
depth with Reference Suspensions A, B, C, and D. Compare the solu-
tions in diffuse daylight 5 minutes after preparation of the Reference
Blank CorrectionTest 20 mL of Blank similarly. Correct the results
obtained for Solution S by subtracting or adding the volume of titrant
required for the Blank, as appropriate. (Reference Titrimetry 541.)
RequirementNot more than 0.3 ml of 0.01 N sodium hydroxide
produces a blue color, or not more than 0.8 ml of 0.01 N hydrochloric

P
acid produces a yellow color, or no titration is required.
Suspensions, viewing vertically against a black background. The light

S
conditions shall be such that Reference Suspension A can be readily
distinguished from water and that Reference Suspension B can be Absorbance
readily distinguished from Reference Suspension A.

U
Procedure [notePerform this test within 5 hours of preparing Solu-
RequirementSolution S is not more opalescent than Reference
tion S.] Filter Solution S through a 0.45-m pore size filter, discarding
Suspension B for Type I closures, and not more opalescent than Refer-
the first few mL of filtrate. Measure the absorbance of the filtrate at

9
ence Suspension C for Type II closures. Solution S is considered clear
wavelengths between 220 and 360 nm in a 1-cm cell using the blank in
if its clarity is the same as that of water when examined as described

0
a matched cell in the reference beam. If dilution of the filtrate is re-
above, or if its opalescence is not more pronounced than that of Refer-
quired before measurement of the absorbance, correct the test results
ence Suspension A (refer to Table 3).

0
for the dilution.
Procedure B: Instrumental ComparisonMeasure the turbidity of
RequirementThe absorbances at these wavelengths do not ex-

2
the Reference Suspensions in a suitable calibrated turbidimeter (see
ceed 0.2 for Type I closures or 4.0 for Type II closures.
Spectrophotometry and Light Scattering 851). The blank should be
run and the results corrected for the blank. Reference Suspensions A,
B, C, and D represent 3, 6, 18 and 30 Nephelometric Turbidity Units

(NTU), respectively. Measure the turbidity of Solution S using the cali-
brated turbidimeter.
RequirementThe turbidity of Solution S is not greater than that
for Reference Suspension B (6 NTU FTU) for Type I closures, and is not
greater than that for Reference Suspension C (18 NTU FTU) for Type II
closures (refer to Table 3).
Determination of Color
Color StandardPrepare a solution by diluting 3.0 mL of Matching
Fluid O (see Color and Achromicity 631) with 97.0 mL of diluted hy-
drochloric acid.
ProcedureUse identical tubes made of colorless, transparent,
neutral glass with a flat base and an internal diameter of 15 to 25 mm.
Fill one tube to a depth of 40 mm with Solution S, and the second with
Color Standard. Compare the liquids in diffuse daylight, viewing verti-
cally against a white background.
RequirementSolution S is not more intensely colored than the
Color Standard.
Reducing Substances
Procedure[notePerform this test within 4 hours of preparing Solu-
tion S.] To 20.0 mL of Solution S add 1 mL of diluted sulfuric acid and
20.0 mL of 0.002 M potassium permanganate. Boil for 3 minutes. Cool,
add 1 g of potassium iodide, and titrate immediately with 0.01 M sodi-
um thiosulfate, using 0.25 mL of starch solution TS as the indicator.
Perform a titration using 20.0 mL of blank and note the difference in
volume of 0.01 M sodium thiosulfate required.
RequirementThe difference between the titration volumes is not
greater than 3.0 mL for Type I closures and not greater than 7.0 mL for
Type II closures.
Heavy Metals
ProcedureProceed as directed for Method 1 under Heavy Metals
231. Prepare the Test Preparation using 10.0 mL of Solution S.
RequirementSolution S contains not more than 2 ppm of heavy
metals as lead.

Acidity or Alkalinity
Bromothymol Blue SolutionDissolve 50 mg of bromothymol blue in
a mixture of 4 mL of 0.02 M sodium hydroxide and 20 mL of alcohol.
Dilute with water to 100 mL.
ProcedureTo 20 ml of Solution S add 0.1 ml of Bromothymol Blue
Solution. If the solution is yellow, titrate with 0.01 N sodium hydroxide
until a blue endpoint is reached. If the solution is blue, titrate with 0.01
N hydrochloric acid until a yellow endpoint is reached. If the solution
is green, it is neutral and no titration is required.
Extractable Zinc
Test SolutionPrepare a Test Solution by diluting 10.0 mL of Solution S
to 100 mL with 0.1N hydrochloric acid. Prepare a test blank similarly,
using the Blank for Solution S.
Zinc Standard SolutionPrepare a solution (10 ppm Zn) by dis-
solving zinc sulfate in 0.1 N hydrochloric acid.
Reference SolutionsPrepare not fewer than 3 Reference Solu-
tions by diluting the Zinc Standard Solution with 0.1 N hydrochloric

Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/54
USP Pharmacists Pharmacopeia
acid. The concentrations of zinc in these Reference Solutions are to
span the expected limit of the Test Solution.
ProcedureUse a suitable atomic absorption spectrophotometer
(see Spectrophotometry and Light Scattering 851) equipped with a
zinc hollow-cathode lamp and an airacetylene flame. An alternative
procedure such as an appropriately validated inductively coupled
plasma analysis (ICP) may be used.
Test each of the Reference Solutions at the zinc emission line of
213.9 nm at least 3 times. Record the steady readings. Rinse the appara-
tus with the test blank solution each time, to ensure that the reading
returns to initial blank value. Prepare a calibration curve from the
mean of the readings obtained for each Reference Solution. Record
the absorbance of the Test Solution. Determine the ppm zinc concen-
tration of the Test Solution using the calibration curve.
RequirementSolution S contains not more than 5 ppm of ex-
tractable zinc.
Ammonium
Alkaline Potassium Tetraiodomercurate SolutionPrepare a 100 mL
solution containing 11 g of potassium iodide and 15 g of mercuric io-
dide in water. Immediately before use, mix 1 volume of this solution
with an equal volume of a 250 g per L solution of sodium hydroxide.
Test SolutionDilute 5 mL of Solution S to 14 mL with water. Make
alkaline if necessary by adding 1 N sodium hydroxide, and dilute with
water to 15 mL. Add 0.3 mL of Alkaline Potassium Tetraiodomercurate
Solution, and close the container.
0
Ammonium Standard SolutionPrepare a solution of ammonium
chloride in water (1 ppm NH4). Mix 10 mL of the 1 ppm ammonium
0
chloride solution with 5 mL water and 0.3 mL of Alkaline Potassium
2
Tetraiodomercurate Solution. Close the container.
RequirementAfter 5 minutes, any yellow color in the Test Solu-
tion is no darker than the Ammonium Standard Solution (no more
than 2 ppm of NH4 in Solution S).
Volatile Sulfides
ProcedurePlace closures, cut if necessary, with a total surface area of
20 2 cm2 in a 100-mL flask, and add 50 mL of a 20 g per L citric acid
solution. In the same manner and at the same time, prepare a control
solution in a separate 100-mL flask by dissolving 0.154 mg of sodium
sulfide in 50 mL of a 20 g per L citric acid solution. Place a piece of lead
acetate paper over the mouth of each flask, and hold the paper in posi-
tion by placing over it an inverted weighing bottle. Heat the flasks in an
autoclave at 121 2 for 30 minutes.
RequirementAny black stain on the paper produced by Solution
S is not more intense than that produced by the control solution.
Functionality Tests
noteSamples treated as described for preparation of Solution S and
air dried should be used for Functionality Tests of Penetrability, Frag-
mentation, and Self-Sealing Capacity. Functionality Tests are performed
on closures intended to be pierced by a hypodermic needle. The Self-
Sealing Capacity test is required only for closures intended for multi-
ple-dose containers. The needle specified for each test is a lubricated
long bevel (bevel angle 12 2) hypodermic needle1.
Refer to ISO 7864, Sterile hypodermic needles for single use with an external
1 undergo distribution between two phases, one of them fixed (station-
diameter of 0.8 mm (21 Gauge).
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/55
621 Chromatography
Penetrability
ProcedureFill 10 suitable vials to the nominal volume with water, fit
the closures to be examined, and secure with a cap. Using a new hypo-
dermic needle as described above for each closure, pierce the closure
with the needle perpendicular to the surface.
RequirementThe force for piercing is no greater than 10 N (1 kgf)
for each closure, determined with an accuracy of 0.25 N (25 gf).
Fragmentation
Closures for Liquid PreparationsFill 12 clean vials with water to 4 mL
less than the nominal capacity. Fit the closures to be examined, secure
with a cap, and allow to stand for 16 hours.
Closures for Dry PreparationsFit closures to be examined into 12
clean vials, and secure each with a cap.
ProcedureUsing a hypodermic needle as described above fitted
to a clean syringe, inject into each vial 1 mL of water while removing
1 mL of air. Repeat this procedure 4 times for each closure, piercing
P
each time at a different site. Use a new needle for each closure, check-
ing that it is not blunted during the test. Filter the total volume of liquid
S
in all the vials through a single filter with a nominal pore size no great-
er than 0.5 mm. Count the rubber fragments on the surface of the filter
U
visible to the naked eye.
RequirementThere are no more than 5 fragments visible. This
limit is based on the assumption that fragments with a diameter
9
>50 mm are visible to the naked eye. In case of doubt or dispute, the
particles are examined microscopically to verify their nature and size.
Self-Sealing Capacity
ProcedureFill 10 suitable vials with water to the nominal volume. Fit
the closures that are to be examined, and cap. Using a new hypoder-
mic needle as described above for each closure, pierce each closure 10
times, piercing each time at a different site. Immerse the 10 vials in a
solution of 0.1% (1 g per L) methylene blue, and reduce the external
pressure by 27 kPa for 10 minutes. Restore to atmospheric pressure,
and leave the vials immersed for 30 minutes. Rinse the outside of the
vials.
RequirementNone of the vials contain any trace of blue solution.
621 Chromatography
Introduction
This chapter defines the terms and procedures used in chromatogra-
phy and provides general information. Specific requirements for chro-
matographic procedures for drug substances and dosage forms, in-
cluding adsorbent and developing solvents, are given in the individual
monographs.
Chromatography is defined as a procedure by which solutes are
separated by a dynamic differential migration process in a system con-
sisting of two or more phases, one of which moves continuously in a
given direction and in which the individual substances exhibit differ-
ent mobilities by reason of differences in adsorption, partition, solubil-
ity, vapor pressure, molecular size, or ionic charge density. The indi-
vidual substances thus separated can be identified or determined by
analytical procedures.
The general chromatographic technique requires that a solute
ary phase), the other moving (mobile phase). It is the mobile phase
USP Pharmacists Pharmacopeia
that transfers the solute through the medium until it eventually emerg-
es separated from other solutes that are eluted earlier or later. Gener-
ally, the solute is transported through the separation medium by
means of a flowing stream of a liquid or a gaseous solvent known as
the eluant. The stationary phase may act through adsorption, as in
the case of adsorbents such as activated alumina and silica gel, or it
may act by dissolving the solute, thus partitioning the latter between
the stationary and mobile phases. In the latter process, a liquid coated
onto an inert support, or chemically bonded onto silica gel, or directly
onto the wall of a fused silica capillary, serves as the stationary phase.
Partitioning is the predominant mechanism of separation in gasliquid
chromatography, paper chromatography, in forms of column chroma-
tography, and in thin-layer chromatography designated as liquid-liquid
chromatography. In practice, separations frequently result from a com-
bination of adsorption and partitioning effects. Other separation prin-
ciples include ion exchange, ion-pair formation, size exclusion, hydro-
phobic interaction, and chiral recognition.
The types of chromatography useful in qualitative and quantitative
analysis that are employed in the USP procedures are column, gas, pa-
per, thin-layer, (including high-performance thin-layer chromatogra-
phy), and pressurized liquid chromatography (commonly called high-
pressure or high-performance liquid chromatography). Paper and
thin-layer chromatography are ordinarily more useful for purposes of
identification, because of their convenience and simplicity. Column
chromatography offers a wider choice of stationary phases and is use-
ful for the separation of individual compounds, in quantity, from mix-
tures. Modern high-performance thin-layer chromatography, gas chro-
matography, and pressurized liquid chromatography require more
0
elaborate apparatus but usually provide high resolution and identify
and quantitate very small amounts of material.
0
Use of Reference Substances in Identity TestsIn paper and thin-layer
2
chromatography, the ratio of the distance (this distance being mea-
sured to the point of maximum intensity of the spot or zone) traveled
on the medium by a given compound to the distance traveled by the
front of the mobile phase, from the point of application of the test
substance, is designated as the RF value of the compound. The ratio
between the distances traveled by a given compound and a reference
substance is the RR value. RF values vary with the experimental condi-
tions, and thus identification is best accomplished where an authentic
specimen of the compound in question is used as a reference sub-
stance on the same chromatogram.
For this purpose, chromatograms are prepared by applying on the
thin-layer adsorbent or on the paper in a straight line, parallel to the
edge of the chromatographic plate or paper, solutions of the substance
to be identified, the authentic specimen, and a mixture of nearly equal
amounts of the substance to be identified and the authentic specimen.
Each sample application contains approximately the same quantity by
weight of material to be chromatographed. If the substance to be iden-
tified and the authentic specimen are identical, all chromatograms
agree in color and RF value and the mixed chromatogram yields a sin-
gle spot; i.e., RR is 1.0.
Location and Identification of ComponentsThe spots produced by
paper or thin-layer chromatography may be located by: (1) direct in-
spection if the compounds are visible under white or either short-
wavelength (254 nm) or long-wavelength (360 nm) UV light, (2) inspec-
tion in white or UV light after treatment with reagents that will make
the spots visible (reagents are most conveniently applied with an at-
omizer), (3) use of a Geiger-Mller counter or autoradiographic tech-
niques in the case of the presence of radioactive substances, or (4) evi-
dence resulting from stimulation or inhibition of bacterial growth by
the placing of removed portions of the adsorbent and substance on
inoculated media.
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/56
621 Chromatography
In open-column chromatography, in pressurized liquid chroma-
tography performed under conditions of constant flow rate, and in gas
chromatography, the retention time, t, defined as the time elapsed be-
tween sample injection and appearance of the peak concentration of
the eluted sample zone, may be used as a parameter of identification.
Solutions of the substance to be identified or derivatives thereof, of
the reference compound, and of a mixture of equal amounts of these
two are chromatographed successively on the same column under the
same chromatographic conditions. Only one peak should be observed
for the mixture. The ratio of the retention times of the test substance,
the reference compound, and a mixture of these, to the retention time
of an internal standard is called the relative retention time RR and is
also used frequently as a parameter of identification.
The deviations of RR, RF, or t values measured for the test sub-
stance from the values obtained for the reference compound and
mixture should not exceed the reliability estimates determined statisti-
cally from replicate assays of the reference compound.
Chromatographic identification by these methods under given
conditions strongly indicates identity but does not constitute definitive
P
identification. Coincidence of identity parameters under three to six
different sets of chromatographic conditions (temperatures, column
S
packings, adsorbents, eluants, developing solvents, various chemical
derivatives, etc.) increases the probability that the test and reference
substances are identical. However, many isomeric compounds cannot
U
be separated. Specific and pertinent chemical, spectroscopic, or physi-
cochemical identification of the eluted component combined with
9
chromatographic identity is the most valid criterion of identification.
For this purpose, the individual components separated by chromatog-
raphy may be collected for further identification.
Paper Chromatography
In paper chromatography the adsorbent is a sheet of paper of suitable
texture and thickness. Chromatographic separation may proceed
through the action of a single liquid phase in a process analogous to
adsorption chromatography in columns. Since the natural water con-
tent of the paper, or selective imbibition of a hydrophilic component
of the liquid phase by the paper fibers, may be regarded as a stationary
phase, a partitioning mechanism may contribute significantly to the
separation.
Alternatively, a two-phase system may be used. The paper is im-
pregnated with one of the phases, which then remains stationary (usu-
ally the more polar phase in the case of unmodified paper). The chro-
matogram is developed by slow passage of the other, mobile phase
over the sheet. Development may be ascending, in which case the sol-
vent is carried up the paper by capillary forces, or descending, in
which case the solvent flow is also assisted by gravitational force.
Differences in the value of RF have been reported where chro-
matograms developed in the direction of the paper grain (machine di-
rection) are compared with others developed at right angles to the
grain; therefore, the orientation of paper grain with respect to solvent
flow should be maintained constant in a series of chromatograms. (The
machine direction is usually designated by the manufacturer on pack-
ages of chromatography paper.)
Descending Chromatography
In descending chromatography, the mobile phase flows downward on
the chromatographic sheet.
ApparatusThe essential equipment for descending chromatography
consists of the following:
USP Pharmacists Pharmacopeia
A vapor-tight chamber provided with inlets for addition of solvent
or for releasing internal pressure. The chamber is constructed prefera-
bly of glass, stainless steel, or porcelain and is so designed as to permit
observation of the progress of the chromatographic run without open-
ing of the chamber. Tall glass cylinders are convenient if they are made
vapor-tight with suitable covers and a sealing compound.
A rack of corrosion-resistant material about 5 cm shorter than the
inside height of the chamber. The rack serves as a support for solvent
troughs and for antisiphon rods which, in turn, hold up the chromato-
graphic sheets.
One or more glass troughs capable of holding a volume of solvent
greater than that needed for one chromatographic run. The troughs
must also be longer than the width of the chromatographic sheets.
Heavy glass antisiphon rods to be supported by the rack and run-
ning outside of, parallel to, and slightly above the edge of the glass
trough.
Chromatographic sheets of special filter paper at least 2.5 cm wide
and not wider than the length of the troughs are cut to a length ap-
proximately equal to the height of the chamber. A fine pencil line is
drawn horizontally across the filter paper at a distance from one end
such that, when the sheet is suspended from the antisiphon rods with
the upper end of the paper resting in the trough and the lower portion
hanging free into the chamber, the line is located a few centimeters
below the rods. Care is necessary to avoid contaminating the filter pa-
per by excessive handling or by contact with dirty surfaces.
ProcedureThe substance or substances to be analyzed are dissolved
in a suitable solvent. Convenient volumes, delivered from suitable mi-
cropipets, of the resulting solution, normally containing 1 to 20 g of
0
the compound, are placed in 6- to 10-mm spots not less than 3 cm
0
apart along the pencil line. If the total volume to be applied would
produce spots of a diameter greater than 6 to 10 mm, it is applied in
2
separate portions to the same spot, each portion being allowed to dry
before the next is added.
The spotted chromatographic sheet is suspended in the chamber
by use of the antisiphon rod, which holds the upper end of the sheet
in the solvent trough. The bottom of the chamber is covered with the
prescribed solvent system. Saturation of the chamber with solvent va-
por is facilitated by lining the inside walls with paper that is wetted
with the prescribed solvent system. It is important to ensure that the
portion of the sheet hanging below the rods is freely suspended in the
chamber without touching the rack or the chamber walls or the fluid in
the chamber. The chamber is sealed to allow equilibration (saturation)
of the chamber and the paper with the solvent vapor. Any excess pres-
sure is released as necessary. For large chambers, equilibration over-
night may be necessary.
A volume of the mobile phase in excess of the volume required
for complete development of the chromatogram is saturated with the
immobile phase by shaking. After equilibration of the chamber, the
prepared mobile solvent is introduced into the trough through the in-
let. The inlet is closed and the mobile solvent phase is allowed to travel
the desired distance down the paper. Precautions must be taken
against allowing the solvent to run down the sheet when opening the
chamber and removing the chromatogram. The location of the solvent
front is quickly marked, and the sheets are dried.
The chromatogram is observed and measured directly or after
suitable development to reveal the location of the spots of the isolated
drug or drugs. The paper section(s) predetermined to contain the iso-
lated drug(s) may be cut out and eluted by an appropriate solvent, and
the solutions may be made up to a known volume and quantitatively
analyzed by appropriate chemical or instrumental techniques. Similar
procedures should be conducted with various amounts of similarly
spotted reference standard on the same paper in the concentration
range appropriate to prepare a valid calibration curve.
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/57
621 Chromatography
Ascending Chromatography
In ascending chromatography, the lower edge of the sheet (or strip) is
dipped into the mobile phase to permit the mobile phase to rise on
the chromatographic sheet by capillary action.
ApparatusThe essential equipment for ascending chromatography
is substantially the same as that described under Descending
Chromatography.
ProcedureThe test materials are applied to the chromatographic
sheets as directed under Descending Chromatography, and above the
level to which the paper is dipped into the developing solvent. The
bottom of the developing chamber is covered with the developing
solvent system. If a two-phase system is used, both phases are added.
It is also desirable to line the walls of the chamber with paper and to
saturate this lining with the solvent system. Empty solvent troughs are
placed on the bottom of the chamber, and the chromatographic sheets
are suspended so that the end on which the spots have been added
hangs free inside the empty trough.
The chamber is sealed, and equilibration is allowed to proceed as
described under Descending Chromatography. Then the developing
P
solvent (mobile phase) is added through the inlet to the trough in ex-
S
cess of the solvent required for complete moistening of the chromato-
graphic sheet. The chamber is resealed. When the solvent front has
reached the desired height, the chamber is opened and the sheet is
U
removed and dried.
Quantitative analyses of the spots may be conducted as described
9
under Descending Chromatography.
Thin-Layer Chromatography
In thin-layer chromatography, the adsorbent is a relatively thin, uni-
form layer of dry, finely powdered material applied to a glass, plastic,
or metal sheet or plate, glass plates being most commonly employed.
The coated plate can be considered an open chromatographic col-
umn and the separations achieved may be based upon adsorption,
partition, or a combination of both effects, depending on the particu-
lar type of stationary phase, its preparation, and its use with different
solvents. Thin-layer chromatography on ion-exchange layers can be
used for the fractionation of polar compounds. Presumptive identifica-
tion can be effected by observation of spots or zones of identical RF
value and about equal magnitude obtained, respectively, with an un-
known and a reference sample chromatographed on the same plate. A
visual comparison of the size or intensity of the spots or zones may
serve for semiquantitative estimation. Quantitative measurements are
possible by means of densitometry (absorbance or fluorescence mea-
surements), or the spots may be carefully removed from the plate, fol-
lowed by elution with a suitable solvent and spectrophotometric mea-
surement. For two-dimensional thin-layer chromatography, the
chromatographed plate is turned at a right angle and again chromato-
graphed, usually in another chamber equilibrated with a different sol-
vent system.
ApparatusAcceptable apparatus and materials for thin-layer chroma-
tography consist of the following.
A TLC or HPTLC plate. The chromatography is generally carried out
using precoated plates or sheets (on glass, aluminum, or polyester sup-
port) of suitable size. It may be necessary to clean the plates prior to
separation. This can be done by migration of, or immersion in, an ap-
propriate solvent. The plates may also be impregnated by procedures
such as development, immersion, or spraying. At the time of use, the
plates may be activated, if necessary, by heating in an oven at 120 for
20 minutes. The stationary phase of TLC plates has an average particle
size of 1015 m, and that of HPTLC plates an average particle size of 5
m. Commercial plates with a preadsorbant zone can be used if they
USP Pharmacists Pharmacopeia
are specified in a monograph. Sample applied to the preabsorbant re-
gion develops into sharp, narrow bands at the preabsorbant-sorbent
interface. Alternatively, flat glass plates of convenient size, typically 20
cm 20 cm can be coated as described under Preparation of Chro-
matographic Plates.
A suitable manual, semiautomatic, or automatic application device
can be used to ensure proper positioning of the plate and proper
transfer of the sample, with respect to volume and position, onto the
plate. Alternatively, a template can be used to guide in manually plac-
ing the test spots at definite intervals, to mark distances as needed,
and to aid in labeling the plates. For the proper application of the solu-
tions, micropipets, microsyringes, or calibrated disposable capillaries
are recommended.
For ascending development, a chromatographic chamber made of
inert, transparent material and having the following specifications is
used: a flat bottom or twin trough, a tightly fitted lid, and a size suitable
for the plates. For horizontal development, the chamber is provided
with a reservoir for the mobile phase, and it also contains a device for
directing the mobile phase to the stationary phase.
Devices for transfer of reagents onto the plate by spraying, immer-
sion, or exposure to vapor and devices to facilitate any necessary heat-
ing for visualization of the separated spots or zones.
A UV light source suitable for observations under short (254 nm)
and long (365 nm) wavelength UV light.
A suitable device for documentation of the visualized chromato-
graphic result.
ProcedureApply the prescribed volume of the test solution and the
0
standard solution in sufficiently small portions to obtain circular spots
of 2 to 5 mm in diameter (1 to 2 mm on HPTLC plates) or bands of 10 to
0
20 mm by 1 to 2 mm (5 to 10 mm by 0.5 to 1 mm on HPTLC plates) at an
appropriate distance from the lower edgeduring chromatography
2
the application position must be at least 3 mm (HPTLC) or 5 mm (TLC)
above the level of the developing solventand from the sides of the
plate. Apply the solutions on a line parallel to the lower edge of the
plate with an interval of at least 10 mm (5 mm on HPTLC plates) be-
tween the centers of spots or 4 mm (2 mm on HPTLC plates) between
the edges of bands, and allow to dry.
Ascending DevelopmentLine at least one wall of the chromato-
graphic chamber with filter paper. Pour into the chromatographic
chamber a quantity of the mobile phase sufficient for the size of the
chamber to give, after impregnation of the filter paper, a level of depth
appropriate to the dimension of the plate used. For saturation of the
chromatographic chamber, close the lid, and allow the system to
equilibrate. Unless otherwise indicated, the chromatographic separa-
tion is performed in a saturated chamber.
Place the plate in the chamber, ensuring that the plate is as vertical
as possible and that the spots or bands are above the surface of the
mobile phase, and close the chamber. The stationary phase faces the
inside of the chamber. Remove the plate when the mobile phase has
moved over the prescribed distance. Dry the plate, and visualize the
chromatograms as prescribed. For two-dimensional chromatography,
dry the plates after the first development, and carry out a second devel-
opment in a direction perpendicular to that of the first development.
Horizontal DevelopmentIntroduce a sufficient quantity of the
developing solvent into the reservoir of the chamber using a syringe or
pipet. Place the plate horizontally in the chamber, connect the mobile
phase direction device according to the manufacturers instructions,
and close the chamber. If prescribed, develop the plate starting simul-
taneously at both ends. Remove the plate when the mobile phase has
moved over the distance prescribed in the monograph. Dry the plate,
and visualize the chromatograms as prescribed.
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/58
621 Chromatography
For two-dimensional chromatography, dry the plates after the first
development, and carry out a second development in a direction per-
pendicular to that of the first development.
DetectionObserve the dry plate first under short-wavelength
UV light (254 nm) and then under long-wavelength UV light (365 nm)
or as stated in the monograph. If further directed, spray, immerse, or
expose the plate to vapors of the specified reagent, heat the plate
when required, observe, and compare the test chromatogram with the
standard chromatogram. Document the plate after each observation.
Measure and record the distance of each spot or zone from the point
of origin, and indicate for each spot or zone the wavelength under
which it was observed. Determine the RF values for the principal spots
or zones (see Glossary of Symbols).
Quantitative MeasurementUsing appropriate instrumentation, sub-
stances separated by TLC and responding to ultraviolet-visible (UV-Vis)
irradiation prior to or after derivatization can be determined directly
on the plate. While moving the plate or the measuring device, the
plate is examined by measuring the reflectance of the incident light.
Similarly, fluorescence may be measured using an appropriate optical
P
system. Substances containing radionuclides can be quantified in
three ways: (1) directly by moving the plate alongside a suitable coun-
S
ter or vice versa; (2) by cutting the plates into strips and measuring the
radioactivity on each individual strip using a suitable counter; or (3) by
scraping off the stationary phase, dissolving it in a suitable scintillation
U
cocktail, and measuring the radioactivity using a liquid scintillation
counter (see Radioactivity 821).
9
The apparatus for direct quantitative measurement on the plate is
a densitometer that is composed of a mechanical device to move the
plate or the measuring device along the x-axis and the y-axis, a record-
er, a suitable integrator or a computer; and, for substances responding
to UV-Vis irradiation, a photometer with a source of light, an optical
device capable of generating monochromatic light, and a photo cell of
adequate sensitivity, all of which are used for the measurement of re-
flectance. In the case where fluorescence is measured, a suitable filter
is also required to prevent the light used for excitation from reaching
the photo cell while permitting the emitted light or specific portions
thereof to pass. The linearity range of the counting device must be
verified.
For quantitative tests, it is necessary to apply to the plate not fewer
than three standard solutions of the substance to be examined, the
concentrations of which span the expected value in the test solution
(e.g., 80%, 100%, and 120%). Derivatize with the prescribed reagent, if
necessary, and record the reflectance or fluorescence in the chromato-
grams obtained. Use the measured results for the calculation of the
amount of substance in the test solution.
Preparation of Chromatographic Plates
Apparatus
Flat glass plates of convenient size, typically 20 cm 20 cm.
An aligning tray or a flat surface upon which to align and rest the
plates during the application of the adsorbent.
A storage rack to hold the prepared plates during drying and trans-
portation. The rack holding the plates should be kept in a desiccator or
be capable of being sealed in order to protect the plates from the envi-
ronment after removal from the drying oven.
The adsorbent consists of finely divided adsorbent materials, nor-
mally 5 to 40 m in diameter, suitable for chromatography. It can be
applied directly to the glass plate or can be bonded to the plate by
means of plaster of Paris [calcium sulfate hemihydrate (at a ratio of 5%
to 15%)] or with starch paste or other binders. The plaster of Paris will
not yield as hard a surface as will the starch, but it is not affected by
strongly oxidizing spray reagents. The adsorbent may contain fluoresc-
ing material to aid in the visualization of spots that absorb UV light.
USP Pharmacists Pharmacopeia
A spreader, which, when moved over the glass plate, will apply a
uniform layer of adsorbent of desired thickness over the entire surface
of the plate.
Procedure[noteIn this procedure, use Purified Water that is
obtained by distillation.] Clean the glass plates scrupulously, using an
appropriate cleaning solution (see Cleaning Glass Apparatus 1051),
rinsing them with copious quantities of water until the water runs off
the plates without leaving any visible water or oily spots, then dry. It is
important that the plates be completely free from lint and dust when
the adsorbent is applied.
Arrange the plate or plates on the aligning tray, place a 5- 20-cm
plate adjacent to the front edge of the first square plate and another
5- 20-cm plate adjacent to the rear edge of the last square, and secure
all of the plates so that they will not slip during the application of the
adsorbent. Position the spreader on the end plate opposite the raised
end of the aligning tray. Mix 1 part of adsorbent with 2 parts of water
(or in the ratio suggested by the supplier) by shaking vigorously for 30
seconds in a glass-stoppered conical flask, and transfer the slurry to
the spreader. Usually 30 g of adsorbent and 60 mL of water are suffi-
cient for five 20- 20-cm plates. Complete the application of adsor-
bents using plaster of Paris binder within 2 minutes of the addition of
the water, because thereafter the mixture begins to harden. Draw the
spreader smoothly over the plates toward the raised end of the align-
ing tray, and remove the spreader when it is on the end plate next to
the raised end of the aligning tray. (Wash away all traces of adsorbent
from the spreader immediately after use.) Allow the plates to remain
undisturbed for 5 minutes, then transfer the square plates, layer side
up, to the storage rack, and dry at 105 for 30 minutes. Preferably place
0
the rack at an angle in the drying oven to prevent the condensation of
moisture on the back sides of plates in the rack. When the plates are
0
dry, allow them to cool to room temperature, and inspect the unifor-
2
mity of the distribution and the texture of the adsorbent layer; trans-
mitted light will show uniformity of distribution, and reflected light will
show uniformity of texture. Store the satisfactory plates over silica gel
in a suitable chamber.
Column Chromatography
ApparatusThe apparatus required for column chromatographic pro-
cedures is simple, consisting only of the chromatographic tube itself
and a tamping rod, which may be needed to pack a pledget of glass
wool or cotton, if needed, in the base of the tube and compress the
adsorbent or slurry uniformly within the tube. In some cases a porous
glass disk is sealed at the base of the tube in order to support the con-
tents. The tube is cylindrical and is made of glass, unless another mate-
rial is specified in the individual monograph. A smaller-diameter deliv-
ery tube is fused or otherwise attached by a leakproof joint to the
lower end of the main tube. Column dimensions are variable; the di-
mensions of those commonly used in pharmaceutical analysis range
from 10 to 30 mm in uniform inside diameter and 150 to 400 mm in
length, exclusive of the delivery tube. The delivery tube, usually 3 to 6
mm in inside diameter, may include a stopcock for accurate control of
the flow rate of solvents through the column. The tamping rod, a cylin-
drical ram firmly attached to a shaft, may be constructed of plastic,
glass, stainless steel, or aluminum, unless another material is specified
in the individual monograph. The shaft of the rod is substantially
smaller in diameter than the column and is not less than 5 cm longer
than the effective length of the column. The ram has a diameter about
1 mm smaller than the inside diameter of the column.
Column Adsorption Chromatography
The adsorbent (such as activated alumina or silica gel, calcined diato-
maceous silica, or chromatographic purified siliceous earth) as a dry
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/59
621 Chromatography
solid or as a slurry is packed into a glass or quartz chromatographic
tube. A solution of the drug in a small amount of solvent is added to
the top of the column and allowed to flow into the adsorbent. The
drug principles are quantitatively removed from the solution and are
adsorbed in a narrow transverse band at the top of the column. As ad-
ditional solvent is allowed to flow through the column, either by grav-
ity or by application of air pressure, each substance progresses down
the column at a characteristic rate resulting in a spatial separation to
give what is known as the chromatogram. The rate of movement for a
given substance is affected by several variables, including the adsorp-
tive power of the adsorbent and its particle size and surface area; the
nature and polarity of the solvent; the hydrostatic head or applied
pressure; and the temperature of the chromatographic system.
If the separated compounds are colored or if they fluoresce under
UV light, the adsorbent column may be extruded and, by transverse
cuts, the appropriate segments may then be isolated. The desired com-
pounds are then extracted from each segment with a suitable solvent.
If the compounds are colorless, they may be located by means of
painting or spraying the extruded column with color-forming reagents.
Chromatographed radioactive substances may be located by means of
P
Geiger-Mller detectors or similar sensing and recording instruments.
S
Clear plastic tubing made of a material such as nylon, which is inert to
most solvents and transparent to short-wavelength UV light, may be
packed with adsorbent and used as a chromatographic column. Such a
U
column may be sliced with a sharp knife without removing the packing
from the tubing. If a fluorescent adsorbent is used, the column may be
marked under UV light in preparation for slicing.
9
A flowing chromatogram, which is extensively used, is obtained
by a procedure in which solvents are allowed to flow through the col-
umn until the separated drug appears in the effluent solution, known
as the eluate. The drug may be determined in the eluate by titration
or by a spectrophotometric or colorimetric method, or the solvent may
be evaporated, leaving the drug in more or less pure form. If a second
drug principle is involved, it is eluted by continuing the first solvent or
by passing a solvent of stronger eluting power through the column.
The efficiency of the separation may be checked by obtaining a thin-
layer chromatogram on the individual fractions.
A modified procedure for adding the mixture to the column is
sometimes employed. The drug, in a solid form, and, as in the case of a
powdered tablet, without separation from the excipients, is mixed with
some of the adsorbent and added to the top of a column. The subse-
quent flow of solvent moves the drug down the column in the manner
described.
Column Partition Chromatography
In partition chromatography the substances to be separated are parti-
tioned between two immiscible liquids, one of which, the immobile
phase, is adsorbed on a Solid Support, thereby presenting a very large
surface area to the flowing solvent or mobile phase. The exceedingly
high number of successive liquid-liquid contacts allows an efficiency
of separation not achieved in ordinary liquid-liquid extraction.
The Solid Support is usually polar, and the adsorbed immobile
phase more polar than the mobile phase. The Solid Support that is
most widely used is chromatographic siliceous earth having a particle
size suitable to permit proper flow of eluant.1 In reverse-phase parti-
tion chromatography the adsorbed immobile phase is less polar than
the mobile phase and the solid adsorbent is rendered nonpolar by
treatment with a silanizing agent, such as dichlorodimethylsilane, to
give silanized chromatographic siliceous earth.
1
A suitable grade is acid-washed Celite 545, available from Johns-Manville Corp.,
22 East 40th St., New York, NY 10016.
USP Pharmacists Pharmacopeia
The sample to be chromatographed is usually introduced into the
chromatographic system in one of two ways: (a) a solution of the sam-
ple in a small volume of the mobile phase is added to the top of the
column; or, (b) a solution of the sample in a small volume of the im-
mobile phase is mixed with the Solid Support and transferred to the
column as a layer above a bed of a mixture of immobile phase with
adsorbent.
Development and elution are accomplished with flowing solvent
as before. The mobile solvent usually is saturated with the immobile
solvent before use.
In conventional liquid-liquid partition chromatography, the degree
of partition of a given compound between the two liquid phases is ex-
pressed by its partition or distribution coefficient. In the case of com-
pounds that dissociate, distribution can be controlled by modifying
the pH, dielectric constant, ionic strength, and other properties of the
two phases. Selective elution of the components of a mixture can be
achieved by successively changing the mobile phase to one that pro-
vides a more favorable partition coefficient, or by changing the pH of
the immobile phase in situ with a mobile phase consisting of a solution
of an appropriate acid or base in an organic solvent.
Unless otherwise specified in the individual monograph, assays
and tests that employ column partition chromatography are performed
according to the following general methods.
Solid SupportUse purified siliceous earth. Use silanized chromato-
graphic siliceous earth for reverse-phase partition chromatography.
Stationary PhaseUse the solvent or solution specified in the individ-
ual monograph. If a mixture of liquids is to be used as the Stationary
0
Phase, mix them prior to the introduction of the Solid Support.
Mobile PhaseUse the solvent or solution specified in the individual
0
monograph. Equilibrate it with water if the Stationary Phase is an aque-
ous solution; if the Stationary Phase is a polar organic fluid, equilibrate
2
with that fluid.
Preparation of Chromatographic ColumnUnless otherwise specified
in the individual monograph, the chromatographic tube is about 22
mm in inside diameter and 200 to 300 mm in length, without porous
glass disk, to which is attached a delivery tube, without stopcock,
about 4 mm in inside diameter and about 50 mm in length. Pack a pled-
get of fine glass wool in the base of the tube. Place the specified vol-
ume of Stationary Phase in a 100- to 250-mL beaker, add the specified
amount of Solid Support, and mix to produce a homogeneous, fluffy
mixture. Transfer this mixture to the chromatographic tube, and tamp,
using gentle pressure, to obtain a uniform mass. If the specified
amount of Solid Support is more than 3 g, transfer the mixture to the
column in portions of approximately 2 g, and tamp each portion. If the
assay or test requires a multisegment column, with a different Station-
ary Phase specified for each segment, tamp after the addition of each
segment, and add each succeeding segment directly to the previous
one.
If a solution of the analyte is incorporated in the Stationary Phase,
complete the quantitative transfer to the chromatographic tube by
scrubbing the beaker used for the preparation of the test mixture with
a mixture of about 1 g of Solid Support and several drops of the solvent
used to prepare the test solution.
Pack a pledget of fine glass wool above the completed column
packing. The Mobile Phase flows through a properly packed column as
a moderate stream or, if reverse-phase chromatography is applied, as a
slow trickle.
ProcedureTransfer the Mobile Phase to the column space above
the column packing, and allow it to flow through the column under
the influence of gravity. Rinse the tip of the chromatographic column
with about 1 mL of Mobile Phase before each change in composition
of Mobile Phase and after completion of the elution. If the analyte is
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/60
621 Chromatography
introduced into the column as a solution in the Mobile Phase, allow it
to pass completely into the column packing, then add Mobile Phase in
several small portions, allowing each to drain completely, before adding
the bulk of the Mobile Phase. Where the assay or test requires the use
of multiple chromatographic columns mounted in series and the addi-
tion of Mobile Phase in divided portions is specified, allow each por-
tion to drain completely through each column, and rinse the tip of each
with Mobile Phase prior to the addition of each succeeding portion.
Gas Chromatography
The distinguishing features of gas chromatography are a gaseous mo-
bile phase and a solid or immobilized liquid stationary phase. Liquid
stationary phases are available in packed or capillary columns. In the
packed columns, the liquid phase is deposited on a finely divided, in-
ert solid support, such as diatomaceous earth, porous polymer, or
graphitized carbon, which is packed into a column that is typically 2 to
4 mm in internal diameter and 1 to 3 m in length. In capillary columns,
which contain no packing, the liquid phase is deposited on the inner
P
surface of the column and may be chemically bonded to it. In gas-solid
chromatography, the solid phase is an active adsorbent, such as alumi-
S
na, silica, or carbon, packed into a column. Polyaromatic porous resins,
which are sometimes used in packed columns, are not coated with a
liquid phase.
U
When a vaporized compound is introduced into the carrier gas
and carried into the column, it is partitioned between the gas and sta-
9
tionary phases by a dynamic countercurrent distribution process. The
compound is carried down the column by the carrier gas, retarded to a
greater or lesser extent by sorption and desorption on the stationary
phase. The elution of the compound is characterized by the partition
ratio, k, a dimensionless quantity also called the capacity factor (see
Glossary of Symbols for the definition of symbols). It is equivalent to
the ratio of the time required for the compound to flow through the
column (the retention time) to the elution time of an unretained com-
pound. The value of the capacity factor depends on the chemical na-
ture of the compound, the nature, amount, and surface area of the liq-
uid phase, the column temperature, and the gas flow rate. Under a
specified set of experimental conditions, a characteristic capacity fac-
tor exists for every compound. Separation by gas chromatography oc-
curs only if the compounds concerned have different capacity factors.
ApparatusA gas chromatograph consists of a carrier gas source, an
injection port, column, detector, and recording device. The injection
port, column, and detector are temperature-controlled. The typical
carrier gas is helium, nitrogen, or hydrogen, depending on the column
and detector in use. The gas is supplied from a high-pressure cylinder
or high-purity gas generator and passes through suitable pressure-
reducing valves and a flow meter to the injection port and column.
Compounds to be chromatographed, either in solution or as gases, are
injected into the gas stream at the injection port. Depending upon the
configuration of the apparatus, the test mixture may be injected di-
rectly into the column or be vaporized in the injection port and mixed
into the flowing carrier gas prior to entering the column.
Once in the column, compounds in the test mixture are separated
by virtue of differences in their capacity factors, which in turn depend
upon vapor pressure and degree of interaction with the stationary
phase. The capacity factor, which governs resolution, retention times,
and column efficiencies of components of the test mixture, is also
temperature-dependent. The use of temperature-programmable col-
umn ovens takes advantage of this dependence to achieve efficient
separation of compounds differing widely in vapor pressure.
As resolved compounds emerge separately from the column, they
pass through a differential detector, which responds to the amount of
each compound present. The type of detector to be used depends
USP Pharmacists Pharmacopeia
upon the nature of the compounds to be analyzed and is specified in
the individual monograph. Detectors are heated to prevent condensa-
tion of the eluting compounds.
Detector output is recorded as a function of time, producing a
chromatogram, which consists of a series of peaks on a time axis. Each
peak represents a compound in the vaporized test mixture, although
some peaks may overlap. The elution time is a characteristic of an indi-
vidual compound; and the instrument response, measured as peak
area or peak height, is a function of the amount present.
InjectorsSample injection devices range from simple syringes to
fully programmable automatic injectors. The amount of sample that
can be injected into a capillary column without overloading is small
compared to the amount that can be injected into packed columns,
and may be less than the smallest amount that can be manipulated
satisfactorily by syringe. Capillary columns, therefore, often are used
with injectors able to split samples into two fractions, a small one
that enters the column and a large one that goes to waste. Such injec-
tors may be used in a splitless mode for analyses of trace or minor
components.
Purge and trap injectors are equipped with a sparging device
by which volatile compounds in solution are carried into a low-
temperature trap. When sparging is complete, trapped compounds are
desorbed into the carrier gas by rapid heating of the temperature-
programmable trap.
Headspace injectors are equipped with a thermostatically con-
trolled sample heating chamber. Solid or liquid samples in tightly
closed containers are heated in the chamber for a fixed period of time,
allowing the volatile components in the sample to reach an equilibri-
0
um between the nongaseous phase and the gaseous or headspace
0
phase.
After this equilibrium has been established, the injector automati-
2
cally introduces a fixed amount of the headspace in the sample con-
tainer into the gas chromatograph.
ColumnsCapillary columns, which are usually made of fused
silica, are typically 0.2 to 0.53 mm in internal diameter and 5 to 60 m in
length. The liquid or stationary phase, which is sometimes chemically
bonded to the inner surface, is 0.1 to 1.0 mm thick, although nonpolar
stationary phases may be up to 5 mm thick. A list of liquid phases in
current use is given in the section Chromatographic Reagents.
Packed columns, made of glass or metal, are 1 to 3 m in length
with internal diameters of 2 to 4 mm. Those used for analysis typically
are porous polymers or solid supports with liquid phase loadings of
about 5% (w/w). High-capacity columns, with liquid phase loadings of
about 20% (w/w), are used for large test specimens and for the deter-
mination of low molecular weight compounds such as water. The ca-
pacity required influences the choice of solid support.
Supports for analysis of polar compounds on low-capacity, low-
polarity liquid phase columns must be inert to avoid peak tailing. The
reactivity of support materials can be reduced by silanizing prior to
coating with liquid phase. Acid-washed, flux-calcined diatomaceous
earth is often used for drug analysis. Support materials are available in
various mesh sizes, with 80- to 100-mesh and 100- to 120-mesh being
most commonly used with 2- to 4-mm columns. Supports and liquid
phases are listed in the section Chromatographic Reagents.
Retention time and the peak efficiency depend on the carrier gas
flow rate; retention time is also directly proportional to column length,
while resolution is proportional to the square root of the column
length. For packed columns, the carrier gas flow rate is usually ex-
pressed in mL per minute at atmospheric pressure and room tempera-
ture. It is measured at the detector outlet with a flowmeter while the
column is at operating temperature. The linear flow rate through a
packed column is inversely proportional to the square of the column
diameter for a given flow volume. Flow rates of 60 mL per minute in a
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/61
621 Chromatography
4-mm column and 15 mL per minute in a 2-mm column give identical
linear flow rates and thus similar retention times. Unless otherwise
specified in the individual monograph, flow rates for packed columns
are about 30 to 60 mL per minute. For capillary columns, linear flow
velocity is often used instead of flow rate. This is conveniently deter-
mined from the length of the column and the retention time of a dilute
methane sample, provided a flame-ionization detector is in use. At
high operating temperatures there is sufficient vapor pressure to result
in a gradual loss of liquid phase, a process called bleeding.
DetectorsFlame-ionization detectors are used for most pharma-
ceutical analyses, with lesser use made of thermal conductivity, elec-
tron-capture, nitrogen-phosphorus, and mass spectrometric detectors.
For quantitative analyses, detectors must have a wide linear dynamic
range: the response must be directly proportional to the amount of
compound present in the detector over a wide range of concentra-
tions. Flame-ionization detectors have a wide linear range and are
sensitive to most organic compounds. Detector response depends on
the structure and concentration of the compound and on the flow
rates of the combustion, air, makeup, and carrier gases. Unless other-
wise specified in individual monographs, flame-ionization detectors
P
with either helium or nitrogen carrier gas are to be used for packed
S
columns, and helium or hydrogen is used for capillary columns.
The thermal conductivity detector employs a heated wire placed
in the carrier gas stream. When an analyte enters the detector with the
U
carrier gas, the difference in thermal conductivity of the gas stream
(carrier and sample components) relative to that of a reference flow of
9
carrier gas alone is measured. In general, the thermal conductivity de-
tector responds uniformly to volatile compounds regardless of struc-
ture; however, it is considerably less sensitive than the flame-ionization
detector.
The alkali flame-ionization detector, sometimes called an NP or
nitrogen-phosphorus detector, contains a thermionic source, such as
an alkali-metal salt or a glass element containing rubidium or other
metal, that results in the efficient ionization of organic nitrogen and
phosphorus compounds. It is a selective detector that shows little re-
sponse to hydrocarbons.
The electron-capture detector contains a radioactive source of
ionizing radiation. It exhibits an extremely high response to com-
pounds containing halogens and nitro groups but little response to
hydrocarbons. The sensitivity increases with the number and atomic
weight of the halogen atoms.
Data Collection DevicesModern data stations receive the detec-
tor output, calculate peak areas and peak heights, and print chromato-
grams, complete with run parameters and peak data. Chromatographic
data may be stored and reprocessed, with integration and other calcu-
lation variables being changed as required. Data stations are used also
to program the chromatograph, controlling most operational variables
and providing for long periods of unattended operation.
Data can also be collected for manual measurement on simple re-
corders or on integrators whose capabilities range from those provid-
ing a printout of peak areas to those providing chromatograms with
peak areas and peak heights calculated and data stored for possible
reprocessing.
ProcedurePacked and capillary columns must be conditioned before
use until the baseline and other characteristics are stable. This may be
done by operation at a temperature above that called for by the meth-
od or by repeated injections of the compound or mixture to be chro-
matographed. The column or packing material supplier provides in-
structions for the recommended conditioning procedure. In the case
of thermally stable methyl- and phenyl-substituted polysiloxanes, a
special sequence increases inertness and efficiency; maintain the col-
umn at a temperature of 250 for 1 hour, with helium flowing, to re-
move oxygen and solvents. Stop the flow of helium, heat at about 340
USP Pharmacists Pharmacopeia
for 4 hours, then reduce the heating to a temperature of 250, and con-
dition with helium flowing until stable.
Most drugs are reactive polar molecules. Successful chromatogra-
phy may require conversion of the drug to a less polar and more vola-
tile derivative by treatment of reactive groups with appropriate re-
agents. Silylating agents are widely used for this purpose and are
readily available.
Assays require quantitative comparison of one chromatogram with
another. A major source of error is irreproducibility in the amount of
sample injected, notably when manual injections are made with a sy-
ringe. The effects of variability can be minimized by addition of an in-
ternal standard, a noninterfering compound present at the same con-
centration in test and standard solutions. The ratio of peak response of
the analyte to that of the internal standard is compared from one chro-
matogram to another. Where the internal standard is chemically similar
to the substance being determined, there is also compensation for
minor variations in column and detector characteristics. In some cases,
the internal standard may be carried through the sample preparation
procedure prior to gas chromatography to control other quantitative
aspects of the assay. Automatic injectors greatly improve the reproduc-
ibility of sample injections and reduce the need for internal standards.
Many monographs require that system suitability requirements be
met before samples are analyzed (see System Suitability and Interpre-
tation of Chromatograms).
High-Pressure Liquid Chromatography
0
High-pressure liquid chromatography (HPLC), sometimes called high-
performance liquid chromatography, is a separation technique based
0
on a solid stationary phase and a liquid mobile phase. Separations are
achieved by partition, adsorption, or ion-exchange processes, depend-
2
ing upon the type of stationary phase used. HPLC has distinct advan-
tages over gas chromatography for the analysis of organic compounds.
Compounds to be analyzed are dissolved in a suitable solvent, and
most separations take place at room temperature. Thus, most drugs,
being nonvolatile or thermally unstable compounds, can be chromato-
graphed without decomposition or the necessity of making volatile
derivatives. Most pharmaceutical analyses are based on partition chro-
matography and are completed within 30 minutes.
As in gas chromatography, the elution time of a compound can be
described by the capacity factor, k (see Glossary of Symbols), which
depends on the chemical nature of the analyte, the composition and
flow rate of the mobile phase, and the composition and surface area of
the stationary phase. Column length is an important determinant of
resolution. Only compounds having different capacity factors can be
separated by HPLC.
ApparatusA liquid chromatograph consists of a reservoir contain-
ing the mobile phase, a pump to force the mobile phase through the
system at high pressure, an injector to introduce the sample into the
mobile phase, a chromatographic column, a detector, and a data col-
lection device such as a computer, integrator, or recorder. Short, small-
bore columns containing densely packed particles of stationary phase
provide for the rapid exchange of compounds between the mobile
and stationary phases. In addition to receiving and reporting detector
output, computers are used to control chromatographic settings and
operations, thus providing for long periods of unattended operation.
Pumping SystemsHPLC pumping systems deliver metered
amounts of mobile phase from the solvent reservoirs to the column
through high-pressure tubing and fittings. Modern systems consist of
one or more computer-controlled metering pumps that can be pro-
grammed to vary the ratio of mobile phase components, as is required
for gradient chromatography, or to mix isocratic mobile phases (i.e.,
mobile phases having a fixed ratio of solvents). However, the propor-
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/62
621 Chromatography
tion of ingredients in premixed isocratic mobile phases can be more
accurately controlled than in those delivered by most pumping sys-
tems. Operating pressures up to 5000 psi or higher, with delivery rates
up to about 10 mL per minute are typical. Pumps used for quantitative
analysis should be constructed of materials inert to corrosive mobile
phase components and be capable of delivering the mobile phase at a
constant rate with minimal fluctuations over extended periods of
time.
InjectorsAfter dissolution in mobile phase or other suitable so-
lution, compounds to be chromatographed are injected into the mo-
bile phase, either manually by syringe or loop injectors, or automati-
cally by autosamplers. The latter consist of a carousel or rack to hold
sample vials with tops that have a pierceable septum or stopper and an
injection device to transfer sample from the vials to a loop from which
it is loaded into the chromatograph. Some autosamplers can be pro-
grammed to control sample volume, the number of injections and
loop rinse cycles, the interval between injections, and other operating
variables.
A syringe can be used for manual injection of samples through a
P
septum when column head pressures are less than 70 atmospheres
(about 1000 psi). At higher pressures an injection valve is essential.
S
Some valve systems incorporate a calibrated loop that is filled with test
solution for transfer to the column in the mobile phase. In other sys-
tems, the test solution is transferred to a cavity by syringe and then
U
switched into the mobile phase.
ColumnsFor most pharmaceutical analyses, separation is
9
achieved by partition of compounds in the test solution between the
mobile and stationary phases. Systems consisting of polar stationary
phases and nonpolar mobile phases are described as normal phase,
while the opposite arrangement, polar mobile phases and nonpolar
stationary phases, is called reverse-phase chromatography. Partition
chromatography is almost always used for hydrocarbon-soluble com-
pounds of molecular weight less than 1000. The affinity of a compound
for the stationary phase, and thus its retention time on the column, is
controlled by making the mobile phase more or less polar. Mobile
phase polarity can be varied by the addition of a second, and some-
times a third or even a fourth, component.
Stationary phases for modern, reverse-phase liquid chromatogra-
phy typically consist of an organic phase chemically bound to silica or
other materials. Particles are usually 3 to 10 m in diameter, but sizes
may range up to 50 m or more for preparative columns. Small parti-
cles thinly coated with organic phase provide for low mass transfer re-
sistance and, hence, rapid transfer of compounds between the station-
ary and mobile phases. Column polarity depends on the polarity of the
bound functional groups, which range from relatively nonpolar octa-
decyl silane to very polar nitrile groups. Liquid, nonbound stationary
phases must be largely immiscible in the mobile phase. Even so, it is
usually necessary to presaturate the mobile phase with stationary
phase to prevent stripping of the stationary phase from the column.
Polymeric stationary phases coated on the support are more durable.
Columns used for analytical separations usually have internal di-
ameters of 2 to 5 mm; larger diameter columns are used for preparative
chromatography. Columns may be heated to give more efficient sepa-
rations, but only rarely are they used at temperatures above 60 be-
cause of potential stationary phase degradation or mobile phase vola-
tility. Unless otherwise specified in the individual monograph, columns
are used at ambient temperature.
Ion-exchange chromatography is used to separate water-soluble,
ionizable compounds of molecular weight less than 1500. The station-
ary phases are usually synthetic organic resins; cation-exchange resins
contain negatively charged active sites and are used to separate basic
substances such as amines, while anion-exchange resins have posi-
tively charged active sites for separation of compounds with negatively
charged groups, such as phosphate, sulfonate, or carboxylate groups.
USP Pharmacists Pharmacopeia
Water-soluble ionic or ionizable compounds are attracted to the res-
ins, and differences in affinity bring about the chromatographic sepa-
ration. The pH of the mobile phase, temperature, ion type, ionic con-
centration, and organic modifiers affect the equilibrium, and these
variables can be adjusted to obtain the desired degree of separation.
In size-exclusion chromatography, columns are packed with a po-
rous stationary phase. Molecules of the compounds being chromato-
graphed are filtered according to size. Those too large to enter the
pores pass unretained through the column. Smaller molecules enter
the pores and are increasingly retained as molecular size decreases.
These columns are typically used to measure aggregation and degrada-
tion of large molecules (see Size-Exclusion Chromatography section).
DetectorsMany compendial HPLC methods require the use of
spectrophotometric detectors. Such a detector consists of a flow-
through cell mounted at the end of the column. A beam of UV radia-
tion passes through the flow cell and into the detector. As compounds
elute from the column, they pass through the cell and absorb the radi-
ation, resulting in measurable energy level changes.
Fixed, variable, and multi-wavelength detectors are widely avail-
able. Fixed wavelength detectors operate at a single wavelength, typi-
cally 254 nm, emitted by a low-pressure mercury lamp. Variable wave-
length detectors contain a continuous source, such as a deuterium or
high-pressure xenon lamp, and a monochromator or an interference
filter to generate monochromatic radiation at a wavelength selected by
the operator. The wavelength accuracy of a variable-wavelength detec-
tor equipped with a monochromator should be checked by the proce-
dure recommended by its manufacturer; if the observed wavelengths
differ by more than 3 nm from the correct values, recalibration of the
0
instrument is indicated. Modern variable wavelength detectors can be
0
programmed to change wavelength while an analysis is in progress.
Multi-wavelength detectors measure absorbance at two or more wave-
2
lengths simultaneously. In diode array multi-wavelength detectors,
continuous radiation is passed through the sample cell, then resolved
into its constituent wavelengths, which are individually detected by the
photodiode array. These detectors acquire absorbance data over the
entire UV-visible range, thus providing the analyst with chromatograms
at multiple, selectable wavelengths and spectra of the eluting peaks.
Diode array detectors usually have lower signal-to-noise ratios than
fixed or variable wavelength detectors, and thus are less suitable for
analysis of compounds present at low concentrations.
Differential refractometer detectors measure the difference be-
tween the refractive index of the mobile phase alone and that of the
mobile phase containing chromatographed compounds as it emerges
from the column. Refractive index detectors are used to detect non-UV
absorbing compounds, but they are less sensitive than UV detectors.
They are sensitive to small changes in solvent composition, flow rate,
and temperature, so that a reference column may be required to ob-
tain a satisfactory baseline.
Fluorometric detectors are sensitive to compounds that are inher-
ently fluorescent or that can be converted to fluorescent derivatives
either by chemical transformation of the compound or by coupling
with fluorescent reagents at specific functional groups. If derivatiza-
tion is required, it can be done prior to chromatographic separation or,
alternatively, the reagent can be introduced into the mobile phase just
prior to its entering the detector.
Potentiometric, voltametric, or polarographic electrochemical de-
tectors are useful for the quantitation of species that can be oxidized
or reduced at a working electrode. These detectors are selective, sensi-
tive, and reliable, but require conducting mobile phases free of dis-
solved oxygen and reducible metal ions. A pulseless pump must be
used, and care must be taken to ensure that the pH, ionic strength, and
temperature of the mobile phase remain constant. Working electrodes
are prone to contamination by reaction products with consequent
variable responses.
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/63
621 Chromatography
Electrochemical detectors with carbon-paste electrodes may be
used advantageously to measure nanogram quantities of easily oxi-
dized compounds, notably phenols and catechols.
New detectors continue to be developed in attempts to overcome
the deficiencies of those being used.
Data Collection DevicesModern data stations receive and store
detector output and print out chromatograms complete with peak
heights, peak areas, sample identification, and method variables. They
are also used to program the liquid chromatograph, controlling most
variables and providing for long periods of unattended operation.
Data also may be collected on simple recorders for manual mea-
surement or on stand-alone integrators, which range in complexity
from those providing a printout of peak areas to those providing chro-
matograms with peak areas and peak heights calculated and data
stored for possible subsequent reprocessing.
ProcedureThe mobile phase composition significantly influences
chromatographic performance and the resolution of compounds in
the mixture being chromatographed. For accurate quantitative work,
high-purity reagents and HPLC grade organic solvents must be used.
P
Water of suitable quality should have low conductivity and low UV ab-
sorption, appropriate to the intended use.
S
Reagents used with special types of detectors (e.g., electrochemi-
cal, mass spectrometer) may require the establishment of additional
U
tolerances for potential interfering species. Composition has a much
greater effect than temperature on the capacity factor, k.
In partition chromatography, the partition coefficient, and hence
9
the separation, can be changed by addition of another component to
the mobile phase. In ion-exchange chromatography, pH and ionic
strength, as well as changes in the composition of the mobile phase,
affect capacity factors. The technique of continuously changing the
solvent composition during the chromatographic run is called gradient
elution or solvent programming. It is sometimes used to chromato-
graph complex mixtures of components differing greatly in their ca-
pacity factors. Detectors that are sensitive to change in solvent compo-
sition, such as the differential refractometer, are more difficult to use
with the gradient elution technique.
The detector must have a broad linear dynamic range, and com-
pounds to be measured must be resolved from any interfering sub-
stances. The linear dynamic range of a compound is the range over
which the detector signal response is directly proportional to the
amount of the compound. For maximum flexibility in quantitative
work, this range should be about three orders of magnitude. HPLC
systems are calibrated by plotting peak responses in comparison with
known concentrations of a reference standard, using either an external
or an internal standardization procedure.
Reliable quantitative results are obtained by external calibration if
automatic injectors or autosamplers are used. This method involves
direct comparison of the peak responses obtained by separately chro-
matographing the test and reference standard solutions. If syringe in-
jection, which is irreproducible at the high pressures involved, must be
used, better quantitative results are obtained by the internal calibra-
tion procedure where a known amount of a noninterfering compound,
the internal standard, is added to the test and reference standard solu-
tions, and the ratios of peak responses of drug and internal standard
are compared.
Because of normal variations in equipment, supplies, and tech-
niques, a system suitability test is required to ensure that a given oper-
ating system may be generally applicable. The main features of system
suitability tests are described below.
For information on the interpretation of results, see the section
Interpretation of Chromatograms.
USP Pharmacists Pharmacopeia
Size-Exclusion Chromatography
Size-exclusion chromatography is a high-pressure liquid chromato-
graphic technique that separates molecules in solution according to
their size. Methods for size-exclusion chromatography are divided into
gel permeation chromatographic methods, which utilize nonpolar or-
ganic mobile phases and hydrophilic packings, and gel filtration chro-
matographic methods, which utilize aqueous mobile phases and hy-
drophobic packings. The sample is introduced into a column, which is
filled with a gel or a porous particle packing material and is carried by
the mobile phase through the column. The size separation takes place
by repeated exchange of the solute molecules between the solvent of
the mobile phase and the same solvent in the stationary liquid phase
within the pores of the packing material. The pore-size range of the
packing material determines the molecular-size range within which
separation can occur.
Molecules small enough to penetrate all the pore spaces elute at
the total permeation volume, VT. On the other hand, molecules appar-
ently larger than the maximum pore size of the packing material mi-
grate along the column only through the spaces between the particles
of the packing material without being retained and elute at the exclu-
sion volume, VO (void volume). Separation according to molecular size
occurs between the exclusion volume and the total permeation vol-
ume, useful separation usually occurring in the first two-thirds of this
range.
ApparatusThe components of the chromatograph are described un-
der High-Pressure Liquid Chromatography.
ColumnIf necessary, the column is temperature-controlled. It is
0
packed with a separation material that is capable of fractionation in the
appropriate range of molecular sizes and through which the eluant is
0
passed at a constant rate. One end of the column is usually fitted with
2
a suitable device for applying the sample, such as a flow adaptor, a sy-
ringe through a septum or an injection valve, and it may also be con-
nected to a suitable pump for controlling the flow of the eluant. Alter-
natively, the sample may be applied directly to the drained bed surface,
or, where the sample is denser than the eluant, it may be layered be-
neath the eluant. The packing material may be a soft support such as a
swollen gel or a rigid support composed of a material such as glass,
silica, or a solvent-compatible, cross-linked organic polymer. Rigid sup-
ports usually require pressurized systems giving faster separations.
The mobile phase is chosen according to sample type, separation me-
dium, and method of detection.
DetectorThe outlet of the column is usually connected to a suit-
able detector fitted with an automatic recorder that enables the moni-
toring of the relative concentrations of separated components of the
sample. Detectors are usually based on photometric, refractometric, or
luminescent properties (see Detectors under High-Pressure Liquid
Chromatography). An automatic fraction collector may be attached, if
necessary.
ProcedureBefore carrying out the separation, the packing material is
treated and the column is packed, as described in the individual
monograph or according to the manufacturers instructions. Where
necessary, procedures for verifying the suitability of the system are
described in the individual monograph. The column efficiency may be
evaluated from the number of theoretical plates, N (see the section
Interpretation of Chromatograms). The elution characteristics of a com-
pound in a particular column may be described by the distribution co-
efficient, KD, which is calculated by the formula:
(VI VO)/(VT VO)
in which VO, VT, and VI are the retention volumes for the nonretained
component, the component that has full access to all the pores in the
support, and the compound under test, respectively. Each retention
volume is measured from the time of application to the time of the
peak maximum.
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/64
621 Chromatography
Determination of Relative Component Composition of Mixture
Carry out the separation as directed in the individual monograph.
Monitor the elution of the components continuously, and measure the
corresponding peak areas. If all the components under test exhibit
equivalent responses to the physicochemical property being moni-
tored (for example, if they exhibit corresponding absorptivities), calcu-
late the relative amount of each component by dividing the respective
peak area by the sum of the peak areas of all the components under
test. If the responses to the property used for detection of the compo-
nents under test are not equivalent, calculate the content using cali-
bration curves obtained from the calibration procedure specified in
the individual monograph.
Determination of Molecular WeightsSize-exclusion chromatog-
raphy is used to determine molecular weights of components under
test by comparison to calibration standards specified in the individual
monograph. Plot the retention volumes of the calibration standards
versus the logarithm of their molecular weights. Draw the line that
best fits the plotted points within the exclusion and total permeation
limits for the particular separation medium. From the calibration curve,
molecular weights of components under test are estimated. This cali-
P
bration is valid only for the particular macromolecular solute-solvent
S
system used under the specified experimental conditions.
Determination of Molecular Weight Distribution of PolymersThe
material used for calibration and the methods for determination of the
U
distribution of molecular weights of polymers are specified in the indi-
vidual monograph. However, sample comparison is valid only for re-
9
sults obtained under identical experimental conditions.
Interpretation of Chromatograms
Figure 1 represents a typical chromatographic separation of two sub-
stances, 1 and 2, where t1 and t2 are the respective retention times; and
h, h/2, and Wh/2 are the height, the half-height, and the width at half-
height, respectively, for peak 1. W1 and W2 are the respective widths of
peaks 1 and 2 at the baseline. Air peaks are a feature of gas chromato-
grams and correspond to the solvent front in liquid chromatography.
The retention time of these unretained components is designated as
tM.
Chromatographic retention times are characteristic of the com-
pounds they represent but are not unique. Coincidence of retention
times of a test and a reference substance can be used as a feature in
construction of an identity profile but is insufficient on its own to es-
tablish identity. Absolute retention times of a given compound vary
from one chromatogram to the next.
Because in most procedures there is no need to identify an unre-
tained peak, comparisons are normally made in terms of relative reten-
tion times, Rr:
where t2 and t1 are the retention times, measured from the point of in-
jection, of the test and the reference substances, respectively, deter-
mined under identical experimental conditions on the same column.
Other procedures may identify the peak position using the rela-
tive retention, r:
where tM is the retention time of a non-retained marker, which needs
to be defined in the procedure.
The number of theoretical plates, N, is a measure of column effi-
ciency. For Gaussian peaks, it is calculated by the equation:
USP Pharmacists Pharmacopeia 621 Chromatography

Figure 1. Chromatographic separation of two substances

may be the drug itself at a level corresponding to, for example, 0.5%
impurity, or in the case of toxic or signal impurities, a standard of the
impurity itself.
where t is the retention time of the substance and W is the width of

P
the peak at its base, obtained by extrapolating the relatively straight
sides of the peak to the baseline. The value of N depends upon the
System Suitability

S
substance being chromatographed as well as the operating conditions
such as mobile phase or carrier gas flow rates and temperature, the System suitability tests are an integral part of gas and liquid chromato-

U
quality of the packing, the uniformity of the packing within the column graphic methods. They are used to verify that the resolution and repro-
and, for capillary columns, the thickness of the stationary phase film, ducibility of the chromatographic system are adequate for the analysis
and the internal diameter and length of the column. to be done. The tests are based on the concept that the equipment,

9
The separation of two components in a mixture, the resolution, R, electronics, analytical operations, and samples to be analyzed consti-

0
is determined by the equation: tute an integral system that can be evaluated as such.
The resolution, R, [noteAll terms and symbols are defined in the

0
Glossary of Symbols] is a function of column efficiency, N, and is speci-
fied to ensure that closely eluting compounds are resolved from each

2
in which t2 and t1 are the retention times of the two components, and other, to establish the general resolving power of the system, and to
W2 and W1 are the corresponding widths at the bases of the peaks ob- ensure that internal standards are resolved from the drug. Column ef-
tained by extrapolating the relatively straight sides of the peaks to the ficiency may be specified also as a system suitability requirement, es-

baseline. pecially if there is only one peak of interest in the chromatogram;
however, it is a less reliable means to ensure resolution than direct
Where electronic integrators are used, it may be convenient to
measurement. Column efficiency is a measure of peak sharpness,
determine the resolution, R, by the equation:
which is important for the detection of trace components.
Replicate injections of a standard preparation used in the assay or
other standard solution are compared to ascertain whether require-
ments for precision are met. Unless otherwise specified in the individ-
and to determine the number of theoretical plates, N, by the equation: ual monograph, data from five replicate injections of the analyte are
used to calculate the relative standard deviation, SR, if the requirement
is 2.0% or less; data from six replicate injections are used if the relative
standard deviation requirement is more than 2.0%.
where Wh/2 is the peak width at half-height, obtained directly by elec-
The tailing factor, T, a measure of peak symmetry, is unity for per-
tronic integrators. However, in the event of dispute, only equations
fectly symmetrical peaks and its value increases as tailing becomes
based on peak width at baseline are to be used.
more pronounced (see Figure 2). In some cases, values less than unity
Peak areas and peak heights are usually proportional to the quan- may be observed. As peak asymmetry increases, integration, and
tity of compound eluting. These are commonly measured by electronic hence precision, becomes less reliable.
integrators but may be determined by more classical approaches. Peak
areas are generally used but may be less accurate if peak interference
occurs. For manual measurements, the chart should be run faster than
usual, or a comparator should be used to measure the width at half-
height and the width at the base of the peak, to minimize error in
these measurements. For accurate quantitative work, the components
to be measured should be separated from any interfering components.
Peak tailing and fronting and the measurement of peaks on solvent
tails are to be avoided.
Chromatographic purity tests for drug raw materials are some-
times based on the determination of peaks due to impurities, ex-
pressed as a percentage of the area due to the drug peak. It is pref
erable, however, to compare impurity peaks with those in the Figure 2. Asymmetrical chromatographic peak
chromatogram of a standard at a similar concentration. The standard

Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/65
USP Pharmacists Pharmacopeia
These tests are performed by collecting data from replicate injec-
tions of standard or other solutions as specified in the individual
monograph. The specification of definitive parameters in a monograph
does not preclude the use of other suitable operating conditions (see
Procedures under Tests and Assays in the General Notices). If adjust-
ments of operating conditions to meet system suitability requirements
are necessary, each of the following is the maximum variation that can
be considered, unless otherwise directed in the monograph. Adjust-
ments are permitted only when suitable standards (including Refer-
ence Standards) are available for all compounds used in the suitability
test and only when those standards are used to show that the adjust-
ments have improved the quality of the chromatography in meeting
system suitability requirements. Adjustments to chromatographic sys-
tems performed in order to comply with system suitability require-
ments are not to be made to compensate for column failure or system
malfunction. The changes described below may require additional vali-
dation data. The user should verify the suitability of the method under
the new conditions by assessing the relevant analytical performance
characteristics potentially affected by the change. Multiple adjustments
can have a cumulative effect in the performance of the system and
should be considered carefully before implementation.
pH of Mobile Phase (HPLC)The pH of the aqueous buffer used in the
preparation of the mobile phase can be adjusted to within 0.2 units of
the value or range specified.
Concentration of Salts in Buffer (HPLC)The concentration of the salts
used in the preparation of the aqueous buffer used in the mobile
phase can be adjusted to within 10%, provided the permitted pH
variation (see above) is met.
0
Ratio of Components in Mobile Phase (HPLC)The following adjust-
0
ment limits apply to minor components of the mobile phase (specified
at 50% or less). The amount(s) of these component(s) can be adjusted
2
by 30% relative. However, the change in any component cannot ex-
ceed 10% absolute (i.e., in relation to the total mobile phase). Adjust-
ment can be made to one minor component in a ternary mixture. Ex-
amples of adjustments for binary and ternary mixtures are given
below.
Binary Mixtures
specified ratio of 50:50Thirty percent of 50 is 15% absolute, but
this exceeds the maximum permitted change of 10% absolute in ei-
ther component. Therefore, the mobile phase ratio may be adjusted
only within the range of 40:60 to 60:40.
specified ratio of 2:98Thirty percent of 2 is 0.6% absolute. There-
fore the maximum allowed adjustment is within the range of 1.4:98.6 to
2.6:97.4.
Ternary Mixtures
specified ratio of 60:35:5For the second component, 30% of 35 is
10.5% absolute, which exceeds the maximum permitted change of
10% absolute in any component. Therefore the second component
may be adjusted only within the range of 25% to 45% absolute. For the
third component, 30% of 5 is 1.5% absolute. In all cases, a sufficient
quantity of the first component is used to give a total of 100%. There-
fore, mixture ranges of 50:45:5 to 70:25:5 or 58.5:35:6.5 to 61.5:35:3.5
would meet the requirement.
Wavelength of UV-Visible Detector (HPLC)Deviations from the wave-
lengths specified in the method are not permitted. The procedure
specified by the detector manufacturer, or another validated proce-
dure, is to be used to verify that error in the detector wavelength is, at
most, 3 nm.
Column Length (GC, HPLC): can be adjusted by as much as 70%.
Column Inner Diameter (GC, HPLC): can be adjusted by as much as
25% for HPLC and 50% for GC.
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/66
621 Chromatography
Film Thickness (Capillary GC): can be adjusted by as much as 50% to
100%.
Particle Size (HPLC): can be reduced by as much as 50%.
Particle Size (GC): going from a larger to a smaller or a smaller to a
larger (if it is the same Range Ratio, which is the diameter of the larg-
est particle divided by the diameter of the smallest particle) particle
size GC mesh support is acceptable, provided the chromatography
meets the requirements of the system suitability.
Flow Rate (GC, HPLC): can be adjusted by as much as 50%.
Injection Volume (GC, HPLC): can be reduced as far as is consistent
with accepted precision and detection limits.
Column Temperature (HPLC): can be adjusted by as much as 10.
Column thermostating is recommended to improve control and repro-
ducibility of retention time.
Oven Temperature (GC): can be adjusted by as much as 10%.
Oven Temperature Program (GC)Adjustment of temperatures is per-
mitted as stated above. For the times specified for the temperature to
be maintained or for the temperature to be changed from one value to
another, an adjustment of up to 20% is permitted.
P
Unless otherwise directed in the monograph, system suitability
S
parameters are determined from the analyte peak.
Relative retention times may be provided in monographs for infor-
U
mational purposes only, to aid in peak identification. There are no ac-
ceptance criteria applied to relative retention times.
To ascertain the effectiveness of the final operating system, it
9
should be subjected to suitability testing. Replicate injections of the
standard preparation required to demonstrate adequate system preci-
sion may be made before the injection of samples or may be inter-
spersed among sample injections. System suitability must be demon-
strated throughout the run by injection of an appropriate control
preparation at appropriate intervals, including at the end of the analy-
sis. The control preparation can be a standard preparation or a solution
containing a known amount of analyte and any additional materials
useful in the control of the analytical system, such as excipients or im-
purities. Whenever there is a significant change in equipment or in a
critical reagent, suitability testing should be performed before the in-
jection of samples. No sample analysis is acceptable unless the re-
quirements of system suitability have been met. Sample analyses ob-
tained while the system fails system suitability requirements are
unacceptable.
Glossary of Symbols
To promote uniformity of interpretation, the following symbols and
definitions are employed where applicable in presenting formulas in
the individual monographs. Where a different symbol or definition is
used in an individual monograph, the monograph text takes prece-
dence (see General Notices). [noteWhere the terms W and t both
appear in the same equation they must be expressed in the same
units.]
f distance from the peak maximum to the leading edge of the
peak, the distance being measured at a point 5% of the peak
height from the baseline.
k capacity factor,2
USP Pharmacists Pharmacopeia
N number of theoretical plates in a chromatographic column,2
r relative retention,2
ri peak response of an impurity obtained from a chromatogram.
rIS peak response of the internal standard obtained from a
chromatogram.
rS peak response of the Reference Standard obtained from a
chromatogram.
rU peak response of the analyte obtained from a chromatogram.
R resolution between two chromatographic peaks,
RF chromatographic retardation factor equal to the ratio of the
distance from the origin to the center of a zone divided by
the distance from the origin to the solvent front.
Rr relative retention time,2
0
0
Rrel relative retardation
2
RS peak response ratio for a Standard preparation containing
Reference Standard and internal standard,
RU peak response ratio for Assay preparation containing the
analyte and internal standard,
%RSD percent relative standard deviation,
where Xi is an individual measurement in a set of N
easurements and X is the arithmetic mean of the set.
m
2
The parameters k, N, r, and Rr were developed for isothermal GC separations
and isocratic HPLC separations. Because these terms are thermodynamic pa-
rameters, they are valid only for separations made at constant temperature,
mobile phase composition, and flow rate. However, for separations made with a
temperature program or solvent gradient, these parameters may be used simply
as comparative means to ensure that adequate chromatographic conditions exist
to perform the methods as intended in the monographs.
Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/67
1111 Microbiological Examination
T tailing factor,3
t retention time measured from time of injection to time of
elution of peak maximum.
tM retention time of nonretarded component, air with thermal
conductivity detection.
W width of peak measured by extrapolating the relatively straight
sides to the baseline.
Wh/2 width of peak at half height.
W0.05 width of peak at 5% height.
Chromatographic Reagents
A complete list of Packings (L), Phases (G), and Supports (S) used in
USPNF tests and assays is located under Chromatographic Reagents in
the Reagents, Indicators, and Solutions section. This list is intended to
be a convenient reference for the chromatographer to identify the per-
tinent chromatographic reagent specified in the individual monograph.
P
[noteParticle sizes given in the listing are those generally pro-
vided. Where other, usually finer, sizes are required, the individual
S
monograph specifies the desired particle size. Within any category of
packings or phases listed there may be a wide range of columns avail-
U
able. Where it is necessary to define more specifically the chromato-
graphic conditions, the individual monograph so indicates.]
1111 Microbiological Examination
of Nonsterile Products: Acceptance
Criteria for Pharmaceutical
Preparations and Substances for
Pharmaceutical Use
The presence of certain microorganisms in nonsterile preparations
may have the potential to reduce or even inactivate the therapeutic
activity of the product and has a potential to adversely affect the health
of the patient. Manufacturers have therefore to ensure a low biobur-
den of finished dosage forms by implementing current guidelines on
Good Manufacturing Practice during the manufacture, storage, and
distribution of pharmaceutical preparations.
Microbial examination of nonsterile products is performed ac-
cording to the methods given in the texts on Microbial Enumeration
Tests 61 and Tests for Specified Microorganisms 62. Acceptance cri-
teria for nonsterile pharmaceutical products based upon the total aer-
obic microbial count (TAMC) and the total combined yeasts and molds
count (TYMC) are given in Tables 1 and 2. Acceptance criteria are based
on individual results or on the average of replicate counts when repli-
cate counts are performed (e.g., direct plating methods).
3
It is also a common practice to measure the Asymmetry factor as the ratio of
the distance between the vertical line connecting the peak apex with the inter-
polated baseline and the peak front, and the distance between that line and the
peak back measured at 10% of the peak height (in Figure 2), it would be (W0.10
f0.10)/f0.10. However, for the purposes of USP, only the formula presented in the
Glossary of Symbols is valid.
USP Pharmacists Pharmacopeia 1121 Nomenclature

Table 1. Acceptance Criteria for Microbiological Quality of Nonsterile Dosage Forms

Total Aerobic Total Combined
Microbial Count Yeasts/Molds Count
Route of Administration (cfu/g or cfu/mL) (cfu/g or cfu/mL) Specified Microorganism(s)
Nonaqueous preparations for oral use 103 102 Absence of Escherichia coli (1 g or 1 mL)
Aqueous preparations for oral use 102 101 Absence of Escherichia coli (1 g or 1 mL)
Rectal use 103 102
Oromucosal use 102 101 Absence of Staphylococcus aureus (1 g or 1 mL)
Absence of Pseudomonas aeruginosa (1 g or 1 mL)
Gingival use 102 101 Absence of Staphylococcus aureus (1 g or 1 mL)
Absence of Pseudomonas aeruginosa (1 g or 1 mL)
Cutaneous use 102 101 Absence of Staphylococcus aureus (1 g or 1 mL)
Absence of Pseudomonas aeruginosa (1 g or 1 mL)
Nasal use 102 101 Absence of Staphylococcus aureus (1 g or 1 mL)
Absence of Pseudomonas aeruginosa (1 g or 1 mL)
Auricular use 102 101 Absence of Staphylococcus aureus (1 g or 1 mL)
Absence of Pseudomonas aeruginosa (1 g or 1 mL)
Vaginal use 102 101 Absence of Pseudomonas aeruginosa (1 g or 1 mL)
Absence of Staphylococcus aureus (1 g or 1 mL)
Absence of Candida albicans (1 g or 1 mL)
Transdermal patches (limits for one patch 102 101 Absence of Staphylococcus aureus (1 patch)
including adhesive layer and backing) Absence of Pseudomonas aeruginosa (1 patch)

P
Inhalation use (special requirements apply 102 101 Absence of Staphylococcus aureus (1 g or 1 mL)
to liquid preparations for nebulization) Absence of Pseudomonas aeruginosa (1 g or 1 mL)

S
Absence of bile-tolerant Gram-negative bacteria (1 g or 1 mL)

U
When an acceptance criterion for microbiological quality is pre- assessment takes account of the processing to which the product is
scribed, it is interpreted as follows: subjected, the current technology of testing, and the availability of

9
101 cfu: maximum acceptable count = 20; materials of the desired quality.
102 cfu: maximum acceptable count = 200; (Official May 1, 2009)

0
103 cfu: maximum acceptable count = 2000; and so forth.

0
Table 1 includes a list of specified microorganisms for which ac-
ceptance criteria are set. The list is not necessarily exhaustive, and for a

2
given preparation it may be necessary to test for other microorganisms 1121 Nomenclature
depending on the nature of the starting materials and the manufactur-
ing process. The USP (or NF) titles for monograph articles are legally recognized

If it has been shown that none of the prescribed tests will allow
valid enumeration of microorganisms at the level prescribed, a validat-
ed method with a limit of detection as close as possible to the indicat-
ed acceptance criterion is used.
Table 2. Acceptance Criteria for Microbiological Quality
of Nonsterile Substances for Pharmaceutical Use
Total Aerobic Total Combined official title for any compound that attains compendial recognition.
Microbial Count Yeasts/Molds Count
(cfu/g or cfu/mL) (cfu/g or cfu/mL)
Substances for
pharmaceutical use 103 102
In addition to the microorganisms listed in Table 1, the significance
of other microorganisms recovered should be evaluated in terms of
the following:
The use of the product: hazard varies according to the route of
administration (eye, nose, respiratory tract).
The nature of the product: does the product support growth?
does it have adequate antimicrobial preservation?
The method of application.
The intended recipient: risk may differ for neonates, infants, the
debilitated.
Use of immunosuppressive agents, corticosteroids.
The presence of disease, wounds, organ damage.
Where warranted, a risk-based assessment of the relevant factors
is conducted by personnel with specialized training in microbiology
and in the interpretation of microbiological data. For raw materials, the
under the Federal Food, Drug, and Cosmetic Act as the designations
for use in labeling the articles to which they apply.
The value of designating each drug by one and only one nonpro-
prietary1 name is important in terms of achieving simplicity and uni
formity in drug nomenclature. In support of the U.S. Adopted Names
program (see Mission and Preface in USPNF), of which the U.S. Phar-
macopeial Convention is a cosponsor, the USP Council of Experts gives
consideration to the adoption of the U.S. Adopted Name, if any, as the
A compilation of the U.S. Adopted Names (USAN) published from
the start of the USAN program in 1961, as well as other names for
drugs, both current and retrospective, is provided in the USP Diction-
ary of USAN and International Drug Names. This publication serves as
a book of names useful for identifying and distinguishing all kinds of
names for drugs, whether public, proprietary, chemical, or code-desig-
nated names.2
A nonproprietary name of a drug serves numerous and varied
purposes, its principal function being to identify the substance to
which it applies by means of a designation that may be used by the
professional and lay public free from the restrictions associated with
registered trademarks. Teaching in the health sciences requires a com-
mon designation, especially for a drug that is available from several
sources or is incorporated into a combination drug product; nonpro-
1
The term generic has been widely used in place of the more accurate and
descriptive term nonproprietary with reference to drug nomenclature.
2
USP Dictionary of USAN and International Drug Names is obtainable on order
from U.S. Pharmacopeia, Customer Service Department, 12601 Twinbrook Park-
way, Rockville, MD 20852.

Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/68
USP Pharmacists Pharmacopeia 1121 Nomenclature

prietary names facilitate communication among healthcare providers; Examples:

nonproprietary names must be used as the titles of the articles recog-
nized by official drug compendia; a nonproprietary name is essential
to the pharmaceutical manufacturer as a means of protecting trade-
mark rights in the brand name for the article concerned; and, finally,
the manufacturer is obligated by federal law to include the established
nonproprietary name in advertising and labeling.
Under the terms of the Drug Amendments of 1962 to the Federal
Food, Drug, and Cosmetic Act, which became law October 10, 1962,
the Secretary of Health and Human Services is authorized to designate
an official name for any drug wherever deemed necessary or desir-
able in the interest of usefulness and simplicity.3
The Commissioner of Food and Drugs and the Secretary of Health
and Human Services published in the Federal Register regulations ef-
fective November 26, 1984, which state, in part:
Sec. 299.4 Established names of drugs.
(e) The Food and Drug Administration will not routinely desig-
nate official names under section 508 of the act. As a result, the estab-
lished name under section 502(e) of the act will ordinarily be either the
Calcium Carbonate Oral Suspension
Cetylpyridinium Chloride Topical Solution
Dexamethasone Ophthalmic Suspension
Epinephrine Bitartrate Ophthalmic Solution
Isosorbide Dinitrate Sublingual Tablets
Miconazole Nitrate Topical Powder
Triple Sulfa Vaginal Cream
The term Vaginal Inserts, rather than Vaginal Tablets, Vaginal
Capsules, or Vaginal Suppositories is used in the title of this type of
vaginal preparation to avoid the potential for misuse of these products
if the term Tablets or Capsules or Suppositories were to appear in
the title.
Example:
Clotrimazole Vaginal Inserts
The term for route of administration is omitted for those dosage
forms for which the route of administration is understood. The general
form then becomes simply [DRUG] [DOSAGE FORM]. Thus, capsules,
tablets, and lozenges are administered via the oral route unless other-

P
compendial name of the drug or, if there is no compendial name, the wise indicated by the title.
common and usual name of the drug. Interested persons, in the ab- Examples:

S
sence of the designation by the Food and Drug Administration of an Acetaminophen Capsules
official name, may rely on as the established name for any drug the Aminophylline Delayed-Release Tablets

U
current compendial name or the USAN adopted name listed in USAN Aspirin Extended-Release Tablets
and the USP Dictionary of Drug Names.4 Hexylresorcinol Lozenges
It will be noted that the monographs on the biologics, which are Meperidine Hydrochloride Tablets

9
produced under licenses issued by the Secretary of the U.S. Depart- Drugs that are injected may be administered via the intravenous,

0
ment of Health and Human Services, represent a special case. Although intramuscular, subcutaneous, etc., route; the route being specified in
efforts continue toward achieving uniformity, there may be a difference the labeling rather than in the name.

0
between the respective title required by federal law and the USP title. Examples:
Such differences are fewer than in past revisions of the Pharmacopeia. Aurothioglucose Injectable Suspension

2
The USP title, where different from the FDA Center for Biologics Evalu- Epinephrine Injection
ation and Research title, does not necessarily constitute a synonym for Fluorouracil Injection
labeling purposes; the conditions of licensing the biologic concerned Hydrocortisone Acetate Injectable Suspension

require that each such article be designated by the name appearing in Phytonadione Injectable Emulsion
the product license issued to the manufacturer. Where a USP title dif- Creams, ointments, lotions, and pastes are applied topically, un-
fers from the title in the federal regulations, the former has been ad- less otherwise indicated by the name.
opted with a view to usefulness, simplicity, and conformity with the
Examples:
principles governing the selection of monograph titles generally.
Benzoyl Peroxide Lotion
Betamethasone Dipropionate Cream
Estradiol Vaginal Cream
General Nomenclature Forms Nystatin Ointment
Some monograph titles existing in the USPNF do not conform to the Zinc Oxide Paste
formats outlined in this general information chapter. Typically, these The term Suppositories is used in the titles of preparations that
monograph titles were adopted before the establishment of the title are intended for rectal administration.
formats and nomenclature policies presented in this general informa-
Example:
tion chapter. Such monograph titles may be subject to subsequent re-
Aspirin Suppositories
vision and should not be interpreted as precedents for other mono-
graph titles. The term for is included in names, as appropriate, of prepara-
tions for which a solid drug substance must be dissolved or suspended
Standardized forms of nomenclature have been devised in the in-
in a suitable liquid to obtain a dosage form, and the general form be-
terest of achieving uniformity for naming compendial articles. The
comes [DRUG] for [ROUTE OF ADMINISTRATION] [DOSAGE FORM].
general nomenclature forms that follow illustrate the terminology used
throughout the official compendia for consistency in establishing titles Examples:
of monographs on official pharmaceutical dosage forms and prepara- Ampicillin for Oral Suspension
tions. Examples are shown for the more frequently encountered cate- Epinephrine Bitartrate for Ophthalmic Solution
gories of dosage forms. Nafcillin for Injection
Spectinomycin for Injectable Suspension
For a variety of dosage forms, titles are in the following general
form: [DRUG] [ROUTE OF ADMINISTRATION] [DOSAGE FORM]. In some instances, the drug is supplied in one dosage form for the
preparation of the intended dosage form.

F.D.&C. Act, Sec. 508 [358].

3

53 Fed. Reg. 5369 (1988) amending 21 CFR 299.4.

4

Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/69
USP Pharmacists Pharmacopeia 1121 Nomenclature

Examples:
Aspirin Effervescent Tablets for Oral Solution
Methadone Hydrochloride Tablets for Oral Suspension
Papain Tablets for Topical Solution
Systems are preparations of drugs in carrier devices that are ap-
plied topically or inserted into body cavities, from which drugs are re- ii. Example: Alendronate Sodium active moiety is Alendronic Acid
leased gradually over extended times, after which the carrier device is
removed. The general form for a system is [DRUG] [ROUTE] [SYSTEM].
Examples:
Nicotine Transdermal System
Progesterone Intrauterine Contraceptive System
Some drugs are available as concentrated solutions that are not
intended for direct administration to humans or animals, but are to be
diluted with suitable liquid vehicles to obtain the intended prepara-
tion. The general form for these preparations, which are not dosage
forms, is [DRUG] [CONCENTRATE].
Examples:
Isosorbide Concentrate (used to prepare Isosorbide Oral
This Policy is followed by USP in naming drug products and com-
Solution)
pounded preparations that are newly recognized in the USP. Revising

P
Glutaral Concentrate (used to prepare Glutaral Disinfectant
existing monographs to conform to this Policy is not intended, except
Solution)

S
where the USP Council of Experts determines that, for reasons such as
For products intended for parenteral administration, the use of the safety, a nomenclature change is warranted.
word Concentrate in the monograph title is restricted to one specific

U
monograph, Potassium Chloride for Injection Concentrate. The word
Concentrate should not appear in the monograph title for any other Related Issues
parenteral product; rather, this issue is to be addressed in the product

9
labeling. LabelingThe labeling clearly states the specific salt form of the active
moiety that is present in the product/preparation, as this information

0
Some drugs are supplied as preparations that may be intermedi-
ates used for convenience in formulating finished dosage forms. The may be useful to practitioners and patients. The names and strengths

0
general form for such preparations, which are not finished dosage of both the active moiety and specific salt form (where applicable) are
forms, is [DRUG] [PREPARATION]. provided in the labeling.

2
Examples: ExceptionsIn those rare cases in which the use of the specific salt
Vitamin E Preparation form of the active moiety in the title provides vital information from a
Cranberry Liquid Preparation clinical perspective, an exception to this Policy may be considered. In

Monograph Naming Policy for Salt Drug
Substances in Drug Products and
Compounded Preparations
The titles of USP monographs for drug products and compounded
preparations formulated with a salt of an acid or base use the name of
the active moiety, as defined below. The strength of the product or
preparation also is expressed in terms of the active moiety.
An active moiety is the molecule or ion, excluding those appended
portions of the molecule that cause the drug to be an ester, salt (in-
cluding a salt with hydrogen or coordination bonds), or other nonco-
valent derivative (such as a complex, chelate, or clathrate) of the mole-
cule, responsible for the physiological or pharmacological action of
the drug substance, without regard to the actual charged state of the
molecule in-vivo.
For example, the active moiety of a hydrochloride salt of a base
will be the free base and not the protonated form of the base. The ac-
tive moiety of a metal acid salt will be the free acid.
i. Example: Chelocardin Hydrochloride active moiety is Chelocardin
such cases, where the monograph title contains the specific salt form
of the active moiety, the strength of the product or preparation also is
expressed in terms of the specific salt form.
Policy for Postponement Schedules
It is the practice of USP to postpone the official dates of nomenclature
and labeling revisions for a reasonable time primarily to allow for
product label changes to be made and to allow health practitioners
and consumers time to become familiar with the new terminology. A
postponement period of 18 months is usually applied when only one
or a small number of products is affected. A postponement period of
30 months is usually applied when names or labeling of multisource
products or multiproduct lines of a firms preparations are being
changed. A postponement period of 60 months is usually applied for
title and labeling changes that affect excipients, because such changes
would require relabeling of very large numbers of prescription-only
and OTC preparations.
There may be exceptions to this postponement schedule where a
shorter time is needed in order to specify nomenclature and labeling
changes in cases where public health and safety are a concern.
The assignment of a postponement schedule is handled by the
USP Expert Committee on Nomenclature. The postponement sched-
ules are presented below. USPs implementation of a postponement
schedule is automatic, unless an exception is sought. Exceptions to the
postponement schedule are rarely made, and must have suitable justi-

Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/70
USP Pharmacists Pharmacopeia 1121 Nomenclature

fication as well as the approval of the Expert Committee on Nomencla-
ture. Any questions or concerns regarding this postponement sched-
ule may be addressed to the USP staff liaison assigned to the Expert
Committee on Nomenclature.
18 monthsSchedule for title and labeling changes for a drug product.
One or few companies are involved. Example: Sterile [Drug] change to
[Drug] for Injection.
30 monthsSchedule for title and labeling changes for prescription-
only and OTC products.
1. Extensive product line for a company. Examples: syrups and elixirs.
2. Several companies are involved. Examples: syrups and elixirs; lo-
tions; sunscreens.
60 monthsSchedule for title and labeling changes for excipient mon
ographs. Ingredient names in numerous multisource products are
affected.

S P
9 U
2 0 0

Official text. Reprinted from USP 32NF 27. Section 7, Pharmacy-Related General Chapters S3/71
USP Pharmacists Pharmacopeia

Section 8
Dietary Supplement Monographs
and General Chapters

S P
T 9 U
0
his section provides abridged versions of monographs for dietary sup-

0
plement ingredients and products. These monographs are followed by

2
selected dietary supplement general chapters related to the practice of
pharmacy.

In 1994, the U.S. Congress enacted the Dietary Supplement Health and
Education Act (DSHEA). Its importance to the profession of pharmacy has
been acknowledged by the National Association of Boards of Pharmacy
(NABP), which added a competency statement related to dietary supplements
to the updated North American Pharmacist Licensure Examination (NAPLEX)
blueprint. NABP has noted that the USP is the official compendia for dietary
supplement standards. Although USP standards are referenced in DSHEA and
by NABP, manufacturer conformance is optional.
USP Pharmacists Pharmacopeia

Section Contents

Arginine Capsules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/74

Arginine Tablets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/74
Curcuminoids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/74
Curcuminoids Capsules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/74
Curcuminoids Tablets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/74
Powdered Soy Isoflavones Extract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/74
Soy Isoflavones Capsules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/74

P
Soy Isoflavones Tablets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/74

S
Turmeric . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/75
Powdered Turmeric . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/75

U
Powdered Turmeric Extract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/75

0 0 9
2

Official text. Reprinted from USP 32NF 27. Section 8, Dietary Supplement Monographs and General Chapters S3/73
USP Pharmacists Pharmacopeia
Arginine Capsules
Arginine Capsules contain not less than 90.0 percent and not
more than 110.0 percent of the labeled amount of arginine or
arginine hydrochloride in an amount equivalent to C6H14N4O2.
Packaging and storagePreserve in tight, light-resistant containers.
LabelingThe label states the form of arginine that is used and the equiva-
lent amount of C6H14N4O2.
Arginine Tablets
Arginine Tablets contain not less than 90.0 percent and not
more than 110.0 percent of the labeled amount of arginine or
arginine hydrochloride in an amount equivalent to C6H14N4O2.
Packaging and storagePreserve in tight, light-resistant containers.
LabelingThe label states the form of the arginine that is used and the
equivalent amount of C6H14N4O2.
Curcuminoids
Curcuminoids is a partially purified natural complex of diaryl
heptanoid derivatives isolated from turmeric, Curcuma longa L.
It contains not less than 95.0 percent of curcuminoids, calculated
on the dried basis, as the sum of curcumin, desmethoxy
curcumin, and bisdesmethoxycurcumin. It contains not less
than 70.0 percent and not more than 80.0 percent of curcumin,
0
not less than 15.0 percent and not more than 25.0 percent of
0
desmethoxycurcumin, and not less than 2.5 percent and not
more than 6.5 percent of bisdesmethoxycurcumin.
2
Packaging and storagePreserve in well-closed containers, protected from
light and moisture, and store at room temperature.
LabelingThe label states the content of curcuminoids and the content of
individual curcuminoids, on the dried basis; the Latin binominal; and the
part of the plant used to prepare the article.
Loss on drying 731Dry 1.0 g at 105 for 2 hours: it loses not more than
2.0% of its weight.
Curcuminoids Capsules
Curcuminoids Capsules are prepared from Curcuminoids and
contain not less than 90.0 percent and not more than 110.0 per-
cent of the labeled amount of curcuminoids, calculated as the
sum of curcumin, desmethoxycurcumin, and bisdesmethoxy
curcumin.
Packaging and storagePreserve in well-closed containers, protected from
light and moisture, and store at room temperature.
LabelingThe label indicates the content of curcuminoids in mg per
Capsule.
Curcuminoids Tablets
Curcuminoids Tablets are prepared from Curcuminoids and
contain not less than 90.0 percent and not more than 110.0 per-
cent of the labeled amount of curcuminoids, calculated as the
sum of curcumin, desmethoxycurcumin, and bisdesmethoxy
curcumin.
Official text. Reprinted from USP 32NF 27. Section 8, Dietary Supplement Monographs and General Chapters S3/74
Arginine
Packaging and storagePreserve in well-closed containers, protected from
light and moisture, and store at room temperature.
LabelingThe label indicates the content of curcuminoids in mg per Tab-
let.
Powdered Soy Isoflavones Extract
Powdered Soy Isoflavones Extract is prepared from the seeds
of Glycine max Merr. (Fam. Fabaceae) by extraction with water
or hydroalcoholic mixtures. It contains not less than 90.0 per-
cent and not more than 110.0 percent of the labeled amount
of isoflavones, calculated on the dried basis as the sum of daid-
zin, glycitin, genistin, and one or more of the following isofla-
vones: malonyl daidzin, malonyl glycitin, malonyl genistin, ace-
tyl daidzin, acetyl glycitin, acetyl genistin, daidzein, glycitein,
and genistein.
Packaging and storagePreserve in tight, light-resistant containers, and
store at controlled room temperature.
LabelingThe label states the Latin binomial and, following the official
P
name, the part of the plant from which the article was prepared. The label
also indicates the content of isoflavones. It meets other requirements for
S
labeling under Botanical Extracts 565.
Loss on drying 731Dry about 1.0 g of the Powdered Soy Isoflavones Ex-
U
tract, accurately weighed, at 130 for 2 hours: it loses not more than 7.0% of
its weight.
9
Soy Isoflavones Capsules
Soy Isoflavones Capsules contain Powdered Soy Isoflavones
Extract. Capsules contain not less than 90.0 percent and not
more than 110.0 percent of the labeled amount of the Extract,
represented by the sum of the content of the isoflavones daid-
zin, glycitin, genistin and one or more of the following isofla-
vones: malonyl daidzin, malonyl glycitin, malonyl genistin, ace-
tyl daidzin, acetyl glycitin, acetyl genistin, daidzein, glycitein,
and genistein.
Packaging and storagePreserve in tight, light-resistant containers, and
store at room temperature.
LabelingThe label states the Latin binomial and, following the official
name, the article from which the Capsules were prepared. Label it to indi-
cate the amount of Extract, in mg, per Capsule. Label it to indicate the
content, in percentage, of the isoflavones in the Extract used to prepare the
Capsules.
Soy Isoflavones Tablets
Soy Isoflavones Tablets contain Powdered Soy Isoflavones
Extract. Tablets contain not less than 90.0 percent and not more
than 110.0 percent of the labeled amount of the Extract, repre-
sented by the sum of the content of the isoflavones daid-
zin, glycitin, genistin, and one or more of the following isofla-
vones: malonyl daidzin, malonyl glycitin, malonyl genistin,
acetyl daidzin, acetyl glycitin, acetyl genistin, daidzein, glycitein,
and genistein.
Packaging and storagePreserve in tight, light-resistant containers, and
store at room temperature.
LabelingThe label states the Latin binomial and, following the official
name, the article from which the Tablets were prepared. Label it to indicate
the amount of Extract, in mg, per Tablet. Label it to indicate the content, in
percentage, of the isoflavones in the Extract used to prepare the Tablets.
USP Pharmacists Pharmacopeia
Turmeric
Turmeric is the dried rhizome of Curcuma longa L., also known
as C. domestica Val., (Fam. Zingiberaceae). It is commonly known
as Curcuma, Curcum, Haridra, and Indian Saffron. It contains
not less than 3.0 percent of curcuminoids, calculated on the
dried basis.
Packaging and storagePreserve in well-closed containers, protected from
light and moisture, and store at room temperature.
LabelingThe label states the Latin binominal and, following the official
name, the part of the plant contained in the article.
Powdered Turmeric
Powdered Turmeric is Turmeric reduced to a fine or very fine
powder.
Packaging and storagePreserve in well-closed containers, protected from
light and moisture, and store at room temperature.
LabelingThe label states the Latin binominal and, following the official
name, the part of the plant contained in the article.
0 0
2
Official text. Reprinted from USP 32NF 27. Section 8, Dietary Supplement Monographs and General Chapters S3/75
Turmeric
Powdered Turmeric Extract
Powdered Turmeric Extract is prepared from the pulverized
rhizomes of Curcuma longa L. (Fam. Zingiberaceae), using ace-
tone, methanol, or other suitable solvents. It contains not less
than 20 percent of total curcuminoids, calculated on the dried
basis. It may contain other added substances.
Packaging and storagePreserve in well-closed containers, protected from
light and moisture, and store at controlled room temperature.
LabelingThe label states the Latin binominal and, following the official
name, the part of the plant contained in the article. It meets other labeling
requirements under Botanical Extracts 565.
Loss on drying 731Dry 1.0 g at 105 for 2 hours: it loses not more than
7.0% of its weight.
P
U S
9
USP Pharmacists Pharmacopeia

Section 13
Reference Tables of USPNF

S P
T U
he following material discusses the description and relative solubilities of

9
articles in USPNF, describes standard buffer solutions, and provides

2 0 0
atomic weights of the elements and relative atomic masses and half-lives of
certain radionuclides. An alcoholometric table, intrinsic viscosity table, and
table of thermometric equivalents also are included. This material, extracted

from the USPNF, is intended as a valuable resource for practicing pharmacists.
USP Pharmacists Pharmacopeia Description and Solubility

Section Contents

Description and Relative Solubility of USP and NF Articles . . . . . . . . . . . . . . . . . S3/78

Solubilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3/78

S P
9 U
2 0 0

Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/77
USP Pharmacists Pharmacopeia
Description and Solubility
Description and Relative Solubility
of USP and NF Articles
The description and solubility statements pertaining to an article Acebutolol Hydrochloride: White or almost white, crystalline powder.
(formerly included in the individual monograph) are general in nature.
The information is provided for those who use, prepare, and dispense
drugs, solely to indicate descriptive and solubility properties of an
article complying with monograph standards. The properties are not
in themselves standards or tests for purity even though they may indi-
rectly assist in the preliminary evaluation of the integrity of an article.
Taste and Odor
Organoleptic characteristics are indicated in many instances because
they may be useful and descriptive properties of substances. However,
they are not meant to be applied as tests for identifying materials.
The inclusion of odor or taste among other descriptive proper-
ties may aid in identifying the causative agent following accidental
exposure to or contact with a substance. This information is provided
as a warning or to make an individual aware of sensations that may be
encountered. The use of odor or taste as a test for identification or
content is strongly discouraged.
The characteristic odor of a volatile substance becomes apparent
immediately on opening a container of it. The odor may be agreeable
(e.g., Peppermint Oil), unpleasant (e.g., Sulfur Dioxide), or potentially
0
hazardous on prolonged exposure (e.g., Coal Tar). Moreover, an unex-
pected odor may be encountered if the characteristics of a substance
0
are not known or if a container is incorrectly labeled. Consequently,
2
containers of such substances should be opened cautiously, preferably
in a well-ventilated fume hood. A characteristic taste or sensation pro-
duced in the oral cavity likewise is apparent if traces of residue materi-
als on fingers are inadvertently brought into contact with the tongue
or adjacent mucosal tissues.
Solubility
Only where a special, quantitative solubility test is given in the indi-
vidual monograph, and is designated by a test heading, is it a test for
purity.
The approximate solubilities of Pharmacopeial and National For-
mulary substances are indicated by the descriptive terms in the ac-
companying table. The term miscible as used in this Pharmacopeia
pertains to a substance that yields a homogeneous mixture when
mixed in any proportion with the designated solvent.
Parts of Solvent Required
Descriptive Term for 1 Part of Solute
Very soluble Less than 1
Freely soluble From 1 to 10
Soluble From 10 to 30
Sparingly soluble From 30 to 100
Slightly soluble From 100 to 1000
Very slightly soluble From 1000 to 10,000
Practically insoluble, or Insoluble 10,000 and over
Soluble Pharmacopeial and National Formulary articles, when
brought into solution, may show traces of physical impurities, such as
minute fragments of filter paper, fibers, and other particulate matter,
unless limited or excluded by definite tests or other specifications in
the individual monographs.
Acacia: Is practically odorless and produces a mucilaginous sensation
on the tongue. Insoluble in alcohol. Optical rotation varies depending
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/78
Description and Solubility
on the source of Acacia. For example, specific rotation values, calcu-
lated on the anhydrous basis and determined on a 1.0% (w/v) solution,
usually are between 25 and 35 for Acacia senegal and between +35
and +60 for Acacia seyal. NF category: Emulsifying and/or solubilizing
agent; suspending and/or viscosity-increasing agent; tablet binder.
Soluble in alcohol and in water; very slightly soluble in acetone and in
methylene chloride; practically insoluble in ether. Melts at about 141
to 144.
Acesulfame Potassium: A white, crystalline powder or colorless crys-
tals. Soluble in water; very slightly soluble in acetone and in alcohol.
NF category: Sweetening agent.
Acetaminophen: White, odorless, crystalline powder, having a slightly
bitter taste. Freely soluble in alcohol; soluble in boiling water and in
1 N sodium hydroxide.
Acetazolamide: White to faintly yellowish-white, crystalline, odorless
powder. Sparingly soluble in practically boiling water; slightly soluble
in alcohol; very slightly soluble in water.
Acetic Acid: Clear, colorless liquid, having a strong, characteristic
P
odor, and a sharply acid taste. Specific gravity is about 1.045. Miscible
with water, with alcohol, and with glycerin. NF category: Acidifying
S
agent; buffering agent.
Glacial Acetic Acid: Clear, colorless liquid, having a pungent, char-
U
acteristic odor and, when well diluted with water, an acid taste. Boils
at about 118. Specific gravity is about 1.05. Miscible with water, with
alcohol, and with glycerin. NF category: Acidifying agent.
9
Acetohexamide: White, crystalline, practically odorless powder.
Soluble in pyridine and in dilute solutions of alkali hydroxides; slightly
soluble in alcohol and in chloroform; practically insoluble in water and
in ether.
Acetohydroxamic Acid: White, slightly hygroscopic, crystalline pow-
der. Melts, after drying at about 80 for 2 to 4 hours, at about 88. Freely
soluble in water and in alcohol; very slightly soluble in chloroform.
Acetone: Transparent, colorless, mobile, volatile liquid, having a char-
acteristic odor. A solution (1 in 2) is neutral to litmus. Miscible with
water, with alcohol, with ether, with chloroform, and with most volatile
oils. NF category: Solvent.
Acetylcholine Chloride: White or off-white crystals or crystalline pow-
der. Very soluble in water; freely soluble in alcohol; insoluble in ether.
Is decomposed by hot water and by alkalies.
Acetylcysteine: White, crystalline powder, having a slight acetic odor.
Freely soluble in water and in alcohol; practically insoluble in chloro-
form and in ether.
Acetyltributyl Citrate: Clear, practically colorless, oily liquid. Freely
soluble in alcohol, in isopropyl alcohol, in acetone, and in toluene;
insoluble in water. NF category: Plasticizer.
Acetyltriethyl Citrate: Clear, practically colorless, oily liquid. Freely
soluble in alcohol, in isopropyl alcohol, in acetone, and in toluene;
insoluble in water. NF category: Plasticizer.
Acitretin: Yellow or greenish, crystalline powder. Sparingly soluble in
tetrahydrofuran; slightly soluble in acetone and in alcohol; very slightly
soluble in cyclohexane; practically insoluble in water.
Acyclovir: White to off-white, crystalline powder. Melts at tempera-
tures higher than 250, with decomposition. Soluble in diluted hydro-
chloric acid; slightly soluble in water; insoluble in alcohol.
Ademetionine Disulfate Tosylate: White powder. Freely soluble in
water.
Adenine: White crystals or crystalline powder. Is odorless and taste-
less. Sparingly soluble in boiling water; slightly soluble in alcohol;
very slightly soluble in water; practically insoluble in ether and in
chloroform.
USP Pharmacists Pharmacopeia
Adenosine: White, odorless, crystalline powder. Slightly soluble in
water; practically insoluble in alcohol. Melts at about 235.
Adipic Acid: A white, crystalline powder. Freely soluble in alcohol and
in methanol; soluble in boiling water and in acetone; slightly soluble in
water. NF category: Buffering agent.
Agar: Odorless or has a slight odor, and produces a mucilaginous sen-
sation on the tongue. Soluble in boiling water; insoluble in cold water.
NF category: Suspending and/or viscosity-increasing agent.
Alamic Acid: NF category: Suspending and/or viscosity-increasing
agent.
Alanine: White, odorless crystals or crystalline powder, having a
slightly sweet taste. Freely soluble in water; slightly soluble in 80%
alcohol; insoluble in ether.
Albendazole: White to faintly yellowish powder. Freely soluble in
anhydrous formic acid; very slightly soluble in ether and in methylene
chloride; practically insoluble in alcohol and in water.
Albumin Human: Practically odorless, moderately viscous, clear,
brownish fluid.
rAlbumin Human:Clear, slightly viscous, and colorless to yellow amber
in color. NF category: Vehicle (sterile).
Albuterol: White, crystalline powder. Soluble in alcohol; sparingly
soluble in water. Melts at about 156.
Albuterol Sulfate: White or practically white powder. Freely soluble in
water; slightly soluble in alcohol, in chloroform, and in ether.
Alcohol: Clear, colorless, mobile, volatile liquid. Has a characteristic
odor and produces a burning sensation on the tongue. Is readily vola
0
tilized even at low temperatures, and boils at about 78. Is flammable.
Miscible with water and with practically all organic solvents. NF cat-
0
egory: Solvent.
Dehydrated Alcohol: Clear, colorless, mobile, volatile liquid. Has a
2
characteristic odor and produces a burning sensation on the tongue.
Is readily volatilized even at low temperatures, and boils at about
78. Is flammable. Miscible with water and with practically all organic
solvents.
Diluted Alcohol: Clear, colorless, mobile liquid, having a characteristic
odor and producing a burning sensation on the tongue. NF category:
Solvent.
Rubbing Alcohol: Transparent, colorless, or colored as desired, mo-
bile, volatile liquid. Has an extremely bitter taste and, in the absence of
added odorous constituents, a characteristic odor. Is flammable.
Alendronate Sodium: White, free-flowing powder. Soluble in water;
very slightly soluble in dimethyl sulfoxide, in methyl alcohol, and in
propylene glycol; practically insoluble in acetone, in acetonitrile, in
alcohol, in chloroform, and in isopropyl alcohol.
Alfadex: A white or almost white, amorphous or crystalline powder.
Freely soluble in water and in propylene glycol; practically insoluble in
ethanol and in methylene chloride.
Alfentanil Hydrochloride: White to almost white powder. Freely
soluble in methanol, in alcohol, and in chloroform; soluble in water;
sparingly soluble in acetone. Melting point range, crystals from ac-
etone: 136 143 (anhydrous) and reported as crystals from aqueous
hydrochloric acid: 116 126 (monohydrate).
Alfentanil Injection: Clear, colorless solution.
Alfuzosin Hydrochloride: White to almost white powder, slightly hy-
groscopic. Freely soluble in water; sparingly soluble in alcohol; practi-
cally insoluble in methylene chloride.
Alginic Acid: White to yellowish white, fibrous powder. Is odorless, or
practically odorless, and is tasteless. Insoluble in water and in organic
solvents; soluble in alkaline solutions. NF category: Suspending and/or
viscosity-increasing agent; tablet binder; tablet disintegrant.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/79
Description and Solubility
Alkyl (C12-15) Benzoate: Clear, practically colorless, oily liquid. Sol-
uble in acetone, in alcohol, in isopropyl alcohol, in ethyl acetate, in
isopropyl myristate, in isopropyl palmitate, in lanolin, in mineral oil, in
vegetable oils, and in volatile silicones; insoluble in water, in glycerin,
and in propylene glycol. NF category: Vehicle (oleaginous); emollient.
Allantoin: White, crystalline powder. Slightly soluble in water; very
slightly soluble in alcohol. Melts at about 225, with decomposition.
Allopurinol: Fluffy white to off-white powder, having only a slight
odor. Soluble in solutions of potassium and sodium hydroxides; very
slightly soluble in water and in alcohol; practically insoluble in chloro-
form and in ether.
Allyl Isothiocyanate: Colorless to pale yellow, very refractive, liquid.
Pungent irritating odor, acrid taste. [Caution: Lachrymator.] Miscible
with alcohol, with carbon disulfide, and with ether. Slightly soluble in
water.
Almond Oil: Clear, pale straw-colored or colorless, oily liquid, having
a bland taste. Remains clear at 10, and does not congeal until cooled
to almost 20. Slightly soluble in alcohol; miscible with ether, with
chloroform, with benzene, and with solvent hexane. NF category: Fla-
P
vors and perfumes; vehicle (oleaginous).
Aloe: Has a characteristic, somewhat sour and disagreeable, odor.
S
Alprazolam: A white to off-white, crystalline powder. Melts at about
225. Freely soluble in chloroform; soluble in alcohol; sparingly soluble
U
in acetone; slightly soluble in ethyl acetate; insoluble in water.
Alprostadil: A white to off-white, crystalline powder. Melts at about
9
110. Freely soluble in alcohol; soluble in water and in acetone; slightly
soluble in ethyl acetate; very slightly soluble in chloroform and in
ether.
Altretamine: White, crystalline powder. Soluble in chloroform; in-
soluble in water.
Ammonium Alum: Large, colorless crystals, crystalline fragments,
or white powder. Is odorless, and has a sweetish, strongly astringent
taste. Its solutions are acid to litmus. Very soluble in boiling water;
freely soluble in water; freely but slowly soluble in glycerin; insoluble
in alcohol.
Potassium Alum: Large, colorless crystals, crystalline fragments, or
white powder. Is odorless, and has a sweetish, strongly astringent
taste. Its solutions are acid to litmus. Very soluble in boiling water;
freely soluble in water; freely but slowly soluble in glycerin; insoluble
in alcohol.
Aluminum Acetate Topical Solution: Clear, colorless liquid having a
faint odor of acetic acid, and a sweetish, astringent taste. Specific grav-
ity is about 1.02.
Aluminum Chloride: White, or yellowish-white, deliquescent, crystal-
line powder. Is practically odorless, and has a sweet, very astringent
taste. Its solutions are acid to litmus. Very soluble in water; freely
soluble in alcohol; soluble in glycerin.
Aluminum Hydroxide Gel: White, viscous suspension, from which
small amounts of clear liquid may separate on standing.
Dried Aluminum Hydroxide Gel: White, odorless, tasteless, amor-
phous powder. Soluble in dilute mineral acids and in solutions of fixed
alkali hydroxides; insoluble in water and in alcohol.
Aluminum Monostearate: Fine, white to yellowish-white, bulky pow-
der, having a faint, characteristic odor. Insoluble in water, in alcohol,
and in ether. NF category: Suspending and/or viscosity-increasing
agent.
Aluminum Phosphate Gel: White, viscous suspension from which
small amounts of water separate on standing.
Aluminum Subacetate Topical Solution: Clear, colorless or faintly yel-
low liquid, having an odor of acetic acid and an acid reaction to litmus.
Gradually becomes turbid on standing, through separation of a more
basic salt.
USP Pharmacists Pharmacopeia
Aluminum Sulfate: White, crystalline powder, shining plates, or crys-
talline fragments. Is stable in air. Is odorless, and has a sweet taste, be-
coming mildly astringent. Freely soluble in water; insoluble in alcohol.
Amantadine Hydrochloride: White or practically white, crystalline
powder, having a bitter taste. Freely soluble in water; soluble in alcohol
and in chloroform.
Amifostine: White, crystalline powder. Freely soluble in water.
Amikacin: White, crystalline powder. Sparingly soluble in water.
Amikacin Sulfate: White, crystalline powder. Freely soluble in water.
Amiloride Hydrochloride: Yellow to greenish-yellow, odorless or prac-
tically odorless powder. Freely soluble in dimethyl sulfoxide; slightly
soluble in water; sparingly soluble in methanol; insoluble in ether, in
ethyl acetate, in acetone, and in chloroform.
Amino Methacrylate Copolymer: Colorless to yellowish granules.
Soluble in acetone, in isopropyl alcohol, and in diluted acids; practi-
cally insoluble in water. The solutions are clear to slightly cloudy. NF
category: Coating agent; polymer membrane; tablet binder.
Aminobenzoate Potassium: White, crystalline powder. The pH of a
1 in 100 solution in water is about 7. Very soluble in water; soluble in
alcohol; practically insoluble in ether.
Aminobenzoic Acid: White or slightly yellow, odorless crystals or crys-
talline powder. Discolors on exposure to air or light. Slightly soluble in
water and in chloroform; freely soluble in alcohol and in solutions of
alkali hydroxides and carbonates; sparingly soluble in ether.
Aminobenzoic Acid Topical Solution: Straw-colored solution having
the odor of alcohol.
0
Aminocaproic Acid: Fine, white, crystalline powder. Is odorless, or
practically odorless. Its solutions are neutral to litmus. Melts at about
0
205. Freely soluble in water, in acids, and in alkalies; slightly soluble
in methanol and in alcohol; practically insoluble in chloroform and in
2
ether.
Aminoglutethimide: Fine, white, or creamy white, crystalline powder.
Very slightly soluble in water; readily soluble in most organic solvents.
Forms water-soluble salts with strong acids.
Aminohippuric Acid: White, crystalline powder. Discolors on exposure
to light. Melts at about 195, with decomposition. Sparingly soluble in
water and in alcohol; freely soluble in alkaline solutions, with some
decomposition, and in diluted hydrochloric acid; very slightly soluble
in benzene, in carbon tetrachloride, in chloroform, and in ether.
Aminopentamide Sulfate: White, crystalline powder. Freely soluble
in water and in alcohol; very slightly soluble in chloroform; practically
insoluble in ether.
Aminophylline: White or slightly yellowish granules or powder, hav-
ing a slight ammoniacal odor and a bitter taste. Upon exposure to air,
it gradually loses ethylenediamine and absorbs carbon dioxide with
the liberation of free theophylline. Its solutions are alkaline to litmus.
One g dissolves in 25 mL of water to give a clear solution; 1 g dissolved
in 5 mL of water crystallizes upon standing, but redissolves when a
small amount of ethylenediamine is added. Insoluble in alcohol and
in ether.
Aminophylline Tablets: May have a faint ammoniacal odor.
Aminosalicylate Sodium: White to cream-colored, crystalline powder.
Is practically odorless, and has a sweet, saline taste. Its solutions de-
compose slowly and darken in color. Freely soluble in water; sparingly
soluble in alcohol; very slightly soluble in ether and in chloroform.
Aminosalicylic Acid: White or practically white, bulky powder, that
darkens on exposure to light and air. Is odorless, or has a slight acetous
odor. Slightly soluble in water and in ether; soluble in alcohol; practi-
cally insoluble in benzene.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/80
Description and Solubility
Amitriptyline Hydrochloride: White or practically white, odorless
or practically odorless, crystalline powder or small crystals. Freely
soluble in water, in alcohol, in chloroform, and in methanol; insoluble
in ether.
Amlodipine Besylate: A white or almost white powder. Freely soluble
in methanol; sparingly soluble in alcohol; slightly soluble in 2-propanol
and in water.
Strong Ammonia Solution: Clear, colorless liquid, having an exceed-
ingly pungent, characteristic odor. Specific gravity is about 0.90. NF
category: Alkalizing agent.
Aromatic Ammonia Spirit: Practically colorless liquid when recently
prepared, but gradually acquiring a yellow color on standing. Has the
taste of ammonia, has an aromatic and pungent odor, and is affected
by light. Specific gravity is about 0.90.
Ammonio Methacrylate Copolymer: Colorless, clear to white-opaque
granules or a white powder, both with a faint amine-like odor. Soluble
to freely soluble in methanol, in alcohol, and in isopropyl alcohol, each
of which contains small amounts of water; soluble to freely soluble in
acetone, in ethyl acetate, and in methylene chloride. The solutions are
P
clear to slightly cloudy. Insoluble in petroleum ether and in water. NF
category: Coating agent; tablet binder; polymer membrane.
S
Ammonio Methacrylate Copolymer Dispersion: Milky-white liquids
of low viscosity with a faint characteristic odor. Miscible with water in
U
any proportion, the milky-white appearance being retained. A clear or
slightly cloudy solution is obtained on mixing one part with five parts
of acetone, alcohol, or isopropyl alcohol. When mixed with methanol
9
in a ratio of 1:5, Ammonio Methacrylate Copolymer Dispersion Type A
dissolves completely, and Ammonio Methacrylate Copolymer Disper-
sion Type B dissolves only partially. NF category: Coating agent; poly-
mer membrane; tablet binder.
Ammonium Carbonate: White powder, or hard, white or translucent
masses, having a strong odor of ammonia, without empyreuma, and a
sharp, ammoniacal taste. Its solutions are alkaline to litmus. On expo-
sure to air, it loses ammonia and carbon dioxide, becoming opaque,
and is finally converted into friable porous lumps or a white powder of
ammonium bicarbonate. Freely soluble in water, but is decomposed by
hot water. NF category: Alkalizing agent; buffering agent.
Ammonium Chloride: Colorless crystals or white, fine or coarse, crys-
talline powder. Has a cool, saline taste, and is somewhat hygroscopic.
Freely soluble in water and in glycerin, and even more so in boiling
water; sparingly soluble in alcohol.
Ammonium Molybdate: Colorless or slightly greenish or yellowish
crystals. Soluble in water; practically insoluble in alcohol.
Ammonium Phosphate: Colorless or white granules or powder,
having a saline taste. Freely soluble in water; practically insoluble in
acetone and in alcohol. NF category: Buffering agent.
Ammonium Sulfate: Colorless or white crystals or granules that de-
compose at temperatures above 280. One g is soluble in about 1.5
mL of water. It is insoluble in alcohol. The pH of a 0.1 M solution is
between 4.5 and 6.0.
Amobarbital Sodium: White, friable, granular powder. Is odorless, has
a bitter taste, and is hygroscopic. Its solutions decompose on standing,
heat accelerating the decomposition. Very soluble in water; soluble in
alcohol; practically insoluble in ether and in chloroform.
Amodiaquine: Very pale yellow to light tan-yellow, odorless powder.
Practically insoluble in water; sparingly soluble in 1.0 N hydrochloric
acid; slightly soluble in alcohol.
Amodiaquine Hydrochloride: Yellow, crystalline powder. Is odorless
and has a bitter taste. Soluble in water; sparingly soluble in alcohol;
very slightly soluble in benzene, in chloroform, and in ether.
USP Pharmacists Pharmacopeia
Amoxapine: White to yellowish crystalline powder. Freely soluble in
chloroform; soluble in tetrahydrofuran; sparingly soluble in methanol
and in toluene; slightly soluble in acetone; practically insoluble in
water.
Amoxicillin: White, practically odorless, crystalline powder. Slightly
soluble in water and in methanol; insoluble in benzene, in carbon
tetrachloride, and in chloroform.
Amphetamine Sulfate: White, odorless, crystalline powder, having
a slightly bitter taste. Its solutions are acid to litmus, having a pH of
5 to 6. Freely soluble in water; slightly soluble in alcohol; practically
insoluble in ether.
Amphotericin B: Yellow to orange powder; odorless or practically so.
Insoluble in water, in anhydrous alcohol, in ether, in benzene, and in
toluene; soluble in dimethylformamide, in dimethyl sulfoxide, and in
propylene glycol; slightly soluble in methanol.
Amphotericin B for Injection: It yields a colloidal dispersion in water.
Ampicillin: White, practically odorless, crystalline powder. Slightly
soluble in water and in methanol; insoluble in benzene, in carbon
tetrachloride, and in chloroform.
Ampicillin Sodium: White to off-white, odorless or practically odor-
less, crystalline powder. Is hygroscopic. Very soluble in water and in
isotonic sodium chloride and dextrose solutions.
Amprolium (C14H19ClN4HCl): White to light yellow powder. Freely
soluble in water, in methanol, in alcohol, and in dimethylformamide;
sparingly soluble in dehydrated alcohol; practically insoluble in isopro-
pyl alcohol, in butyl alcohol, and in acetone.
Amyl Nitrite: Clear, yellowish liquid, having a peculiar, ethereal, fruity
0
odor. Is volatile even at low temperatures, and is flammable. Boils at
0
about 96. Practically insoluble in water. Miscible with alcohol and with
ether.
2
Amylene Hydrate: Clear, colorless liquid, having a camphoraceous
odor. Its solutions are neutral to litmus. Freely soluble in water. Mis-
cible with alcohol, with chloroform, with ether, and with glycerin. NF
category: Solvent.
Anethole: Colorless or faintly yellow liquid at or above 23. Has a
sweet taste and the aromatic odor of anise. Is affected by light. Very
slightly soluble in water; freely soluble in alcohol. Readily miscible with
ether and with chloroform. NF category: Flavors and perfumes.
Anileridine: White to yellowish-white, odorless to practically odorless,
crystalline powder. Is oxidized on exposure to air and light, becoming
darker in color. It exhibits polymorphism, and of two crystalline forms
observed, one melts at about 80 and the other at about 89. Very
slightly soluble in water; freely soluble in alcohol and in chloroform;
soluble in ether, although it may show turbidity.
Anileridine Hydrochloride: White or nearly white, odorless, crystalline
powder. Is stable in air. Melts at about 270, with decomposition. Freely
soluble in water; sparingly soluble in alcohol; practically insoluble in
ether, and in chloroform.
Antazoline Phosphate: White to off-white, crystalline powder, having
a bitter taste. Soluble in water; sparingly soluble in methanol; practi-
cally insoluble in benzene and in ether.
Anthralin: Yellowish-brown, crystalline powder. Is odorless and taste-
less. Insoluble in water; soluble in chloroform, in acetone, in benzene,
and in solutions of alkali hydroxides; slightly soluble in alcohol, in
ether, and in glacial acetic acid.
Anticoagulant Citrate Dextrose Solution: Clear, colorless, odorless
liquid. Is dextrorotatory.
Anticoagulant Citrate Phosphate Dextrose Solution: Clear, colorless
to slightly yellow, odorless liquid. Is dextrorotatory.
Anticoagulant Sodium Citrate Solution: Clear and colorless liquid.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/81
Description and Solubility
Antihemophilic Factor: White or yellowish powder. On constitution is
opalescent with a slight blue tinge or is a yellowish liquid.
Cryoprecipitated Antihemophilic Factor: Yellowish, frozen solid. On
thawing becomes a very viscous, yellow, gummy liquid.
Antimony Potassium Tartrate: Colorless, odorless, transparent crystals,
or white powder. The crystals effloresce upon exposure to air and do
not readily rehydrate even on exposure to high humidity. Its solutions
are acid to litmus. Freely soluble in boiling water; soluble in water and
in glycerin; insoluble in alcohol.
Antimony Sodium Tartrate: Colorless, odorless, transparent crystals,
or white powder. The crystals effloresce upon exposure to air. Freely
soluble in water; insoluble in alcohol.
Antipyrine: Colorless crystals, or white, crystalline powder. Is odorless
and has a slightly bitter taste. Its solutions are neutral to litmus. Very
soluble in water; freely soluble in alcohol and in chloroform; sparingly
soluble in ether.
Antivenin (Crotalidae) Polyvalent: Solid exhibiting the characteristic
structure of a freeze-dried solid; light cream in color.
Antivenin (Micrurus Fulvius): Solid exhibiting the characteristic struc-
P
ture of a freeze-dried solid; light cream in color.
S
Apomorphine Hydrochloride: Minute, white or grayish-white, glisten-
ing crystals or white powder. Is odorless. It gradually acquires a green
color on exposure to light and air. Its solutions are neutral to litmus.
U
Sparingly soluble in water and in alcohol; soluble in water at 80; very
slightly soluble in chloroform and in ether.
9
Apraclonidine Hydrochloride: White to off-white, odorless to prac-
tically odorless powder. Soluble in methanol; sparingly soluble in
water and in alcohol; insoluble in chloroform, in ethyl acetate, and in
hexanes.
Arginine: White, practically odorless crystals. Freely soluble in water;
sparingly soluble in alcohol; insoluble in ether.
Arginine Hydrochloride: White crystals or crystalline powder, practi-
cally odorless. Freely soluble in water.
Aromatic Elixir: NF category: Vehicle (flavored and/or sweetened).
Arsanilic Acid: White to off-white, crystalline powder. Melts at about
232. Soluble in hot water, in amyl alcohol, and in solutions of alkali
carbonates; sparingly soluble in concentrated mineral acids; slightly
soluble in cold water, in alcohol, and in acetic acid; insoluble in ac-
etone, in benzene, in chloroform, in ether, and in dilute mineral acids.
Ascorbic Acid: White or slightly yellow crystals or powder. On ex-
posure to light it gradually darkens. In the dry state, is reasonably
stable in air, but in solution rapidly oxidizes. Melts at about 190. Freely
soluble in water; sparingly soluble in alcohol; insoluble in chloroform,
in ether, and in benzene. NF category: Antioxidant.
Ascorbyl Palmitate: White to yellowish white powder, having a char-
acteristic odor. Very slightly soluble in water and in vegetable oils;
soluble in alcohol. NF category: Antioxidant.
Asparagine: White crystals or a crystalline powder. Soluble in water;
practically insoluble in alcohol and in ether. Its solutions are acid to
litmus. It melts at about 234.
Aspartame: White, odorless, crystalline powder, having a sweet taste.
Sparingly soluble in water; slightly soluble in alcohol. Melts at about
246. The pH of an 8 in 1000 solution is about 5. NF category: Sweeten-
ing agent.
Aspartame Acesulfame: White, odorless, crystalline powder. Slightly
soluble in water and in ethanol. NF category: Sweetening agent.
Aspartic Acid: White or almost white, crystalline powder, or colorless
crystals. Soluble in dilute solutions of alkali hydroxides and in dilute
mineral acids; slightly soluble in water; practically insoluble in alcohol
and in ether.
USP Pharmacists Pharmacopeia
Aspirin: White crystals, commonly tabular or needle-like, or white,
crystalline powder. Is odorless or has a faint odor. Is stable in dry air;
in moist air it gradually hydrolyzes to salicylic and acetic acids. Slightly
soluble in water; freely soluble in alcohol; soluble in chloroform and in
ether; sparingly soluble in absolute ether.
Atenolol: White or practically white, odorless powder. Melting point
146 148 (crystals from ethyl acetate). Freely soluble in methanol; spar-
ingly soluble in alcohol; slightly soluble in water and in isopropanol.
Atovaquone: Yellow powder. Freely soluble in N-methyl-2-pyrrolidone
and in tetrahydrofuran; soluble in chloroform; sparingly soluble in ac-
etone, in di-n-butyl adipate, in dimethyl sulfoxide, and in polyethylene
glycol 400; slightly soluble in alcohol, in 1,3-butanediol, in ethyl acetate,
in glycerin, in octanol, and in polyethylene glycol 200; very slightly
soluble in 0.1 N sodium hydroxide; insoluble in water.
Atracurium Besylate: White to off-white solid.
Atropine: White crystals, usually needle-like, or white, crystalline pow-
der. Its saturated solution is alkaline to phenolphthalein TS. Is optically
inactive, but usually contains some levorotatory hyoscyamine. Slightly
soluble in water, and sparingly soluble in water at 80; freely soluble in
alcohol and in chloroform; soluble in glycerin and in ether.
Atropine Sulfate: Colorless crystals, or white, crystalline powder.
Odorless; effloresces in dry air; is slowly affected by light. Very soluble
in water; freely soluble in alcohol and even more so in boiling alcohol;
freely soluble in glycerin.
Activated Attapulgite: Cream-colored, micronized, nonswelling pow-
der, free from gritty particles. The high heat treatment used in its
preparation causes it to yield only moderately viscous aqueous sus-
0
pensions, its dispersion consisting mainly of particle groups. Insoluble
in water. NF category: Suspending and/or viscosity-increasing agent.
0
Colloidal Activated Attapulgite: Cream-colored, micronized, non-
2
swelling powder, free from gritty particles. Yields viscous aqueous
suspensions, as a result of dispersion into its constituent ultimate
particles. Insoluble in water. NF category: Suspending and/or viscosity-
increasing agent.
Aurothioglucose: Yellow, odorless or practically odorless powder. Is
stable in air. An aqueous solution is unstable on long standing. The pH
of its 1 in 100 solution is about 6.3. Freely soluble in water; practically
insoluble in acetone, in alcohol, in chloroform, and in ether.
Azatadine Maleate: White to light cream-colored, odorless powder.
Melts at about 153. Freely soluble in water, in alcohol, in chloroform,
and in methanol; practically insoluble in benzene and in ether.
Azathioprine: Pale yellow, odorless powder. Insoluble in water; solu-
ble in dilute solutions of alkali hydroxides; sparingly soluble in dilute
mineral acids; very slightly soluble in alcohol and in chloroform.
Azathioprine Sodium for Injection: Bright yellow, hygroscopic, amor-
phous mass or cake.
Aztreonam: White, odorless, crystalline powder. Soluble in dimeth-
ylformamide and in dimethyl sulfoxide; slightly soluble in methanol;
very slightly soluble in dehydrated alcohol; practically insoluble in
ethyl acetate, in chloroform, and in toluene.
Bacampicillin Hydrochloride: White or practically white powder. Is hy-
groscopic. Soluble in methylene chloride and in water; freely soluble
in alcohol and in chloroform; very slightly soluble in ether.
Bacitracin: White to pale buff powder, odorless or having a slight
odor. Is hygroscopic. Its solutions deteriorate rapidly at room tem-
perature. Is precipitated from its solutions and is inactivated by salts of
many of the heavy metals. Freely soluble in water; soluble in alcohol,
in methanol, and in glacial acetic acid, the solution in the organic sol-
vents usually showing some insoluble residue; insoluble in acetone, in
chloroform, and in ether.
Bacitracin Zinc: White to pale tan powder, odorless or having a slight
odor. Is hygroscopic. Sparingly soluble in water.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/82
Description and Solubility
Baclofen: White to off-white, crystalline powder. Is odorless or practi-
cally so. Slightly soluble in water; very slightly soluble in methanol;
insoluble in chloroform.
Adhesive Bandage: The compress of Adhesive Bandage is substantially
free from loose threads or ravelings. The adhesive strip may be perfo-
rated, and the back may be coated with a water-repellent film.
Gauze Bandage: One continuous piece, tightly rolled, in various widths
and lengths and substantially free from loose threads and ravelings.
Barium Hydroxide Lime: White or grayish-white granules. May have
a color if an indicator has been added. NF category: Sorbent, carbon
dioxide.
Barium Sulfate: Fine, white, odorless, tasteless, bulky powder, free
from grittiness. Practically insoluble in water, in organic solvents, and
in solutions of acids and of alkalies.
Barium Sulfate for Suspension: White or colored, bulky or granular
powder.
BCG Vaccine: White to creamy white, dried mass, having the charac-
teristic texture of material dried in the frozen state.
P
Beclomethasone Dipropionate: White to cream white, odorless pow-
der. Very slightly soluble in water; very soluble in chloroform; freely
S
soluble in acetone and in alcohol.
Belladonna Leaf: When moistened, its odor is slight, somewhat to-
bacco-like. Its taste is somewhat bitter and acrid.
U
Benazepril Hydrochloride: White to off-white, crystalline powder.
Soluble in water, in methanol, and in alcohol.
9
Bendroflumethiazide: White to cream-colored, finely divided, crystal-
line powder. Is odorless, or has a slight odor. Melts at about 220. Prac-
tically insoluble in water; freely soluble in alcohol and in acetone.
Benoxinate Hydrochloride: White, or slightly off-white, crystals or
crystalline powder. Is odorless, or has a slight characteristic odor, has a
salty taste, and exhibits local anesthetic properties when placed upon
the tongue. Its solutions are neutral to litmus, and it melts at about
158. Very soluble in water; freely soluble in chloroform and in alcohol;
insoluble in ether.
Bentonite: Very fine, odorless, pale buff or cream-colored to gray-
ish powder, free from grit. Has a slightly earthy taste. Is hygroscopic.
Insoluble in water, but swells to approximately twelve times its volume
when added to water; insoluble in, and does not swell in, organic sol-
vents. NF category: Suspending and/or viscosity-increasing agent.
Purified Bentonite: Odorless, tasteless, fine (micronized) powder or
small flakes that are creamy when viewed on their flat surfaces and tan
to brown when viewed on their edges. Insoluble in water and in alco-
hol. Swells when added to water or glycerin. NF category: Suspending
and/or viscosity-increasing agent.
Bentonite Magma: NF category: Suspending and/or viscosity-increas-
ing agent.
Benzaldehyde: Colorless, strongly refractive liquid, having an odor
resembling that of bitter almond oil, and having a burning, aromatic
taste. Is affected by light. Slightly soluble in water. Miscible with alco-
hol, with ether, and with fixed and volatile oils. NF category: Flavors
and perfumes.
Benzaldehyde Elixir, Compound: NF category: Flavored and/or sweet-
ened vehicle.
Benzalkonium Chloride: White or yellowish-white, thick gel or ge-
latinous pieces. Usually has a mild, aromatic odor. Its aqueous solution
has a bitter taste, foams strongly when shaken, and usually is slightly
alkaline. Very soluble in water and in alcohol. Anhydrous form freely
soluble in benzene, and slightly soluble in ether. NF category: Antimi-
crobial preservative; wetting and/or solubilizing agent.
Benzalkonium Chloride Solution: Clear liquid; colorless or slightly
yellow unless a color has been added. Has an aromatic odor and a bit-
ter taste. NF category: Antimicrobial preservative.
USP Pharmacists Pharmacopeia
Benzethonium Chloride: White crystals, having a mild odor. Its solu-
tion (1 in 100) is slightly alkaline to litmus. Soluble in water, in alcohol,
and in chloroform; slightly soluble in ether. NF category: Antimicrobial
preservative; wetting and/or solubilizing agent.
Benzethonium Chloride Solution: Odorless, clear liquid, slightly
alkaline to litmus.
Benzethonium Chloride Tincture: Clear liquid, having the characteris-
tic odor of acetone and of alcohol.
Benzocaine: Small, white crystals or white, crystalline powder. Is
odorless, is stable in air, and exhibits local anesthetic properties when
placed upon the tongue. Very slightly soluble in water; freely soluble
in alcohol, in chloroform, and in ether; sparingly soluble in almond oil
and in olive oil. Dissolves in dilute acids.
Benzoic Acid: White crystals, scales, or needles. Has a slight odor,
usually suggesting benzaldehyde or benzoin. Somewhat volatile
at moderately warm temperatures. Freely volatile in steam. Slightly
soluble in water; freely soluble in alcohol, in chloroform, and in ether.
NF category: Antimicrobial preservative.
Benzoin: Sumatra Benzoin has an aromatic and balsamic odor. When
heated it does not emit a pinaceous odor. When Sumatra Benzoin is
digested with boiling water, the odor suggests cinnamates or storax.
Its taste is aromatic and slightly acrid. Siam Benzoin has an agreeable,
balsamic, vanilla-like odor. Its taste is aromatic and slightly acrid.
Benzonatate: Clear, pale yellow, viscous liquid, having a faint, charac-
teristic odor. Has a bitter taste, and exhibits local anesthetic properties
when placed upon the tongue. Miscible with water in all proportions.
Freely soluble in chloroform, in alcohol, and in benzene.
0
Hydrous Benzoyl Peroxide: White, granular powder, having a char-
acteristic odor. Sparingly soluble in water and in alcohol; soluble in
0
acetone, in chloroform, and in ether.
2
Benzoyl Peroxide Gel: A soft, white gel, having a characteristic odor.
Benzoyl Peroxide Lotion: White, viscous, creamy lotion, having a
characteristic odor.
Benztropine Mesylate: White, slightly hygroscopic, crystalline powder.
Very soluble in water; freely soluble in alcohol; very slightly soluble in
ether.
Benzyl Alcohol: Clear, colorless, oily liquid. Boils at about 206, with-
out decomposition. Is neutral to litmus. Freely soluble in 50% alcohol;
sparingly soluble in water. Miscible with alcohol, with ether, and with
chloroform. The specific gravity is between 1.042 and 1.047. NF cat-
egory: Antimicrobial preservative.
Benzyl Benzoate: Clear, colorless, oily liquid having a slight aromatic
odor and producing a sharp, burning sensation on the tongue. Practi-
cally insoluble in water and in glycerin. Miscible with alcohol, with
ether, and with chloroform. NF category: Solvent.
Beta Carotene: Red or reddish-brown to violet-brown crystals or crys-
talline powder. Insoluble in water and in acids and in alkalies; soluble
in carbon disulfide, in benzene, and in chloroform; sparingly soluble in
ether, in solvent hexane, and in vegetable oils; practically insoluble in
methanol and in alcohol.
Betadex: White, practically odorless, fine crystalline powder having a
slightly sweet taste. Sparingly soluble in water. NF category: Sequester-
ing agent.
Betahistine Hydrochloride: White to almost yellow, crystalline powder.
Very hygroscopic. Melts between 151 and 154. Very soluble in water;
freely soluble in alcohol; practically insoluble in isopropyl alcohol.
Betaine Hydrochloride: White, crystalline powder. Soluble in water
and in alcohol; practically insoluble in chloroform and in ether.
Betamethasone: White to practically white, odorless, crystalline pow-
der. Melts at about 240, with some decomposition. Insoluble in water;
sparingly soluble in acetone, in alcohol, in dioxane, and in methanol;
very slightly soluble in chloroform and in ether.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/83
Description and Solubility
Betamethasone Acetate: White to creamy white, odorless powder.
Sinters and resolidifies at about 165, and remelts at about 200 or 220,
with decomposition (see Melting Range or Temperature 741). Practi-
cally insoluble in water; freely soluble in acetone; soluble in alcohol
and in chloroform.
Betamethasone Benzoate: White to practically white, practically odor-
less powder. Melts at about 220, with decomposition. Insoluble in
water; soluble in alcohol, in methanol, and in chloroform.
Betamethasone Dipropionate: White to cream-white, odorless pow-
der. Insoluble in water; freely soluble in acetone and in chloroform;
sparingly soluble in alcohol.
Betamethasone Sodium Phosphate: White to practically white, odor-
less powder. Is hygroscopic. Freely soluble in water and in methanol;
practically insoluble in acetone and in chloroform.
Betamethasone Valerate: White to practically white, odorless powder.
Melts at about 190, with decomposition. Practically insoluble in water;
freely soluble in acetone and in chloroform; soluble in alcohol; slightly
soluble in benzene and in ether.
Betaxolol Hydrochloride: White, crystalline powder. Freely soluble in
P
water, in alcohol, in chloroform, and in methanol.
Bethanechol Chloride: Colorless or white crystals or white, crystalline
S
powder, usually having a slight, amine-like odor. Is hygroscopic. Exhib-
its polymorphism, and of two crystalline forms observed, one melts at
U
about 211 and the other melts at about 219. Freely soluble in water
and in alcohol; insoluble in chloroform and in ether.
9
Bicalutamide: Fine, white to off-white powder. Freely soluble in tetra-
hydrofuran and in acetone; soluble in acetonitrile; sparingly soluble in
methanol; slightly soluble in alcohol.
Biotin: Practically white, crystalline powder. Very slightly soluble in
water and in alcohol; insoluble in other common organic solvents.
Biperiden: White, practically odorless, crystalline powder. Practically
insoluble in water; freely soluble in chloroform; sparingly soluble in
alcohol.
Biperiden Hydrochloride: White, practically odorless, crystalline
powder. Melts at about 275, with decomposition. Is optically inactive.
Slightly soluble in water, in ether, in alcohol, and in chloroform; spar-
ingly soluble in methanol.
Bisacodyl: White to off-white, crystalline powder, in which the number
of particles having a longest diameter smaller than 50 m predominate.
Practically insoluble in water; soluble in chloroform and in benzene;
sparingly soluble in alcohol and in methanol; slightly soluble in ether.
Milk of Bismuth: Thick, white, opaque suspension that separates on
standing. Is odorless and practically tasteless. Miscible with water and
with alcohol.
Bismuth Citrate: White, amorphous or crystalline powder. Stable in
air. Melts at about 300, with decomposition. Soluble in ammonia TS
and in solutions of alkali citrates; insoluble in water and in alcohol.
Bismuth Subcarbonate: White or almost white powder. Practically
insoluble in water, in alcohol, and in ether. Dissolves in dilute acids
with effervescence.
Bismuth Subgallate: Amorphous, bright yellow powder. Is odorless
and tasteless. Is stable in air, but is affected by light. Dissolves readily
with decomposition in warm, moderately dilute hydrochloric, nitric,
or sulfuric acid; readily dissolved by solutions of alkali hydroxides,
forming a clear, yellow liquid that rapidly assumes a deep red color.
Practically insoluble in water, in alcohol, in chloroform, and in ether;
insoluble in very dilute mineral acids.
Bismuth Subnitrate: White, slightly hygroscopic powder. Practically
insoluble in water and in alcohol; readily dissolved by hydrochloric
acid or by nitric acid.
USP Pharmacists Pharmacopeia
Bismuth Subsalicylate: Fine to off-white, microcrystalline, odorless,
tasteless powder. Practically insoluble in water, in alcohol, and in ether.
Reacts with alkalies and mineral acids.
Bisoprolol Fumarate: White, crystalline powder. Very soluble in water
and in methanol; freely soluble in chloroform, in glacial acetic acid,
and in alcohol; slightly soluble in acetone and in ethyl acetate.
Bleomycin Sulfate: Cream-colored, amorphous powder. Very soluble
in water.
Anti-A Blood Grouping Serum: Liquid Serum is a clear or slightly opal-
escent fluid unless artificially colored blue. Dried Serum is light yellow
to deep cream color, unless artificially colored as indicated for liquid
Serum. The liquid Serum may develop slight turbidity on storage. The
dried Serum may show slight turbidity upon reconstitution for use.
Anti-B Blood Grouping Serum: Liquid Serum is a clear or slightly
opalescent fluid unless artificially colored yellow. Dried Serum is light
yellow to deep cream color, unless artificially colored as indicated for
liquid Serum. The liquid Serum may develop a slight turbidity on stor-
age. The dried Serum may show slight turbidity upon reconstitution
for use.
Blood Grouping Serums Anti-D, Anti-C, Anti-E, Anti-c, Anti-e: The liq-
uid Serums are clear, slightly yellowish fluids, that may develop slight
turbidity on storage. The dried Serums are light yellow to deep cream
color.
Blood Group Specific Substances A, B, and AB: Clear solution that
may have a slight odor because of the preservative.
Red Blood Cells: Dark red in color when packed. May show a slight
creamy layer on the surface and a small supernatant layer of yellow
0
or opalescent plasma. Also supplied in deep-frozen form with added
cryophylactic substance to extend storage time.
0
Whole Blood: Deep red, opaque liquid from which the corpuscles
2
readily settle upon standing for 24 to 48 hours, leaving a clear, yellow-
ish or pinkish supernatant layer of plasma.
Boric Acid: Colorless, odorless scales of a somewhat pearly luster,
or crystals, or white powder that is slightly unctuous to the touch. Is
stable in air. Soluble in water and in alcohol; freely soluble in glycerin,
in boiling water, and in boiling alcohol. NF category: Buffering agent.
Botulism Antitoxin: Transparent or slightly opalescent liquid, practi-
cally colorless, and practically odorless or having an odor because of
the antimicrobial agent.
Bretylium Tosylate: White, crystalline powder. Is hygroscopic. Freely
soluble in water, in methanol, and in alcohol; practically insoluble in
ether, in ethyl acetate, and in hexane.
Brinzolamide: White or almost white powder. Insoluble in water;
slightly soluble in alcohol and in methanol.
Bromocriptine Mesylate: White or slightly colored, fine crystalline
powder, odorless or having a weak, characteristic odor.
Bromodiphenhydramine Hydrochloride: White to pale buff, crystal-
line powder, having no more than a faint odor. Freely soluble in water
and in alcohol; soluble in isopropyl alcohol; insoluble in ether and in
solvent hexane.
Brompheniramine Maleate: White, odorless, crystalline powder.
Freely soluble in water; soluble in alcohol and in chloroform; slightly
soluble in ether and in benzene.
Budesonide: White to off-white, odorless, crystalline powder. Freely
soluble in chloroform; sparingly soluble in alcohol; practically insolu-
ble in water and in heptane.
Bumetanide: Practically white powder. Slightly soluble in water;
soluble in alkaline solutions.
Bupivacaine Hydrochloride: White, odorless, crystalline powder.
Melts at about 248, with decomposition. Freely soluble in water and in
alcohol; slightly soluble in chloroform and in acetone.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/84
Description and Solubility
Bupivacaine Hydrochloride Injection: Clear, colorless solution.
Bupivacaine Hydrochloride and Epinephrine Injection: Clear, color-
less solution.
Bupropion Hydrochloride: White powder. Soluble in water, in 0.1 N
hydrochloric acid, and in alcohol.
Busulfan: White, crystalline powder. Very slightly soluble in water;
sparingly soluble in acetone; slightly soluble in alcohol.
Buspirone Hydrochloride: White crystalline powder. Very soluble in
water; freely soluble in methanol and in methylene chloride; sparingly
soluble in ethanol and in acetonitrile; very slightly soluble in ethyl ac-
etate; practically insoluble in hexanes.
Butabarbital: White, odorless, crystalline powder. Very slightly soluble
in water; soluble in alcohol, in chloroform, in ether, and in solutions of
alkali hydroxides and carbonates.
Butabarbital Sodium: White powder, having a bitter taste. Freely solu-
ble in water and in alcohol; practically insoluble in absolute ether.
Butalbital: White, crystalline, odorless powder, having a slightly bit-
ter taste. Is stable in air. Its saturated solution is acid to litmus. Freely
P
soluble in alcohol, in ether, and in chloroform; slightly soluble in cold
water; soluble in boiling water, and in solutions of fixed alkalies and
S
alkali carbonates.
Butamben: White, crystalline powder. Is odorless and tasteless. Very
slightly soluble in water; soluble in dilute acids, in alcohol, in chloro-
U
form, in ether, and in fixed oils. Is slowly hydrolyzed when boiled with
water.
9
Butane: Colorless, flammable gas (boiling temperature is about 0.5).
One volume of water dissolves 0.15 volume, and 1 volume of alcohol
dissolves 18 volumes at 17 and 770 mm; 1 volume of ether or chloro-
form at 17 dissolves 25 or 30 volumes, respectively. Vapor pressure
at 21 is about 1620 mm of mercury (17 psig). NF category: Aerosol
propellant.
Butoconazole Nitrate: White to off-white, crystalline powder. Melts at
about 160. Practically insoluble in water; very slightly soluble in ethyl
acetate; slightly soluble in acetonitrile, in acetone, in dichloromethane,
and in tetrahydrofuran; sparingly soluble in methanol.
Butorphanol Tartrate: White powder. Its solutions are slightly acidic.
Melts between 217 and 219, with decomposition. Sparingly soluble in
water; slightly soluble in methanol; insoluble in alcohol, in chloroform,
in ethyl acetate, in ethyl ether, and in hexane; soluble in dilute acids.
Butyl Alcohol: Clear, colorless, mobile liquid, having a characteristic,
penetrating vinous odor. Soluble in water. Miscible with alcohol, with
ether, and with many other organic solvents. NF category: Solvent.
Butylated Hydroxyanisole: White or slightly yellow, waxy solid, hav-
ing a faint, characteristic odor. Insoluble in water; freely soluble in
alcohol, in propylene glycol, in chloroform, and in ether. NF category:
Antioxidant.
Butylated Hydroxytoluene: White, crystalline solid, having a faint, char-
acteristic odor. Insoluble in water and in propylene glycol; freely solu-
ble in alcohol, in chloroform, and in ether. NF category: Antioxidant.
Butylparaben: Small, colorless crystals or white powder. Very slightly
soluble in water and in glycerin; freely soluble in acetone, in alcohol, in
ether, and in propylene glycol. NF category: Antimicrobial preservative.
Cabergoline: White or almost white, crystalline powder. Freely solu-
ble in alcohol (96%); slightly soluble in 0.1 M hydrochloric acid; very
slightly soluble in hexane; practically insoluble in water.
Caffeine: White powder or white, glistening needles, usually matted
together. Is odorless and has a bitter taste. Its solutions are neutral to
litmus. The hydrate is efflorescent in air. Sparingly soluble in water and
in alcohol; freely soluble in chloroform; slightly soluble in ether.
Calamine: Pink, odorless, practically tasteless, fine powder. Insoluble
in water; practically completely soluble in mineral acids.
USP Pharmacists Pharmacopeia
Calcitriol: White or almost white crystals. Freely soluble in alcohol;
soluble in ether and in fatty oils; practically insoluble in water. It is
sensitive to air, heat, and light.
Calcium Acetate: White, odorless or almost odorless, hygroscopic,
crystalline powder. When heated to above 160, it decomposes to cal-
cium carbonate and acetone. Freely soluble in water; slightly soluble in
methanol; practically insoluble in acetone, in dehydrated alcohol, and
in benzene.
Calcium Ascorbate: White to slightly yellow, practically odorless pow-
der. Freely soluble in water (approximately 50 g per 100 mL); slightly
soluble in alcohol; insoluble in ether.
Calcium Carbonate: Fine, white, odorless, tasteless, microcrystalline
powder. Is stable in air. Practically insoluble in water. Its solubility in
water is increased by the presence of any ammonium salt or of carbon
dioxide. The presence of any alkali hydroxide reduces its solubility.
Insoluble in alcohol. Dissolves with effervescence in 1 N acetic acid, in
3 N hydrochloric acid, and in 2 N nitric acid. NF category: Tablet and/or
capsule diluent.
Calcium Chloride: White, hard, odorless fragments or granules. Is
deliquescent. Freely soluble in water, in alcohol, and in boiling alcohol;
very soluble in boiling water. NF category: Desiccant.
Calcium Citrate: White, odorless, crystalline powder. Slightly soluble
in water; freely soluble in diluted 3 N hydrochloric acid and in diluted 2
N nitric acid; insoluble in alcohol.
Calcium Gluceptate: White to faintly yellow, amorphous powder. Is
stable in air, but the hydrous forms may lose part of their water of hy-
dration on standing. Freely soluble in water; insoluble in alcohol and in
0
many other organic solvents.
Calcium Gluconate: White, crystalline, odorless, tasteless granules
0
or powder. Is stable in air. Its solutions are neutral to litmus. Sparingly
2
(and slowly) soluble in water; freely soluble in boiling water; insoluble
in alcohol.
Calcium Hydroxide: White powder. Has an alkaline, slightly bitter
taste. Slightly soluble in water; soluble in glycerin and in syrup; very
slightly soluble in boiling water; insoluble in alcohol.
Calcium Hydroxide Solution: Clear, colorless liquid having an alkaline
taste. Is alkaline to litmus.
Calcium Lactate: White, practically odorless granules or powder. The
pentahydrate is somewhat efflorescent and at 120 becomes anhy-
drous. The pentahydrate is soluble in water; it is practically insoluble
in alcohol.
Calcium Levulinate: White, crystalline or amorphous, powder, having
a faint odor suggestive of burnt sugar. Has a bitter, salty taste. Freely
soluble in water; slightly soluble in alcohol; insoluble in ether and in
chloroform.
Calcium Pantothenate: Slightly hygroscopic, white powder. Is odor-
less and has a bitter taste. Freely soluble in water; soluble in glycerin;
practically insoluble in alcohol, in chloroform, and in ether.
Racemic Calcium Pantothenate: White, slightly hygroscopic powder,
having a faint, characteristic odor, and a bitter taste. Is stable in air. Its
solutions are neutral or alkaline to litmus. Is optically inactive. Freely
soluble in water; soluble in glycerin; practically insoluble in alcohol, in
chloroform, and in ether.
Dibasic Calcium Phosphate: White, odorless, tasteless powder. Is
stable in air. Practically insoluble in water; soluble in 3 N hydrochloric
acid and in 2 N nitric acid; insoluble in alcohol. NF category: Tablet
and/or capsule diluent.
Tribasic Calcium Phosphate: White, odorless, tasteless powder. Is
stable in air. Practically insoluble in water; readily soluble in 3 N hydro-
chloric acid and in 2 N nitric acid; insoluble in alcohol. NF category:
Tablet and/or capsule diluent.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/85
Description and Solubility
Calcium Polycarbophil: White to creamy white powder. Insoluble
in water, in dilute acids, in dilute alkalies, and in common organic
solvents.
Calcium Saccharate: White, odorless, tasteless, crystalline powder.
Very slightly soluble in cold water; slightly soluble in boiling water;
very slightly soluble in alcohol; practically insoluble in ether and in
chloroform; soluble in dilute mineral acids and in solutions of calcium
gluconate.
Calcium Silicate: White to off-white, free-flowing powder that remains
so after absorbing relatively large amounts of water or other liquids.
Insoluble in water. Forms a gel with mineral acids. NF category: Glidant
and/or anticaking agent.
Calcium Stearate: Fine, white to yellowish-white, bulky powder having
a slight, characteristic odor. Is unctuous, and is free from grittiness.
Insoluble in water, in alcohol, and in ether. NF category: Tablet and/or
capsule lubricant.
Calcium Sulfate: Fine, white to slightly yellow-white, odorless powder.
Slightly soluble in water; soluble in 3 N hydrochloric acid. NF category:
Desiccant; tablet and/or capsule diluent.
P
Calcium Undecylenate: Fine, white powder, having a characteristic
odor and no grit. Practically insoluble in water, in ether, in chloroform,
S
in acetone, and in cold alcohol; slightly soluble in hot alcohol.
Camphor: Colorless or white crystals, granules, or crystalline masses;
U
or colorless to white, translucent, tough masses. Has a penetrating,
characteristic odor and a pungent, aromatic taste. Specific gravity is
about 0.99. Slowly volatilizes at ordinary temperatures. Slightly soluble
9
in water; very soluble in alcohol, in chloroform, and in ether; freely
soluble in carbon disulfide, in solvent hexane, and in fixed and volatile
oils.
Candelilla Wax: A hard, yellowish-brown-opaque to translucent wax.
Its specific gravity is about 0.983. Soluble in chloroform and in toluene;
insoluble in water.
Canola Oil: Clear, pale yellow, slightly viscous liquid. Practically in-
soluble in water and in alcohol; miscible with light petroleum (bp: 40
to 60). NF category: Solvent; vehicle (oleaginous).
Capecitabine: White to off-white crystalline powder. Freely soluble
in methanol; soluble in acetonitrile and in alcohol; sparingly soluble
in water.
Capreomycin Sulfate: White to practically white, amorphous powder.
Freely soluble in water; practically insoluble in most organic solvents.
Caprylocaproyl Polyoxylglycerides: Pale yellow, oily liquids. Dispers-
ible in hot water; freely soluble in methylene chloride. NF category:
Ointment base; solvent.
Capsaicin: Off-white powder. Melts at about 65. Soluble in alcohol, in
benzene, in chloroform; slightly soluble in carbon disulfide; practically
insoluble in cold water.
Capsicum Oleoresin: Dark red, oily liquid. Soluble in alcohol, in
acetone, in ether, in chloroform, and in volatile oils; soluble with opal-
escence in fixed oils.
Captopril: White to off-white, crystalline powder, which may have
a characteristic, sulfide-like odor. Melts in the range of 104 to 110.
Freely soluble in water, in methanol, in alcohol, and in chloroform.
Caramel: Thick, dark brown liquid having the characteristic odor of
burnt sugar, and a pleasant, bitter taste. One part dissolved in 1000
parts of water yields a clear solution having a distinct yellowish-orange
color. The color of this solution is not changed and no precipitate is
formed after exposure to sunlight for 6 hours. When spread in a thin
layer on a glass plate, it appears homogeneous, reddish-brown, and
transparent. Miscible with water. Soluble in dilute alcohol up to 55%
(v/v). Immiscible with ether, with chloroform, with acetone, with ben-
zene, and with solvent hexane. NF category: Color.
USP Pharmacists Pharmacopeia
Carbachol: White powder. Freely soluble in water; sparingly soluble in
alcohol; practically insoluble in chloroform and in ether.
Carbamazepine: White to off-white powder. Practically insoluble in
water; soluble in alcohol and in acetone.
Carbamide Peroxide Topical Solution: Clear, colorless, viscous liquid,
having a characteristic odor and taste.
Carbenicillin Disodium: White to off-white, crystalline powder. Freely
soluble in water; soluble in alcohol; practically insoluble in chloroform
and in ether.
Carbenicillin Indanyl Sodium: White to off-white powder. Soluble in
water and in alcohol.
Carbidopa: White to creamy white, odorless or practically odorless,
powder. Slightly soluble in water; freely soluble in 3 N hydrochloric
acid; slightly soluble in methanol; practically insoluble in alcohol, in
acetone, in chloroform, and in ether.
Carbinoxamine Maleate: White, odorless, crystalline powder. Very
soluble in water; freely soluble in alcohol and in chloroform; very
slightly soluble in ether.
Carbol-Fuchsin Topical Solution: Dark purple liquid, which appears
purplish red when spread in a thin film.
Carbomer 910: White, fluffy powder, having a slight, characteristic
odor. Is hygroscopic. The pH of a 1 in 100 dispersion is about 3. When
neutralized with alkali hydroxides or with amines, it dissolves in water,
in alcohol, and in glycerin. NF category: Suspending and/or viscosity-
increasing agent.
Carbomer 934: See Carbomer 910.
0
Carbomer 934P: See Carbomer 910.
Carbomer 940: See Carbomer 910.
0
Carbomer 941: See Carbomer 910.
2
Carbomer 1342: See Carbomer 910.
Carbomer Copolymer: White, hygroscopic powder. It swells in water
when a dispersion of it is neutralized with sodium hydroxide to a pH
within the range of 7.9 to 7.8. NF category: Emulsifying and/or solubiliz-
ing agent; suspending and/or viscosity increasing agent; tablet binder.
Carbomer Homopolymer: White, fluffy hygroscopic powder, having
a slight, characteristic odor. The pH of a 1 in 100 dispersion in water
is about 3. When neutralized with alkali hydroxides or with amines, it
swells giving the appearance of dissolving in water; when neutralized
with lower amines and alkanolamines, it swells giving the appearance
of dissolving in methanol or glycerin; when neutralized with ethoxyl-
ated long-chain (C 14C 18) amines, it swells giving the appearance of
dissolving in ethanol. NF category: Tablet binder; suspending and/or
viscosity-increasing agent.
Carbomer Interpolymer: White, hygroscopic powder. It swells in
water when a dispersion of it is neutralized with sodium hydroxide
to a pH within the range of 5.5 to 9. NF category: Emulsifying and/or
solubilizing agent; suspending and/or viscosity increasing agent; tablet
binder.
Urea C 13: See Urea.
Carbon Dioxide: Odorless, colorless gas. Its solutions are acid to lit-
mus. One L at 0 and at a pressure of 760 mm of mercury weighs 1.977
g. One volume dissolves in about 1 volume of water. NF category: Air
displacement.
Carboprost Tromethamine: White to off-white powder. Soluble in
water.
Carboxymethylcellulose Calcium: White to yellowish-white powder.
Is hygroscopic. Practically insoluble in alcohol, in acetone, in ether,
in chloroform, and in benzene. It swells with water to form a suspen-
sion; the pH of the suspension, obtained by shaking 1 g with 100 mL of
water, is between 4.5 and 6.0. NF category: Suspending and/or viscos-
ity-increasing agent.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/86
Description and Solubility
Carboxymethylcellulose Sodium: White to cream-colored powder
or granules. The powder is hygroscopic. Is easily dispersed in water
to form colloidal solutions. Insoluble in alcohol, in ether, and in most
other organic solvents. NF category: Coating agent; suspending and/or
viscosity-increasing agent; tablet binder.
Carboxymethylcellulose Sodium 12: Colorless or white to off-white
powder or granules. Is odorless. Water solubility depends on degree
of substitution (easily dispersed in water at all temperatures, forming a
clear, colloidal solution). Insoluble in acetone, in alcohol, in ether, and
in toluene. NF category: Suspending and/or viscosity-increasing agent.
Low-Substituted Carboxymethylcellulose Sodium: A white or almost
white powder or short fibers. Practically insoluble in acetone, in alco-
hol, and in toluene. It swells in water to form a gel.
Carisoprodol: White, crystalline powder, having a mild, characteristic
odor and a bitter taste. Very slightly soluble in water; freely soluble in
alcohol, in chloroform, and in acetone.
Carprofen: White crystalline powder. Freely soluble in ether, in ac-
etone, in ethyl acetate, and in sodium hydroxide TS or sodium carbon-
ate TS; practically insoluble in water.
P
Carrageenan: Yellowish or tan to white, coarse to fine powder. Is
practically odorless and has a mucilaginous taste. Soluble in water at
S
a temperature of about 80, forming a viscous, clear or slightly opales-
cent solution that flows readily. Disperses in water more readily if first
U
moistened with alcohol, with glycerin, or with a saturated solution of
sucrose in water. NF category: Suspending and/or viscosity-increasing
agent.
9
Carvedilol: White or nearly white, crystalline powder. Slightly soluble
in alcohol; practically insoluble in water and in dilute acids.
Casanthranol: Light tan to brown, amorphous, hygroscopic powder.
Freely soluble in water, with some residue; partially soluble in metha-
nol and in hot isopropyl alcohol; practically insoluble in acetone.
Cascara Sagrada: Has a distinct odor and a bitter and slightly acrid
taste.
Castor Oil: Pale yellowish or almost colorless, transparent, viscid
liquid. Has a faint, mild odor; is free from foreign and rancid odor;
and has a bland, characteristic taste. Soluble in alcohol. Miscible with
dehydrated alcohol, with glacial acetic acid, with chloroform, and with
ether. NF category: Plasticizer.
Hydrogenated Castor Oil: White, crystalline wax. Insoluble in water
and in most common organic solvents. NF category: Stiffening agent.
Cefaclor: White to off-white, crystalline powder. Slightly soluble
in water; practically insoluble in methanol, in chloroform, and in
benzene.
Cefadroxil: White to off-white, crystalline powder. Slightly soluble in
water; practically insoluble in alcohol, in chloroform, and in ether.
Cefamandole Nafate: White, odorless, crystalline solid. Soluble in
water and in methanol; practically insoluble in ether, in chloroform, in
benzene, and in cyclohexane.
Cefazolin: White to slightly off-white, odorless, crystalline powder.
Melts at about 198 to 200, with decomposition. Soluble in dimeth-
ylformamide and in pyridine; sparingly soluble in acetone; slightly
soluble in alcohol, in methanol, and in water; very slightly soluble in
ethyl acetate, in isopropyl alcohol, and in methyl isobutyl ketone; prac-
tically insoluble in benzene, in chloroform, in ether, and in methylene
chloride.
Cefazolin Sodium: White to off-white, practically odorless, crystalline
powder, or white to off-white solid. Freely soluble in water, in saline TS,
and in dextrose solutions; very slightly soluble in alcohol; practically
insoluble in chloroform and in ether.
Cefdinir: White to light yellow crystalline powder. Soluble in 0.1 M
phosphate buffer (pH 7) solution; practically insoluble in water, in alco-
hol, and in diethyl ether.
USP Pharmacists Pharmacopeia
Cefepime Hydrochloride: White to off-white, crystalline, nonhygro-
scopic solid. Freely soluble in water.
Cefepime for Injection: White to pale yellow powder. Freely soluble
in water.
Cefixime: White to light yellow, crystalline powder. Soluble in metha-
nol and in propylene glycol; slightly soluble in alcohol, in acetone, and
in glycerin; very slightly soluble in 70% sorbitol and in octanol; practi-
cally insoluble in ether, in ethyl acetate, in hexane, and in water.
Cefmenoxime Hydrochloride: White to light orange-yellow crystals
or crystalline powder. Very slightly soluble in water; freely soluble in
formamide; slightly soluble in methanol; practically insoluble in dehy-
drated alcohol and in ether.
Cefmetazole Sodium: White solid. Very soluble in water and in meth-
anol; soluble in acetone; practically insoluble in chloroform.
Cefonicid Sodium: White to off-white solid. Freely soluble in water, in
0.9% sodium chloride solution, and in 5% dextrose solution; soluble in
methanol; very slightly soluble in dehydrated alcohol.
Cefoperazone Sodium: White to pale buff crystalline powder. Freely
soluble in water and in methanol; slightly soluble in dehydrated alco-
hol; insoluble in acetone, in ethyl acetate, and in ether.
Ceforanide: White to off-white powder. Practically insoluble in water,
in methanol, in chloroform, and in ether; very soluble in 1 N sodium
hydroxide.
Cefotaxime Sodium: Off-white to pale yellow crystalline powder.
Freely soluble in water; practically insoluble in organic solvents.
Cefoxitin Sodium: White to off-white, granules or powder, having a
slight characteristic odor. Is somewhat hygroscopic. Very soluble in
0
water; soluble in methanol; sparingly soluble in dimethylformamide;
0
slightly soluble in acetone; insoluble in ether and in chloroform.
Cefpodoxime Proxetil: White to light brownish-white powder. Odor-
2
less or having a faint odor, and has a bitter taste. Very slightly soluble in
water; soluble in acetonitrile and in methanol; freely soluble in dehy-
drated alcohol; slightly soluble in ether.
Ceftazidime: White to cream-colored, crystalline powder. Soluble in
alkali and in dimethyl sulfoxide; slightly soluble in dimethylformamide,
in methanol, and in water; insoluble in acetone, in alcohol, in chloro-
form, in dioxane, in ether, in ethyl acetate, and in toluene.
Ceftizoxime Sodium: White to pale yellow crystalline powder. Freely
soluble in water.
Ceftriaxone Sodium: White to yellowish-orange crystalline powder.
Freely soluble in water; sparingly soluble in methanol; very slightly
soluble in alcohol.
Cefuroxime Axetil: White to almost white powder. The amorphous
form is freely soluble in acetone; soluble in chloroform, in ethyl ace-
tate, and in methanol; slightly soluble in dehydrated alcohol; insoluble
in ether and in water. The crystalline form is freely soluble in acetone;
sparingly soluble in chloroform, in ethyl acetate, and in methanol;
slightly soluble in dehydrated alcohol; insoluble in ether and in water.
Cefuroxime Sodium: White or faintly yellow powder. Freely soluble in
water; soluble in methanol; very slightly soluble in alcohol, in ether, in
ethyl acetate, and in chloroform.
Cellaburate: Fine white or almost white powder or granules. Available
in a range of viscosities, acetyl and butyl contents. Slightly hygroscopic;
soluble in acetone, in methylene chloride, in pyridine, and in dimethyl
sulfoxide; practically insoluble in water and in alcohol. NF category:
Coating agent; polymer membrane.
Cellacefate: Free-flowing, white powder. May have a slight odor of
acetic acid. Insoluble in water and in alcohol; soluble in acetone and in
dioxane. NF category: Coating agent.
Cellulose Acetate: Fine, white powder or free-flowing pellets. Avail-
able in a range of viscosities and acetyl contents. High viscosity, which
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/87
Description and Solubility
reflects high molecular weight, decreases solubility slightly. High acetyl
content cellulose acetates generally have more limited solubility in
commonly used organic solvents than low acetyl content cellulose
acetates, but are more soluble in methylene chloride. All acetyl con-
tent cellulose acetates are insoluble in alcohol and in water; soluble
in dioxane and in dimethylformamide. NF category: Coating agent;
polymer membrane.
Microcrystalline Cellulose: Fine, white or almost white powder. It con-
sists of free-flowing, nonfibrous particles. Insoluble in water, in dilute
acids, and in most organic solvents; practically insoluble in sodium
hydroxide solution (1 in 20). NF category: Tablet binder; tablet disinte-
grant; tablet and/or capsule diluent.
Microcrystalline Cellulose and Carboxymethylcellulose Sodium: Taste-
less, odorless, white to off-white, coarse to fine powder. Swells in
water, producing, when dispersed, a white, opaque dispersion or gel.
Insoluble in organic solvents and in dilute acids. NF category: Suspend-
ing and/or viscosity-increasing agent.
Oxidized Cellulose: In the form of gauze or lint. Is slightly off-white in
color, is acidic to the taste, and has a slight, charred odor. Insoluble in
P
water and in acids; soluble in dilute alkalies.
Oxidized Regenerated Cellulose: A knit fabric, usually in the form of
S
sterile strips. Slightly off-white, having a slight odor. Insoluble in water
and in dilute acids; soluble in dilute alkalies.
U
Powdered Cellulose: White or almost white powder. Exhibits degrees
of fineness ranging from a free-flowing dense powder to a coarse,
fluffy, nonflowing material. Insoluble in water, in dilute acids, and in
9
nearly all organic solvents; slightly soluble in sodium hydroxide solu-
tion (1 in 20). NF category: Filtering aid; sorbent; tablet and/or capsule
diluent.
Cellulose Sodium Phosphate: Free-flowing cream-colored, odorless,
tasteless powder. Insoluble in water, in dilute acids, and in most or-
ganic solvents.
Cephalexin: White to off-white, crystalline powder. Slightly soluble in
water; practically insoluble in alcohol, in chloroform, and in ether.
Cephalexin Hydrochloride: White to off-white, crystalline powder.
Soluble to the extent of 10 mg per mL in water, in acetone, in aceto-
nitrile, in alcohol, in dimethylformamide, and in methanol; practically
insoluble in chloroform, in ether, in ethyl acetate, and in isopropyl
alcohol.
Cephalothin Sodium: White to off-white, practically odorless, crystal-
line powder. Freely soluble in water, in saline TS, and in dextrose solu-
tions; insoluble in most organic solvents.
Cephapirin Benzathine: White, crystalline powder. Practically in-
soluble in water, in ether, and in toluene; insoluble in alcohol; soluble
in 0.1 N hydrochloric acid.
Cephapirin Sodium: White to off-white, crystalline powder, odorless
or having a slight odor. Very soluble in water; insoluble in most organic
solvents.
Cephradine: White to off-white, crystalline powder. Sparingly soluble
in water; very slightly soluble in alcohol and in chloroform; practically
insoluble in ether.
Cetostearyl Alcohol: Unctuous, white flakes or granules, having a
faint, characteristic odor, and a bland, mild taste. Insoluble in water;
soluble in alcohol and in ether. NF category: Stiffening agent.
Cetrimonium Bromide: A white to creamy white, voluminous, free-
flowing powder, with a characteristic faint odor and bitter, soapy taste.
Freely soluble in water and in alcohol; practically insoluble in ether. NF
category: Antimicrobial preservative.
Cetyl Alcohol: Unctuous, white flakes, granules, cubes, or castings.
Has a faint characteristic odor and a bland, mild taste. Usually melts in
the range between 45 and 50. Insoluble in water; soluble in alcohol
and in ether, the solubility increasing with an increase in temperature.
NF category: Stiffening agent.
USP Pharmacists Pharmacopeia
Cetyl Esters Wax: White to off-white, somewhat translucent flakes,
having a crystalline structure and a pearly luster when caked. Has a
faint odor and a bland, mild taste, free from rancidity, and has a spe-
cific gravity of about 0.83 at 50. Insoluble in water; soluble in boiling
alcohol, in ether, in chloroform, and in fixed and volatile oils; slightly
soluble in cold solvent hexane; practically insoluble in cold alcohol. NF
category: Stiffening agent.
Cetyl Palmitate: White crystals or flakes. Freely soluble in alcohol and
in ether; practically insoluble in water. NF category: Stiffening agent.
Cetylpyridinium Chloride: White powder, having a slight, character-
istic odor. Very soluble in water, in alcohol, and in chloroform; slightly
soluble in benzene and in ether. NF category: Antimicrobial preserva-
tive; wetting and/or solubilizing agent.
Cetylpyridinium Chloride Topical Solution: Clear liquid. Is colorless
unless a color has been added; has an aromatic odor and a bitter taste.
Activated Charcoal: Fine, black, odorless, tasteless powder, free from
gritty matter. NF category: Sorbent.
Chloral Hydrate: Colorless, transparent, or white crystals having an
aromatic, penetrating, and slightly acrid odor, and a slightly bitter,
caustic taste. Melts at about 55, and slowly volatilizes when exposed
to air. Very soluble in water and in olive oil; freely soluble in alcohol, in
chloroform, and in ether.
Chlorambucil: Off-white, slightly granular powder. Very slightly solu-
ble in water; freely soluble in acetone; soluble in dilute alkali.
Chloramphenicol: Fine, white to grayish-white or yellowish-white,
needle-like crystals or elongated plates. Its solutions are practically
neutral to litmus. Is reasonably stable in neutral or moderately acid so-
0
lutions. Its alcohol solution is dextrorotatory and its ethyl acetate solu-
tion is levorotatory. Slightly soluble in water; freely soluble in alcohol,
0
in propylene glycol, in acetone, and in ethyl acetate.
2
Chloramphenicol Palmitate: Fine, white, unctuous, crystalline pow-
der, having a faint odor and a bland, mild taste. Insoluble in water;
freely soluble in acetone and in chloroform; soluble in ether; sparingly
soluble in alcohol; very slightly soluble in solvent hexane.
Chloramphenicol Sodium Succinate: Light yellow powder. Freely
soluble in water and in alcohol.
Chlordiazepoxide: Yellow, practically odorless, crystalline powder. Is
sensitive to sunlight. Melts at about 240. Insoluble in water; sparingly
soluble in chloroform and in alcohol.
Chlordiazepoxide Hydrochloride: White or practically white, odorless,
crystalline powder. Is affected by sunlight. Soluble in water; sparingly
soluble in alcohol; insoluble in solvent hexane.
Chlorhexidine Gluconate Solution: Almost colorless or pale yellow,
clear liquid. Miscible with glacial acetic acid and with water; miscible
with three times its volume of acetone and with five times its volume
of dehydrated alcohol; further addition of acetone or dehydrated alco-
hol yields a white turbidity.
Chlorhexidine Hydrochloride: White or almost white, crystalline pow-
der. Sparingly soluble in propylene glycol and in water; very slightly
soluble in alcohol.
Chlorobutanol: Colorless to white crystals, having a characteristic,
somewhat camphoraceous, odor and taste. Anhydrous form melts
at about 95, and hydrous form melts at about 76. Slightly soluble in
water; freely soluble in alcohol, in ether, in chloroform, and in volatile
oils; soluble in glycerin. NF category: Antimicrobial preservative.
Chlorocresol: Colorless or practically colorless crystals or crystalline
powder, having a characteristic, nontarry odor. Is volatile in steam.
Slightly soluble in water and more soluble in hot water; very soluble in
alcohol; soluble in ether, in terpenes, in fixed oils, and in solutions of
alkali hydroxides. NF category: Antimicrobial preservative.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/88
Description and Solubility
Chloroprocaine Hydrochloride: White, crystalline powder. Is odor-
less, and is stable in air. Its solutions are acid to litmus. Exhibits local
anesthetic properties when placed upon the tongue. Soluble in water;
slightly soluble in alcohol; very slightly soluble in chloroform; practi-
cally insoluble in ether.
Chloroquine: White or slightly yellow, crystalline powder. Is odorless,
and has a bitter taste. Very slightly soluble in water; soluble in dilute
acids, in chloroform, and in ether.
Chloroquine Hydrochloride Injection: Colorless liquid.
Chloroquine Phosphate: White, crystalline powder. Is odorless, has a
bitter taste, and is discolored slowly on exposure to light. Its solutions
have a pH of about 4.5. Exists in two polymorphic forms, one melting
between 193 and 195 and the other between 210 and 215 (see Melt-
ing Range or Temperature 741); mixture of the forms melts between
193 and 215. Freely soluble in water; practically insoluble in alcohol,
in chloroform, and in ether.
Chlorothiazide: White or practically white, crystalline, odorless pow-
der. Melts at about 340, with decomposition. Very slightly soluble in
water; freely soluble in dimethylformamide and in dimethyl sulfoxide;
P
slightly soluble in methanol and in pyridine; practically insoluble in
ether, in benzene, and in chloroform.
S
Chloroxylenol: White crystals or crystalline powder, having a charac-
teristic odor. Is volatile in steam. Very slightly soluble in water; freely
U
soluble in alcohol, in ether, in terpenes, in fixed oils, and in solutions
of alkali hydroxides.
Chlorpheniramine Maleate: White, odorless, crystalline powder. Its
9
solutions have a pH between 4 and 5. Freely soluble in water; soluble
in alcohol and in chloroform; slightly soluble in ether and in benzene.
Chlorpromazine: White, crystalline solid, having an amine-like odor.
Darkens on prolonged exposure to light. Melts at about 60. Practically
insoluble in water and in dilute alkali hydroxides; freely soluble in al-
cohol, in benzene, in chloroform, in ether, and in dilute mineral acids.
Chlorpromazine Hydrochloride: White or slightly creamy white, odor-
less, crystalline powder. Darkens on prolonged exposure to light. Very
soluble in water; freely soluble in alcohol and in chloroform; insoluble
in ether and in benzene.
Chlorpropamide: White, crystalline powder, having a slight odor.
Practically insoluble in water; soluble in alcohol; sparingly soluble in
chloroform.
Chlortetracycline Hydrochloride: Yellow, crystalline powder. Is odor-
less, and has a bitter taste. Is stable in air, but is slowly affected by light.
Sparingly soluble in water; soluble in solutions of alkali hydroxides and
carbonates; slightly soluble in alcohol; practically insoluble in acetone,
in chloroform, in dioxane, and in ether.
Chlorthalidone: White to yellowish-white, crystalline powder. Melts at
a temperature above 215, with decomposition. Practically insoluble in
water, in ether, and in chloroform; soluble in methanol; slightly soluble
in alcohol.
Chlorzoxazone: White or practically white, practically odorless, crys-
talline powder. Slightly soluble in water; sparingly soluble in alcohol,
in isopropyl alcohol, and in methanol; soluble in solutions of alkali
hydroxides and ammonia.
Cholecalciferol: White, odorless crystals. Is affected by air and by
light. Melts at about 85. Insoluble in water; soluble in alcohol, in chlo-
roform, and in fatty oils.
Cholesterol: White or faintly yellow, practically odorless, pearly leaf-
lets, needles, powder, or granules. Acquires a yellow to pale tan color
on prolonged exposure to light. Insoluble in water; soluble in acetone,
in chloroform, in dioxane, in ether, in ethyl acetate, in solvent hexane,
and in vegetable oils; sparingly soluble in dehydrated alcohol; slightly
(and slowly) soluble in alcohol. NF category: Emulsifying and/or solu-
bilizing agent.
USP Pharmacists Pharmacopeia
Cholestyramine Resin: White to buff-colored, hygroscopic, fine
powder. Is odorless or has not more than a slight amine-like odor. In-
soluble in water, in alcohol, in chloroform, and in ether.
Choline Bitartrate: White, hygroscopic, crystalline powder. Clear, col-
orless liquid in solution. Melts between 148 and 153. Is odorless, or
may have a faint trimethylamine odor. Freely soluble in water; slightly
soluble in alcohol; insoluble in ether and in chloroform.
Choline Chloride: Colorless or white crystals or crystalline powder,
usually having a slight odor of trimethylamine. Clear and colorless in
solution. Hygroscopic. Soluble in alcohol and in water.
Sodium Chromate Cr 51 Injection: Clear, slightly yellow solution.
Chromic Chloride: Dark green, odorless, slightly deliquescent crys-
tals. Soluble in water and in alcohol; slightly soluble in acetone; practi-
cally insoluble in ether.
Chymotrypsin: White to yellowish-white, crystalline or amorphous,
odorless, powder. An amount equivalent to 100,000 USP Units is
soluble in 10 mL of water and in 10 mL of saline TS.
Ciclopirox: White to slightly yellowish-white, crystalline powder.
Slightly soluble in water; freely soluble in ethanol and in methylene
chloride; soluble in ether.
Ciclopirox Olamine: White to slightly yellowish-white, crystalline
powder. Very soluble in alcohol and in methylene chloride; slightly
soluble in water; practically insoluble in cyclohexane.
Cilastatin Sodium: White to tan-colored powder. Soluble in water and
in methanol.
Cilostazol: White to off-white crystals. Freely soluble in chloroform;
slightly soluble in methanol and in alcohol; practically insoluble in
0
water.
0
Cimetidine: White to off-white, crystalline powder; odorless, or hav-
ing a slight mercaptan odor. Soluble in alcohol and in polyethylene
2
glycol 400; freely soluble in methanol; sparingly soluble in isopropyl al-
cohol; slightly soluble in water and in chloroform; practically insoluble
in ether.
Cinoxacin: White to yellowish-white, crystalline solid. Is odorless, and
has a bitter taste and a lingering aftertaste. Insoluble in water and in
most common organic solvents; soluble in alkaline solution.
Ciprofloxacin Hydrochloride: Faintly yellowish to light yellow crystals.
Sparingly soluble in water; slightly soluble in acetic acid and in metha-
nol; very slightly soluble in dehydrated alcohol; practically insoluble in
acetone, in acetonitrile, in ethyl acetate, in hexane, and in methylene
chloride.
Citalopram Hydrobromide: White to almost white, crystalline powder.
Freely soluble in water, in alcohol, and in chloroform.
Anhydrous Citric Acid: Colorless, translucent crystals, or white, granu-
lar to fine, crystalline powder. Melts at about 153, with decomposition.
Very soluble in water; freely soluble in alcohol; very slightly soluble in
ether. NF category: Acidifying agent; buffering agent.
Citric Acid Monohydrate: Colorless, translucent crystals, or white,
granular to fine, crystalline powder. Efflorescent in dry air. Very soluble
in water; freely soluble in alcohol; very slightly soluble in ether. NF
category: Acidifying agent; buffering agent.
Clarithromycin: White to off-white, crystalline powder. Soluble in ac-
etone; slightly soluble in dehydrated alcohol, in methanol, and in ace-
tonitrile; practically insoluble in water. Slightly soluble in phosphate
buffer at pH values of 2 to 5.
Clavulanate Potassium: White to off-white powder. Is moisture-sensi-
tive. Freely soluble in water, but stability in aqueous solution is not
good, optimum stability at a pH of 6.0 to 6.3; soluble in methanol, with
decomposition.
Clemastine Fumarate: White to off-white, odorless powder. Its solu-
tions are acid to litmus. Very slightly soluble in water; slightly soluble
in methanol; very slightly soluble in chloroform.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/89
Description and Solubility
Clidinium Bromide: White to nearly white, practically odorless, crys-
talline powder. Is optically inactive. Melts at about 242. Soluble in
water and in alcohol; slightly soluble in benzene and in ether.
Clindamycin Hydrochloride: White or practically white, crystalline
powder. Is odorless or has a faint mercaptan-like odor. Is stable in the
presence of air and light. Its solutions are acidic and are dextrorota-
tory. Freely soluble in water, in dimethylformamide, and in methanol;
soluble in alcohol; practically insoluble in acetone.
Clindamycin Palmitate Hydrochloride: White to off-white amorphous
powder, having a characteristic odor. Very soluble in ethyl acetate and
in dimethylformamide; freely soluble in water, in benzene, in ether, in
chloroform, and in alcohol.
Clindamycin Phosphate: White to off-white, hygroscopic, crystalline
powder. Is odorless or practically odorless, and has a bitter taste. Freely
soluble in water; slightly soluble in dehydrated alcohol; very slightly
soluble in acetone; practically insoluble in chloroform, in benzene,
and in ether.
Clioquinol: Voluminous, spongy, yellowish-white to brownish-yellow
powder, having a slight, characteristic odor. Darkens on exposure to
P
light. Melts at about 180, with decomposition. Practically insoluble
in water and in alcohol; soluble in hot ethyl acetate and in hot glacial
S
acetic acid.
Clobetasol Propionate: White to cream, crystalline powder. Practically
U
insoluble in water; slightly soluble in benzene and in diethyl ether;
sparingly soluble in ethanol; soluble in acetone, in dimethyl sulfoxide,
in chloroform, in methanol, and in dioxane.
9
Clocortolone Pivalate: White to yellowish-white, odorless powder.
Melts at about 230, with decomposition. Freely soluble in chloroform
and in dioxane; soluble in acetone; sparingly soluble in alcohol; slightly
soluble in benzene and in ether.
Clofazimine: Dark red crystals. Melts at about 217, with decomposi-
tion. Practically insoluble in water; soluble in chloroform and in ben-
zene; sparingly soluble in alcohol, in acetone, and in ethyl acetate.
Clofibrate: Colorless to pale yellow liquid having a characteristic odor.
Insoluble in water; soluble in acetone, in alcohol, in benzene, and in
chloroform.
Clomiphene Citrate: White to pale yellow, essentially odorless pow-
der. Slightly soluble in water and in chloroform; freely soluble in
methanol; sparingly soluble in alcohol; insoluble in ether.
Clomipramine Hydrochloride: White to faintly yellow, crystalline pow-
der. Very soluble in water.
Clonazepam: Light yellow powder, having a faint odor. Insoluble in
water; sparingly soluble in acetone and in chloroform; slightly soluble
in alcohol and in ether.
Clonidine: White to almost white, crystalline powder. Melting point is
about 130. Freely soluble in methanol and in alcohol.
Clopidogrel Bisulfate: White to off-white powder. Freely soluble in
water and in methanol; practically insoluble in ether.
Clorazepate Dipotassium: Light yellow, crystalline powder. Darkens
on exposure to light. Soluble in water but, upon standing, may pre-
cipitate from the solution; slightly soluble in alcohol and in isopropyl
alcohol; practically insoluble in acetone, in benzene, in chloroform, in
ether, and in methylene chloride.
Clorsulon: White to off-white powder. Slightly soluble in water; freely
soluble in acetonitrile and in methanol; very slightly soluble in methy-
lene chloride.
Clotrimazole: White to pale yellow, crystalline powder. Melts at about
142, with decomposition. Practically insoluble in water; freely soluble
in methanol, in acetone, in chloroform, and in alcohol.
USP Pharmacists Pharmacopeia
Cloxacillin Benzathine: White or almost white, almost odorless, crys-
tals or crystalline powder. Slightly soluble in water, in alcohol, and in
isopropyl alcohol; soluble in chloroform and in methanol; sparingly
soluble in acetone.
Cloxacillin Sodium: White, odorless, crystalline powder. Freely soluble
in water; soluble in alcohol; slightly soluble in chloroform.
Clozapine: Yellow, crystalline powder. Soluble in chloroform, in
acetone, and in alcohol; sparingly soluble in acetonitrile; insoluble in
water.
Coal Tar: Nearly black, viscous liquid, heavier than water, having a
characteristic, naphthalene-like odor, and producing a sharp, burning
sensation on the tongue. Slightly soluble in water, to which it imparts
its characteristic odor and taste and a faintly alkaline reaction; partially
soluble in acetone, in alcohol, in carbon disulfide, in chloroform, in
ether, in methanol, and in solvent hexane; is more soluble in ben-
zene, only about 5% remaining undissolved, and is almost completely
soluble in nitrobenzene, only a small amount of undissolved matter
remaining suspended in the solution.
Cyanocobalamin Co 57 Capsules: May contain a small amount of solid
or solids, or may appear empty.
Cyanocobalamin Co 57 Oral Solution: Clear, colorless to pink
solution.
Cocaine: Colorless to white crystals or white, crystalline powder. Is
levorotatory in 3 N hydrochloric acid solution. Its saturated solution
is alkaline to litmus. Slightly soluble in water; very soluble in warm
alcohol; freely soluble in alcohol, in chloroform, and in ether; soluble
in olive oil; sparingly soluble in mineral oil.
0
Cocaine Hydrochloride: Colorless crystals or white, crystalline pow-
der. Very soluble in water; freely soluble in alcohol; soluble in chloro-
0
form and in glycerin; insoluble in ether.
2
Coccidioidin: Clear, practically colorless or amber-colored liquid.
Cocoa Butter: Yellowish-white solid, having a faint, agreeable odor,
and a bland, chocolate-like taste if the cocoa butter is obtained by
pressing. If obtained by extraction, the taste is bland. Is usually brittle
at temperatures below 25. Freely soluble in ether and in chloroform;
soluble in boiling dehydrated alcohol; slightly soluble in alcohol. NF
category: Suppository base.
Coconut Oil: Clear, white to light yellow-tan, viscous liquid. Freely
soluble in methylene chloride and in light petroleum (bp: 65 to 70);
very slightly soluble in alcohol; practically insoluble in water. NF cat-
egory: Coating agent; emulsifying and/or solubilizing agent.
Cod Liver Oil: Thin, oily liquid, having a characteristic, slightly fishy
but not rancid odor, and a fishy taste. Slightly soluble in alcohol;
freely soluble in ether, in chloroform, in carbon disulfide, and in ethyl
acetate.
Codeine: Colorless or white crystals or white, crystalline powder. It
effloresces slowly in dry air, and is affected by light. In acid or alcohol
solutions it is levorotatory. Its saturated solution is alkaline to litmus.
Slightly soluble in water; very soluble in chloroform; freely soluble in
alcohol; sparingly soluble in ether. When heated in an amount of water
insufficient for complete solution, it melts to oily drops that crystallize
on cooling.
Codeine Phosphate: Fine, white, needle-shaped crystals, or white,
crystalline powder. Is odorless. Is affected by light. Its solutions are
acid to litmus. Freely soluble in water; very soluble in hot water; slightly
soluble in alcohol but more so in boiling alcohol.
Codeine Sulfate: White crystals, usually needle-like, or white, crystal-
line powder. Is affected by light. Soluble in water; freely soluble in
water at 80; very slightly soluble in alcohol; insoluble in chloroform
and in ether.
Colchicine: Pale yellow to pale greenish-yellow, amorphous scales,
or powder or crystalline powder. Is odorless or nearly so, and darkens
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/90
Description and Solubility
on exposure to light. Soluble in water; freely soluble in alcohol and in
chloroform; slightly soluble in ether.
Colestipol Hydrochloride: Yellow to orange beads. Swells but does
not dissolve in water or dilute aqueous solutions of acid or alkali. In-
soluble in the common organic solvents.
Colistimethate Sodium: White to slightly yellow, odorless, fine pow-
der. Freely soluble in water; soluble in methanol; insoluble in acetone
and in ether.
Colistin Sulfate: White to slightly yellow, odorless, fine powder. Freely
soluble in water; slightly soluble in methanol; insoluble in acetone and
in ether.
Collodion: Clear, or slightly opalescent, viscous liquid. Is colorless, or
slightly yellowish, and has the odor of ether.
Flexible Collodion: Clear, or slightly opalescent, viscous liquid. Is col-
orless or slightly yellow, and has the odor of ether. The strong odor of
camphor becomes noticeable as the ether evaporates.
Copovidone: White to yellowish-white powder or flakes. Is hygro-
scopic. Freely soluble in water, in alcohol, and in methylene chloride;
practically insoluble in ether. NF category: Tablet binder; coating
P
agent.
S
Corn Oil: Clear, light yellow, oily liquid, having a faint, characteristic
odor and taste. Slightly soluble in alcohol. Miscible with ether, with
chloroform, with benzene, and with solvent hexane. NF category: Sol-
U
vent; vehicle (oleaginous).
Corn Syrup: Clear, white to light yellow, viscous liquid. Is miscible
9
in all proportions with water. NF category: Suspending and/or viscos-
ity-increasing agent; sweetening agent; tablet and/or capsule diluent;
tablet binder; tonicity agent.
Corn Syrup Solids: Sweet, white to light yellow powder or granules.
Soluble in water. NF category: Coating agent; flavored and/or sweet-
ened vehicle; humectant; solid carrier; suspending and/or viscosity-
increasing agent; sweetening agent; tablet and/or capsule diluent; tab-
let binder; tonicity agent.
Corticotropin Injection: Colorless or light straw-colored liquid.
Corticotropin for Injection: White or practically white, soluble, amor-
phous solid having the characteristic appearance of substances pre-
pared by freeze-drying.
Repository Corticotropin Injection: Colorless or light straw-colored
liquid, which may be quite viscid at room temperature. Is odorless or
has an odor of an antimicrobial agent.
Corticotropin Zinc Hydroxide Injectable Suspension: Flocculent,
white, aqueous suspension, free from large particles following moder-
ate shaking.
Cortisone Acetate: White or practically white, odorless, crystalline
powder. Is stable in air. Melts at about 240, with some decomposition
(see Melting Range or Temperature 741). Insoluble in water; freely sol-
uble in chloroform; soluble in dioxane; sparingly soluble in acetone;
slightly soluble in alcohol.
Purified Cotton: White, soft, fine filament-like hairs appearing under
the microscope as hollow, flattened, and twisted bands, striate and
slightly thickened at the edges. Is practically odorless and practically
tasteless. Insoluble in ordinary solvents; soluble in ammoniated cupric
oxide TS.
Cottonseed Oil: Pale yellow, oily liquid. Is odorless or nearly so, and
has a bland taste. At temperatures below 10 particles of solid fat may
separate from the Oil, and at about 0 to 5 the Oil becomes a solid
or nearly so. Slightly soluble in alcohol. Miscible with ether, with chlo-
roform, with solvent hexane, and with carbon disulfide. NF category:
Solvent; vehicle (oleaginous).
Hydrogenated Cottonseed Oil: A white mass or powder that melts to
a clear, pale yellow liquid when heated. Freely soluble in methylene
USP Pharmacists Pharmacopeia
chloride and in toluene; very slightly soluble in alcohol; practically
insoluble in water.
Creatinine: White crystals or crystalline powder; odorless. Soluble in
water; slightly soluble in alcohol; practically insoluble in acetone, in
ether, and in chloroform. NF category: Bulking agent for freeze-drying.
Cresol: Colorless, or yellowish to brownish-yellow, or pinkish, highly
refractive liquid, becoming darker with age and on exposure to light.
Has a phenol-like, sometimes empyreumatic odor. A saturated solution
of it is neutral or only slightly acid to litmus. Sparingly soluble in water,
usually forming a cloudy solution; dissolves in solutions of fixed alkali
hydroxides. Miscible with alcohol, with ether, and with glycerin. NF
category: Antimicrobial preservative.
Cromolyn Sodium: White, odorless, crystalline powder. Is tasteless at
first, with a slightly bitter aftertaste. Is hygroscopic. Soluble in water;
insoluble in alcohol and in chloroform.
Cromolyn Sodium for Inhalation: White to creamy white, odorless,
hygroscopic, and very finely divided powder.
Croscarmellose Sodium: White, free-flowing powder. Partially soluble
in water; insoluble in alcohol, in ether, and in other organic solvents.
NF category: Tablet disintegrant.
Crospovidone: White to creamy-white, hygroscopic powder, having
a faint odor. Insoluble in water and in ordinary organic solvents. NF
category: Tablet disintegrant.
Crotamiton: Colorless to slightly yellowish oil, having a faint amine-
like odor. Soluble in alcohol and in methanol.
Cupric Chloride: Bluish green, deliquescent crystals. Freely soluble in
water; soluble in alcohol; slightly soluble in ether.
0
Cupric Sulfate: Deep blue, triclinic crystals or blue, crystalline gran-
0
ules or powder. It effloresces slowly in dry air. Its solutions are acid to
litmus. Freely soluble in water and in glycerin; very soluble in boiling
2
water; slightly soluble in alcohol.
Cyanocobalamin: Dark red crystals or amorphous or crystalline red
powder. In the anhydrous form, it is very hygroscopic and when ex-
posed to air it may absorb about 12% of water. Sparingly soluble in
water; soluble in alcohol; insoluble in acetone, in chloroform, and in
ether.
Cyclandelate: White, crystalline powder. Very soluble in acetonitrile,
in alcohol, and in ether; practically insoluble in water. Melts at about
58.
Cyclizine Hydrochloride: White, crystalline powder or small, colorless
crystals. Is odorless or nearly so, and has a bitter taste. Melts indis-
tinctly at about 285, with decomposition. Slightly soluble in water and
in alcohol; sparingly soluble in chloroform; insoluble in ether.
Cyclobenzaprine Hydrochloride: White to off-white, odorless, crys-
talline powder. Freely soluble in water, in alcohol, and in methanol;
sparingly soluble in isopropanol; slightly soluble in chloroform and in
methylene chloride; insoluble in hydrocarbons.
Cyclopentolate Hydrochloride: White, crystalline powder, which upon
standing develops a characteristic odor. Its solutions are acid to litmus.
Melts at about 138, the melt appearing opaque. Very soluble in water;
freely soluble in alcohol; insoluble in ether.
Cyclophosphamide: White, crystalline powder. Liquefies upon loss of
its water of crystallization. Soluble in water and in alcohol.
Cyclopropane: Colorless gas having a characteristic odor. Has a pun-
gent taste. One L at a pressure of 760 mm and a temperature of 0
weighs about 1.88 g. One volume dissolves in about 2.7 volumes of
water at 15. Freely soluble in alcohol; soluble in fixed oils.
Cycloserine: White to pale yellow, crystalline powder. Is odorless or
has a faint odor. Is hygroscopic and deteriorates upon absorbing water.
Its solutions are dextrorotatory. Freely soluble in water.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/91
Description and Solubility
Cyclosporine: White to almost white powder. Soluble in acetone, in
alcohol, in methanol, in ether, in chloroform, and in methylene chlo-
ride; slightly soluble in saturated hydrocarbons; practically insoluble
in water.
Cyproheptadine Hydrochloride: White to slightly yellow, odorless or
practically odorless, crystalline powder. Slightly soluble in water; freely
soluble in methanol; soluble in chloroform; sparingly soluble in alco-
hol; practically insoluble in ether.
Cyromazine: White or off-white, odorless, crystalline powder. Slight-
ly soluble in methanol and in water.
Cysteine Hydrochloride: White crystals or crystalline powder. Soluble
in water, in alcohol, and in acetone.
Cytarabine: Odorless, white to off-white, crystalline powder. Freely
soluble in water; slightly soluble in alcohol and in chloroform.
Dactinomycin: Bright red, crystalline powder. Is somewhat hygro-
scopic and is affected by light and by heat. Soluble in water at 10 and
slightly soluble in water at 37; freely soluble in alcohol; very slightly
soluble in ether.
Danazol: White to pale yellow, crystalline powder. Melts at about 225,
P
with some decomposition. Practically insoluble or insoluble in water
S
and in hexane; freely soluble in chloroform; soluble in acetone; spar-
ingly soluble in alcohol and in benzene; slightly soluble in ether.
Dantrolene Sodium: Fine orange to orange-brown powder. Sparingly
U
soluble in acetone, in dimethyformamide, and in glycerine.
Dapsone: White or creamy white, crystalline powder. Is odorless and
9
has a slightly bitter taste. Very slightly soluble in water; freely soluble in
alcohol; soluble in acetone and in dilute mineral acids.
Daunorubicin Hydrochloride: Orange-red, crystalline, hygroscopic
powder. Freely soluble in water and in methanol; slightly soluble in
alcohol; very slightly soluble in chloroform; practically insoluble in
acetone.
Deferoxamine Mesylate: White to off-white powder. Freely soluble in
water; slightly soluble in methanol.
Dehydrocholic Acid: White, fluffy, odorless powder, having a bitter
taste. Practically insoluble in water; soluble in glacial acetic acid and
in solutions of alkali hydroxides and carbonates; slightly soluble in
alcohol and in ether; sparingly soluble in chloroform (the solutions in
alcohol and in chloroform usually are slightly turbid).
Dehydroacetic Acid: White or nearly white, crystalline powder. Solu-
ble in aqueous solutions of alkalies; very slightly soluble in water. One
g of sample dissolves in about 35 mL of alcohol and in 5 mL of acetone.
NF category: Antimicrobial preservative.
Demecarium Bromide: White or slightly yellow, slightly hygroscopic,
crystalline powder. Freely soluble in water and in alcohol; soluble in
ether; sparingly soluble in acetone.
Demeclocycline: Yellow, crystalline, odorless powder, having a bitter
taste. Sparingly soluble in water; soluble in alcohol. Dissolves readily in
3 N hydrochloric acid and in alkaline solutions.
Demeclocycline Hydrochloride: Yellow, crystalline, odorless powder,
having a bitter taste. Sparingly soluble in water and in solutions of
alkali hydroxides and carbonates; slightly soluble in alcohol; practically
insoluble in acetone and in chloroform.
Denatonium Benzoate: Freely soluble in water and in alcohol; very
soluble in chloroform and in methanol; very slightly soluble in ether.
NF category: Alcohol denaturant.
Desipramine Hydrochloride: White to off-white, crystalline powder.
Melts at about 213. Soluble in water and in alcohol; freely soluble in
methanol and in chloroform; insoluble in ether.
Desmopressin Acetate: White, fluffy powder. Soluble in water, in alco-
hol, and in acetic acid.
USP Pharmacists Pharmacopeia
Desoximetasone: White to practically white, odorless, crystalline
powder. Insoluble in water; freely soluble in alcohol, in acetone, and
in chloroform.
Desoxycorticosterone Acetate: White or creamy white, crystalline
powder. Is odorless, and is stable in air. Practically insoluble in water;
sparingly soluble in alcohol, in acetone, and in dioxane; slightly soluble
in vegetable oils.
Dexamethasone: White to practically white, odorless, crystalline
powder. Is stable in air. Melts at about 250, with some decomposition.
Practically insoluble in water; sparingly soluble in acetone, in alco-
hol, in dioxane, and in methanol; slightly soluble in chloroform; very
slightly soluble in ether.
Dexamethasone Acetate: Clear, white to off-white, odorless powder.
Practically insoluble in water; freely soluble in methanol, in acetone,
and in dioxane.
Dexamethasone Sodium Phosphate: White or slightly yellow, crystal-
line powder. Is odorless or has a slight odor of alcohol, and is exceed-
ingly hygroscopic. Freely soluble in water; slightly soluble in alcohol;
very slightly soluble in dioxane; insoluble in chloroform and in ether.
Dexbrompheniramine Maleate: White, odorless, crystalline powder.
Exists in two polymorphic forms, one melting between 106 and 107
and the other between 112 and 113. Mixtures of the forms may melt
between 105 and 113. The pH of a solution (1 in 100) is about 5. Freely
soluble in water; soluble in alcohol and in chloroform.
Dexchlorpheniramine Maleate: White, odorless, crystalline powder.
Freely soluble in water; soluble in alcohol and in chloroform; slightly
soluble in benzene and in ether.
0
Dexpanthenol: Clear, viscous, somewhat hygroscopic liquid, having a
slight, characteristic odor. Some crystallization may occur on standing.
0
Freely soluble in water, in alcohol, in methanol, and in propylene gly-
2
col; soluble in chloroform and in ether; slightly soluble in glycerin.
Dextran 1: A white to off-white powder. Is hygroscopic. Very soluble
in water; sparingly soluble in alcohol.
Dextrates: Free-flowing, porous, white, odorless, spherical granules
consisting of aggregates of microcrystals, having a sweet taste and pro-
ducing a cooling sensation in the mouth. May be compressed directly
into self-binding tablets. Freely soluble in water (heating increases its
solubility in water); soluble in dilute acids and alkalies and in basic
organic solvents such as pyridine; insoluble in the common organic
solvents. NF category: Sweetening agent; tablet and/or capsule diluent.
Dextrin: Free-flowing, white, yellow, or brown powder. Its solubility in
water varies; it is usually very soluble, but often contains an insoluble
portion. NF category: Tablet binder; tablet and/or capsule diluent.
Dextroamphetamine Sulfate: White, odorless, crystalline powder.
Soluble in water; slightly soluble in alcohol; insoluble in ether.
Dextromethorphan: Practically white to slightly yellow, odorless,
crystalline powder. Eleven mg of Dextromethorphan is equivalent to
15 mg of dextromethorphan hydrobromide monohydrate. Practically
insoluble in water; freely soluble in chloroform.
Dextromethorphan Hydrobromide: Practically white crystals or crys-
talline powder, having a faint odor. Melts at about 126, with decom-
position. Sparingly soluble in water; freely soluble in alcohol and in
chloroform; insoluble in ether.
Dextrose: Colorless crystals or white, crystalline or granular powder.
Is odorless, and has a sweet taste. Freely soluble in water; very soluble
in boiling water; soluble in boiling alcohol; slightly soluble in alcohol.
NF category: Sweetening agent; tonicity agent; vehicle (flavored and/or
sweetened).
Dextrose Excipient: Colorless crystals or white, crystalline or granular
powder. Is odorless and sweet-tasting. Freely soluble in water; very
soluble in boiling water; sparingly soluble in boiling alcohol; slightly
soluble in alcohol. NF category: Sweetening agent; tablet and/or cap-
sule diluent.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/92
Description and Solubility
Diacetylated Monoglycerides: Clear liquid. Very soluble in 80%
(w/w) aqueous alcohol, in vegetable oils, and in mineral oils; sparingly
soluble in 70% alcohol. NF category: Plasticizer.
Diatrizoate Meglumine: White, odorless powder. Freely soluble in
water.
Diatrizoate Meglumine Injection: Clear, colorless to pale yellow,
slightly viscous liquid.
Diatrizoate Meglumine and Diatrizoate Sodium Injection: Clear, col-
orless to pale yellow, slightly viscous liquid. May crystallize at room
temperature or below.
Diatrizoate Sodium: White, odorless powder. Soluble in water; slightly
soluble in alcohol; practically insoluble in acetone and in ether.
Diatrizoate Sodium Injection: Clear, colorless to pale yellow, slightly
viscous liquid.
Diatrizoate Sodium Solution: Clear, pale yellow to light brown liquid.
Diatrizoic Acid: White, odorless powder. Very slightly soluble in water
and in alcohol; soluble in dimethylformamide and in alkali hydroxide
solutions.
P
Diazepam: Off-white to yellow, practically odorless, crystalline pow-
der. Practically insoluble in water; freely soluble in chloroform; soluble
S
in alcohol.
Diazoxide: White or cream-white crystals or crystalline powder. Prac-
U
tically insoluble to sparingly soluble in water and in most organic
solvents; very soluble in strong alkaline solutions; freely soluble in
dimethylformamide.
9
Dibucaine: White to off-white powder, having a slight, characteristic
odor. Darkens on exposure to light. Slightly soluble in water; soluble in
1 N hydrochloric acid and in ether.
Dibucaine Hydrochloride: Colorless or white to off-white crystals
or white to off-white, crystalline powder. Is odorless, is somewhat
hygroscopic, and darkens on exposure to light. Its solutions have a
pH of about 5.5. Freely soluble in water, in alcohol, in acetone, and in
chloroform.
Dibutyl Phthalate: A clear, oily liquid, colorless or very slightly yellow.
Practically insoluble in water; miscible with alcohol and with ether.
Dibutyl Sebacate: Colorless, oily liquid of very mild odor. Soluble in
alcohol, in isopropyl alcohol, and in mineral oil; very slightly soluble
in propylene glycol; practically insoluble in water and in glycerin. NF
category: Plasticizer.
Dichloralphenazone: White, microcrystalline powder. Has a slight
odor characteristic of chloral hydrate. Decomposed by dilute alkali,
liberating chloroform. Freely soluble in water, in alcohol, and in chlo-
roform; soluble in dilute acids.
Dichlorodifluoromethane: Clear, colorless gas, having a faint, ethereal
odor. Its vapor pressure at 25 is about 4880 mm of mercury (80 psig).
NF category: Aerosol propellant.
Dichlorotetrafluoroethane: Clear, colorless gas, having a faint, ethe-
real odor. Its vapor pressure at 25 is about 1620 mm of mercury (17
psig). Usually contains between 6% and 10% of its isomer, CCl2F-CF3.
NF category: Aerosol propellant.
Diclofenac Sodium: White to off-white, hygroscopic, crystalline pow-
der. Melts at about 284. Freely soluble in methanol; soluble in ethanol;
sparingly soluble in water; practically insoluble in chloroform and in
ether.
Dicloxacillin Sodium: White to off-white, crystalline powder. Freely
soluble in water.
Dicyclomine Hydrochloride: Fine, white, crystalline powder. Is prac-
tically odorless and has a very bitter taste. Soluble in water; freely
soluble in alcohol and in chloroform; very slightly soluble in ether.
Dicyclomine Hydrochloride Injection: Colorless solution, which may
have the odor of a preservative.
USP Pharmacists Pharmacopeia
Didanosine: White to off-white, crystalline powder. Very soluble in
dimethyl sulfoxide; practically insoluble or insoluble in acetone and
in methanol.
Dienestrol: Colorless, white or practically white, needle-like crystals,
or white or practically white, crystalline powder. Is odorless. Practically
insoluble in water; soluble in alcohol, in acetone, in ether, in metha-
nol, in propylene glycol, and in solutions of alkali hydroxides; slightly
soluble in chloroform and in fatty oils.
Diethanolamine: White or clear, colorless crystals, deliquescing in
moist air; or colorless liquid. Miscible with water, with alcohol, with ac-
etone, with chloroform, and with glycerin. Slightly soluble to insoluble
in benzene, in ether, and in petroleum ether. NF category: Alkalizing
agent; emulsifying and/or solubilizing agent.
Diethylcarbamazine Citrate: White, crystalline powder. Melts at about
136, with decomposition. Is odorless or has a slight odor; is slightly
hygroscopic. Very soluble in water; sparingly soluble in alcohol; practi-
cally insoluble in acetone, in chloroform, and in ether.
Diethylene Glycol Monoethyl Ether: Clear, colorless liquid. Is hy-
groscopic. Miscible with water, with acetone, and with alcohol; par-
tially miscible with vegetable oils; immiscible with mineral oils. Specific
gravity about 0.991. NF category: Ointment base; solvent.
Diethylene Glycol Stearates: White or almost white, waxy solid.
Soluble in acetone and in hot alcohol; practically insoluble in water. NF
category: Emulsifying and/or solubilizing agent.
Diethyl Phthalate: Colorless, practically odorless, oily liquid. Insoluble
in water. Miscible with alcohol, with ether, and with other usual or-
ganic solvents. NF category: Plasticizer.
0
Diethylpropion Hydrochloride: White to off-white, fine crystalline
powder. Is odorless, or has a slight characteristic odor. It melts at about
0
175, with decomposition. Freely soluble in water, in chloroform, and
2
in alcohol; practically insoluble in ether.
Diethylstilbestrol: White, odorless, crystalline powder. Practically
insoluble in water; soluble in alcohol, in chloroform, in ether, in fatty
oils, and in dilute alkali hydroxides.
Diethylstilbestrol Diphosphate: Off-white, odorless, crystalline pow-
der. Sparingly soluble in water; soluble in alcohol and in dilute alkali.
Diethylstilbestrol Diphosphate Injection: Colorless to light, straw-
colored liquid.
Diethyltoluamide: Colorless liquid, having a faint, pleasant odor. Boils
at about 111 under a pressure of 1 mm of mercury. Practically in-
soluble in water and in glycerin. Miscible with alcohol, with isopropyl
alcohol, with ether, with chloroform, and with carbon disulfide.
Diflorasone Diacetate: White to pale yellow, crystalline powder. Insol-
uble in water; soluble in methanol and in acetone; sparingly soluble in
ethyl acetate; slightly soluble in toluene; very slightly soluble in ether.
Diflunisal: White to off-white, practically odorless powder. Freely
soluble in alcohol and in methanol; soluble in acetone and in ethyl
acetate; slightly soluble in chloroform, in carbon tetrachloride, and in
methylene chloride; insoluble in hexane and in water.
Digitoxin: White or pale buff, odorless, microcrystalline powder.
Practically insoluble in water; sparingly soluble in chloroform; slightly
soluble in alcohol; very slightly soluble in ether.
Digoxin: Clear to white, odorless crystals or white, odorless crystalline
powder. Practically insoluble in water and in ether; freely soluble in
pyridine; slightly soluble in diluted alcohol and in chloroform.
Dihydroergotamine Mesylate: White to slightly yellowish powder, or
off-white to faintly red powder, having a faint odor. Slightly soluble in
water and in chloroform; soluble in alcohol.
Dihydrostreptomycin Sulfate: White or almost white, amorphous or
crystalline powder. Amorphous form is hygroscopic. Freely soluble in
water; practically insoluble in acetone, in chloroform, and in methanol.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/93
Description and Solubility
Dihydrotachysterol: Colorless or white, odorless crystals, or white,
odorless, crystalline powder. Practically insoluble in water; soluble in
alcohol; freely soluble in ether and in chloroform; sparingly soluble in
vegetable oils.
Dihydroxyacetone: White to off-white crystalline powder. The mo-
nomeric form is freely soluble in water, in alcohol, and in ether. The
dimeric form is freely soluble in water; soluble in alcohol; and spar-
ingly soluble in ether.
Dihydroxyaluminum Aminoacetate: White, odorless powder having a
faintly sweet taste. Insoluble in water and in organic solvents; soluble
in dilute mineral acids and in solutions of fixed alkalies.
Dihydroxyaluminum Aminoacetate Magma: White, viscous suspen-
sion, from which small amounts of water may separate on standing.
Dihydroxyaluminum Sodium Carbonate: Fine, white, odorless pow-
der. Practically insoluble in water and in organic solvents; soluble in
dilute mineral acids with the evolution of carbon dioxide.
Diloxanide Furoate: White or almost white, crystalline powder. Freely
soluble in chloroform; slightly soluble in alcohol and in ether; very
slightly soluble in water.
P
Diltiazem Hydrochloride: White, odorless, crystalline powder or small
S
crystals. Freely soluble in chloroform, in formic acid, in methanol, and
in water; sparingly soluble in dehydrated alcohol; insoluble in ether.
Melts at about 210, with decomposition.
U
Dimenhydrinate: White, crystalline, odorless powder. Slightly soluble
in water; freely soluble in alcohol and in chloroform; sparingly soluble
9
in ether.
Dimercaprol: Colorless or practically colorless liquid, having a dis-
agreeable, mercaptan-like odor. Soluble in water, in alcohol, in benzyl
benzoate, and in methanol.
Dimercaprol Injection: Yellow, viscous solution having a pungent,
disagreeable odor. Specific gravity is about 0.978.
Dimethicone: A clear, colorless, and odorless liquid. Soluble in chlo-
rinated hydrocarbons, in benzene, in toluene, in xylene, in n-hexane,
in petroleum spirits, in ether, and in amyl acetate; very slightly soluble
in isopropyl alcohol; insoluble in water, in methanol, in alcohol, and in
acetone. NF category: Antifoaming agent; water repelling agent.
Dimethyl Sulfoxide: Clear, colorless, odorless, hygroscopic liquid.
Melts at about 18.4. Boils at about 189. Soluble in water; practically in-
soluble in acetone, in alcohol, in benzene, in chloroform, and in ether.
Dinoprostone: White to off-white, crystalline powder. Freely soluble
in acetone, in alcohol, in ether, in ethyl acetate, in isopropyl alcohol, in
methanol, and in methylene chloride; soluble in toluene and in diiso-
propyl ether; practically insoluble in hexanes.
Dinoprost Tromethamine: White to off-white, crystalline powder.
Very soluble in water; freely soluble in dimethylformamide; soluble in
methanol; slightly soluble in chloroform.
Dioxybenzone: Yellow powder. Practically insoluble in water; freely
soluble in alcohol and in toluene.
Diphenhydramine Hydrochloride: White, odorless, crystalline pow-
der. Slowly darkens on exposure to light. Its solutions are practically
neutral to litmus. Freely soluble in water, in alcohol, and in chloroform;
sparingly soluble in acetone; very slightly soluble in benzene and in
ether.
Diphenoxylate Hydrochloride: White, odorless, crystalline powder. Its
saturated solution has a pH of about 3.3. Slightly soluble in water and
in isopropanol; freely soluble in chloroform; soluble in methanol; spar-
ingly soluble in alcohol and in acetone; practically insoluble in ether
and in solvent hexane.
Diphtheria and Tetanus Toxoids Adsorbed: Turbid, and white, slightly
gray, or slightly pink suspension, free from evident clumps after
shaking.
USP Pharmacists Pharmacopeia
Dipivefrin Hydrochloride: White, crystalline powder or small crystals,
having a faint odor. Very soluble in water.
Dipyridamole: Intensely yellow, crystalline powder or needles. Very
soluble in methanol, in alcohol, and in chloroform; slightly soluble in
water; very slightly soluble in acetone and in ethyl acetate.
Dirithromycin: White or practically white powder. Very slightly soluble
in water; very soluble in methanol and in methylene chloride.
Disopyramide Phosphate: White or practically white, odorless pow-
der. Melts at about 205, with decomposition. Freely soluble in water;
slightly soluble in alcohol; practically insoluble in chloroform and in
ether.
Disulfiram: White to off-white, odorless, crystalline powder. Very
slightly soluble in water; soluble in acetone, in alcohol, in carbon disul-
fide, and in chloroform.
Divalproex Sodium: White to off-white powder. Very soluble in
chloroform; freely soluble in methanol and in ethyl ether; soluble in
acetone; practically insoluble in acetonitrile.
Dobutamine Hydrochloride: White to practically white, crystalline
powder. Sparingly soluble in water and in methanol; soluble in alcohol
and in pyridine.
Docusate Calcium: White, amorphous solid, having the characteris-
tic odor of octyl alcohol. It is free of the odor of other solvents. Very
slightly soluble in water; very soluble in alcohol, in polyethylene glycol
400, and in corn oil.
Docusate Potassium: White, amorphous solid, having a characteris-
tic odor suggestive of octyl alcohol. Sparingly soluble in water; very
soluble in solvent hexane; soluble in alcohol and in glycerin.
0
Docusate Sodium: White, wax-like, plastic solid, having a character-
0
istic odor suggestive of octyl alcohol, but no odor of other solvents.
Sparingly soluble in water; very soluble in solvent hexane; freely
2
soluble in alcohol and in glycerin. NF category: Wetting and/or solubi-
lizing agent.
Dolasetron Mesylate: White to off-white powder. Freely soluble in wa-
ter and in propylene glycol; slightly soluble in alcohol and in saline TS.
Dopamine Hydrochloride: White to off-white, crystalline powder. May
have a slight odor of hydrochloric acid. Melts at about 240, with de-
composition. Freely soluble in water and in aqueous solutions of alkali
hydroxides; soluble in methanol; insoluble in ether and in chloroform.
Dorzolamide Hydrochloride: White to off-white, crystalline powder.
Soluble in water.
Doxapram Hydrochloride: White to off-white, odorless, crystalline
powder. Melts at about 220. Soluble in water and in chloroform; spar-
ingly soluble in alcohol; practically insoluble in ether.
Doxazosin Mesylate: White to tan-colored powder. Freely soluble in
formic acid. Very slightly soluble in methanol and in water.
Doxorubicin Hydrochloride: Red-orange, hygroscopic, crystalline or
amorphous powder. Soluble in water, in isotonic sodium chloride solu-
tion, and in methanol; practically insoluble in chloroform, in ether, and
in other organic solvents.
Doxycycline: Yellow, crystalline powder. Very slightly soluble in water;
freely soluble in dilute acid and in alkali hydroxide solutions; sparingly
soluble in alcohol; practically insoluble in chloroform and in ether.
Doxycycline Hyclate: Yellow, crystalline powder. Soluble in water and
in solutions of alkali hydroxides and carbonates; slightly soluble in
alcohol; practically insoluble in chloroform and in ether.
Doxylamine Succinate: White or creamy white powder, having a char-
acteristic odor. Very soluble in water and in alcohol; freely soluble in
chloroform; very slightly soluble in ether and in benzene.
Dronabinol: Light yellow resinous oil that is sticky at room tempera-
ture and hardens upon refrigeration. Insoluble in water.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/94
Description and Solubility
Droperidol: White to light tan, amorphous or microcrystalline pow-
der. Practically insoluble in water; freely soluble in chloroform; slightly
soluble in alcohol and in ether. Melts at about 145.
Drospirenone: White to off-white powder. Freely soluble in methy-
lene chloride; soluble in acetone and in methanol; sparingly soluble
in ethyl acetate and in alcohol; practically insoluble in hexane and in
water.
Absorbable Dusting Powder: White, odorless powder.
Dyclonine Hydrochloride: White crystals or white crystalline powder,
which may have a slight odor. Exhibits local anesthetic properties
when placed upon the tongue. Soluble in water, in acetone, in alcohol,
and in chloroform.
Dydrogesterone: White to pale yellow, crystalline powder. Practically
insoluble in water; sparingly soluble in alcohol.
Dyphylline: White, odorless, extremely bitter, amorphous or crystal-
line solid. Freely soluble in water; sparingly soluble in alcohol and in
chloroform; practically insoluble in ether.
Echothiophate Iodide: White, crystalline, hygroscopic solid having a
slight mercaptan-like odor. Its solutions have a pH of about 4. Freely
P
soluble in water and in methanol; soluble in dehydrated alcohol; prac-
S
tically insoluble in other organic solvents.
Echothiophate Iodide for Ophthalmic Solution: White, amorphous
powder.
U
Econazole Nitrate: White or practically white, crystalline powder,
having not more than a slight odor. Very slightly soluble in water and
9
in ether; slightly soluble in alcohol; sparingly soluble in chloroform;
soluble in methanol.
Edetate Calcium Disodium: White, crystalline granules or white,
crystalline powder. Is odorless, is slightly hygroscopic, and has a faint,
saline taste. Is stable in air. Freely soluble in water. NF category: Chelat-
ing agent; complexing agent.
Edetate Disodium: White, crystalline powder. Soluble in water. NF
category: Chelating agent; complexing agent.
Edetic Acid: White, crystalline powder. Melts above 220, with decom-
position. Soluble in solutions of alkali hydroxides; very slightly soluble
in water. NF category: Chelating agent; complexing agent.
Edrophonium Chloride: White, odorless, crystalline powder. Its
solution (1 in 10) is practically colorless. Very soluble in water; freely
soluble in alcohol; insoluble in chloroform and in ether.
Emedastine Fumarate: White to faintly yellow, crystalline powder.
Soluble in water.
Emetine Hydrochloride: White or very slightly yellowish, odorless,
crystalline powder. Is affected by light. Freely soluble in water and in
alcohol.
Enalapril Maleate: Off-white, crystalline powder. Melts at about 144.
Practically insoluble in nonpolar organic solvents; slightly soluble in
semipolar organic solvents; sparingly soluble in water; soluble in alco-
hol; freely soluble in methanol and in dimethylformamide.
Enalaprilat: White to nearly white, hygroscopic, crystalline powder.
Sparingly soluble in methanol and in dimethylformamide; slightly
soluble in water and in isopropyl alcohol; very slightly soluble in ac-
etone, in alcohol, and in hexane; practically insoluble in acetonitrile
and in chloroform.
Enflurane: Clear, colorless, stable, volatile liquid, having a mild, sweet
odor. Is nonflammable. Slightly soluble in water. Miscible with organic
solvents, with fats, and with oils.
Ephedrine: Unctuous, practically colorless solid or white crystals or
granules. Gradually decomposes on exposure to light. Melts between
33 and 40, the variability in the melting point being the result of dif-
ferences in the moisture content, anhydrous Ephedrine having a lower
melting point than the hemihydrate of Ephedrine. Its solutions are
USP Pharmacists Pharmacopeia
alkaline to litmus. Soluble in water, in alcohol, in chloroform, and in
ether; moderately and slowly soluble in mineral oil, the solution be-
coming turbid if the Ephedrine contains more than about 1% of water.
Ephedrine Hydrochloride: Fine, white, odorless crystals or powder. Is
affected by light. Freely soluble in water; soluble in alcohol; insoluble
in ether.
Ephedrine Sulfate: Fine, white, odorless crystals or powder. Darkens
on exposure to light. Freely soluble in water; sparingly soluble in
alcohol.
Ephedrine Sulfate Nasal Solution: Clear, colorless solution. Is neutral
or slightly acid to litmus.
Epinephrine: White to practically white, odorless, microcrystalline
powder or granules, gradually darkening on exposure to light and air.
With acids, it forms salts that are readily soluble in water, and the base
may be recovered by the addition of ammonia water or alkali carbon-
ates. Its solutions are alkaline to litmus. Very slightly soluble in water
and in alcohol; insoluble in ether, in chloroform, and in fixed and
volatile oils.
Epinephrine Injection: Practically colorless, slightly acid liquid. Gradu-
ally turns dark on exposure to light and air.
Epinephrine Inhalation Solution: Practically colorless, slightly acid
liquid. Gradually turns dark on exposure to light and air.
Epinephrine Nasal Solution: Nearly colorless, slightly acid liquid.
Gradually turns dark on exposure to light and air.
Epinephrine Ophthalmic Solution: Colorless to faint yellow solution.
Gradually turns dark on exposure to light and air.
Epinephrine Bitartrate: White, or grayish-white or light brownish-
0
gray, odorless, crystalline powder. Slowly darkens on exposure to air
0
and light. Its solutions are acid to litmus, having a pH of about 3.5.
Freely soluble in water; slightly soluble in alcohol; practically insoluble
2
in chloroform and in ether.
Epinephrine Bitartrate for Ophthalmic Solution: White to off-white
solid.
Epinephryl Borate Ophthalmic Solution: Clear, pale yellow liquid,
gradually darkening on exposure to light and air.
Eprinomectin: White to off-white powder. Insoluble in cold water.
Ergocalciferol: White, odorless crystals. Is affected by air and by light.
Insoluble in water; soluble in alcohol, in chloroform, in ether, and in
fatty oils.
Ergocalciferol Oral Solution: Clear liquid having the characteristics of
the solvent used in preparing the Solution.
Ergoloid Mesylates: White to off-white, microcrystalline or amor-
phous, practically odorless powder. Slightly soluble in water; soluble in
methanol and in alcohol; sparingly soluble in acetone.
Ergonovine Maleate: White to grayish-white or faintly yellow, odor-
less, microcrystalline powder. Darkens with age and on exposure to
light. Sparingly soluble in water; slightly soluble in alcohol; insoluble in
ether and in chloroform.
Ergotamine Tartrate: Colorless crystals or white to yellowish-white,
crystalline powder. Is odorless. Melts at about 180, with decomposi-
tion. One g dissolves in about 3200 mL of water; in the presence of
a slight excess of tartaric acid 1 g dissolves in about 500 mL of water.
Slightly soluble in alcohol.
Erythorbic Acid: White or slightly yellow crystals or powder. It gradu-
ally darkens when exposed to light. In the dry state, it is reasonably sta-
ble in air, but in solution, it rapidly deteriorates in the presence of air.
It melts between 164 and 171 with decomposition. One g is soluble in
about 2.5 mL of water and in about 20 mL of alcohol. Slightly soluble in
glycerin. NF category: Antimicrobial preservative; antioxidant.
Erythritol: White or almost white, crystalline powder or free-flowing
granules. It is stable to heat and is nonhygroscopic. Freely soluble in
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/95
Description and Solubility
water; very slightly soluble in alcohol. NF category: Humectant; sweet-
ening agent.
Erythromycin: White or slightly yellow, crystalline powder. Is odorless
or practically odorless. Slightly soluble in water; soluble in alcohol, in
chloroform, and in ether.
Erythromycin Estolate: White, crystalline powder. Is odorless or
practically odorless, and is practically tasteless. Soluble in alcohol, in
acetone, and in chloroform; practically insoluble in water.
Erythromycin Ethylsuccinate: White or slightly yellow crystalline pow-
der. Is odorless or practically odorless, and is practically tasteless. Very
slightly soluble in water; freely soluble in alcohol, in chloroform, and
in polyethylene glycol 400.
Erythromycin Gluceptate: Colorless to white crystals. Slightly hygro-
scopic. Freely soluble in water, in alcohol, in methanol, in dioxane,
and in propylene glycol; slightly soluble in acetone and in chloroform;
practically insoluble in ether, in carbon tetrachloride, in benzene, and
in toluene.
Erythromycin Lactobionate for Injection: White or slightly yellow
crystals or powder, having a faint odor. Its solution (1 in 20) is neutral
P
or slightly alkaline. Freely soluble in water, in alcohol, and in methanol;
slightly soluble in acetone and in chloroform; practically insoluble in
S
ether.
Erythromycin Stearate: White or slightly yellow crystals or powder.
U
Is odorless or may have a slight, earthy odor, and has a slightly bitter
taste. Practically insoluble in water; soluble in alcohol, in chloroform,
in methanol, and in ether.
9
Esomeprazole Magnesium: White to slightly colored powder. Soluble
in methanol; slightly soluble in water; practically insoluble in heptane.
Estradiol: White or creamy white, small crystals or crystalline powder.
Is odorless, and is stable in air. Is hygroscopic. Practically insoluble in
water; soluble in alcohol, in acetone, in dioxane, in chloroform, and in
solutions of fixed alkali hydroxides; sparingly soluble in vegetable oils.
Estradiol Benzoate: White to off-white, crystalline powder. Soluble in
alcohol and in acetone; slightly soluble in diethyl ether; insoluble in
water.
Estradiol Cypionate: White to practically white, crystalline powder. Is
odorless or has a slight odor. Insoluble in water; soluble in alcohol, in
acetone, in chloroform, and in dioxane; sparingly soluble in vegetable
oils.
Estradiol Valerate: White, crystalline powder. Is usually odorless but
may have a faint, fatty odor. Practically insoluble in water; soluble in
castor oil, in methanol, in benzyl benzoate, and in dioxane; sparingly
soluble in sesame oil and in peanut oil.
Estriol: White to practically white, odorless, crystalline powder. Melts
at about 280. Insoluble in water; sparingly soluble in alcohol; soluble
in acetone, in chloroform, in dioxane, in ether, and in vegetable oils.
Conjugated Estrogens: Conjugated Estrogens obtained from natural
sources is a buff-colored, amorphous powder, odorless or having a
slight, characteristic odor. The synthetic form is a white to light buff,
crystalline or amorphous powder, odorless or having a slight odor.
Synthetic Conjugated Estrogens: A white to light buff, crystalline or
amorphous powder that is odorless or has a slight odor.
Esterified Estrogens: White or buff-colored, amorphous powder, odor-
less or having a slight, characteristic odor.
Estrone: Small, white crystals or white to creamy white, crystalline
powder. Is odorless, and is stable in air. Melts at about 260. Practically
insoluble in water; soluble in alcohol, in acetone, in dioxane, and in
vegetable oils; slightly soluble in solutions of fixed alkali hydroxides.
Estropipate: White to yellowish-white, fine, crystalline powder. Is
odorless, or may have a slight odor. Melts at about 190 to a light
brown, viscous liquid, which solidifies on further heating and finally
USP Pharmacists Pharmacopeia
melts at about 245, with decomposition. Very slightly soluble in water,
in alcohol, in chloroform, and in ether; soluble in warm water.
Ethacrynic Acid: White or practically white, odorless or practically
odorless, crystalline powder. Very slightly soluble in water; freely
soluble in alcohol, in chloroform, and in ether.
Ethambutol Hydrochloride: White, crystalline powder. Freely soluble
in water; soluble in alcohol and in methanol; slightly soluble in ether
and in chloroform.
Ethchlorvynol: Colorless to yellow, slightly viscous liquid, having a
characteristic pungent odor. Darkens on exposure to light and air. Im-
miscible with water; miscible with most organic solvents.
Ether: Colorless, mobile, volatile liquid, having a characteristic sweet,
pungent odor. Is slowly oxidized by the action of air and light, with the
formation of peroxides. It boils at about 35. Soluble in water and in
hydrochloric acid. Miscible with alcohol, with benzene, with chloro-
form, with solvent hexane, with methylene chloride, and with fixed
and volatile oils.
Ethinyl Estradiol: White to creamy white, odorless, crystalline powder.
Insoluble in water; soluble in alcohol, in chloroform, in ether, in veg-
etable oils, and in solutions of fixed alkali hydroxides.
Ethiodized Oil Injection: Straw-colored to amber-colored, oily liquid.
It may possess an alliaceous odor. Insoluble in water; soluble in ac-
etone, in chloroform, in ether, and in solvent hexane.
Ethionamide: Bright yellow powder, having a faint to moderate sul-
fide-like odor. Slightly soluble in water, in chloroform, and in ether;
soluble in methanol; sparingly soluble in alcohol and in propylene
glycol.
0
Ethopabate: White to pinkish-white, odorless or practically odor-
less powder. Very slightly soluble in water; soluble in acetonitrile, in
0
acetone, in dehydrated alcohol, and in methanol; sparingly soluble in
2
isopropyl alcohol, in dioxane, in ethyl acetate, and in methylene chlo-
ride; slightly soluble in ether.
Ethosuximide: White to off-white, crystalline powder or waxy solid,
having a characteristic odor. Freely soluble in water and in chloroform;
very soluble in alcohol and in ether; very slightly soluble in solvent
hexane.
Ethotoin: White, crystalline powder. Insoluble in water; freely soluble
in dehydrated alcohol and in chloroform; soluble in ether.
Ethyl Acetate: Transparent, colorless liquid, having a fragrant, re-
freshing, slightly acetous odor, and a peculiar, acetous, burning taste.
Soluble in water. Miscible with alcohol, with ether, with fixed oils, and
with volatile oils. NF category: Flavors and perfumes; solvent.
Ethyl Acrylate and Methyl Methacrylate Copolymer Dispersion: Milky-
white liquid of low viscosity with a faint, characteristic odor. It is mis-
cible with water in any proportion; the milky-white appearance is
retained. A clear or slightly opalescent, viscous solution is obtained
on mixing one part with five parts of acetone, alcohol, or isopropyl
alcohol; the polymer substance first precipitates, but then dissolves in
the excess organic solvent. When mixed with 1 N sodium hydroxide
in a ratio of 1:2, the dispersion does not dissolve; the milky-white ap-
pearance is retained. NF category: Coating agent; polymer membrane;
tablet binder.
Ethyl Chloride: Colorless, mobile, very volatile liquid at low tempera-
tures or under pressure, having a characteristic, ethereal odor. It boils
between 12 and 13, and its specific gravity at 0 is about 0.921. When
liberated at room temperature from its sealed container, it vaporizes
immediately. It burns with a smoky, greenish flame, producing hydro-
gen chloride. Slightly soluble in water; freely soluble in alcohol and in
ether.
Ethyl Oleate: Mobile, practically colorless liquid, having an agreeable
taste. Insoluble in water. Miscible with vegetable oils, with mineral
oil, with alcohol, and with most organic solvents. NF category: Vehicle
(oleaginous).
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/96
Description and Solubility
Ethyl Vanillin: Fine, white or slightly yellowish crystals. Its taste and
odor are similar to the taste and odor of vanillin. Is affected by light.
Its solutions are acid to litmus. Sparingly soluble in water at 50; freely
soluble in alcohol, in chloroform, in ether, and in solutions of alkali
hydroxides. NF category: Flavors and perfumes.
Ethylcellulose: Free-flowing, white to light tan powder. It forms films
that have a refractive index of about 1.47. Its aqueous suspensions
are neutral to litmus. Insoluble in water, in glycerin, and in propylene
glycol. Ethylcellulose containing less than 46.5% of ethoxy groups is
freely soluble in tetrahydrofuran, in methyl acetate, in chloroform,
and in mixtures of aromatic hydrocarbons with alcohol. Ethylcellulose
containing not less than 46.5% of ethoxy groups is freely soluble in
alcohol, in methanol, in toluene, in chloroform, and in ethyl acetate.
NF category: Coating agent; tablet binder.
Ethylenediamine: Clear, colorless or only slightly yellow liquid, having
an ammonia-like odor and a strong alkaline reaction. Miscible with
water and with alcohol.
Ethylene Glycol Stearates: White or almost white, waxy solid. Soluble
in acetone and in hot alcohol; practically insoluble in water. NF cat-
P
egory: Emulsifying and/or solubilizing agent.
Ethylparaben: Small, colorless crystals or white powder. Slightly
S
soluble in water and in glycerin; freely soluble in acetone, in alco-
hol, in ether, and in propylene glycol. NF category: Antimicrobial
U
preservative.
Ethynodiol Diacetate: White, odorless, crystalline powder. Is stable
in air. Insoluble in water; very soluble in chloroform; freely soluble in
9
ether; soluble in alcohol; sparingly soluble in fixed oils.
Etidronate Disodium: White powder, which may contain lumps. Freely
soluble in water; practically insoluble in alcohol.
Etoposide: Fine, white to off-white, crystalline powder. Very slightly
soluble in water; slightly soluble in alcohol, in chloroform, in ethyl ac-
etate, and in methylene chloride; sparingly soluble in methanol.
Eucatropine Hydrochloride: White, granular, odorless powder. Its
solutions are neutral to litmus. Very soluble in water; freely soluble in
alcohol and in chloroform; insoluble in ether.
Eugenol: Colorless or pale yellow liquid, having a strongly aromatic
odor of clove and a pungent, spicy taste. Upon exposure to air, it
darkens and thickens. Is optically inactive. Slightly soluble in water.
Miscible with alcohol, with chloroform, with ether, and with fixed oils.
Famotidine: White to pale yellowish-white, crystalline powder. Is
sensitive to light. Freely soluble in dimethylformamide and in glacial
acetic acid; slightly soluble in methanol; very slightly soluble in water;
practically insoluble in acetone, in alcohol, in chloroform, in ether, and
in ethyl acetate.
Hard Fat: White mass; almost odorless and free from rancid odor;
greasy to the touch. On warming, melts to give a colorless or slightly
yellowish liquid. When the molten material is shaken with an equal
quantity of hot water, a white emulsion is formed. Practically insoluble
in water; freely soluble in ether; slightly soluble in alcohol. NF category:
Stiffening agent; suppository base.
Felodipine: Light yellow to yellow, crystalline powder. Freely soluble
in acetone and in methanol; very slightly soluble in heptane; insoluble
in water.
Fenbendazole: White to off-white powder. Sparingly soluble in di-
methylformamide; very slightly soluble in methanol; practically in-
soluble in water.
Fenofibrate: White or almost white, crystalline powder. Very soluble
in methylene chloride; slightly soluble in alcohol; practically insoluble
in water.
Fenoldopam Mesylate: White to off-white powder. Soluble in water.
Fenoprofen Calcium: White, crystalline powder. Slightly soluble in n-hex-
anol, in methanol, and in water; practically insoluble in chloroform.
USP Pharmacists Pharmacopeia
Fentanyl Citrate: White, crystalline powder or white, glistening crys-
tals. Melts at about 150, with decomposition. Sparingly soluble in
water; soluble in methanol; slightly soluble in chloroform.
Ferric Oxide: Powder exhibiting two basic colors (red and yellow),
or other shades produced on blending the basic colors. Insoluble in
water and in organic solvents; dissolves in hydrochloric acid upon
warming, a small amount of insoluble residue usually remaining. NF
category: Color.
Ferric Subsulfate Solution: Reddish-brown liquid, odorless or nearly
so. Acid to litmus, and is affected by light. Specific gravity is about
1.548.
Ferric Sulfate: Grayish-white or yellowish powder or fawn-colored
pearls. Hygroscopic. Rapidly soluble in the presence of a trace of
ferrous sulfate; slowly soluble in water; sparingly soluble in alcohol;
practically insoluble in acetone and in ethyl acetate. Hydrolyzes slowly
in aqueous solution.
Ferrous Fumarate: Reddish-orange to red-brown, odorless powder.
May contain soft lumps that produce a yellow streak when crushed.
Slightly soluble in water; very slightly soluble in alcohol. Its solubility
in dilute hydrochloric acid is limited by the separation of fumaric acid.
Ferrous Gluconate: Yellowish-gray or pale greenish-yellow, fine pow-
der or granules, having a slight odor resembling that of burned sugar.
Its solution (1 in 20) is acid to litmus. Soluble in water, with slight heat-
ing; practically insoluble in alcohol.
Ferrous Sulfate: Pale, bluish-green crystals or granules. Is odorless and
is efflorescent in dry air. Oxidizes readily in moist air to form brownish
yellow basic ferric sulfate. Its solution (1 in 10) is acid to litmus, having
0
a pH of about 3.7. Freely soluble in water; very soluble in boiling water;
insoluble in alcohol.
0
Dried Ferrous Sulfate: Grayish-white to buff-colored powder, con-
2
sisting primarily of FeSO4H2O with varying amounts of FeSO44H2O.
Slowly soluble in water; insoluble in alcohol.
Ferumoxides Injection: Black to reddish-brown, aqueous colloid. It is
stable for 24 hours after dilution.
Finasteride: White to off-white, crystalline solid. Melts at about 257.
Freely soluble in chloroform and in alcohol; very slightly soluble in
water.
Fish Oil Containing Omega-3 Acids: Pale yellow liquid. Very soluble in
acetone and in heptane; slightly soluble in anhydrous alcohol; practi-
cally insoluble in water.
Flavoxate Hydrochloride: White or almost white, crystalline powder.
Slightly soluble in alcohol, in water, and in methylene chloride.
Flecainide Acetate: White to slightly off-white, crystalline powder.
Freely soluble in alcohol; soluble in water. pKa is 9.3.
Fluconazole: White or almost white, crystalline powder. Freely soluble
in methanol; soluble in alcohol and in acetone; sparingly soluble in
isopropanol and in chloroform; slightly soluble in water; very slightly
soluble in toluene.
Flucytosine: White to off-white, crystalline powder. Is odorless or has
a slight odor. Sparingly soluble in water; slightly soluble in alcohol;
practically insoluble in chloroform and in ether.
Fludarabine Phosphate: White to off-white, crystalline, hygroscopic
powder. Freely soluble in dimethylformamide; slightly soluble in water
and in 0.1 M hydrochloric acid; practically insoluble in ethanol.
Fludrocortisone Acetate: White to pale yellow crystals or crystalline
powder. Is odorless or practically odorless. Is hygroscopic. Insoluble
in water; slightly soluble in ether; sparingly soluble in alcohol and in
chloroform.
Flumazenil: White to off-white powder. Slightly soluble in acidic aque-
ous solutions; practically insoluble in water.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/97
Description and Solubility
Flumethasone Pivalate: White to off-white, crystalline powder. In-
soluble in water; slightly soluble in methanol; very slightly soluble in
chloroform and in methylene chloride.
Flunisolide: White to creamy-white, crystalline powder. Melts at about
245, with decomposition. Practically insoluble in water; soluble in ac-
etone; sparingly soluble in chloroform; slightly soluble in methanol.
Flunixin Meglumine: White to off-white crystalline powder. Soluble
in water, in alcohol, and in methanol; practically insoluble in ethyl
acetate.
Fluocinolone Acetonide: White or practically white, odorless, crystal-
line powder. Is stable in air. Melts at about 270, with decomposition.
Insoluble in water; soluble in methanol; slightly soluble in ether and in
chloroform.
Fluocinonide: White to cream-colored, crystalline powder, having not
more than a slight odor. Practically insoluble in water; sparingly soluble
in acetone and in chloroform; slightly soluble in alcohol, in methanol,
and in dioxane; very slightly soluble in ether.
Fluorescein: Yellowish-red to red, odorless powder. Insoluble in wa-
ter; soluble in dilute alkali hydroxides.
P
Fluorescein Sodium: Orange-red, hygroscopic, odorless powder.
S
Freely soluble in water; sparingly soluble in alcohol.
Fluorescein Sodium Ophthalmic Strip: Each Strip is a dry, white piece
of paper, one end of which is rounded and is uniformly orange-red in
U
color because of the fluorescein sodium impregnated in the paper.
Fluorometholone: White to yellowish-white, odorless, crystalline
9
powder. Melts at about 280, with some decomposition. Practically
insoluble in water; slightly soluble in alcohol; very slightly soluble in
chloroform and in ether.
Fluorouracil: White to practically white, practically odorless, crystal-
line powder. Decomposes at about 282. Sparingly soluble in water;
slightly soluble in alcohol; practically insoluble in chloroform and in
ether.
Fluoxetine Hydrochloride: White to off-white crystalline powder.
Sparingly soluble in water and in dichloromethane; freely soluble in
alcohol and in methanol; practically insoluble in ether.
Fluoxymesterone: White or practically white, odorless, crystalline
powder. Melts at about 240, with some decomposition. Practically
insoluble in water; sparingly soluble in alcohol; slightly soluble in
chloroform.
Fluphenazine Enanthate: Pale yellow to yellow-orange, clear to slightly
turbid, viscous liquid, having a characteristic odor. Is unstable in strong
light, but stable to air at room temperature. Insoluble in water; freely
soluble in alcohol, in chloroform, and in ether.
Fluphenazine Hydrochloride: White or nearly white, odorless, crystal-
line powder. Melts, within a range of 5, at a temperature above 225.
Freely soluble in water; slightly soluble in acetone, in alcohol, and in
chloroform; practically insoluble in benzene and in ether.
Flurandrenolide: White to off-white, fluffy, crystalline powder. Is
odorless. Practically insoluble in water and in ether; freely soluble in
chloroform; soluble in methanol; sparingly soluble in alcohol.
Flurazepam Hydrochloride: Off-white to yellow, crystalline powder. Is
odorless, or has a slight odor, and its solutions are acid to litmus. Melts
at about 212, with decomposition. Freely soluble in water and in alco-
hol; slightly soluble in isopropyl alcohol and in chloroform.
Flurbiprofen: White, crystalline powder. Freely soluble in acetone, in
dehydrated alcohol, in ether, and in methanol; soluble in acetonitrile;
practically insoluble in water. Optically inactive (1 in 50 solution in
dehydrated alcohol).
Flutamide: Pale yellow, crystalline powder. Freely soluble in acetone,
in ethyl acetate, and in methanol; soluble in chloroform and in ether;
practically insoluble in mineral oil, in petroleum ether, and in water.
Fluticasone Propionate (micronized): Fine, white powder.
USP Pharmacists Pharmacopeia
Fluvastatin Sodium: White to pale yellow, brownish-pale yellow, or
reddish-pale yellow, hygroscopic powder. Soluble in alcohol, in metha-
nol, and in water.
Fluvoxamine Maleate: White to off-white, crystalline powder. Freely
soluble in alcohol and in chloroform; sparingly soluble in water; and
practically insoluble in diethyl ether.
Folic Acid: Yellow, yellow-brownish, or yellowish-orange, odorless,
crystalline powder. Very slightly soluble in water; insoluble in alcohol,
in acetone, in chloroform, and in ether. It readily dissolves in dilute
solutions of alkali hydroxides and carbonates, and is soluble in hot, 3 N
hydrochloric acid and in hot, 2 N sulfuric acid. Soluble in hydrochloric
acid and in sulfuric acid, yielding very pale yellow solutions.
Folic Acid Injection: Clear, yellow to orange-yellow, alkaline liquid.
Formaldehyde Solution: Clear, colorless or practically colorless liquid,
having a pungent odor. The vapor from it irritates the mucous mem-
brane of the throat and nose. On long standing, especially in the cold,
it may become cloudy because of the separation of paraformaldehyde.
This cloudiness disappears when the solution is warmed. Miscible with
water and with alcohol.
Formoterol Fumarate Dihydrate: White or almost white or slightly
yellow powder. Freely soluble in dimethyl sulfoxide and in acetic acid;
soluble in methanol; slightly soluble in water and in 2-propanol; practi-
cally insoluble in acetonitrile and in diethyl ether.
Foscarnet Sodium: White to almost white, crystalline powder. Soluble
in water; practically insoluble in alcohol.
Fosphenytoin Sodium: White to pale yellow solid. Freely soluble in
water.
0
Fructose: Colorless crystals or as a white, crystalline powder. Is odor-
0
less, and has a sweet taste. Freely soluble in water; soluble in alcohol
and in methanol. NF category: Sweetening agent; tablet and/or capsule
2
diluent.
Basic Fuchsin: Dark green powder or greenish glistening crystalline
fragments, having a bronze-like luster and not more than a faint odor.
Soluble in water, in alcohol, and in amyl alcohol; insoluble in ether.
Fulvestrant: White powder. Freely soluble in alcohol.
Fumaric Acid: White, odorless granules or crystalline powder. Soluble
in alcohol; slightly soluble in water and in ether; very slightly soluble in
chloroform. NF category: Acidifying agent.
Furazolidone: Yellow, odorless, crystalline powder. Is tasteless at first,
then a bitter aftertaste develops. Practically insoluble in water, in alco-
hol, and in carbon tetrachloride.
Furosemide: White to slightly yellow, odorless, crystalline powder.
Practically insoluble in water; freely soluble in acetone, in dimethyl-
formamide, and in solutions of alkali hydroxides; soluble in methanol;
sparingly soluble in alcohol; slightly soluble in ether; very slightly
soluble in chloroform.
Furosemide Injection: Clear, colorless solution.
Gabapentin: White to off-white, crystalline solid. Freely soluble in
water and in alkaline and acidic solutions.
Gadodiamide: White, odorless powder. Freely soluble in water and in
methanol; soluble in ethyl alcohol; slightly soluble in acetone and in
chloroform.
Gadoteridol: White to off-white, crystalline, odorless powder. Freely
soluble in water and in methyl alcohol. Soluble in isopropyl alcohol.
Melts at about 300.
Gadoversetamide: White, odorless powder. Freely soluble in water.
Galactose: A white, crystalline or finely granulated powder. Soluble in
water; very slightly soluble in alcohol. NF category: Sweetening agent.
Galantamine Hydrobromide: White to almost white powder. Soluble
in 0.1 N sodium hydroxide; sparingly soluble in water; very slightly
soluble in alcohol; insoluble in n-propanol.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/98
Description and Solubility
Gallamine Triethiodide: White, odorless, amorphous powder. Is
hygroscopic. Very soluble in water; sparingly soluble in alcohol; very
slightly soluble in chloroform.
Gamma Cyclodextrin: White or almost white, amorphous or crystal-
line powder. Freely soluble in water and in propylene glycol; very
slightly soluble in alcohol. NF category: Sequestering agent; emulsify-
ing and/or solubilizing agent.
Ganciclovir: White to off-white, crystalline powder.
Ganciclovir for Injection: White to off-white powder. Soluble in water.
Petrolatum Gauze: The petrolatum recovered by draining in the Assay
is a white or faintly yellowish, unctuous mass, transparent in thin layers
even after cooling to 0.
Gelatin: Sheets, flakes, or shreds, or coarse to fine powder. Is faintly
yellow or amber in color, the color varying in depth according to the
particle size. Has a slight, characteristic bouillon-like odor in solution.
Is stable in air when dry, but is subject to microbic decomposition
when moist or in solution. Gelatin has any suitable strength that is
designated by Bloom Gelometer number (see Gel Strength of Gelatin
1081). Type A Gelatin exhibits an isoelectric point between pH 7 and
P
pH 9, and Type B Gelatin exhibits an isoelectric point between pH 4.7
and pH 5.2. Insoluble in cold water, but swells and softens when im-
S
mersed in it, gradually absorbing from 5 to 10 times its own weight of
water. Soluble in hot water, in 6 N acetic acid, and in a hot mixture of
U
glycerin and water. Insoluble in alcohol, in chloroform, in ether, and in
fixed and volatile oils. NF category: Coating agent; suspending and/or
viscosity-increasing agent; tablet binder.
9
Absorbable Gelatin Film: Light amber, transparent, pliable film which
becomes rubbery when moistened. Insoluble in water.
Absorbable Gelatin Sponge: Light, nearly white, nonelastic, tough,
porous, hydrophilic solid. Insoluble in water.
Gellan Gum: Off-white powder. Soluble in hot or in cold deionized
water. NF category: Suspending and/or viscosity-increasing agent.
Gemcitabine Hydrochloride: White to off-white solid. Soluble in wa-
ter; slightly soluble in methanol; practically insoluble in alcohol and in
polar organic solvents.
Gemfibrozil: White, waxy, crystalline solid. Practically insoluble in
water; soluble in alcohol, in methanol, and in chloroform.
Gentamicin Sulfate: White to buff powder. Freely soluble in water; in-
soluble in alcohol, in acetone, in chloroform, in ether, and in benzene.
Gentamicin Injection: Clear, slightly yellow solution, having a faint
odor.
Gentian Violet: Dark green powder or greenish, glistening pieces hav-
ing a metallic luster, and having not more than a faint odor. Sparingly
soluble in water; soluble in alcohol, in glycerin, and in chloroform;
insoluble in ether.
Gentian Violet Cream: Dark purple, water-washable cream.
Gentian Violet Topical Solution: Purple liquid, having a slight odor of
alcohol. A dilution (1 in 100), viewed downward through 1 cm of depth,
is deep purple in color.
Powdered Asian Ginseng Extract: Pale yellow-brown, hygroscopic,
powdery or easily pulverizable mass. Soluble in water, forming a
slightly cloudy solution.
Glaze, Pharmaceutical: Denatured alcohol solution. NF category:
Coating agent.
Glimepiride: White to almost white powder. Soluble in dimethylfor-
mamide; slightly soluble in methanol; sparingly soluble in methylene
chloride; practically insoluble in water.
Glipizide: White to off-white powder. Freely soluble in dimethylfor-
mamide; soluble in 0.1 N sodium hydroxide; slightly soluble in methy-
lene chloride.
USP Pharmacists Pharmacopeia
Immune Globulin: Transparent or slightly opalescent liquid, either
colorless or of a brownish color due to denatured hemoglobin. Is prac-
tically odorless. May develop a slight, granular deposit during storage.
Rh0 (D) Immune Globulin: Transparent or slightly opalescent liquid.
Is practically colorless and odorless. May develop a slight, granular
deposit during storage.
Glucagon: Fine, white or faintly colored, crystalline powder. Is practi-
cally odorless and tasteless. Soluble in dilute alkali and acid solutions;
insoluble in most organic solvents.
Glucagon for Injection: White, odorless powder.
Gluconolactone: Fine, white, practically odorless, crystalline powder.
Melts at about 153, with decomposition. Freely soluble in water; spar-
ingly soluble in alcohol; insoluble in ether.
Liquid Glucose: Colorless or yellowish, thick, syrupy liquid. Odorless
or nearly odorless, and has a sweet taste. Miscible with water; sparingly
soluble in alcohol. NF category: Tablet binder.
Glutamine: White crystals or crystalline powder. Soluble in water;
practically insoluble in alcohol and in ether.
Glutaral Concentrate: Clear, colorless or faintly yellow liquid, having a
characteristic, irritating odor.
Glycerin: Clear, colorless, syrupy liquid, having a sweet taste. Has not
more than a slight characteristic odor, which is neither harsh nor dis-
agreeable. Is hygroscopic. Its solutions are neutral to litmus. Miscible
with water and with alcohol. Insoluble in chloroform, in ether, and in
fixed and volatile oils. NF category: Humectant; plasticizer; solvent;
tonicity agent.
Glyceryl Behenate: Fine powder, having a faint odor. Melts at about
0
70. Practically insoluble in water and in alcohol; soluble in chloroform.
0
Glyceryl Distearate: Hard, waxy mass or powder or white or almost
white flakes. Soluble in methylene chloride and in tetrahydrofuran;
2
partly soluble in hot alcohol; insoluble in water. NF category: Emulsify-
ing and/or solubilizing agent.
Glyceryl Monolinoleate: Amber, oily liquids that may be partially
solidified at room temperature. Practically insoluble in water; soluble
in tetrahydrofuran; freely soluble in methylene chloride. NF category:
Emulsifying and/or solubilizing agent.
Glyceryl Monooleate: Amber, oily liquids that may be partially so-
lidified at room temperature. Practically insoluble in water; soluble
in tetrahydrofuran; freely soluble in methylene chloride. NF category:
Emulsifying and/or solubilizing agent.
Glyceryl Monostearate: White to yellowish wax-like solid; or white
to yellowish wax-like beads, flakes, or powder. Slight, agreeable, fatty
odor and taste. Is affected by light. Dissolves in hot organic solvents
such as alcohol, minerals or fixed oils, benzene, ether, and acetone.
Insoluble in water, but it may be dispersed in hot water with the aid
of a small amount of soap or other suitable surface-active agent. NF
category: Emulsifying and/or solubilizing agent.
Glycine: White, odorless, crystalline powder, having a sweetish taste.
Its solutions are acid to litmus. Freely soluble in water; very slightly
soluble in alcohol and in ether.
Glycopyrrolate: White, odorless, crystalline powder. Soluble in water
and in alcohol; practically insoluble in chloroform and in ether.
Gonadorelin Acetate: White to slightly yellowish powder. Soluble in
water; sparingly soluble in methanol.
Chorionic Gonadotropin: White or practically white, amorphous pow-
der. Freely soluble in water.
Chorionic Gonadotropin for Injection: White or practically white,
amorphous solid having the characteristic appearance of substances
prepared by freeze-drying.
Gramicidin: White or practically white, odorless, crystalline powder.
Insoluble in water; soluble in alcohol.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/99
Description and Solubility
Granisetron Hydrochloride: White or almost white powder. Freely
soluble in water; sparingly soluble in methylene chloride; slightly
soluble in methanol.
Green Soap: Soft, unctuous, yellowish-white to brownish or green-
ish yellow, transparent to translucent mass. Has a slight, characteristic
odor, often suggesting the oil from which it was prepared. Its solution
(1 in 20) is alkaline to bromothymol blue TS.
Griseofulvin: White to creamy white, odorless powder, in which
particles of the order of 4 m in diameter predominate. Very slightly
soluble in water; soluble in acetone, in dimethylformamide, and in
chloroform; sparingly soluble in alcohol.
Guaifenesin: White to slightly gray, crystalline powder. May have a
slight characteristic odor. Soluble in water, in alcohol, in chloroform,
and in propylene glycol; sparingly soluble in glycerin.
Guanabenz Acetate: White or almost white powder having not more
than a slight odor. Sparingly soluble in water and in 0.1 N hydrochloric
acid; soluble in alcohol and in propylene glycol.
Guanadrel Sulfate: White to off-white, crystalline powder. Melts at
about 235, with decomposition. Soluble in water; sparingly soluble in
P
methanol; slightly soluble in alcohol and in acetone.
Guanethidine Monosulfate: White to off-white, crystalline powder.
S
Very soluble in water; sparingly soluble in alcohol; practically insoluble
in chloroform.
U
Guar Gum: White to yellowish-white, practically odorless powder.
Dispersible in hot or cold water, forming a colloidal solution. NF cat-
9
egory: Suspending and/or viscosity-increasing agent; tablet binder.
Gutta Percha: Lumps or blocks of variable size; externally brown or
grayish-brown to grayish-white in color; internally reddish yellow or
reddish gray and having a laminated or fibrous appearance. Is flexible
but only slightly elastic. Has a slight, characteristic odor and a slight
taste. Insoluble in water; about 90% soluble in chloroform; partly
soluble in benzene, in carbon disulfide, and in turpentine oil.
Halazone: White, crystalline powder, having a characteristic chlorine-
like odor. Is affected by light. Melts at about 194, with decomposition.
Very slightly soluble in water and in chloroform; soluble in glacial ace-
tic acid. Dissolves in solutions of alkali hydroxides and carbonates with
the formation of a salt.
Halazone Tablets for Solution: Soluble in water.
Halcinonide: White to off-white, odorless, crystalline powder. Soluble
in acetone and in chloroform; slightly soluble in alcohol and in ethyl
ether; insoluble in water and in hexanes.
Haloperidol: White to faintly yellowish, amorphous or microcrystal-
line powder. Its saturated solution is neutral to litmus. Practically
insoluble in water; soluble in chloroform; sparingly soluble in alcohol;
slightly soluble in ether.
Halothane: Colorless, mobile, nonflammable, heavy liquid, having a
characteristic odor resembling that of chloroform. Its taste is sweet
and produces a burning sensation. Slightly soluble in water. Miscible
with alcohol, with chloroform, with ether, and with fixed oils.
Helium: Colorless, odorless, tasteless gas, which is not combustible
and does not support combustion. Very slightly soluble in water. At
0 and at a pressure of 760 mm of mercury, 1000 mL of the gas weighs
about 180 mg.
Heparin Sodium: White or pale-colored, amorphous powder. Is odor-
less or practically so, and is hygroscopic. Soluble in water.
Hexachlorophene: White to light tan, crystalline powder. Is odorless
or has only a slight, phenolic odor. Insoluble in water; freely soluble in
acetone, in alcohol, and in ether; soluble in chloroform and in dilute
solutions of fixed alkali hydroxides.
Hexachlorophene Liquid Soap: Clear, amber-colored liquid, having
a slight, characteristic odor. Its solution (1 in 20) is clear and has an
alkaline reaction.
USP Pharmacists Pharmacopeia
Hexylene Glycol: Clear, colorless, viscous liquid. Absorbs moisture
when exposed to moist air. Miscible with water and with many organic
solvents, including alcohol, ether, chloroform, acetone, and hexanes.
NF category: Humectant; solvent.
Histamine Phosphate: Colorless, odorless, long prismatic crystals.
Is stable in air but is affected by light. Its solutions are acid to litmus.
Freely soluble in water.
Histidine: White, odorless crystals, having a slightly bitter taste. Solu-
ble in water; very slightly soluble in alcohol; insoluble in ether.
Histoplasmin: Clear, red liquid. Miscible with water.
Homatropine Hydrobromide: White crystals, or white, crystalline
powder. Slowly darkens on exposure to light. Freely soluble in water;
sparingly soluble in alcohol; slightly soluble in chloroform; insoluble in
ether. Melts between 214 and 217, with slight decomposition.
Homatropine Methylbromide: White, odorless powder. Slowly dark-
ens on exposure to light. Melts at about 190. Very soluble in water;
freely soluble in alcohol and in acetone containing about 20% of water;
practically insoluble in ether and in acetone.
Hydralazine Hydrochloride: White to off-white, odorless, crystalline
powder. Melts at about 275, with decomposition. Soluble in water;
slightly soluble in alcohol; very slightly soluble in ether.
Hydrochloric Acid: Colorless, fuming liquid having a pungent odor.
It ceases to fume when it is diluted with 2 volumes of water. Specific
gravity is about 1.18. NF category: Acidifying agent.
Diluted Hydrochloric Acid: Colorless, odorless liquid. Specific gravity
is about 1.05. NF category: Acidifying agent.
Hydrochlorothiazide: White, or practically white, practically odorless,
0
crystalline powder. Slightly soluble in water; freely soluble in sodium
0
hydroxide solution, in n-butylamine, and in dimethylformamide; spar-
ingly soluble in methanol; insoluble in ether, in chloroform, and in
2
dilute mineral acids.
Hydrocodone Bitartrate: Fine, white crystals or a crystalline powder. Is
affected by light. Soluble in water; slightly soluble in alcohol; insoluble
in ether and in chloroform.
Hydrocortisone: White to practically white, odorless, crystalline pow-
der. Melts at about 215, with decomposition. Very slightly soluble in
water and in ether; sparingly soluble in acetone and in alcohol; slightly
soluble in chloroform.
Hydrocortisone Acetate: White to practically white, odorless, crystal-
line powder. Melts at about 200, with decomposition. Insoluble in
water; slightly soluble in alcohol and in chloroform.
Hydrocortisone Butyrate: White to practically white, practically odor-
less, crystalline powder. Practically insoluble in water; slightly soluble
in ether; soluble in methanol, in alcohol, and in acetone; freely soluble
in chloroform.
Hydrocortisone Sodium Phosphate: White to light yellow, odorless or
practically odorless, powder. Is exceedingly hygroscopic. Freely soluble
in water; slightly soluble in alcohol; practically insoluble in chloroform,
in dioxane, and in ether.
Hydrocortisone Sodium Succinate: White or nearly white, odorless,
hygroscopic, amorphous solid. Very soluble in water and in alcohol;
very slightly soluble in acetone; insoluble in chloroform.
Hydroflumethiazide: White to cream-colored, finely divided, odor-
less, crystalline powder. Very slightly soluble in water; freely soluble in
acetone; soluble in alcohol.
Hydrogen Peroxide Concentrate: Clear, colorless liquid. Is acid to
litmus. Slowly decomposes, and is affected by light.
Hydrogen Peroxide Solution: Clear, colorless liquid, odorless, or
having an odor resembling that of ozone. Is acid to litmus and to the
taste and produces a froth in the mouth. Rapidly decomposes when in
contact with many oxidizing as well as reducing substances. When rap-
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/100
Description and Solubility
idly heated, it may decompose suddenly. Is affected by light. Specific
gravity is about 1.01.
Hydromorphone Hydrochloride: Fine, white or practically white,
odorless, crystalline powder. Is affected by light. Freely soluble in wa-
ter; sparingly soluble in alcohol; practically insoluble in ether.
Hydroquinone: Fine white needles. Darkens upon exposure to light
and air. Freely soluble in water, in alcohol, and in ether.
Hydroxocobalamin: Dark red crystals or red crystalline powder. Is
odorless, or has not more than a slight acetone odor. The anhydrous
form is very hygroscopic. Sparingly soluble in water, in alcohol, and in
methanol; practically insoluble in acetone, in ether, in chloroform, and
in benzene.
Hydroxyamphetamine Hydrobromide: White, crystalline powder.
Its solutions are slightly acid to litmus, having a pH of about 5. Freely
soluble in water and in alcohol; slightly soluble in chloroform; practi-
cally insoluble in ether.
Hydroxychloroquine Sulfate: White or practically white, crystalline
powder. Is odorless, and has a bitter taste. Its solutions have a pH of
about 4.5. Exists in two forms, the usual form melting at about 240 and
P
the other form melting at about 198. Freely soluble in water; practi-
cally insoluble in alcohol, in chloroform, and in ether.
S
Hydroxyethyl Cellulose: White to light tan, practically odorless and
tasteless, hygroscopic powder. Soluble in hot water and in cold water,
U
giving a colloidal solution; practically insoluble in alcohol and in most
organic solvents. NF category: Suspending and/or viscosity-increasing
agent.
9
Hydroxyprogesterone Caproate: White or creamy white, crystalline
powder. Is odorless or has a slight odor. Insoluble in water; soluble in
ether; slightly soluble in benzene.
Hydroxypropyl Betadex: White or almost white, amorphous or crys-
talline powder. Freely soluble in water and in propylene glycol. NF
category: Sequestering agent.
Hydroxypropyl Cellulose: White to cream-colored, practically odor-
less and tasteless, granular solid or powder. Is hygroscopic after dry-
ing. Soluble in cold water, in alcohol, in chloroform, and in propylene
glycol, giving a colloidal solution; insoluble in hot water. NF category:
Coating agent; suspending and/or viscosity-increasing agent.
Low-Substituted Hydroxypropyl Cellulose: White to yellowish-white,
practically odorless and tasteless, fibrous or granular powder. Is hygro
scopic. Practically insoluble in alcohol and in ether. Dissolves in a
solution of sodium hydroxide (1 in 10), and produces a viscous solu-
tion. Swells in water, in sodium carbonate TS, and in 2 N hydrochloric
acid. The pH of the suspension, obtained by shaking 1.0 g with 100
mL of water, is between 5.0 and 7.5. NF category: Tablet binder; tablet
disintegrant.
Hydroxyurea: White to off-white powder. Is somewhat hygroscopic,
decomposing in the presence of moisture. Melts at a temperature
exceeding 133, with decomposition. Freely soluble in water and in hot
alcohol.
Hydroxyzine Hydrochloride: White, odorless powder. Melts at about
200, with decomposition. Very soluble in water; soluble in chloroform;
slightly soluble in acetone; practically insoluble in ether.
Hydroxyzine Pamoate: Light yellow, practically odorless powder.
Practically insoluble in water and in methanol; freely soluble in
dimethylformamide.
Hymetellose: A white, yellowish-white or grayish-white powder or
granules. Hygroscopic after drying. Dissolves in cold water, giving a
colloidal solution; insoluble in hot water, in acetone, in alcohol, in
ether, and in toluene.
Hyoscyamine: White, crystalline powder. Is affected by light. Its solu-
tions are alkaline to litmus. Slightly soluble in water and in benzene;
freely soluble in alcohol, in chloroform, and in dilute acids; sparingly
soluble in ether.
USP Pharmacists Pharmacopeia
Hyoscyamine Hydrobromide: White, odorless crystals or crystalline
powder. The pH of a solution (1 in 20) is about 5.4. Is affected by light.
Freely soluble in water, in alcohol, and in chloroform; very slightly
soluble in ether.
Hyoscyamine Sulfate: White or almost white, crystalline powder or
colorless needles. Is deliquescent and is affected by light. The pH of a
solution (1 in 100) is about 5.3. Very soluble in water; freely soluble in
alcohol; practically insoluble in ether. Melts at a temperature not less
than 200.
Hypophosphorous Acid: Colorless or slightly yellow, odorless liquid.
Specific gravity is about 1.13. NF category: Antioxidant.
Hypromellose: White to slightly off-white, fibrous or granular powder.
Swells in water and produces a clear to opalescent, viscous, colloidal
mixture. Insoluble in dehydrated alcohol, in ether, and in chloroform.
NF category: Coating agent; suspending and/or viscosity-increasing
agent; tablet binder.
Hypromellose 2208: White to slightly off-white, fibrous or granular
powder. Swells in water and produces a clear to opalescent, viscous,
colloidal mixture. Insoluble in dehydrated alcohol, in ether, and in
chloroform. NF category: Coating agent; suspending and/or viscosity-
increasing agent; tablet binder.
Hypromellose 2906: White to slightly off-white, fibrous or granular
powder. Swells in water and produces a clear to opalescent, viscous,
colloidal mixture. Insoluble in dehydrated alcohol, in ether, and in
chloroform. NF category: Coating agent; suspending and/or viscosity-
increasing agent; tablet binder.
Hypromellose 2910: White to slightly off-white, fibrous or granular
0
powder. Swells in water and produces a clear to opalescent, viscous,
colloidal mixture. Insoluble in dehydrated alcohol, in ether, and in
0
chloroform. NF category: Coating agent; suspending and/or viscosity-
increasing agent; tablet binder.
2
Hypromellose Acetate Succinate: White to yellowish-white powder
or pills. Odorless, or has a faint, acetic acid-like odor, and tasteless.
Practically insoluble in water, in dehydrated alcohol, in xylene, and
in hexane. On the addition of a mixture of dehydrated alcohol and
dichloromethane (1:1) or acetone, a clear or turbid viscous liquid is
produced. Dissolves in 1 N sodium hydroxide. Slightly hygroscopic. NF
category: Coating agent; tablet binder.
Hypromellose Phthalate: White powder or granules. Is odorless and
tasteless. Practically insoluble in water, in dehydrated alcohol, and
in hexane. Produces a viscous solution in a mixture of methanol and
dichloromethane (1:1), or in a mixture of dehydrated alcohol and ac-
etone (1:1). Dissolves in 1 N sodium hydroxide. NF category: Coating
agent.
Ibuprofen: White to off-white, crystalline powder, having a slight,
characteristic odor. Practically insoluble in water; very soluble in al-
cohol, in methanol, in acetone, and in chloroform; slightly soluble in
ethyl acetate.
Ichthammol: Reddish-brown to brownish-black, viscous fluid, having
a strong, characteristic, empyreumatic odor. Miscible with water, with
glycerin, and with fixed oils and fats. Partially soluble in alcohol and in
ether.
Idarubicin Hydrochloride: Red-orange to red-brown powder. Soluble
in methanol; slightly soluble in water; insoluble in acetone and in ethyl
ether.
Idoxuridine: White, crystalline, practically odorless powder. Slightly
soluble in water and in alcohol; practically insoluble in chloroform and
in ether.
Ifosfamide: White, crystalline powder. Melts at about 40. Freely
soluble in water; very soluble in alcohol, in ethyl acetate, in isopropyl
alcohol, in methanol, and in methylene chloride; very slightly soluble
in hexanes.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/101
Description and Solubility
Imidurea: White, odorless, tasteless powder. Soluble in water and
in glycerin; sparingly soluble in propylene glycol; insoluble in most
organic solvents.
Imipenem: White to tan-colored crystalline powder. Sparingly soluble
in water; slightly soluble in methanol.
Imipramine Hydrochloride: White to off-white, odorless or practically
odorless, crystalline powder. Freely soluble in water and in alcohol;
soluble in acetone; insoluble in ether and in benzene.
Inamrinone: Pale yellow to tan powder. It is odorless or has a faint
odor. Slightly soluble in methanol; practically insoluble or insoluble in
chloroform and in water.
Indapamide: White to off-white, crystalline powder. Melts between
167 and 170. Soluble in methanol, in alcohol, in acetonitrile, in glacial
acetic acid, and in ethyl acetate; very slightly soluble in ether and in
chloroform; practically insoluble in water.
Indigotindisulfonate Sodium: Dusky, purplish-blue powder, or blue
granules having a coppery luster. Is affected by light. Its solutions have
a blue or bluish purple color. Slightly soluble in water and in alcohol;
practically insoluble in most other organic solvents.
P
Indocyanine Green: Olive-brown, dark green, blue-green, dark blue,
S
or black powder. Is odorless or has a slight odor. Its solutions are deep
emerald-green in color. The pH of a solution (1 in 200) is about 6. Its
aqueous solutions are stable for about 8 hours. Soluble in water and in
U
methanol; practically insoluble in most other organic solvents.
Indomethacin: Pale yellow to yellow-tan, crystalline powder, having
9
not more than a slight odor. Is sensitive to light. Melts at about 162.
Exhibits polymorphism. Practically insoluble in water; sparingly soluble
in alcohol, in chloroform, and in ether.
Influenza Virus Vaccine: Slightly turbid liquid or suspension, which
may have a slight yellow or reddish tinge and may have an odor be-
cause of the preservative.
Inositol: White or almost white, crystalline powder. Very soluble in
water; practically insoluble in alcohol absolute and in ether.
Insulin: White or practically white crystals. Soluble in solutions of
dilute acids and alkalies.
Insulin Injection: The Injection containing, in each mL, not more than
100 USP Units is a clear, colorless or almost colorless liquid; the Injec-
tion containing, in each mL, 500 Units may be straw-colored. Contains
between 0.1% and 0.25% (w/v) of either phenol or cresol. Contains
between 1.4% and 1.8% (w/v) of glycerin.
Insulin Lispro: White or practically white crystals. Soluble in solutions
of dilute acids and alkalies.
Insulin Zinc Suspension: Practically colorless suspension of a mixture
of characteristic crystals predominantly between 10 and 40 m in maxi-
mum dimension and many particles that have no uniform shape and do
not exceed 2 m in maximum dimension. Contains between 0.15% and
0.17% (w/v) of sodium acetate, between 0.65% and 0.75% (w/v) of so-
dium chloride, and between 0.09% and 0.11% (w/v) of methylparaben.
Isophane Insulin Suspension: White suspension of rod-shaped
crystals, free from large aggregates of crystals following moderate
agitation. Contains either (1) between 1.4% and 1.8% (w/v) of glycerin,
between 0.15% and 0.17% (w/v) of metacresol, and between 0.06%
and 0.07% (w/v) of phenol, or (2) between 1.4% and 1.8% (w/v) of glyc-
erin and between 0.20% and 0.25% (w/v) of phenol. Contains between
0.15% and 0.25% (w/v) of dibasic sodium phosphate. When examined
microscopically, the insoluble matter in the Suspension is crystalline,
and contains not more than traces of amorphous material.
Extended Insulin Zinc Suspension: Practically colorless suspension of
a mixture of characteristic crystals the maximum dimension of which
is predominantly between 10 and 40 m. Contains between 0.15% and
0.17% (w/v) of sodium acetate, between 0.65% and 0.75% (w/v) of so-
dium chloride, and between 0.09% and 0.11% (w/v) of methylparaben.
USP Pharmacists Pharmacopeia
Prompt Insulin Zinc Suspension: Practically colorless suspension of
particles that have no uniform shape and the maximum dimension of
which does not exceed 2 m. Contains between 0.15% and 0.17% (w/v)
of sodium acetate, between 0.65% and 0.75% (w/v) of sodium chloride,
and between 0.09% and 0.11% (w/v) of methylparaben.
Inulin: White, friable, chalk-like, amorphous, odorless, tasteless pow-
der. Soluble in hot water; slightly soluble in cold water and in organic
solvents.
Iodine: Heavy, grayish-black plates or granules, having a metallic
luster and a characteristic odor. Very slightly soluble in water; freely
soluble in carbon disulfide, in chloroform, in carbon tetrachloride,
and in ether; soluble in alcohol and in solutions of iodides; sparingly
soluble in glycerin.
Iodine Topical Solution: Transparent, reddish-brown liquid, having
the odor of iodine.
Strong Iodine Solution: Transparent liquid having a deep brown color
and having the odor of iodine.
Iodine Tincture: Transparent liquid having a reddish-brown color and
the odor of iodine and of alcohol.
Sodium Iodide I 123 Capsules: Capsules may contain a small amount
of solid or solids, or may appear empty.
Sodium Iodide I 123 Solution: Clear, colorless solution. Upon stand-
ing, both the Solution and the glass container may darken as a result of
the effects of the radiation.
Iodinated I 125 Albumin Injection: Clear, colorless to slightly yellow
solution. Upon standing, both the Albumin and the glass container
may darken as a result of the effects of the radiation.
0
Iodinated I 131 Albumin Injection: Clear, colorless to slightly yellow
0
solution. Upon standing, both the Albumin and the glass container
may darken as a result of the effects of the radiation.
2
Iodinated I 131 Albumin Aggregated Injection: Dilute suspension of
white to faintly yellow particles, which may settle on standing. The
glass container may darken on standing, as a result of the effects of
the radiation.
Sodium Rose Bengal I 131 Injection: Clear, deep-red solution.
Iodohippurate Sodium I 131 Injection: Clear, colorless solution. Upon
standing, both the Injection and the glass container may darken as a
result of the effects of the radiation.
Sodium Iodide I 131 Capsules: May contain a small amount of solid or
solids, or may appear empty.
Sodium Iodide I 131 Solution: Clear, colorless solution. Upon stand-
ing, both the Solution and the glass container may darken as a result of
the effects of the radiation.
Iodipamide: White, practically odorless, crystalline powder. Very
slightly soluble in water, in chloroform, and in ether; slightly soluble
in alcohol.
Iodipamide Meglumine Injection: Clear, colorless to pale yellow,
slightly viscous liquid.
Iodixanol: White to off-white, amorphous, odorless, hygroscopic
powder. Freely soluble in water.
Iodoform: Lustrous greenish yellow powder, or lustrous crystals. It is
slightly volatile even at ordinary temperatures, and distills slowly with
steam. Freely soluble in ether and in chloroform; soluble in boiling
alcohol; sparingly soluble in alcohol, in glycerin, and in olive oil; prac-
tically insoluble in water. Melts to a brown liquid at about 115, and
decomposes at a higher temperature, emitting vapors of iodine.
Iodoquinol: Light yellowish to tan, microcrystalline powder not read-
ily wetted by water. Is odorless or has a faint odor; is stable in air. Melts
with decomposition. Practically insoluble in water; sparingly soluble in
alcohol and in ether.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/102
Description and Solubility
Iohexol: White to off-white, hygroscopic, odorless powder. Very
soluble in water and in methanol; practically insoluble or insoluble in
ether and in chloroform.
Iohexol Injection: Clear, colorless to pale yellow liquid.
Iopamidol: Practically odorless, white to off-white powder. Very
soluble in water; sparingly soluble in methanol; practically insoluble in
alcohol and in chloroform.
Iopanoic Acid: Cream-colored powder. Is tasteless or practically so,
and has a faint, characteristic odor. Is affected by light. Insoluble in wa-
ter; soluble in alcohol, in chloroform, and in ether; soluble in solutions
of alkali hydroxides and carbonates.
Iophendylate: Colorless to pale yellow, viscous liquid, the color dark-
ening on long exposure to air. Is odorless or has a faintly ethereal odor.
Very slightly soluble in water; freely soluble in alcohol, in benzene, in
chloroform, and in ether.
Iophendylate Injection: Colorless to pale yellow, viscous liquid, the
color darkening on long exposure to air. Is odorless or has a faintly
ethereal odor. Very slightly soluble in water; freely soluble in alcohol,
in benzene, in chloroform, and in ether.
P
Iopromide: White to slightly yellow powder. Freely soluble in water
S
and in dimethyl sulfoxide; practically insoluble in alcohol, in acetone,
and in ether.
Iothalamate Meglumine Injection: Clear, colorless to pale yellow,
U
slightly viscous liquid.
Iothalamate Meglumine and Iothalamate Sodium Injection: Clear,
9
colorless to pale yellow, slightly viscous liquid.
Iothalamate Sodium Injection: Clear, colorless to pale yellow, slightly
viscous liquid.
Iothalamic Acid: White, odorless powder. Slightly soluble in water and
in alcohol; soluble in solutions of alkali hydroxides.
Ioxilan: White to off-white, practically odorless powder. Soluble in
water and in methanol.
Ioxilan Injection: Clear, colorless to pale yellow liquid.
Powdered Ipecac: Pale brown, weak yellow, or light olive-gray powder.
Ipodate Sodium: White to off-white, odorless, fine, crystalline pow-
der. Freely soluble in water, in alcohol, and in methanol; very slightly
soluble in chloroform.
Ipratropium Bromide: White to off-white, crystalline powder. Soluble
in water; freely soluble in methanol; slightly soluble in alcohol.
Irbesartan: White to off-white, crystalline powder. Slightly soluble in
alcohol and in methylene chloride; practically insoluble in water.
Iron Dextran Injection: Dark brown, slightly viscous liquid.
Iron Sorbitex Injection: Clear liquid, having a dark brown color.
Isobutane: Colorless, flammable gas (boiling temperature is about
11). Vapor pressure at 21 is about 2950 mm of mercury (31 psig). NF
category: Aerosol propellant.
Isoetharine Inhalation Solution: Colorless or slightly yellow, slightly
acid liquid, gradually turning dark on exposure to air and light.
Isoetharine Hydrochloride: White to off-white, odorless, crystalline
solid. Melts between 196 and 208, with decomposition. Soluble in
water; sparingly soluble in alcohol; practically insoluble in ether.
Isoetharine Mesylate: White or practically white, odorless crystals
having a salty, bitter taste. Freely soluble in water; soluble in alcohol;
practically insoluble in acetone and in ether.
Isoflurane: Clear, colorless, volatile liquid, having a slight odor. Boils at
about 49. Insoluble in water. Miscible with common organic solvents
and with fats and oils.
Isoflurophate: Clear, colorless or faintly yellow liquid. Its vapor is ex-
tremely irritating to the eye and mucous membranes. Is decomposed
by moisture, with the formation of hydrogen fluoride. Specific gravity
USP Pharmacists Pharmacopeia
is about 1.05. Sparingly soluble in water; soluble in alcohol and in veg-
etable oils.
Isoleucine: White, practically odorless crystals, having a slightly bit-
ter taste. Soluble in water; slightly soluble in hot alcohol; insoluble in
ether.
Isometheptene Mucate: White, crystalline powder. Freely soluble in
water; soluble in alcohol; practically insoluble in chloroform and in
ether.
Isoniazid: Colorless or white crystals or white, crystalline powder.
Is odorless and is slowly affected by exposure to air and light. Freely
soluble in water; sparingly soluble in alcohol; slightly soluble in chloro-
form; and very slightly soluble in ether.
Isoniazid Injection: Clear, colorless to faintly greenish-yellow liquid.
Gradually darkens on exposure to air and light. Tends to crystallize at
low temperatures.
Isopropamide Iodide: White to pale yellow, crystalline powder, having
a bitter taste. Sparingly soluble in water; freely soluble in chloroform
and in alcohol; very slightly soluble in benzene and in ether.
Isopropyl Alcohol: Transparent, colorless, mobile, volatile liquid,
having a characteristic odor and a slightly bitter taste. Is flammable.
Miscible with water, with alcohol, with ether, and with chloroform. NF
category: Solvent.
Azeotropic Isopropyl Alcohol: Transparent, colorless, mobile, vola-
tile liquid, having a characteristic odor and a slightly bitter taste. Is
flammable. Miscible with water, with alcohol, with ether, and with
chloroform.
Isopropyl Myristate: Clear, practically colorless, oily liquid. Is practically
0
odorless, and congeals at about 5. Insoluble in water, in glycerin, and
in propylene glycol; freely soluble in 90% alcohol. Miscible with most
0
organic solvents and with fixed oils. NF category: Vehicle (oleaginous).
2
Isopropyl Palmitate: Colorless, mobile liquid having a very slight odor.
Soluble in acetone, in castor oil, in chloroform, in cottonseed oil, in
ethyl acetate, in alcohol, and in mineral oil; insoluble in water, in glyc-
erin, and in propylene glycol. NF category: Vehicle (oleaginous).
Isoproterenol Inhalation Solution: Colorless or practically colorless,
slightly acid liquid, gradually turning dark on exposure to air and light.
Isoproterenol Hydrochloride: White to practically white, odorless,
crystalline powder, having a slightly bitter taste. Gradually darkens on
exposure to air and light. Its solutions become pink to brownish pink
on standing exposed to air, doing so almost immediately when ren-
dered alkaline. Its solution (1 in 100) has a pH of about 5. Freely soluble
in water; sparingly soluble in alcohol and less soluble in dehydrated
alcohol; insoluble in chloroform and in ether.
Isoproterenol Hydrochloride Injection: Colorless or practically color-
less liquid, gradually turning dark on exposure to air and light.
Isoproterenol Sulfate: White to practically white, odorless, crystalline
powder. It gradually darkens on exposure to air and light. Its solutions
become pink to brownish pink on standing exposed to air, doing so
almost immediately when rendered alkaline. A solution (1 in 100) has a
pH of about 5. Freely soluble in water; very slightly soluble in alcohol,
in benzene, and in ether.
Isosorbide Concentrate: Colorless to slightly yellow liquid. Soluble in
water and in alcohol.
Diluted Isosorbide Dinitrate: Ivory-white, odorless powder. [note
Undiluted isosorbide dinitrate occurs as white, crystalline rosettes.]
Undiluted isosorbide dinitrate is very slightly soluble in water; very
soluble in acetone; freely soluble in chloroform; sparingly soluble in
alcohol.
Isotretinoin: Yellow crystals. Practically insoluble in water; soluble in
chloroform; sparingly soluble in alcohol, in isopropyl alcohol, and in
polyethylene glycol 400.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/103
Description and Solubility
Isoxsuprine Hydrochloride: White, odorless, crystalline powder, hav-
ing a bitter taste. Melts at about 200, with decomposition. Slightly
soluble in water; sparingly soluble in alcohol.
Isradipine: Yellow, fine crystalline powder.
Ivermectin: White to yellowish-white, crystalline powder. Slightly
hygroscopic. Freely soluble in methanol and in methylene chloride;
soluble in acetone and in acetonitrile; practically insoluble in hexane
and in water.
Juniper Tar: Dark brown, clear, thick liquid, having a tarry odor and
a faintly aromatic, bitter taste. Very slightly soluble in water; partially
soluble in solvent hexane. One volume dissolves in 9 volumes of al-
cohol. Dissolves in 3 volumes of ether, leaving only a slight, flocculent
residue. Miscible with amyl alcohol, with chloroform, and with glacial
acetic acid.
Kanamycin Sulfate: White, odorless, crystalline powder. Freely soluble
in water; insoluble in acetone, in ethyl acetate, and in benzene.
Kaolin: Soft, white or yellowish-white powder or lumps. Has an earthy
or clay-like taste and, when moistened with water, assumes a darker
color and develops a marked clay-like odor. Insoluble in water, in cold
P
dilute acids, and in solutions of alkali hydroxides. NF category: Tablet
and/or capsule diluent.
S
Ketamine Hydrochloride: White, crystalline powder, having a slight,
characteristic odor. Freely soluble in water and in methanol; soluble in
U
alcohol; sparingly soluble in chloroform.
Ketorolac Tromethamine: White to off-white, crystalline powder.
9
Melts between 165 and 170, with decomposition. Freely soluble in
water and in methanol; slightly soluble in alcohol, in dehydrated alco-
hol, and in tetrahydrofuran; practically insoluble in acetone, in dichlo-
romethane, in toluene, in ethyl acetate, in dioxane, in hexane, in butyl
alcohol, and in acetonitrile.
Labetalol Hydrochloride: White to off-white powder. Melts at about
180, with decomposition. Soluble in water and in alcohol; insoluble in
ether and in chloroform.
Lactic Acid: Colorless or yellowish, practically odorless, syrupy liquid.
Is hygroscopic. When it is concentrated by boiling, lactic acid lactate is
formed. Specific gravity is about 1.20. Miscible with water, with alcohol,
and with ether. Insoluble in chloroform. NF category: Buffering agent.
Lactitol: A white or light brown, odorless crystal. Has a mild, sweet
taste, and no aftertaste. NF category: Flavors and perfumes; tablet and/
or capsule diluent.
Anhydrous Lactose: White or almost white powder. Freely soluble
in water; practically insoluble in alcohol. NF category: Tablet and/or
capsule diluent.
Lactose Monohydrate: White, free-flowing powder. Freely but slowly
soluble in water; practically insoluble in alcohol. NF category: Tablet
and/or capsule diluent.
Lactulose Concentrate: Colorless to amber syrupy liquid, which may
exhibit some precipitation and darkening upon standing. Miscible with
water.
Lamivudine: White to off-white solid. Soluble in water. Melts at about
176.
Lanolin: Yellow, tenacious, unctuous mass, having a slight, charac-
teristic odor. Insoluble in water, but mixes without separation with
about twice its weight of water. Sparingly soluble in cold alcohol; more
soluble in hot alcohol; freely soluble in ether and in chloroform. NF
category: Ointment base.
Lanolin Alcohols: Hard, waxy, amber solid, having a characteristic
odor. Insoluble in water; slightly soluble in alcohol; freely soluble in
chloroform, in ether, and in petroleum ether. NF category: Emulsifying
and/or solubilizing agent.
USP Pharmacists Pharmacopeia
Lansoprazole: White to brownish-white powder. Freely soluble in
dimethylformamide; practically insoluble in water. Melts at about 166,
with decomposition.
Lauroyl Polyoxylglycerides: Pale yellow, waxy liquids. Freely soluble in
methylene chloride; dispersible in hot water. NF category: Ointment
base; solvent.
Lecithin: The consistency of both natural grades and refined grades of
lecithin may vary from plastic to fluid, depending upon free fatty acid
and oil content, and upon the presence or absence of other diluents.
Its color varies from light yellow to brown, depending on the source,
on crop variations, and on whether it is bleached or unbleached. It is
odorless or has a characteristic, slight nut-like odor and a bland taste.
Practically insoluble in water, but it readily hydrates to form emulsions.
The oil-free phosphatides are soluble in fatty acids, but are practically
insoluble in fixed oils. When all phosphatide fractions are present, lec-
ithin is partially soluble in alcohol and practically insoluble in acetone.
NF category: Emulsifying and/or solubilizing agent.
Leflunomide: White to almost white powder. Freely soluble in metha-
nol, in alcohol, in 2-propanol, in ethyl acetate, in acetone, in acetoni-
trile, and in chloroform; practically insoluble in water.
Letrozole: White to yellowish, crystalline powder. Freely soluble in
dichloromethane; slightly soluble in alcohol; practically insoluble in
water.
Leucine: White, practically odorless, tasteless crystals. Sparingly
soluble in water; insoluble in ether.
Leucovorin Calcium: Yellowish-white or yellow, odorless powder. Very
soluble in water; practically insoluble in alcohol.
0
Leucovorin Calcium Injection: Clear, yellowish solution.
Levamisole Hydrochloride: White or almost white, crystalline powder.
0
Freely soluble in water; soluble in alcohol; slightly soluble in methy-
2
lene chloride; practically insoluble in ether.
Levmetamfetamine: Clear, practically colorless liquid.
Levobunolol Hydrochloride: White crystalline, odorless powder.
Soluble in water and in methanol; slightly soluble in alcohol and in
chloroform.
Levocarnitine: White crystals or crystalline powder. Hygroscopic.
Freely soluble in water, and in hot alcohol. Practically insoluble in ac-
etone, in ether, and in benzene.
Levodopa: White to off-white, odorless, crystalline powder. In the
presence of moisture, is rapidly oxidized by atmospheric oxygen and
darkens. Slightly soluble in water; freely soluble in 3 N hydrochloric
acid; insoluble in alcohol.
Levonordefrin: White to buff-colored, odorless, crystalline solid. Melts
at about 210. Practically insoluble in water; freely soluble in aqueous
solutions of mineral acids; slightly soluble in acetone, in chloroform, in
alcohol, and in ether.
Levonorgestrel: White or practically white, odorless powder. Practical-
ly insoluble in water; soluble in chloroform; slightly soluble in alcohol.
Levorphanol Tartrate: Practically white, odorless, crystalline powder.
Sparingly soluble in water; slightly soluble in alcohol; insoluble in
chloroform and in ether. Melts, in a sealed tube, at about 110, with
decomposition.
Levothyroxine Sodium: Light yellow to buff-colored, odorless, taste-
less, hygroscopic powder. Is stable in dry air but may assume a slight
pink color upon exposure to light. The pH of a saturated solution is
about 8.9. Very slightly soluble in water; soluble in solutions of alkali
hydroxides and in hot solutions of alkali carbonates; slightly soluble in
alcohol; insoluble in acetone, in chloroform, and in ether.
Lidocaine: White or slightly yellow, crystalline powder. Has a char-
acteristic odor and is stable in air. Practically insoluble in water; very
soluble in alcohol and in chloroform; freely soluble in benzene and in
ether. Dissolves in oils.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/104
Description and Solubility
Lidocaine Hydrochloride: White, odorless, crystalline powder, having
a slightly bitter taste. Very soluble in water and in alcohol; soluble in
chloroform; insoluble in ether.
Lime: Hard, white or grayish-white masses or granules, or white or
grayish white powder. Is odorless. Slightly soluble in water; very slightly
soluble in boiling water.
Lincomycin Hydrochloride: White or practically white, crystalline
powder. Is odorless or has a faint odor. Is stable in the presence of air
and light. Its solutions are acid and dextrorotatory. Freely soluble in
water; soluble in dimethylformamide; very slightly soluble in acetone.
Lincomycin Hydrochloride Injection: Clear, colorless to slightly yellow
solution, having a slight odor.
Lincomycin Hydrochloride Soluble Powder: White to off-white, or
light tan free-flowing, fine powder.
Lindane: White, crystalline powder, having a slight, musty odor.
Practically insoluble in water; freely soluble in chloroform; soluble
in dehydrated alcohol; sparingly soluble in ether; slightly soluble in
ethylene glycol.
Linoleoyl Polyoxylglycerides: Amber, oily liquids. May develop depos-
P
it after prolonged storage periods at 20. Freely soluble in methylene
S
chloride; practically insoluble but dispersible in water. NF category:
Ointment base; solvent.
Liothyronine Sodium: Light tan, odorless, crystalline powder. Very
U
slightly soluble in water; slightly soluble in alcohol; practically insolu-
ble in most other organic solvents.
9
Lisinopril: White, crystalline powder. Melts at about 160, with decom-
position. Soluble in water; sparingly soluble in methanol; practically
insoluble in alcohol, in acetone, in acetonitrile, and in chloroform.
Lithium Carbonate: White, granular, odorless powder. Sparingly
soluble in water; very slightly soluble in alcohol. Dissolves, with effer-
vescence, in dilute mineral acids.
Lithium Citrate: White, odorless, deliquescent powder or granules,
having a cooling, faintly alkaline taste. Freely soluble in water; slightly
soluble in alcohol.
Loperamide Hydrochloride: White to slightly yellow powder. Melts at
about 225, with some decomposition. Freely soluble in methanol and
in chloroform; slightly soluble in water and in dilute acids; very slightly
soluble in isopropyl alcohol.
Loratadine: White to off-white powder. Freely soluble in acetone, in
chloroform, in methanol, and in toluene; insoluble in water.
Lorazepam: White or practically white, practically odorless powder.
Insoluble in water; sparingly soluble in alcohol; slightly soluble in
chloroform.
Losartan Potassium: White to off-white powder. Freely soluble in wa-
ter; soluble in isopropyl alcohol; slightly soluble in acetonitrile.
Lovastatin: White to off-white, crystalline powder. Freely soluble in
chloroform; soluble in acetone, in acetonitrile, and in methanol; spar-
ingly soluble in alcohol; practically insoluble in hexane; insoluble in
water.
Loxapine Succinate: White to yellowish, crystalline powder. Is
odorless.
Lutein: Red, crystalline powder. Soluble in ethanol, in ethyl acetate,
and in methylene chloride; partially soluble in hexane.
Lysine Acetate: White, odorless crystals or crystalline powder, having
an acid taste. Freely soluble in water.
Lysine Hydrochloride: White, odorless powder. Freely soluble in
water.
Mafenide Acetate: White to pale yellow, crystalline powder. Freely
soluble in water.
Magaldrate: White, odorless, crystalline powder. Insoluble in water
and in alcohol; soluble in dilute solutions of mineral acids.
USP Pharmacists Pharmacopeia
Milk of Magnesia: White, opaque, more or less viscous suspension
from which varying proportions of water usually separate on standing.
pH is about 10.
Magnesium Aluminometasilicate: White powder or granules having
an amorphous structure. Partially soluble in acids and in alkalies; prac-
tically insoluble in water and in alcohol.
Magnesium Aluminosilicate: White powder or granules having an
amorphous structure. Partially soluble in acids and in alkalies; practi-
cally insoluble in water and in alcohol.
Magnesium Aluminum Silicate: Odorless, tasteless, fine (micronized)
powder, small cream to tan granules, or small flakes that are creamy
when viewed on their flat surfaces and tan to brown when viewed on
their edges. Insoluble in water and in alcohol. Swells when added to
water or glycerin. NF category: Suspending and/or viscosity-increasing
agent.
Magnesium Carbonate: Light, white, friable masses or bulky, white
powder. Is odorless, and is stable in air. Practically insoluble in water
to which, however, it imparts a slightly alkaline reaction; insoluble in
alcohol, but is dissolved by dilute acids with effervescence.
Magnesium Chloride: Colorless, odorless, deliquescent flakes or crys-
tals, which lose water when heated to 100 and lose hydrochloric acid
when heated to 110. Very soluble in water; freely soluble in alcohol.
Magnesium Citrate Oral Solution: Colorless to slightly yellow, clear,
effervescent liquid, having a sweet, acidulous taste and a lemon flavor.
Magnesium Gluconate: Colorless crystals or white powder or gran-
ules. Is odorless and tasteless. Freely soluble in water; very slightly
soluble in alcohol; insoluble in ether.
0
Magnesium Hydroxide: Bulky, white powder. Practically insoluble in
0
water and in alcohol; soluble in dilute acids.
Magnesium Oxide: Very bulky, white powder or relatively dense,
2
white powder or granulated powder. Soluble in dilute acids; practically
insoluble in water; insoluble in alcohol.
Magnesium Phosphate: White, odorless, tasteless powder. Almost
insoluble in water; readily soluble in diluted mineral acids.
Magnesium Salicylate: White, odorless, efflorescent, crystalline pow-
der. Freely soluble in methanol; soluble in alcohol and in water; slightly
soluble in ether.
Magnesium Silicate: Fine, white, odorless, tasteless powder, free from
grittiness. Insoluble in water and in alcohol. Is readily decomposed by
mineral acids. NF category: Glidant and/or anticaking agent.
Magnesium Stearate: Very fine, light, white powder, slippery to touch.
Insoluble in water, in alcohol, and in ether. NF category: Tablet and/or
capsule lubricant.
Magnesium Sulfate: Small, colorless crystals, usually needle-like,
with a cooling, saline, bitter taste. It effloresces in warm, dry air. Freely
soluble in water; freely (and slowly) soluble in glycerin; very soluble in
boiling water; sparingly soluble in alcohol.
Magnesium Trisilicate: Fine, white, odorless, tasteless powder, free
from grittiness. Insoluble in water and in alcohol. Is readily decom-
posed by mineral acids.
Malathion: Clear, colorless, or slightly yellowish liquid, having a char-
acteristic odor. Congeals at about 2.9. Slightly soluble in water. Misci-
ble with alcohols, with esters, with ketones, with ethers, with aromatic
and alkylated aromatic hydrocarbons, and with vegetable oils.
Maleic Acid: White, crystalline powder. Freely soluble in water and in
alcohol; sparingly soluble in ether.
Malic Acid: White or practically white, crystalline powder or granules,
having a strongly acid taste. Melts at about 130. Very soluble in water;
freely soluble in alcohol. NF category: Acidifying agent.
Maltitol: White, crystalline powder. Very soluble in water; practically
insoluble in ethanol. NF category: Humectant; sweetening agent; tablet
and/or capsule diluent.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/105
Description and Solubility
Maltodextrin: White, hygroscopic powder or granules. Freely soluble
or readily dispersible in water; slightly soluble to insoluble in anhy-
drous alcohol. NF category: Coating agent; suspending and/or viscos-
ity-increasing agent; tablet binder; tablet and/or capsule diluent.
Maltol: A white, crystalline powder having a characteristic caramel-
butterscotch odor, suggestive of a fruity-strawberry aroma in dilute
solution. One g dissolves in about 82 mL of water, in 21 mL of alcohol,
in 80 mL of glycerin, and in 28 mL of propylene glycol. NF category:
Flavors and perfumes.
Maltose: Maltose occurs in either the anhydrous state or as a mono-
hydrate. It is a white, crystalline powder, odorless, and has a sweet
taste. Freely soluble in water; slightly soluble in methanol; very soluble
in ethanol; and practically insoluble in ether.
Mangafodipir Trisodium: Pale yellow crystals or cystalline powder.
Freely soluble in water; sparingly soluble in methanol; slightly soluble
in chloroform; very slightly soluble in alcohol and in acetone.
Manganese Chloride: Large, irregular, pink, odorless, translucent
crystals. Soluble in water and in alcohol; insoluble in ether.
Manganese Chloride for Oral Solution: Off-white to tan-colored pow-
P
der with a strawberry odor. Soluble in water.
Manganese Sulfate: Pale red, slightly efflorescent crystals, or purple,
S
odorless powder. Soluble in water; insoluble in alcohol.
Mannitol: White, crystalline powder or free-flowing granules. Is odor-
U
less and has a sweet taste. Freely soluble in water; soluble in alkaline
solutions; slightly soluble in pyridine; very slightly soluble in alcohol;
9
practically insoluble in ether. NF category: Sweetening agent; tablet
and/or capsule diluent; tonicity agent; bulking agent for freeze-drying.
Maprotiline Hydrochloride: Fine, white to off-white, crystalline pow-
der. Is practically odorless. Freely soluble in methanol and in chloro-
form; slightly soluble in water; practically insoluble in isooctane.
Mazindol: White to off-white, crystalline powder, having not more
than a faint odor. Insoluble in water; slightly soluble in methanol and
in chloroform.
Measles Virus Vaccine Live: Solid having the characteristic appearance
of substances dried from the frozen state. Undergoes loss of potency
on exposure to sunlight. The Vaccine is to be constituted with a suit-
able diluent just prior to use.
Measles, Mumps, and Rubella Virus Vaccine Live: Solid having the
characteristic appearance of substances dried from the frozen state.
The Vaccine is to be constituted with a suitable diluent just prior to
use. Constituted vaccine undergoes loss of potency on exposure to
sunlight.
Measles and Rubella Virus Vaccine Live: Solid having the characteristic
appearance of substances dried from the frozen state. The Vaccine is
to be constituted with a suitable diluent just prior to use. Constituted
vaccine undergoes loss of potency on exposure to sunlight.
Mebendazole: White to slightly yellow powder. Is almost odorless.
Melts at about 290. Practically insoluble in water, in dilute solutions of
mineral acids, in alcohol, in ether, and in chloroform; freely soluble in
formic acid.
Mechlorethamine Hydrochloride: White, crystalline powder. Is
hygroscopic.
Meclizine Hydrochloride: White or slightly yellowish, crystalline pow-
der. Has a slight odor and is tasteless. Practically insoluble in water and
in ether; freely soluble in chloroform, in pyridine, and in acid-alcohol-
water mixtures; slightly soluble in dilute acids and in alcohol.
Meclofenamate Sodium: A white to creamy white, odorless to almost
odorless, crystalline powder. Soluble in methanol; slightly soluble in
chloroform; practically insoluble in ether. Freely soluble in water, the
solution sometimes being somewhat turbid due to partial hydrolysis
and absorption of carbon dioxide; the solution is clear above pH 11.5.
USP Pharmacists Pharmacopeia
Medroxyprogesterone Acetate: White to off-white, odorless, crystal-
line powder. Melts at about 205. Is stable in air. Insoluble in water;
freely soluble in chloroform; soluble in acetone and in dioxane; spar-
ingly soluble in alcohol and in methanol; slightly soluble in ether.
Mefenamic Acid: White to off-white, crystalline powder. Melts at
about 230, with decomposition. Soluble in solutions of alkali hydrox-
ides; sparingly soluble in chloroform; slightly soluble in alcohol and in
methanol; practically insoluble in water.
Mefloquine Hydrochloride: White or slightly yellow, crystalline pow-
der. It exhibits polymorphism. Freely soluble in methanol; soluble in
alcohol; very slightly soluble in water.
Megestrol Acetate: White to creamy white, tasteless and essentially
odorless, crystalline powder. Insoluble in water; sparingly soluble in
alcohol; slightly soluble in ether and in fixed oils; soluble in acetone;
very soluble in chloroform. Is unstable under aqueous conditions at
pH 7 or above.
Meglumine: White to faintly yellowish-white, odorless crystals or
powder. Freely soluble in water; sparingly soluble in alcohol.
Melengestrol Acetate: White to light yellow, crystalline powder. Freely
soluble in chloroform and in ethyl acetate; slightly soluble in alcohol;
insoluble in water.
Meloxicam: Pale yellow powder. Soluble in dimethylformamide;
slightly soluble in acetone; very slightly soluble in methanol and in
alcohol; practically insoluble in water.
Melphalan: Off-white to buff powder, having a faint odor. Melts at
about 180, with decomposition. Practically insoluble in water, in chlo-
roform, and in ether; soluble in dilute mineral acids; slightly soluble in
0
alcohol and in methanol.
Menadiol Sodium Diphosphate: White to pink powder, having a char-
0
acteristic odor. Is hygroscopic. Its solutions are neutral or slightly alka-
2
line to litmus, having a pH of about 8. Very soluble in water; insoluble
in alcohol.
Menadione: Bright yellow, crystalline, practically odorless powder. Is
affected by sunlight. Practically insoluble in water; soluble in vegetable
oils; sparingly soluble in chloroform and in alcohol.
Menthol: Colorless, hexagonal crystals, usually needle-like, or in
fused masses, or crystalline powder. Has a pleasant, peppermint-like
odor. Slightly soluble in water; very soluble in alcohol, in chloroform,
in ether, and in solvent hexane; freely soluble in glacial acetic acid,
in mineral oil, and in fixed and volatile oils. NF category: Flavors and
perfumes.
Meperidine Hydrochloride: Fine, white, crystalline, odorless powder.
The pH of a solution (1 in 20) is about 5. Very soluble in water; soluble
in alcohol; sparingly soluble in ether.
Mephobarbital: White, odorless, crystalline powder, having a bitter
taste. Its saturated solution is acid to litmus. Slightly soluble in water,
in alcohol, and in ether; soluble in chloroform and in solutions of fixed
alkali hydroxides and carbonates.
Mepivacaine Hydrochloride: White, odorless, crystalline solid. The pH
of a solution (1 in 50) is about 4.5. Freely soluble in water and in metha-
nol; very slightly soluble in chloroform; practically insoluble in ether.
Meprobamate: White powder, having a characteristic odor and a bitter
taste. Slightly soluble in water; freely soluble in acetone and in alcohol;
practically insoluble or insoluble in ether.
Mercaptopurine: Yellow, odorless or practically odorless, crystalline
powder. Melts at a temperature exceeding 308, with decomposition.
Insoluble in water, in acetone, and in ether; soluble in hot alcohol and
in dilute alkali solutions; slightly soluble in 2 N sulfuric acid.
Ammoniated Mercury: White, pulverulent pieces or white, amor-
phous powder. Is odorless, and is stable in air, but darkens on expo-
sure to light. Insoluble in water, and in alcohol; readily soluble in warm
hydrochloric, nitric, and acetic acids.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/106
Description and Solubility
Meropenem: Colorless to white crystals. Soluble in dimethylfor-
mamide and in 5% dibasic potassium phosphate solution; sparingly
soluble in water and in 5% monobasic potassium phosphate solution;
very slightly soluble in alcohol; practically insoluble in acetone and in
ether.
Mesalamine: Light tan to pink colored, needle-shaped crystals. Color
may darken on exposure to air. Is odorless or may have a slight charac-
teristic odor. Slightly soluble in water; very slightly soluble in methanol,
in dehydrated alcohol, and in acetone; practically insoluble in n-butyl
alcohol, in chloroform, in ether, in ethyl acetate, in n-hexane, in methy-
lene chloride, and in n-propyl alcohol; soluble in dilute hydrochloric
acid and in dilute alkali hydroxides.
Mesoridazine Besylate: White to pale yellowish powder, having not
more than a faint odor. Melts at about 178, with decomposition. Freely
soluble in water, in chloroform, and in methanol.
Mestranol: White to creamy white, odorless, crystalline powder. In-
soluble in water; freely soluble in chloroform; soluble in dioxane; spar-
ingly soluble in dehydrated alcohol; slightly soluble in methanol.
Metaproterenol Sulfate: White to off-white, crystalline powder. Freely
P
soluble in water.
Metformin Hydrochloride: White, crystalline powder. Freely soluble
S
in water; slightly soluble in alcohol; practically insoluble in acetone
and in methylene chloride.
U
Methacholine Chloride: Colorless or white crystals, or white, crystal-
line powder. Is odorless or has a slight odor, and is very hygroscopic.
Its solutions are neutral to litmus. Very soluble in water; freely soluble
9
in alcohol and in chloroform.
Methacrylic Acid Copolymer: White powder having a faint, charac-
teristic odor. The polymer is soluble in diluted alkali, in simulated
intestinal fluid TS, and in buffer solutions of pH 7 and above. The solu-
bility between pH 5.5 and pH 7 depends on the content of methacrylic
acid units in the copolymer. The polymer is soluble to freely soluble
in methanol, in alcohol, in isopropyl alcohol, and in acetone, each of
which contains not less than 3% of water insoluble in water, in diluted
acids, in simulated gastric fluid TS, and in buffer solutions of up to pH
5. NF category: Coating agent.
Methacrylic Acid Copolymer Dispersion: Milky-white liquid of low
viscosity. It is miscible with water in any proportion; the milky-white
appearance is retained. A clear or slightly opalescent, viscous solution
is obtained on mixing one part with five parts of acetone, alcohol, or
isopropyl alcohol; the polymer substance is first precipitated, but then
dissolves in the excess organic solvent. A clear or slightly opalescent,
viscous solution is obtained on mixing one part with two parts of 1 N
sodium hydroxide.
Methacycline Hydrochloride: Yellow to dark yellow, crystalline pow-
der. Soluble in water.
Methadone Hydrochloride: Colorless crystals or white, crystalline,
odorless powder. Soluble in water; freely soluble in alcohol and in
chloroform; practically insoluble in ether and in glycerin.
Methadone Hydrochloride Oral Concentrate: Clear to slightly hazy,
syrupy liquid.
Methamphetamine Hydrochloride: White crystals or white, crystalline
powder. Is odorless or practically so. Its solutions have a pH of about
6. Freely soluble in water, in alcohol, and in chloroform; very slightly
soluble in absolute ether.
Methazolamide: White or faintly yellow, crystalline powder having a
slight odor. Melts at about 213. Very slightly soluble in water and in
alcohol; soluble in dimethylformamide; slightly soluble in acetone.
Methdilazine Hydrochloride: Light tan, crystalline powder, having a
slight, characteristic odor. Freely soluble in water, in alcohol, and in
chloroform.
USP Pharmacists Pharmacopeia
Methenamine: Colorless, lustrous crystals or white, crystalline pow-
der. Is practically odorless. When brought into contact with fire, it
readily ignites, burning with a smokeless flame. It sublimes at about
260, without melting. Its solutions are alkaline to litmus. Freely soluble
in water; soluble in alcohol and in chloroform.
Methenamine Mandelate: White, crystalline powder. Has a sour taste
and is practically odorless. Its solutions have a pH of about 4. Melts at
about 127, with decomposition. Very soluble in water; soluble in alco-
hol and in chloroform; slightly soluble in ether.
Methimazole: White to pale buff, crystalline powder, having a faint,
characteristic odor. Its solutions are practically neutral to litmus. Freely
soluble in water, in alcohol, and in chloroform; slightly soluble in
ether.
Methionine: White crystals, having a characteristic odor and taste.
Soluble in water, in warm dilute alcohol, and in dilute mineral acids;
insoluble in ether, in absolute alcohol, in benzene, and in acetone
( l-form).
Methocarbamol: White powder, odorless, or having a slight char-
acteristic odor. Melts at about 94, or, if previously ground to a fine
powder, melts at about 90. Sparingly soluble in water and in chloro-
form; soluble in alcohol only with heating; insoluble in benzene and
in n-hexane.
Methohexital: White to faintly yellowish-white, crystalline, odorless
powder. Very slightly soluble in water; slightly soluble in alcohol, in
chloroform, and in dilute alkalies.
Methohexital Sodium for Injection: White to off-white, hygroscopic
powder. Is essentially odorless.
0
Methotrexate: Orange-brown, or yellow, crystalline powder. Practi-
cally insoluble in water, in alcohol, in chloroform, and in ether; freely
0
soluble in dilute solutions of alkali hydroxides and carbonates; slightly
2
soluble in 6 N hydrochloric acid.
Methotrimeprazine: Fine, white, practically odorless, crystalline pow-
der. Melts at about 126. Practically insoluble in water; freely soluble
in chloroform and in ether; sparingly soluble in methanol. Is sparingly
soluble in alcohol at 25, but is freely soluble in boiling alcohol.
Methoxsalen: White to cream-colored, fluffy, needle-like crystals. Is
odorless. Practically insoluble in water; freely soluble in chloroform;
soluble in boiling alcohol, in acetone, in acetic acid, in propylene gly-
col, and in benzene; sparingly soluble in boiling water and in ether.
Methoxsalen Topical Solution: Clear, colorless liquid.
Methoxyflurane: Clear, practically colorless, mobile liquid, having
a characteristic odor. Boils at about 105. Miscible with alcohol, with
acetone, with chloroform, with ether, and with fixed oils.
Methsuximide: White to grayish white, crystalline powder. Is odorless,
or has not more than a slight odor. Slightly soluble in hot water; very
soluble in chloroform; freely soluble in alcohol and in ether.
Methyclothiazide: White or practically white, crystalline powder. Is
odorless, or has a slight odor. Very slightly soluble in water, in chloro-
form, and in benzene; freely soluble in acetone and in pyridine; spar-
ingly soluble in methanol; slightly soluble in alcohol.
Methyl Alcohol: Clear, colorless liquid, having a characteristic odor. Is
flammable. Miscible with water, with alcohol, with ether, with benzene,
and with most other organic solvents. NF category: Solvent.
Methyl Benzylidene Camphor: A white, fine crystalline powder. Very
soluble in chloroform; freely soluble in alcohol; practically insoluble
in water.
Methyl Isobutyl Ketone: Transparent, colorless, mobile, volatile liquid,
having a faint ketonic and camphoraceous odor. Slightly soluble in wa-
ter; miscible with alcohol, with ether, and with benzene. NF category:
Alcohol denaturant; solvent.
Methyl Salicylate: Colorless, yellowish, or reddish liquid, having the
characteristic odor and taste of wintergreen. It boils between 219 and
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/107
Description and Solubility
224, with some decomposition. Slightly soluble in water; soluble in
alcohol and in glacial acetic acid. NF category: Flavors and perfumes.
Methylbenzethonium Chloride: White, hygroscopic crystals, hav-
ing a mild odor. Its solutions are neutral or slightly alkaline to litmus.
Very soluble in water, in alcohol, and in ether; practically insoluble in
chloroform.
Methylcellulose: White, fibrous powder or granules. Its aqueous sus-
pensions are neutral to litmus. It swells in water and produces a clear
to opalescent, viscous, colloidal suspension. Insoluble in alcohol, in
ether, and in chloroform; soluble in glacial acetic acid and in a mixture
of equal volumes of alcohol and chloroform. NF category: Coating
agent; suspending and/or viscosity-increasing agent; tablet binder.
Methyldopa: White to yellowish-white, odorless, fine powder, which
may contain friable lumps. Sparingly soluble in water; very soluble in
3 N hydrochloric acid; slightly soluble in alcohol; practically insoluble
in ether.
Methyldopate Hydrochloride: White or practically white, odorless
or practically odorless, crystalline powder. Freely soluble in water, in
alcohol, and in methanol; slightly soluble in chloroform; practically
P
insoluble in ether.
Methylene Blue: Dark green crystals or crystalline powder having a
S
bronze-like luster. Is odorless or practically so, and is stable in air. Its
solutions in water and in alcohol are deep blue in color. Soluble in
U
water and in chloroform; sparingly soluble in alcohol.
Methylene Chloride: Clear, colorless, mobile liquid, having an odor
resembling that of chloroform. Miscible with alcohol, with ether, and
9
with fixed and volatile oils. NF category: Solvent.
Methylergonovine Maleate: White to pinkish-tan, microcrystalline
powder. Is odorless. Slightly soluble in water and in alcohol; very
slightly soluble in chloroform and in ether.
Methylparaben: White, crystalline powder or colorless crystals. Slight-
ly soluble in water; freely soluble in alcohol and in methanol. NF cat-
egory: Antimicrobial preservative.
Methylparaben Sodium: White, hygroscopic powder. Freely soluble in
water; sparingly soluble in alcohol; insoluble in fixed oils. NF category:
Antimicrobial preservative.
Methylphenidate Hydrochloride: White, odorless, fine, crystalline
powder. Its solutions are acid to litmus. Freely soluble in water and
in methanol; soluble in alcohol; slightly soluble in chloroform and in
acetone.
Methylprednisolone: White to practically white, odorless, crystalline
powder. Melts at about 240, with some decomposition (see Melting
Range or Temperature 741). Practically insoluble in water; sparingly
soluble in alcohol, in dioxane, and in methanol; slightly soluble in ac-
etone and in chloroform; very slightly soluble in ether.
Methylprednisolone Acetate: White or practically white, odorless,
crystalline powder. Melts at about 225, with some decomposition (see
Melting Range or Temperature 741). Practically insoluble in water;
soluble in dioxane; sparingly soluble in acetone, in alcohol, in chloro-
form, and in methanol; slightly soluble in ether.
Methylprednisolone Hemisuccinate: White or nearly white, odorless
or nearly odorless, hygroscopic solid. Very slightly soluble in water;
freely soluble in alcohol; soluble in acetone.
Methylprednisolone Sodium Succinate: White or nearly white, odor-
less, hygroscopic, amorphous solid. Very soluble in water and in alco-
hol; very slightly soluble in acetone; insoluble in chloroform.
Methylsulfonylmethane: White powder or flake crystal. Melts at about
109. Freely soluble in water, in methanol, in alcohol, and in acetone.
Sparingly soluble in ether.
Methyltestosterone: White or creamy white crystals or crystalline
powder. Is odorless and is stable in air, but is slightly hygroscopic. Is
affected by light. Practically insoluble in water; soluble in alcohol, in
USP Pharmacists Pharmacopeia
methanol, in ether, and in other organic solvents; sparingly soluble in
vegetable oils.
Methysergide Maleate: White to yellowish-white or reddish-white,
crystalline powder. Is odorless or has not more than a slight odor.
Slightly soluble in water and in alcohol; very slightly soluble in chloro-
form; practically insoluble in ether.
Metoclopramide Hydrochloride: White or practically white, crystal-
line, odorless or practically odorless powder. Very soluble in water;
freely soluble in alcohol; sparingly soluble in chloroform; practically
insoluble in ether.
Metoprolol Succinate: White to off-white powder. Freely soluble
in water; soluble in methanol; sparingly soluble in alcohol; slightly
soluble in isopropyl alcohol.
Metoprolol Tartrate: White, crystalline powder. Very soluble in water;
freely soluble in methylene chloride, in chloroform, and in alcohol;
slightly soluble in acetone; insoluble in ether.
Metronidazole: White to pale yellow, odorless crystals or crystalline pow-
der. Is stable in air, but darkens on exposure to light. Sparingly soluble
in water and in alcohol; slightly soluble in ether and in chloroform.
Metronidazole Benzoate: White to slightly yellow, crystalline powder.
Freely soluble in methylene chloride; soluble in acetone; slightly solu-
ble in alcohol; very slightly soluble in ethyl ether; practically insoluble
in water.
Metyrapone: White to light amber, fine, crystalline powder, having a
characteristic odor. Darkens on exposure to light. Sparingly soluble in
water; soluble in methanol and in chloroform. It forms water-soluble
salts with acids.
0
Mexiletine Hydrochloride: White powder. Freely soluble in dehy-
drated alcohol and in water; slightly soluble in acetonitrile; practically
0
insoluble in ether. Optically inactive (1 in 20 solution in water).
2
Mezlocillin Sodium: White to pale yellow, crystalline powder. Freely
soluble in water.
Mibolerone: White to off-white powder. Slightly soluble in chloro-
form, in dioxane, and in methylene chloride; practically insoluble in
water (0.0454 mg per mL at 37).
Miconazole: White to pale cream powder. Melts in the range of 78
to 88. May exhibit polymorphism. Insoluble in water; soluble in ether;
freely soluble in alcohol, in methanol, in isopropyl alcohol, in acetone,
in propylene glycol, in chloroform, and in dimethylformamide.
Miconazole Nitrate: White or practically white, crystalline powder,
having not more than a slight odor. Melts in the range of 178 to 183,
with decomposition. Insoluble in ether; very slightly soluble in water
and in isopropyl alcohol; slightly soluble in alcohol, in chloroform, and
in propylene glycol; sparingly soluble in methanol; soluble in dimeth-
ylformamide; freely soluble in dimethyl sulfoxide.
Milrinone: White to tan, crystalline solid. Is hygroscopic. Freely solu-
ble in dimethyl sulfoxide; very slightly soluble in methanol; practically
insoluble in water and in chloroform.
Mineral Oil: Colorless, transparent, oily liquid, free or practically free
from fluorescence. Is odorless and tasteless when cold, and develops
not more than a faint odor of petroleum when heated. Insoluble in wa-
ter and in alcohol; soluble in volatile oils. Miscible with most fixed oils
but not with castor oil. NF category: Solvent; vehicle (oleaginous).
Light Mineral Oil: Colorless, transparent, oily liquid, free, or practi-
cally free, from fluorescence. Is odorless and tasteless when cold,
and develops not more than a faint odor of petroleum when heated.
Insoluble in water and in alcohol; soluble in volatile oils. Miscible with
most fixed oils, but not with castor oil. NF category: Tablet and/or cap-
sule lubricant; vehicle (oleaginous).
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/108
Description and Solubility
Minocycline Hydrochloride: Yellow, crystalline powder. Sparingly
soluble in water; soluble in solutions of alkali hydroxides and carbon-
ates; slightly soluble in alcohol; practically insoluble in chloroform and
in ether.
Minoxidil: White to off-white, crystalline powder. Melts in the approx-
imate range of between 248 and 268, with decomposition. Soluble in
alcohol and in propylene glycol; sparingly soluble in methanol; slightly
soluble in water; practically insoluble in chloroform, in acetone, in
ethyl acetate, and in hexane.
Mirtazapine: White to creamy white, crystalline powder. Freely soluble
in methanol and in toluene; soluble in ethyl ether; sparingly soluble in
n-hexane; practically insoluble in water.
Mitomycin: Blue-violet, crystalline powder. Slightly soluble in water; sol-
uble in acetone, in methanol, in butyl acetate, and in cyclohexanone.
Mitotane: White, crystalline powder, having a slight, aromatic odor.
Practically insoluble in water; soluble in alcohol, in ether, in solvent
hexane, and in fixed oils and fats.
Mitoxantrone Hydrochloride: Dark blue powder. Sparingly soluble in
water; slightly soluble in methanol; practically insoluble in acetone, in
P
acetonitrile, and in chloroform.
Modafinil: White to off-white, crystalline powder. Slightly soluble in
S
absolute alcohol; sparingly soluble in methanol; very slightly soluble
in water.
U
Mometasone Furoate: White to off-white powder. Melts at about 220,
with decomposition. Soluble in acetone and in methylene chloride.
9
Monensin Sodium: Off-white to tan, crystalline powder. Slightly
soluble in water; soluble in chloroform and in methanol; practically
insoluble in solvent hexane.
Mono- and Di-glycerides: Vary in consistency from yellow liquids,
through ivory-colored plastics, to ivory white-colored solids (bead or
flake forms). Insoluble in water, but soluble in alcohol, in ethyl acetate,
in chloroform, and in other chlorinated hydrocarbons. NF category:
Emulsifying and/or solubilizing agent.
Monobenzone Ointment: Dispersible with, but not soluble in, water.
Monoethanolamine: Clear, colorless, moderately viscous liquid, hav-
ing a distinctly ammoniacal odor. Miscible with water, with acetone,
with alcohol, with glycerin, and with chloroform. Immiscible with
ether, with solvent hexane, and with fixed oils, although it dissolves
many essential oils. NF category: Emulsifying and/or solubilizing agent.
Monoglyceride Citrate: Soft white to ivory-colored, waxy solid with a
lard-like consistency and bland odor. Dispersible in most common fat
solvents and in alcohol; insoluble in water.
Monosodium Glutamate: White, practically odorless, free-flowing
crystals or crystalline powder. Freely soluble in water; sparingly soluble
in alcohol. May have either a slightly sweet or a slightly salty taste. NF
category: Flavors and perfumes.
Monothioglycerol: Colorless or pale yellow, viscous liquid, having
a slight sulfidic odor. Is hygroscopic. Miscible with alcohol. Freely
soluble in water; insoluble in ether. NF category: Antioxidant.
Morantel Tartrate: A white or pale yellow, crystalline powder. Very
soluble in water and in alcohol; practically insoluble in ethyl acetate.
Moricizine Hydrochloride: White to off-white, crystalline powder.
Melts at about 189, with decomposition. Soluble in water and in
alcohol.
Morphine Sulfate: White, feathery, silky crystals, cubical masses of
crystals, or white, crystalline powder. Is odorless, and when exposed
to air it gradually loses water of hydration. Darkens on prolonged
exposure to light. Soluble in water; freely soluble in hot water; slightly
soluble in alcohol but more so in hot alcohol; insoluble in chloroform
and in ether.
USP Pharmacists Pharmacopeia
Mumps Skin Test Antigen: Slightly turbid liquid.
Mumps Virus Vaccine Live: Solid having the characteristic appearance
of substances dried from the frozen state. The Vaccine is to be con-
stituted with a suitable diluent just prior to use. Constituted vaccine
undergoes loss of potency on exposure to sunlight.
Mupirocin: White to off-white, crystalline solid. Freely soluble in ac-
etone, in chloroform, in dehydrated alcohol, and in methanol; slightly
soluble in ether; very slightly soluble in water.
Mycophenolate Mofetil: White or almost white, crystalline powder.
Freely soluble in acetone; soluble in methanol; sparingly soluble in
ethanol; and slightly soluble in water.
Myristic Acid: Hard, white or faintly yellow, somewhat glossy, crys-
talline solid or white or yellow-white powder. Soluble in alcohol, in
chloroform, and in ether; practically insoluble in water. NF category:
Antifoaming agent.
Nabumetone: A white, or almost white, crystalline powder. Freely
soluble in acetone; sparingly soluble in alcohol and in methanol; prac-
tically insoluble in water.
Nadolol: White to off-white, practically odorless, crystalline powder.
Freely soluble in alcohol and in methanol; soluble in water at pH 2;
slightly soluble in chloroform, in methylene chloride, in isopropyl al-
cohol, and in water (between pH 7 and pH 10); insoluble in acetone, in
benzene, in ether, in hexane, and in trichloroethane.
Nafcillin Sodium: White to yellowish-white powder, having not more
than a slight characteristic odor. Freely soluble in water and in chloro-
form; soluble in alcohol.
Nalidixic Acid: White to very pale yellow, odorless, crystalline pow-
0
der. Soluble in chloroform, in methylene chloride, and in solutions of
0
fixed alkali hydroxides and carbonates; slightly soluble in acetone, in
alcohol, in methanol, and in toluene; very slightly soluble in ether and
2
in water.
Naloxone Hydrochloride: White to slightly off-white powder. Its aque-
ous solution is acidic. Soluble in water, in dilute acids, and in strong
alkali; slightly soluble in alcohol; practically insoluble in ether and in
chloroform.
Naloxone Hydrochloride Injection: Clear, colorless liquid.
Nandrolone Decanoate: Fine, white to creamy white, crystalline pow-
der. Is odorless, or may have a slight odor. Practically insoluble in wa-
ter; soluble in chloroform, in alcohol, in acetone, and in vegetable oils.
Naphazoline Hydrochloride: White, crystalline powder. Is odor-
less and has a bitter taste. Melts at a temperature of about 255, with
decomposition. Freely soluble in water and in alcohol; very slightly
soluble in chloroform; practically insoluble in ether.
Naproxen: White to off-white, practically odorless, crystalline powder.
Soluble in chloroform, in dehydrated alcohol, and in alcohol; sparingly
soluble in ether; practically insoluble in water.
Naproxen Sodium: White to creamy crystalline powder. Soluble in wa-
ter and in methanol; sparingly soluble in alcohol; very slightly soluble
in acetone; and practically insoluble in chloroform and in toluene.
Melts at about 255, with decomposition.
Narasin: White to off-white, crystalline powder. Melts at about 217,
with decomposition. Soluble in methanol and in water.
Naratriptan Hydrochloride: White to pale yellow solid. Soluble in
water.
Natamycin: Off-white to cream-colored powder, which may contain
up to 3 moles of water. Practically insoluble in water; slightly soluble in
methanol; soluble in glacial acetic acid and in dimethylformamide.
Nefazodone Hydrochloride: Nonhygroscopic, white powder. Freely
soluble in chloroform; soluble in propylene glycol; slightly soluble in
polyethylene glycol and in water.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/109
Description and Solubility
Neomycin Sulfate: White to slightly yellow powder, or cryodesiccated
solid. Is odorless or practically so and is hygroscopic. Its solutions are
dextrorotatory. Freely soluble in water; very slightly soluble in alcohol;
insoluble in acetone, in chloroform, and in ether.
Netilmicin Sulfate: White to pale yellowish-white powder. Freely solu-
ble in water; practically insoluble in dehydrated alcohol and in ether.
Nevirapine: White to off-white, odorless to nearly odorless, crystalline
powder. Practically insoluble in water; slightly soluble in alcohol and in
methanol. Hydrous form also slightly soluble in propylene glycol.
Niacin: White crystals or crystalline powder. Is odorless, or has a slight
odor. Melts at about 235. Sparingly soluble in water; freely soluble in
boiling water, in boiling alcohol, and in solutions of alkali hydroxides
and carbonates; practically insoluble in ether.
Niacinamide: White, crystalline powder. Is odorless or practically so,
and has a bitter taste. Its solutions are neutral to litmus. Freely soluble
in water and in alcohol; soluble in glycerin.
Nifedipine: Yellow powder. Is affected by exposure to light. Practically
insoluble in water; freely soluble in acetone.
Nimodipine: Light yellow or yellow, crystalline powder, affected by
P
light. Freely soluble in ethyl acetate; sparingly soluble in alcohol; prac-
S
tically insoluble in water. Exhibits polymorphism.
Nitric Acid: Highly corrosive fuming liquid, having a characteristic,
highly irritating odor. Stains animal tissues yellow. Boils at about 120.
U
Specific gravity is about 1.41. NF category: Acidifying agent.
Nitrofurantoin: Lemon-yellow, odorless crystals or fine powder. Has a
9
bitter aftertaste. Very slightly soluble in water and in alcohol; soluble in
dimethylformamide.
Nitrofurazone: Lemon yellow, odorless, crystalline powder. Darkens
slowly on exposure to light. Melts at about 236, with decomposition.
Very slightly soluble in alcohol and in water; soluble in dimethylfor-
mamide; slightly soluble in propylene glycol and in polyethylene glycol
mixtures; practically insoluble in chloroform and in ether.
Nitrofurazone Ointment: Yellow, opaque, and water-miscible, and has
ointment-like consistency.
Nitrofurazone Topical Solution: Light yellow, clear, somewhat viscous
liquid, having a faint characteristic odor. Miscible with water.
Nitrogen: Colorless, odorless, tasteless gas. Is nonflammable and
does not support combustion. One L at 0 and at a pressure of 760
mm of mercury weighs about 1.251 g. One volume dissolves in about
65 volumes of water and in about 9 volumes of alcohol at 20 and at a
pressure of 760 mm of mercury. NF category: Air displacement.
Diluted Nitroglycerin: When diluted with lactose, it is a white, odor-
less powder. When diluted with propylene glycol or alcohol, it is a
clear, colorless, or pale yellow liquid. [noteUndiluted nitroglycerin
occurs as a white to pale yellow, thick, flammable, explosive liquid.]
Undiluted nitroglycerin is slightly soluble in water; soluble in metha-
nol, in alcohol, in carbon disulfide, in acetone, in ethyl ether, in ethyl
acetate, in glacial acetic acid, in benzene, in toluene, in nitrobenzene,
in phenol, in chloroform, and in methylene chloride.
Nitromersol: Brownish yellow to yellow granules or brownish yellow
to yellow powder. Is odorless and tasteless and is affected by light. Very
slightly soluble in water, in alcohol, in acetone, and in ether; soluble in
solutions of alkalies and of ammonia by opening of the anhydride ring
and the formation of a salt.
Nitromersol Topical Solution: Clear, reddish-orange solution. Is af-
fected by light.
Nitrous Oxide: Colorless gas, without appreciable odor or taste. One
L at 0 and at a pressure of 760 mm of mercury weighs about 1.97 g.
One volume dissolves in about 1.4 volumes of water at 20 and at a
pressure of 760 mm of mercury. Freely soluble in alcohol; soluble in
ether and in oils.
USP Pharmacists Pharmacopeia
Nizatidine: Off-white to buff crystalline solid. Freely soluble in chloro-
form; soluble in methanol; sparingly soluble in water.
Nonoxynol 9: Clear, colorless to light yellow, viscous liquid. Soluble in
water, in alcohol, and in corn oil. NF category: Wetting and/or solubiliz-
ing agent.
Norepinephrine Bitartrate: White or faintly gray, odorless, crystalline
powder. Slowly darkens on exposure to air and light. Its solutions are
acid to litmus, having a pH of about 3.5. Freely soluble in water; slightly
soluble in alcohol; practically insoluble in chloroform and in ether.
Melts between 98 and 104, without previous drying of the specimen,
the melt being turbid.
Norepinephrine Bitartrate Injection: Colorless or practically colorless
liquid, gradually turning dark on exposure to air and light.
Norethindrone: White to creamy white, odorless, crystalline powder.
Is stable in air. Practically insoluble in water; soluble in chloroform and
in dioxane; sparingly soluble in alcohol; slightly soluble in ether.
Norethindrone Acetate: White to creamy white, odorless, crystalline
powder. Practically insoluble in water; very soluble in chloroform;
freely soluble in dioxane; soluble in ether and in alcohol.
Norethynodrel: White or practically white, odorless, crystalline pow-
der. Melts at about 175, over a range of about 3. Is stable in air. Very
slightly soluble in water and in solvent hexane; freely soluble in chlo-
roform; soluble in acetone; sparingly soluble in alcohol.
Norfloxacin: White to pale yellow, crystalline powder. Sensitive to
light and moisture. Slightly soluble in acetone, in water, and in alco-
hol; freely soluble in acetic acid; sparingly soluble in chloroform; very
slightly soluble in methanol and in ethyl acetate; insoluble in ether.
0
Norgestimate: White to pale yellow powder. Freely to very soluble
0
in methylene chloride; insoluble in water; sparingly soluble in
acetonitrile.
2
Norgestrel: White or practically white, practically odorless, crystalline
powder. Insoluble in water; freely soluble in chloroform; sparingly
soluble in alcohol.
Nortriptyline Hydrochloride: White to off-white powder, having a
slight, characteristic odor. Its solution (1 in 100) has a pH of about 5.
Soluble in water and in chloroform; sparingly soluble in methanol;
practically insoluble in ether, in benzene, and in most other organic
solvents.
Noscapine: Fine, white or practically white, crystalline powder. Freely
soluble in chloroform; soluble in acetone; slightly soluble in alcohol
and in ether; practically insoluble in water.
Novobiocin Calcium: White or yellowish-white, odorless, crystalline
powder. Slightly soluble in water and in ether; freely soluble in alcohol
and in methanol; sparingly soluble in acetone and in butyl acetate;
very slightly soluble in chloroform.
Novobiocin Sodium: White or yellowish-white, odorless, hygroscopic,
crystalline powder. Freely soluble in water, in alcohol, in methanol, in
glycerin, and in propylene glycol; slightly soluble in butyl acetate; prac-
tically insoluble in acetone, in chloroform, and in ether.
Nystatin: Yellow to light tan powder, having an odor suggestive of
cereals. Is hygroscopic, and is affected by long exposure to light, heat,
and air. Freely soluble in dimethylformamide and in dimethyl sulfoxide;
slightly to sparingly soluble in methanol, in n-propyl alcohol, and in n-
butyl alcohol; practically insoluble in water and in alcohol; insoluble in
chloroform and in ether.
Octoxynol 9: Clear, pale yellow, viscous liquid, having a faint odor
and a bitter taste. Miscible with water, with alcohol, and with acetone.
Soluble in benzene and in toluene; practically insoluble in solvent hex-
ane. NF category: Wetting and/or solubilizing agent.
Octyldodecanol: Clear water-white, free-flowing liquid. Soluble in alco-
hol and in ether; insoluble in water. NF category: Vehicle (oleaginous).
Octyl Methoxycinnamate: Pale yellow oil. Insoluble in water.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/110
Description and Solubility
Ofloxacin: Pale yellowish-white to light yellowish-white crystals or
crystalline powder. Slightly soluble in alcohol, in methanol, and in
water; sparingly soluble in chloroform.
Hydrophilic Ointment: NF category: Ointment base.
White Ointment: NF category: Ointment base.
Yellow Ointment: NF category: Ointment base.
Oleic Acid: Colorless to pale yellow, oily liquid when freshly pre-
pared, but on exposure to air it gradually absorbs oxygen and darkens.
Has a characteristic, lard-like odor and taste. When strongly heated in
air, it is decomposed with the production of acrid vapors. Practically
insoluble in water. Miscible with alcohol, with chloroform, with ether,
with benzene, and with fixed and volatile oils. NF category: Emulsifying
and/or solubilizing agent.
Oleovitamin A and D: Yellow to red, oily liquid, practically odorless
or having a fish-like odor, and having no rancid odor or taste. Is a clear
liquid at temperatures exceeding 65, and may crystallize on cooling.
Is unstable in air and in light. Insoluble in water and in glycerin; very
soluble in ether and in chloroform; soluble in dehydrated alcohol and
in vegetable oils.
P
Oleovitamin A and D Capsules: The oil contained in Oleovitamin A
S
and D Capsules is a yellow to red, oily liquid, practically odorless or
having a fish-like odor, and having no rancid odor or taste. Is a clear
liquid at temperatures exceeding 65, and may crystallize on cooling. Is
U
unstable in air and in light.
Oleoyl Polyoxylglycerides: Amber, oily liquids. May develop deposit
9
after prolonged storage at 20. Freely soluble in methylene chloride;
practically insoluble but dispersible in water. NF category: Ointment
base; solvent.
Oleyl Alcohol: Clear, colorless to light yellow, oily liquid. Has a faint
characteristic odor and a bland taste. Insoluble in water; soluble in
alcohol, in ether, in isopropyl alcohol, and in light mineral oil. NF cat-
egory: Emulsifying and/or solubilizing agent.
Oleyl Oleate: Clear, colorless to light yellow liquid. Has a faint char-
acteristic odor. Slightly soluble in alcohol; miscible with chloroform
and with ether. NF category: Emollient; emulsifying and/or solubilizing
agent.
Olive Oil: Pale yellow, or light greenish-yellow, oily liquid, having
a slight, characteristic odor and taste, with a faintly acrid aftertaste.
Slightly soluble in alcohol. Miscible with ether, with chloroform, and
with carbon disulfide. NF category: Vehicle (oleaginous).
Omeprazole: White to off-white powder. Melts between 150 and
160, with decomposition. Soluble in dichloromethane; sparingly
soluble in methanol and in alcohol; very slightly soluble in water.
Omeprazole Magnesium: White to off-white powder. Sparingly
soluble in methanol; slightly soluble in alcohol; very slightly soluble in
water and in dichloromethane.
Ondansetron: White to off-white powder. Very soluble in acid solu-
tions; sparingly soluble in water.
Ondansetron Hydrochloride: White to off-white powder. Sparingly
soluble in water and in alcohol; soluble in methanol; slightly soluble
in isopropyl alcohol and in dichloromethane; very slightly soluble in
acetone, in chloroform, and in ethyl acetate.
Opium: Has a very characteristic odor and a very bitter taste.
Powdered Opium: Light brown or moderately yellowish-brown
powder.
Orphenadrine Citrate: White, practically odorless, crystalline powder,
having a bitter taste. Sparingly soluble in water; slightly soluble in alco-
hol; insoluble in chloroform, in benzene, and in ether.
Oxacillin Sodium: Fine, white, crystalline powder, odorless or having
a slight odor. Freely soluble in water, in methanol, and in dimethyl sulf-
oxide; slightly soluble in absolute alcohol, in chloroform, in pyridine,
USP Pharmacists Pharmacopeia
and in methyl acetate; insoluble in ethyl acetate, in ether, in benzene,
and in ethylene chloride.
Oxacillin Sodium for Injection: Fine, white, crystalline powder, odor-
less or having a slight odor. Freely soluble in water, in methanol, and in
dimethyl sulfoxide; slightly soluble in absolute alcohol, in chloroform,
in pyridine, and in methyl acetate; insoluble in ethyl acetate, in ether,
in benzene, and in ethylene chloride.
Oxandrolone: White, odorless, crystalline powder. Is stable in air, but
darkens on exposure to light. Melts at about 225. Practically insoluble
in water; freely soluble in chloroform; sparingly soluble in alcohol and
in acetone.
Oxaprozin: White to yellowish-white, crystalline powder.
Oxazepam: Creamy white to pale yellow powder. Is practically odor-
less. Practically insoluble in water; slightly soluble in alcohol and in
chloroform; very slightly soluble in ether.
Oxfendazole: White or almost white powder. Slightly soluble in alco-
hol and in methylene chloride; practically insoluble in water.
Oxprenolol Hydrochloride: White, crystalline powder. Freely soluble
in alcohol, in chloroform, and in water; sparingly soluble in acetone;
practically insoluble in ether.
Oxtriphylline: White, crystalline powder, having an amine-like odor. A
solution (1 in 100) has a pH of about 10.3. Freely soluble in water and in
alcohol; very slightly soluble in chloroform.
Oxybenzone: Pale yellow powder. Practically insoluble in water; freely
soluble in alcohol and in toluene.
Oxybutynin Chloride: White, crystalline, practically odorless powder.
Freely soluble in water and in alcohol; very soluble in methanol and in
0
chloroform; soluble in acetone; slightly soluble in ether; very slightly
0
soluble in hexane.
Oxycodone Hydrochloride: White to off-white, hygroscopic crystals
2
or powder. Is odorless. Soluble in water; slightly soluble in alcohol.
Oxygen: Colorless, odorless, tasteless gas, which supports combus-
tion more energetically than does air. One L at 0 and at a pressure
of 760 mm of mercury weighs about 1.429 g. One volume dissolves in
about 32 volumes of water and in about 7 volumes of alcohol at 20 and
at a pressure of 760 mm of mercury.
Oxymetazoline Hydrochloride: White to practically white, fine crystal-
line powder. Is hygroscopic. Melts at about 300, with decomposition.
Soluble in water and in alcohol; practically insoluble in benzene, in
chloroform, and in ether.
Oxymetholone: White to creamy white, crystalline powder. Is odor-
less, and is stable in air. Practically insoluble in water; freely soluble in
chloroform; soluble in dioxane; sparingly soluble in alcohol; slightly
soluble in ether.
Oxymorphone Hydrochloride: White or slightly off-white, odor-
less powder. Darkens on exposure to light. Its aqueous solutions are
slightly acidic. Freely soluble in water; sparingly soluble in alcohol and
in ether.
Oxyquinoline Sulfate: Yellow powder. Melts at about 185. Very
soluble in water; freely soluble in methanol; slightly soluble in alcohol;
practically insoluble in acetone and in ether. NF category: Complexing
agent.
Oxytetracycline: Pale yellow to tan, odorless, crystalline powder. Is
stable in air, but exposure to strong sunlight causes it to darken. It
loses potency in solutions of pH below 2, and is rapidly destroyed by
alkali hydroxide solutions. Very slightly soluble in water; freely soluble
in 3 N hydrochloric acid and in alkaline solutions; sparingly soluble in
alcohol.
Oxytetracycline Calcium: Yellow to light brown, crystalline powder.
Insoluble in water.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/111
Description and Solubility
Oxytetracycline Hydrochloride: Yellow, odorless, crystalline powder,
having a bitter taste. Is hygroscopic. Decomposes at a temperature
exceeding 180, and exposure to strong sunlight or to temperatures
exceeding 90 in moist air causes it to darken. Its potency is diminished
in solutions having a pH below 2, and is rapidly destroyed by alkali
hydroxide solutions. Freely soluble in water, but crystals of oxytet-
racycline base separate as a result of partial hydrolysis of the hydro-
chloride. Sparingly soluble in alcohol and in methanol, and even less
soluble in dehydrated alcohol; insoluble in chloroform and in ether.
Paclitaxel: White to off-white powder. Insoluble in water; soluble in
alcohol.
Padimate O: A light yellow, mobile liquid having a faint, aromatic
odor. Practically insoluble in water; soluble in alcohol, in isopropyl
alcohol, and in mineral oil; practically insoluble in glycerin and in pro-
pylene glycol.
Palm Kernel Oil: White to yellowish, fatty solid. Insoluble in water. NF
category: Coating agent; emulsifying and/or solubilizing agent.
Palmitic Acid: Hard, white or faintly yellow, somewhat glossy crystal-
line solid, or white or yellowish-white powder. It has a slight charac-
P
teristic odor and taste. Soluble in alcohol, in ether, and in chloroform;
practically insoluble in water.
S
Pamidronate Disodium: White, crystalline powder. Soluble in water
and in 2 N sodium hydroxide; sparingly soluble in 0.1 N hydrochloric
U
acid and in 0.1 N acetic acid; practically insoluble in organic solvents.
Pancreatin: Cream-colored, amorphous powder, having a faint, char-
acteristic, but not offensive odor. It hydrolyzes fats to glycerol and
9
fatty acids, changes protein into proteoses and derived substances,
and converts starch into dextrins and sugars. Its greatest activities are
in neutral or faintly alkaline media; more than traces of mineral acids
or large amounts of alkali hydroxides make it inert. An excess of alkali
carbonate also inhibits its action.
Pancrelipase: Cream-colored, amorphous powder, having a faint,
characteristic, but not offensive odor. Pancrelipase hydrolyzes fats to
glycerol and fatty acids, changes protein into proteoses and derived
substances, and converts starch into dextrins and sugars. Its greatest
activities are in neutral or faintly alkaline media; more than traces of
mineral acids or large amounts of alkali hydroxides make it inert. An
excess of alkali carbonate also inhibits its action.
Pancrelipase Capsules: The contents of Capsules conform to the
Description under Pancrelipase, except that the odor may vary with the
flavoring agent used.
Pancuronium Bromide: White, yellowish-white, or slightly pink, crys-
talline powder. Is hygroscopic. Freely soluble in water, in methylene
chloride, and in alcohol.
Panthenol: White to creamy white, crystalline powder having a slight,
characteristic odor. Freely soluble in water, in alcohol, and in propylene
glycol; soluble in chloroform and in ether; slightly soluble in glycerin.
Pantoprazole Sodium: White to off-white powder. Freely soluble in
water, in methanol, and in dehydrated alcohol; practically insoluble in
hexane and in dichloromethane.
Papain: White to light tan, amorphous powder. Soluble in water, the
solution being colorless to light yellow and more or less opalescent;
practically insoluble in alcohol, in chloroform, and in ether.
Papaverine Hydrochloride: White crystals or white, crystalline pow-
der. Is odorless, and has a slightly bitter taste. Is optically inactive. Its
solutions are acid to litmus. Melts at about 220, with decomposition.
Soluble in water and in chloroform; slightly soluble in alcohol; practi-
cally insoluble in ether.
Parachlorophenol: White or pink crystals having a characteristic
phenolic odor. When undiluted, it whitens and cauterizes the skin and
mucous membranes. Melts at about 42. Sparingly soluble in water and
in liquid petrolatum; very soluble in alcohol, in glycerin, in chloroform,
in ether, and in fixed and volatile oils; soluble in petrolatum.
USP Pharmacists Pharmacopeia
Paraffin: Colorless or white, more or less translucent mass showing
a crystalline structure. Is odorless and tasteless, and is slightly greasy
to the touch. Insoluble in water and in alcohol; freely soluble in chlo-
roform, in ether, in volatile oils, and in most warm fixed oils; slightly
soluble in dehydrated alcohol. NF category: Stiffening agent.
Synthetic Paraffin: Very hard, white, practically tasteless and odorless
wax. Contains mostly long-chain, unbranched, saturated hydrocar-
bons, with a small amount of branched hydrocarbons. Is represented
by the formula CnH2n2, in which n may range from 20 to about 100. The
average molecular weight may range from 400 to 1400. Insoluble in
water; very slightly soluble in aliphatic, oxygenated, and halogenated
hydrocarbon solvents; slightly soluble in aromatic and normal paraf-
finic solvents. NF category: Stiffening agent.
Paraldehyde: Colorless, transparent liquid. Has a strong, characteristic
but not unpleasant or pungent odor, and a disagreeable taste. Specific
gravity is about 0.99. Soluble in water, but less soluble in boiling water.
Miscible with alcohol, with chloroform, with ether, and with volatile
oils.
Paramethasone Acetate: Fluffy, white to creamy white, odorless, crys-
talline powder. Melts at about 240, with decomposition. Insoluble in
water; soluble in chloroform, in ether, and in methanol.
Paricalcitol: White to almost white powder. Soluble in alcohol; in-
soluble in water.
Paromomycin Sulfate: Creamy white to light yellow powder. Is odor-
less or practically odorless, and is very hygroscopic. Very soluble in
water; insoluble in alcohol, in chloroform, and in ether.
Paroxetine Hydrochloride: White to off-white solid. Slightly soluble in
0
water; soluble in methanol and in alcohol.
Peanut Oil: Colorless or pale yellow, oily liquid with a bland taste.
0
May have a characteristic, nutty odor. Very slightly soluble in alcohol.
2
Miscible with ether, with chloroform, and with carbon disulfide. NF
category: Solvent; vehicle (oleaginous).
Pectin: Coarse or fine powder, yellowish-white in color, almost odor-
less, and having a mucilaginous taste. Almost completely soluble in 20
parts of water, forming a viscous, opalescent, colloidal solution that
flows readily and is acid to litmus; practically insoluble in alcohol or in
diluted alcohol and in other organic solvents. Pectin dissolves in water
more readily if first moistened with alcohol, glycerin, or simple syrup,
or if first mixed with 3 or more parts of sucrose. NF category: Suspend-
ing and/or viscosity-increasing agent.
Penbutolol Sulfate: White to off-white, crystalline powder. Melts at
about 217, with decomposition. Soluble in water and in methanol.
Penicillamine: White or practically white, crystalline powder, having
a slight, characteristic odor. Freely soluble in water; slightly soluble in
alcohol; insoluble in chloroform and in ether.
Penicillin G Benzathine: White, odorless, crystalline powder. Very
slightly soluble in water; sparingly soluble in alcohol.
Penicillin G Potassium: Colorless or white crystals, or white, crystal-
line powder. Is odorless or practically so, and is moderately hygro-
scopic. Its solutions are dextrorotatory. Its solutions retain substantially
full potency for several days at temperatures below 15, but are rapidly
inactivated by acids, by alkali hydroxides, by glycerin, and by oxidizing
agents. Very soluble in water, in saline TS, and in dextrose solutions;
sparingly soluble in alcohol.
Penicillin G Procaine: White crystals or white, very fine, microcrystal-
line powder. Is odorless or practically odorless, and is relatively stable
in air. Its solutions are dextrorotatory. Is rapidly inactivated by acids,
by alkali hydroxides, and by oxidizing agents. Slightly soluble in water;
soluble in alcohol and in chloroform.
Penicillin G Sodium: Colorless or white crystals or white to slightly
yellow, crystalline powder. Is odorless or practically odorless, and is
moderately hygroscopic. Its solutions are dextrorotatory. Is relatively
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/112
Description and Solubility
stable in air, but is inactivated by prolonged heating at about 100,
especially in the presence of moisture. Its solutions lose potency
fairly rapidly at room temperature, but retain substantially full potency
for several days at temperatures below 15. Its solutions are rapidly
inactivated by acids, by alkali hydroxides, by oxidizing agents, and by
penicillinase.
Penicillin V: White, odorless, crystalline powder. Very slightly soluble
in water; freely soluble in alcohol and in acetone; insoluble in fixed
oils.
Penicillin V Benzathine: Practically white powder, having a character-
istic odor. Very slightly soluble in water; slightly soluble in alcohol and
in ether; sparingly soluble in chloroform.
Penicillin V Potassium: White, odorless, crystalline powder. Very
soluble in water; slightly soluble in alcohol; insoluble in acetone.
Pentazocine: White or very pale, tan-colored powder. Practically in-
soluble in water; freely soluble in chloroform; soluble in alcohol, in ac-
etone, and in ether; sparingly soluble in benzene and in ethyl acetate.
Pentazocine Hydrochloride: White, crystalline powder. It exhibits
polymorphism, one form melting at about 254 and the other at about
P
218. Freely soluble in chloroform; soluble in alcohol; sparingly soluble
in water; very slightly soluble in acetone and in ether; practically in-
S
soluble in benzene.
Pentetic Acid: White, odorless or almost odorless powder. Melts with
U
foaming and degradation at 220.
Pentobarbital: White to practically white, fine, practically odorless
9
powder. May occur in a polymorphic form that melts at about 116.
This form gradually reverts to the more stable higher-melting form
upon being heated at about 110. Very slightly soluble in water and in
carbon tetrachloride; very soluble in alcohol, in methanol, in ether, in
chloroform, and in acetone; soluble in benzene.
Pentobarbital Sodium: White, crystalline granules or white powder.
Is odorless or has a slight characteristic odor, and has a slightly bit-
ter taste. Its solutions decompose on standing, heat accelerating the
decomposition. Very soluble in water; freely soluble in alcohol; practi-
cally insoluble in ether.
Pentoxifylline: White to almost white crystalline powder. Freely solu-
ble in chloroform and in methanol; soluble in water; sparingly soluble
in alcohol; slightly soluble in ether.
Peppermint: Has an aromatic, characteristic odor and a pungent taste,
and produces a cooling sensation in the mouth. NF category: Flavors
and perfumes.
Peppermint Oil: Colorless or pale yellow liquid, having a strong, pen-
etrating, characteristic odor and a pungent taste, followed by a sensa-
tion of cold when air is drawn into the mouth. NF category: Flavors and
perfumes.
Peppermint Spirit: A clear, colorless liquid with a peppermint fra-
grance. Completely soluble in water; easily soluble in methanol and in
diethyl ether. NF category: Flavors and perfumes.
Peppermint Water: NF category: Vehicle (flavored and/or sweetened).
Perflubron: Clear, colorless, practically odorless liquid.
Pergolide Mesylate: White to off-white powder. Sparingly soluble in
methanol; slighly soluble in water, in dehydrated alcohol, and in chlo-
roform; very slightly soluble in acetone; practically insoluble in ether.
Perphenazine: White to creamy white, odorless powder. Practically
insoluble in water; freely soluble in alcohol and in chloroform; soluble
in acetone.
Pertussis Immune Globulin: Transparent or slightly opalescent liq-
uid, practically colorless, free from turbidity or particles, and practi-
cally odorless. May develop a slight, granular deposit during storage.
Is standardized for agglutinating activity with the U.S. Standard Anti-
pertussis Serum.
USP Pharmacists Pharmacopeia
Petrolatum: Unctuous yellowish to light amber mass, having not more
than a slight fluorescence even after being melted. Is transparent in
thin layers. Is free or practically free from odor and taste. Insoluble in
water; freely soluble in benzene, in carbon disulfide, in chloroform,
and in turpentine oil; soluble in ether, in solvent hexane, and in most
fixed and volatile oils; practically insoluble in cold and hot alcohol and
in cold dehydrated alcohol. NF category: Ointment base.
Hydrophilic Petrolatum: NF category: Ointment base.
White Petrolatum: White or faintly yellowish, unctuous mass, trans-
parent in thin layers even after cooling to 0. Insoluble in water; slightly
soluble in cold or hot alcohol, and in cold dehydrated alcohol; freely
soluble in benzene, in carbon disulfide, and in chloroform; soluble
in ether, in solvent hexane, and in most fixed and volatile oils. NF cat-
egory: Ointment base.
Phenazopyridine Hydrochloride: Light or dark red to dark violet,
crystalline powder. Is odorless, or has a slight odor. Melts at about
235, with decomposition. Slightly soluble in water, in alcohol, and in
chloroform.
Phendimetrazine Tartrate: White, odorless, crystalline powder. Freely
soluble in water; sparingly soluble in warm alcohol; insoluble in chlo-
roform, in acetone, in ether, and in benzene. Phendimetrazine base is
extracted by organic solvents from alkaline solution.
Phenelzine Sulfate: White to yellowish white powder, having a charac-
teristic odor. Freely soluble in water; practically insoluble in alcohol, in
chloroform, and in ether.
Pheniramine Maleate: White, crystalline powder having a faint amine-
like odor. Soluble in water and in alcohol.
0
Phenmetrazine Hydrochloride: White to off-white, crystalline powder.
Very soluble in water; freely soluble in alcohol and in chloroform.
0
Phenobarbital: White, odorless, glistening, small crystals, or white,
2
crystalline powder, which may exhibit polymorphism. Is stable in air. Its
saturated solution has a pH of about 5. Very slightly soluble in water;
soluble in alcohol, in ether, and in solutions of fixed alkali hydroxides
and carbonates; sparingly soluble in chloroform.
Phenobarbital Sodium: Flaky crystals, or white, crystalline granules,
or white powder. Is odorless, has a bitter taste, and is hygroscopic.
Its solutions are alkaline to phenolphthalein TS, and decompose on
standing. Very soluble in water; soluble in alcohol; practically insoluble
in ether and in chloroform.
Phenol: Colorless to light pink, interlaced or separate, needle-shaped
crystals, or white to light pink, crystalline mass. Has a characteristic
odor. Is liquefied by warming and by the addition of 10% of water.
Boils at about 182, and its vapor is flammable. Gradually darkens on
exposure to light and air. Soluble in water; very soluble in alcohol, in
glycerin, in chloroform, in ether, and in fixed and volatile oils; sparingly
soluble in mineral oil. NF category: Antimicrobial preservative.
Liquefied Phenol: Colorless to pink liquid, which may develop a red
tint upon exposure to air or light. Has a characteristic, somewhat aro-
matic odor. It whitens and cauterizes the skin and mucous membranes.
Specific gravity is about 1.065. Miscible with alcohol, with ether, and
with glycerin. A mixture of equal volumes of Liquefied Phenol and
glycerin is miscible with water.
Camphorated Phenol Topical Gel: Clear, colorless, oily gel.
Phenolsulfonphthalein: A bright-red to dark-red, crystalline powder.
Very slightly soluble in water; slightly soluble in alcohol.
Phenoxyethanol: A colorless, slightly viscous liquid. Slightly soluble in
water; miscible with acetone, with alcohol, and with glycerol; slightly
soluble in peanut oil and in olive oil. NF category: Antimicrobial pre-
servative.
Phensuximide: White to off-white, crystalline powder. Is odorless, or
has not more than a slight odor. Slightly soluble in water; very soluble
in chloroform; soluble in alcohol.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/113
Description and Solubility
Phentermine Hydrochloride: White, odorless, hygroscopic, crystalline
powder. Soluble in water and in the lower alcohols; slightly soluble in
chloroform; insoluble in ether.
Phentolamine Mesylate: White or off-white, odorless, crystalline pow-
der. Its solutions are acid to litmus, having a pH of about 5, and slowly
deteriorate. Melts at about 178. Freely soluble in water and in alcohol;
slightly soluble in chloroform.
Phenylalanine: White, odorless crystals, having a slightly bitter taste.
Sparingly soluble in water; very slightly soluble in methanol, in alcohol,
and in dilute mineral acids.
Phenylbenzimidazole Sulfonic Acid: White to ivory-colored, odorless
powder. Soluble in alcohol; practically insoluble in oily solvents and in
water. Its salts are freely soluble in water.
Phenylbutazone: White to off-white, odorless, crystalline powder.
Very slightly soluble in water; freely soluble in acetone and in ether;
soluble in alcohol.
Phenylephrine Bitartrate: White or almost white powder or colorless
crystals. Freely soluble in water.
Phenylephrine Hydrochloride: White or practically white, odorless
P
crystals, having a bitter taste. Freely soluble in water and in alcohol.
S
Phenylephrine Hydrochloride Nasal Solution: Clear, colorless or
slightly yellow, odorless liquid. Is neutral or acid to litmus.
Phenylephrine Hydrochloride Ophthalmic Solution: Clear, colorless
U
or slightly yellow liquid, depending on the concentration.
Phenylethyl Alcohol: Colorless liquid, having a rose-like odor and a
9
sharp, burning taste. Sparingly soluble in water; very soluble in alco-
hol, in fixed oils, in glycerin, and in propylene glycol; slightly soluble in
mineral oil. NF category: Antimicrobial preservative.
Phenylmercuric Acetate: White to creamy white, crystalline pow-
der, or small white prisms or leaflets. Is odorless. Slightly soluble in
water; soluble in alcohol and in acetone. NF category: Antimicrobial
preservative.
Phenylmercuric Nitrate: White, crystalline powder. Is affected by light.
Its saturated solution is acid to litmus. Very slightly soluble in water;
slightly soluble in alcohol and in glycerin. It is more soluble in the
presence of either nitric acid or alkali hydroxides. NF category: Antimi-
crobial preservative.
Phenylpropanolamine Bitartrate: White, crystalline powder.
Phenylpropanolamine Hydrochloride: White, crystalline powder, hav-
ing a slight aromatic odor. Is affected by light. Freely soluble in water
and in alcohol; insoluble in ether.
Phenyltoloxamine Citrate: White, crystalline powder. Very soluble in
boiling water; slightly soluble in cold water and in alcohol; practically
insoluble in cold acetone, in ethyl ether, and in toluene.
Phenytoin: White, odorless powder. Melts at about 295. Practically in-
soluble in water; soluble in hot alcohol; slightly soluble in cold alcohol,
in chloroform, and in ether.
Phenytoin Sodium: White, odorless powder. Is somewhat hygro-
scopic and on exposure to air gradually absorbs carbon dioxide. Freely
soluble in water, the solution usually being somewhat turbid due to
partial hydrolysis and absorption of carbon dioxide; soluble in alcohol;
practically insoluble in ether and in chloroform.
Sodium Phosphate P 32 Solution: Clear, colorless solution. Upon
standing, both the Solution and the glass container may darken as a
result of the effects of the radiation.
Phosphoric Acid: Colorless, odorless liquid of syrupy consistency.
Specific gravity is about 1.71. Miscible with water and with alcohol. NF
category: Acidifying agent; buffering agent.
Diluted Phosphoric Acid: Clear, colorless, odorless liquid. Specific
gravity is about 1.057. NF category: Acidifying agent.
USP Pharmacists Pharmacopeia
Physostigmine: White, odorless, microcrystalline powder. Acquires a
red tint when exposed to heat, light, air, or contact with traces of met-
als. Melts at a temperature not lower than 103. Slightly soluble in wa-
ter; very soluble in chloroform and in dichloromethane; freely soluble
in alcohol; soluble in benzene and in fixed oils.
Physostigmine Salicylate: White, shining, odorless crystals or white
powder. Acquires a red tint when exposed to heat, light, air, or con-
tact with traces of metals for long periods. Melts at about 184. Spar-
ingly soluble in water; freely soluble in chloroform; soluble in alcohol;
slightly soluble in ether.
Physostigmine Sulfate: White, odorless, microcrystalline powder. Is
deliquescent in moist air and acquires a red tint when exposed to heat,
light, air, or contact with traces of metals for long periods. Melts at
about 143. Freely soluble in water; very soluble in alcohol; very slightly
soluble in ether.
Phytonadione: Clear, yellow to amber, very viscous, odorless or practi-
cally odorless liquid, having a specific gravity of about 0.967. Is stable
in air, but decomposes on exposure to sunlight. Insoluble in water;
soluble in dehydrated alcohol, in benzene, in chloroform, in ether, and
in vegetable oils; slightly soluble in alcohol.
Pilocarpine: A viscous, oily liquid, or crystals melting at about 34. Ex-
ceedingly hygroscopic. Soluble in water, in alcohol, and in chloroform;
practically insoluble in petroleum ether; sparingly soluble in ether and
in benzene.
Pilocarpine Hydrochloride: Colorless, translucent, odorless, faintly
bitter crystals. Is hygroscopic and is affected by light. Its solutions are
acid to litmus. Very soluble in water; freely soluble in alcohol; slightly
0
soluble in chloroform; insoluble in ether.
Pilocarpine Nitrate: Shining, white crystals. Is stable in air but is af-
0
fected by light. Its solutions are acid to litmus. Freely soluble in water;
sparingly soluble in alcohol; insoluble in chloroform and in ether.
2
Pimozide: White, crystalline powder. Insoluble in water; slightly
soluble in ether and in alcohol; freely soluble in chloroform.
Pindolol: White to off-white, crystalline powder, having a faint odor.
Practically insoluble in water; slightly soluble in methanol; very slightly
soluble in chloroform.
Piperacillin: White to off-white, crystalline powder. Very slightly sol-
uble in water; very soluble in methanol; sparingly soluble in isopropyl
alcohol; slightly soluble in ethyl acetate.
Piperacillin Sodium: White to off-white solid. Freely soluble in water
and in alcohol.
Piperazine: White to slightly off-white lumps or flakes, having an am-
moniacal odor. Soluble in water and in alcohol; insoluble in ether.
Piperazine Adipate: White crystalline powder. Soluble in water; practi-
cally insoluble in alcohol.
Piperazine Citrate: White, crystalline powder, having not more than a
slight odor. Its solution (1 in 10) has a pH of about 5. Soluble in water;
insoluble in alcohol and in ether.
Piperazine Dihydrochloride: White crystalline powder. Soluble in
water.
Piperazine Phosphate: White crystalline powder. Sparingly soluble in
water; practically insoluble in alcohol.
Piroxicam: Off-white to light tan or light yellow, odorless powder.
Forms a monohydrate that is yellow. Very slightly soluble in water, in
dilute acids, and in most organic solvents; slightly soluble in alcohol
and in aqueous alkaline solutions.
Plantago Seed: All varieties are practically odorless and have a bland,
mucilaginous taste.
Plicamycin: Yellow, odorless, hygroscopic, crystalline powder. Slightly
soluble in water and in methanol; very slightly soluble in alcohol;
freely soluble in ethyl acetate.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/114
Description and Solubility
Podophyllum: Has a slight odor and a disagreeably bitter and acrid
taste.
Podophyllum Resin: Amorphous powder, varying in color from light
brown to greenish yellow, turning darker when subjected to a tem-
perature exceeding 25 or when exposed to light. Has a slight, peculiar,
faintly bitter taste. Its alcohol solution is acid to moistened litmus
paper. Soluble in alcohol with a slight opalescence; partially soluble in
ether and in chloroform.
Polacrilin Potassium: White to off-white, free-flowing powder. Has a
faint odor or is odorless. Insoluble in water and in most liquids. NF
category: Tablet disintegrant.
Poliovirus Vaccine Inactivated: Clear, reddish-tinged or yellowish liq-
uid, that may have a slight odor because of the preservative.
Poloxalene: Colorless or pale yellow liquid. Soluble in water, in chlo-
roform, and in ethylene dichloride.
Poloxamer: NF category: Emulsifying and/or solubilizing agent; wet-
ting and/or solubilizing agent.
Poloxamer 124: Colorless liquid, having a mild odor. When solidi-
fied, it melts at about 16. Freely soluble in water, in alcohol, in isopro-
P
pyl alcohol, in propylene glycol, and in xylene.
S
Poloxamer 188: White, prilled or cast solid. Is odorless, or has
a very mild odor. Melts at about 52. Freely soluble in water and in
alcohol.
U
Poloxamer 237: White, prilled or cast solid. Is odorless, or has a
very mild odor. Melts at about 49. Freely soluble in water and in alco-
9
hol; sparingly soluble in isopropyl alcohol and in xylene.
Poloxamer 338: White, prilled or cast solid. Is odorless, or has a
very mild odor. Melts at about 57. Freely soluble in water and in alco-
hol; sparingly soluble in propylene glycol.
Poloxamer 407: White, prilled or cast solid. Is odorless, or has a
very mild odor. Melts at about 56. Freely soluble in water, in alcohol,
and in isopropyl alcohol.
Polycarbophil: White to creamy white granules, having a characteris-
tic, ester-like odor. Swells in water to a range of volumes, depending
primarily on the pH. Insoluble in water, in dilute acids, in dilute alka-
lies, and in common organic solvents.
Hydrogenated Polydecene: Clear, colorless, odorless, tasteless liquid.
Very slightly soluble in water. NF category: Emollient; ointment base;
solvent; vehicle (oleaginous).
Polydextrose: Off-white to light tan-colored solid. Very soluble in
water; slightly soluble in glycerin and in propylene glycol; insoluble in
alcohol. NF category: Bulking agent; humectant.
Polyethylene Glycol: Polyethylene Glycol is usually designated by
a number that corresponds approximately to its average molecular
weight. As the average molecular weight increases, the water solubil-
ity, vapor pressure, hygroscopicity, and solubility in organic solvents
decrease, while congealing temperature, specific gravity, flash point,
and viscosity increase. Liquid grades occur as clear to slightly hazy,
colorless or practically colorless, slightly hygroscopic, viscous liquids,
having a slight, characteristic odor, and a specific gravity at 25 of
about 1.12. Solid grades occur as practically odorless and tasteless,
white, waxy, plastic material having a consistency similar to beeswax,
or as creamy white flakes, beads, or powders. The accompanying table
states the approximate congealing temperatures that are characteristic
of commonly available grades. Liquid grades are miscible with water;
solid grades are freely soluble in water; and all are soluble in acetone,
in alcohol, in chloroform, in ethylene glycol monoethyl ether, in ethyl
acetate, and in toluene; all are insoluble in ether and in hexane. NF
category: Coating agent; plasticizer; solvent; suppository base; tablet
and/or capsule lubricant.
USP Pharmacists Pharmacopeia
Nominal Molecular Weight Approximate Congealing
Polyethylene Glycol Temperature ()
300 11
400 6
600 20
900 34
1000 38
1450 44
3350 56
4500 58
8000 60
Polyethylene Glycol Monomethyl Ether: Polyethylene Glycol Mono-
methyl Ether is usually designated by a number that corresponds ap-
proximately to its average molecular weight. As the average molecular
weight increases, the water solubility, vapor pressure, hygroscopicity,
and solubility in organic solvents decrease, while congealing tempera-
ture, specific gravity, flash point, and viscosity increase. Liquid grades
occur as clear to slightly hazy, colorless or practically colorless, slightly
hygroscopic, viscous liquids, having a slight, characteristic odor, and
a specific gravity at 25 of about 1.09 1.10. Solid grades occur as
practically odorless and tasteless, white, waxy, plastic material having
a consistency similar to beeswax, or as creamy white flakes, beads, or
powders. The accompanying table states the approximate congealing
temperatures that are characteristic of commonly available grades.
Liquid grades are miscible with water; solid grades are freely soluble
in water; and all are soluble in acetone, in alcohol, in chloroform, in
ethylene glycol monoethyl ether, in ethyl acetate, and in toluene; all
are insoluble in ether and in hexane. NF category: Ointment base;
solvent; plasticizer.
0
0
Nominal Molecular Weight
Polyethylene Glycol Approximate Congealing
2
Monomethyl Ether Temperature ()
350 7
550 17
750 28
1000 35
2000 51
5000 59
8000 60
10000 61
Polyethylene Oxide: Polyethylene oxide resins are high molecular
weight polymers having the common structure:
(OCH2CH2)n
in which n, the degree of polymerization, varies from about 2000 to
over 100,000. Polyethylene oxide, being a polyether, strongly hydrogen,
bonds with water. It is nonionic and undergoes salting-out effects as-
sociated with neutral molecules in solutions of high dielectric media.
Salting-out effects manifest themselves in depressing the upper tem-
perature limit of solubility, and in reducing the viscosity of both dilute
and concentrated solutions of the polymers. All molecular weight
grades are powdered or granular solids. They are soluble in water but,
because of the high solution viscosities obtained (see table), solutions
over 1% in water may be difficult to prepare. The water solubility,
hygroscopicity, solubility in organic solvents, and melting point do not
vary in the specified molecular weight range. At room temperature
polyethylene oxide is miscible with water in all proportions. At concen-
trations of about 20% polymer in water, the solutions are nontacky, re-
versible, elastic gels. At higher concentrations, the solutions are tough,
elastic materials with the water acting as a plasticizer. Polyethylene
oxide is also freely soluble in acetonitrile, in ethylene dichloride, in
trichloroethylene, and in methylene chloride. Heating may be required
to obtain solutions in many other organic solvents. It is insoluble in
aliphatic hydrocarbons, in ethylene glycol, in diethylene glycol, and in
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/115
Description and Solubility
glycerol. NF category: Suspending and/or viscosity-increasing agent;
tablet binder.
Approximate Typical Solution Viscosity (cps), 25
Molecular Weight 5% Solution 1% Solution
0,100,000 40
0,200,000 100
0,300,000 800
0,400,000 3000
0,600,000 6000
0,900,000 15000
4,000,000 3500
5,000,000 5500
Polyethylene 50 Stearate: NF category: Emulsifying and/or solubilizing
agent.
Polyisobutylene: Low molecular-weight grades are soft and gummy;
high molecular-weight grades are tough and elastic. All grades are light
in color, odorless, and tasteless. Soluble in diisobutylene, in toluene,
and in chloroform; insoluble in water.
P
Polymyxin B Sulfate: White to buff-colored powder. Is odorless or has
a faint odor. Freely soluble in water; slightly soluble in alcohol.
S
Polyoxyl Lauryl Ether: A material with 35 oxyethylene units per mol-
ecule is a colorless liquid. Soluble or dispersible in alcohol; practically
insoluble in water and in hexane. A material with 923 oxyethylene
U
units per molecule is a white, waxy mass. Soluble or dispersible in
water; soluble in alcohol; practically insoluble in hexane. NF category:
9
Emulsifying and/or solubilizing agent.
Polyoxyl Oleate: A slightly yellowish, viscous liquid. Dispersible in
water and in oils; soluble in alcohol and in isopropyl alcohol; miscible
with fatty oils and with waxes. Its refractive index is about 1.466.
Polyoxyl 10 Oleyl Ether: White, soft semisolid, or pale yellow liquid,
having a bland odor. Soluble in water and in alcohol; dispersible in
mineral oil and in propylene glycol, with possible separation on stand-
ing. NF category: Emulsifying and/or solubilizing agent; tablet and/or
capsule lubricant; wetting and/or solubilizing agent.
Polyoxyl 20 Cetostearyl Ether: Cream-colored, waxy, unctuous mass,
melting, when heated, to a clear brownish-yellow liquid. Soluble in
water, in alcohol, and in acetone; insoluble in solvent hexane. NF
category: Emulsifying and/or solubilizing agent; tablet and/or capsule
lubricant; wetting and/or solubilizing agent.
Polyoxyl 35 Castor Oil: Yellow, oily liquid, having a faint, characteristic
odor and a somewhat bitter taste. Very soluble in water, producing a
practically odorless and colorless solution; soluble in alcohol and in
ethyl acetate; insoluble in mineral oils. NF category: Emulsifying and/
or solubilizing agent; tablet and/or capsule lubricant; wetting and/or
solubilizing agent.
Polyoxyl 40 Hydrogenated Castor Oil: White to yellowish paste or
pasty liquid, having a faint odor and a slight taste. Very soluble in wa-
ter, producing a practically tasteless, odorless, and colorless solution;
soluble in alcohol and in ethyl acetate; insoluble in mineral oils. NF
category: Emulsifying and/or solubilizing agent; tablet and/or capsule
lubricant; wetting and/or solubilizing agent.
Polyoxyl 40 Stearate: Waxy, white to light tan solid. Is odorless or has a
faint, fat-like odor. Soluble in water, in alcohol, in ether, and in acetone;
insoluble in mineral oil and in vegetable oils. NF category: Emulsify-
ing and/or solubilizing agent; tablet and/or capsule lubricant; wetting
and/or solubilizing agent.
Polyoxyl Stearyl Ether: A white to yellowish-white, waxy, unctuous
mass, pellets, microbeads, or flakes. Polyoxyl Stearyl Ether with 2 oxy-
ethylene units per molecule is practically insoluble in water; soluble
in alcohol, with heating, and in methylene chloride. Polyoxyl Stearyl
Ether with 10 oxyethylene units per molecule is soluble in water and in
alcohol. Polyoxyl Stearyl Ether with 20 oxethylene units per molecule is
soluble in water, in alcohol, and in methylene chloride. After melting,
it solidifies at about 45.
USP Pharmacists Pharmacopeia
Polysorbate 20: Lemon to amber liquid having a faint characteristic
odor. Soluble in water, in alcohol, in ethyl acetate, in methanol, and
in dioxane; insoluble in mineral oil. NF category: Emulsifying and/or
solubilizing agent; tablet and/or capsule lubricant; wetting and/or
solubilizing agent.
Polysorbate 40: Yellow liquid having a faint, characteristic odor. Solu-
ble in water and in alcohol; insoluble in mineral oil and in vegetable
oils. NF category: Emulsifying and/or solubilizing agent; tablet and/or
capsule lubricant; wetting and/or solubilizing agent.
Polysorbate 60: Lemon- to orange-colored, oily liquid or semi-gel hav-
ing a faint, characteristic odor. Soluble in water, in ethyl acetate, and
in toluene; insoluble in mineral oil and in vegetable oils. NF category:
Emulsifying and/or solubilizing agent; tablet and/or capsule lubricant;
wetting and/or solubilizing agent.
Polysorbate 80: Lemon- to amber-colored, oily liquid having a faint,
characteristic odor and a warm, somewhat bitter taste. Very soluble in
water, producing an odorless and practically colorless solution; soluble
in alcohol and in ethyl acetate; insoluble in mineral oil. NF category:
Emulsifying and/or solubilizing agent; tablet and/or capsule lubricant;
wetting and/or solubilizing agent.
Polyvinyl Acetate Phthalate: Free-flowing white powder. May have a
slight odor of acetic acid. Insoluble in water, in methylene chloride,
and in chloroform; soluble in methanol and in alcohol. NF category:
Coating agent.
Polyvinyl Alcohol: White to cream-colored granules, or white to
cream-colored powder. Is odorless. Freely soluble in water at room
temperature. Solution may be effected more rapidly at somewhat
higher temperatures. NF category: Suspending and/or viscosity-
increasing agent.
0
Sulfurated Potash: Irregular, liver-brown pieces when freshly made,
0
changing to a greenish yellow. Has an odor of hydrogen sulfide and a
bitter, acrid, and alkaline taste, and decomposes on exposure to air. A
2
solution (1 in 10) is light brown in color and is alkaline to litmus. Freely
soluble in water, usually leaving a slight residue. Alcohol dissolves only
the sulfides.
Potassium Acetate: Colorless, monoclinic crystals or white, crystalline
powder having a saline and slightly alkaline taste. Is odorless, or has a
faint acetous odor. Deliquesces on exposure to moist air. Very soluble
in water; freely soluble in alcohol.
Potassium Alginate: White to yellow, fibrous or granular powder.
Dissolves in water to form a viscous, colloidal solution; insoluble in
alcohol and in hydroalcoholic solutions in which the alcohol content
is greater than 30% by weight; insoluble in chloroform, in ether, and in
acids having a pH lower than about 3.
Potassium Benzoate: White, odorless, or practically odorless, granular
or crystalline powder. Is stable in air. Freely soluble in water; sparingly
soluble in alcohol and somewhat more soluble in 90% alcohol. NF
category: Antimicrobial preservative.
Potassium Bicarbonate: Colorless, transparent, monoclinic prisms or
as a white, granular powder. Is odorless, and is stable in air. Its solu-
tions are neutral or alkaline to phenolphthalein TS. Freely soluble in
water; practically insoluble in alcohol.
Potassium Bitartrate: Colorless or slightly opaque crystals, or white,
crystalline powder. A saturated solution is acid to litmus. Soluble
in boiling water; slightly soluble in water; very slightly soluble in
alcohol.
Potassium Bromide: White, crystalline powder or colorless, cubical
crystals. Freely soluble in water and in glycerol; slightly soluble in
alcohol.
Potassium Chloride: Colorless, elongated, prismatic, or cubical crys-
tals, or white, granular powder. Is odorless, has a saline taste, and is
stable in air. Its solutions are neutral to litmus. Freely soluble in water
and even more soluble in boiling water; insoluble in alcohol. NF cat-
egory: Tonicity agent.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/116
Description and Solubility
Potassium Citrate: Transparent crystals or white, granular powder. Is
odorless, has a cooling, saline taste, and is deliquescent when exposed
to moist air. Freely soluble in water; almost insoluble in alcohol. NF
category: Buffering agent.
Potassium Gluconate: White to yellowish-white, crystalline powder
or granules. Is odorless, has a slightly bitter taste, and is stable in air.
Its solutions are slightly alkaline to litmus. Freely soluble in water;
practically insoluble in dehydrated alcohol, in ether, in benzene, and
in chloroform.
Potassium Hydroxide: White or practically white, fused masses, or
small pellets, or flakes, or sticks, or other forms. Is hard and brittle and
shows a crystalline fracture. Exposed to air, it rapidly absorbs carbon
dioxide and moisture, and deliquesces. Freely soluble in water, in
alcohol, and in glycerin; very soluble in boiling alcohol. NF category:
Alkalizing agent.
Potassium Iodide: Hexahedral crystals, either transparent and color-
less or somewhat opaque and white, or a white, granular powder. Is
slightly hygroscopic. Its solutions are neutral or alkaline to litmus. Very
soluble in water and even more soluble in boiling water; freely soluble
in glycerin; soluble in alcohol.
P
Potassium Iodide Oral Solution: Clear, colorless, odorless liquid, hav-
ing a characteristic, strongly salty taste. Is neutral or alkaline to litmus.
S
Specific gravity is about 1.70.
Potassium Metabisulfite: White or colorless, free-flowing crystals,
U
crystalline powder, or granules, usually having an odor of sulfur diox-
ide. Gradually oxidizes in air to the sulfate. Its solutions are acid to lit-
mus. Soluble in water; insoluble in alcohol. NF category: Antioxidant.
9
Potassium Metaphosphate: White, odorless powder. Insoluble in
water; soluble in dilute solutions of sodium salts. NF category: Buffer-
ing agent.
Potassium Nitrate: White, crystalline powder or colorless crystals.
Freely soluble in water; very soluble in boiling water; soluble in glyc-
erin; practically insoluble in alcohol.
Potassium Permanganate: Dark purple crystals, almost opaque by
transmitted light and of a blue metallic luster by reflected light. Its
color is sometimes modified by a dark bronze-like appearance. Is
stable in air. Soluble in water; freely soluble in boiling water.
Dibasic Potassium Phosphate: Colorless or white, somewhat hy-
groscopic, granular powder. The pH of a solution (1 in 20) is about
8.5 to 9.6. Freely soluble in water; very slightly soluble in alcohol. NF
category: Buffering agent.
Monobasic Potassium Phosphate: Colorless crystals or white, granular
or crystalline powder. Is odorless, and is stable in air. The pH of a solu-
tion (1 in 100) is about 4.5. Freely soluble in water; practically insoluble
in alcohol. NF category: Buffering agent.
Potassium Sodium Tartrate: Colorless crystals or white, crystalline
powder, having a cooling, saline taste. As it effloresces slightly in
warm, dry air, the crystals are often coated with a white powder. Freely
soluble in water; practically insoluble in alcohol.
Potassium Sorbate: White crystals or powder, having a characteristic
odor. Melts at about 270, with decomposition. Freely soluble in water;
soluble in alcohol. NF category: Antimicrobial preservative.
Povidone: White to slightly creamy white powder. Is hygroscopic.
Freely soluble in water, in methanol, and in alcohol; slightly soluble in
acetone; practically insoluble in ether. NF category: Suspending and/or
viscosity-increasing agent; tablet binder.
Povidone-Iodine: Yellowish-brown to reddish-brown, amorphous
powder, having a slight, characteristic odor. Its solution is acid to
litmus. Soluble in water and in alcohol; practically insoluble in chlo-
roform, in carbon tetrachloride, in ether, in solvent hexane, and in
acetone.
Povidone-Iodine Topical Aerosol Solution: The liquid obtained from
Povidone-Iodine Topical Aerosol Solution is transparent, having a red-
dish brown color.
USP Pharmacists Pharmacopeia
Pralidoxime Chloride: White to pale-yellow, crystalline powder. Is
odorless and is stable in air. Freely soluble in water.
Pramoxine Hydrochloride: White to practically white, crystalline
powder, having a numbing taste. May have a slight aromatic odor. The
pH of a solution (1 in 100) is about 4.5. Freely soluble in water and in
alcohol; soluble in chloroform; very slightly soluble in ether.
Pravastatin Sodium: White to yellowish white, hygroscopic powder.
Freely soluble in water and in methanol; soluble in alcohol; very
slightly soluble in acetonitrile; practically insoluble in ether, in ethyl
acetate, and in chloroform.
Praziquantel: White or practically white, crystalline powder; odorless
or having a faint characteristic odor. Very slightly soluble in water;
freely soluble in alcohol and in chloroform.
Prazosin Hydrochloride: White to tan powder. Slightly soluble in
water, in methanol, in dimethylformamide, and in dimethylacetamide;
very slightly soluble in alcohol; practically insoluble in chloroform and
in acetone.
Prednicarbate: White to almost white, crystalline powder. Freely sol-
uble in acetone and in alcohol; sparingly soluble in propylene glycol;
practically insoluble in water.
Prednisolone: White to practically white, odorless, crystalline powder.
Melts at about 235, with some decomposition (see Melting Range or
Temperature 741). Very slightly soluble in water; soluble in methanol
and in dioxane; sparingly soluble in acetone and in alcohol; slightly
soluble in chloroform.
Prednisolone Acetate: White to practically white, odorless, crystalline
powder. Melts at about 235, with some decomposition (see Melting
Range or Temperature 741). Practically insoluble in water; slightly
0
soluble in acetone, in alcohol, and in chloroform.
Prednisolone Hemisuccinate: Fine, creamy white powder with friable
0
lumps; practically odorless. Melts at about 205, with decomposition.
Very slightly soluble in water; freely soluble in alcohol; soluble in
2
acetone.
Prednisolone Sodium Phosphate: White or slightly yellow, friable
granules or powder. Is odorless or has a slight odor. Is slightly hygro-
scopic. Freely soluble in water; soluble in methanol; slightly soluble
in alcohol and in chloroform; very slightly soluble in acetone and in
dioxane.
Prednisolone Sodium Succinate for Injection: Creamy white powder
with friable lumps, having a slight odor.
Prednisolone Tebutate: White to slightly yellow, free-flowing powder,
which may show some soft lumps. Is odorless or has not more than a
moderate, characteristic odor. Is hygroscopic. Very slightly soluble in
water; freely soluble in chloroform and in dioxane; soluble in acetone;
sparingly soluble in alcohol and in methanol.
Prednisone: White to practically white, odorless, crystalline powder.
Melts at about 230, with some decomposition (see Melting Range or
Temperature 741). Very slightly soluble in water; slightly soluble in
alcohol, in chloroform, in dioxane, and in methanol.
Prilocaine: White or almost white powder or crystal aggregates. Very
soluble in alcohol and in acetone; slightly soluble in water.
Prilocaine Hydrochloride: White, odorless, crystalline powder, having
a bitter taste. Freely soluble in water and in alcohol; slightly soluble
in chloroform; very slightly soluble in acetone; practically insoluble
in ether.
Primaquine Phosphate: Orange-red, crystalline powder. Is odorless
and has a bitter taste. Its solutions are acid to litmus. Melts at about
200. Soluble in water; insoluble in chloroform and in ether.
Primidone: White, crystalline powder. Is odorless and has a slightly
bitter taste. Very slightly soluble in water and in most organic solvents;
slightly soluble in alcohol.
Probucol: White to off-white, crystalline powder. Insoluble in water;
freely soluble in chloroform and in n-propyl alcohol; soluble in alcohol
and in solvent hexane.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/117
Description and Solubility
Probenecid: White or practically white, fine, crystalline powder. Is
practically odorless. Practically insoluble in water and in dilute acids;
soluble in dilute alkali, in chloroform, in alcohol, and in acetone.
Procainamide Hydrochloride: White to tan, crystalline powder. Is
odorless. Its solution (1 in 10) has a pH between 5 and 6.5. Very soluble
in water; soluble in alcohol; slightly soluble in chloroform; very slightly
soluble in benzene and in ether.
Procainamide Hydrochloride Injection: Colorless, or having not more
than a slight yellow color.
Procaine Hydrochloride: Small, white crystals or white, crystalline
powder. Is odorless. Exhibits local anesthetic properties when placed
on the tongue. Freely soluble in water; soluble in alcohol; slightly
soluble in chloroform; practically insoluble in ether.
Procaine Hydrochloride Injection: Clear, colorless liquid.
Prochlorperazine: Clear, pale yellow, viscous liquid. Is sensitive to
light. Very slightly soluble in water; freely soluble in alcohol, in chlo-
roform, and in ether.
Prochlorperazine Edisylate: White to very light yellow, odorless, crys-
talline powder. Its solutions are acid to litmus. Freely soluble in water;
very slightly soluble in alcohol; insoluble in ether and in chloroform.
P
Prochlorperazine Maleate: White or pale yellow, practically odorless,
S
crystalline powder. Its saturated solution is acid to litmus. Practically in-
soluble in water and in alcohol; slightly soluble in warm chloroform.
Procyclidine Hydrochloride: White, crystalline powder, having a mod-
U
erate, characteristic odor. Melts at about 225, with decomposition.
Soluble in water and in alcohol; insoluble in ether and in acetone.
9
Progesterone: White or creamy white, odorless, crystalline powder.
Is stable in air. Practically insoluble in water; soluble in alcohol, in
acetone, and in dioxane; sparingly soluble in vegetable oils.
Proline: White, odorless crystals, having a slightly sweet taste. Freely
soluble in water and in absolute alcohol; insoluble in ether, in butanol,
and in isopropanol.
Promazine Hydrochloride: White to slightly yellow, practically odor-
less, crystalline powder. It oxidizes upon prolonged exposure to
air and acquires a blue or pink color. Freely soluble in water and in
chloroform.
Promethazine Hydrochloride: White to faint yellow, practically odor-
less, crystalline powder. Slowly oxidizes, and acquires a blue color, on
prolonged exposure to air. Freely soluble in water, in hot dehydrated
alcohol, and in chloroform; practically insoluble in ether, in acetone,
and in ethyl acetate.
Propafenone Hydrochloride: White powder. Soluble in methanol and
in hot water; slightly soluble in alcohol and in chloroform; very slightly
soluble in acetone; insoluble in diethyl ether and in toluene.
Propane: Colorless, flammable gas (boiling temperature is about
42). One hundred volumes of water dissolves 6.5 volumes at 17.8
and 753 mm pressure; 100 volumes of anhydrous alcohol dissolves 790
volumes at 16.6 and 754 mm pressure; 100 volumes of ether dissolves
926 volumes at 16.6 and 757 mm pressure; 100 volumes of chloroform
dissolves 1299 volumes at 21.6 and 757 mm pressure. Vapor pressure
at 21 is about 10290 mm of mercury (108 psig). NF category: Aerosol
propellant.
Propantheline Bromide: White or practically white crystals. Is odorless
and has a bitter taste. Melts at about 160, with decomposition. Very
soluble in water, in alcohol, and in chloroform; practically insoluble in
ether and in benzene.
Proparacaine Hydrochloride: White to off-white, or faintly buff-col-
ored, odorless, crystalline powder. Its solutions are neutral to litmus.
Soluble in water, in warm alcohol, and in methanol; insoluble in ether
and in benzene.
Proparacaine Hydrochloride Ophthalmic Solution: Colorless or faint
yellow solution.
Propionic Acid: Oily liquid having a slight pungent, rancid odor. Mis-
cible with water and with alcohol and various other organic solvents.
NF category: Acidifying agent.
USP Pharmacists Pharmacopeia
Propofol: Clear, colorless to slightly yellowish liquid. Very soluble in
methanol and in ethanol; slightly soluble in cyclohexane and in isopro-
pyl alcohol; very slightly soluble in water.
Propoxycaine Hydrochloride: White, odorless, crystalline solid, which
discolors on prolonged exposure to light and air. The pH of a solu-
tion (1 in 50) is about 5.4. Freely soluble in water; soluble in alcohol;
sparingly soluble in ether; practically insoluble in acetone and in
chloroform.
Propoxyphene Hydrochloride: White, crystalline powder. Is odorless,
and has a bitter taste. Freely soluble in water; soluble in alcohol, in
chloroform, and in acetone; practically insoluble in benzene and in
ether.
Propoxyphene Napsylate: White powder, having essentially no odor,
but having a bitter taste. Very slightly soluble in water; soluble in
methanol, in alcohol, in chloroform, and in acetone.
Propranolol Hydrochloride: White to off-white, crystalline powder.
Is odorless and has a bitter taste. Melts at about 164. Soluble in water
and in alcohol; slightly soluble in chloroform; practically insoluble in
ether.
Propyl Gallate: White, crystalline powder having a very slight, char-
acteristic odor. Slightly soluble in water; freely soluble in alcohol. NF
category: Antioxidant.
Propylene Glycol: Clear, colorless, viscous liquid having a slight, char-
acteristic taste. Is practically odorless. Absorbs moisture when exposed
to moist air. Miscible with water, with acetone, and with chloroform.
Soluble in ether and will dissolve many essential oils, but is immiscible
with fixed oils. NF category: Humectant; plasticizer; solvent.
Propylene Glycol Alginate: White to yellowish fibrous or granular
0
powder. Practically odorless and tasteless. Soluble in water, in solutions
of dilute organic acids, and, depending on the degree of esterification,
0
in hydroalcoholic mixture containing up to 60% by weight of alcohol
to form stable, viscous colloidal solutions at a pH of 3. NF category:
2
Suspending and/or viscosity-increasing agent.
Propylene Glycol Dicaprylate/Dicaprate: Clear, colorless or slightly
yellow oily liquid at 20. Soluble in fatty oils and in light petroleum;
slightly soluble in dehydrated alcohol; practically insoluble in water. NF
category: Emulsifying and/or solubilizing agent; vehicle.
Propylene Glycol Dilaurate: Clear, oily liquid at 20. Colorless or
slightly yellow. Very soluble in alcohol, in methanol, and in methylene
chloride; practically insoluble in water.
Propylene Glycol Monocaprylate: Clear, colorless, or slightly yellow,
oily liquid at 20. Very soluble in alcohol, in chloroform, and in methy-
lene chloride; practically insoluble in water. NF category: Emulsifying
and/or solubilizing agent; tablet and/or capsule diluent; vehicle.
Propylene Glycol Monolaurate: Clear, oily liquid at 20. Colorless or
slightly yellow. Very soluble in alcohol, in methanol, and in methylene
chloride; practically insoluble in water.
Propylene Glycol Monostearate: White, wax-like solid or as white,
wax-like beads or flakes. Has a slight, agreeable, fatty odor and taste.
Insoluble in water, but may be dispersed in hot water with the aid of a
small amount of soap or other suitable surface-active agent; soluble in
organic solvents such as alcohol, mineral or fixed oils, benzene, ether,
and acetone. NF category: Emulsifying and/or solubilizing agent.
Propylhexedrine: Clear, colorless liquid, having a characteristic,
amine-like odor. Volatilizes slowly at room temperature. Absorbs car-
bon dioxide from the air, and its solutions are alkaline to litmus. Boils
at about 205. Very slightly soluble in water. Miscible with alcohol, with
chloroform, and with ether.
Propyliodone: White or almost white, crystalline powder. Is odorless
or has a faint odor. Practically insoluble in water; soluble in acetone, in
alcohol, and in ether.
Propylparaben: Small, colorless crystals or white powder. Very slightly
soluble in water; freely soluble in alcohol and in ether; slightly soluble
in boiling water. NF category: Antimicrobial preservative.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/118
Description and Solubility
Propylparaben Sodium: White powder. Is odorless and hygroscopic.
Freely soluble in water; sparingly soluble in alcohol; insoluble in fixed
oils. NF category: Antimicrobial preservative.
Propylthiouracil: White, powdery, crystalline substance. Is starch-like
in appearance and to the touch, and has a bitter taste. Slightly solu-
ble in water; sparingly soluble in alcohol; slightly soluble in chlo-
roform and in ether; soluble in ammonium hydroxide and in alkali
hydroxides.
Protamine Sulfate Injection: Colorless solution, which may have the
odor of a preservative.
Protamine Sulfate for Injection: White, odorless powder, having the
characteristic appearance of solids dried from the frozen state.
Protein Hydrolysate Injection: Yellowish to reddish-amber, transpar-
ent liquid.
Protriptyline Hydrochloride: White to yellowish powder. Is odorless,
or has not more than a slight odor. Melts at about 168. Freely soluble
in water, in alcohol, and in chloroform; practically insoluble in ether.
Pseudoephedrine Hydrochloride: Fine, white to off-white crystals or
powder, having a faint characteristic odor. Very soluble in water; freely
soluble in alcohol; slightly soluble in chloroform.
P
Pseudoephedrine Sulfate: White crystals or crystalline powder. Is
S
odorless. Freely soluble in alcohol.
Pullulan: White powder. Freely soluble in water; practically insoluble
in dehydrated alcohol. NF category: Bulking agent for freeze-drying;
U
coating agent; plasticizer; polymer membrane; sequestering agent; sus-
pending and/or viscosity-increasing agent; tablet binder; tablet and/or
9
capsule diluent; tablet disintegrant; wetting and/or solubilizing agent.
Pumice: Very light, hard, rough, porous, grayish masses or gritty, gray-
ish powder. Is odorless and tasteless, and is stable in air. Practically
insoluble in water; is not attacked by acids.
Pyrantel Pamoate: Yellow to tan solid. Practically insoluble in water
and in methanol; soluble in dimethyl sulfoxide; slightly soluble in
dimethylformamide.
Pyrazinamide: White to practically white, odorless or practically odor-
less, crystalline powder. Sparingly soluble in water; slightly soluble in
alcohol, in ether, and in chloroform.
Pyrethrum Extract: Pale yellow liquid having a bland, flowery odor.
Insoluble in water; soluble in mineral oil and in most organic solvents.
Pyrethrins I denotes the group containing pyrethrin 1, cinerin 1, and
jasmolin 1; Pyrethrins II denotes the group containing pyrethrin 2,
cinerin 2, and jasmolin 2.
Pyridostigmine Bromide: White or practically white, crystalline pow-
der, having an agreeable, characteristic odor. Is hygroscopic. Freely
soluble in water, in alcohol, and in chloroform; slightly soluble in
solvent hexane; practically insoluble in ether.
Pyridoxine Hydrochloride: White to practically white crystals or crys-
talline powder. Is stable in air, and is slowly affected by sunlight. Its
solutions have a pH of about 3. Freely soluble in water; slightly soluble
in alcohol; insoluble in ether.
Pyrilamine Maleate: White, crystalline powder, usually having a faint
odor. Its solutions are acid to litmus. Very soluble in water; freely
soluble in alcohol and in chloroform; slightly soluble in ether and in
benzene.
Pyrimethamine: White, odorless, crystalline powder. Practically
insoluble in water; slightly soluble in acetone, in alcohol, and in
chloroform.
Pyrvinium Pamoate: Bright orange or orange-red to practically black,
crystalline powder. Practically insoluble in water and in ether; freely
soluble in glacial acetic acid; slightly soluble in chloroform and in
methoxyethanol; very slightly soluble in methanol.
Pyrvinium Pamoate Oral Suspension: Dark red, opaque suspension
of essentially very fine, amorphous particles or aggregates, usually less
than 10 m in size. Larger particles, some of which may be crystals, up
to 100 m in size also may be present.
USP Pharmacists Pharmacopeia
Quazepam: Off-white to yellowish powder.
Quinapril Hydrochloride: White to off-white powder, with a pink cast
at times. Freely soluble in aqueous solvents.
Quinidine Gluconate: White powder. Is odorless and has a very bitter
taste. Freely soluble in water; slightly soluble in alcohol.
Quinidine Sulfate: Fine, needle-like, white crystals, frequently co-
hering in masses, or fine, white powder. Is odorless, and darkens on
exposure to light. Its solutions are neutral or alkaline to litmus. Slightly
soluble in water; soluble in alcohol; sparingly soluble in chloroform;
insoluble in ether.
Quinine Sulfate: White, fine, needle-like crystals, usually lusterless,
making a light and readily compressible mass. Is odorless. It darkens
on exposure to light. Its saturated solution is neutral or alkaline to
litmus. Slightly soluble in water, in alcohol, and in chloroform; very
slightly soluble in ether; freely soluble in alcohol at 80, and in a mix-
ture of 2 volumes of chloroform and 1 volume of dehydrated alcohol;
sparingly soluble in water at 100.
Rabies Immune Globulin: Transparent or slightly opalescent liquid,
practically colorless and practically odorless. May develop a slight,
granular deposit during storage.
Rabies Vaccine: White to straw-colored, amorphous pellet, which may
or may not become fragmented when shaken.
Racepinephrine: White to nearly white, crystalline, odorless powder,
gradually darkening on exposure to light and air. With acids, it forms
salts that are readily soluble in water, and the base may be recovered
by the addition of ammonium hydroxide. Very slightly soluble in water
and in alcohol; insoluble in ether, in chloroform, and in fixed and
volatile oils.
0
Racepinephrine Hydrochloride: Fine, white, odorless powder. Dark-
ens on exposure to light and air. Its solutions are acid to litmus. Melts
0
at about 157. Freely soluble in water; sparingly soluble in alcohol.
2
Raloxifene Hydrochloride: Almost white to pale yellow powder. Freely
soluble in dimethylsulfoxide; sparingly soluble in methanol; slightly
soluble in alcohol; very slightly soluble in water, in isopropyl alcohol,
and in octanol; practically insoluble in ether and in ethyl acetate.
Ramipril: White to almost white crystalline powder. Freely soluble in
methanol; sparingly soluble in water.
Ranitidine Hydrochloride: White to pale yellow, crystalline, practically
odorless powder. Is sensitive to light and moisture. Melts at about
140, with decomposition. Very soluble in water; sparingly soluble in
alcohol.
Fully Hydrogenated Rapeseed Oil: White, waxy solid. Insoluble in
water and in alcohol. NF category: Coating agent; stiffening agent.
Superglycerinated Fully Hydrogenated Rapeseed Oil: White solid.
Insoluble in water and in alcohol. NF category: Coating agent; emulsi-
fying and/or solubilizing agent; stiffening agent.
Purified Rayon: White, lustrous or dull, fine, soft, filamentous fibers,
appearing under the microscope as round, oval, or slightly flattened
translucent rods, straight or crimped, striate and with serrate cross-
sectional edges. Is practically odorless and practically tasteless. Very
soluble in ammoniated cupric oxide TS and in dilute sulfuric acid (3 in
5); insoluble in ordinary solvents.
Repaglinide: White to off-white solid. Melts at about 132 to 136. readily dissolved by dilute solutions of ammonia, by solutions of alkali
Soluble in methanol.
Reserpine: White or pale buff to slightly yellowish, odorless, crystal-
line powder. Darkens slowly on exposure to light, but more rapidly
when in solution. Insoluble in water; freely soluble in acetic acid and
in chloroform; slightly soluble in benzene; very slightly soluble in
alcohol and in ether.
Resorcinol: White, or practically white, needle-shaped crystals or
powder. Has a faint, characteristic odor and a sweetish, followed by
a bitter, taste. Acquires a pink tint on exposure to light and air. Its
solution (1 in 20) is neutral or acid to litmus. Freely soluble in water, in
alcohol, in glycerin, and in ether; slightly soluble in chloroform.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/119
Description and Solubility
Ribavirin: White, crystalline powder. Freely soluble in water; slightly
soluble in dehydrated alcohol.
Riboflavin: Yellow to orange-yellow, crystalline powder having a slight
odor. Melts at about 280. Its saturated solution is neutral to litmus.
When dry, it is not appreciably affected by diffused light, but when
in solution, light induces quite rapid deterioration, especially in the
presence of alkalies. Very slightly soluble in water, in alcohol, and in
isotonic sodium chloride solution; soluble in dilute solutions of alka-
lies; insoluble in ether and in chloroform.
Riboflavin 5'-Phosphate Sodium: Fine, orange-yellow, crystalline
powder, having a slight odor. Sparingly soluble in water. When dry, it
is not affected by diffused light, but when in solution, light induces
deterioration rapidly. Is hygroscopic.
Rifabutin: Amorphous red-violet powder. Soluble in chloroform
and in methanol; sparingly soluble in alcohol; very slightly soluble in
water.
Rifampin: Red-brown, crystalline powder. Very slightly soluble in
water; freely soluble in chloroform; soluble in ethyl acetate and in
methanol.
Rimexolone: White to off-white powder. Freely soluble in chloroform;
P
sparingly soluble in methanol.
Risperidone: White or almost white powder. Soluble in methylene
S
chloride; sparingly soluble in alcohol; practically insoluble in water.
Ritodrine Hydrochloride: White to nearly white, odorless or practi-
U
cally odorless, crystalline powder. Melts at about 200. Freely soluble in
water and in alcohol; soluble in n-propyl alcohol; practically insoluble
in ether.
9
Ritonavir: Freely soluble in methanol and in methylene chloride; very
slightly soluble in acetonitrile; practically insoluble in water.
Ropivacaine Hydrochloride: White, crystalline powder. Soluble in
water.
Rose Oil: Colorless or yellow liquid, having the characteristic odor
and taste of rose. At 25 is a viscous liquid. Upon gradual cooling,
changes to a translucent, crystalline mass, easily liquefied by warming.
NF category: Flavors and perfumes.
Rose Water Ointment: NF category: Ointment base.
Stronger Rose Water: Practically colorless and clear, having the pleas-
ant odor and taste of fresh rose blossoms. Is free from empyreuma,
mustiness, and fungal growths. NF category: Flavors and perfumes.
Roxarsone: Pale yellow, crystalline powder. Slightly soluble in cold
water; soluble in boiling water; freely soluble in acetic acid, in acetone,
in alkalies, in methanol, and in dehydrated alcohol; sparingly soluble
in dilute mineral acids; insoluble in ether and in ethyl acetate. Puffs up
and deflagrates on heating.
Rubella Virus Vaccine Live: Solid having the characteristic appearance
of substances dried from the frozen state. Undergoes loss of potency
on exposure to sunlight. The Vaccine is to be constituted with a suit-
able diluent just prior to use.
Saccharin: White crystals or white, crystalline powder. Is odorless or
has a faint, aromatic odor. In dilute solution, it is intensely sweet. Its
solutions are acid to litmus. Slightly soluble in water, in chloroform,
and in ether; soluble in boiling water; sparingly soluble in alcohol. Is
hydroxides, and by solutions of alkali carbonates with the evolution of
carbon dioxide. NF category: Sweetening agent.
Saccharin Calcium: White crystals or white, crystalline powder. Is
odorless, or has a faint, aromatic odor, and has an intensely sweet taste
even in dilute solutions. Its dilute solution is about 300 times as sweet
as sucrose. Freely soluble in water. NF category: Sweetening agent.
Saccharin Sodium: White crystals or white, crystalline powder. Is
odorless, or has a faint, aromatic odor, and has an intensely sweet
taste even in dilute solutions. Its dilute solution is about 300 times as
sweet as sucrose. When in powdered form, it usually contains about
one-third the theoretical amount of water of hydration as a result of
USP Pharmacists Pharmacopeia
efflorescence. Freely soluble in water; sparingly soluble in alcohol. NF
category: Sweetening agent.
Saccharin Sodium Oral Solution: Clear, colorless, odorless liquid,
having a sweet taste.
Safflower Oil: Light yellow oil. Thickens and becomes rancid on pro-
longed exposure to air. Insoluble in water. Miscible with ether and with
chloroform. NF category: Vehicle (oleaginous).
Salicylamide: White, practically odorless, crystalline powder. Slightly
soluble in water and in chloroform; soluble in alcohol and in propyl-
ene glycol; freely soluble in ether and in solutions of alkalies.
Salicylic Acid: White crystals, usually in fine needles, or fluffy, white,
crystalline powder. Has a sweetish, followed by an acrid, taste and is
stable in air. The synthetic form is white and odorless. When prepared
from natural methyl salicylate, it may have a slightly yellow or pink tint,
and a faint, mint-like odor. Slightly soluble in water and in benzene;
freely soluble in alcohol and in ether; soluble in boiling water; spar-
ingly soluble in chloroform.
Scopolamine Hydrobromide: Colorless or white crystals or white,
granular powder. Melts at about 197, with decomposition. Is odorless,
and slightly efflorescent in dry air. Freely soluble in water; soluble in
alcohol; slightly soluble in chloroform; insoluble in ether.
Secobarbital: White, amorphous or crystalline, odorless powder,
having a slightly bitter taste. Its saturated solution has a pH of about
5.6. Very slightly soluble in water; freely soluble in alcohol, in ether,
and in solutions of fixed alkali hydroxides and carbonates; soluble in
chloroform.
Secobarbital Sodium: White powder. Is odorless, has a bitter taste,
and is hygroscopic. Its solutions decompose on standing, heat accel-
0
erating the decomposition. Very soluble in water; soluble in alcohol;
practically insoluble in ether.
0
Selegiline Hydrochloride: White, odorless, crystalline powder. Freely
soluble in water, in chloroform, and in methanol.
2
Selenium Sulfide: Reddish-brown to bright orange powder, having
not more than a faint odor. Practically insoluble in water and in organic
solvents.
Sennosides: Brownish powder.
Serine: White, odorless crystals, having a sweet taste. Soluble in wa-
ter; practically insoluble in absolute alcohol and in ether.
Sesame Oil: Pale yellow, oily liquid. Is practically odorless, and has a
bland taste. Slightly soluble in alcohol. Miscible with ether, with chlo-
roform, with solvent hexane, and with carbon disulfide. NF category:
Solvent, vehicle (oleaginous).
Sevoflurane: Clear, colorless, volatile, nonflammable liquid. Slightly
soluble in water. Miscible with alcohol, with chloroform, and with
ether.
Shellac: Orange ShellacThin, hard, brittle, transparent, pale lemon-
yellow to brownish orange flakes, having little or no odor; Bleached
ShellacOpaque, amorphous cream to yellow granules or coarse
powder, having little or no odor. Insoluble in water; soluble (very
slowly) in alcohol, 85% to 95% (w/w); in ether, 13% to 15%; in benzene,
10% to 20%; in petroleum ether, 2% to 6%; soluble in aqueous solu-
tions of ethanolamines, alkalies, and borax; sparingly soluble in oil of
turpentine. NF category: Coating agent.
Dental-Type Silica: Fine, white, hygroscopic, odorless, amorphous
powder, in which the diameter of the average particles ranges be-
tween 0.5 and 40 m. Insoluble in water, in alcohol, and in acid (except
hydrofluoric acid); soluble in hot solutions of alkali hydroxides. NF
category: Glidant and/or anticaking agent; suspending and/or viscos-
ity-increasing agent.
Hydrophobic Colloidal Silica: Light, fine, white or almost white, amor-
phous powder, not wettable by water. Dissolves slowly in hot solutions
of alkali hydroxides; practically insoluble in water and in mineral acids,
except hydrofluoric acid. NF category: Glidant and/or anticaking agent;
suspending and/or viscosity-increasing agent.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/120
Description and Solubility
Purified Siliceous Earth: Very fine, white, light gray, or pale buff
mixture of amorphous powder and lesser amounts of crystalline
polymorphs, including quartz and cristobalite. Is gritty, readily absorbs
moisture, and retains about four times its weight of water without be-
coming fluid. Insoluble in water, in acids, and in dilute solutions of the
alkali hydroxides. NF category: Filtering aid; sorbent.
Silicon Dioxide: Fine, white, hygroscopic, odorless, amorphous pow-
der, in which the diameter of the average particles ranges between 2
and 10 m. Insoluble in water, in alcohol, and in other organic solvents;
soluble in hot solutions of alkali hydroxides. NF category: Desiccant;
suspending and/or viscosity-increasing agent.
Colloidal Silicon Dioxide: Light, white, nongritty powder of extremely
fine particle size (about 15 nm). Insoluble in water and in acid (except
hydrofluoric); soluble in hot solutions of alkali hydroxides. NF cat-
egory: Glidant and/or anticaking agent; suspending and/or viscosity-
increasing agent.
Silver Nitrate: Colorless or white crystals. The pH of its solutions is
about 5.5. On exposure to light in the presence of organic matter, it
becomes gray or grayish black. Very soluble in water and even more so
in boiling water; sparingly soluble in alcohol; freely soluble in boiling
P
alcohol; slightly soluble in ether.
Toughened Silver Nitrate: White, crystalline masses generally molded
S
as pencils or cones. It breaks with a fibrous fracture. Its solutions are
neutral to litmus. It becomes gray or grayish black upon exposure
to light. Soluble in water to the extent of its nitrate content (there is
U
always a residue of silver chloride). Partially soluble in alcohol; slightly
soluble in ether.
9
Simethicone: Translucent, gray, viscous fluid. The liquid phase is
soluble in chloroform, in ether, and in benzene, but silicon dioxide re-
mains as a residue in these solvents. Insoluble in water and in alcohol.
NF category: Antifoaming agent; water repelling agent.
Simvastatin: White to off-white powder. Practically insoluble in water;
freely soluble in chloroform, in methanol, and in alcohol; sparingly
soluble in propylene glycol; very slightly soluble in hexane.
Smallpox Vaccine: Liquid Vaccine is a turbid, whitish to greenish
suspension, which may have a slight odor due to the antimicrobial
agent. Dried Vaccine is a yellow to grayish pellet, which may or may
not become fragmented when shaken.
Soda Lime: White or grayish-white granules. May have a color if an
indicator has been added. NF category: Sorbent, carbon dioxide.
Sodium Acetate: Colorless, transparent crystals, or white, granular
crystalline powder, or white flakes. Is odorless or has a faint acetous
odor, and has a slightly bitter, saline taste. Is efflorescent in warm, dry
air. Very soluble in water; soluble in alcohol. NF category: Buffering
agent.
Sodium Alginate: Practically odorless and tasteless, coarse or fine
powder, yellowish white in color. Soluble in water, forming a viscous,
colloidal solution; insoluble in alcohol and in hydroalcoholic solutions
in which the alcohol content is greater than about 30% by weight;
insoluble in chloroform, in ether, and in acids when the pH of the re-
sulting solution becomes lower than about 3. NF category: Suspending
and/or viscosity-increasing agent.
Sodium Ascorbate: White or very faintly yellow crystals or crystalline
powder. Is odorless or practically odorless. Is relatively stable in air.
On exposure to light it gradually darkens. Freely soluble in water; very
slightly soluble in alcohol; insoluble in chloroform and in ether.
Sodium Benzoate: White, odorless or practically odorless, granular
or crystalline powder. Is stable in air. Freely soluble in water; sparingly
soluble in alcohol and somewhat more soluble in 90% alcohol. NF
category: Antimicrobial preservative.
Sodium Bicarbonate: White, crystalline powder. Is stable in dry air, but
slowly decomposes in moist air. Its solutions, when freshly prepared
with cold water, without shaking, are alkaline to litmus. The alkalinity
increases as the solutions stand, as they are agitated, or as they are
heated. Soluble in water; insoluble in alcohol. NF category: Alkalizing
agent.
USP Pharmacists Pharmacopeia
Sodium Bisulfite: White, crystalline powder. Freely soluble in cold
water and in hot water; sparingly soluble in alcohol. NF category:
Antioxidant.
Sodium Borate: Colorless, transparent crystals or white, crystalline
powder. Is odorless. Its solutions are alkaline to phenolphthalein TS.
As it effloresces in warm, dry air, the crystals are often coated with
white powder. Soluble in water; freely soluble in boiling water and in
glycerin; insoluble in alcohol. NF category: Alkalizing agent.
Sodium Bromide: White, crystalline powder or colorless, cubical
crystals. Freely soluble in water; soluble in alcohol.
Sodium Butyrate: Clear, colorless, hygroscopic powder. Soluble in
water and in methanol. Melting range is about 250 to 253.
Sodium Caprylate: A white, crystalline powder. Very soluble or freely
soluble in water; freely soluble in acetic acid; sparingly soluble in alco-
hol; practically insoluble in acetone.
Sodium Carbonate: Colorless crystals, or white, crystalline powder
or granules. Is stable in air under ordinary conditions. When exposed
to dry air above 50, the hydrous salt effloresces and, at 100, becomes
anhydrous. Freely soluble in water, but still more soluble in boiling
water. NF category: Alkalizing agent.
Sodium Cetostearyl Sulfate: A white or pale yellow, amorphous or
crystalline powder. Soluble in hot water giving an opalescent solution;
partly soluble in alcohol; practically insoluble in cold water.
Sodium Chloride: Colorless, cubic crystals or white crystalline pow-
der. Has a saline taste. Freely soluble in water; and slightly more solu-
ble in boiling water; soluble in glycerin; slightly soluble in alcohol. NF
category: Tonicity agent.
Sodium Chloride Inhalation Solution: Clear, colorless solution.
0
Bacteriostatic Sodium Chloride Injection: Clear, colorless solution,
odorless or having the odor of the bacteriostatic substance. NF cat-
0
egory: Vehicle (sterile).
2
Sodium Chloride Irrigation: Clear, colorless solution.
Sodium Citrate: Colorless crystals, or white, crystalline powder. Hy-
drous form freely soluble in water and very soluble in boiling water.
Insoluble in alcohol. NF category: Buffering agent.
Sodium Citrate and Citric Acid Oral Solution: Clear solution having
the color of any added preservative or flavoring agents.
Sodium Dehydroacetate: White or practically white, odorless powder,
having a slight characteristic taste. Freely soluble in water, in propylene
glycol, and in glycerin. NF category: Antimicrobial preservative.
Sodium Fluoride: White, odorless powder. Soluble in water; insoluble
in alcohol.
Sodium Formaldehyde Sulfoxylate: White crystals or hard, white
masses, having the characteristic odor of garlic. Freely soluble in water;
slightly soluble in alcohol, in ether, in chloroform, and in benzene. NF
category: Antioxidant.
Sodium Hydroxide: White, or practically white, fused masses, in small
pellets, in flakes, or sticks, and in other forms. Is hard and brittle and
shows a crystalline fracture. Exposed to the air, it rapidly absorbs car-
bon dioxide and moisture. Freely soluble in water and in alcohol. NF
category: Alkalizing agent.
Sodium Hypochlorite Solution: Clear, pale greenish-yellow liquid,
having the odor of chlorine. Is affected by light.
Sodium Iodide: Colorless, odorless crystals, or white, crystalline
powder. Is deliquescent in moist air, and develops a brown tint upon
decomposition. Very soluble in water; freely soluble in alcohol and in
glycerin.
Sodium Lactate Solution: Clear, colorless or practically colorless,
slightly viscous liquid, odorless or having a slight, not unpleasant odor.
Miscible with water. NF category: Buffering agent.
Sodium Lauryl Sulfate: Small, white or light yellow crystals having a
slight, characteristic odor. Freely soluble in water, forming an opales-
cent solution. NF category: Emulsifying and/or solubilizing agent; tablet
and/or capsule lubricant; wetting and/or solubilizing agent.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/121
Description and Solubility
Sodium Metabisulfite: White crystals or white to yellowish, crystalline
powder, having the odor of sulfur dioxide. Freely soluble in water and
in glycerin; slightly soluble in alcohol. NF category: Antioxidant.
Sodium Monofluorophosphate: White to slightly gray, odorless pow-
der. Freely soluble in water.
Sodium Nitrite: White to slightly yellow, granular powder, or white
or practically white, opaque, fused masses or sticks. Has a mild, saline
taste and is deliquescent in air. Its solutions are alkaline to litmus.
Freely soluble in water; sparingly soluble in alcohol.
Sodium Nitrite Injection: Clear, colorless liquid.
Sodium Nitroprusside: Reddish-brown, practically odorless, crystals
or powder. Freely soluble in water; slightly soluble in alcohol; very
slightly soluble in chloroform; insoluble in benzene.
Dibasic Sodium Phosphate (dried): White powder that readily absorbs
moisture. Freely soluble in water; insoluble in alcohol. NF category:
Buffering agent.
Dibasic Sodium Phosphate (heptahydrate): Colorless or white, granu-
lar or caked salt. Effloresces in warm, dry air. Its solutions are alkaline
to phenolphthalein TS, a 0.1 M solution having a pH of about 9. Freely
soluble in water; very slightly soluble in alcohol. NF category: Buffer-
P
ing agent.
S
Monobasic Sodium Phosphate: Colorless crystals or white, crystalline
powder. Is odorless and is slightly deliquescent. Its solutions are acid
to litmus and effervesce with sodium carbonate. Freely soluble in wa-
U
ter; practically insoluble in alcohol. NF category: Buffering agent.
Tribasic Sodium Phosphate: The formula for a crystalline material is
approximately 4(Na3PO412H2O)NaOH. It occurs as white, odorless
9
crystals or granules or as a crystalline powder. It is freely soluble in
water; insoluble in alcohol. The pH of a 1 in 100 solution is between
11.5 and 12.0.
Sodium Polystyrene Sulfonate: Golden brown, fine powder. Is odor-
less and has a characteristic taste. Insoluble in water.
Sodium Propionate: Colorless, transparent crystals or granular, crys-
talline powder. Is odorless, or has a faint acetic-butyric odor and is
deliquescent in moist air. Very soluble in water; soluble in alcohol. NF
category: Antimicrobial preservative.
Sodium Salicylate: Amorphous or microcrystalline powder or scales.
Is colorless, or has not more than a faint, pink tinge. Is odorless, or
has a faint, characteristic odor, and is affected by light. A freshly made
solution (1 in 10) is neutral or acid to litmus. Freely (and slowly) soluble
in water and in glycerin; very soluble in boiling water and in boiling
alcohol; slowly soluble in alcohol.
Sodium Starch Glycolate: White, tasteless, odorless, relatively free-
flowing powder; available in several different viscosity grades. A 2%
(w/v) dispersion in cold water settles, on standing, in the form of a
highly hydrated layer. NF category: Tablet disintegrant.
Sodium Stearate: Fine, white powder, soapy to the touch, usually
having a slight, tallow-like odor. Is affected by light. Its solutions are al-
kaline to phenolphthalein TS. Slowly soluble in cold water and in cold
alcohol; readily soluble in hot water and in hot alcohol. NF category:
Emulsifying and/or solubilizing agent.
Sodium Stearyl Fumarate: Fine, white powder. Slightly soluble in
methanol; practically insoluble in water. NF category: Tablet and/or
capsule lubricant.
Sodium Sulfate: Large, colorless, odorless, transparent crystals, or
a granular powder. Effloresces rapidly in air, liquefies in its water of
hydration at about 33, and loses all of its water of hydration at about
100. Freely soluble in water; soluble in glycerin; insoluble in alcohol.
Sodium Sulfite: Colorless crystals. Freely soluble in water; very slightly
soluble in alcohol. NF category: Antioxidant.
Sodium Tartrate: Transparent, colorless, odorless crystals. Freely solu-
ble in water; insoluble in alcohol. NF category: Sequestering agent.
Sodium Thiosulfate: Large, colorless crystals or coarse, crystalline
powder. Is deliquescent in moist air and effloresces in dry air at tem-
USP Pharmacists Pharmacopeia
peratures exceeding 33. Its solutions are neutral or faintly alkaline
to litmus. Very soluble in water; insoluble in alcohol. NF category:
Antioxidant.
Sorbic Acid: Free-flowing, white, crystalline powder, having a charac-
teristic odor. Slightly soluble in water; soluble in alcohol and in ether.
NF category: Antimicrobial preservative.
Sorbitan Monolaurate: Yellow to amber-colored, oily liquid, having
a bland, characteristic odor. Soluble in mineral oil; slightly soluble in
cottonseed oil and in ethyl acetate; insoluble in water. NF category:
Emulsifying and/or solubilizing agent; tablet and/or capsule lubricant;
wetting and/or solubilizing agent.
Sorbitan Monooleate: Viscous, yellow to amber-colored, oily liquid,
having a bland, characteristic odor. Insoluble in water and in propylene
glycol. Miscible with mineral and vegetable oils. NF category: Emulsify-
ing and/or solubilizing agent; tablet and/or capsule lubricant; wetting
and/or solubilizing agent.
Sorbitan Monopalmitate: Cream-colored, waxy solid having a faint fat-
ty odor. Soluble in warm absolute alcohol; soluble, with haze, in warm
peanut oil and in warm mineral oil; insoluble in water. NF category:
Emulsifying and/or solubilizing agent; tablet and/or capsule lubricant;
wetting and/or solubilizing agent.
Sorbitan Monostearate: Cream-colored to tan, hard, waxy solid, hav-
ing a bland odor and taste. Soluble, with haze, above 50 in mineral oil
and in ethyl acetate; dispersible in warm water; insoluble in cold water
and in acetone. NF category: Emulsifying and/or solubilizing agent;
tablet and/or capsule lubricant; wetting and/or solubilizing agent.
Sorbitan Sesquioleate: Viscous, yellow to amber-colored, oily liquid.
Soluble in alcohol, in isopropyl alcohol, in cottonseed oil, and in
mineral oil; insoluble in water and in propylene glycol. NF category:
0
Emulsifying and/or solubilizing agent; tablet and/or capsule lubricant;
0
wetting and/or solubilizing agent.
Sorbitan Trioleate: Yellow to amber-colored, oily liquid. Soluble in
2
methyl alcohol, in alcohol, in isopropyl alcohol, in corn oil, in cotton-
seed oil, and in mineral oil; insoluble in water, in ethylene glycol, and
in propylene glycol. NF category: Emulsifying and/or solubilizing agent;
tablet and/or capsule lubricant; wetting and/or solubilizing agent.
Sorbitol: d-Sorbitol occurs as white granules, powder, or crystalline
masses. Is odorless, and has a sweet taste with a cold sensation. Very
soluble in water; sparingly soluble in alcohol; and practically insoluble
in ethyl ether. Is hygroscopic. NF category: Humectant; sweetening
agent; tablet and/or capsule diluent.
Sorbitol Solution: Clear, colorless, syrupy liquid. Is odorless and has
a sweet taste. It sometimes separates into crystalline masses. Miscible
with water, with alcohol, with glycerin, and with propylene glycol. Is
neutral to litmus. NF category: Sweetening agent; vehicle (flavored
and/or sweetened).
Sorbitol Sorbitan Solution: A clear, colorless to pale yellow, syrupy
liquid. Is odorless and has a sweet taste. Miscible with water, with
alcohol, with glycerin, and with propylene glycol; insoluble in mineral
oil and in vegetable oil. NF category: Humectant; plasticizer.
Sotalol Hydrochloride: White to off-white powder. Freely soluble in
water; soluble in alcohol; very slightly soluble in chloroform.
Soybean Oil: Clear, pale yellow, oily liquid having a characteristic odor
and taste. Insoluble in water. Miscible with ether and with chloroform.
NF category: Vehicle (oleaginous).
Hydrogenated Soybean Oil: A white mass or powder that melts to
a clear, pale yellow liquid when heated. Freely soluble in methylene
chloride, in hexane after heating, and in toluene; very slightly soluble
in alcohol; practically insoluble in water. NF category: Emollient.
Spectinomycin Hydrochloride: White to pale-buff crystalline powder.
Freely soluble in water; practically insoluble in alcohol, in chloroform,
and in ether.
Spironolactone: Light cream-colored to light tan, crystalline powder.
Has a faint to mild mercaptan-like odor; is stable in air. Practically in-
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/122
Description and Solubility
soluble in water; freely soluble in benzene and in chloroform; soluble
in ethyl acetate and in alcohol; slightly soluble in methanol and in
fixed oils.
Squalane: Colorless, practically odorless transparent oil. Insoluble
in water; very slightly soluble in absolute alcohol; slightly soluble in
acetone. Miscible with ether and with chloroform. NF category: Oint-
ment base; vehicle (oleaginous).
Stannous Chloride: White, crystalline powder or colorless crystals, ef-
florescent in air. Freely soluble in water (the solution becomes cloudy
after standing or on dilution) and in alcohol; dissolves in dilute hydro-
chloric acid. NF category: Emulsifying agent; antioxidant.
Stannous Fluoride: White, crystalline powder, having a bitter, salty
taste. Melts at about 213. Freely soluble in water; practically insoluble
in alcohol, in ether, and in chloroform.
Stanozolol: Odorless, crystalline powder, occurring in two forms: as
needles, melting at about 155, and as prisms, melting at about 235.
Insoluble in water; soluble in dimethylformamide; sparingly soluble
in alcohol and in chloroform; slightly soluble in ethyl acetate and in
acetone; very slightly soluble in benzene.
Starch: Irregular, angular, white masses or fine powder. Is odorless,
P
and has a slight, characteristic taste. Insoluble in cold water and in
alcohol. NF category: Tablet and/or capsule diluent; tablet disintegrant;
S
tablet and/or capsule lubricant.
Corn Starch: Irregular, angular, white masses or fine powder. Is odor-
U
less, and has a slight, characteristic taste. Insoluble in cold water and in
alcohol. NF category: Tablet and/or capsule diluent; tablet disintegrant;
tablet binder; suspending and/or viscosity-increasing agent.
9
Potato Starch: Irregular, angular, white masses or fine powder. Is odor-
less, and has a slight, characteristic taste. Insoluble in cold water and in
alcohol. NF category: Tablet and/or capsule diluent; tablet disintegrant;
tablet binder; suspending and/or viscosity-increasing agent.
Pregelatinized Starch: Moderately coarse to fine, white to off-white
powder. Is odorless and has a slight, characteristic taste. Slightly solu-
ble to soluble in cold water; insoluble in alcohol. NF category: Tablet
binder; tablet and/or capsule diluent; tablet disintegrant.
Pregelatinized Modified Starch: Moderately coarse to fine, white to
off-white powder. Is odorless and has a slight, characteristic taste.
Slightly soluble to soluble in cold water; insoluble in alcohol. NF cat-
egory: Tablet binder; tablet and/or capsule diluent; tablet disintegrant.
Tapioca Starch: Irregular, angular, white to pale yellow masses or fine
powder. Insoluble in cold water and in alcohol. NF category: Suspend-
ing and/or viscosity-increasing agent; tablet binder; tablet and/or cap-
sule diluent; tablet disintegrant.
Wheat Starch: Irregular, angular, white masses or fine powder. Is odor-
less and has a slight, characteristic taste. Insoluble in cold water and in
alcohol. NF category: Tablet and/or capsule diluent; tablet disintegrant;
tablet binder; suspending and/or viscosity-increasing agent.
Stavudine: White to off-white, crystalline powder. Soluble in water,
in dimethylacetamide, and in dimethyl sulfoxide; sparingly soluble in
methanol, in alcohol, and in acetonitrile; slightly soluble in dichloro-
methane; insoluble in hexane.
Stearic Acid: Hard, white or faintly yellowish, somewhat glossy and
crystalline solid, or white or yellowish-white powder. Its odor and
taste are slight, suggesting tallow. Practically insoluble in water; freely
soluble in chloroform and in ether; soluble in alcohol. NF category:
Emulsifying and/or solubilizing agent; tablet and/or capsule lubricant.
Purified Stearic Acid: Hard, white or faintly yellowish, somewhat
glossy and crystalline solid, or white or yellowish-white powder. Its
odor and taste are slight, suggesting tallow. Freely soluble in chloro-
form and in ether; soluble in alcohol; practically insoluble in water. NF
category: Tablet and/or capsule lubricant.
Stearoyl Polyoxylglycerides: Pale yellow, waxy solids. Dispersible in
warm water and in warm paraffin; freely soluble in methylene chloride;
soluble in warm methanol. NF category: Ointment base; solvent.
USP Pharmacists Pharmacopeia
Stearyl Alcohol: Unctuous, white flakes or granules. Has a faint, char-
acteristic odor and a bland, mild taste. Insoluble in water; soluble in
alcohol and in ether. NF category: Stiffening agent.
Storax: Semiliquid, grayish to grayish-brown, sticky, opaque mass
depositing on standing a heavy dark brown layer (Levant Storax);
or semisolid, sometimes a solid mass, softened by gently warming
(American Storax). Is transparent in thin layers, has a characteristic
odor and taste, and is more dense than water. Insoluble in water;
soluble, usually incompletely, in an equal weight of warm alcohol;
soluble in acetone, in carbon disulfide, and in ether, some insoluble
residue usually remaining.
Streptomycin Sulfate: White or practically white powder. Is odorless
or has not more than a faint odor. Is hygroscopic, but is stable in air
and on exposure to light. Its solutions are acid to practically neutral to
litmus. Freely soluble in water; very slightly soluble in alcohol; practi-
cally insoluble in chloroform.
Streptomycin Sulfate Injection: Clear, colorless to yellow, viscous
liquid. Is odorless or has a slight odor.
Strontium Chloride: Colorless, odorless crystals or white granules. Ef-
floresces in air; deliquesces in moist air. Very soluble in water; soluble
in alcohol.
Succinic Acid: White, odorless crystals. Soluble in water, in alcohol,
and in glycerin; freely soluble in boiling water. NF category: Buffering
agent.
Succinylcholine Chloride: White, odorless, crystalline powder. Its
solutions have a pH of about 4. The dihydrate form melts at about 160;
the anhydrous form melts at about 190, and is hygroscopic. Freely
soluble in water; slightly soluble in alcohol and in chloroform; practi-
cally insoluble in ether.
0
Sucralose: White to off-white, crystalline powder. Freely soluble in
0
water, in methanol, and in alcohol; slightly soluble in ethyl acetate. NF
category: Sweetening agent.
2
Sucrose: White, crystalline powder or lustrous, dry, colorless or white
crystals. Very soluble in water; slightly soluble in alcohol; practically
insoluble in dehydrated alcohol. NF category: Coating agent; sweeten-
ing agent; tablet and/or capsule diluent.
Sucrose Octaacetate: White, practically odorless powder, having an
intensely bitter taste. Is hygroscopic. Very slightly soluble in water; very
soluble in methanol and in chloroform; soluble in alcohol and in ether.
NF category: Alcohol denaturant.
Sufentanil Citrate: White powder. Soluble in water; freely soluble in
methanol; sparingly soluble in acetone, in alcohol, and in chloroform.
Melts between 133 and 140.
Compressible Sugar: Practically white, crystalline, odorless powder,
having a sweet taste. Is stable in air. The sucrose portion of Compress-
ible Sugar is very soluble in water. NF category: Sweetening agent;
tablet and/or capsule diluent.
Confectioners Sugar: Fine, white, odorless powder, having a sweet
taste. Is stable in air. The sucrose portion of Confectioners Sugar is
soluble in cold water. Confectioners Sugar is freely soluble in boiling
water. NF category: Sweetening agent; tablet and/or capsule diluent.
Sugar Spheres: Hard, brittle, free-flowing, spherical masses ranging
generally in size from 10- to 60-mesh. Usually white, but may be col-
ored. Solubility in water varies according to the sugar-to-starch ratio.
NF category: Vehicle (solid carrier).
Sulbactam Sodium: White to off-white, crystalline powder. Freely
soluble in water and in dilute acid; sparingly soluble in acetone, in
ethyl acetate, and in chloroform.
Sulconazole Nitrate: White to off-white, crystalline powder. Melts
at about 130, with decomposition. Very slightly soluble in water, in
toluene, and in dioxane; slightly soluble in alcohol, in chloroform, in
acetone, and in methylene chloride; sparingly soluble in methanol;
freely soluble in pyridine.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/123
Description and Solubility
Sulfabenzamide: Fine, white, practically odorless powder. Insoluble
in water and in ether; soluble in alcohol, in acetone, and in sodium
hydroxide TS.
Sulfacetamide: White, crystalline powder, odorless and having a char-
acteristic sour taste. Its aqueous solutions are sensitive to light, and
are unstable when acidic or strongly alkaline. Slightly soluble in water
and in ether; freely soluble in dilute mineral acids and in solutions of
potassium and sodium hydroxides; soluble in alcohol; very slightly
soluble in chloroform; practically insoluble in benzene.
Sulfacetamide Sodium: White, crystalline powder. Is odorless and
has a bitter taste. Freely soluble in water; sparingly soluble in alcohol;
practically insoluble in chloroform and in ether.
Sulfadiazine: White or slightly yellow powder. Is odorless or nearly
odorless and is stable in air, but slowly darkens on exposure to light.
Practically insoluble in water; freely soluble in dilute mineral acids, in
solutions of potassium and sodium hydroxides, and in ammonia TS;
sparingly soluble in alcohol and in acetone; slightly soluble in human
serum at 37.
Silver Sulfadiazine: White to creamy-white, crystalline powder, odor-
P
less to having a slight odor. Is stable in air, but turns yellow on ex-
posure to light. Slightly soluble in acetone; practically insoluble in
S
alcohol, in chloroform, and in ether; freely soluble in 30% ammonium
solution; decomposes in moderately strong mineral acids.
Sulfadiazine Sodium: White powder. On prolonged exposure to
U
humid air it absorbs carbon dioxide with the liberation of sulfadiazine
and becomes incompletely soluble in water. Its solutions are alkaline
9
to phenolphthalein. Is affected by light. Freely soluble in water; slightly
soluble in alcohol.
Sulfadimethoxine: Practically white, crystalline powder. Soluble in 2 N
sodium hydroxide; sparingly soluble in 2 N hydrochloric acid; slightly
soluble in alcohol, in ether, in chloroform, and in hexane; practically
insoluble in water.
Sulfamethazine: White to yellowish-white powder, which may darken
on exposure to light. Has a slightly bitter taste and is practically odor-
less. Very slightly soluble in water and in ether; soluble in acetone;
slightly soluble in alcohol.
Sulfamethizole: White crystals or powder, having a slightly bitter
taste. Is practically odorless, and has no odor of hydrogen sulfide. Very
slightly soluble in water, in chloroform, and in ether; freely soluble in
solutions of ammonium, potassium, and sodium hydroxides; soluble
in dilute mineral acids and in acetone; sparingly soluble in alcohol;
practically insoluble in benzene.
Sulfamethoxazole: White to off-white, practically odorless, crystalline
powder. Practically insoluble in water, in ether, and in chloroform;
freely soluble in acetone and in dilute solutions of sodium hydroxide;
sparingly soluble in alcohol.
Sulfapyridine: White or faintly yellowish-white crystals, granules, or
powder. Is odorless or practically odorless, and is stable in air, but
slowly darkens on exposure to light. Very slightly soluble in water;
freely soluble in dilute mineral acids and in solutions of potassium
and sodium hydroxides; sparingly soluble in acetone; slightly soluble
in alcohol.
Sulfasalazine: Bright yellow or brownish-yellow, odorless, fine pow-
der. Melts at about 255, with decomposition. Very slightly soluble in
alcohol; practically insoluble in water, in ether, in chloroform, and in
benzene; soluble in aqueous solutions of alkali hydroxides.
Sulfathiazole: Fine, white or faintly yellowish-white, practically odor-
less powder. Very slightly soluble in water; soluble in acetone, in dilute
mineral acids, in solutions of alkali hydroxides, and in 6 N ammonium
hydroxide; slightly soluble in alcohol.
USP Pharmacists Pharmacopeia
Sulfinpyrazone: White to off-white powder. Practically insoluble in
water and in solvent hexane; soluble in alcohol and in acetone; spar-
ingly soluble in dilute alkali.
Sulfisoxazole: White to slightly yellowish, odorless, crystalline pow-
der. Very slightly soluble in water; soluble in boiling alcohol and in 3 N
hydrochloric acid.
Sulfisoxazole Acetyl: White or slightly yellow, crystalline powder.
Practically insoluble in water; sparingly soluble in chloroform; slightly
soluble in alcohol.
Precipitated Sulfur: Very fine, pale yellow, amorphous or micro-
crystalline powder. Is odorless and tasteless. Practically insoluble in
water; very soluble in carbon disulfide; slightly soluble in olive oil; very
slightly soluble in alcohol.
Sublimed Sulfur: Fine, yellow, crystalline powder, having a faint odor
and taste. Practically insoluble in water; sparingly soluble in olive oil;
practically insoluble in alcohol.
Sulfur Dioxide: Colorless, nonflammable gas, possessing a strong, suf-
focating odor characteristic of burning sulfur. Under pressure, it con-
denses readily to a colorless liquid that boils at 10 and has a density
of approximately 1.5. At 20 and at standard pressure, approximately 36
volumes dissolve in 1 volume of water and approximately 114 volumes
dissolve in 1 volume of alcohol. Soluble also in ether and in chloro-
form. NF category: Antioxidant.
Sulfuric Acid: Clear, colorless, oily liquid. Miscible with water and with
alcohol with the generation of much heat. Is very caustic and corrosive.
Specific gravity is about 1.84. NF category: Acidifying agent.
0
Sulindac: Yellow, crystalline powder, which is odorless or practically
so. Slightly soluble in methanol, in alcohol, in acetone, and in chloro-
0
form; very slightly soluble in isopropanol and in ethyl acetate; practi-
cally insoluble in hexane and in water.
2
Sulisobenzone: Light tan powder, with a melting point of about 145.
Freely soluble in methanol, in alcohol, and in water; sparingly soluble
in ethyl acetate.
Sumatriptan: White to pale yellow powder. Very slightly soluble in
water.
Sumatriptan Succinate: White or almost white powder. Freely soluble
in water; sparingly soluble in methanol; practically insoluble in methy-
lene chloride.
Suprofen: White to off-white powder, odorless to having a slight odor.
Sparingly soluble in water.
Syrup: NF category: Sweetening agent; tablet binder; vehicle (flavored
and/or sweetened).
Tacrine Hydrochloride: White powder. Freely soluble in water, in 0.1
N hydrochloric acid, in pH 4.0 acetate buffer, in phosphate buffer (pH
between 7.0 and 7.4), in methanol, in dimethylsulfoxide, in alcohol, and
in propylene glycol; sparingly soluble in linoleic acid and in polyethyl-
ene glycol 400.
Tagatose: White or almost white crystals, having a sweet taste. Very
soluble in water; very slightly soluble in alcohol. NF category: Sweeten-
ing agent; humectant.
Talc: Very fine, white or grayish-white, crystalline powder. Is unctuous,
adheres readily to the skin, and is free from grittiness. NF category: Gli-
dant and/or anticaking agent; tablet and/or capsule lubricant.
Tamoxifen Citrate: White, fine, crystalline powder. Very slightly sol-
uble in water, in acetone, in chloroform, and in alcohol; soluble in
methanol. Melts at about 142, with decomposition.
Tamsulosin Hydrochloride: White or almost white crystalline powder.
Melts with decomposition at approximately 230. Freely soluble in for-
mic acid; sparingly soluble in methanol; slightly soluble in water and in
dehydrated alcohol; practically insoluble in ether.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/124
Description and Solubility
Tannic Acid: Amorphous powder, glistening scales, or spongy masses,
varying in color from yellowish-white to light brown. Is odorless or
has a faint, characteristic odor, and has a strongly astringent taste. Very
soluble in water, in acetone, and in alcohol; is freely soluble in diluted
alcohol, and only slightly soluble in dehydrated alcohol; practically
insoluble in benzene, in chloroform, in ether, and in solvent hexane;
1 g dissolves in about 1 mL of warm glycerin.
Tartaric Acid: Colorless or translucent crystals or white, fine to granu-
lar, crystalline powder. Is odorless, has an acid taste, and is stable in air.
Very soluble in water; freely soluble in alcohol. NF category: Acidifying
agent.
Taurine: White crystals or crystalline powder. Soluble in water.
Tazobactam: White to pale yellow, nonhygroscopic, crystalline pow-
der. Soluble in dimethylformamide; slightly soluble in water, in metha-
nol, in acetone, and in alcohol; very slightly soluble in ethyl acetate, in
ethyl ether, and in chloroform; insoluble in hexane.
Technetium Tc 99m Aggregated Albumin Injection: Milky suspension,
from which particles settle upon standing.
P
Technetium Tc 99m Pentetate Injection: Clear, colorless solution.
Sodium Pertechnetate Tc 99m Injection: Clear, colorless solution.
S
Technetium Tc 99m (Pyro- and trimeta-) Phosphates Injection: Clear
solution.
U
Technetium Tc 99m Sulfur Colloid Injection: Colloidal dispersion.
Slightly opalescent, colorless to light tan liquid.
9
Temazepam: White or nearly white, crystalline powder. Very slightly
soluble in water; sparingly soluble in alcohol. Melts between 157 and
163, within a 3 range.
Terazosin Hydrochloride: White to pale yellow, crystalline powder.
Freely soluble in isotonic saline solution; soluble in methanol and in
water; slightly soluble in alcohol and in 0.1 N hydrochloric acid; very
slightly soluble in chloroform; practically insoluble in acetone and in
hexanes.
Terbinafine Hydrochloride: White or off-white powder. Freely soluble
in dehydrated alcohol and in methanol; slightly soluble in acetone;
very slightly or slightly soluble in water.
Terbutaline Sulfate: White to gray-white, crystalline powder. Is odor-
less or has a faint odor of acetic acid. Soluble in water and in 0.1 N hy-
drochloric acid; slightly soluble in methanol; insoluble in chloroform.
Terpin Hydrate: Colorless, lustrous crystals or white powder. Has a
slight odor, and effloresces in dry air. A hot solution (1 in 100) is neutral
to litmus. When dried in vacuum at 60 for 2 hours, it melts at about
103. Slightly soluble in water, in chloroform, and in ether; very soluble
in boiling alcohol; soluble in alcohol; sparingly soluble in boiling water.
Testolactone: White to off-white, practically odorless, crystalline pow-
der. Melts at about 218. Slightly soluble in water and in benzyl alcohol;
soluble in alcohol and in chloroform; insoluble in ether and in solvent
hexane.
Testosterone: White or slightly creamy white crystals or crystalline
powder. Is odorless, and is stable in air. Practically insoluble in water;
freely soluble in dehydrated alcohol and in chloroform; soluble in di-
oxane and in vegetable oils; slightly soluble in ether.
Testosterone Cypionate: White or creamy white, crystalline powder.
Is odorless or has a slight odor, and is stable in air. Insoluble in wa-
ter; freely soluble in alcohol, in chloroform, in dioxane, and in ether;
soluble in vegetable oils.
Testosterone Enanthate: White or creamy white, crystalline powder. Is
odorless or has a faint odor characteristic of heptanoic acid. Insoluble
in water; very soluble in ether; soluble in vegetable oils.
USP Pharmacists Pharmacopeia
Testosterone Propionate: White or creamy white crystals or crystal-
line powder. Is odorless and is stable in air. Insoluble in water; freely
soluble in alcohol, in dioxane, in ether, and in other organic solvents;
soluble in vegetable oils.
Tetanus Immune Globulin: Transparent or slightly opalescent liquid,
practically colorless and practically odorless. May develop a slight
granular deposit during storage.
Tetanus Toxoid: Clear, colorless to brownish-yellow, or slightly turbid
liquid, free from evident clumps or particles, having a characteristic
odor or an odor of formaldehyde.
Tetanus Toxoid Adsorbed: Turbid, white, slightly gray, or slightly pink
suspension, free from evident clumps after shaking.
Tetanus and Diphtheria Toxoids Adsorbed for Adult Use: Turbid,
white, slightly gray, or cream-colored suspension, free from evident
clumps after shaking.
Tetracaine: White or light yellow, waxy solid. Very slightly soluble in
water; soluble in alcohol, in ether, in benzene, and in chloroform.
Tetracaine Hydrochloride: Fine, white, crystalline, odorless powder.
Has a slightly bitter taste followed by a sense of numbness. Its solu-
tions are neutral to litmus. Melts at about 148, or may occur in either
of two other polymorphic modifications that melt at about 134 and
139, respectively. Mixtures of the forms may melt within the range of
134 to 147. Is hygroscopic. Very soluble in water; soluble in alcohol;
insoluble in ether and in benzene.
Tetracycline: Yellow, odorless, crystalline powder. Is stable in air, but
exposure to strong sunlight causes it to darken. It loses potency in
0
solutions of pH below 2, and is rapidly destroyed by alkali hydroxide
solutions. Very slightly soluble in water; freely soluble in dilute acid
0
and in alkali hydroxide solutions; sparingly soluble in alcohol; practi-
cally insoluble in chloroform and in ether.
2
Tetracycline Hydrochloride: Yellow, odorless, crystalline powder. Is
moderately hygroscopic. Is stable in air, but exposure to strong sun-
light in moist air causes it to darken. It loses potency in solution at a pH
below 2, and is rapidly destroyed by alkali hydroxide solutions. Soluble
in water and in solutions of alkali hydroxides and carbonates; slightly
soluble in alcohol; practically insoluble in chloroform and in ether.
Tetrahydrozoline Hydrochloride: White, odorless solid. Melts at about
256, with decomposition. Freely soluble in water and in alcohol; very
slightly soluble in chloroform; practically insoluble in ether.
Thalidomide: White to off-white powder. Very soluble in dimethyl-
formamide, in dioxane, and in pyridine; sparingly soluble in acetone,
in butyl acetate, in ethanol, in ethyl acetate, in glacial acetic acid, in
methanol, and in water; practically insoluble in benzene, in chloro-
form, and in ether.
Theophylline: White, odorless, crystalline powder, having a bitter
taste. Is stable in air. Slightly soluble in water, but more soluble in hot
water; freely soluble in solutions of alkali hydroxides and in ammonia;
sparingly soluble in alcohol, in chloroform, and in ether.
Theophylline Sodium Glycinate: White, crystalline powder having a
slight ammoniacal odor and a bitter taste. Freely soluble in water; very
slightly soluble in alcohol; practically insoluble in chloroform.
Thiabendazole: White to practically white, odorless or practically
odorless powder. Practically insoluble in water; slightly soluble in ac-
etone and in alcohol; very slightly soluble in chloroform and in ether.
Thiacetarsamide: White to yellowish, crystalline powder. Sparingly
soluble in cold dehydrated alcohol, in cold methanol, and in cold
water; more soluble in water above 90; soluble in warm dehydrated
alcohol and in warm methanol; insoluble in warm isopropyl alcohol.
pKa is 4.
Thiamine Hydrochloride: White crystals or crystalline powder, usually
having a slight, characteristic odor. When exposed to air, the anhy-
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/125
Description and Solubility
drous product rapidly absorbs about 4% of water. Melts at about 248,
with some decomposition. Freely soluble in water; soluble in glycerin;
slightly soluble in alcohol; insoluble in ether and in benzene.
Thiamine Mononitrate: White crystals or crystalline powder, usually
having a slight, characteristic odor. Sparingly soluble in water; slightly
soluble in alcohol; very slightly soluble in chloroform.
Thiethylperazine Maleate: Yellowish, granular powder. Is odorless or
has not more than a slight odor. Melts at about 183, with decomposi-
tion. Practically insoluble in water; slightly soluble in methanol; practi-
cally insoluble in chloroform.
Thimerosal: Light cream-colored, crystalline powder, having a slight
characteristic odor. Is affected by light. The pH of a solution (1 in 100)
is about 6.7. Freely soluble in water; soluble in alcohol; practically in-
soluble in ether. NF category: Antimicrobial preservative.
Thimerosal Topical Solution: Clear liquid, having a slight characteristic
odor. Is affected by light.
Thimerosal Tincture: Transparent, mobile liquid, having the character-
istic odor of alcohol and acetone. Is affected by light.
P
Thioguanine: Pale yellow, odorless or practically odorless, crystal-
line powder. Insoluble in water, in alcohol, and in chloroform; freely
S
soluble in dilute solutions of alkali hydroxides.
Thiopental Sodium: White to off-white, crystalline powder, or yel-
U
lowish-white to pale greenish-yellow, hygroscopic powder. May have
a disagreeable odor. Its solutions are alkaline to litmus. Its solutions
decompose on standing, and on boiling precipitation occurs. Soluble
9
in water and in alcohol; insoluble in benzene, in absolute ether, and in
solvent hexane.
Thiopental Sodium for Injection: White to off-white, crystalline pow-
der, or yellowish-white to pale greenish-yellow, hygroscopic powder.
May have a disagreeable odor. Its solutions are alkaline to litmus.
Its solutions decompose on standing, and on boiling precipitation
occurs.
Thioridazine: White to slightly yellow, crystalline or micronized
powder, odorless or having a faint odor. Practically insoluble in water;
freely soluble in dehydrated alcohol and in ether; very soluble in
chloroform.
Thioridazine Hydrochloride: White to slightly yellow, granular pow-
der, having a faint odor and a very bitter taste. Freely soluble in water,
in methanol, and in chloroform; insoluble in ether.
Thiostrepton: White to off-white, crystalline solid. Practically in-
soluble in water, in the lower alcohols, in nonpolar organic solvents,
and in dilute aqueous acids or alkali; soluble in glacial acetic acid, in
chloroform, in dimethylformamide, in dimethyl sulfoxide, in dioxane,
and in pyridine.
Thiotepa: Fine, white, crystalline flakes, having a faint odor. Freely
soluble in water, in alcohol, in chloroform, and in ether.
Thiotepa for Injection: White powder.
Thiothixene: White to tan, practically odorless crystals. Is affected by
light. Practically insoluble in water; very soluble in chloroform; slightly
soluble in methanol and in acetone.
Thiothixene Hydrochloride: White, or practically white, crystalline
powder, having a slight odor. Is affected by light. Soluble in water;
slightly soluble in chloroform; practically insoluble in benzene, in
acetone, and in ether.
Threonine: White, odorless crystals, having a slightly sweet taste.
Freely soluble in water; insoluble in absolute alcohol, in ether, and in
chloroform.
Thrombin: White to grayish, amorphous substance dried from the
frozen state.
USP Pharmacists Pharmacopeia
Thymol: Colorless, often large, crystals, or white, crystalline powder,
having an aromatic, thyme-like odor and a pungent taste. Is affected
by light. Its alcohol solution is neutral to litmus. Very slightly soluble in
water; freely soluble in alcohol, in chloroform, in ether, and in olive oil;
soluble in glacial acetic acid and in fixed and volatile oils. NF category:
Antimicrobial preservative; flavors and perfumes.
Thyroid: Yellowish to buff-colored, amorphous powder, having a
slight, characteristic, meat-like odor and a saline taste.
Tiagabine Hydrochloride: White to off-white powder. Freely soluble
in methanol and in alcohol; soluble in isopropanol; very slightly sol-
uble in chloroform; sparingly soluble in water; practically insoluble in
n-heptane.
Tiamulin: A sticky, translucent yellowish mass, slightly hygroscopic.
Very soluble in dichloromethane; freely soluble in dehydrated alcohol;
practically insoluble in water.
Ticarcillin Disodium: White to pale yellow powder, or white to pale
yellow solid. Freely soluble in water.
Tiletamine Hydrochloride: White to off-white, crystalline powder.
Freely soluble in water and in 0.1 N hydrochloric acid; soluble in meth-
anol; slightly soluble in chloroform; practically insoluble in ether.
Tilmicosin: White to off-white, amorphous solid. Slightly soluble in
water and in n-hexane.
Timolol Maleate: White to practically white, odorless or practically
odorless powder. Soluble in water, in alcohol, and in methanol; spar-
ingly soluble in chloroform and in propylene glycol; insoluble in ether
and in cyclohexane.
0
Tinidazole: Almost white or pale yellow, crystalline powder. Soluble
in acetone and in methylene chloride; sparingly soluble in methanol;
0
practically insoluble in water.
2
Titanium Dioxide: White, odorless, tasteless powder. Its 1 in 10 sus-
pension in water is neutral to litmus. Insoluble in water, in hydrochlo-
ric acid, in nitric acid, and in 2 N sulfuric acid. Dissolves in hydrofluoric
acid and in hot sulfuric acid. Is rendered soluble by fusion with potas-
sium bisulfate or with alkali carbonates or hydroxides. NF category:
Coating agent.
Tizanidine Hydrochloride: Almost white to slightly yellow, crystalline
powder. Slightly soluble in water and in methanol.
Tobramycin: White to off-white, hygroscopic powder. Freely soluble
in water; very slightly soluble in alcohol; practically insoluble in chlo-
roform and in ether.
Tobramycin Sulfate Injection: Clear, colorless solution.
Tocainide Hydrochloride: Fine, white, odorless powder. Freely soluble
in water and in alcohol; practically insoluble in chloroform and in
ether.
Tocopherol: Clear, colorless to yellow, yellowish-brown, or greenish-
yellow, viscous oil. Is odorless. Soluble in oils, in fats, in acetone, in
alcohol, in chloroform, in ether, and in alcohol; insoluble in water. NF
category: Antioxidant.
Tocopherols Excipient: Brownish-red to red, clear, viscous oil, having
a mild, characteristic odor and taste. May show a slight separation of
waxlike constituents in microcrystalline form. Oxidizes and darkens
slowly in air and on exposure to light, particularly in alkaline media.
Insoluble in water; soluble in alcohol; miscible with acetone, with chlo-
roform, with ether, and with vegetable oils. NF category: Antioxidant.
Tolazamide: White to off-white, crystalline powder, odorless or having
a slight odor. Melts with decomposition in the approximate range of
161 to 173. Very slightly soluble in water; freely soluble in chloroform;
soluble in acetone; slightly soluble in alcohol.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/126
Description and Solubility
Tolazoline Hydrochloride: White to off-white, crystalline powder.
Its solutions are slightly acid to litmus. Freely soluble in water and in
alcohol.
Tolbutamide: White, or practically white, crystalline powder. Is slightly
bitter and practically odorless. Practically insoluble in water; soluble in
alcohol and in chloroform.
Tolbutamide Sodium: White to off-white, practically odorless, crys-
talline powder, having a slightly bitter taste. Freely soluble in water;
soluble in alcohol and in chloroform; very slightly soluble in ether.
Tolcapone: Yellow, fine powder or fine powder with lumps. Freely
soluble in acetone and in tetrahydrofuran; soluble in methanol and in
ethyl acetate; sparingly soluble in chloroform and in dichloromethane;
insoluble in water and in n-hexane.
Tolmetin Sodium: Light yellow to light orange, crystalline powder.
Freely soluble in water and in methanol; slightly soluble in alcohol;
very slightly soluble in chloroform.
Tolnaftate: White to creamy white, fine powder, having a slight odor.
Practically insoluble in water; freely soluble in acetone and in chloro-
P
form; sparingly soluble in ether; slightly soluble in alcohol.
Tolu Balsam: Brown or yellowish-brown, plastic solid, transparent in
S
thin layers and brittle when old, dried, or exposed to cold tempera-
tures. Has a pleasant, aromatic odor resembling that of vanilla, and a
U
mild, aromatic taste. Practically insoluble in water and in solvent hex-
ane; soluble in alcohol, in chloroform, and in ether, sometimes with
slight residue or turbidity. NF category: Flavors and perfumes.
9
Topiramate: White to off-white powder. Freely soluble in dichloro-
methane.
Torsemide: White to off-white, crystalline powder. Slightly soluble in
0.1 N sodium hydroxide, in 0.1 N hydrochloric acid, in alcohol, and in
methanol; very slightly soluble in acetone and in chloroform; practi-
cally insoluble in water and in ether.
Tragacanth: Is odorless, and has an insipid, mucilaginous taste. NF
category: Suspending and/or viscosity-increasing agent.
Trazodone Hydrochloride: White to off-white, crystalline powder.
Sparingly soluble in chloroform and in water. Melts between 231 and
234 when the melting point determination is carried out in an evacu-
ated capillary tube; otherwise melts with decomposition over a broad
range below 230.
Tretinoin: Yellow to light-orange, crystalline powder. Insoluble in wa-
ter; slightly soluble in alcohol and in chloroform.
Triacetin: Colorless, somewhat oily liquid having a slight, fatty odor
and a bitter taste. Soluble in water; slightly soluble in carbon disulfide.
Miscible with alcohol, with ether, and with chloroform. NF category:
Plasticizer.
Triamcinolone: White or practically white, odorless, crystalline pow-
der. Very slightly soluble in water, in chloroform, and in ether; slightly
soluble in alcohol and in methanol.
Triamcinolone Acetonide: White to cream-colored, crystalline powder,
having not more than a slight odor. Practically insoluble in water; spar-
ingly soluble in dehydrated alcohol, in chloroform, and in methanol.
Triamcinolone Diacetate: Fine, white to off-white, crystalline powder,
having not more than a slight odor. Practically insoluble in water;
soluble in chloroform; sparingly soluble in alcohol and in methanol;
slightly soluble in ether.
Triamcinolone Hexacetonide: White to cream-colored powder. Prac-
tically insoluble in water; soluble in chloroform; slightly soluble in
methanol.
Triamterene: Yellow, odorless, crystalline powder. Practically insoluble
in water, in benzene, in chloroform, in ether, and in dilute alkali hy-
droxides; soluble in formic acid; sparingly soluble in methoxyethanol;
USP Pharmacists Pharmacopeia
very slightly soluble in acetic acid, in alcohol, and in dilute mineral
acids.
Triazolam: White to off-white, practically odorless, crystalline powder.
Soluble in chloroform; slightly soluble in alcohol; practically insoluble
in ether and in water.
Tributyl Citrate: Clear, practically colorless, oily liquid. Insoluble in
water; freely soluble in alcohol, in isopropyl alcohol, in acetone, and in
toluene. NF category: Plasticizer.
Trichlorfon: White crystalline powder. Freely soluble in acetone, in
alcohol, in benzene, in chloroform, in ether, and in water; very soluble
in methylene chloride; very slightly soluble in hexane and in pentane.
Decomposed by alkali. Melts at about 78 with decomposition.
Trichlormethiazide: White or practically white, crystalline powder. Is
odorless, or has a slight characteristic odor. Melts at about 274, with
decomposition. Very slightly soluble in water, in ether, and in chloro-
form; freely soluble in acetone; soluble in methanol; sparingly soluble
in alcohol.
Trichloromonofluoromethane: Clear, colorless gas, having a faint,
ethereal odor. Its vapor pressure at 25 is about 796 mm of mercury (1
psig). NF category: Aerosol propellant.
Triclosan: Fine, whitish, crystalline powder. Melts at about 57. Practi-
cally insoluble in water; soluble in methanol, in alcohol, and in ac-
etone; slightly soluble in hexane.
Trientine Hydrochloride: White to pale yellow, crystalline powder.
Melts at about 117. Insoluble in chloroform and in ether; slightly
soluble in alcohol; soluble in methanol; freely soluble in water.
0
Triethyl Citrate: Practically colorless, oily liquid. Soluble in water; mis-
cible with alcohol and with ether. NF category: Plasticizer.
0
Trifluoperazine Hydrochloride: White to pale yellow, crystalline pow-
2
der. Is practically odorless, and has a bitter taste. Melts at about 242,
with decomposition. Freely soluble in water; soluble in alcohol; spar-
ingly soluble in chloroform; insoluble in ether and in benzene.
Triflupromazine: Viscous, light amber-colored, oily liquid, which crys-
tallizes on prolonged standing into large, irregular crystals. Practically
insoluble in water.
Triflupromazine Hydrochloride: White to pale tan, crystalline pow-
der, having a slight, characteristic odor. Melts between 170 and 178.
Soluble in water, in alcohol, and in acetone; insoluble in ether.
Trifluridine: Odorless, white powder appearing under the microscope
as rodlike crystals; melts at 175, with sublimation.
Medium-Chain Triglycerides: Colorless or slightly yellowish, oily
liquid. Practically insoluble in water; miscible with alcohol, with methy-
lene chloride, with hexane, and with fatty oils.
Trihexyphenidyl Hydrochloride: White or slightly off-white, crystalline
powder, having not more than a very faint odor. Melts at about 250.
Slightly soluble in water; soluble in alcohol and in chloroform.
Trimeprazine Tartrate: White to off-white, odorless, crystalline pow-
der. Freely soluble in water and in chloroform; soluble in alcohol; very
slightly soluble in ether and in benzene.
Trimethobenzamide Hydrochloride: White, crystalline powder having
a slight phenolic odor. Soluble in water and in warm alcohol; insoluble
in ether and in benzene.
Trimethoprim: White to cream-colored, odorless crystals, or crystal-
line powder. Very slightly soluble in water; soluble in benzyl alcohol;
sparingly soluble in chloroform and in methanol; slightly soluble in
alcohol and in acetone; practically insoluble in ether and in carbon
tetrachloride.
Trimethoprim Sulfate: White to off-white, crystalline powder. Soluble
in water, in alcohol, in dilute mineral acids, and in fixed alkalies.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/127
Description and Solubility
Trimipramine Maleate: White to almost white crystalline powder.
Slightly soluble in water and in alcohol.
Trioxsalen: White to off-white or grayish, odorless, crystalline solid.
Melts at about 230. Practically insoluble in water; sparingly soluble in
chloroform; slightly soluble in alcohol.
Tripelennamine Hydrochloride: White, crystalline powder. Slowly
darkens on exposure to light. Its solutions are practically neutral to lit-
mus. Freely soluble in water, in alcohol, and in chloroform; slightly sol-
uble in acetone; insoluble in benzene, in ether, and in ethyl acetate.
Triprolidine Hydrochloride: White, crystalline powder, having no
more than a slight, but unpleasant, odor. Its solutions are alkaline to
litmus, and it melts at about 115. Soluble in water, in alcohol, and in
chloroform; insoluble in ether.
Trolamine: Colorless to pale yellow, viscous, hygroscopic liquid hav-
ing a slight, ammoniacal odor. Miscible with water and with alcohol.
Soluble in chloroform. NF category: Alkalizing agent; emulsifying and/
or solubilizing agent.
Troleandomycin: White, odorless, crystalline powder. Freely soluble in
P
alcohol; soluble in chloroform; slightly soluble in ether and in water.
Tromethamine: White, crystalline powder, having a slight, characteris-
S
tic odor. Freely soluble in water and in low molecular weight aliphatic
alcohols; practically insoluble in chloroform, in benzene, and in car-
U
bon tetrachloride.
Tropicamide: White or practically white, crystalline powder, odorless
or having not more than a slight odor. Slightly soluble in water; freely
9
soluble in chloroform and in solutions of strong acids.
Crystallized Trypsin: White to yellowish white, odorless, crystalline or
amorphous powder.
Tryptophan: White to slightly yellowish-white crystals or crystalline
powder, having a slightly bitter taste. Soluble in hot alcohol and in
dilute hydrochloric acid.
Tuberculin: Old Tuberculin is a clear, brownish liquid, which is read-
ily miscible with water and has a characteristic odor. Purified Protein
Derivative (PPD) of Tuberculin is a very slightly opalescent, colorless
solution. Old Tuberculin and PPD concentrates contain 50% of glycerin
for use with various application devices. Old Tuberculin and PPD are
also dried on the tines of multiple-puncture devices.
Tubocurarine Chloride: White or yellowish-white to grayish-white,
crystalline powder. Melts at about 270, with decomposition. Soluble in
water; sparingly soluble in alcohol.
Tylosin: White to buff-colored powder. Freely soluble in methanol;
soluble in alcohol, in amyl acetate, in chloroform, and in dilute mineral
acids; slightly soluble in water.
Tylosin Tartrate: Almost white or slightly yellow, hygroscopic powder.
Freely soluble in water and in dichloromethane; slightly soluble in
alcohol. It dissolves in dilute solutions of mineral acids.
Tyloxapol: Viscous, amber liquid, having a slight, aromatic odor. May
exhibit a slight turbidity. Slowly but freely miscible with water. Soluble
in glacial acetic acid, in benzene, in toluene, in carbon tetrachloride,
in chloroform, and in carbon disulfide. NF category: Wetting and/or
solubilizing agent.
Tyrosine: White, odorless, tasteless crystals or crystalline powder. Very
slightly soluble in water; insoluble in alcohol and in ether.
Ubidecarenone: Yellow to orange, crystalline powder. Melts at about
48. Soluble in ether; very slightly soluble in dehydrated alcohol; prac-
tically insoluble in water.
Undecylenic Acid: Clear, colorless to pale yellow liquid having a char-
acteristic odor. Practically insoluble in water; miscible with alcohol,
with chloroform, with ether, with benzene, and with fixed and volatile
oils.
USP Pharmacists Pharmacopeia
Urea: Colorless to white, prismatic crystals, or white, crystalline pow-
der, or small white pellets. Is practically odorless, but may gradually
develop a slight odor of ammonia upon long standing. Its solutions are
neutral to litmus. Freely soluble in water and in boiling alcohol; practi-
cally insoluble in chloroform and in ether.
Ursodiol: White or almost white, crystalline powder. Practically in-
soluble in water; freely soluble in alcohol and in glacial acetic acid;
sparingly soluble in chloroform; slightly soluble in ether.
Vaccinia Immune Globulin: Transparent or slightly opalescent liquid.
Is practically colorless and practically odorless. May develop a slight,
granular deposit during storage.
Powdered Valerian Extract: Brown, hygroscopic, powdery or eas-
ily pulverizable mass. Soluble in water to form a slightly cloudy solu-
tion; sparingly soluble in 70 percent alcohol; practically insoluble in
alcohol.
Valganciclovir Hydrochloride: White to off-white powder. Very solu-
ble in 2-propanol; freely soluble in alcohol; slightly soluble in hexane;
practically insoluble in acetone or in ethyl acetate.
Valine: White, odorless, tasteless crystals. Soluble in water; practically
insoluble in ether, in alcohol, and in acetone.
Valproic Acid: Colorless to pale yellow, slightly viscous, clear liq-
uid, having a characteristic odor. Refractive index: about 1.423 at 20.
Slightly soluble in water; freely soluble in 1 N sodium hydroxide, in
methanol, in alcohol, in acetone, in chloroform, in benzene, in ether,
and in n-heptane; slightly soluble in 0.1 N hydrochloric acid.
Valrubicin: Orange to orange-red, crystalline powder. Soluble in
0
methylene chloride, in dehydrated alcohol, in methanol, and in ace-
tone; very slightly soluble in water, in hexane, and in petroleum ether.
0
Vancomycin Hydrochloride: White, almost white, or tan to brown,
2
free-flowing powder, odorless, and having a bitter taste. Freely soluble
in water; insoluble in ether and in chloroform.
Sterile Vancomycin Hydrochloride: Tan to brown, free-flowing pow-
der, odorless and having a bitter taste. Freely soluble in water; insolu-
ble in ether and in chloroform.
Vanillin: Fine, white to slightly yellow crystals, usually needle-like,
having an odor and taste suggestive of vanilla. Is affected by light. Its
solutions are acid to litmus. Slightly soluble in water; freely soluble
in alcohol, in chloroform, in ether, and in solutions of the fixed alkali
hydroxides; soluble in glycerin and in hot water. NF category: Flavors
and perfumes.
Vasopressin Injection: Clear, colorless or practically colorless liquid,
having a faint, characteristic odor.
Vecuronium Bromide: White or creamy white crystals, or a crystalline
powder. Slightly soluble in water and in acetone; sparingly soluble in
alcohol.
Hydrogenated Vegetable Oil: Type I Hydrogenated Vegetable Oil
Fine, white powder, beads, or small flakes. Type II Hydrogenated Veg-
etable OilPlastic (semi-solid) or flakes having a softer consistency
than Type I. Insoluble in water; soluble in hot isopropyl alcohol, in hex-
ane, and in chloroform. NF category: Type I Hydrogenated Vegetable
OilTablet and/or capsule lubricant; Type II Hydrogenated Vegetable
OilOintment base.
Verapamil Hydrochloride: White or practically white, crystalline
powder. Is practically odorless and has a bitter taste. Soluble in water;
freely soluble in chloroform; sparingly soluble in alcohol; practically
insoluble in ether.
Vidarabine: White to off-white powder. Very slightly soluble in water;
slightly soluble in dimethylformamide.
Vinblastine Sulfate: White or slightly yellow, odorless, amorphous or
crystalline powder. Is hygroscopic. Freely soluble in water.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/128
Description and Solubility
Vincristine Sulfate: White to slightly yellow, odorless, amorphous or
crystalline powder. Is hygroscopic. Freely soluble in water; soluble in
methanol; slightly soluble in alcohol.
Vincristine Sulfate for Injection: Yellowish-white solid, having the
characteristic appearance of products prepared by freeze-drying.
Vinorelbine Tartrate: White to yellow or light brown, amorphous pow-
der. Freely soluble in water.
Vitamin A: In liquid form, a light-yellow to red oil that may solidify
upon refrigeration. In solid form, has the appearance of any diluent
that has been added. May be practically odorless or may have a mild
fishy odor, but has no rancid odor or taste. Is unstable to air and light.
In liquid form, insoluble in water and in glycerin; very soluble in chlo-
roform and in ether; soluble in absolute alcohol and in vegetable oils.
In solid form, may be dispersible in water.
Vitamin E: Practically odorless and tasteless. The alpha tocopherols
and alpha tocopheryl acetates occur as clear, yellow, or greenish
yellow, viscous oils. d-Alpha tocopheryl acetate may solidify in the
cold. Alpha tocopheryl acid succinate occurs as a white powder; the
d-isomer melts at about 75, and the dl-form melts at about 70. The
P
alpha tocopherols are unstable to air and light, particularly when in
S
alkaline media. The esters are stable to air and light, but are unstable
to alkali; the acid succinate is also unstable when held molten. Alpha
tocopheryl acid succinate is insoluble in water; slightly soluble in alka-
U
line solutions; soluble in alcohol, in ether, in acetone, and in vegetable
oils; very soluble in chloroform. The other forms of Vitamin E are in-
soluble in water; soluble in alcohol; miscible with ether, with acetone,
9
with vegetable oils, and with chloroform.
Vitamin E Preparation: The liquid forms are clear, yellow to brown-
ish red, viscous oils. The solid forms are white to tan-white granular
powders. The liquid forms are insoluble in water; soluble in alcohol;
miscible with ether, with acetone, with vegetable oils, and with chloro-
form. The solid forms disperse in water to give cloudy suspensions.
Warfarin Sodium: White, odorless, amorphous or crystalline powder,
having a slightly bitter taste. Is discolored by light. Very soluble in
water; freely soluble in alcohol; very slightly soluble in chloroform and
in ether.
Water for Injection: Clear, colorless, odorless liquid. NF category:
Solvent.
Bacteriostatic Water for Injection: Clear, colorless liquid, odorless or
having the odor of the antimicrobial substance. NF category: Vehicle
(sterile).
Sterile Water for Inhalation: Clear, colorless solution.
Sterile Water for Injection: Clear, colorless, odorless liquid. NF cat-
egory: Solvent.
Sterile Water for Irrigation: Clear, colorless, odorless liquid. NF cat-
egory: Solvent.
Purified Water: Clear, colorless, odorless liquid. NF category: Solvent.
Carnauba Wax: Light brown to pale yellow, moderately coarse powder
or flakes, possessing a characteristic bland odor, and free from rancid-
ity. Specific gravity is about 0.99. Insoluble in water; freely soluble in
warm benzene; soluble in warm chloroform and in warm toluene;
slightly soluble in boiling alcohol. NF category: Coating agent.
Emulsifying Wax: Creamy white, wax-like solid, having a mild, charac-
teristic odor. Insoluble in water; freely soluble in ether, in chloroform,
in most hydrocarbon solvents, and in aerosol propellants; soluble in
alcohol. NF category: Emulsifying and/or solubilizing agent; stiffening
agent.
Microcrystalline Wax: White or cream-colored, odorless, waxy solid.
Insoluble in water; sparingly soluble in dehydrated alcohol; soluble in
chloroform, in ether, in volatile oils, and in most warm fixed oils. NF
category: Coating agent.
USP Pharmacists Pharmacopeia
White Wax: Yellowish-white solid, somewhat translucent in thin lay-
ers. Has a faint, characteristic odor, and is free from rancidity. Specific
gravity is about 0.95. Insoluble in water; sparingly soluble in cold al-
cohol. Boiling alcohol dissolves the cerotic acid and a portion of the
myricin, which are constituents of White Wax. Completely soluble in
chloroform, in ether, and in fixed and volatile oils. Partly soluble in
cold benzene and in cold carbon disulfide; completely soluble in these
liquids at about 30. NF category: Stiffening agent.
Yellow Wax: Solid varying in color from yellow to grayish brown. Has
an agreeable, honey-like odor. Is somewhat brittle when cold, and
presents a dull, granular, noncrystalline fracture when broken. It be-
comes pliable from the heat of the hand. Specific gravity is about 0.95.
Insoluble in water; sparingly soluble in cold alcohol. Boiling alcohol
dissolves the cerotic acid and a portion of the myricin, that are con-
stituents of Yellow Wax. Completely soluble in chloroform, in ether,
in fixed oils, and in volatile oils; partly soluble in cold benzene and in
cold carbon disulfide; completely soluble in these liquids at about 30.
NF category: Stiffening agent.
Wheat Bran: Light tan powder having a characteristic aroma. Practi-
cally insoluble in cold water and in alcohol. Available in a variety of
particle sizes depending upon the degree of milling to which it is
subjected. Color and flavor development variable, depending on the
extent to which it is heat-stabilized.
Xanthan Gum: Cream-colored powder. Its solutions in water are neu-
tral to litmus. Soluble in hot or cold water. NF category: Suspending
and/or viscosity-increasing agent.
Xenon Xe 127: Clear, colorless gas.
0
Xenon Xe 133 Injection: Clear, colorless solution.
0
Xylazine: Colorless to white crystals. Sparingly soluble in dilute acid,
in acetone, and in chloroform; insoluble in dilute alkali.
2
Xylazine Hydrochloride: Colorless to white crystals. Sparingly soluble
in dilute acid, in acetone, and in methanol; insoluble in dilute alkali.
Xylitol: White crystals or crystalline powder. It has a sweet taste and
produces a cooling sensation in the mouth. One g dissolves in about
0.65 mL of water. Sparingly soluble in alcohol. Crystalline xylitol has a
melting range between 92 and 96.
Xylometazoline Hydrochloride: White to off-white, odorless, crystal-
line powder. Melts above 300, with decomposition. Soluble in water;
freely soluble in alcohol; sparingly soluble in chloroform; practically
insoluble in benzene and in ether.
Xylose: Colorless needles or white, crystalline powder. Is odorless,
and has a slightly sweet taste. Very soluble in water; slightly soluble in
alcohol.
Yellow Fever Vaccine: Slightly dull, light-orange colored, flaky or crust-
like, desiccated mass.
Yohimbine Hydrochloride: White to yellow powder. Melts at about
295, with decomposition. Slightly soluble in water and in alcohol;
soluble in boiling water.
Official text. Reprinted from USP 32NF 27. Section 13, Reference Tables S3/129
Description and Solubility
Yttrium Chloride: Colorless, deliquescent crystals. Soluble in water
and in alcohol.
Zalcitabine: White to off-white, crystalline powder. Soluble in water
and in methanol; sparingly soluble in alcohol, in acetonitrile, in chloro-
form, and in methylene chloride; slightly soluble in cyclohexane.
Zein: White to yellow powder. Soluble in aqueous alcohols, in glycols,
in ethylene glycol ethyl ether, in furfuryl alcohol, in tetrahydrofurfuryl
alcohol, and in aqueous alkaline solutions of pH 11.5 or greater; readily
soluble in acetone-water mixtures between the limits of 60% and 80%
of acetone by volume; insoluble in water, in acetone, and in all anhy-
drous alcohols except methanol. NF category: Coating agent.
Zidovudine: White to yellowish powder. Melts at about 124. Exhibits
polymorphism. Sparingly soluble in water; soluble in alcohol.
Zileuton: White to off-white powder.
Zinc Acetate: White crystals or granules, having a slight acetous odor
and an astringent taste. Is slightly efflorescent. Freely soluble in water
and in boiling alcohol; slightly soluble in alcohol.
Zinc Chloride: White or practically white, odorless, crystalline pow-
P
der, or white or practically white crystalline granules. May also be in
porcelain-like masses or molded into cylinders. Is very deliquescent. A
S
solution (1 in 10) is acid to litmus. Very soluble in water; freely soluble
in alcohol and in glycerin. Its solution in water or in alcohol is usually
U
slightly turbid, but the turbidity disappears when a small quantity of
hydrochloric acid is added.
Zinc Gluconate: White or practically white powder or granules.
9
Soluble in water; very slightly soluble in alcohol.
Zinc Oxide: Very fine, odorless, amorphous, white or yellowish white
powder, free from gritty particles. It gradually absorbs carbon dioxide
from air. Insoluble in water and in alcohol; soluble in dilute acids.
Zinc Stearate: Fine, white, bulky powder, free from grittiness. Has
a faint, characteristic odor. Is neutral to moistened litmus paper. In-
soluble in water, in alcohol, and in ether. NF category: Tablet and/or
capsule lubricant.
Zinc Sulfate: Colorless, transparent prisms, or small needles. May
occur as a white, granular, crystalline powder. Is odorless and is efflo-
rescent in dry air. Its solutions are acid to litmus. Very soluble in water
(heptahydrate); freely soluble in water (monohydrate); freely soluble in
glycerin (heptahydrate); practically insoluble in alcohol (monohydrate);
insoluble in alcohol (heptahydrate).
Zinc Undecylenate: Fine, white powder. Practically insoluble in water
and in alcohol.
Zolazepam Hydrochloride: White to off-white, crystalline powder.
Freely soluble in water and in 0.1 N hydrochloric acid; soluble in meth-
anol; slightly soluble in chloroform; practically insoluble in ether.
USP Pharmacists Pharmacopeia AbbreAlcoh

Combined Index to USP

Pharmacists Pharmacopeia
including Third Supplement

Page citations refer to the pages of the First Supplement, Second Supplement,Third Supplement, and to pages of the USP Pharmacists Pharmacopeia main volume, where
monographs, general chapters, or other sections of text being revised in these Supplements originally appeared. First Supplement page citations are preceded by S1/ desig-
nation.

11225 MainVolume of USP Pharmacists Pharmacopeia

S1/1S1/134 First Supplement
S2/1S2/159 Second Supplement
S3/1S3/157 Third Supplement

Numbers in angle brackets such as h421i refer to chapter numbers in the General Chapters section.

A
Abbreviations , 22 Acetyltriethyl citrate , 56 Aerosols, nasal sprays, metered-dose inhalers, and
medication error prevention ,1186 Acid dry powder inhalers h601i, 725
Abbreviations can lead to medication errors! Alginic, 377 Agar, 56
abbreviations, 1186 alpha Lipoic ,1011 Ahuja, E., Bares, D., Fagan, D.T., Hacche, L., Lenzie,W.,
medication error prevention ,1186 Butyric , 395 and Murphy, J.
Acacia , 53 Cinnamic , 397 Compendial Standard for Subvisible Particulate
Matter in Ophthalmic Solutions: Results of an
syrup, 53 dehydroacetic , S2/5
Industry Collaborative Study and Proposed
Acarbose , S1/3 Hexanoic , 415 Standards, 1376
Accreditation Isobutyric , 422 Air, medical , 56
Pharmacy Compounding Accreditation Board, Isovaleric , 422 Alanine , 56
1151 Levulinic , 423 Albendazole , 57
Acebutolol hydrochloride , 53 Linoleic , 382 rAlbumin
Acepromazine maleate , 53 2-Mercaptopropionic , 425 human, S3/24
Acesulfame potassium , 377, 53 2-Methyl-2-pentenoic , 430 Albuterol, 57
Acetaldehyde , 387 2-Methylbutyric , 431 sulfate , 57
diethyl acetal , 387 2-Methylpentanoic , 432 Alclometasone dipropionate , 57
Acetaminophen , 53 4-Methylpentanoic , 432 Alcohol , 57
Acetanisole , 387 Myristic , 383 1-Amyl , 389
Acetate buffer,1480 Nonanoic , 434 Anisyl , 391
Acetazolamide , 54 Palmitic , 384 Benzyl , 392
oral suspension, 54 Phenylacetic , 439 Butyl , 57, 394
Acetic acid , 54 Phthalate buffer,1479 Cinnamyl , 397
diluted , 54 Valeric , 447 Decyl , 401
glacial , 55 Acitretin , S1/3 Dehydrated , 57
Acetohexamide , 55 capsules , S1/3 Diluted , 58
Acetohydroxamic acid , 55 Acyclovir, 56 Fenchyl , 412
Acetoin (dimer) , 387 Additional resources Furfuryl , 412
Acetone , 55 animal toxins list, 696 Heptyl, 415
Acetophenone , 387 FrequentlyAsked Questions about USP and USP Hexyl , 416
3-Acetyl-2,5-dimethyl furan , 387 standards ,11
Isoamyl , 419
Acetylcholine chloride , 55 important veterinary contacts , 689
Isobutyl , 420
Acetylcysteine , 55 poison control center directories , 689,1194
Lauryl , 422
2-Acetylpyrazine , 388 Ademetionine disulfate tosylate ,1004
-Methylbenzyl , 431
3-Acetylpyridine , 388 Adenine , 56
Myristyl , 433
2-Acetylpyrrole , 388 Adenosine , 56
Nonyl , 435
2-Acetyl thiazole , 388 Adipic acid , 56
Octyl , 437
Acetyltributyl citrate , 55
Phenethyl , 438

INDEX S3/130
USP Pharmacists Pharmacopeia AlcohAntic

Alcohol (continued) Allyl isothiocyanate , 60 Aminosalicylate sodium, 68

Propyl , 441 Almond oil, 60 Aminosalicylic acid , 68
Rubbing , 58 Aloe , 60 Amitraz , 68
Tetrahydrofurfuryl , 444 Alpha lipoic acid ,1011 Amitriptyline hydrochloride , 68
Undecyl , 446 Alprazolam , S2/3, 60 Amlodipine besylate , 68
Alcoholometric table ,1487 oral suspension , 60 Ammonia solution, strong , 68
Alendronate sodium, 58 Alprostadil , 61 Ammonio methacrylate copolymer, 69
tablets , S2/3, S3/24 An Alternative Methodology for the GeneralTest dispersion , 69
Alfadex , S3/24, 58 Chapter Microbial LimitTests h61i Ammonium
Alfentanil hydrochloride , 58 Casey,W.M., Heath, J., Hughes, K., and Goodwin, J., alum, 61
Alfuzosin hydrochloride , S3/24 1348 carbonate , 69
Alginic acid , 377, 59 Altretamine , 61 chloride , 69
Alkaline borate buffer,1480 Alum citrate, ferric , 69
Alkyl (C12-15) benzoate , 59 ammonium, 61 molybdate , 69
Allantoin , 59 potassium , 61 phosphate , 69
Allen, L.V. Aluminum sulfate , 70
Basics of CompoundingBiotechnologic acetate topical solution, 61 Ammonium alginate , 377
Preparations, 1134 chloride , 62 Amobarbital sodium, 70
Basics of CompoundingClinical Studies ,1137 chlorohydrate , 62 Amodiaquine , 70
Basics of CompoundingCompounding Creams chlorohydrex polyethylene glycol , 62 hydrochloride , 70
and Lotions ,1086 chlorohydrex propylene glycol , 62 Amoxapine , 70
Basics of CompoundingCompounding Gels , dichlorohydrate , 62 Amoxicillin, 70
1089 dichlorohydrex polyethylene glycol , 62 and Clavulanate (Systemic) , 501
Basics of CompoundingCompounding dichlorohydrex propylene glycol , 62 Amphetamine sulfate , 71
Medication Sticks ,1093 monostearate , 63 Amphotericin B , 71
Basics of CompoundingCompounding sesquichlorohydrate , 63
Ointments and Pastes ,1084 Ampicillin , 71
sesquichlorohydrex polyethylene glycol , 63 sodium, 71
Basics of CompoundingCompounding Powder-
sesquichlorohydrex propylene glycol , 63 Amprolium , 71
Filled Capsules ,1101
subacetate topical solution , 63 Amyl
Basics of CompoundingCompounding
Solutions ,1114 sulfate , 64 butyrate, 389
Basics of CompoundingCompounding Special zirconium octachlorohydrate , 64 cinnamate , 389
Capsules ,1105 zirconium octachlorohydrex gly, 64 formate , 390
Basics of CompoundingCompounding zirconium pentachlorohydrate , 64 heptanoate , 390
Suppositories: Part 1Theoretical zirconium pentachlorohydrex gly, 64 nitrite , 72
Considerations ,1096 zirconium tetrachlorohydrate , 64 octanoate , 390
Basics of CompoundingCompounding zirconium tetrachlorohydrex gly, 64 propionate , 390
Suppositories: Part 2Extemporaneous zirconium trichlorohydrate , 65
Preparation ,1099 1-Amyl alcohol , 389
zirconium trichlorohydrex gly, 65 -Amylcinnamaldehyde , 390
Basics of CompoundingCompounding Hard,
Amantadine hydrochloride , 65 Amylene hydrate , 72
Soft and ChewableTroches/Lozenges/Drops ,
1108 Ambulances Analytical instrument qualication h1058i , S1/77
Basics of CompoundingEmulsions, Part 1,1121 stability, 1344 Anethole , 72, 390
Basics of CompoundingEmulsions, Part 2 ,1124 storage ,1344 Angustifolia
Basics of CompoundingInhalation Preparations , temperature ,1344 extract, powdered echinacea, 165
1116 Amcinonide , 65 powdered echinacea ,166
Basics of CompoundingParenteral Preparations , American Association of Poison Control Centers , Anhydrous
1129 689,1194
calsium phosphate, dibasic, 101
Basics of CompoundingPowders and Granules , American ginseng ,1009
citric acid ,129
1119 extract, powdered ,1009
Anileridine , 72
Basics of CompoundingSuspensions ,1136 powdered ,1009
hydrochloride , 72
Basics of CompoundingTablets and Pills ,1111 Amifostine , 65
Animal Medicinal Drug Use Clarication Act
CompoundingTips ,1075 Amikacin , 65
Regulations Regarding Extra-Label Drug Use in
Allen, L.V., and Okeke, C.C. sulfate , 66 Animals, 686
History and Background Information on USPs Amiloride hydrochloride , 66 Animal toxins , 696
Activities in Compounding Pharmacy Practices, Amiloxate , 66 Anise oil, 72
13 Aminobenzoate Anisole , 391
Allopurinol , 59 potassium, 66 Anisyl
oral suspension, 59 sodium , 66 acetate, 391
Allyl Aminobenzoic acid , 66 alcohol , 391
cyclohexanepropionate, 388 Aminocaproic acid , 67 formate , 391
heptanoate , 388 Aminoglutethimide , 67 Antazoline phosphate , 72
hexanoate , 388 Aminoglycosides (Systemic) , 468 Anthralin , 73
-ionone , 389 Aminohippuric acid , 67 Antibiotic index
isothiocyanate , 389 Amino methacrylate copolymer, 67 veterinary monographs, 668
isovalerate , 389 Aminopenicillins (Systemic) , 494 Anticoagulant
phenoxy acetate , 389 Aminopentamide sulfate , 67 citrate dextrose solution, 73
propionate , 389 Aminophylline , S3/25, 67

INDEX S3/131
USP Pharmacists Pharmacopeia AnticBenzo

Anticoagulant (continued)
citrate phosphate dextrose adenine solution , 74
B Basics of CompoundingCompounding Powder-
Filled Capsules
citrate phosphate dextrose solution , 75 Allen, L.V., 1101
heparin solution , 75 Bacampicillin hydrochloride , 82 Basics of CompoundingCompounding Solutions
sodium citrate solution , 76 Bacitracin , S2/3, 82 Allen, L.V., 1114
Antimicrobial effectiveness testing h51i, 706 methylene disalicylate, soluble , 83 Basics of CompoundingCompounding Special
Antimony zinc , S2/3, 83 Capsules
potassium tartrate, 76 Baclofen , 83 Allen, L.V., 1105
sodium tartrate , 76 oral suspension , 83 Basics of CompoundingCompounding
Bacterial endotoxins test h85i , 718 Suppositories: Part 1Theoretical
Antineoplastic agents
Bailey, L.C., Brown, L.H., Medwick,T., Okeke, C.C., Considerations
occupational hazards in hospitals, 1141
Krumperman, K., andTran, C.D. Allen, L.V., 1096
safety for hospital workers,1141
Medication StorageTemperatures on U.S. Basics of CompoundingCompounding
Antipyrine , 76 Suppositories: Part 2Extemporaneous
Ambulances: A Prospective Multicenter
Apomorphine hydrochloride , 77 Observational Study, 1344 Preparation
Application of USPNF Standards to Pharmacy Bailey, L.C., Grady, L.T., Medwick,T., and Okeke, C.C. Allen, L.V., 1099
Compounding Basics of CompoundingCompounding Hard, Soft
Temperature Fluctuations During Mail Order
Bormel, F.G.,Valentino, J.G., and Williams, R.L., 1205 Shipment of Pharmaceutical Articles Using and ChewableTroches/Lozenges/Drops
Application of water activity determination to Mean KineticTemperatureApproach, 1339 Allen, L.V., 1108
nonsterile pharmaceutical products h1112i , 899 Bares, D., Ahuja, E., Fagan, D.T., Hacche, L., Lenzie,W., Basics of CompoundingEmulsions, Part 1
Apraclonidine hydrochloride , 77 and Murphy, J. Allen, L.V., 1121
Aprotinin , 77 Compendial Standard for Subvisible Particulate Basics of CompoundingEmulsions, Part 2
Arginine , 77 Matter in Ophthalmic Solutions: Results of an Allen, L.V., 1124
hydrochloride , 77 Industry Collaborative Study and Proposed
Basics of CompoundingInhalation Preparations
capsules , S3/74 Standards, 1376
Allen, L.V., 1116
tablets , S3/74 Barium
Basics of CompoundingParenteral Preparations
L-Arginine , 377 hydroxide lime, 84
Allen, L.V., 1129
monohydrochloride , 377 sulfate , 84
Basics of CompoundingPowders and Granules
Aromatic elixir, 77 Basics of Compounding
Allen, L.V., 1119
Arsanilic acid , 78 Biotechnologic Preparations, 1134
Basics of CompoundingSuspensions
Articles of botanical origin h561i,1014 Clinical Studies ,1137
Allen, L.V., 1136
Ascorbic acid , 78 Compounding Creams and Lotions ,1086
Basics of CompoundingTablets and Pills
Ascorbyl palmitate , 78 Compounding Gels ,1089
Allen, L.V., 1111
Ashworth, L. Compounding Medication Sticks ,1093
Bay oil, 377
Quality-Control: Standard Operating Compounding Ointments and Pastes ,1084
BCG live , 84
ProceduresAn EssentialTool for Developing Compounding Powder-Filled Capsules ,1101
Becker, S.C., and Bormel, F.G.
Quality Preparations, 1139 Compounding Solutions ,1114
Proposed Standards for Medical Gases: A Public
Asian ginseng ,1009 Compounding Special Capsules ,1105
Health Initiative, 1411
extract, powdered ,1009 Compounding Suppositories: Part 1Theoretical
Beclomethasone dipropionate , 84
powdered ,1009 Considerations ,1096
Belladonna
Asparagine , 78 Compounding Suppositories: Part 2
Extemporaneous Preparation ,1099 leaf, 84
Aspartame , 78
Compounding Hard, Soft and ChewableTroches/ extract , 84
acesulfame , 78
Lozenges/Drops ,1108 tincture , 85
Aspartic acid , 79
Emulsions, Part 1,1121 Benazepril hydrochloride , 85
Aspirin , 79
Emulsions, Part 2 ,1124 Bender,T., and the PSD ProjectTeam Representative
Assay for citric acid/citrate and phosphate h345i , 723 Membership
Inhalation Preparations ,1116
Astemizole , 79 Drug Products Distribution Chain, 1389
Parenteral Preparations ,1129
Atenolol , 79, S1/3 Bendroumethiazide , 85
Powders and Granules ,1119
oral solution , 79 Benoxinate hydrochloride , 85
Suspensions ,1136
Atomic mass ,1484 Bentonite , 85
Tablets and Pills ,1111
Atomic weights ,1481 magma , 86
Basics of CompoundingBiotechnologic
and chemical formulas , 22 puried , 86
Preparations
Atovaquone , 79 Benzaldehyde , 391, 86
Allen, L.V., 1134
Atracurium besylate , 80 elixir, compound , 86
Basics of CompoundingClinical Studies
Atropine , 80 glyceryl acetal , 391
Allen, L.V., 1137
sulfate , 80 Benzalkonium chloride , 86
Basics of CompoundingCompounding Creams
Attapulgite, activated , 80 and Lotions solution , 86
colloidal , 80 Allen, L.V., 1086 Benzethonium chloride , 87
Aurothioglucose , 80 Basics of CompoundingCompounding Gels concentrate , 87
Avobenzone , 81 Allen, L.V., 1089 tincture , 87
Azaperone , 81 Basics of CompoundingCompounding Benzocaine , 87
Azatadine maleate , 81 Medication Sticks 1,2-Benzodihydropyrone , 391
Azathioprine , 81 Allen, L.V., 1093 Benzoic acid , 87
oral suspension, 81 Basics of CompoundingCompounding Benzoin, 87
Azithromycin , 82, S1/3 Ointments and Pastes tincture, compound , 88
Aztreonam , 82, S2/3 Allen, L.V., 1084 Benzonatate , 88
Benzophenone , 392

INDEX S3/132
USP Pharmacists Pharmacopeia BenzoCapsa

Benzoyl peroxide, hydrous , 88 Bormel, F.G., and Becker, S.C. phenylacetate , 395
Benztropine mesylate , 88 Proposed Standards for Medical Gases: A Public stearate , 395
Benzyl Health Initiative, 1411 Butylated
acetate, 392 Bormel, F.G.,Valentino, J.G., and Williams, R.L. hydroxyanisole, 97
alcohol , 88, 392 Application of USPNF Standards to Pharmacy hydroxytoluene , 97
benzoate , 88, 392 Compounding, 1205 2-sec-Butyl cyclohexanone , 394
benzoate lotion , 89 Borneol , 393 Butylparaben , 97
butyrate , 392 Bornyl acetate , 393 Butyraldehyde , 395
cinnamate , 392 Botanical Butyric acid , 395
formate , 392 extracts h565i, 1027 -Butyrolactone , 395
isobutyrate , 393 origin, identication of articles of h563i ,1020
isovalerate , 393 Boylan, J.C.
phenylacetate , 393 Report and Recommendations from theWater and
Parenterals Subcommittee Meeting, October
propionate , 393
salicylate , 393
1999Labeling, Injections, and Particulate
Matter, 1344 C
Bergamot oil, coldpressed , 377 Bretylium tosylate , 94
Beta carotene , 89 Brinzolamide , 94 Cabergoline , S3/25
Betadex , 89, S3/25 Bromide (Systemic) , 463 Caffeine , 97
Betaine hydrochloride , 89 Bromocriptine mesylate , 94 Calamine , 97
Betamethasone , 89 Bromodiphenhydramine hydrochloride , 94 topical suspension, 97
acetate , 89 Brompheniramine maleate , 94 topical suspension, phenolated , 98
benzoate , 89 Brown, L.H., Bailey, L.C., Medwick,T., Okeke, C.C., Calcifediol, 98
dipropionate , 90 Krumperman, K., andTran, C.D. Calcitonin salmon , S2/4, 98
sodium phosphate , 90 Medication StorageTemperatures on U.S. Calcitriol, 98
valerate , 90 Ambulances: A Prospective Multicenter Calcium
Betaxolol hydrochloride , 90 Observational Study, 1344
acetate, 98
Bethanechol chloride , 90 Budesonide , 95
alginate , 377
oral solution , 90 Buffer
ascorbate , 98
oral suspension, 91 Acetate, 1480
carbonate , 99
Bevilacqua, A. Acid phthalate ,1479
carbonate and magnesia chewable tablets , S1/4
Revision of the pH Compendial Requirement for Alkaline borate ,1480
chloride , 99
SterileWater for Injection, 1346 Hydrochloric acid ,1479
citrate , 99
Bicalutamide , S2/4 Neutralized phthalate ,1479
disodium EDTA , 378
tablets , S3/25 Phosphate ,1479
gluceptate , 99
Bilberry Buffer solutions ,1479
gluconate , 99
extract, powdered, S2/72 Acetate buffer,1480
glycerophosphate ,1004
Biological Acid phthalate buffer,1479
hydroxide , 99
indicators for moist heat, dry heat, and gaseous Alkaline borate buffer,1480
hydroxide topical solution ,100
modes of sterilization, liquid spore suspensions, compounding ,1075
S1/4 lactate ,100
Hydrochloric acid buffer,1479
indicators for moist heat, dry heat, and gaseous lactobionate ,100
Neutralized phthalate buffer,1479
modes of sterilization, nonpaper carriers , S1/4 levulinate ,100
Phosphate buffer,1479
Biological indicators for sterilization h1035i , 847 pantothenate ,100
Bulk pharmaceutical excipientscerticate of
Biologics h1041i, 851 pantothenate, racemic ,101
analysis h1080i , 884
Biotechnology-derived articles h1045i , 851 phosphate, dibasic ,101
Bumetanide , 95
Biotin , 91 phosphate, anhydrous dibasic ,101
Bupivacaine hydrochloride , S3/25, 95
Biperiden , 91 phosphate, tribasic ,101
Buprenorphine hydrochloride , 95
hydrochloride , 92 polycarbophil ,101
Bupropion hydrochloride , 95
Bisacodyl , 92 saccharate ,101
Buspirone hydrochloride , 95
Bishara, R., and the PSD ProjectTeam Representative saccharin (anhydrous) , 378
Busulfan , 96
Membership silicate ,101
Butabarbital , 96
Drug Products Distribution Chain, 1389 stearate ,101
sodium , 96
Bismuth sulfate ,102
Butalbital , 96
citrate, 92 undecylenate ,102
Butamben , 96
milk of, 92 Camphene , 395
Butan-3-one-2-yl butanoate , 394
subcarbonate , 92 Camphor,102
Butane , 96
subgallate , 93 spirit ,102
2-Butanone , 394
subnitrate , 93 D-Camphor, 396
Butoconazole nitrate , 96
subsalicylate , 93 Canadian Poison Control Centers , 694,1199
Butorphanol tartrate , 97
subsalicylate magma , S2/4, 93 Candelilla wax , 378,102
Butyl , 394
Bisoctrizole , 93 Canola oil ,1004, 378
acetate , 394
Bisoprolol fumarate , 93 Capecitabine ,102
alcohol , 57, 394
Bleomycin sulfate , 93 Capreomycin sulfate ,102
butyrate , 394
Boric acid , 94 Caprylocaproyl polyoxylglycerides ,103
isobutyrate , 394
Capsaicin ,103
isovalerate , 395
2-methyl butyrate , 395

INDEX S3/133
USP Pharmacists Pharmacopeia CapsiChymo

Capsicum ,103 -Carotene , 378 Cephalexin ,120

oleoresin ,103 Carprofen ,111 hydrochloride ,120
Capsules Carrageenan ,111 Cephalosporins (Systemic) , 504
Acitretin, S1/3 Carteolol hydrochloride ,112 Cephalothin sodium,120
Arginine , S3/74 Carvacrol, 396 Cephapirin
Cats claw, S1/83 L-Carveol , 396 benzathine, 121
Cefdinir, S3/28 D-Carvone , 396 sodium,121
compounding ,1101,1105 L-Carvone , 396 Cephradine ,121
Curcuminoids , S3/74 L-Carvyl acetate , 396 Cetostearyl alcohol ,121
Dantrolene sodium, S2/5 -Caryophyllene , 397 Cetrimonium bromide ,121
Fenobrate , S3/30 Cascara uidextract, aromatic ,112 Cetyl
Fish oil containing omega-3 acids , S1/83 Casey,W.M., Heath, J., Hughes, K., and Goodwin, J. alcohol, 121
Isotretinoin , S2/7 An Alternative Methodology for the GeneralTest esters wax ,122
powder-lled ,1101 Chapter Microbial LimitTests h61i, 1348 palmitate ,122
preparation ,1101,1105 Cassia oil, 378 Cetylpyridinium chloride ,122
Simethicone , S2/11 Castor oil ,112 Chamomile , S2/72,1004
Soy isoavones, S3/74 hydrogenated ,112 Chapters, general, notices and requirements , 23
special ,1105 polyoxyl 35 , 288 Charcoal, activated ,122
stability,1101,1105 Cats claw, S1/83 Chaste tree ,1004
storage ,1101,1105 capsules , S1/83 powdered ,1004
Captopril ,103 extract, powdered , S1/83 powdered extract ,1004
oral solution ,103 powdered , S1/83 Cherry
oral suspension,104 tablets , S1/83 juice, 122
Caramel ,104 Cefaclor,112 syrup,123
Caraway,104 chewable tablets , S2/4 Chloral hydrate ,123
oil ,105 Cefadroxil,112 Chlorambucil ,123
Carbachol ,105 Cefamandole nafate ,113 Chloramphenicol ,123
Carbamazepine ,105 Cefazolin,113 palmitate ,123
Carbamide peroxide ,105 ophthalmic solution ,113 sodium succinate ,123
Carbenicillin sodium ,114 (Systemic) , 526
disodium, 105 Cefdinir, S3/28 Chlordiazepoxide ,124
indanyl sodium ,106 capsules , S3/28 hydrochloride ,124
Carbidopa ,106 for oral suspension , S3/29 Chloride
Carbinoxamine maleate ,106 Cefepime hydrochloride ,114 stannous, S2/11
Carbol-fuchsin topical solution ,106 Cexime ,114 Chlorobutanol ,124
Carbomer Cefmenoxime hydrochloride ,114 Chlorocresol,124
1342, 107 Cefmetazole ,115 Chlorophyllin copper complex sodium,124
934 ,106, S3/26 sodium ,115 Chloroprocaine hydrochloride ,124
934 P,106, S3/26 Cefonicid sodium,115 Chloroquine ,124
940 ,107, S3/26 Cefoperazone sodium,115 phosphate ,125
941,107, S3/27 Ceforanide ,115 Chlorothiazide ,125
copolymer,107, S3/27 Cefotaxime sodium,116 Chloroxylenol,125
homopolymer,108, S3/27 Cefotetan ,116 Chlorpheniramine maleate ,125
interpolymer,109, S3/28 disodium ,116 Chlorpromazine ,125
Carbon Cefotiam hydrochloride ,116 hydrochloride ,125
C 13, urea, 109 Cefoxitin sodium,117 Chlorpropamide ,126
dioxide ,109 Cefpiramide ,117 Chlortetracycline
Carboplatin,109 Cefpodoxime proxetil ,117 bisulfate, 126
Carboprost tromethamine ,109 Cefprozil,117 hydrochloride ,126
Carboxymethylcellulose Ceftazidime ,117 Chlorthalidone ,126
calcium, 109 Ceftizoxime sodium,118 Chlorzoxazone ,126
sodium,110 Ceftriaxone sodium,118 Chocolate ,126
sodium 12 ,110 Cefuroxime syrup,127
sodium, low-substituted ,110 axetil, 118 Cholecalciferol ,1004
sodium and microcrystalline cellulose ,119 sodium ,118 Cholesterol ,127
sodium paste ,110 Cellaburate ,118 Cholestyramine resin ,127
Cardamom Cellacefate ,119 Choline
oil, 110 Cellulose bitartrate, 1005
seed ,110 acetate, 119 chloride ,1005
tincture, compound ,111 microcrystalline ,119 Chondroitin sulfate
Carisoprodol ,111 microcrystalline and carboxymethylcellulose sodium, 1005
Carlin, H.S., Marshall, K., Foster,T.S., and Williams, R.L. sodium,119 Chromatography h621i, 742, S3/55
Development of a CompendialTaxonomy and oxidized ,119 Chromic chloride ,127
Glossary for Pharmaceutical Dosage Forms, 1402 oxidized regenerated ,120 Chromium picolinate ,1005
Carnauba wax , 378 powdered ,120 Chymotrypsin,127
sodium phosphate ,120

INDEX S3/134
USP Pharmacists Pharmacopeia CicloContr

Ciclopirox ,127 Clorsulon ,134 biotechnologic preparations ,1134

olamine ,127 and ivermectin injection, S2/8 buffer solutions ,1075
Cilastatin sodium,128 Clotrimazole ,134 capsules, powder-lled ,1101
Cilostazol,128 Clove oil,134, 379 colors ,1075
tablets , S1/4 Clover, red ,1005 compliance policy guides ,1265
Cimetidine ,128 extract, powdered ,1005 creams,1086
hydrochloride ,128 powdered ,1005 drops ,1108
Cinnamaldehyde , 397 Clower, L., and the PSD ProjectTeam Representative drugs for animal use , 680
Cinnamic acid , 397 Membership emulsions ,1121
Cinnamon leaf oil, 378 Drug Products Distribution Chain, 1389 FDCA ,1205
Cinnamyl Cloxacillin avors ,1075
acetate, 397 benzathine, 135 masking avors ,1075
alcohol , 397 sodium ,135 gels ,1089
butyrate , 397 Clozapine ,135, S2/4 granules ,1119
cinnamate , 397 Coal tar,135 inhalation preparations ,1116
formate , 398 ointment ,135 lotions ,1086
isobutyrate , 398 topical solution ,136 lozenges ,1108
isovalerate , 398 Cocaine ,136 ointments ,1084
propionate , 398 hydrochloride ,136 packaging ,1084
Cinoxacin ,128 and tetracaine hydrochlorides and epinephrine parenteral preparations ,1129
Ciprooxacin ,128 topical solution ,136 pastes ,1084
hydrochloride ,129 Cocoa butter,137 PCAB code of ethics for pharmacists ,1144
Cisapride , 460 Coconut oil ,137 PCAB Principles of Compounding ,1143
Veterinary - Systemic , S1/17 (unhydrogenated) , 379 pharmaceutical ,1067
Cisplatin ,129 Cod liver oil,137 pills,1111
Citalopram hydrobromide ,129 Code of Ethics for Pharmacists powders,1119
Citral , 398 Pharmacy Compounding Accreditation Board, preparing for clinical studies ,1137
1144
Citric acid proposed monographs , 449
Codeine ,137
anhydrous, 129 saltiness ,1075
phosphate ,138
monohydrate ,130 sodium chloride equivalency table ,1075
sulfate ,138
Citronellal , 398 solutions ,1114
Cohosh
Citronellol , 398 stability,1084
black, 1006, S2/72
Citronellyl Steps in PCAB Accreditation ,1151
black uidextract ,1006, S2/72
acetate, 399 sticks, medication ,1093
black, powdered ,1006, S2/72
butyrate , 399 suppositories ,1096,1099
black, powdered extract ,1006, S2/72
formate , 399 suspensions ,1136
black tablets , S2/72
isobutyrate , 399 sweeteners ,1075
Colchicine ,138, S1/5
propionate , 399 sweetening agents ,1075
Colestipol hydrochloride ,138
Cladribine ,130 tablets ,1111
tablets , S2/4
Clarithromycin ,130 taste ,1075
Colistimethate sodium,138
Clavulanate troches ,1108
Colistin sulfate ,138
and Amoxicillin (Systemic), 501 United States Pharmacopeial Convention
Collodion ,139 Standards and Clinical Information for
potassium ,130
exible ,139 Compounded Medications Used inVeterinary
Clemastine fumarate ,130
Colors, compounding ,1075 Medicine , 675
Clidinium bromide ,131
Comparison of MicrobiologicalTesting Practices in USP history,13
Clindamycin
Clinical, Food,Water and Pharmaceutical USP standards ,1205
hydrochloride, 131 Microbiology in Relation to the Microbiological viscosity increasing agents for aqueous systems
palmitate hydrochloride ,131 Attributes of Nutritional and Dietary table ,1075
phosphate ,131 Supplements
Compounding drugs withdrawn from market
Clinical studies, preparing compounds for,1137 Cundell, A.M., 1352 (Appendix A)
Clioquinol ,131 Compendial Standard for Subvisible Particulate compliance policy guides, 1267
topical powder, compound ,131 Matter in Ophthalmic Solutions: Results of an
CompoundingTips
Clobetasol propionate ,132 Industry Collaborative Study and Proposed
Standards Allen, L.V., 1075
Clocortolone pivalate ,132 Concentrations , 31
Ahuja, E., Bares, D., Fagan, D.T., Hacche, L., Lenzie,
Clofazimine ,132 Containers
W., and Murphy, J., 1376
Clobrate ,132 glass h660i, 753
Compliance
Clomiphene citrate ,132 permeation h671i, 760, S1/38
PCAB standards with indicators, 1144
Clomipramine hydrochloride ,133 plastics h661i, 756
Compliance policy guides
Clonazepam ,133 Containersperformance testing h671i, 760, S1/38
Appendix A: Compounding drugs withdrawn from
oral suspension,133 market, 1267 Contaminants
Clonidine ,133 compounding for use in animals , 680 injections, 1383
hydrochloride ,134 pharmacy compounding ,1265 particulate matter limits ,1383
Clopidogrel bisulfate ,134 Compound cardamom tincture ,111 Controlled substances
Clorazepate dipotassium ,134 Compounding Controlled Substances Act Regulations, 1268
antineoplastic agents hazards, 1141 Food and Drug Administration (FDA) ,1268

INDEX S3/135
USP Pharmacists Pharmacopeia ContrDieta

Controlled substances (continued) Cyclomethicone ,142 Dexamethasone ,147

labeling ,1268 Cyclopentolate hydrochloride ,142 acetate ,147
packaging ,1268 Cyclopropane ,143 sodium phosphate ,148
registration of dispensers ,1268 Cycloserine ,143 Dexbrompheniramine maleate ,148
registration of distributors ,1268 Cyclosporine ,143 Dexchlorpheniramine maleate ,148
registration of manufacturers,1268 P-Cymene , 400 Dexpanthenol,148
security,1268 Cyproheptadine hydrochloride ,143 preparation ,148
Controlled Substances Act Regulations ,1268 Cysteine hydrochloride ,143 Dextran
Food and Drug Administration (FDA) ,1268 L-Cysteine monohydrochloride , 380 1, 148
labeling ,1268 L-Cystine , 380 40 ,149
packaging ,1268 Cytarabine ,143 70 ,149
registration of dispensers ,1268 Dextrates ,149
registration of distributors ,1268 Dextrin,149
registration of manufacturers,1268 Dextroamphetamine sulfate ,149
security,1268 Dextromethorphan ,149
Copaiba oil, 379
Copovidone ,139
D hydrobromide ,150
Dextrose
Copper gluconate ,140 Dacarbazine ,144 excipient, 150
Coriander oil,140, 379 Dactinomycin ,144 solution, anticoagulant citrate , 73
Corn Danazol,144 Diacetyl , 401
oil, 140 Dantrolene sodium,144 Diacetylated monoglycerides ,150
oil (unhydrogenated) , 379 capsules , S2/5 Diatrizoate
starch , 324 Dapsone ,144 meglumine, 150
syrup, S3/29 Data collection sodium,150
syrup, high-fructose ,140, 379 rounding, 1412 Diatrizoic acid ,150
syrup solids ,140 signicant digits ,1412 Diazepam ,150
Cortisone acetate ,140 Daunorubicin hydrochloride ,144 Diazoxide ,151
Cottonseed oil ,140 (E),(E)-2,4-Decadienal , 400 Dibasic
hydrogenated ,141 -Decalactone , 400 calcium phosphate, 101
Cranberry liquid preparation ,1006 -Decalactone , 400 calcium phosphate, anhydrous ,101
Creams Decanal , 400 potassium phosphate , 292
compounding, 1086 (E)-2-Decenal , 401 sodium phosphate , 319
stability,1086 (Z)-4-Decenal , 401 Dibenzyl ether, 401
Creatinine ,141 Decoquinate ,145 Dibucaine ,151
Cresol,141 Decyl alcohol , 401 hydrochloride ,151
p-Cresyl acetate , 399 Deferoxamine mesylate ,145 Dibutyl
Cromolyn sodium,141 Dehydroacetic Acid , S2/5 phthalate, 151
Croscarmellose sodium,141 Dehydrocholic acid ,145 sebacate ,151
Crospovidone ,141 Demecarium bromide ,145 Dichloralphenazone ,151
Crotamiton,141 Demeclocycline ,145 Dichlorodiuoromethane ,151
Cuminic aldehyde , 399 hydrochloride ,146 Dichlorotetrauoroethane ,151
Cundell, A.M. Denatonium benzoate ,146 Dichlorphenamide ,152
Comparison of MicrobiologicalTesting Practices in Denman, J., and the PSD ProjectTeam Representative Diclofenac potassium ,152
Clinical, Food,Water and Pharmaceutical Membership Diclofenac sodium,152
Microbiology in Relation to the Microbiological extended-release tablets , S1/5
Drug Products Distribution Chain, 1389
Attributes of Nutritional and Dietary
Description and relative solubility of USP and NF Dicloxacillin sodium,152
Supplements, 1352
articles ,1421, S1/87, S2/81, S3/78 Dicyclomine hydrochloride ,152
Review of the Media Selection and Incubation
Conditions for the Compendial Sterility and Desurane ,146 Didanosine ,152, S3/29
Microbial LimitTests ,1364 Desipramine hydrochloride ,146 tablets for oral suspension, S2/5
Cundell, A.M., and Sutton, S.V.W. Deslanoside ,146 Dienestrol,153
Microbial Identication in the Pharmaceutical Desmopressin acetate ,146 Dietary supplements
Industry, 1368 Desoximetasone ,147 Ademetionine disulfate tosylate, 1004
Cupric Desoxycorticosterone Arginine capsules , S3/74
chloride, 141 acetate, 147 Arginine tablets , S3/74
sulfate ,142 pivalate ,147 Bilberry, powdered, extract , S2/72
Curcuminoids , S3/74 deVeau, I.F. Cats claw, S1/83
capsules , S3/74 United States Pharmacopeial Convention Cats claw capsules , S1/83
tablets , S3/74 Standards and Clinical Information for Cats claw extract, powdered , S1/83
Cyanocobalamin,142 Compounded Medications Used inVeterinary Cats claw, powdered , S1/83
Medicine, 675
Cyclamen aldehyde , 400 Cats claw tablets , S1/83
Development of a CompendialTaxonomy and
Cyclizine hydrochloride ,142 Chamomile ,1004, S2/72
Glossary for Pharmaceutical Dosage Forms
Cyclobenzaprine hydrochloride ,142 Chaste tree ,1004
Marshall, K., Foster,T.S., Carlin, H.S., and Williams,
beta-Cyclodextrin , 379 R.L., 1402 Chaste tree, powdered ,1004
gamma-Cyclodextrin, 379 Chaste tree extract, powdered ,1004
Cyclohexyl acetate , 400 Cholecalciferol,1004

INDEX S3/136
USP Pharmacists Pharmacopeia DietaDobut

Dietary supplements (continued) Licorice uidextract ,1010 Digoxin ,155

Choline bitartrate ,1005 Licorice, powdered ,1011 Dihydrocarveol , 402
Choline chloride ,1005 Licorice, powdered extract ,1011 d-Dihydrocarvone , 402
Chondroitin sulfate sodium,1005 Lipoic acid, alpha ,1011 Dihydrocodeine bitartrate ,155, S1/5
Chromium picolinate ,1005 Lutein ,1011 Dihydroergotamine mesylate ,155
Clover, red ,1005 Lutein preparation ,1011, S1/84 Dihydrostreptomycin sulfate ,155
Clover, powdered red ,1005 manufacture ,1240 Dihydrotachysterol,156
Clover extract, powdered red ,1005 Maritime pine ,1011 Dihydroxyacetone ,156
Black cohosh ,1006, S2/72 Maritime pine extract ,1011 Dihydroxyaluminum
Black cohosh uidextract ,1006, S2/72 Methylsulfonylmethane ,1012 aminoacetate, 156
Black cohosh, powdered ,1006, S2/72 Microbial limit tests h61i,1352 sodium carbonate ,156
Black cohosh powdered extract ,1006, S2/72 microbial tests for specied microorganisms ,1352 Diisopropanolamine ,156
Black cohosh tablets , S2/72 Microbiological attributes of nonsterile nutritional Diloxanide furoate ,156
Cranberry liquid preparation ,1006 and dietary supplements h2023i ,1352 Diltiazem hydrochloride ,157, S2/5
Curcuminoids , S3/74 Microbiological attributes of nonsterile oral solution ,157
Curcuminoids capsules , S3/74 pharmaceutical products h1111i,1352 oral suspension ,157
Curcuminoids tablets , S3/74 Microbiological procedures for absence of Diluted acetic acid , 54
specied microorganismsnutritional and
drugs for animal use ,1240 Dimenhydrinate ,158
dietary supplements h2022i ,1352
drugs for human use ,1240 Dimercaprol,158
Milk thistle ,1012
Echinacea angustifolia ,1006 Dimethicone ,158
Milk thistle, powdered ,1012
Echinacea angustifolia, powdered ,166 2,6-Dimethoxy phenol , 402
Milk thistle, powdered extract ,1012
Echinacea angustifolia, powdered extract ,165 Dimethyl
Nettle, stinging ,1012
Echinacea pallida ,1006 anthranilate, 402
Nettle, stinging, powdered ,1012
Echinacea pallida, powdered ,1006 benzyl carbinol , 402
Nettle, stinging, powdered extract ,1012
Echinacea pallida, powdered extract ,1006 benzyl carbinyl acetate , 402
nonsterile products ,1352
Echinacea purpurea aerial parts ,1007 benzyl carbinyl butyrate , 403
regulations ,1240
Echinacea purpurea, powdered extract ,1007 succinate , 403
Saw palmetto,1013
Echinacea purpurea root ,1007 sulde , 403
Saw palmetto, powdered ,1013
Eleuthero,1007 3,4-Dimethyl 1,2-cyclopentandione , 403
Saw palmetto extract ,1013
Eleuthero, powdered ,1007 2,6-Dimethyl-5-heptenal , 403
Selenomethionine ,1013
Eleuthero, powdered extract ,1007 3,7-Dimethyl-1-octanol , 403
Soy isoavones capsules , S3/74
FDCA ,1240 2,3-Dimethylpyrazine , 403
Soy isoavones extract, powdered , S3/74
Feverfew,1007 2,5-Dimethylpyrazine , 404
Soy isoavones tablets , S3/74
Feverfew, powdered ,1007 2,6-Dimethylpyrazine , 404
St. Johns wort ,1012
Fish oil containing omega-3 acids , S1/83 2,5-Dimethylpyrrole , 404
St. Johns wort, powdered ,1013
Fish oil containing omega-3 acids capules , S1/83 Dimethyl sulfoxide ,158, S3/29
St. Johns wort, powdered extract ,1013
Garlic ,1008 Dinoprost tromethamine ,158
Supplemental information for articles of botanical
Garlic, powdered ,1008 origin h2030i ,1031, S2/73 Dinoprostone ,159
Garlic extract, powdered ,1008 Tagatose ,1013 Dioxybenzone ,159
Garlic uidextract ,1008 testing practices ,1352 Diphenhydramine
Ginger,1008, S1/83 Tumeric , S3/75 citrate, 159
Ginger, powdered ,1008, S1/84 Tumeric, powdered , S3/75 hydrochloride ,159
Ginger tincture ,1008 Tumeric extract, powdered , S3/75 Diphenoxylate hydrochloride ,159
Ginkgo,1008 Ubidecarenone , 352 Diphenyl ether, 404
Ginkgo extract, powdered ,1008 Valerian ,1013 Dipivefrin hydrochloride ,159
Ginseng, American ,1009 Valerian, powdered extract ,1014 Dipyridamole ,160
Ginseng, American, powdered ,1009 Diethanolamine ,153 oral suspension ,160
Ginseng, American, powdered extract ,1009 Diethyl Dirithromycin ,160
Ginseng, Asian,1009 malonate, 401 Disinfectants and antiseptics h1072i , 862
Ginseng, Asian, powdered ,1009 phthalate ,153 Disintegration and dissolution of dietary
Ginseng, Asian, powdered extract ,1009 supplements h2040i ,1037
sebacate , 401
Glucosamine hydrochloride ,190, S2/73 Disodium EDTA , 380
succinate , 401
Glucosamine sulfate potassium chloride ,1009 Disopyramide phosphate ,161
Diethylcarbamazine citrate ,153
Glucosamine sulfate sodium chloride ,1009 The Dissolution procedure: development and
Diethylene glycol
Goldenseal ,1009 validation h1092i , 893
monoethyl ether, 153
Goldenseal, powdered ,1010 Distribution
stearates ,153
Goldenseal, powdered extract ,1010 humidity, 1339
Diethylpropion hydrochloride ,153
Green tea, decaffeinated, powdered, extract , S2/73 packaging ,1339,1389
Diethylstilbestrol,154
Hawthorn leaf with ower,1010 risk analysis ,1389
diphosphate ,154
Hawthorn leaf with ower, powdered ,1010 stability,1339
Diethyltoluamide ,154
Horse chestnut ,1010 storage ,1339
Diorasone diacetate ,154
Horse chestnut, powdered ,1010 temperature ,1339
Diunisal ,154
Horse chestnut, powdered extract ,1010 Disulram ,161
Digitalis ,154
laws ,1240 Divalproex sodium,161
powdered ,154
Licorice ,1010 Dobutamine hydrochloride ,161
Digitoxin,155

INDEX S3/137
USP Pharmacists Pharmacopeia DocusEthyl

Docusate Eleuthero,1007 Estrone ,172

calcium, 161 extract, powdered ,1007 Estropipate ,172
potassium ,161 powdered ,1007 Ethacrynic acid ,172
sodium,162 Elixir Ethambutol hydrochloride ,172
-Dodecalactone , 404 Aromatic, 77 Ethchlorvynol ,173
-Dodecalactone , 404 Benzaldehyde, compound , 86 Ether,173
(E)-2-Dodecen-1-al , 404 Elm ,167 Ethics, PCAB code for pharmacists ,1144
Dolasetron mesylate ,162 Emedastine difumarate ,167 Ethinyl estradiol ,173
oral solution ,162 Emergency medical services vehicles and Ethionamide ,173
oral suspension,162 ambulancesstorage of preparations h1070i , Ethone , 405
Dopamine hydrochloride ,163 862 Ethopabate ,173
Dorzolamide hydrochloride ,163 Emetine hydrochloride ,167 Ethosuximide ,173
Dosage forms Emulsions Ethotoin ,174
glossary, 1402 compounding, ,1121,1124 1,2-di[(1-Ethoxy)ethoxy]propane , 405
Pharmaceutical dosage forms h1151i,1402 distribution ,1396 Ethyl
taxonomy,1402 globule size ,1396 acetate, 174, 405
Doxapram hydrochloride ,163 intravenous ,1396 acetoacetate , 405
Doxazosin mesylate ,163 preparation ,1121,1124 acrylate , 405
Doxepin hydrochloride ,164 quality control,1124 acrylate and methyl methacrylate copolymer
Doxorubicin hydrochloride ,164 stability,1124,1396 dispersion,174
Doxycycline ,164 testing practices ,1396 p-anisate , 405
hyclate ,164 Enalapril maleate ,167 anthranilate , 405
Doxylamine succinate ,164 Enalaprilat ,167 benzoate , 405
Driscoll, D.F. Enurane ,167 benzoyl acetate , 406
Examination of Selection of Light-Scattering and Enoxaparin sodium, S2/6 butyrate , 406
Light-Obscuration Acceptance Criteria for Lipid injection , S2/6 chloride ,174
Injectable Emulsions, 1396 Ensulizole ,167 cinnamate , 406
Dronabinol ,165, S3/29 Enzacamene ,168 decanoate , 406
Droperidol,165 Ephedrine ,168 formate , 406
Drops hydrochloride ,168 heptanoate , 407
compounding, 1108 sulfate ,168 hexanoate , 407
preparation ,1108 Epinephrine ,168 isobutyrate , 407
quality control,1108 bitartrate ,168 isovalerate , 407
stability,1108 and cocaine and tetracaine hydrochlorides topical lactate , 408
storage ,1108 solution ,136 laurate , 408
Drug Products Distribution Chain Epitetracycline hydrochloride ,168 levulinate , 408
PSD ProjectTeam Representative Membership, Eprinomectin , S1/5 maltol, 380
1389 Epstein, A., and the PSD ProjectTeam Representative 2-methylbutyrate , 408
Dyclonine hydrochloride ,165, S3/29 Membership
2-methylpentanoate , 408
Dydrogesterone ,165 Drug Products Distribution Chain, 1389
methylphenylglycidate , 408
Dyphylline ,165 Equilin ,169
3-methylthiopropionate , 409
Ergocalciferol ,169
myristate , 409
Ergoloid mesylates ,169
nonanoate , 409
Ergonovine maleate ,169
octanoate , 409
Ergotamine tartrate ,169
oleate , 409,174
E Erythorbic acid , S3/30
Erythritol ,170
oxyhydrate (so-called) , 409
phenylacetate , 409
Erythromycin ,170
Echinacea phenylglycidate , 409
estolate ,170
angustifolia, 1006 propionate , 410
ethylsuccinate ,170
angustifolia extract, powdered ,165 salicylate , 410
ethylsuccinate, sterile ,170
angustifolia, powdered ,166 10-undecenoate , 410
gluceptate, sterile ,171
pallida ,1006 valerate , 410
lactobionate, sterile ,171
pallida extract, powdered ,1006 vanillin,174, 410
stearate ,171
pallida, powdered ,1006 2-Ethyl-3,5(6)-dimethylpyrazine , 410
Esomeprazole
purpurea aerial parts ,1007 Ethyl-(E)-2-butenoate , 406
magnesium, S1/5
purpurea extract, powdered ,1007 2-Ethylbutyraldehyde , 411
Estradiol ,171
purpurea root ,1007 2-Ethylbutyric acid , 411
transdermal system ,1007
Echothiophate iodide ,166 Ethylcellulose ,174
benzoate , S1/6
Econazole nitrate ,166 aqueous dispersion,175
cypionate ,171
Edetate Ethylene
valerate ,171
calcium disodium, 166 glycol stearates, 175
Estragole , 404
disodium,166 Ethylene brassylate , 411
Estriol ,171
Edetic acid ,166
Estrogens
Edrophonium chloride ,166
conjugated, 172
Elastomeric closures for injections h381i, 724, S1/35,
S3/51 esteried ,172

INDEX S3/138
USP Pharmacists Pharmacopeia EthylFreed

Ethylenediamine ,175
2-Ethyl fenchol, 406
F Floxuridine ,179
Fluconazole ,180
4-Ethyl guaiacol , 407 Flucytosine ,180
2-Ethyl hexanol , 407 Factor IX complex ,176 oral suspension ,180
5-Ethyl 3-hydroxy 4-methyl 2(5H)-furanone , 407 Fagan, D.T., Ahuja, E., Bares, D., Hacche, L., Lenzie,W., Fludarabine phosphate ,180
and Murphy, J.
2-Ethyl-3-methylpyrazine , 408 injection , S1/6
Compendial Standard for Subvisible Particulate
Ethylparaben ,175 Fludrocortisone acetate ,181
Matter in Ophthalmic Solutions: Results of an
3-Ethyl pyridine , 410 Industry Collaborative Study and Proposed Flumazenil ,181
Ethynodiol diacetate ,175 Standards, 1376 Flumethasone pivalate ,181
Etidronate disodium ,175 Famotidine ,176 Flunisolide ,181
Etodolac ,176 Farnesol , 411 Flunixin meglumine ,181
Etoposide ,176 Fat, hard ,177 Fluocinolone acetonide ,181
Eucalyptol ,176, 411 FDA MedWatch Form ,1191 Fluocinonide ,182
Eucatropine hydrochloride ,176 FDCA Fluorescein,182
Eucalyptus oil, 380 dietary supplements, 1240 sodium,182
Eugenol ,176, 411 drugs for animal use ,1206 Fluorometholone ,182
Eugenyl acetate , 411 drugs for human use ,1206 acetate ,182
Examination of Selection of Light-Scattering and laws ,1206 Fluoroquinolones (Systemic) , 534
Light-Obscuration Acceptance Criteria for Lipid manufacture ,1206 Fluorouracil ,182
Injectable Emulsions Fluoxetine hydrochloride ,183
regulations ,1206
Driscoll, D.F., 1396 Fluoxymesterone ,183
Federal Food, Drug, and Cosmetic Act (FDCA)
Excipients Fluphenazine
Requirements Relating to Drugs for Human and
USPand NF, listed bycategory, 364, S1/10, S2/13, S3/ Animal Use and to Dietary Supplements, 1206 decanoate, 183
35
USP standards ,1205 enanthate ,183
Extract
Felodipine ,177 hydrochloride ,183
Belladonna, 84
Fenbendazole ,177 Flurandrenolide ,183
Bilberry, powdered , S2/72
d-Fenchone , 412 Flurazepam hydrochloride ,184
Cascara uidextract, aromatic ,112
Fenchyl alcohol , 412 Flurbiprofen ,184
Cats claw, powdered , S1/83
Fennel oil,177 sodium,184
Chaste tree, powdered ,1004
Fenobrate ,177 Flutamide ,184
Clover, red, powdered ,1005
capsules , S3/30 Fluticasone propionate ,184
Echinacea pallida, powdered ,1006
Fenoldopam mesylate ,177 nasal spray,184
Echinacea purpurea, powdered ,1007
Fenoprofen calcium ,178 Fluvastatin sodium,185
Eleuthero, powdered ,1007
Fentanyl citrate ,178 Fluvoxamine maleate ,185
Garlic, powdered ,1008
Ferguson, B., and the PSD ProjectTeam Folic acid ,185
Garlic uidextract ,1008 Representative Membership Food and Drug Administration (FDA)
Ginkgo, powdered ,1008 Drug Products Distribution Chain, 1389 compliance policy guides, 1265
Ginseng, American, powdered ,1009 Ferric Controlled Substances Act Regulations ,1268
Ginseng, Asian, powdered ,1009 ammonium citrate, 69 drugs for animal use , 682
Goldenseal, powdered ,1010 oxide ,178 nished pharmaceuticals ,1253
Grape skin , 381 sulfate ,178 Good Manufacturing Practices ,1253
Green tea, decaffeinated, powdered , S2/73 Ferrous labeling , 682,1268
Horse chestnut, powdered ,1010 citrate, 380 manufacture , 682
Licorice, powdered ,1011 fumarate ,178 MedWatch Form ,1191
Licorice uidextract ,1010 gluconate ,178 packaging ,1253,1268
Maritime pine ,1011 glycinate , 380 processing ,1253
Milk thistle, powdered ,1012 sulfate ,178 registration of dispensers ,1268
Nettle, stinging, powdered ,1012 sulfate, dried ,178 registration of distributors ,1268
Pyrethrum, 303 sulfate syrup,179 registration of manufacturers ,1268
Saw palmetto,1013 Feverfew,1007 Regulations Regarding Extralabel Drug Use in
Senna uidextract , 313 powdered ,1007 Animals , 682
Soy isoavones, powdered , S3/74 Fexofenadine hydrochloride ,179 security,1268
St. Johns wort, powdered ,1013 Filtration storage ,1253
Tumeric, powdered , S3/75 microporous membranes, 1378 Form 1932A
Valerian, powdered ,1014 sterlizing ,1378 veterinarian ADR report, 687
Extralabel Drug Use Finasteride ,179 Formoterol fumarate , S3/30
algorithm, 684, S2/26 Fish oil containing omega-3 acids , S1/83 Foscarnet sodium, S3/30
An Informational Outline of theAMDUCA , 684, capsules , S1/83 Fosinopril sodium,185
S2/26
Flavors Fosphenytoin sodium,185
compounding, 1075 Foster,T.S., Marshall, K., Carlin, H.S., and Williams, R.L.
compounding, masking ,1075 Development of a CompendialTaxonomy and
Flavoxate hydrochloride , S3/30 Glossary for Pharmaceutical Dosage Forms, 1402
tablets , S3/30 Freedman, J., Sagona, P., Spano,W., and Pangborn, R.
Flecainide acetate ,179 The Impact of Multiple-Unit Desiccating
Florfenicol (Systemic) , 530 Containers for Prescription Packaging, 1416

INDEX S3/139
USP Pharmacists Pharmacopeia FrequGener

FrequentlyAsked Questions about USP and USP h151i Pyrogen test , 721 h1111i Microbiological examination of nonsterile
standards ,11 h201i Thin-layer chromatographic identication products: acceptance criteria for
Fructose ,186 test , 722 pharmaceutical preparations and substances for
Fuchsin basic ,186 h345i Assay for citric acid/citrate and phosphate , pharmaceutical use , S3/67
Fumaric acid ,186 723 h1112i Application of water activity determination
h381i Elastomeric closures for injections , 724, S1/ to nonsterile pharmaceutical products , 899
Furazolidone ,186
35, S3/51 h1116i Microbiological evaluation of clean rooms
Furfural , 412
h561i Articles of botanical origin ,1014 and other controlled environments , 900
Furfuryl
h563i Identication of articles of botanical origin , h1117i Microbiological best laboratory practices ,
alcohol, 412 908
1020
mercaptan , 412 h1118i Monitoring devicestime, temperature,
h565i Botanical extracts ,1027
Furosemide ,186 and humidity, 911
h601i Aerosols, nasal sprays, metered-dose
2-Furyl methyl ketone , 412 h1121i Nomenclature , 914, S3/68
inhalers, and dry powder inhalers , 725
Fusel oil, rened , 412 h1136i Packagingunit-of-use , 916
h621i Chromatography, 742, S3/55
h660i Containersglass , 753 h1146i Packaging practicerepackaging a single
solid oral drug product into a unit-dose
h661i Containersplastics , 756
container, 918
h671i Containersperformance testing , 760,
h1150i Pharmaceutical stability, 922
S1/38
G h671i Containerspermeation, 760, S1/38
h1151i Pharmaceutical dosage forms , 923,1402
h1160i Pharmaceutical calculations in prescription
h681i Repackaging into single-unit containers and
compounding , 934
Gabapentin ,186 unit-dose containers for nonsterile solid and
liquid dosage forms , 763 h1163i Quality assurance in pharmaceutical
Gadodiamide ,186 compounding , 943
Gadoteridol,187 h729i Globule size distribution in lipid injectable
emulsions , 765 h1176i Prescription balances and volumetric
Gadoversetamide ,187 apparatus , 946
h731i Loss on drying , 767
Galactose ,187 h1177i Good packaging practices , 947
h741i Melting range or temperature , 767, S2/32
Galageenan ,187 h1178i Good repackaging practices , 949
h771i Ophthalmic ointments , 768
Galantamine h1184i Sensitization testing , 950
h776i Optical microscopy, 768
hydrobromide, S1/6 h1191i Stability considerations in dispensing
h785i Osmolality and osmolarity, 770
tablets , S1/6 practice , 957
h788i Particulate matter in injections, 772,1376,
Gallamine triethiodide ,187 h1207i Sterile product packagingintegrity
1383
Gallo, M., and the PSD ProjectTeam Representative evaluation , 960
h789i Particulate matter in ophthalmic solutions ,
Membership h1208i Sterility testingvalidation of isolator
1376
Drug Products Distribution Chain, 1389 systems , 961
h791i pH , 774
Gamma Cyclodextrin , S2/5 h1211i Sterilization and sterility assurance of
h795i Pharmaceutical compoundingnonsterile compendial articles , 964
Ganciclovir,188 preparations , 775
oral suspension,188 h1221i Teaspoon, 970
h797i Pharmaceutical compoundingsterile
Gap Analysis Checklist for Chapter 795 ,1045 h1222i Terminally sterilized pharmaceutical
preparations , 779, 797,1067, S1/41, S2/33
productsparametric release , 970
Gap Analysis Checklist for Chapter 797,1053 h821i Radioactivity, 832
h1223i Validation of alternative microbiological
Garlic ,1008 h823i Radiopharmaceuticals for positron emission methods , 973
extract, powdered ,1008 tomographycompounding , 838
h1231i Water for pharmaceutical purposes , 975
uidextract ,1008 h831i Refractive index , 842
h1241i Watersolid interactions in pharmaceutical
powdered ,1008 h841i Specic gravity, 842 systems , 994
Gases h905i Uniformity of dosage units , 843 h1251i Weighing on an analytical balance , 996
medication error prevention, 1411 h911i Viscosity, 846 h1265i Written prescription drug information
standards ,1411 h1035i Biological indicators for sterilization , 847 guidelines , 999
Gelatin,188 h1041i Biologics , 851 h2022i Microbiological procedures for absence of
Gellan gum ,188 h1045i Biotechnology-derived articles , 851 specied microorganismsnutritional and
Gels h1058i Analytical instrument qualication, S1/77 dietary supplements ,1352
compounding, 1089 h1070i Emergency medical services vehicles and h2023i Microbiological attributes of nonsterile
preparation ,1089 ambulancesstorage of preparations , 862 nutritional and dietary supplements ,1029,1352
quality control,1089 h1072i Disinfectants and antiseptics , 862 h2030i Supplemental information for articles of
h1075i Good compounding practices , 866 botanical origin ,1031, S2/73
stability,1089
h1078i Good manufacturing practices for bulk h2040i Disintegration and dissolution of dietary
Gemcitabine hydrochloride ,189
pharmaceutical excipients , 869 supplements ,1037
Gembrozil,189
h1079i Good storage and shipping practices , 879 h2091i Weight variation of dietary supplements ,
General chapters, numeric 1040
h1i Injections, 701 h1080i Bulk pharmaceutical excipients
certicate of analysis , 884 General chapters
h21i Thermometers , 705 Analytical instrument qualication h1058i, S1/77
h1086i Impurities in ofcial articles , 890
h31i Volumetric apparatus , 705 Containersperformance testing h671i, 760,
h1091i Labeling of inactive ingredients , 892
h41i Weights and balances , 706 S1/38
h1092i The Dissolution procedure: development
h51i Antimicrobial effectiveness testing , 706 Microbiological examination of nonsterile
and validation , 893
h61i Microbial limit tests , 708,1348,1352,1364 products: acceptance criteria for
h1101i Medicine dropper, 898
h61i Microbiological examination of nonsterile pharmaceutical preparations and substances for
h1111i Microbiological attributes of nonsterile pharmaceutical use h1111i, S3/67
products: microbial enumeration tests , S3/43
pharmaceutical products , 898,1352
h62i Microbiological examination of nonsterile Microbiological examination of nonsterile
products: tests for specied organisms , S3/47 products: microbial enumeration tests h61i,
h71i Sterility tests , 713,1364 S3/43
h85i Bacterial endotoxins test , 718

INDEX S3/140
USP Pharmacists Pharmacopeia Gener4-Hex

General chapters (continued) Gluconolactone ,190 Guaifenesin ,194

Microbiological examination of nonsterile Glucosamine Guanabenz acetate ,194
products: tests for specied organisms h62i , hydrochloride, 190, S2/73 Guanadrel sulfate ,194
S3/47 sulfate potassium chloride ,1009 Guanethidine monosulfate ,194
General notices and requirements sulfate sodium chloride ,1009 Guanfacine hydrochloride ,194
Abbreviations, 22 Glucose, liquid ,190, S3/31 Guar gum ,194
Atomic weights and chemical formulas , 22 Glucose syrup, 380 Gum arabic , 381
Concentrations , 31 dried , 381 Gutta percha ,194
General chapters, 23 Glutamine ,190
Ingredients and processes , 24 Glutaral
Ofcialand Ofcial articles , 21 concentrate, 191
Pharmacopeial forum , 23 disinfectant solution ,191
Prescribing and dispensing , 28
Preservation, packaging, storage, and labeling , 28
Glyburide ,191 H
Glycerin,191, S2/6
Reagent standards , 23 Glyceryl Hacche, L., Ahuja, E., Bares, D., Fagan, D.T., Lenzie,W.,
Reference reagents , 23 behenate, 191 and Murphy, J.
Signicant gures and tolerances , 22 distearate ,191 Compendial Standard for Subvisible Particulate
Summation,19 monolinoleate ,191 Matter in Ophthalmic Solutions: Results of an
Supplements , 23 monooleate ,191, S3/31 Industry Collaborative Study and Proposed
Tests and assays , 25 monostearate ,192 Standards, 1376
Title , 21 Glyceryl tripropanoate , 414 Halazone ,194
Units of potency, 24 Glycine ,192 Halcinonide ,195
USP, 21, S3/11 Glycopyrrolate ,192 Haloperidol ,195
USP Reference standards , 23 Goldenseal ,1009 Halothane ,195
Vegetable and animal substances , 31 extract, powdered ,1010 Hawthorn leaf
Weights and measures , 31 powdered ,1010 with ower, 1010
Gentamicin sulfate ,189 Gold sodium thiomalate ,192 with ower, powdered ,1010
Gentian violet ,189 Gonadorelin Hazard Communication Guidelines for Compliance
Geraniol, 412 acetate, 192 Occupational Safety and Health Act, 1327
Geranyl hydrochloride ,192 Heath, J., Casey,W.M., Hughes, K., and Goodwin, J.
acetate, 413 Gonadotropin, chorionic ,193 An Alternative Methodology for the GeneralTest
benzoate , 413 Chapter Microbial LimitTests h61i, 1348
Good compounding practices h1075i , 866
butyrate , 413 Helium ,195
Good Manufacturing Practices
formate , 413 (E),(E)-2,4-Heptadienal , 414
nished pharmaceuticals, 1253
isogeranyl isovalerate , 413 -Heptalactone , 414
packaging ,1253
phenylacetate , 413 Heptanal , 414
processing ,1253
propionate , 413 2,3-Heptandione , 414
storage ,1253
Gehring, Ronette 2-Heptanone , 414
Good manufacturing practices for bulk
The Use of Drugs in Food-Producing Animal pharmaceutical excipients h1078i , 869 3-Heptanone , 414
Species: Making Sense of the Law, S1/30 Good packaging practices h1177i, 947 (Z)-4-Hepten-1-al , 414
Ginger,1008, S1/83 Good repackaging practices h1178i , 949 Heptyl alcohol , 415
powdered ,1008, S1/84 Good storage and shipping practices h1079i , 879 Hexachlorophene ,195
tincture ,1008 Goodwin, J., Casey,W.M., Heath, J., and Hughes, K. -Hexalactone , 415
Ginkgo,1008 An Alternative Methodology for the GeneralTest Hexanal , 415
extract, powdered ,1008 Chapter Microbial LimitTests h61i, 1348 Hexanoic acid , 415
Ginseng Grady, L.T., Bailey, L.C., Medwick,T., and Okeke, C.C. (E)-2-Hexen-1-al , 415
American, 1009 Temperature Fluctuations During Mail Order (E)-2-Hexen-1-ol , 415
Asian ,1009 Shipment of Pharmaceutical Articles Using (Z)-3-Hexenol , 415
extract, powdered American ,1009 Mean KineticTemperatureApproach, 1339 (Z)-3-Hexenyl 2-methylbutyrate , 416
extract, powdered Asian,1009 Grady, L.T., andTaborsky, C.J. (E)-2-Hexenyl acetate , 415
powdered, American ,1009 WaterVapor Permeation of PrescriptionVials, 1388 (Z)-3-Hexenyl acetate , 416
powdered, Asian,1009 Gramicidin ,193 (Z)-3-Hexenyl butyrate , 416
Glacial acetic acid , 55 Granisetron hydrochloride , S3/31 (Z)-3-Hexenyl formate , 416
Glaze, pharmaceutical ,189 Granisetron hydrochloride oral suspension, 453 (Z)-3-Hexenyl isovalerate , 416
Glimepiride ,190 Granules Hexyl
tablets , S1/6 compounding, 1119 acetate, 416
Glipizide ,190 quality control,1119 alcohol , 416
Globule size stability,1119 butyrate , 417
distribution, 1396 Grape skin extract , 381 hexanoate , 417
emulsions ,1396 Gravity, specic h841i, 842 Hexyl-2-Butenoate , 417
intravenous ,1396 Green Hexyl 2-methylbutyrate , 417
stability,1396 soap, 193 -Hexylcinnamaldehyde , 417
testing practices ,1396 soap tincture ,193 Hexylene glycol ,195
Globule size distribution in lipid injectable emulsions GreenTea Hexyl isovalerate , 417
h729i , 765 decaffeinated, powdered, extract, S2/73 Hexylresorcinol,195
Glucagon ,190 Griseofulvin ,193 4-Hexylresorcinol , 381

INDEX S3/141
USP Pharmacists Pharmacopeia HistaIsoam

Histamine phosphate ,196 Hydroxyzine Ivermectin and clorsulon , S2/8

L-Histidine monohydrochloride , 381 hydrochloride, 201 ophthalmic solution ,1376
History and Background Information on USPs pamoate , 201 particulate matter,1344,1376
Activities in Compounding Pharmacy Practices Hymetellose , 201 particulate matter contaminants ,1383
Allen, L.V., and Okeke, C.C., 13 Hyoscyamine , 201 Particulate matter in injections h788i , 772,1376
Hollander, R., and the PSD ProjectTeam hydrobromide , 201 particulate matter limits ,1383
Representative Membership sulfate , 202 Propofol injectable emulsion , S3/33
Drug Products Distribution Chain, 1389 Hypophosphorous acid , 202 Ringers , 309
Homatropine Hypromellose , 202 Sodium bromide, veterinary, 462, S3/34
hydrobromide, 196 ophthalmic solution , 202 stability,1396
methylbromide ,196 phthalate , 202 testing practices ,1396
Homosalate ,196 Injections h1i, 701
Puried Honey,196 Inositol , 381, S2/6
Horse chestnut ,1010 Insulin, 206
extract, powdered ,1010 human , 206
powdered ,1010
Hughes, K., Casey,W.M., Heath, J., and Goodwin, J.
I human suspension, isophane , 206
human zinc suspension , 208
An Alternative Methodology for the GeneralTest human zinc suspension, extended , 208
Chapter Microbial LimitTests h61i, 1348 Ibuprofen , 203
Ichthammol , 203 lispro, 207
Humidity
ointment , 203 suspension, isophane , 207
distribution, 1339
Idarubicin hydrochloride , 203 zinc suspension, 207
packaging ,1339
Identication zinc suspension, extended , 207
stability,1339
of articles of botanical origin h563i, 1020 zinc suspension, prompt , 208
temperature ,1339
test, thin-layer chromatographic h201i, 722 Intrinsic viscosity table ,1491
Hydralazine hydrochloride ,196
Idoxuridine , 203 Introduction
oral solution ,196
Ifosfamide , 204 USP Pharmacists Pharmacopeia, v, S1/iv, S2/iv,
Hydrochloric acid ,197 S3/iv
buffer,1479 Imidurea , 204
veterinary monographs , 459
diluted ,197 Imipenem , 204
Inulin , 208
Hydrochlorothiazide ,197 Imipramine hydrochloride , 204
Iodine , 208
and lisinopril tablets , S3/32 The Impact of Multiple-Unit Desiccating Containers
for Prescription Packaging solution, strong , 208
Hydrocodone bitartrate ,197 tincture , 209
Sagona, P., Freedman, J., Spano,W., and Pangborn,
Hydrocortisone ,197 tincture, strong , 209
R., 1416
acetate ,198 topical solution , 209
ImportantVeterinary Contacts , 689
butyrate ,198 Iodipamide , 209
Impurities in ofcial articles h1086i , 890
hemisuccinate ,198 Iodixanol , 210
Inamrinone , 204
sodium phosphate ,198 Iodoform , 210
Indapamide , 204
sodium succinate ,198 Iodoquinol , 210
Indigotindisulfonate sodium, 205
valerate ,198 Iohexol , 210
Indinavir sulfate , 205
Hydroumethiazide ,198 -Ionone , 418
Indocyanine green , 205
Hydrogen -Ionone , 418
Indole , 418
peroxide, 381 Iopamidol , 210, S3/31
Indomethacin , 205
peroxide concentrate ,199 Iopanoic acid , 210
topical gel , 205
Hydrogenated vegetable oil , 355 Iophendylate , 210
sodium , 206
Hydromorphone hydrochloride ,199 Iopromide , 211
Industry
Hydrophobic Colloidal Silica , S2/6 Iothalamic acid , 211
microbial identication methods, 1368
Hydroquinone ,199 Ioversol , 211
regulations ,1368
Hydroxocobalamin,199 Ioxaglic acid , 211
An Informational Outline of theAMDUCA
4-Hydroxy-2,5-dimethyl-3(2H)-furanone , 417 Ioxilan , 211
Extralabel Drug Use, 684, S2/26
6-Hydroxy-3,7-dimethyloctanoic acid lactone , 418 Ipecac , 211
Ingredients and processes , 24
Hydroxyamphetamine hydrobromide ,199 oral solution , 212
Inhalation
Hydroxyanisole, butylated , 97 powdered , 212
Levalbuterol solution, S1/7
Hydroxychloroquine sulfate ,199 Ipodate sodium, 212
Inhalation preparations
Hydroxycitronellal , 418 Ipratropium bromide , S1/7
compounding, 1116
dimethyl acetal , 418 Irbesartan , 213
quality control,1116
Hydroxyethyl cellulose , 200 Isoamyl
stability,1116
4-(p-Hydroxyphenyl)-2-butanone , 418 acetate, 419
storage ,1116
Hydroxyprogesterone caproate , 200 alcohol , 419
Injection
Hydroxypropyl benzoate , 419
content uniformity, 1344
betadex, 200 butyrate , 419
distribution ,1396
cellulose , 200 formate , 419
emulsions ,1396
cellulose low-substituted , 200 hexanoate , 419
Fludarabine phosphate , S1/6
cellulose ocular system , 201 isobutyrate , 419
globule size ,1396
Hydroxytoluene, butylated , 97 isovalerate , 420
intravenous ,1396
Hydroxyurea , 201 phenyl acetate , 420
Ivermectin , S2/7

INDEX S3/142
USP Pharmacists Pharmacopeia IsoamLinal

Isoamyl (continued) Jornitz, M.W., and Meltzer,T.H. Lauryl

salicylate , 420 Sterilizing Filtrations with Microporous alcohol, 422
Isoborneol , 420 Membranes, 1378 aldehyde , 423
Isobornyl acetate , 420 Juniper tar, 217 Laws
Isobutane , 213 dietary supplements, 1240
Isobutyl drugs for animal use , 682,1206
acetate, 421 drugs for human use ,1206
alcohol , 420 FDCA ,1206
butyrate , 420 K nished pharmaceuticals ,1253
cinnamate , 421 Good Manufacturing Practices ,1253
formate , 421 Kanamycin sulfate , 217 labeling , 682
hexanoate , 421 Kaolin, 217 manufacture , 682,1206
phenylacetate , 421 Karaya gum , 382 packaging ,1253
salicylate , 421 Kelp, 382 processing ,1253
Isobutyl-2-Butenoate , 421 Ketamine hydrochloride , 217 regulations ,1206
Isobutyraldehyde , 422 Ketoconazole , 217 Regulations Regarding Extralabel Drug Use in
Isobutyric acid , 422 oral suspension , 217 Animals , 682
Isoetharine Ketoprofen , 218 storage ,1253
hydrochloride, 213 Ketorolac tromethamine , 218 Lecithin , 221, S3/31
mesylate , 213 Kr 81m, Krypton, 218 Leunomide , 221
Isoeugenol , 422 Krumperman, K., Brown, L.H., Bailey, L.C., Medwick,T., Lemon
Isoeugenyl acetate , 422 Okeke, C.C., andTran, C.D. oil, 221
Isoupredone acetate , 213 Medication StorageTemperatures on U.S. oil, coldpressed , 382
Isourane , 213 Ambulances: A Prospective Multicenter tincture , 221
Isourophate , 214 Observational Study, 1344 Lemongrass oil, 382
Isoleucine , 214 Krypton Kr 81m, 218 Lenzie,W., Ahuja, E., Bares, D., Fagan, D.T., Hacche, L.,
Isomalt , 214 and Murphy, J.
Isometheptene mucate , 214 Compendial Standard for Subvisible Particulate
Matter in Ophthalmic Solutions: Results of an
Isoniazid , 214
Industry Collaborative Study and Proposed
Isopropamide iodide , 214
Isopropyl L Standards, 1376
Letrozole , 221
acetate, 422 Leucine , 221
alcohol , 214, S3/31 Labeling Leucovorin calcium , 222
alcohol, azeotropic , 215 biotechnologic preparations, 1134 Leuprolide acetate , 222
alcohol, rubbing , 215 controlled substances ,1268 Levalbuterol
myristate , 215 Controlled Substances Act Regulations ,1268 inhalation solution, S1/7
palmitate , 215 drugs for animal use , 682 Levalbuterol hydrochloride , S1/7
Isoproterenol Food and Drug Administration (FDA) ,1268 Levamisole hydrochloride , 222
hydrochloride, 215 manufacture , 682 Levmetamfetamine , 222
sulfate , 215 neuromuscular blockers ,1344 Levobunolol hydrochloride , 222
Isopulegol , 422 packaging ,1268 Levocabastine hydrochloride , 222
Isosorbide dinitrate, diluted , 215 parenteral preparations ,1129 Levocarnitine , 223
Isotretinoin , 216 registration of dispensers ,1268 Levodopa , 223
capsules , S2/7 registration of distributors ,1268 Levonordefrin, 223
Isovaleric acid , 422 registration of manufacturers ,1268 Levonorgestrel , 223
Isoxsuprine hydrochloride , 216 Regulations Regarding Extralabel Drug Use in Levorphanol tartrate , 223
Isradipine , 216 Animals , 682
Levothyroxine sodium, 223, S1/7
Ivermectin , 216, S2/7 security,1268
Levulinic acid , 423
and clorsulon injection , S2/8 vials ,1344
Licorice ,1010
injection, S2/7 Labeling , 892
extract, powdered ,1011
paste , S2/7 Labetalol hydrochloride , 218
uidextract ,1010
tablets , S2/7 oral suspension , 219
powdered ,1011
topical solution , S2/8 Lactase , 219
Lidocaine , 224
Lactitol, 219
hydrochloride , 224
Lactose
Lime , 224
anhydrous, 219
D-Limonene , 423
monohydrate , 220
L-Limonene , 423
J Lamivudine , 220
Lanolin , 220
Linalool , 423
oxide , 423
alcohols , 220
Jones, K., and the PSD ProjectTeam Representative Linalyl
Membership modied , 220
acetate, 423
Drug Products Distribution Chain, 1389 Lansoprazole , 220
benzoate , 424
Lauroyl polyoxylglycerides , 220
formate , 424
isobutyrate , 424
propionate , 424

INDEX S3/143
USP Pharmacists Pharmacopeia LincoMetha

Lincomycin hydrochloride , 224 sulfate , 230 standards ,1411

Lincosamides (Systemic) , 558 trisilicate , 230 USP and Patient Safety,1155
Lindane , 224 Malathion, 230 Medication error reporting
Linoleic acid , 382 Maleic acid , 230 FDA MedWatch Form, 1191
Linoleoyl polyoxylglycerides , 224 Malic acid , 230 USP Medication Errors Reporting Program (form) ,
Liothyronine sodium , 224 Maltitol, 230 1157
Lipid injectable emulsion , S1/7 solution , 231 USP and Patient Safety,1155
Lipoic acid syrup, 383 Veterinarian ADR Form 1932 , 687
alpha, 1011 Maltodextrin , 231, 383 Medication StorageTemperatures on U.S.
Lisinopril , 225 Maltol, 231, 383 Ambulances: A Prospective Multicenter
Observational Study
and hydrochlorothiazide tablets , S3/32 Maltol isobutyrate , 424
Brown, L.H., Bailey, L.C., Medwick,T., Okeke, C.C.,
Lithium Maltose , 231
Krumperman, K., andTran, C.D., 1344
carbonate, 225 Malt syrup, 382
Medication Use Process (chart)
citrate , 225 Mangafodipir trisodium, 231
safe medication practices, 1156
hydroxide , 225 Manganese
Medicine dropper h1101i, 898
Locust (carob) bean gum , 382 chloride, 231
Medium-chain trigylcerides , 349
Look-Alike and/or Sound-Alike Product Errors ,1165 sulfate , 232
Medroxyprogesterone acetate , 233
Loperamide hydrochloride , 225 Mannitol, 232
Medication sticks
Loracarbef, 225 Manufacture
compounding, 1093
Loratadine , 226 dietary supplements, 1240
quality control,1093
Lorazepam , 226 drugs for animal use , 682,1206
stability,1093
Losartan potassium , 226 drugs for human use ,1206
Medwick,T., Bailey, L.C., Grady, L.T., and Okeke, C.C.
Loss on drying h731i, 767 FDCA ,1206
Temperature Fluctuations During Mail Order
Lotion nished pharmaceuticals ,1253 Shipment of Pharmaceutical Articles Using
Benzyl benzoate, 89 Good Manufacturing Practices ,1253 Mean KineticTemperatureApproach, 1339
compounding ,1086 labeling , 682 Medwick,T., Brown, L.H., Bailey, L.C., Okeke, C.C.,
stability,1086 laws ,1206 Krumperman, K., andTran, C.D.
Lovastatin , 226 packaging ,1253 Medication StorageTemperatures on U.S.
Loxapine succinate , 226 processing ,1253 Ambulances: A Prospective Multicenter
Lozenges regulations ,1206 Observational Study, 1344
compounding, 1108 Regulations Regarding Extralabel Drug Use in Mefenamic acid , 233
preparation ,1108 Animals , 682 Meoquine hydrochloride , 233
quality control,1108 storage ,1253 Megestrol acetate , 234
stability,1108 USP standards ,1205 Meglumine , 234
storage ,1108 Maprotiline hydrochloride , 232 Melengestrol acetate , 234
Lutein ,1011 Maritime pine ,1011 Meloxicam, 234
preparation ,1011, S1/84 extract ,1011 Melphalan , 234
Lysine Marshall, K., Foster,T.S., Carlin, H.S., and Williams, R.L. Melting range or temperature h741i, 767, S2/32
acetate, 226 Development of a CompendialTaxonomy and Meltzer,T.H., andJornitz, M.W.
hydrochloride , 227 Glossary for Pharmaceutical Dosage Forms, 1402 Sterilizing Filtrations with Microporous
Mayberry, P., and the PSD ProjectTeam Membranes, 1378
Representative Membership Menadiol sodium diphosphate , 234
Drug Products Distribution Chain, 1389 Menadione , 235
Mazindol , 232 Menthol , 235, 424

M McNeal, E., Nath, N., Obenhuber, D., Pillari, B., Shelton,

L., Stevens-Riley, M., and Sweeney, N.
L-Menthone , 425
DL-Menthyl acetate , 425
Particulate Contaminants of Intravenous Meperidine hydrochloride , 235
Macrolides (Systemic) , 565 Medication and the Limits Set by USP General Mephenytoin , 235
Mafenide acetate , 227 Chapter h788i, 1383
Mephobarbital , 235
Magaldrate , 227 Measurement results
Mepivacaine hydrochloride , 235
Magnesium rounding, 1412
Meprednisone , 236
aluminometasilicate, 227 signicant digits ,1412
Meprobamate , 236
aluminosilicate , 227 Mebendazole , 232
2-Mercaptopropionic acid , 425
aluminum silicate , 227 Mecamylamine hydrochloride , 232
Mercaptopurine , 236
carbonate , 228 Mechlorethamine hydrochloride , 232
Mercury, ammoniated , 236
chloride , 228 Meclizine hydrochloride , 233
Meropenem , 236
citrate , 228 Meclocycline sulfosalicylate , 233
Mesalamine , 236
citrate oral solution , 228 Meclofenamate sodium, 233
Mesoridazine besylate , 236
gluconate , 229 Medical air, 56
Mestranol , 237
hydroxide , 229 Medication error denition
Metacresol, 237
oxide , 229 NCC MERP, 1159
Metaproterenol sulfate , 237
phosphate , 229 Medication error prevention
Metaraminol bitartrate , 237
salicylate , 229 abbreviations, 1186
Metformin hydrochloride , 237
silicate , 230 gases ,1411
Methacholine chloride , 237
stearate , 230 names, similarity,1165
Methacrylic
acid copolymer, 238

INDEX S3/144
USP Pharmacists Pharmacopeia MethaMissi

Methacrylic (continued) 2-Methyl butanal , 426 Microbial limit tests h61i, 708
acid copolymer dispersion , 238 3-Methyl butanal, 430 alternative methodology,1348
Methacycline hydrochloride , 238 2-Methylbutyl acetate , 426 dietary supplements ,1352
Methadone hydrochloride , 238 2-Methylbutyl isovalerate , 426 incubation conditions ,1364
Methamphetamine hydrochloride , 238 2-Methylbutyric acid , 431 media selection ,1364
Methazolamide , 239 Methylcellulose , 241 microbial tests for specied microorganisms ,1352
Methdilazine hydrochloride , 239 -Methylcinnamaldehyde , 431 nonsterile products ,1352
Methenamine , 239 6-Methylcoumarin , 432 testing practices ,1352,1364
hippurate , 239 5H-5-Methyl-6,7-dihydrocyclopenta[b]pyrazine , Microbial tests for specied microorganisms
mandelate , 239 427 dietary supplements, 1352
Methimazole , 239 Methyldopa , 242 Microbial limit tests h61i,1352
Veterinary - Systemic , S1/22 Methyldopate hydrochloride , 242 Microbiological attributes of nonsterile nutritional
Methocarbamol , 239 Methylene and dietary supplements h2023i ,1352
Methodology blue, 242 Microbiological attributes of nonsterile
alternative limit tests, 1348 chloride , 242 pharmaceutical products h1111i,1352
Methohexital , 240 Methylene Blue Microbiological procedures for absence of
injection, veterinary, S2/20 specied microorganismsnutritional and
Methotrexate , 240
dietary supplements h2022i ,1352
Methotrimeprazine , 240 Veterinary - Systemic , S2/21
nonsterile products ,1352
Methoxsalen , 240 Methylergonovine maleate , 242
testing practices ,1352
2-Methoxy-3(5)-methylpyrazine , 425 5-Methyl furfural , 430
Microbiological attributes of nonsterile nutritional
2-Methoxy 3- (or 5- or 6-) isopropyl pyrazine , 425 L-Menthyl butanal , 426
and dietary supplements h2023i ,1029
p-Methoxybenzaldehyde , 425 Methylparaben , 242
dietary supplements ,1352
Methoxyurane , 240 sodium , 242
microbial tests for specied microorganisms ,1352
4-p-Methoxyphenyl-2-butanone , 425 2-Methylpentanoic acid , 432
nonsterile products ,1352
2-Methoxypyrazine , 426 4-Methylpentanoic acid , 432
testing practices ,1352
Methscopolamine bromide , 240 4-Methyl-2-pentanone , 429
Microbiological attributes of nonsterile
Methsuximide , 241 Methylphenidate hydrochloride , 243 pharmaceutical products h1111i, 898
Methyclothiazide , 241 5-Methyl 2-phenyl 2-hexenal , 429 dietary supplements ,1352
Methyl Methylprednisolone , 243 microbial tests for specied microorganisms ,1352
acetate, 426 acetate , 243 nonsterile products ,1352
alcohol , 241 hemisuccinate , 243 testing practices ,1352
anthranilate , 426 sodium succinate , 243 Microbiological best laboratory practices h1117i, 908
benzoate , 426 2-Methyl propyl 3-methyl butyrate , 429 Microbiological evaluation of clean rooms and other
butyrate , 427 2-Methylpyrazine , 432 controlled environments h1116i , 900
cinnamate , 427 Methylsulfonylmethane ,1012 Microbiological examination of nonsterile products:
cyclopentenolone , 427 Methyltestosterone , 243 acceptance criteria for pharmaceutical
eugenol , 427 3-Methylthiopropionaldehyde , 432 preparations and substances for pharmaceutical
2-Methylundecanal , 432 use h1111i, S3/67
furoate , 427
Methysergide maleate , 243 Microbiological examination of nonsterile products:
hexanoate , 427
microbial enumeration tests h61i, S3/43
hexyl ketone , 428 Metoclopramide hydrochloride , 244
Microbiological examination of nonsterile products:
ionones , 428 Metolazone , 244
tests for specied organisms h62i , S3/47
isobutyl ketone , 241 oral suspension , 244
Microbiological procedures for absence of specied
isobutyrate , 428 Metoprolol microorganismsnutritional and dietary
isoeugenol , 428 fumarate, 244 supplements h2022i
isovalerate , 428 succinate , 244 dietary supplements, 1352
methacrylate and ethyl acrylate copolymer tartrate , 245 microbial tests for specied microorganisms ,1352
dispersion ,174 tartrate oral solution , 245 nonsterile products ,1352
2-methylbutyrate , 428 tartrate oral suspension, 245 testing practices ,1352
-naphthyl ketone , 428 Metrifonate , 246 Microscopy, optical h776i , 768
2-octynoate , 429 Metronidazole , 246 Milk thistle ,1012
phenylacetate , 429 benzoate , 246 extract, powdered ,1012
phenylcarbinyl acetate , 429 (Systemic) , 586 powdered ,1012
salicylate , 241, 429 Metyrapone , 246 Milrinone , 247
thiobutyrate , 429 Metyrosine , 246 Mineral
valerate , 430 Mexiletine hydrochloride , 246 oil, 247, S2/8
5-Methyl-2-isopropyl-2-hexenal , 430 Mezlocillin sodium, 247 oil emulsion , 248
2-Methyl-2-pentenoic acid , 430 Mibolerone , 247 oil, light , 248, S2/8
Methyl-3-methylthiopropionate , 431 Miconazole , 247 oil, rectal , S2/8
6-Methyl-5-hepten-2-one , 431 nitrate , 247 oil, topical light , S2/8
4-Methyl-5-thiazole ethanol , 431 Microbial identication Minocycline hydrochloride , 248
4-Methyl acetophenone , 430 methods, 1368 Minoxidil , 248
p-Methyl anisole , 430 pharmaceutical industry,1368 Mirtazapine , 248
Methylbenzethonium chloride , 241 regulations ,1368 orally disintegrating tablets , S3/32
-Methylbenzyl alcohol , 431 Microbial Identication in the Pharmaceutical Mission
Methylbenzyl acetate , 431 Industry and preface, 5, S3/3
Cundell, A.M., and Sutton, S.V.W., 1368

INDEX S3/145
USP Pharmacists Pharmacopeia Missi3-Oct

Mission (continued) Naproxen , 254 Nomenclature h1121i, 914, S3/68

statement , 5, S3/3 sodium , 255 (E),(E)-2,4-Nonadienal , 433
Mitomycin , 248 Naratriptan (E),(Z)-2,6-Nonadienal , 433
Mitotane , 249 hydrochloride, 255 (E),(Z)-2,6-Nonadienol , 434
Mitoxantrone hydrochloride , 249 hydrochloride oral suspension, 453 -Nonalactone , 434
Modanil , 249 Natamycin , 255 -Nonalactone , 434
Moisture Nath, N., McNeal, E., Obenhuber, D., Pillari, B., Shelton, Nonanal , 434
desiccants, 1416 L., Stevens-Riley, M., and Sweeney, N. Nonanoic acid , 434
desiccating containers,1416 Particulate Contaminants of Intravenous 2-Nonanone , 434
packaging ,1416 Medication and the Limits Set by USP General (E)-2-Nonen-1-ol, 434
Chapter h788i, 1383
Molindone hydrochloride , 249 (Z)-6-Nonen-1-ol , 434
National Coordinating Council for Medication Error
Mometasone furoate , 249 (E)-2-Nonenal , 435
Reporting and Prevention (NCC MERP)
Monensin , 249 Nonoxynol 9 , 259
error denition, 1159
granulated , 250 Nonsterile products
Recommendations ,1159
sodium, 250 dietary supplements, 1352
National Institute for Occupational Safety and
Monitoring devicestime, temperature, and Health Microbial limit tests h61i,1352
humidity h1118i , 911 microbial tests for specied microorganisms ,1352
antineoplastic agents hazards, 1141
Monobasic Microbiological attributes of nonsterile nutritional
NCC MERP
potassium phosphate, 292 and dietary supplements h2023i ,1352
error denition, 1159
sodium phosphate , 319 Microbiological attributes of nonsterile
NCC MERP: recommendations ,1159
Monobenzone , 250 pharmaceutical products h1111i,1352
Nefazodone hydrochloride , 255
Mono- and di-glycerides , 250 Microbiological procedures for absence of
Neomycin sulfate , 255 specied microorganismsnutritional and
Monoethanolamine , 250
Neostigmine dietary supplements h2022i ,1352
Monosodium glutamate , 250
bromide, 255 testing practices ,1352
Monothioglycerol, 250
methylsulfate , 256 Nonyl
Moricizine hydrochloride , 251
Neotame , 256 acetate, 435
Morphine sulfate , 251
Nerol, 433 alcohol , 435
suppositories , 251
Nerolidol, 433 Norepinephrine bitartrate , 259
Mupirocin , 252
Neryl acetate , 433 Norethindrone , 259
calcium , 252
Netilmicin sulfate , 256 acetate , 260
Murphy, J., Ahuja, E., Bares, D., Fagan, D.T., Hacche, L.,
Nettle tablets , S2/9
and Lenzie,W.
stinging, 1012 Norethynodrel , 260
Compendial Standard for Subvisible Particulate
Matter in Ophthalmic Solutions: Results of an stinging, powdered ,1012 Noroxacin , 260
Industry Collaborative Study and Proposed stinging, powdered extract ,1012 Norgestimate , 260
Standards, 1376 Neutralized phthalate buffer,1479 Norgestrel , 260
Mustard oil, 383 Nevirapine , 256 Nortriptyline hydrochloride , 260
Mycophenolate mofetil , S2/9 oral suspension , 256 Noscapine , 261
Myrcene , 432 Newton, D.W. Novobiocin
Myristaldehyde , 432 The Role ofTemperature in the Life of a sodium, 261
Myristic acid , 383 Pharmaceutical Preparation, 1339 sodium and tetracycline hydrochloride tablets ,
Myristyl alcohol , 252 Newton, D.W. andTrissel, L.A. 337
Myristyl alcohol , 433 A Primer on USP Chapter h797i Pharmaceutical Nutmeg oil, 384
Myrrh , 252 CompoundingSterile Preparations, and USP Nystatin , 261
Process for Drug and Practice Standards, 1067
oil , 383
Niacin , 256, 383
topical solution , 252
Niacinamide , 257, 383
ascorbate , 383
Nicotine , 257
polacrilex , 257
O
N polacrilex gum , 257
Nifedipine , 257 Obenhuber, D., Nath, N., McNeal, E., Pillari, B., Shelton,
L., Stevens-Riley, M., and Sweeney, N.
Nimodipine , 257
Nabumetone , 253 Particulate Contaminants of Intravenous
Nitrate
Nadolol, 253 Medication and the Limits Set by USP General
silver, 315 Chapter h788i, 1383
Nafcillin sodium, 253 toughened silver, 315 Occupational Safety and Health Act
Naftine hydrochloride , 253 Nitric acid , 257 hazard communication standard, 1327
Nalidixic acid , 253 Nitrofurantoin , 258 Regulations RegardingToxic and Hazardous
Nalorphine hydrochloride , 253 Nitrofurazone , 258 Substances ,1313
Naloxone hydrochloride , 254 Nitrogen , 258 OConnor, L.E., and the PSD ProjectTeam
Naltrexone hydrochloride , 254 97 percent , 258 Representative Membership
Nandrolone Nitroglycerin, diluted , 258 Drug Products Distribution Chain, 1389
decanoate, 254 Nitromersol , 258 -Octalactone , 435
phenpropionate , 254 topical solution , 258 -Octalactone , 435
Naphazoline hydrochloride , 254 Nitrous oxide , 259 Octanal , 435
ophthalmic solution , S2/9 Nizatidine , 259 3-Octanol , 435
-Naphthyl ethyl ether, 433

INDEX S3/146
USP Pharmacists Pharmacopeia
(E)-2-Octen-1-al , 436
(Z)-3-Octen-1-ol, 436
1-Octen-3-ol , 436
1-Octen-3-yl Acetate , 436
1-Octen-3-yl Butyrate , 436
Octinoxate , 261
Octisalate , 261
Octocrylene , 261
Octoxynol 9 , 261
Octyl
acetate, 436
alcohol , 437
formate , 436
isobutyrate , 437
3-Octyl acetate , 436
Octyldodecanol , 262
Ofcialand Ofcial articles
General notices and requirements, 21
Ooxacin , 262
Oil
Almond, 60
Anise , 72
Bay, 377
Bergamot, coldpressed , 377
Canola , 378,1004
Caraway,105
Cardamom ,110
Cassia , 378
Castor,112
Castor, hydrogenated ,112
Cinnamon leaf, 378
Clove ,134, 379
Coconut ,137
Coconut (unhydrogenated) , 379
Cod liver,137
Copaiba , 379
Coriander,140, 379
Corn ,140
Corn (unhydrogenated) , 379
Cottonseed ,140
Cottonseed, hydrogenated ,141
Eucalyptus , 380
Fennel ,177
Fusel, rened , 412
Lemon , 221
Lemon, coldpressed , 382
Lemongrass , 382
Mineral , 247, S2/8
Mineral emulsion, 248
Mineral, light , 248, S2/8
Mineral, rectal , S2/8
Mineral, topical light , S2/8
Mustard , 383
Myrrh , 383
Nutmeg , 384
Olive , 263
Orange , 265
Palm kernel , 270
Palm kernel (unhydrogenated) , 384
Palm (unhydrogenated) , 384
Peanut , 274
Pennyroyal , 384
Peppermint , 277
Polyoxyl 35 castor, 288
Polyoxyl 40 hydrogenated castor, 288
(E)-2Orang
Rapeseed, fully hydrogenated , 384 Optical microscopy h776i , 768
Rapeseed, superglycinated , 385 Oral solution
Rose , 310 Acacia syrup, 53
Rosemary, 385 Aromatic elixir, 77
Safower, 311 Atenolol, 79
Sesame , 314 Benzaldehyde elixir, compound , 86
Soybean , 323 Bethanechol chloride , 90
Soybean, hydrogenated , 323 Captopril ,103
Sunower, 332 Cherry syrup,123
Sunower (unhydrogenated) , 385 Chocolate syrup,127
Tarragon , 386 Diltiazem hydrochloride ,157
Thyme , 386 Dolasetron mesylate ,162
Vegetable, hydrogenated , 355 Ferrous sulfate syrup,179
Ointment Hydralazine hydrochloride ,196
Coal tar, 135 Ipecac , 212
Hydrophilic , 262 Magnesium citrate , 228
Ichthammol , 203 Metoprolol tartrate , 245
Polyethylene glycol , 287 Orange syrup, 266
Resorcinol, compound , 307 Potassium bromide, veterinary, 461, S3/33
Rose water, 310 Saccharin sodium, 311
White , 262 Senna , 314
Yellow, 262 Sodium bromide , 462, S3/34
Zinc oxide , 362 Syrup, 333
Ointments Tolu balsam syrup, 345
compounding, 1084 Vehicle for, 264
ophthalmic h771i, 768 Vehicle for, sugar free , 265
packaging ,1084 Verapamil hydrochloride , 356
stability,1084 Oral suspension
Okeke, C.C., Bailey, L.C., Grady, L.T., and Medwick,T. Acetazolamide, 54
Temperature Fluctuations During Mail Order Allopurinol , 59
Shipment of Pharmaceutical Articles Using Alprazolam , 60
Mean KineticTemperatureApproach, 1339 Azathioprine , 81
Okeke, C.C., Brown, L.H., Bailey, L.C., Medwick,T., Baclofen , 83
Krumperman, K., andTran, C.D.
Bethanechol chloride , 91
Medication StorageTemperatures on U.S.
Captopril ,104
Ambulances: A Prospective Multicenter
Observational Study, 1344 Cefdinir for, S3/29
Okeke, C.C., and the PSD ProjectTeam Clonazepam ,133
Representative Membership Didanosine tablets for, S2/5
Drug Products Distribution Chain, 1389 Diltiazem hydrochloride ,157
Okeke, C.C., and Allen, L.V. Dipyridamole ,160
History and Background Information on USPs Dolasetron mesylate ,162
Activities in Compounding Pharmacy Practices, Flucytosine ,180
13 Ganciclovir,188
Oleic acid , 262 Granisetron hydrochloride , 453
Oleoresin, capsicum ,103 Ketoconazole , 217
Oleovitamin A and D, 262 Labetalol hydrochloride , 219
Oleoyl polyoxylglycerides , 263 Metolazone , 244
Oleyl alcohol , 263 Metoprolol tartrate , 245
Olive oil, 263 Naratriptan hydrochloride , 453
Omeprazole , 263 Nevirapine , 256
magnesium, S1/8 Ondansetron hydrochloride , 263
Ondansetron, 263 Pantoprazole sodium , 453
hydrochloride , 263 Pergolide, veterinary, 461
hydrochloride oral suspension, 263 Quinidine sulfate , 305
Ophthalmic ointments h771i, 768 Rifampin , 308
Ophthalmic solution Sumatriptan succinate , 331
Cefazolin, 113 Terbinane hydrochloride , 453
Hypromellose , 202 Terbutaline sulfate , 454
injections ,1376 Tetracycline hydrochloride , 337
particulate matter,1376 Tiagabine hydrochloride , 454
Particulate matter in ophthalmic solutions h789i , Vehicle for, 265
1376 Verapamil hydrochloride , 356
Particulate matter in injections h788i ,1376 Orange
Opium , 264 oil, 265
powdered , 264 peel tincture, sweet , 265
tincture , 264
INDEX S3/147
USP Pharmacists Pharmacopeia OrangpH

Orange (continued) Packaging practicerepackaging a single solid oral Parenteral preparations

spirit, compound , 265 drug product into a unit-dose container h1146i , compounding, 1129
syrup, 266 918 labeling ,1129
Orphenadrine citrate , 266 Packaging, Storage, Distribution (PSD) ProjectTeam quality control,1129
Representative Membership
Osmolality and osmolarity h785i , 770 stability,1129
Bender,T., 1389
Oxacillin sodium, 266 storage ,1129
Bishara, R. ,1389
Oxandrolone , 266 Paricalcitol, 273
Clower, L. ,1389
tablets , S2/9 Paromomycin
Denman, J. ,1389
Oxaprozin, 266 sulfate, 273
Drug Products Distribution Chain,1389
Oxazepam , 267 Paroxetine
Epstein, A. ,1389
Oxfendazole , 267 tablets, S2/9
Ferguson, B. ,1389
Oxidized cellulose ,119 Paroxetine hydrochloride , 273
Gallo, M. ,1389
regenerated ,120 Particulate Contaminants of Intravenous Medication
Hollander, R. ,1389 and the Limits Set by USP General Chapter h788i
Oxprenolol hydrochloride , 267
Jones, K. ,1389 Nath, N., McNeal, E., Obenhuber, D., Pillari, B.,
Oxtriphylline , 267
Mayberry, P. ,1389 Shelton, L., Stevens-Riley, M., and Sweeney, N.,
Oxybenzone , 267
OConnor, L.E. ,1389 1383
Oxybutynin chloride , 267, S2/9
Okeke, C.C. ,1389 Particulate matter in injections h788i , 772
Oxycodone
Pringle,T. ,1389 contaminants ,1383
hydrochloride, 268
Russell, S. ,1389 injections ,1383
terephthalate , 268
Schafer,T. ,1389 limits ,1383
Oxymetazoline hydrochloride , 268
Seeley, J. ,1389 ophthalmic solution ,1376
Oxymetholone , 268
Shada, E. ,1389 particulate matter,1376
Oxymorphone hydrochloride , 268
Sharpless, B. ,1389 Particulate matter injections ,1344
Oxyquinoline sulfate , 268
Sheinin, E. ,1389 Pastes
Oxytetracycline , 269
Smith, I. ,1389 compounding, 1084
calcium , 269
Taborsky, J. ,1389 packaging ,1084
hydrochloride , 269
Valentino, J. ,1389 stability,1084
Oxytocin , 269
Wallner, B. ,1389 Peanut oil, 274
Williams, R. ,1389 Pectin , 274
Packagingunit-of-use h1136i , 916 Penbutolol sulfate , 274
Paclitaxel , 269, S1/8 Penicillamine , 274

P Padimate O, 270
Pallida
Penicillin
G benzathine, 274
echinacea, 1006 G potassium , 274
Packaging extract, powdered echinacea ,1006 G procaine , 275
biotechnologic preparations, 1134 powdered echinacea ,1006 G sodium, 275
containers,1388 Palm G (Systemic) , 589
controlled substances ,1268 kernel oil, 270 V, 275
Controlled Substances Act Regulations ,1268 kernel oil (unhydrogenated) , 384 V benzathine , 275
desiccants ,1416 oil (unhydrogenated) , 384 V potassium , 276
desiccating containers,1416 Palmitic acid , 270 Pennyroyal oil , 384
distribution ,1339,1389 Palmitic acid , 384 !-Pentadecalactone , 437
nished pharmaceuticals ,1253 Pamabrom , 270 2,3-Pentanedione , 437
Food and Drug Administration (FDA) ,1268,1331, Pamidronate disodium, 270 2-Pentanone , 437
1334
Pancreatin , 270 Pentazocine , 276
Good Manufacturing Practices ,1253
Pancrelipase , 271 hydrochloride , 276
humidity,1339
Pangborn, R., Sagona, P., Freedman, J., and Spano,W. Pentetic acid , 276
labeling ,1268
The Impact of Multiple-Unit Desiccating Pentobarbital , 276
moisture ,1416 Containers for Prescription Packaging, 1416 sodium, 276
ointments ,1084 Panthenol , 271 Pentoxifylline , 277
pastes ,1084 DL-Panthenol , 384 Peppermint , 277
Poison Prevention Act ,1331 Pantoprazole oil, 277
processing ,1253 sodium oral suspension, 453 spirit , 277
registration of dispensers ,1268 Pantoprazole sodium, S3/32 water, 277
registration of distributors ,1268 delayed-release tablets , S3/32 Perubron , 277
registration of manufacturers,1268 Papain , 271 Pergolide
risk analysis ,1389 Papaverine hydrochloride , 271 mesylate, 277
security,1268 Parachlorophenol, 271 oral suspension, veterinary, 461
stability,1084,1339 camphorated , 272 Veterinary - Systemic , S1/27
storage ,1253,1389 Parafn , 272, S2/9 Perphenazine , 278
temperature ,1339 synthetic , 272 Petrolatum , 278
vials ,1388 Paraldehyde , 272 hydrophilic , 278
water vapor permeation,1388 Paramethasone acetate , 272 white , 278
Paregoric , 272 pH
requirements, 1346

INDEX S3/148
USP Pharmacists Pharmacopeia pHPowde

pH (continued) Phenylpropanolamine Polyisobutylene , 287

water,1346 bitartrate, 281 Polymyxin B sulfate , 288
pH h791i, 774 hydrochloride , 281 Polyoxyl
Pharmaceutical calculations in prescription 2-Phenylpropionaldehyde , 440 10 oleyl ether, 288
compounding h1160i , 934 3-Phenylpropionaldehyde , 440 20 cetostearyl ether, 288
Pharmaceutical compounding 2-Phenylpropionaldehyde dimethyl acetal , 440 35 castor oil, 288
nonsterile preparations h795i, 775 3-Phenylpropyl acetate , 440 40 hydrogenated castor oil , 288
sterile preparations h797i, 779, 797, S1/41, S2/33 Phenyltoloxamine citrate , 281 40 stearate , 288
Pharmaceutical compoundingnonsterile Phenytoin , 282 lauryl ether, 288
preparations h795i sodium , 282 oleate , 288
gap analysis checklist, 1045 Phosphate buffer,1479 stearyl ether, 289
Pharmaceutical compoundingsterile preparations Phosphoric acid , 282 Polysorbate
h797i
diluted , 282 20, 289
gap analysis checklist, 1053
Physostigmine , 282 40 , 289
Pharmaceutical dosage forms h1151i, 923
salicylate , 282 60 , 289
dosage forms ,1402
sulfate , 282 80 , 289
glossary,1402
Phytonadione , 283 Polyvinyl
taxonomy,1402
Pillari, B., Nath, N., McNeal, E., Obenhuber, D., Shelton, acetate phthalate, 289
Pharmaceutical stability h1150i , 922 L., Stevens-Riley, M., and Sweeney, N. alcohol , 289, S3/33
Pharmacopeial forum , 23 Particulate Contaminants of Intravenous Potash, sulfurated , 290
Pharmacy Compounding Accreditation Board Medication and the Limits Set by USP General Potassium
code of ethics for pharmacists, 1144 Chapter h788i, 1383
acetate, 290
principles of compounding ,1143 Pills
alginate , 290
standards with compliance indicators ,1144 compounding, 1111
alum , 61
steps to accreditation ,1151 quality control,1111
benzoate , 290
-Phellandrene , 437 stability,1111
bicarbonate , 290
Phenazopyridine hydrochloride , 278 storage ,1111
bitartrate , 290
Phendimetrazine tartrate , 278 Pilocarpine , 283
bromide , 290
Phenelzine sulfate , 278 hydrochloride , 283
bromide oral solution, veterinary, 461, S3/33
Phenethyl , 437 nitrate , 283
carbonate , 290
acetate , 438 Pimozide , 283
chloride , 290
alcohol , 438 Pindolol , 283
gluconate , 291
isobutyrate , 438 Pinene
guaiacolsulfonate , 291
isovalerate , 438 -, 440
hydroxide , 291
phenylacetate , 438 - , 440
iodide , 291
2-Phenethyl 2-methylbutyrate , 438 Piperacillin , 284
metabisulte , 291
Pheniramine maleate , 278 sodium , 284
metaphosphate , 291
Phenmetrazine hydrochloride , 279 Piperazine , 284
nitrate , 291
Phenobarbital , 279 adipate , S3/32
perchlorate , 291
sodium, 279 citrate , 284
permanganate , 292
Phenol , 279 dihydrochloride , S3/32
phosphate, dibasic , 292
Phenolated calamine topical suspension, 98 phosphate , S3/33
phosphate, monobasic , 292
Phenolsulfonphthalein , 279 Piperidine , 441
sodium tartrate , 292
Phenoxybenzamine hydrochloride , 280 Piperonal , 441
sorbate , 292
Phenoxyethanol , 280 Piroxicam, 284
Potato starch , 324
Phenoxyethyl isobutyrate , 438 cream, 284
Potentiated sulfonamides (Systemic) , 597
Phensuximide , 280 Plantago seed , 285
Povidone , 292
Phentermine hydrochloride , 280 Plicamycin , 285
-iodine , 292
Phentolamine mesylate , 280 Podophyllum , 285
Powder
Phenylacetaldehyde , 439 resin , 285
Soy isoavones, powdered extract, S3/74
dimethyl acetal , 439 Poison Control Centers
Tumeric, powdered , S3/75
Phenylacetic acid , 439 American directory, 689,1194
Tumeric extract, powdered , S3/75
Phenylalanine , 280 Canadian directory, 694,1199
Powdered
Phenylbutazone , 280 important veterinary contacts , 689
American ginseng, 1009
Phenylephrine hydrochloride , 281 Poison Prevention Packaging Act ,1331
American ginseng extract ,1009
Phenylethyl requirements ,1334
Asian ginseng ,1009
alcohol, 281 Polacrilin potassium , 285
Asian ginseng extract ,1009
anthranilate , 439 Poloxalene , 286
bilberry extract , S2/72
butyrate , 439 Poloxamer, 286, S2/10
cats claw, S1/83
cinnamate , 439 Polycarbophil, 286
cats claw extract , S1/83
propionate , 439 calcium ,101
Cellulose ,120
Phenylmercuric Polyethylene
Black cohosh ,1006, S2/72
acetate, 281 glycol, 286
Black cohosh extract ,1006, S2/72
nitrate , 281 glycol monomethyl ether, 287
Digitalis ,154
3- Phenyl-1-propanol , 439 glycol ointment , 287
Echinacea angustifolia ,166
oxide , 287

INDEX S3/149
USP Pharmacists Pharmacopeia PowdeQuali

Powdered (continued) Prescribing and dispensing , 28 Propylene

Echinacea angustifolia extract ,165 Prescription balances and volumetric apparatus carbonate, 300
Echinacea pallida ,1006 h1176i , 946 glycol , 300
Echinacea pallida extract ,1006 Preservation, packaging, storage, and labeling , 28 glycol alginate , 300
Echinacea purpurea extract ,1007 Prilocaine hydrochloride , 295 glycol dicaprylate/dicaprate , S2/10
Eleuthero,1007 Primaquine phosphate , 295 glycol dilaurate , 300
Eleuthero extract ,1007 tablets , S2/10 glycol monocaprylate , S1/8
Feverfew,1007 A Primer on USP Chapter h797i Pharmaceutical glycol monolaurate , 301, S3/34
Garlic ,1008 CompoundingSterile Preparations, and USP glycol monostearate , 301
Process for Drug and Practice Standards
Garlic extract ,1008 Propyliodone , 301
Newton, D.W. andTrissel, L.A., 1067
Ginger,1008, S1/84 Propylparaben , 301
Primidone , 295
Ginkgo extract ,1008 sodium, 301
Principles of Compounding
Goldenseal ,1010 Propylthiouracil , 301
Pharmacy Compounding Accreditation Board,
Goldenseal extract ,1010 Protamine sulfate , 301
1143
Green tea extract, decaffeinated , S2/73 Protriptyline hydrochloride , 301
Pringle,T., and the PSD ProjectTeam Representative
Hawthorn leaf with ower,1010 Membership Pseudoephedrine
Horse chestnut ,1010 Drug Products Distribution Chain, 1389 hydrochloride, 302
Horse chestnut, extract ,1010 Probenecid , 295 sulfate , 302
Ipecac , 212 Probucol , 295 Psyllium
Licorice ,1011 Procainamide hydrochloride , 295 hemicellulose, 302
Licorice extract ,1011 Procaine hydrochloride , 296 husk , 302
Milk thistle ,1012 Procarbazine hydrochloride , 296 Pullulan , S2/10
Milk thistle extract ,1012 Prochlorperazine , 296 Pumice , 302
Stinging nettle ,1012 edisylate , 296 Pure Steam, 359
Stinging nettle extract ,1012 maleate , 296 Purpurea
Opium , 264 Procyclidine hydrochloride , 296 extract, powdered echinacea, 1007
Rauwola serpentina , 306 Product errors root, echinacea ,1007
Saw palmetto,1013 look-alike and/or sound-alike names, 1165 Pyrantel pamoate , 302
St. Johns wort ,1013 Progesterone , 297 Pyrazinamide , 302
St. Johns wort extract ,1013 vaginal suppositories , 297 Pyrethrum extract , 303
Valerian extract ,1014 Proline , 298 Pyridostigmine bromide , 303
Powders Promazine hydrochloride , 298 Pyridoxine hydrochloride , 303
compounding, 1119 Promethazine hydrochloride , 298 Pyrilamine maleate , 303
quality control,1119 Propafenone hydrochloride , 298 Pyrimethamine , 303
stability,1119 Propantheline bromide , 299 (Systemic) , 614
Pralidoxime chloride , 293 Proparacaine hydrochloride , 299 Pyrogen test h151i, 721
Pramoxine hydrochloride , 293 Propenylguaethol , 441 Pyroxylin , 303
Pravastatin sodium, 293 Propionaldehyde , 441 Pyrrole , 442
Praziquantel , 293 Propionic acid , 299 Pyrvinium pamoate , 304
Prazosin hydrochloride , 293 Propofol, 299
Prednicarbate , 293 injectable emulsion , S3/33
Prednisolone , 294 Proposed monographs
acetate , 294 Granisetron hydrochloride oral suspension, 453
hemisuccinate , 294
sodium phosphate , 294, S3/33
Naratriptan hydrochloride oral suspension, 453 Q
Pantoprazole sodium oral suspension , 453
tebutate , 294 Terbinane hydrochloride oral suspension, 453 Quality assurance in pharmaceutical compounding
Prednisone , 294 Terbutaline sulfate oral suspension , 454 h1163i , 943
Preface Tiagabine hydrochloride oral suspension, 454 Quality control
and mission, S3/3, 5 Proposed Standards for Medical Gases: A Public biotechnologic preparations, 1134
Preparation Health Initiative capsules, powder-lled ,1101
capsules, powder-lled, 1101 Becker, S.C., and Bormel, F.G., 1411 capsules, special ,1105
capsules, special ,1105 Propoxycaine hydrochloride , 299 compounds for clinical studies ,1137
drops ,1108 Propoxyphene drops ,1108
emulsions ,1121,1124 hydrochloride, 299 emulsions ,1124
gels ,1089 napsylate , 300 gels ,1089
lozenges ,1108 Propranolol hydrochloride , 300 granules ,1119
parenteral, compounding ,1129 Propyl inhalation preparations ,1116
sticks, medication,1093 acetate, 441 lozenges ,1108
suppositories ,1096,1099 alcohol , 441 parenteral preparations ,1129
suspensions ,1136 formate , 441 pills,1111
troches ,1108 gallate , 300 powders,1119
Preparations, biotechnologic compounding ,1134 mercaptan , 442 solutions ,1114
Preparations, sterile propionate , 442 standard operating procedures ,1139
stability, 1067 p-Propyl anisole , 441 sticks, medication ,1093
storage ,1067 suspensions ,1136

INDEX S3/150
USP Pharmacists Pharmacopeia QualiSelen

Quality control (continued) drugs for human use ,1206 The Role ofTemperature in the Life of a
tablets ,1111 FDCA ,1206 Pharmaceutical Preparation
troches ,1108 nished pharmaceuticals ,1253 Newton, D.W., 1339
Quality-Control: Standard Operating Procedures Good Manufacturing Practices ,1253 Rose
An EssentialTool for Developing Quality labeling , 682 oil, 310
Preparations laws ,1206 water ointment , 310
Ashworth, L., 1139 manufacture , 682,1206 water, stronger, 310
Quazepam , 304 microbial identication methods ,1368 Rosemary oil, 385
Quinapril hydrochloride , 304 packaging ,1253 Roxarsone , 311
Quinidine pharmaceutical industry,1368 Russell, S., and the PSD ProjectTeam Representative
gluconate, 304 processing ,1253 Membership
sulfate , 304 Regarding Extralabel Drug Use in Animals , 682 Drug Products Distribution Chain, 1389
sulfate oral suspension , 305 regarding toxic and hazardous substances ,1313
Quinine hydrochloride , 384 storage ,1253
Quinine sulfate , 305 Regulations Regarding Extra-Label Drug Use in
Animals , 682
Animal Medicinal Drug Use Clarication Act , 686 S
Relative atomic masses and half-lives of selected
radionuclides ,1484 Saccharin , 311, 385
R Repackaging into single-unit containers and unit-
dose containers for nonsterile solid and liquid
calcium , 311
sodium, 311
dosage forms h681i, 763
Racemic calcium pantothenate ,101 sodium oral solution , 311
Repaglinide , 306
Racepinephrine hydrochloride , 305 Safe medication practices
Report and Recommendations from theWater and
Radioactivity h821i, 832 Parenterals Subcommittee Meeting, October Medication Use Process (chart), 1156
Radiopharmaceuticals 1999Labeling, Injections, and Particulate USP and Patient Safety,1155
C 13, urea, 109 Matter Safe medication use
Krypton Kr 81m, 218 Boylan, J.C., 1344 USP and Patient Safety, 1155
for positron emission tomographycompounding Requirements under the Poison Prevention Safower oil, 311
h823i , 838 Packaging Act ,1334 Sagona, P., Freedman, J., Spano,W., and Pangborn, R.
Raloxifene hydrochloride , S2/10 Reserpine , 306 The Impact of Multiple-Unit Desiccating
tablets , S2/11 Resin Containers for Prescription Packaging, 1416
Ramipril , 305 Capsicum oleoresin, 103 Salicylaldehyde , 442
Ranitidine hydrochloride , 306 Cholestyramine ,127 Salicylamide , 311
Rapeseed oil Podophyllum, 285 Salicylic
fully hydrogenated, 384 Resorcinol , 306 acid, 312
superglycinated , 385 monoacetate , 306 acid collodion, 312
Rauwola serpentina , 306 ointment, compound , 307 acid and zinc paste , 362
powdered , 306 Review of the Media Selection and Incubation Salsalate , 312
Reagents, reference , 23 Conditions for the Compendial Sterility and Saltiness, compounding ,1075
Reagent standards , 23 Microbial LimitTests Santalol, 442
Reference Cundell, A.M., 1364 Santalyl acetate , 443
reagents, 23 Revision of the pH Compendial Requirement for Saquinavir mesylate , 312
SterileWater for Injection
standards, USP, 23 Sargramostim , 312
Bevilacqua, A., 1346
ReferenceTables Saw palmetto,1013
Rhodinol, 442
Alcoholometric, 1487 extract ,1013
Rhodinyl
Atomic weights ,1481 powdered ,1013
acetate, 442
Description and relative solubility of USP and NF Schafer,T., and the PSD ProjectTeam Representative
articles ,1421, S1/87, S2/81, S3/78 formate , 442 Membership
Intrinsic viscosity table ,1491 Ribavirin , 307 Drug Products Distribution Chain, 1389
Relative atomic masses and half-lives of selected Riboavin , 307 Scopolamine hydrobromide , 313
radionuclides ,1484 5-phosphate sodium, 307 Secobarbital , 313
Solubilities ,1469 Rifabutin, 307 sodium, 313
Thermometric equivalents ,1495 Rifampin , 308 Security
Refractive index h831i, 842 oral suspension , 308 controlled substances, 1268
Registration (Systemic) , 618 Controlled Substances Act Regulations ,1268
controlled substances, 1268 Rimantadine hydrochloride , 308 Food and Drug Administration (FDA) ,1268
Controlled Substances Act Regulations ,1268 Rimexolone , 308 labeling ,1268
dispensers ,1268 Ringers injection , 309 packaging ,1268
distributors ,1268 Risk analysis registration of dispensers ,1268
Food and Drug Administration (FDA) ,1268 distribution, 1389 registration of distributors ,1268
manufacturers,1268 packaging ,1389 registration of manufacturers ,1268
security,1268 storage ,1389 Seeley, J., and the PSD ProjectTeam Representative
Regulations Risperidone , 310 Membership
compliance policy guides, 1265 Ritodrine hydrochloride , 310 Drug Products Distribution Chain, 1389
dietary supplements ,1240 Ritonavir, 310 Selegiline hydrochloride , 313
drugs for animal use , 680, 682,1206 Selenious acid , 313

INDEX S3/151
USP Pharmacists Pharmacopeia SelenStabi

Selenium sulde , 313 cefazolin,114 Dolasetron mesylate oral ,162

Selenomethionine ,1013 cefmetazole ,115 Ferrous sulfate syrup,179
Senna cefoperazone ,115 Glutaral disinfectant ,191
uidextract, 313 cefotaxime ,116 Hydralazine hydrochloride oral ,196
leaf, 314 cetostearyl sulfate , 317 Hypromellose ophthalmic , 202
oral solution , 314 chloride , 317 Iodine, strong , 208
pods , 314 chloride equivalency table ,1075 Iodine topical , 209
Sensitization testing h1184i , 950 cilastatin ,128 Ipecac oral , 212
Serine , 314 citrate , 318 Ivermectin topical , S2/8
Sesame oil , 314 dehydroacetate , 318 Levalbuterol inhalation , S1/7
Shada, E., and the PSD ProjectTeam Representative Enoxaparin , S2/6 Magnesium citrate oral , 228
Membership Enoxaparin, injection , S2/6 Maltitol , 231
Drug Products Distribution Chain, 1389 uoride , 318 Metoprolol tartrate oral , 245
Sharpless, B., and the PSD ProjectTeam formaldehyde sulfoxylate , 318 Myrrh topical , 252
Representative Membership gluconate , 318 Nitromersol topical , 258
Drug Products Distribution Chain, 1389 hydroxide , 318 Orange syrup, 266
Sheinin, E., and the PSD ProjectTeam Representative hypochlorite topical solution , 318 Potassium bromide oral, veterinary, 461, S3/33
Membership
iodide , 319 quality control,1114
Drug Products Distribution Chain, 1389
lauryl sulfate , 319 Saccharin sodium oral , 311
Shellac , 314
low-substituted carboxymethylcellulose ,110 Senna oral , 314
bleached , 385
metabisulte , 319 Sodium bromide oral , 462, S3/34
Shelton, L., Nath, N., McNeal, E., Obenhuber, D., Pillari,
monouorophosphate , 319 Sodium hypochlorite topical , 318
B., Stevens-Riley, M., and Sweeney, N.
nitrite , 319 stability,1114
Particulate Contaminants of Intravenous
Medication and the Limits Set by USP General nitroprusside , 319 Syrup, 333
Chapter h788i, 1383 phosphate, dibasic , 319 Tolu balsam syrup, 345
Signicant Digits and Rounding phosphate, monobasic , 319 Vehicle for oral , 264
Torbeck, L., 1412 phosphate, tribasic , 320 Vehicle for oral, sugar free , 265
Signicant gures and tolerances , 22 polystyrene sulfonate , 320 vehicles, compounding ,1114
Silica propionate , 320 Verapamil hydrochloride oral , 356
colloidal, hydrophobic, S2/6 saccharin , 385 Xanthan gum , 360
Silica, dental-type , 314 salicylate , 320 Somatropin , 321
Siliceous earth, puried , 315 starch glycolate , 320 Sorbic acid , 321
Silicon dioxide , 315 stearate , 320 Sorbitan
colloidal , 315 stearyl fumarate , 321 monolaurate, 322
Silver sulfate , 321 monooleate , 322
nitrate, 315 sulde , 321 monopalmitate , 322
nitrate, toughened , 315 sulte , 321 monostearate , 322
Simethicone , 315 tartrate , 321 sesquioleate , 322
capsules , S2/11 thiosulfate , 321 trioleate , 322
tablets , S2/11 Solubilities ,1469 Sorbitol, 322
Simvastatin , 315, S2/11 Solution Sotalol hydrochloride , 322
Sisomicin sulfate , 316 Aluminum acetate topical, 61 Soybean oil, 323
Smith, I., and the PSD ProjectTeam Representative Aluminum subacetate topical , 63 hydrogenated , 323
Membership Ammonia, strong , 68 Soy isoavones
Drug Products Distribution Chain, 1389 Anticoagulant citrate dextrose , 73 capsules, S3/74
Soda lime , 316 Anticoagulant citrate phosphate dextrose , 75 powdered extract , S3/74
Sodium Anticoagulant citrate phosphate dextrose tablets , S3/74
acetate, 316 adenine , 74 Spano,W., Sagona, P., Freedman, J., and Pangborn, R.
Alendronate, tablets , S2/3, S3/24 Anticoagulant heparin , 75 The Impact of Multiple-Unit Desiccating
alginate , 316 Anticoagulant sodium citrate , 76 Containers for Prescription Packaging, 1416
ascorbate , 316, 385 Aromatic elixir, 77 Specic gravity h841i, 842
benzoate , 316 Atenolol oral , 79 Spectinomycin
bicarbonate , 316 Benzaldehyde elixir, compound , 86 hydrochloride, 323
borate , 317 Benzalkonium chloride , 86 (Systemic) , 626
bromide , 317 Bethanechol chloride oral , 90 Spironolactone , 323
bromide injection, veterinary, 462, S3/34 Calcium hydroxide topical ,100 Squalane , 323
bromide oral solution, veterinary, 462, S3/34 Captopril oral ,103 Stability
butyrate , 317 Carbol-fuchsin topical ,106 ambulances, 1344
caprylate , 317 Cefazolin ophthalmic ,113 biotechnologic preparations ,1134
carbonate , 317 Cherry syrup,123 capsules, powder-lled ,1101
carboxymethylcellulose ,110 Chocolate syrup,127 capsules, special ,1105
carboxymethylcellulose, and microcrystalline Coal tar topical ,136 compounding ,1075,1084
cellulose ,119 Cocaine and tetracaine hydrochlorides and creams,1086
carboxymethylcellulose, paste ,110 epinephrine topical ,136 distribution ,1339,1396
12, carboxymethylcellulose ,110 compounding basics ,1114 drops ,1108
Diltiazem hydrochloride oral ,157

INDEX S3/152
USP Pharmacists Pharmacopeia StabiSuspe

Stability (continued) Sterilization and sterility assurance of compendial Sulconazole nitrate , 327
emulsions ,1124,1396 articles h1211i, 964 Sulfabenzamide , 328
gels ,1089 Vancomycin hydrochloride , 354 Sulfacetamide , 328
globule size ,1396 Water, puried , 358 sodium, 328
granules ,1119 Sterile product packagingintegrity evaluation Sulfachlorpyridazine , 328
humidity,1339 h1207i, 960 Sulfadiazine , 328
inhalation preparations ,1116 Sterile water for injection silver, 328
intravenous ,1396 pH, 1346 sodium, 328
lotions ,1086 Sterility Sulfadimethoxine , 329
lozenges ,1108 testingvalidation of isolator systems h1208i, 961 sodium, 329
ointments ,1084 Sterility tests h71i, 713 Sulfadoxine , 329
packaging ,1084,1339 incubation conditions ,1364 Sulfamethazine , 329
parenteral preparations ,1129 media selection ,1364 Sulfamethizole , 329
pastes ,1084 testing practices ,1364 Sulfamethoxazole , 329, S1/8
pills,1111 Sterilization and sterility assurance of compendial Sulfapyridine , 330
articles h1211i, 964
powders ,1119 Sulfaquinoxaline , 330
Sterilizing Filtrations with Microporous Membranes
preparations, sterile ,1067 Sulfasalazine , 330
Jornitz, M.W. and Meltzer,T.H., 1378
quality control,1084 Sulfathiazole , 330
Stevens-Riley, M., Nath, N., McNeal, E., Obenhuber,
solutions ,1114 Sulnpyrazone , 330
D., Pillari, B., Shelton, L., and Sweeney, N.
sticks, medication,1093 Sulsoxazole , 330
Particulate Contaminants of Intravenous
storage ,1339,1344 Medication and the Limits Set by USP General acetyl , 330
suppositories ,1096,1099 Chapter h788i, 1383 Sulfonamides (Systemic) , 630
suspensions ,1136 Sticks, medication,1093 Sulfur
tablets ,1111 Stinging nettle ,1012 dioxide, 331
temperature ,1339,1344 powdered ,1012 precipitated , 331
testing practices ,1396 powdered extract ,1012 sublimed , 331
troches ,1108 St. Johns wort ,1012 Sulfuric acid , 331
Stability considerations in dispensing practice extract, powdered ,1013 Sulindac , 331
h1191i, 957 powdered ,1013 Sulisobenzone , 331, S1/8
Standards with Compliance Indicators Storage Sumatriptan, 331
Pharmacy Compounding Accreditation Board, ambulances, 1344 succinate , S1/9
1144 succinate oral suspension , 331
biotechnologic preparations ,1134
Stannous Sunower oil, 332
capsules, powder-lled ,1101
chloride, S2/11 (unhydrogenated) , 385
distribution ,1339,1389
Stannous uoride , 323 Supplements , 23
drops ,1108
Stanozolol , 324 Supplemental information for articles of botanical
nished pharmaceuticals ,1253
Starch origin h2030i ,1031, S2/73
Good Manufacturing Practices ,1253
corn, 324 Suppositories
inhalation preparations ,1116
modied , 324 compounding, ,10961099
lozenges ,1108
potato, 324 Morphine sulfate , 251
packaging ,1253,1389
pregelatinized , 324 preparation ,1099
parenteral preparations ,1129
pregelatinized modied , 324 Progesterone vaginal , 297
pills,1111
sodium, glycolate , 320 stability,1096,1099
preparations, sterile ,1067
tapioca , 324 storage ,1099
processing ,1253
topical , 324 Suprofen , 333
risk analysis ,1389
wheat , 324 Suspension
stability,1339,1344
Statistics Acetazolamide oral, 54
suppositories ,1099
rounding, 1412 Allopurinol oral , 59
tablets ,1111
signicant digits ,1412 Alprazolam oral , 60
temperature ,1339,1344
Stavudine , 325 Azathioprine oral , 81
troches ,1108
Steam, pure , 359 Baclofen oral , 83
Storax , 325
Stearic acid , 325 Bethanechol chloride oral , 91
Streptomycin sulfate , 326
puried , 325 Calamine topical , 97
Succinic acid , 326
Stearoyl polyoxylglycerides , 325 Calamine topical, phenolated , 98
Succinylcholine chloride , 326
Stearyl alcohol , 325 Captopril oral ,104
Sucralfate , 326
Sterile Cefdinir for oral , S3/29
Sucralose , 326
Erythromycin ethylsuccinate, 170 Clonazepam oral ,133
Sucrose , 326
Erythromycin gluceptate ,171 Didanosine tablets for oral , S2/5
octaacetate , 327
Erythromycin lactobionate ,171 Diltiazem hydrochloride oral ,157
Sufentanil citrate , 327
Pharmaceutical compoundingsterile Dipyridamole oral ,160
Sugar
preparations h797i, 779, 797, S1/41, S2/33 Dolasetron mesylate oral ,162
compressible, 327
Sterile product packagingintegrity evaluation Flucytosine oral ,180
h1207i, 960 confectioners , 327
free suspension structured vehicle , 333 Ganciclovir oral ,188
Sterility testingvalidation of isolator systems
spheres , 327 Granisetron hydrochloride oral , 453
h1208i , 961
Sulbactam sodium , 327 Isophane insulin human , 206

INDEX S3/153
USP Pharmacists Pharmacopeia SuspeThime

Suspension (continued) Calcium carbonate and magnesia chewable , S1/4 Terbutaline sulfate , 335
Insulin human zinc , 208 Cats claw, S1/83 oral suspension , 454
Insulin human zinc, extended , 208 Cefaclor chewable , S2/4 Terminally sterilized pharmaceutical products
Isophane insulin , 207 Cilostazol, S1/4 parametric release h1222i , 970
Insulin zinc , 207 Black cohosh , S2/72 Terpinen-4-ol , 443
Insulin zinc, extended , 207 Colestipol hydrochloride , S2/4 Terpinene
Insulin zinc, prompt , 208 compounding ,1111 -, 443
Ketoconazole oral , 217 Curcuminoids , S3/74 gamma- , 443
Labetalol hydrochloride oral , 219 Diclofenac sodium extended-release , S1/5 Terpineol alpha- , 443
Metolazone oral , 244 Didanosine for oral suspension , S2/5 Terpin hydrate , 335
Metoprolol tartrate oral , 245 Flavoxate hydrochloride , S3/30 Terpinyl
Naratriptan hydrochloride oral , 453 Galantamine , S1/6 acetate, 443
Nevirapine oral , 256 Glimepiride , S1/6 propionate , 443
Ondansetron hydrochloride oral , 263 Ivermectin , S2/7 Testing practices
Pantoprazole sodium oral , 453 Lisinopril and hydrochlorothiazide , S3/32 dietary supplements, 1352
Pergolide oral, veterinary, 461 Mirtazapine orally disintegrating , S3/32 distribution ,1396
Quinidine sulfate oral , 305 Norethindrone , S2/9 emulsions ,1396
Rifampin oral , 308 Oxandrolone , S2/9 globule size ,1396
structured vehicle , 333 Pantoprazole sodium delayed-release , S3/32 incubation conditions ,1364
Structured vehicle, sugar-free , 333 Paroxetine , S2/9 intravenous ,1396
Sumatriptan succinate oral , 331 Primaquine phosphate , S2/10 media selection ,1364
Terbinane hydrochloride oral , 453 quality control,1111 Microbial limit tests h61i,1352,1364
Terbutaline sulfate oral , 454 Raloxifene hydrochloride , S2/11 microbial tests for specied microorganisms ,1352
Tetracycline hydrochloride oral , 337 Simethicone , S2/11 Microbiological attributes of nonsterile nutritional
Tiagabine hydrochloride oral , 454 Soy isoavones , S3/74 and dietary supplements h2023i ,1352
Vehicle for oral , 265 stability,1111 Microbiological attributes of nonsterile
pharmaceutical products h1111i,1352
Verapamil hydrochloride oral , 356 storage ,1111
Microbiological procedures for absence of
Zinc sulde topical , 363 Tetracycline hydrochloride and novobiocin
specied microorganismsnutritional and
Suspensions sodium, 337
dietary supplements h2022i ,1352
compounding, 1136 Taborsky, C.J., and Grady, L.T.
nonsterile products ,1352
preparation ,1136 WaterVapor Permeation of PrescriptionVials, 1388
review,1364
quality control,1136 Taborsky, J., and the PSD ProjectTeam Representative
stability,1396
stability,1136 Membership
Sterility tests h71i,1364
Sutton, S.V.W., and Cundell, A.M. Drug Products Distribution Chain, 1389
Testolactone , 335
Microbial Identication in the Pharmaceutical Tacrine hydrochloride , 333
Testosterone , 335
Industry, 1368 Tagatose ,1013
cypionate , 336
Sweeney, N., Nath, N., McNeal, E., Obenhuber, D., Talc , 334
enanthate , 336
Pillari, B., Shelton, L., and Stevens-Riley, M. Tamoxifen citrate , 334
propionate , 336
Particulate Contaminants of Intravenous Tamsulosin hydrochloride , S3/34
Medication and the Limits Set by USP General Tests and assays , 25
Tannic acid , 334
Chapter h788i, 1383 Tetracaine , 336
Tapioca starch , 324
Syrup, 333 and cocaine hydrochlorides and epinephrine
Tarragon oil , 386
Acacia , 53 topical solution,136
Tartaric acid , 334
Cherry,123 hydrochloride , 336
Taurine , 334
Chocolate ,127 Tetracycline , 336
Taxonomy
Corn , S3/29 hydrochloride , 336
dosage forms, 1402
Corn, solids ,140 hydrochloride and novobiocin sodium tablets , 337
Pharmaceutical dosage forms h1151i,1402
High fructose corn ,140, 379 hydrochloride oral suspension , 337
Tazobactam , 334, S1/9
Ferrous sulfate ,179 Tetracyclines (Systemic) , 644
Teaspoon h1221i, 970
Glucose , 380 -Tetradecalactone , 444
Temazepam , 335
Glucose, dried , 381 Tetrahydrofurfuryl alcohol , 444
Temperature
Malt , 382 Tetrahydrolinalool , 444
ambulances, 1344
Maltitol, 383 Tetrahydrozoline hydrochloride , 337
distribution ,1339
Orange , 266 2,3,5,6-Tetramethylpyrazine , 444
humidity,1339
Syrup, 333 Thalidomide , 337
packaging ,1339
Tolu balsam , 345 Theophylline , 338
stability,1339,1344
sodium glycinate , 338
storage ,1339,1344
Thermometers h21i, 705
Temperature Fluctuations During Mail Order
Thermometric equivalents ,1495
Shipment of Pharmaceutical Articles Using
Mean KineticTemperatureApproach Thiabendazole , 338
T Bailey, L.C., Grady, L.T., Medwick,T., and Okeke,
C.C., 1339
Thiamine
hydrochloride, 338
Terazosin hydrochloride , 335 mononitrate , 338
Tablets
Terbinane hydrochloride , S1/9 Thiethylperazine maleate , 338
Alendronate sodium, S2/3, S3/24
Terbinane hydrochloride oral suspension , 453 Thimerosal , 339
Arginine , S3/74
Bicalutamide , S3/25

INDEX S3/154
USP Pharmacists Pharmacopeia Thin-USP a

Thin-layer chromatographic identication test h201i, Coal tar,136 Trissel, L.A. and Newton, D.W.
722 Cocaine and tetracaine hydrochlorides and A Primer on USP Chapter h797i Pharmaceutical
Thioguanine , 339 epinephrine ,136 CompoundingSterile Preparations, and USP
Thiopental sodium, 339 Iodine , 209 Process for Drug and Practice Standards, 1067
Thioridazine , 339 Ivermectin , S2/8 Troches
hydrochloride , 339 Myrrh , 252 compounding, 1108
Thiostrepton, 339 Nitromersol , 258 preparation ,1108
Thiotepa , 340 Sodium hypochlorite , 318 quality control,1108
Thiothixene , 340 Topical suspension stability,1108
hydrochloride , 340 Calamine, 97 storage ,1108
Threonine , 340 Calamine, phenolated , 98 Trolamine , 350
Thyme oil , 386 Zinc sulde , 363 salicylate , 350
Thymol, 340, 444 Topiramate , 345, S1/9, S2/11 Troleandomycin , 350
Thyroid , 340 Torbeck, L. Tromethamine , 350
Tiagabine hydrochloride , 341 Signicant Digits and Rounding, 1412 carboprost ,109
oral suspension, 454 Torsemide , 345 Tropicamide , 351
Tiamulin , 341 Total Parenteral Nutrition Trypsin, crystallized , 351
fumarate , 341 Admixtures Mixing SequenceTable, 1134 Tryptophan , 351
Ticarcillin Toxic and hazardous substances Tubocurarine chloride , 351
disodium, 341 OSHA regulations, 1313 Tumeric , S3/75
monosodium , 341 TPN Admixtures Mixing SequenceTable ,1134 powdered, extract , S3/75
Tiletamine hydrochloride , 342 Tragacanth , 345 powdered , S3/75
Tilmicosin , 342 Tran, C.D., Brown, L.H., Bailey, L.C., Medwick,T., Tylosin , 351
Timolol maleate , 342 Okeke, C.C., and Krumperman, K. tartrate , 351
Tincture Medication StorageTemperatures on U.S. Tyloxapol , 352
Belladonna, 85 Ambulances: A Prospective Multicenter Tyrosine , 352
Observational Study, 1344 L-Tyrosine , 386
Benzethonium chloride , 87
Trazodone hydrochloride , 345 Tyrothricin , 352
Benzoin, compound , 88
Trenbolone acetate , 346
Cardamom, compound ,111
Tretinoin , 346
Ginger ,1008
Triacetin , 346
Green soap,193
Triamcinolone , 346
Iodine , 209
Iodine, strong , 209
acetonide , 346
diacetate , 346
U
Lemon , 221
hexacetonide , 347
Opium , 264 Ubidecarenone , 352
Triamterene , 347
Orange peel, sweet , 265 -Undecalactone , 445
Triazolam , 347
Tolu balsam , 345 -Undecalactone , 446
Tribasic
Vanilla , 355 Undecanal , 446
calcium phosphate, 101
Tinidazole , 342 2-Undecanone , 446
sodium phosphate , 320
Tioconazole , 342 1,3,5-Undecatriene , 446
Tributyl citrate , 347
Titanium dioxide , 343 10-Undecenal , 446
Tributyrin , 445
Title , 21 (E)-2-Undecenol , 446
Trichlormethiazide , 347
Tizanidine hydrochloride , 343 Undecyl alcohol , 446
Trichloromonouoromethane , 347
Tobramycin , 343 Undecylenic acid , 352
Triclosan , 347
sulfate , 343 Uniformity of dosage units h905i , 843
2-Tridecanone , 445
Tocainide hydrochloride , 343 Units of potency, 24
2-Tridecenal , 445
Tocopherols excipient , 344 Urea , 352
Trientine hydrochloride , 348
All-rac--Tocopheryl Acetate , 386 C 13 ,109
Triethyl citrate , 348
Tolazamide , 344 Ursodiol , 353
Triuoperazine hydrochloride , 348
Tolazoline hydrochloride , 344 United States Pharmacopeial Convention Standards
Triupromazine , 348
Tolbutamide , 344 and Clinical Information for Compounded
hydrochloride , 348 Medications Used inVeterinary Medicine
Tolcapone , 344
Triuridine , 348 deVeau, I.F., 675
Tolmetin sodium, 344
Trigylcerides, medium-chain , 349 USP Medication Errors Reporting Program (USP MER
Tolnaftate , 344
Trihexyphenidyl hydrochloride , 349 form)
Tolualdehyde, mixed isomers , 444
Trimeprazine tartrate , 349 medication error reporting, 1157
p-Tolualdehyde , 444
Trimethobenzamide hydrochloride , 349 USP MER Program (form)
Tolu balsam , 345
Trimethoprim , 349 medication error reporting, 1157
syrup, 345
sulfate , 349 USP and NF excipients, listed by category, 364, S1/10,
tincture , 345
2,4,5-Trimethyl -3-Oxazoline , 445 S2/13
p-Tolyl isobutyrate , 444
Trimethylamine , 445 USP and Patient Safety
Topical solution
3,5,5-Trimethyl hexanal , 445 medication error prevention, 1155
Aluminum acetate, 61
2,3,5-Trimethylpyrazine , 445 medication error reporting ,1155
Aluminum subacetate , 63
Trioxsalen , 350 safe medication practices ,1155
Calcium hydroxide ,100
Tripelennamine hydrochloride , 350
Carbol-fuchsin ,106
Triprolidine hydrochloride , 350

INDEX S3/155
USP Pharmacists Pharmacopeia USP QYohim

USP Quality Review Bulletins Veterinary monographs pharmaceutical ,1344

Abbreviations can lead to medication errors! No. Aminoglycosides (Systemic), 468 Pure Steam, 359
80, 1186 Aminopenicillins (Systemic) , 494 Puried , 359
USP reference standards , 23 Amoxicillin and Clavulanate (Systemic) , 501 Puried, sterile , 358
USP standards Antibiotic Index , 668 Rose ointment , 310
FrequentlyAsked Questions, 11 Bromide (Systemic) , 463 Rose, stronger, 310
Cephalosporins (Systemic) , 504 sterile, for injections ,1346
Chloramphenicol (Systemic) , 526 vapor permeation ,1388
Cisapride , 460 vials ,1388
Cisapride (Veterinary - Systemic) , S1/17 Water for pharmaceutical purposes h1231i, 975
V Clavulanate (Systemic), and Amoxicillin , 501 Watersolid interactions in pharmaceutical
systems h1241i, 994
Florfenicol (Systemic) , 530
Valentino, J.G., Bormel, F.G., and Williams, R.L. Fluoroquinolones (Systemic) , 534 WaterVapor Permeation of PrescriptionVials
Application of USPNF Standards to Pharmacy Lincosamides (Systemic) , 558 Grady, L.T., andTaborsky, C.J., 1388
Compounding, 1205 Macrolides (systemic) , 565 Wax
Valentino, J., and the PSD ProjectTeam Methimazole (Veterinary - Systemic) , S1/22 Candelilla, 378
Representative Membership Methylene Blue Injection, S2/20 Carnauba , 359, 378
Drug Products Distribution Chain, 1389 Metronidazole (Systemic) , 586 emulsifying , 359
Valeraldehyde , 446 Methylene Blue (Veterinary - Systemic) , S2/21 microcrystalline , 359
Valerian ,1013 Pencillin G (Systemic) , 589 white , 359
extract, powdered ,1014 Pergolide (Veterinary - Systemic) , S1/27 yellow, 360
Valeric acid , 447 Pergolide oral suspension, veterinary, 461 Weighing on an analytical balance h1251i, 996
-Valerolactone , 447 Potassium bromide oral solution, veterinary, 461, Weight variation of dietary supplements h2091i,
Valganciclovir hydrochloride , S2/11 S3/33 1040
Validation of alternative microbiological methods Potentiated Sulfonamides (Systemic) , 597 Weights and balances h41i, 706
h1223i , 973 Pyrimethamine (Systemic) , 614 Weights and measures , 31
Valine , 353 Rifampin (Systemic) , 618 What is a Medication Error?
Valproic acid , 353 Sodium bromide injection, veterinary, 462, S3/34 denition, 1159
Valrubicin , 353 Sodium bromide oral solution , 462, S3/34 NCC MERP,1159
Valsartan , 353 Spectinomycin (Systemic) , 626 Wheat starch , 324
Vancomycin , 353 Sulfonamides (Systemic) , 630 Williams, R.L., Bormel, F.G., and Valentino, J.G.
hydrochloride , 354 Tetracyclines (Systemic) , 644 Application of USPNF Standards to Pharmacy
hydrochloride, sterile , 354 Vials, water vapor permeation,1388 Compounding, 1205
Vanilla , 354 Vidarabine , 357 Williams, R.L., Marshall, K., Foster,T.S., and Carlin, H.S.
tincture , 355 Vinblastine sulfate , 357 Development of a CompendialTaxonomy and
Vanillin, 355, 447 Glossary for Pharmaceutical Dosage Forms, 1402
Vincristine sulfate , 357
Vasopressin , 355 Williams, R.L., and the PSD ProjectTeam
Vinorelbine tartrate , 358
Representative Membership
Vegetable Viscosity h911i, 846
Drug Products Distribution Chain, 1389
and animal substances, 31 increasing agents for aqueous systems table ,1083
Written prescription drug informationguidelines
oil, hydrogenated , 355 Vitamin h1265i , 999
Vehicle A, 358
for oral solution, 264 D2 , 386
for oral solution, sugar free , 265 D3 , 386
for oral suspension , 265 E , 358
suspension structured , 333
suspension structured, sugar-free , 333
E polyethylene glycol succinate , 358
K , 386
X
Vehicles, compounding solutions ,1114 Volumetric apparatus h31i, 705
Verapamil hydrochloride , 355, S2/12 Xanthan gum , 360
oral solution , 356 solution , 360
oral suspension, 356 Xylazine , 360
Veratraldehyde , 447 hydrochloride , 360
Verteporn , 357
Veterinarian ADR report
W Xylitol, 360
Xylose , 361
Form 1932A, 687
Wallner, B., and the PSD ProjectTeam Representative
Veterinary antibiotics index , 668 Membership
Veterinary introduction Drug Products Distribution Chain, 1389
veterinary monographs, 459
Veterinary medicine
Warfarin sodium, 358, S1/9
Water
Y
United States Pharmacopeial Convention packaging, 1388
Standards and Clinical Information for Yohimbine hydrochloride , 361
Peppermint , 277
Compounded Medications Used inVeterinary
Medicine, 675 pH ,1346

INDEX S3/156
USP Pharmacists Pharmacopeia ZalciZolaz

Z carbonate , 362
chloride , 362
sulfate , 363
sulde topical suspension, 363
gluconate , 362 undecylenate , 363
Zalcitabine , 361 oxide , 362 Zingerone , 447
Zein , 361 oxide ointment , 362 Zolazepam hydrochloride , 363
Zidovudine , 361 oxide paste , 363
Zileuton, 361 oxide and salicylic acid paste , 362
Zinc stearate , 363
acetate, 361

INDEX S3/157